PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BOWRING, SA; HOUSH, T				BOWRING, SA; HOUSH, T			THE EARTH EARLY EVOLUTION	SCIENCE			English	Article							SOUTHERN WEST GREENLAND; LOWER CONTINENTAL-CRUST; ND-ISOTOPIC EVIDENCE; MEAN-LIFE; CLASTIC METASEDIMENTS; MANTLE FRACTIONATION; DETRITAL ZIRCONS; GNEISS COMPLEX; HF ISOTOPES; GROWTH	The Archean crust contains direct geochemical information of the Earth's early planetary differentiation. A major outstanding question in the Earth sciences is whether the volume of continental crust today represents nearly all that formed over Earth's history or whether its rates of creation and destruction have been approximately balanced since the Archean. Analysis of neodymium isotopic data from the oldest remnants of Archean crust suggests that crustal recycling is important and that preserved continental crust comprises fragments of crust that escaped recycling. Furthermore, the data suggest that the isotopic evolution of Earth's mantle reflects progressive eradication of primordial heterogeneities related to early differentiation.	UNIV TEXAS, DEPT GEOL SCI, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	BOWRING, SA (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA.							ABBOTT D, 1991, GEOPHYS RES LETT, V18, P585, DOI 10.1029/91GL00813; ALLEGRE CJ, 1989, EARTH PLANET SC LETT, V96, P61, DOI 10.1016/0012-821X(89)90124-6; ANDERSON DL, 1994, GEOLOGY, V22, P39, DOI 10.1130/0091-7613(1994)022<0039:SOS>2.3.CO;2; ANDERSON DL, 1981, SCIENCE, V213, P82, DOI 10.1126/science.213.4503.82; ANDERSON DL, 1994, EARTH PLANET SC LETT, V128, P303, DOI 10.1016/0012-821X(94)90152-X; ARMSTRONG RL, 1981, PHILOS T R SOC A, V301, P443, DOI 10.1098/rsta.1981.0122; ARMSTRONG RL, 1968, REV GEOPHYS, V6, P175, DOI 10.1029/RG006i002p00175; ARMSTRONG RL, 1991, AUST J EARTH SCI, V38, P613, DOI 10.1080/08120099108727995; ARMSTRONG RL, 1981, GEOCHIM COSMOCHIM AC, V45, P1251, DOI 10.1016/0016-7037(81)90149-6; ARNDT NT, 1989, TECTONOPHYSICS, V161, P201, DOI 10.1016/0040-1951(89)90154-6; ARTH JG, 1975, GEOCHIM COSMOCHIM AC, V39, P325, DOI 10.1016/0016-7037(75)90200-8; BARKER F, 1976, GEOLOGY, V4, P596, DOI 10.1130/0091-7613(1976)4<596:GOTLAA>2.0.CO;2; BENNETT VC, 1993, EARTH PLANET SC LETT, V119, P299, DOI 10.1016/0012-821X(93)90140-5; BLACK LP, 1986, CONTRIB MINERAL PETR, V94, P427, DOI 10.1007/BF00376336; BLICHERTTOFT J, 1994, SCIENCE, V263, P1593, DOI 10.1126/science.263.5153.1593; BOAK JM, 1993, GEOL SOC AM ABSTR, V25, P74; BOWRING SA, 1989, GEOLOGY, V17, P971, DOI 10.1130/0091-7613(1989)017<0971:GGFTSP>2.3.CO;2; BOWRING SA, 1989, NATURE, V340, P222, DOI 10.1038/340222a0; BOWRING SA, UNPUB; BOWRING SA, 1990, ORIGIN EARTH, P319; BOWRING SA, 1994, EOS, V75, P59; CAMPBELL IH, 1983, GEOPHYS RES LETT, V10, P1061, DOI 10.1029/GL010i011p01061; CAMPBELL IH, 1988, EARTH PLANET SC LETT, V90, P11, DOI 10.1016/0012-821X(88)90107-0; CARLSON RW, 1979, EARTH PLANET SC LETT, V45, P123, DOI 10.1016/0012-821X(79)90114-6; CARLSON RW, 1994, REV GEOPHYS, V32, P337, DOI 10.1029/94RG01874; CHASE CG, 1988, EARTH PLANET SC LETT, V91, P66, DOI 10.1016/0012-821X(88)90151-3; CHRISTENSEN NI, 1995, J GEOPHYS RES-SOL EA, V100, P9761, DOI 10.1029/95JB00259; Collerson K.D., 1979, TRONDHJEMITES DACITE, V6, P205; COLLERSON KD, 1991, NATURE, V349, P209, DOI 10.1038/349209a0; CONDIE KC, 1984, GEOPHYS RES LETT, V11, P283, DOI 10.1029/GL011i004p00283; DePaolo, 1988, MINERALS ROCKS; DEPAOLO DJ, 1980, GEOCHIM COSMOCHIM AC, V44, P1185, DOI 10.1016/0016-7037(80)90072-1; DEPAOLO DJ, 1983, GEOPHYS RES LETT, V10, P705, DOI 10.1029/GL010i008p00705; DEPAOLO DJ, 1984, GEOPHYS RES LETT, V11, P154, DOI 10.1029/GL011i002p00154; DEPAOLO DJ, 1981, GEOCHIM COSMOCHIM AC, V45, P1253, DOI 10.1016/0016-7037(81)90150-2; DEWIT MJ, 1992, NATURE, V357, P553, DOI 10.1038/357553a0; DRUMMOND MS, 1990, J GEOPHYS RES-SOLID, V95, P21503, DOI 10.1029/JB095iB13p21503; ENGLAND P, 1993, TECTONOPHYSICS, V223, P67, DOI 10.1016/0040-1951(93)90158-G; FROST CD, 1993, GEOLOGY, V21, P351, DOI 10.1130/0091-7613(1993)021<0351:NIEFTA>2.3.CO;2; FROUDE DO, 1983, NATURE, V304, P616, DOI 10.1038/304616a0; FYFE WS, 1978, CHEM GEOL, V23, P89, DOI 10.1016/0009-2541(78)90068-2; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; Goldstein S. L., 1992, EOS T AM GEOPHYS UN, V73, P323; GOODWIN AM, 1991, PRECAMBRIAN GEOLOGY; GURNIS M, 1986, GEOLOGY, V14, P396, DOI 10.1130/0091-7613(1986)14<396:AECGAF>2.0.CO;2; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, 1992, P LUNAR PLANET SCI C, V23, P487; HOFFMAN PF, 1989, GEOLOGY, V17, P135, DOI 10.1130/0091-7613(1989)017<0135:SOLSFG>2.3.CO;2; HOUSH TB, UNPUB; HOUSH TB, 1993, GEOL SOC AM ABSTR, V25, P73; HURLEY PM, 1969, SCIENCE, V164, P1229, DOI 10.1126/science.164.3885.1229; JACOBSEN SB, 1981, TECTONOPHYSICS, V75, P163, DOI 10.1016/0040-1951(81)90214-6; JACOBSEN SB, 1988, J GEOPHYS RES-SOLID, V93, P338, DOI 10.1029/JB093iB01p00338; JACOBSEN SB, 1988, EARTH PLANET SC LETT, V90, P315, DOI 10.1016/0012-821X(88)90133-1; JACOBSEN SB, IN PRESS AM GEOPHYS; JACOBSEN SB, 1993, P LUNAR PLANET SCI C, V24, P709; JAHN B, 1984, CONTRIB MINERAL PETR, V86, P398, DOI 10.1007/BF01187143; JORDAN TH, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i003p00001; JORDAN TH, 1988, J PETROL, P11, DOI DOI 10.1093/PETROLOGY/SPECIAL_VOLUME.1.11; KAY RW, 1991, GEOL RUNDSCH, V80, P259, DOI 10.1007/BF01829365; LAUBSCHER H, 1990, TECTONOPHYSICS, V182, P9, DOI 10.1016/0040-1951(90)90338-9; LIU DY, 1992, GEOLOGY, V20, P339, DOI 10.1130/0091-7613(1992)020<0339:ROMCIT>2.3.CO;2; LUAIS B, 1994, J PETROL, V35, P43, DOI 10.1093/petrology/35.1.43; Lugmair G. W., 1978, LUNAR PLANETARY SCI, V9, P689; MAAS R, 1991, GEOCHIM COSMOCHIM AC, V55, P1915, DOI 10.1016/0016-7037(91)90033-2; MAAS R, 1992, GEOCHIM COSMOCHIM AC, V56, P1281, DOI 10.1016/0016-7037(92)90062-N; MARTIN H, 1986, GEOLOGY, V14, P753, DOI 10.1130/0091-7613(1986)14<753:EOSAGG>2.0.CO;2; MCCULLOCH MT, 1993, LITHOS, V30, P237, DOI 10.1016/0024-4937(93)90038-E; MCCULLOCH MT, 1993, EARTH PLANET SC LETT, V115, P89, DOI 10.1016/0012-821X(93)90215-U; MCCULLOCH MT, 1994, GEOCHIM COSMOCHIM AC, V58, P4717, DOI 10.1016/0016-7037(94)90203-8; MORGAN P, 1989, 28TH INT GEOL C 1989, V2, P462; MORGAN P, 1985, P LUNAR PLANET SCI C, V15, pC561; MUELLER PA, 1992, GEOLOGY, V20, P327, DOI 10.1130/0091-7613(1992)020<0327:GZFAAQ>2.3.CO;2; NUTMAN AP, 1986, CONTRIB MINERAL PETR, V94, P137, DOI 10.1007/BF00592931; NUTMAN AP, 1993, GEOLOGY, V21, P415, DOI 10.1130/0091-7613(1993)021<0415:AOAEAG>2.3.CO;2; NUTMAN AP, 1991, GEOLOGY, V19, P791, DOI 10.1130/0091-7613(1991)019<0791:VEACAC>2.3.CO;2; NYQUIST LE, 1992, GEOCHIM COSMOCHIM AC, V56, P2213, DOI 10.1016/0016-7037(92)90185-L; PATCHETT J, 1984, GEOPHYS RES LETT, V11, P151, DOI 10.1029/GL011i002p00151; RAPP RP, 1991, PRECAMBRIAN RES, V51, P1, DOI 10.1016/0301-9268(91)90092-O; REYMER A, 1984, TECTONICS, V3, P63, DOI 10.1029/TC003i001p00063; SCHREYER W, 1995, J GEOPHYS RES-SOL EA, V100, P8353, DOI 10.1029/94JB02912; SHEARER CK, 1993, GEOCHIM COSMOCHIM AC, V57, P4785, DOI 10.1016/0016-7037(93)90200-G; SHIREY SB, 1986, GEOCHIM COSMOCHIM AC, V50, P2631, DOI 10.1016/0016-7037(86)90215-2; SILVER PG, 1988, ANNU REV EARTH PL SC, V16, P477, DOI 10.1146/annurev.ea.16.050188.002401; SNYDER GA, 1994, GEOCHIM COSMOCHIM AC, V58, P4795, DOI 10.1016/0016-7037(94)90209-7; STEVENSON RK, 1990, GEOCHIM COSMOCHIM AC, V54, P1683, DOI 10.1016/0016-7037(90)90400-F; Taylor S.R., 1974, P 5 LUNAR SCI C, V1287-1305; Taylor S.R, 1985, CONTINENTAL CRUST IT; TAYLOR SR, 1975, LUNAR SCI POST APOLL; VONHUENE R, 1991, REV GEOPHYS, V29, P279, DOI 10.1029/91RG00969; WARREN PH, 1989, TECTONOPHYSICS, V161, P165, DOI 10.1016/0040-1951(89)90153-4; WILLIAMS IS, 1992, EOS, V73, P324; ZARTMAN RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1327, DOI 10.1016/0016-7037(88)90204-9	93	235	245	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1535	1540		10.1126/science.7667634	http://dx.doi.org/10.1126/science.7667634			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667634				2022-12-24	WOS:A1995RU81300030
J	PAULOVICH, AG; HARTWELL, LH				PAULOVICH, AG; HARTWELL, LH			A CHECKPOINT REGULATES THE RATE OF PROGRESSION THROUGH S-PHASE IN SACCHAROMYCES-CEREVISIAE IN RESPONSE TO DNA-DAMAGE	CELL			English	Article							DOUBLE-STRAND BREAKS; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; REPAIR; ARREST; GENE; RECOMBINATION; TRANSCRIPTION; REPLICATION	We demonstrate that in S. cerevisiae the rate of ongoing S phase is slowed when the DNA is subjected to alkylation. Slowing of replication is dependent on the MEC1 and RAD53 genes, indicating that lesions alone do not slow replication in vivo and that the slowing is an active process. While it has been shown that a MEC1- and RAD53-dependent checkpoint responds to blocked replication or DNA damage by inhibiting the onset of mitosis, we demonstrate that this checkpoint must also have an additional target within S phase that controls replication rate. MEC1 is a homolog of the human ATM gene, which is mutated in ataxia telangiectasia (AT) patients. Like mec1 yeast, AT cells are characterized by damage-resistant DNA synthesis, highlighting the congruence of the yeast and mammalian systems.			PAULOVICH, AG (corresponding author), UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195, USA.							Allen JB, 1994, GENE DEV, V8, P2416; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BRUNBORG G, 1980, RADIAT RES, V82, P547, DOI 10.2307/3575321; BRUNBORG G, 1978, MOL GEN GENET, V182, P277; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KADYK LC, 1993, GENETICS, V133, P469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LEADON SA, 1992, J BIOL CHEM, V267, P23175; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY AW, 1993, CURR OPIN GENET DEV, V5, P5; NAEGELI H, 1994, BIOESSAYS, V16, P557, DOI 10.1002/bies.950160809; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PAULES RS, 1995, CANCER RES, V55, P1763; PETES TD, 1973, BIOCHEM BIOPH RES CO, V55, P603, DOI 10.1016/0006-291X(73)91186-8; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; SINGER B, 1983, MOL BIOL MUTAGENS CA, P68; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040; ZAMPETTIBOSSELE.F, 1981, INT J RADIAT BIOL, V39, P547	40	531	537	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					841	847		10.1016/0092-8674(95)90481-6	http://dx.doi.org/10.1016/0092-8674(95)90481-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671311	Bronze			2022-12-24	WOS:A1995RU75500019
J	PEACOCK, JL; BLAND, JM; ANDERSON, HR				PEACOCK, JL; BLAND, JM; ANDERSON, HR			PRETERM DELIVERY - EFFECTS OF SOCIOECONOMIC-FACTORS, PSYCHOLOGICAL STRESS, SMOKING, ALCOHOL, AND CAFFEINE	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; PSYCHOSOCIAL STRESS; PREGNANCY; CONSUMPTION; CIGARETTE; LABOR	Objective-To examine the relation between preterm birth and socioeconomic and psychological factors, smoking, and alcohol and caffeine consumption. Design-Prospective study of outcome of pregnancy. Setting-District general hospital in inner London. Participants-1860 consecutive white women booking for delivery; 1513 women studied after exclusion because of multiple pregnancy and diabetes, refusals, and loss to follow up. Measurements-Gestational age was determined from ultrasound and maternal dates; preterm birth was defined as less than 37 completed weeks. Independent variables included smoking, alcohol and caffeine consumption, and a range of indicators of socioeconomic status and psychological stress. Main results-Unifactorial analyses showed that lower social class, less education, single marital status, low income, trouble with ''nerves'' and depression, help from professional agencies, and little contact with neighbours were all significantly associated with an increased risk of preterm birth. There were no apparent effects of smoking, alcohol, or caffeine on the length of gestation overall, although there was an association between smoking and delivery before 32 weeks. Cluster analysis indicated three subgroups of women delivering preterm: two predominantly of low social status and a third of older women with higher social status who did not smoke. Mean gestational age was highest in the third group. Conclusions-Adverse social circumstances are associated with preterm birth but smoking is not, apart from an association with very early births. This runs counter to findings for fetal growth (birth weight for gestational age) in this study, where a strong effect of smoking on fetal growth was observed but there was no evidence for any association with psychosocial factors.			PEACOCK, JL (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Peacock, Janet/0000-0002-0310-2518				ABERNATHY JR, 1966, AM J PUBLIC HEALTH N, V56, P626, DOI 10.2105/AJPH.56.4.626; [Anonymous], 1980, CLASSIFICATION OCCUP; ARBUCKLE RE, 1989, PAEDIATRIC PERINATAL, V3, P115; BAKKETEIG LS, 1981, PRETERM LABOR, P17; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BERENDES H, 1992, P INT COLLABORATIVE, V3; BERKOWITZ GS, 1981, AM J EPIDEMIOL, V113, P81, DOI 10.1093/oxfordjournals.aje.a113068; BERKOWITZ GS, 1983, J PSYCHOM RES, V27, P282; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; Everitt B., 1980, CLUSTER ANAL; FEDRICK J, 1976, BRIT J OBSTET GYNAEC, V83, P342, DOI 10.1111/j.1471-0528.1976.tb00840.x; FORTIER I, 1993, AM J EPIDEMIOL, V137, P931, DOI 10.1093/oxfordjournals.aje.a116763; GARN SM, 1977, EPIDEMIOLOGY PREMATU, P127; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRIFFIN J, 1993, BORN TOO SOON; HARTIKAINENSORR.AL, 1989, OBSTET GYNECOL, V74, P13; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HEDEGAARD M, 1993, BMJ-BRIT MED J, V307, P234, DOI 10.1136/bmj.307.6898.234; MACNAUGHTONSMIT.P, 1965, SOME STATISTICAL OTH; MAIN DM, 1988, CLIN OBSTET GYNECOL, V31, P521, DOI 10.1097/00003081-198809000-00004; MCDONALD AD, 1992, AM J PUBLIC HEALTH, V82, P87, DOI 10.2105/AJPH.82.1.87; McIntosh I D, 1984, Public Health Rev, V12, P29; MEYER LC, 1994, PAEDIATR PERINAT EP, V8, P145, DOI 10.1111/j.1365-3016.1994.tb00445.x; MEYER MB, 1976, AM J EPIDEMIOL, V103, P464, DOI 10.1093/oxfordjournals.aje.a112248; MEYER MB, 1977, EPIDEMIOLOGY PREMATU, P81; NEWTON RW, 1979, BRIT MED J, V2, P411, DOI 10.1136/bmj.2.6187.411; PAYKEL ES, 1969, ARCH GEN PSYCHIAT, V21, P753; PEACOCK JL, 1991, J EPIDEMIOL COMMUN H, V45, P159, DOI 10.1136/jech.45.2.159; PEACOCK JL, 1991, INT J EPIDEMIOL, V20, P405, DOI 10.1093/ije/20.2.405; PICKERING RM, 1991, INT J EPIDEMIOL, V20, P456, DOI 10.1093/ije/20.2.456; ROBERTS WE, 1990, OBSTET GYNECOL, V76, pS85; Rose G., 1992, STRATEGY PREVENTIVE; RUTTER DR, 1990, SOC SCI MED, V30, P553, DOI 10.1016/0277-9536(90)90154-K; STEIN A, 1987, BRIT MED J, V295, P291, DOI 10.1136/bmj.295.6593.291; 1985, SAS USERS GUIDE	35	234	241	0	30	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					531	535		10.1136/bmj.311.7004.531	http://dx.doi.org/10.1136/bmj.311.7004.531			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663207	Green Published			2022-12-24	WOS:A1995RR73700015
J	ZHOU, W; REINES, D; DOETSCH, PW				ZHOU, W; REINES, D; DOETSCH, PW			T7 RNA-POLYMERASE BYPASS OF LARGE GAPS ON THE TEMPLATE STRAND REVEALS A CRITICAL ROLE OF THE NONTEMPLATE STRAND IN ELONGATION	CELL			English	Article							TRANSCRIPTION TERMINATION; DNA; SEQUENCE; ELEMENTS; INVITRO	We show that T7 RNA polymerase can efficiently transcribe DNA containing gaps from one to five bases in the template strand. Surprisingly, broken template strands missing up to 24 bases can still be transcribed, although at reduced efficiency. The resulting transcripts contain the full template sequence with the RNA deleted for the gapped region missing on the template strand. These findings indicate that the end of a downstream template strand can be brought into the polymerase and transcribed as ii it were a part of an intact polynucleotide chain by utilizing the unpaired nontemplate strand. This, as well as transcription of an intact template strand, relies heavily upon the nontemplate strand, suggesting that a duplex DNA-binding site on the leading edge of RNA polymerase is required for RNA chain elongation on DNA templates. This work contributes substantially to the emerging picture that the nontemplate strand is an important element of the transcription elongation complex.	EMORY UNIV,SCH MED,DIV BIOL & BIOMED SCI,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,ATLANTA,GA 30322	Emory University; Emory University	ZHOU, W (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322, USA.		excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NATIONAL CANCER INSTITUTE [R01CA055896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NCI NIH HHS [CA55896] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331, GM46311] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERLIN M, 1964, J MOL BIOL, V8, P297, DOI 10.1016/S0022-2836(64)80139-X; Chamberlin M., 1982, ENZYMES, V15, P87; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JENG ST, 1990, J BIOL CHEM, V265, P3823; JENG ST, 1992, J BIOL CHEM, V267, P19306; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORRIS CE, 1986, RNA POLYM REGULATION, P47; OAKLEY JL, 1977, P NATL ACAD SCI USA, V74, P4266, DOI 10.1073/pnas.74.10.4266; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; ROSA MD, 1979, CELL, V16, P815, DOI 10.1016/0092-8674(79)90097-7; RYAN T, 1987, J BIOL CHEM, V258, P4690; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SAUCIER JM, 1972, NATURE-NEW BIOL, V239, P167, DOI 10.1038/newbio239167a0; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHI YB, 1988, J BIOL CHEM, V263, P527; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZHOU W, 1994, BIOCHEMISTRY-US, V33, P14926, DOI 10.1021/bi00253a032	28	48	49	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					577	585		10.1016/0092-8674(95)90030-6	http://dx.doi.org/10.1016/0092-8674(95)90030-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664337	Green Accepted, Bronze			2022-12-24	WOS:A1995RR73400009
J	VESA, J; HELLSTEN, E; VERKRUYSE, LA; CAMP, LA; RAPOLA, J; SANTAVUORI, P; HOFMANN, SL; PELTONEN, L				VESA, J; HELLSTEN, E; VERKRUYSE, LA; CAMP, LA; RAPOLA, J; SANTAVUORI, P; HOFMANN, SL; PELTONEN, L			MUTATIONS IN THE PALMITOYL PROTEIN THIOESTERASE GENE CAUSING INFANTILE NEURONAL CEROID-LIPOFUSCINOSIS	NATURE			English	Article							L-MYC; CHROMOSOME-1; POLYMORPHISM; ASSIGNMENT; JUVENILE; DISEASE; CLONING; MAPS; FORM; 1P32	NEURONAL ceroid lipofuscinoses (NCL) represent a group of common progressive encephalopathies of children which have a global incidence of 1 in 12,500 (ref. 1). These severe brain diseases are divided into three autosomal recessive subtypes, assigned to different chromosomal loci(2-4). The infantile subtype of NCL (INCL), linked to chromosome 1p32, is characterized by early visual loss and rapidly progressing mental deterioration, resulting in a pat electroencephalogram by 3 years of age; death occurs at 8 to 11 years(5), and characteristic storage bodies are found in brain and other tissues at autopsy(6). The molecular pathogenesis underlying the selective loss of neurons of neocortical origin has remained unknown. Here we report the identification, by positional candidate methods, of defects in the palmitoyl-protein thioesterase gene in all 42 Finnish INCL patients and several non-Finnish patients. The most common mutation results in intracellular accumulation of the polypeptide and undetectable enzyme activity in the brain of patients.	NATL PUBL HLTH INST,DEPT HUMAN MOLEC GENET,SF-00300 HELSINKI,FINLAND; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV HELSINKI,CHILDRENS HOSP,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT CHILD NEUROL,SF-00290 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Helsinki; University of Helsinki								CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; ERLANSON CH, 1970, SCAND J GASTROENTERO, V5, P333; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GARDINER M, 1990, GENOMICS, V8, P387, DOI 10.1016/0888-7543(90)90297-8; HEISKANEN M, 1994, BIOTECHNIQUES, V17, P928; HELLSTEN E, 1993, GENOMICS, V16, P720, DOI 10.1006/geno.1993.1253; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JARVELA I, 1991, GENOMICS, V9, P170, DOI 10.1016/0888-7543(91)90235-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKELA TP, 1992, HUM MOL GENET, V1, P217, DOI 10.1093/hmg/1.3.217-a; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PROLA RL, 1984, J BIOL CHEM, V259, P3350; RAPOLA J, 1973, BRAIN, V96, P833, DOI 10.1093/brain/96.4.833; Rider J A, 1988, Am J Med Genet Suppl, V5, P21; RILKONEN A, 1994, DNA CELL BIOL, V13, P257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTAVUORI P, 1974, DEV MED CHILD NEUROL, V16, P644; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; SYVANEN AC, 1989, FEBS LETT, V258, P71, DOI 10.1016/0014-5793(89)81618-7; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WILLIAMS R, 1993, AM J HUM GENET, V53, P931; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379	30	587	592	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					584	587		10.1038/376584a0	http://dx.doi.org/10.1038/376584a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637805				2022-12-24	WOS:A1995RP75600048
J	DRESCHER, U; KREMOSER, C; HANDWERKER, C; LOSCHINGER, J; NODA, M; BONHOEFFER, F				DRESCHER, U; KREMOSER, C; HANDWERKER, C; LOSCHINGER, J; NODA, M; BONHOEFFER, F			IN-VITRO GUIDANCE OF RETINAL GANGLION-CELL AXONS BY RAGS, A 25 KDA TECTAL PROTEIN RELATED TO LIGANDS FOR EPH RECEPTOR TYROSINE KINASES	CELL			English	Article							GROWTH CONES; ANCHORED PROTEINS; NEURONS INVITRO; COLLAPSE; POSITION; FAMILY; BRAIN; GENE; IDENTIFICATION; RECOGNITION	The results of previous in vitro experiments indicate that a glycosylphosphatidylinositol (GPl)-anchored protein may play an important role in the guidance of temporal retinal axons during the formation of the topographically ordered retinotectal projection. We have purified and cloned a GPl-anchored, 25 kDa glycoprotein that is a good candidate for a molecule involved in this process. During the time of innervation by retinal ganglion cells, this protein is gradedly expressed in the posterior part of the developing tectum, In two different in vitro assay systems, the recombinant protein induces growth cone collapse and repulsion of retinal ganglion cell axons. These phenomena are observed for axons of temporal as well as nasal origin, indicating that an additional activity may be necessary to confer the nasotemporal specificity observed in previous assays, We named the protein RAGS (for repulsive axon guidance signal), The sequence of RAGS shows significant homology to recently identified ligands for receptor tyrosine kinases of the Eph subfamily.			DRESCHER, U (corresponding author), MAX PLANCK INST DEV BIOL, DEPT PHYS BIOL, D-72076 TUBINGEN, GERMANY.		Noda, Masaharu/D-7146-2016; Drescher, Uwe/C-5438-2009	Noda, Masaharu/0000-0002-3796-524X; 				BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; CROWE J, 1992, QUIAEXPRESS INSTRUCT; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; FAWCETT JW, 1989, J CELL SCI, V92, P93; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FLETCHER FA, 1994, ONCOGENE, V9, P3241; FLETCHER FA, 1994, GENOMICS, V24, P127, DOI 10.1006/geno.1994.1589; GILLARDIHEBENST.P, 1992, ONCOGENE, V7, P2499; GLERER A, 1987, DEVELOPMENT, V101, P479; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JOHNSTON AR, 1991, DEVELOPMENT, V113, P409; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MOORMAN SJ, 1990, J NEUROSCI, V10, P3158; MULLER B, 1992, THESIS U TUBINGEN TU; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAQUALE EB, 1994, DEV BIOL, V163, P491; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RAPER JA, 1990, EXP NEUROBIOL, V109, P71; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; SIMON DK, 1992, NEURON, V9, P977, DOI 10.1016/0896-6273(92)90249-D; STAHL B, 1990, NEURON, V5, P733; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VONBOXBERG Y, 1993, NEURON, V10, P345; VONBOXBERG Y, 1988, ANAL BIOCHEM, V169, P372; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; 1992, SEQUENCE ANAL SOFTWA	72	742	759	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					359	370		10.1016/0092-8674(95)90425-5	http://dx.doi.org/10.1016/0092-8674(95)90425-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634326	Bronze			2022-12-24	WOS:A1995RP24200006
J	GODOWSKI, PJ; MARK, MR; CHEN, JA; SADICK, MD; RAAB, H; HAMMOND, RG				GODOWSKI, PJ; MARK, MR; CHEN, JA; SADICK, MD; RAAB, H; HAMMOND, RG			REEVALUATION OF THE ROLES OF PROTEIN-S AND GAS6 AS LIGANDS FOR THE RECEPTOR TYROSINE KINASE RSE/TYRO-3	CELL			English	Article							GROWTH		GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	GODOWSKI, PJ (corresponding author), GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080, USA.			Hammonds, Glenn/0000-0003-0727-121X				MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARK MR, 1994, J BIOL CHEM, V269, P10720; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	6	189	201	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					355	358		10.1016/0092-8674(95)90424-7	http://dx.doi.org/10.1016/0092-8674(95)90424-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634325	Bronze			2022-12-24	WOS:A1995RP24200005
J	FRANK, J; ZHU, J; PENCZEK, P; LI, YH; SRIVASTAVA, S; VERSCHOOR, A; RADERMACHER, M; GRASSUCCI, R; LATA, RK; AGRAWAL, RK				FRANK, J; ZHU, J; PENCZEK, P; LI, YH; SRIVASTAVA, S; VERSCHOOR, A; RADERMACHER, M; GRASSUCCI, R; LATA, RK; AGRAWAL, RK			A MODEL OF PROTEIN-SYNTHESIS BASED ON CRYOELECTRON MICROSCOPY OF THE E-COLI RIBOSOME	NATURE			English	Article							3-DIMENSIONAL RECONSTRUCTION; IMAGE-RECONSTRUCTION; ESCHERICHIA-COLI; SINGLE PARTICLES; RNA; SUBUNIT; TUNNEL; ICE	THE ribosome is formed by assembly of proteins and nucleic acids, and synthesizes proteins according to genetic instructions in all organisms. Many of the biochemical steps of this fundamental process are known, but a detailed understanding requires a well-defined structural model of the ribosome. Electron microscopy combined with image reconstruction of two-dimensional crystals or single ribosomes(4) has been the most promising technique, but the resolution of the resulting models has been insufficient. Here we report a 25-Angstrom reconstruction of the ribosome from Escherichia coli, obtained by combining 4,300 projections of ice-embedded single particles. Our new reconstruction reveals a channel in the small ribosomal subunit and a bifurcating tunnel in the large subunit which may constitute pathways for the incoming message and the nascent polypeptide chain, respectively. Based on these new findings, a three-dimensional model of the basic framework of protein synthesis is presented.	SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12222; SUNY ALBANY,DEPT COMP SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany	FRANK, J (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,BOX 509,ALBANY,NY 12201, USA.							AVILASAKAR AJ, 1994, J MOL BIOL, V239, P689, DOI 10.1006/jmbi.1994.1406; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; EASTERWOOD TR, 1994, NUCLEIC ACIDS RES, V22, P3779, DOI 10.1093/nar/22.18.3779; EISENSTEIN M, 1991, BIOCHIMIE, V73, P879, DOI 10.1016/0300-9084(91)90129-O; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1990, RIBOSOME, P107; GILBERT P, 1972, J THEOR BIOL, V36, P105, DOI 10.1016/0022-5193(72)90180-4; KUDLICKI W, 1995, J BIOL CHEM, V270, P10650, DOI 10.1074/jbc.270.18.10650; LEPAULT J, 1983, J MICROSC-OXFORD, V129, P89, DOI 10.1111/j.1365-2818.1983.tb04163.x; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MONTESANORODITIS L, 1994, J BIOL CHEM, V269, P6458; OAKES MI, 1990, J MOL BIOL, V211, P897, DOI 10.1016/0022-2836(90)90082-W; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; SCHRODER RR, 1990, J STRUCT BIOL, V105, P28, DOI 10.1016/1047-8477(90)90095-T; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; SUNDARALINGAM M, 1975, P101; YONATH A, 1989, TRENDS BIOCHEM SCI, V14, P329, DOI 10.1016/0968-0004(89)90166-7; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	24	353	363	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					441	444		10.1038/376441a0	http://dx.doi.org/10.1038/376441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630422				2022-12-24	WOS:A1995RM63900057
J	BERRA, E; DIAZMECO, MT; DOMINGUEZ, I; MUNICIO, MM; SANZ, L; LOZANO, J; CHAPKIN, RS; MOSCAT, J				BERRA, E; DIAZMECO, MT; DOMINGUEZ, I; MUNICIO, MM; SANZ, L; LOZANO, J; CHAPKIN, RS; MOSCAT, J			PROTEIN KINASE-C-ZETA ISOFORM IS CRITICAL FOR MITOGENIC SIGNAL-TRANSDUCTION	CELL			English	Article							HYDROLYZING PHOSPHOLIPASE-C; XENOPUS-LAEVIS OOCYTES; T-CELL ACTIVATION; GROWTH-FACTOR; RAS ONCOGENE; PHOSPHATIDYLCHOLINE; DIACYLGLYCEROL; STIMULATION; FIBROBLASTS; EXPRESSION	The requirement of protein kinase C zeta(zetaPKC) for maturation of X. laevis oocytes in response to insulin, p21ras, and phosphatidylcholine-hydrolyzing phospholipase C has recently been shown. Here we present experimental evidence demonstrating that activation of zetaPKC is not only necessary but also sufficient by itself to activate maturation in oocytes and to produce deregulation of growth control in mouse fibroblasts. Furthermore, by using a dominant kinase-defective mutant zetaPKC, we confirm that this kinase is required for mitogenic activation in oocytes and fibroblasts. These results permit us to propose zetaPKC as a critical step downstream of p21ras in mitogenic signal transduction.			BERRA, E (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN.		Moscat, Jorge/A-7011-2009; Berra, Edurne/F-9692-2011; Lozano, José/C-2760-2014	Berra, Edurne/0000-0002-3820-5744; Lozano, José/0000-0002-8187-2833; Diaz-Meco, Maria/0000-0003-0147-0998; Chapkin, Robert/0000-0002-6515-3898; /0000-0001-9617-4141				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EXTON JH, 1990, J BIOL CHEM, V265, P1; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KALENIC G, 1992, MOL CELL BIOL, V12, P4687; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONDO T, 1992, J BIOL CHEM, V267, P23609; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; WAYS DK, 1992, J BIOL CHEM, V267, P4799; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	32	387	390	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					555	563		10.1016/0092-8674(93)80056-K	http://dx.doi.org/10.1016/0092-8674(93)80056-K			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	7688666				2022-12-24	WOS:A1993LT73900016
J	LAFONCAZAL, M; PIETRI, S; CULCASI, M; BOCKAERT, J				LAFONCAZAL, M; PIETRI, S; CULCASI, M; BOCKAERT, J			NMDA-DEPENDENT SUPEROXIDE PRODUCTION AND NEUROTOXICITY	NATURE			English	Article							NITRIC-OXIDE SYNTHASE; AMINO-ACID RELEASE; STRIATAL NEURONS; NERVOUS-SYSTEM; GLUTAMATE; RECEPTORS; ISCHEMIA; QUANTIFICATION; CULTURES; INJURY	NEURONAL injury resulting from acute brain insults and some neurodegenerative diseases implicates N-methyl-D-aspartate (NMDA) glutamate receptors1-4. The fact that antioxidants reduce some types of brain damage suggests that oxygen radicals may have a roles5-7. It has been shown that mutations in Cu/Zn-superoxide dismutase (SOD), an enzyme catalysing superoxide (O2.-) detoxification in the cell, are linked to a familial form of amyotrophic lateral sclerosis (ALS)4. Here we report that O2.- is produced upon NMDA receptor stimulation in cultured cerebellar granule cells. Electron paramagnetic resonance was used to assess O2.- production that was due in part to the release of arachidonic acid. Activation of kainic acid receptors, or voltage-sensitive Ca2+ channels, did not produce detectable O2.-. We also find that the nitrone DMPO (5,5-dimethyl pyrroline 1-oxide), used as a spin trap, is more efficient than the nitric oxide synthase inhibitor, L-N(G)-nitroarginine, in reducing NMDA-induced neuronal death in these cultures.	CRIPDOM,F-34172 CASTELNAU LEZ,FRANCE; UNIV AIX MARSEILLE 1,SREP,CNRS,URA 1412,F-13397 MARSEILLE 4,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	LAFONCAZAL, M (corresponding author), CNRS,INSERM,CTR PHARMACOL ENDOCRINOL,RUE DE LA CARDONILLE,F-34094 MONTPELLIER 5,FRANCE.							BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIDIER M, 1990, J NEUROSCI RES, V27, P25, DOI 10.1002/jnr.490270105; DIDIER M, 1993, EUR J PHARMACOL, V224, P57; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; FAVARON M, 1990, P NATL ACAD SCI USA, V87, P1983, DOI 10.1073/pnas.87.5.1983; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; LAFONCAZAL M, 1992, BRAIN RES, V593, P63, DOI 10.1016/0006-8993(92)91264-F; LERNERNATOLI M, 1992, J NEUROREPORT, V3, P1109; MARIN P, 1992, EUR J NEUROSCI, V4, P425, DOI 10.1111/j.1460-9568.1992.tb00892.x; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONCADA C, 1992, NEUROREPORT, V3, P530; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OLNEY JW, 1989, DRUG DEVELOP RES, V17, P299, DOI 10.1002/ddr.430170406; PAUWELS PJ, 1992, NEUROSCI LETT, V143, P27, DOI 10.1016/0304-3940(92)90225-V; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POU S, 1989, ANAL BIOCHEM, V177, P1, DOI 10.1016/0003-2697(89)90002-X; POU S, 1992, J BIOL CHEM, V267, P24173; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; ROSEN GM, 1988, J MED CHEM, V31, P428, DOI 10.1021/jm00397a028; SAEZ JC, 1987, P NATL ACAD SCI USA, V84, P3056, DOI 10.1073/pnas.84.9.3056; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229	29	1098	1113	0	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					535	537		10.1038/364535a0	http://dx.doi.org/10.1038/364535a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687749				2022-12-24	WOS:A1993LQ66700057
J	CATARSI, S; DRAPEAU, P				CATARSI, S; DRAPEAU, P			TYROSINE KINASE-DEPENDENT SELECTION OF TRANSMITTER RESPONSES INDUCED BY NEURONAL CONTACT	NATURE			English	Article							IDENTIFIED LEECH NEURON; ACETYLCHOLINE-RECEPTOR; CULTURE; REINNERVATION; CONNECTIONS; SEROTONIN	TRANSMITTER receptors are localized to discrete cellular sites1 such that only those responses appropriate for a particular pattern of inputs are activated2-4. How neurons select between synaptic and extrasynaptic responses during development is not understood. We have investigated how contact during synapse formation between identified leech neurons5-7 selectively suppresses the modulation of extrasynaptic channels by protein kinase C8-10. A microelectrode with an isolated membrane patch containing channels from an uninnervated target neuron was 'crammed'11 into a similar cell contacted by a presynaptic partner. We report here that within a few minutes, the crammed channels were rendered insensitive to activation of protein kinase C, demonstrating the action of a cytoplasmic signal. Treatment of the neurons with selective inhibitors of tyrosine kinases12, which are signalling molecules during normal and oncogenic cellular differentiation13,14, prevented the loss of channel modulation. Thus, tyrosine kinases mediate early functional changes during specific synapse formation that are induced by neuronal contact.	MONTREAL GEN HOSP,RES INST,MONTREAL H3G 1A4,QUEBEC,CANADA	McGill University	CATARSI, S (corresponding author), MCGILL UNIV,CTR RES NEUROSCI,1650 CEDAR AVE,MONTREAL H3G 1A4,PQ,CANADA.							ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CATARSI S, 1992, NEURON, V8, P275, DOI 10.1016/0896-6273(92)90294-N; COHEN MW, 1987, J NEUROSCI, V7, P2849; DIETZEL ID, 1986, J PHYSIOL-LONDON, V372, P191, DOI 10.1113/jphysiol.1986.sp016004; DRAPEAU P, 1989, J NEUROBIOL, V20, P312, DOI 10.1002/neu.480200505; DRAPEAU P, 1989, J NEUROSCI, V9, P2502; DRAPEAU P, 1988, J NEUROSCI, V8, P4718; DRAPEAU P, 1990, NEURON, V4, P875, DOI 10.1016/0896-6273(90)90140-B; FUCHS PA, 1981, J PHYSIOL-LONDON, V316, P203, DOI 10.1113/jphysiol.1981.sp013783; GERSCHENFELD HM, 1973, PHYSIOL REV, V53, P1, DOI 10.1152/physrev.1973.53.1.1; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KRAMER RH, 1990, NEURON, V2, P335; MERZ DC, 1992, P ROY SOC B-BIOL SCI, V248, P129, DOI 10.1098/rspb.1992.0052; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEHER E, 1976, J PHYSIOL-LONDON, V258, P705, DOI 10.1113/jphysiol.1976.sp011442; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PURVES D, 1985, PRINCIPLES NEURAL DE; QU Z, 1990, NEURON, V2, P367; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125	29	35	35	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					353	355		10.1038/363353a0	http://dx.doi.org/10.1038/363353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	7684513				2022-12-24	WOS:A1993LD91700054
J	BREWSTER, JL; DEVALOIR, T; DWYER, ND; WINTER, E; GUSTIN, MC				BREWSTER, JL; DEVALOIR, T; DWYER, ND; WINTER, E; GUSTIN, MC			AN OSMOSENSING SIGNAL TRANSDUCTION PATHWAY IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; MAP KINASE; PHOSPHORYLATION; PHEROMONE; GENES; DNA; ACCUMULATION; RESISTANCE	Yeast genes were isolated that are required for restoring the osmotic gradient across the cell membrane in response to increased external osmolarity. Two of these genes, HOG1 and PBS2, encode members of the mitogen-activated protein kinase (MAP kinase) and MAP kinase kinase gene families, respectively. MAP kinases are activated by extracellular ligands such as growth factors and function as intermediate kinases in protein phosphorylation cascades. A rapid, PBS2-dependent tyrosine phosphorylation of HOG1 protein occurred in response to increases in extracellular osmolarity. These data define a signal transduction pathway that is activated by changes in the osmolarity of the extracellular environment.	RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; THOMAS JEFFERSON UNIV, JEFFERSON INST MOLEC MED, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA	Rice University; Jefferson University; Jefferson University				Gustin, Michael/0000-0003-0097-9194; Dwyer, Noelle/0000-0002-1995-7203	NIGMS NIH HHS [GM45772] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLARD MJ, 1991, EMBO J, V10, P3753, DOI 10.1002/j.1460-2075.1991.tb04944.x; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, UNPUB; Chamberlin ME, 1989, AM J PHYSIOL, Vl257, P159; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; EDGELY M, 1983, J GEN MICROBIOL, V129, P3453; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; FRINGS CS, 1966, ANAL CHIM ACTA, V34, P225, DOI 10.1016/S0003-2670(00)89030-3; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; MEIKLE AJ, 1988, J GEN MICROBIOL, V134, P3049; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; REED RH, 1987, APPL ENVIRON MICROB, V53, P2119, DOI 10.1128/AEM.53.9.2119-2123.1987; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; [No title captured]	38	1021	1101	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1760	1763		10.1126/science.7681220	http://dx.doi.org/10.1126/science.7681220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	7681220				2022-12-24	WOS:A1993KT81000039
J	ZAMBRANO, MM; SIEGELE, DA; ALMIRON, M; TORMO, A; KOLTER, R				ZAMBRANO, MM; SIEGELE, DA; ALMIRON, M; TORMO, A; KOLTER, R			MICROBIAL COMPETITION - ESCHERICHIA-COLI MUTANTS THAT TAKE OVER STATIONARY PHASE CULTURES	SCIENCE			English	Article							SPONTANEOUS MUTATIONS; STARVATION SURVIVAL; GENERAL RESISTANCE; BACTERIA; KATF; EXPRESSION; SELECTION; EVOLUTION; PROTEINS; SEQUENCE	Many microorganisms, including Escherichia coli, can survive extended periods of starvation. The properties of cells that survived prolonged incubation in stationary phase were studied by mixture of 10-day-old (aged) cultures with 1-day-old (young) cultures of the same strain of Escherichia coli. Mutants from the aged cultures that could grow eventually took over the population, which resulted in the death of the cells from the young cultures. This phenotype was conferred by mutations in rpoS, which encodes a putative stationary phase-specific sigma factor. These rapid population shifts have implications for the studies of microbial evolution and ecology.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School			Zambrano, Maria Mercedes/AAD-2805-2019	Zambrano, Maria Mercedes/0000-0002-0796-4473; Siegele, Deborah/0000-0001-8935-0696				ATWOOD KC, 1951, P NATL ACAD SCI USA, V37, P146, DOI 10.1073/pnas.37.3.146; BENNETT AF, 1990, NATURE, V346, P79, DOI 10.1038/346079a0; BOHANNON DE, 1991, J BACTERIOL, V173, P4482, DOI 10.1128/JB.173.14.4482-4492.1991; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; GROAT RG, 1986, J BACTERIOL, V168, P486, DOI 10.1128/jb.168.2.486-493.1986; HALL BG, 1988, GENETICS, V120, P887; HALL BG, 1991, NEW BIOL, V3, P729; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HENGGEARONIS R, 1991, J BACTERIOL, V173, P7918, DOI 10.1128/jb.173.24.7918-7924.1991; KJELLEBERG S, 1987, ANNU REV MICROBIOL, V41, P25, DOI 10.1146/annurev.mi.41.100187.000325; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LANGE R, 1991, J BACTERIOL, V173, P4474, DOI 10.1128/JB.173.14.4474-4481.1991; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; MATIN A, 1989, ANNU REV MICROBIOL, V43, P293, DOI 10.1146/annurev.mi.43.100189.001453; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; MCCANN MP, 1991, J BACTERIOL, V173, P4188, DOI 10.1128/jb.173.13.4188-4194.1991; Miller J.H., 1972, EXPT MOL GENETICS; MITTLER JE, 1992, NATURE, V356, P446, DOI 10.1038/356446a0; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; NOVICK A, 1950, P NATL ACAD SCI USA, V36, P708, DOI 10.1073/pnas.36.12.708; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; SIEGELE DA, IN PRESS STARVATION; Small P. L. C., 1992, ASM B, V74, P38; SPECTOR MP, 1986, J BACTERIOL, V168, P420, DOI 10.1128/jb.168.1.420-424.1986; SYKES RB, 1982, ANTIMICROB AGENTS CH, V21, P85, DOI 10.1128/AAC.21.1.85; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X	29	430	433	1	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1757	1760		10.1126/science.7681219	http://dx.doi.org/10.1126/science.7681219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	7681219				2022-12-24	WOS:A1993KT81000038
J	FUKAURA, A; TAZAWA, H; NAKAJIMA, H; ADACHI, M				FUKAURA, A; TAZAWA, H; NAKAJIMA, H; ADACHI, M			DO-NOT-RESUSCITATE ORDERS AT A TEACHING HOSPITAL IN JAPAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CARDIOPULMONARY RESUSCITATION; POLICY; CHOICE; STILL				FUKAURA, A (corresponding author), SHOWA UNIV,SCH MED,TOKYO 142,JAPAN.							[Anonymous], 1990, CRIT CARE MED, V18, P1435; Arai T, 1994, Masui, V43, P600; ARAI T, 1994, ICU CCU, V18, P657; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BERLOWITZ DR, 1991, J AM GERIATR SOC, V39, P472, DOI 10.1111/j.1532-5415.1991.tb02492.x; BROWN BW, 1977, STATISTICS BIOMEDICA; Fukaura Asato, 1994, Journal of Japan Society for Cancer Therapy, V29, P1696; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; MILES SH, 1982, ANN INTERN MED, V96, P660, DOI 10.7326/0003-4819-96-5-660; Murakami K, 1986, Gan To Kagaku Ryoho, V13, P2693; Murakami K, 1989, Gan To Kagaku Ryoho, V16, P740; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Sato Ikuyo, 1994, Journal of Japan Society for Cancer Therapy, V29, P1677; SCHWARTZ DA, 1986, J AM GERIATR SOC, V34, P807, DOI 10.1111/j.1532-5415.1986.tb03986.x; SHAPIRO GR, 1991, PROG P AM SOC CLIN O, V10, P325; STANLEY DP, 1989, MED J AUSTRALIA, V151, P257, DOI 10.5694/j.1326-5377.1989.tb101190.x; STANLEY DP, 1989, MED J AUSTRALIA, V151, P260; STERN SG, 1992, CRIT CARE MED, V20, P1263, DOI 10.1097/00003246-199209000-00013; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; STOLMAN CJ, 1989, ARCH INTERN MED, V149, P1851, DOI 10.1001/archinte.149.8.1851; TAZAWA H, 1990, Journal of Japan Society for Cancer Therapy, V25, P1448; TAZAWA H, 1986, Journal of Japan Society for Cancer Therapy, V21, P2454; Teshima H, 1987, Nihon Kyobu Shikkan Gakkai Zasshi, V25, P305; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; UHLMANN RF, 1984, CRIT CARE MED, V12, P879, DOI 10.1097/00003246-198410000-00009; VANDELDEN JJM, 1993, J MED ETHICS, V19, P200, DOI 10.1136/jme.19.4.200; WITTE KL, 1984, HEART LUNG, V13, P159; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1989, J MED ETHICS, V15, P129; 1995, ASSAHI SHIMBUN  0328, P3; 1991, PUBLIC OPINION POLL, V23, P46; 1992, NIHON ISIKAI ZASSI, V107, P1209; 1974, JAMA-J AM MED ASSOC, V227, P864	34	27	28	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					805	808		10.1056/NEJM199509213331218	http://dx.doi.org/10.1056/NEJM199509213331218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU809	7643902				2022-12-24	WOS:A1995RU80900028
J	HAY, J				HAY, J			COMPLICATIONS AT SITE OF INJECTION OF DEPOT NEUROLEPTICS	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT PSYCHIAT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BELANGERANNABLE MC, 1985, CANADIAN NURSE, V81, P1; FOSTER P, 1989, PHARM J, V243, P431; HAMANN GL, 1990, J CLIN PSYCHIAT, V51, P502; SVENDSEN O, 1989, STUDIES TISSUE INJUR; WRIGHT NF, 1990, PSYCHIATRIC B, V14, P594	5	38	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					421	421		10.1136/bmj.311.7002.421	http://dx.doi.org/10.1136/bmj.311.7002.421			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640587	Green Published			2022-12-24	WOS:A1995RP55400014
J	BAKOULA, CG; KAFRITSA, YJ; KAVADIAS, GD; LAZOPOULOU, DD; THEODORIDOU, MC; MARAVELIAS, KP; MATSANIOTIS, NS				BAKOULA, CG; KAFRITSA, YJ; KAVADIAS, GD; LAZOPOULOU, DD; THEODORIDOU, MC; MARAVELIAS, KP; MATSANIOTIS, NS			OBJECTIVE PASSIVE-SMOKING INDICATORS AND RESPIRATORY MORBIDITY IN YOUNG-CHILDREN	LANCET			English	Note							ENVIRONMENTAL TOBACCO-SMOKE; URINARY COTININE; EXPOSURE	Exposure to environmental tobacco smoke is associated with increased respiratory morbidity in young children, but few studies have assessed such exposure objectively by urinary cotinine measurements. 501 children aged 1-5 years, a random 5% sample of children attending an outpatient clinic, were classified as exposed or nonexposed to environmental tobacco smoke with a cut-off of 10 ng cotinine per mg creatinine in urine. Exposed children were 3.5 times (95% Cl 1.56-7.90, p<0.0024) more likely to have increased respiratory morbidity (three or more episodes during the previous 12 months) than non-exposed children after adjustment for potential confounding factors.	UNIV ATHENS,DEPT PAEDIAT 1,ATHENS,GREECE; UNIV ATHENS,DEPT FORENS MED & TOXICOL,ATHENS,GREECE	National & Kapodistrian University of Athens; National & Kapodistrian University of Athens								CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; DALLAVORGIA P, 1990, SCAND J SOC MED, V18, P81, DOI 10.1177/140349489001800201; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V788, P696; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; MARBURY MC, 1993, AM J EPIDEMIOL, V137, P1089, DOI 10.1093/oxfordjournals.aje.a116612; REESE AC, 1992, AM REV RESPIR DIS, V146, P66, DOI 10.1164/ajrccm/146.1.66; RICHARDSON MA, 1988, J ALLERGY CLIN IMMUN, V81, P1032, DOI 10.1016/0091-6749(88)90175-3; RUBIN DH, 1988, YALE J BIOL MED, V61, P401; STRACHAN DP, 1990, AM REV RESPIR DIS, V142, P147, DOI 10.1164/ajrccm/142.1.147; WALD NJ, 1984, LANCET, V1, P230	10	46	50	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					280	281		10.1016/S0140-6736(95)92167-2	http://dx.doi.org/10.1016/S0140-6736(95)92167-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RL757	7630249				2022-12-24	WOS:A1995RL75700012
J	HELD, W; ROLAND, J; RAULET, DH				HELD, W; ROLAND, J; RAULET, DH			ALLELIC EXCLUSION OF LY49-FAMILY GENES ENCODING CLASS-I MHC-SPECIFIC RECEPTORS ON NK CELLS	NATURE			English	Article							NATURAL-KILLER-CELLS; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEINS; MULTIGENE FAMILY; ANTIGEN; LY-49; IDENTIFICATION; COMPLEX; CLONING; NKR-P1	AN important feature of natural killer (NK) cell activity is the lysis of cells that have extinguished expression of some or all class I major histocompatibility (MHC) molecules(1-7). Accordingly, the Ly49A NK-cell antigen receptor has been shown to deliver an inhibitory signal to NK cells on encounter with D-d or D-k class I MHC on target cells(4). Ly49A belongs to a family of eight or more highly related, tightly linked genes(2,8-10). Expression of Ly49A and Ly49C, another member of the Ly49 family with distinct MHC specificity, define subpopulations of NK cells that are only partly overlapping(10-12). The mechanisms regulating the expression of Ly49 family members are unknown. We show here that the Ly49A and Ly49C NK-cell receptors are each subject to allelic exclusion. Because Ly49 genes are not thought to undergo DNA rearrangement(13,14), allelic exclusion of Ly49 genes could involve a mechanism distinct from that used by B and T lymphocytes(15,16) and is likely to play an important role in the genesis of a putative NK-cell repertoire specific for class I molecules.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; INST PASTEUR,DEPT IMMUNOL,F-75724 PARIS,FRANCE	University of California System; University of California Berkeley; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HELD, W (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Raulet, David/0000-0002-1257-8649				BRENNAN J, 1994, J EXP MED, V180, P2287, DOI 10.1084/jem.180.6.2287; Casanova J L, 1993, Methods Mol Biol, V23, P191; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHAN PY, 1989, J IMMUNOL, V142, P1727; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CORREA I, 1994, EUR J IMMUNOL, V24, P1323, DOI 10.1002/eji.1830240613; HELD W, 1993, J EXP MED, V177, P359, DOI 10.1084/jem.177.2.359; KARLHOFER FM, 1994, J IMMUNOL, V153, P2407; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; NAGASAWA R, 1987, J IMMUNOL, V138, P815; RAULET D, IN PRESS SEMIN IMMUN, V7; RAULET DH, 1980, J IMMUNOL, V125, P1136; ROLAND J, 1992, INT IMMUNOL, V4, P699, DOI 10.1093/intimm/4.6.699; SENTMAN CL, 1989, J EXP MED, V170, P191, DOI 10.1084/jem.170.1.191; SMITH HRC, 1994, J IMMUNOL, V153, P1068; STONEMAN E, 1993, J IMMUNOL, V150, pA1465; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TAKEI F, 1983, J IMMUNOL, V130, P2794; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; WONG S, 1991, J IMMUNOL, V147, P1417; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	30	175	176	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					355	358		10.1038/376355a0	http://dx.doi.org/10.1038/376355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630404				2022-12-24	WOS:A1995RL44300051
J	SIDDIQUE, AK; SALAM, A; ISLAM, MS; AKRAM, K; MAJUMDAR, RN; ZAMAN, K; FRONCZAK, N; LASTON, S				SIDDIQUE, AK; SALAM, A; ISLAM, MS; AKRAM, K; MAJUMDAR, RN; ZAMAN, K; FRONCZAK, N; LASTON, S			WHY TREATMENT CENTERS FAILED TO PREVENT CHOLERA DEATHS AMONG RWANDAN REFUGEES IN GOMA, ZAIRE	LANCET			English	Article							BANGLADESH; EPIDEMIC	In July, 1994, in one of the worst cholera outbreaks in recent times, an estimated 12 000 Rwandan refugees died in Goma in eastern Zaire, The Vibrio cholerae strains were resistant to tetracycline and doxycycline, the commonly used drugs for cholera treatment. Despite the efforts of international organisations, which provided medical relief by establishing treatment centres in Goma, mortality from the disease was much higher than expected. In the area of Muganga camp, which had the largest concentration of refugees and where most of the medical aid organisations were active, the highest reported case-fatality ratio for a single day was 48%. The slow rate of rehydration, inadequate use of oral rehydration therapy, use of inappropriate intravenous fluids, and inadequate experience of health workers in management of severe cholera are thought to be some of the factors associated with the failure to prevent so many deaths during the epidemic. In one of the temporary treatment centres with the worst case-fatality record, our team showed that improvement of these factors could increase the odds of survival of cholera patients even in a disaster setting.	INT CTR DIARRHOEAL DIS RES, DIV CLIN SCI, DHAKA 1000, BANGLADESH; INT CTR DIARRHOEAL DIS RES, DIV SCI LAB, DHAKA 1000, BANGLADESH; INT CTR DIARRHOEAL DIS RES, DIV FAMILY PLANNING & POPULAT, DHAKA 1000, BANGLADESH	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)	SIDDIQUE, AK (corresponding author), INT CTR DIARRHOEAL DIS RES, DIV COMMUNITY HLTH, GPO BOX 128, DHAKA 1000, BANGLADESH.		Salam, Abdul/GWC-1029-2022					BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; PIERCE NF, 1969, ANN INTERN MED, V70, P1173, DOI 10.7326/0003-4819-70-6-1173; SACK R B, 1970, Bulletin of the World Health Organization, V43, P351; SIDDIQUE AK, 1990, TROP DOCT, V20, P83, DOI 10.1177/004947559002000215; SIDDIQUE AK, 1989, TROP GEOGR MED, V41, P377; SIDDIQUE AK, 1992, J DIARRHOEAL DIS RES, V10, P79; SIDDIQUE AK, 1991, J DIARRHOEAL DIS RES, V9, P310; 1987, MANUAL LABORATORY IN; 1992, WEEKLY EPIDEMIOL REC, V67, P253	9	122	124	3	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	1995	345	8946					359	361		10.1016/S0140-6736(95)90344-5	http://dx.doi.org/10.1016/S0140-6736(95)90344-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7646639				2022-12-24	WOS:A1995QF72200012
J	GIRALT, S; ESCUDIER, S; KANTARJIAN, H; DEISSEROTH, A; FREIREICH, EJ; ANDERSSON, BS; OBRIEN, S; ANDREEFF, M; FISHER, H; CORK, A; HIRSCHGINSBERG, C; TRUJILLO, J; STASS, S; CHAMPLIN, RE				GIRALT, S; ESCUDIER, S; KANTARJIAN, H; DEISSEROTH, A; FREIREICH, EJ; ANDERSSON, BS; OBRIEN, S; ANDREEFF, M; FISHER, H; CORK, A; HIRSCHGINSBERG, C; TRUJILLO, J; STASS, S; CHAMPLIN, RE			PRELIMINARY-RESULTS OF TREATMENT WITH FILGRASTIM FOR RELAPSE OF LEUKEMIA AND MYELODYSPLASIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONY-STIMULATING FACTOR; TOTAL-BODY IRRADIATION; HEMATOLOGICAL MALIGNANCIES; HOST DISEASE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; METHOTREXATE; BUSULFAN; REGIMEN	Background. Patients whose leukemia relapses after allogeneic bone marrow transplantation have a poor prognosis; few respond to further chemotherapy, and almost none survive over the long term. We present preliminary observations on the use of filgrastim (granulocyte colony-stimulating factor) for relapse after transplantation. Methods. Seven female patients with leukemia (one with chronic myelogenous leukemia, five with acute myelogenous leukemia, and one with a myelodysplastic syndrome that transformed into.acute myelogenous leukemia) whose disease relapsed within 360 days after allogeneic bone marrow transplantation received filgrastim (5 mug per kilogram of body weight per day by subcutaneous injection) to reinduce remission by stimulating residual donor marrow cells. Cytogenetic analysis of bone marrow, fluorescence in situ hybridization, and determination of restriction-fragment-length polymorphisms were used to assess response and chimerism. Results. Three of the seven patients had a complete hematologic and cytogenetic remission, with reestablishment of hematopoiesis of donor origin. Mild chronic graft-versus-host disease developed in one patient, and acute graft-versus-host disease in none. One patient had a relapse 12 months after treatment, and two others remained in remission after 10 and 11 months. In two of the patients with a response, fluorescence in situ hybridization demonstrated stimulation of donor cells without differentiation of the leukemic clone. Conclusions. Filgrastim may be effective in selected cases of leukemic relapse after allogeneic bone marrow transplantation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT LAB MED,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center								ARCESE W, 1990, BONE MARROW TRANSPL, V5, P309; BOSTROM B, 1987, J CLIN ONCOL, V5, P376, DOI 10.1200/JCO.1987.5.3.376; FORMAN SJ, 1987, TRANSPLANT P, V19, P2605; FRASSONI F, 1988, BRIT J HAEMATOL, V70, P317, DOI 10.1111/j.1365-2141.1988.tb02488.x; GABRILOVE JL, 1989, HEMATOL ONCOL CLIN N, V3, P427, DOI 10.1016/S0889-8588(18)30539-2; GIRALT S, 1991, BLOOD S1, V78, pA503; HIGANO CS, 1990, TRANSPLANTATION, V50, P175; HOROWITZ MM, 1990, BLOOD, V75, P555; ISCN An international system for human cytogenetic nomen-clature, 1978, CYTOGENET CELL GENET, V21, P309; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; METCALF D, 1980, INT J CANCER, V25, P225, DOI 10.1002/ijc.2910250210; MORTIMER J, 1989, J CLIN ONCOL, V7, P50, DOI 10.1200/JCO.1989.7.1.50; Mortimer J, 1989, J CLIN ONCOL, V7, P5451; PETERSEN FB, 1989, BONE MARROW TRANSPL, V4, P617; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRZEPIORKA D, 1992, BLOOD S1, V80, pA337; Sambrook J., 1989, MOL CLONING LAB MANU; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRUJILLO JM, 1979, BLOOD, V53, P695; TUTSCHKA PJ, 1987, BLOOD, V70, P1382; VADHANRAJ S, 1987, NEW ENGL J MED, V317, P1545, DOI 10.1056/NEJM198712173172501; WAGNER JE, 1989, BONE MARROW TRANSPL, V4, P115; WELTE K, 1985, P NATL ACAD SCI USA, V82, P1526, DOI 10.1073/pnas.82.5.1526; YAU JC, 1990, BONE MARROW TRANSPL, V5, P269; YAU JC, 1992, AM J HEMATOL, V41, P40, DOI 10.1002/ajh.2830410108; 1989, BONE MARROW TRANSPL, V4, P221	26	100	101	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					757	761		10.1056/NEJM199309093291103	http://dx.doi.org/10.1056/NEJM199309093291103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	7688862				2022-12-24	WOS:A1993LV64200003
J	TAN, RY; CHEN, L; BUETTNER, JA; HUDSON, D; FRANKEL, AD				TAN, RY; CHEN, L; BUETTNER, JA; HUDSON, D; FRANKEL, AD			RNA RECOGNITION BY AN ISOLATED ALPHA-HELIX	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL NUCLEAR RIBONUCLEOPROTEIN; HIV-1 REV PROTEIN; TAT PROTEIN; CRYSTAL-STRUCTURE; BINDING DOMAIN; CIRCULAR-DICHROISM; DNA-BINDING; AMINO-ACIDS; SYNTHETASE	A 17 amino acid peptide containing the arginine-rich region of the HIV Rev protein binds specifically to Rev response element (RRE) RNA. Even though it is highly charged, the peptide forms an alpha helix in solution, but only when its N- and C-termini are modified to provide favorable electrostatic interactions with the helix macrodipole. Binding affinity for IIB RNA (the primary binding site within the RRE) increases with alpha helix content, whereas nonspecific binding affinity is independent of helix content. Binding of mutant peptides demonstrates that one threonine, one asparagine, and four arginine side chains are important for sequence-specific recognition. Transactivation of the HIV LTR using Tat-Rev peptide hybrids and the RRE IIB site indicates that the peptide adopts an alpha-helical conformation in vivo. The results suggest that interactions with the RNA backbone may help to orient the alpha helix in the major groove of RNA.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; ARRIS PHARMACEUT, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes	TAN, RY (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIAID NIH HHS [AI29135, AI08591] Funding Source: Medline; NIGMS NIH HHS [GM39589] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135, F32AI008591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039589] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BOHNLEIN E, 1991, J VIROL, V65, P7051; BUETTNER JA, 1993, IN PRESS PEPTIDES 19; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; Creighton T. E., 1993, PROTEINS STRUCTURES; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PUGLISI JD, 1993, IN PRESS P NATL ACAD, V90; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RIORDAN FA, 1992, J MOL BIOL, V226, P305, DOI 10.1016/0022-2836(92)90947-I; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TAN RY, 1992, BIOCHEMISTRY-US, V31, P10288, DOI 10.1021/bi00157a016; TAO JS, 1993, P NATL ACAD SCI USA, V90, P1571, DOI 10.1073/pnas.90.4.1571; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Turner DH, 1992, CURR OPIN STRUC BIOL, V2, P334; VANDERGRAAF M, 1992, BIOCHEMISTRY-US, V31, P9177, DOI 10.1021/bi00153a009; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	58	252	257	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					1031	1040		10.1016/0092-8674(93)90280-4	http://dx.doi.org/10.1016/0092-8674(93)90280-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	7684657				2022-12-24	WOS:A1993LF06100018
J	NEOTE, K; DIGREGORIO, D; MAK, JY; HORUK, R; SCHALL, TJ				NEOTE, K; DIGREGORIO, D; MAK, JY; HORUK, R; SCHALL, TJ			MOLECULAR-CLONING, FUNCTIONAL EXPRESSION, AND SIGNALING CHARACTERISTICS OF A C-C CHEMOKINE RECEPTOR	CELL			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACROPHAGE INFLAMMATORY PROTEIN; NEUTROPHIL CHEMOTACTIC FACTOR; HUMAN INTERLEUKIN-8 RECEPTOR; HUMAN BETA-HEXOSAMINIDASE; CELL-SURFACE RECEPTORS; CYTOKINE FAMILY; LYMPHOCYTES-T; IDENTIFICATION; BINDING	The immunoregulatory proteins C-C chemokines are potent chemoattractants of lymphocytes and monocytes, as well as activators and attractants of eosinophils and basophils. We have isolated a cDNA that encodes a seven transmembrane-spanning receptor, with homology to other chemoattractant receptors, that encodes a protein designated C-C CKR-1 that acts as a receptor for the C-C chemokines. Human and murine macrophage inflammatory protein 1alpha (MIP-1alpha), human macrophage inflammatory protein 1beta (MIP-1beta), human monocyte chemotactic protein 1 (MCP-1), and RANTES all bind to the C-C CKR-1 with varying affinities. Chemokine binding affinity does not predict how well the ligand will transmit a signal through the receptor: RANTES and human MIP-1alpha induce a similar intracellular calcium flux while binding with disparate affinities, while MCP-1 and human MIP-1beta induce calcium mobilization only at high concentrations. Finally, C-C chemokines were shown to bind a C-C CKR-1-related gene product encoded by cytomegalovirus, suggesting a role for C-C chemokines in viral immunity.			NEOTE, K (corresponding author), GENENTECH INC, DEPT IMMUNOL, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.							ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Bankier A T, 1991, DNA Seq, V2, P1, DOI 10.3109/10425179109008433; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BROWNE H, 1990, J VIROL, V64, P2181; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVATELIS G, 1989, SCIENCE, V243, P1066, DOI 10.1126/science.2646711; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUNLOP DJ, 1992, BLOOD, V79, P2221; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRAHAM GJ, 1992, DEV BIOL, V151, P377, DOI 10.1016/0012-1606(92)90177-I; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1987, J BIOL CHEM, V262, P16275; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; LARRICK JW, 1992, TRENDS BIOTECHNOL, V10, P146, DOI 10.1016/0167-7799(92)90202-7; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NACCACHE PH, 1989, J IMMUNOL, V142, P2438; NAPOLITANO M, 1990, J EXP MED, V172, P285, DOI 10.1084/jem.172.1.285; NEOTE K, 1990, J BIOL CHEM, V265, P20799; NEOTE K, 1990, J CLIN INVEST, V86, P1524, DOI 10.1172/JCI114871; NGUYEN T, 1991, GENE, V109, P211, DOI 10.1016/0378-1119(91)90611-E; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OH KO, 1991, J IMMUNOL, V147, P2978; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHILD HO, 1973, DRUG RECEPTORS, P29; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; VALENTE AJ, 1991, BIOCHEM BIOPH RES CO, V176, P309, DOI 10.1016/0006-291X(91)90925-W; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1990, J IMMUNOL, V145, P292	61	744	885	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					415	425		10.1016/0092-8674(93)90118-A	http://dx.doi.org/10.1016/0092-8674(93)90118-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	7679328				2022-12-24	WOS:A1993KM16200011
J	KUBESCH, P; DORK, T; WULBRAND, U; KALIN, N; NEUMANN, T; WULF, B; GEERLINGS, H; WEISSBRODT, H; VONDERHARDT, H; TUMMLER, B				KUBESCH, P; DORK, T; WULBRAND, U; KALIN, N; NEUMANN, T; WULF, B; GEERLINGS, H; WEISSBRODT, H; VONDERHARDT, H; TUMMLER, B			GENETIC-DETERMINANTS OF AIRWAYS COLONIZATION WITH PSEUDOMONAS-AERUGINOSA IN CYSTIC-FIBROSIS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; DELTA-F508 MUTATION; DNA; IDENTIFICATION; PATHOGENESIS; DISEASE	Exocrine pancreatic insufficiency and lung infection with Pseudomonas aeruginosa are major features of cystic fibrosis (CF). This monogenic disease is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. 267 children and adolescents with CF who were regularly seen at the same centre were assessed for an association of the CFTR mutation genotype with exocrine pancreatic function and the age of onset of chronic colonisation with P aeruginosa. The major mutation DELTAF508 accounted for 74% of CF alleles; 33 further CFTR mutations had been detected on the CF chromosomes of the study population by June, 1992. With the exception of DELTAF508/R347P compound heterozygotes, patients of the same mutation genotype were either pancreas insufficient (PI) or pancreas sufficient (PS). The age-specific colonisation rates with P aeruginosa were significantly lower in PS than in PI patients. The missense and splice site mutations that are ''mild'' CF alleles with respect to exocrine pancreatic function were also ''low risk'' alleles for the acquisition of P aeruginosa. On the other hand, the proportion of P aeruginosa-positive patients increased most rapidly in the PI DELTAF508 compound heterozygotes who were carrying a termination mutation in the nucleotide binding fold-encoding exons. Pancreatic status and the risk of chronic airways' colonisation with P aeruginosa are predisposed by the CFTR mutation genotype and can be differentiated by the type and location of the mutations in the CFTR gene.	HANNOVER MED SCH, DEPT BIOPHYS CHEM,BIOPHYS CHEM ABT, ZENTRUM BIOCHEM 2,KONSTANTY GUTSCHOW STR 8, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT PAEDIAT RESP DIS, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT BIOMETRY, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT MED MICROBIOL, W-3000 HANNOVER 61, GERMANY	Hannover Medical School; Hannover Medical School; Hannover Medical School; Hannover Medical School			Dörk, Thilo/J-8620-2012	Dörk, Thilo/0000-0002-9458-0282				BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650, DOI 10.1164/ajrccm/140.6.1650; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREMER S, 1992, EUR J BIOCHEM, V206, P137, DOI 10.1111/j.1432-1033.1992.tb16911.x; CLAUSTRES M, 1992, GENOMICS, V13, P907, DOI 10.1016/0888-7543(92)90187-W; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DORK T, 1992, HUM GENET, V88, P417, DOI 10.1007/BF00215676; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; GEOKAS MC, 1979, AM J PHYSIOL, V236, pE77, DOI 10.1152/ajpendo.1979.236.1.E77; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HOIBY N, 1989, ACTA PAEDIATR SCAND, V78, P395, DOI 10.1111/j.1651-2227.1989.tb11099.x; HOIBY N, 1986, ANNU REV MICROBIOL, V40, P29, DOI 10.1146/annurev.mi.40.100186.000333; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS J, 1990, AM J HUM GENET, V46, P395; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; Suter S, 1989, Antibiot Chemother (1971), V42, P158; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; Tsui L C, 1991, Adv Hum Genet, V20, P153; TUMMLER B, 1991, J CLIN MICROBIOL, V29, P1265; VANDEKAMER JH, 1949, J BIOL CHEM, V177, P347; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	31	83	83	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1993	341	8839					189	193		10.1016/0140-6736(93)90062-L	http://dx.doi.org/10.1016/0140-6736(93)90062-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	7678316				2022-12-24	WOS:A1993KJ21900001
J	TOWNSEND, SE; ALLISON, JP				TOWNSEND, SE; ALLISON, JP			TUMOR REJECTION AFTER DIRECT COSTIMULATION OF CD8+ T-CELLS BY B7-TRANSFECTED MELANOMA-CELLS	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-I; ACTIVATION ANTIGEN-B7; INTERLEUKIN-2; GENERATION; PROLIFERATION; RECOGNITION; EXPRESSION; RESPONSES; PEPTIDES	A variety of tumors are potentially immunogenic but do not stimulate an effective anti-tumor immune response in vivo. Tumors may be capable of delivering antigen-specific signals to T cells, but may not deliver the costimulatory signals necessary for full activation of T cells. Expression of the costimulatory ligand B7 on melanoma cells was found to induce the rejection of a murine melanoma in vivo. This rejection was mediated by CD8+ T cells; CD4+ T cells were not required. These results suggest that B7 expression renders tumor cells capable of effective antigen presentation, leading to their eradication in vivo.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				Allison, James/0000-0001-8980-5697	NCI NIH HHS [CA57986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTH RJ, 1990, J IMMUNOL, V144, P1531; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CANTOR H, 1975, J EXP MED, V141, P1390, DOI 10.1084/jem.141.6.1390; DONAWHO C, 1990, CANCER COMMUN, V2, P101, DOI 10.3727/095535490820874597; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GREENBERG PD, 1981, J IMMUNOL, V126, P2100; GROSS JA, 1992, J IMMUNOL, V149, P380; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARDING FR, UNPUB; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1991, J IMMUNOL, V147, P2461; KAHN M, 1991, J IMMUNOL, V146, P3235; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; LARSEN CP, 1992, J EXP MED, V176, P1215, DOI 10.1084/jem.176.4.1215; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MIZUOCHI T, 1986, J EXP MED, V163, P603, DOI 10.1084/jem.163.3.603; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; RESTIFO NP, 1992, J EXP MED, V175, P1423, DOI 10.1084/jem.175.6.1423; SCHREIBER H, 1988, ANNU REV IMMUNOL, V6, P465; SPRENT J, 1985, J EXP MED, V162, P2068, DOI 10.1084/jem.162.6.2068; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VONBOEHMER H, 1984, J IMMUNOL, V133, P59; VONBOEHMER H, 1983, EUR J IMMUNOL, V13, P176, DOI 10.1002/eji.1830130216; WAGNER H, 1978, J EXP MED, V148, P1523, DOI 10.1084/jem.148.6.1523	36	1179	1288	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					368	370		10.1126/science.7678351	http://dx.doi.org/10.1126/science.7678351			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	7678351				2022-12-24	WOS:A1993KG62400034
J	CHI, TH; LIEBERMAN, P; ELLWOOD, K; CAREY, M				CHI, TH; LIEBERMAN, P; ELLWOOD, K; CAREY, M			A GENERAL MECHANISM FOR TRANSCRIPTIONAL SYNERGY BY EUKARYOTIC ACTIVATORS	NATURE			English	Article							EPSTEIN-BARR-VIRUS; RNA POLYMERASE-II; PREINITIATION COMPLEX; GAL4 DERIVATIVES; DNA-BINDING; PROMOTER; DOMAINS; ZEBRA; INITIATION; INTERACTS	One of the important regulatory concepts to emerge from studies of eukaryotic gene expression is that RNA polymerase II promoters and their upstream activators are composed of functional modules whose synergistic action regulates the transcriptional activity of a nearby gene(1-3). Biochemical analysis of synergy by ZEBRA, a non-acidic activator of the Epstein-Barr virus (EBV) lytic cycle(4), showed that the synergistic transcriptional effect of promoter sites and activation modules correlates with assembly of the TFIID:TFIIA (DA) complex in DNase I footprinting and gel shift assays, The activator-dependent DA complex differs from a basal DA complex by its ability to bind TFIIB stably in an interaction regulated by TATA-binding protein-associated factors (TAFs), TFIIB enhances the degree of synergism by increasing complex stability. Similar findings were made with the acidic activator GAL4-VP16. Our data suggest a unifying mechanism for gene activation and synergy by acidic and non-acidic activators, and indicate that synergy is manifested at the earliest stage of preinitiation complex assembly.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; ROCHE INST MOLEC BIOL,DEPT GENE EXPRESS,NUTLEY,NJ 07110	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Carey, Michael/0000-0003-3899-6280				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MILLER G, 1993, J VIROL, V67, P7472, DOI 10.1128/JVI.67.12.7472-7481.1993; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDYKE MW, 1990, MOL CELL BIOL, V10, P3415, DOI 10.1128/MCB.10.7.3415; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	29	175	180	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					254	257		10.1038/377254a0	http://dx.doi.org/10.1038/377254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675113				2022-12-24	WOS:A1995RV87200047
J	HUNTER, CP; KENYON, C				HUNTER, CP; KENYON, C			SPECIFICATION OF ANTEROPOSTERIOR CELL FATES IN CAENORHABDITIS-ELEGANS BY DROSOPHILA HOX PROTEINS	NATURE			English	Article							C-ELEGANS; FUNCTIONAL SPECIFICITY; BODY REGION; GENE; HOMEODOMAIN; NEMATODE; EMBRYOS; LARVAE	ANTENNAPEDIA class homeobox (Hox) genes specify cell fates in successive anteroposterior body domains in vertebrates, insects and nematodes(1-3). The DNA-binding homeodomain sequences are very similar between vertebrate and Drosophila Hox proteins, and this similarity allows vertebrate Hox proteins to function in Drosophila(4-7). In contrast, the Caenorhabditis elegans homeodomains are substantially divertent(8). Further, C. elegans differs from both insects and vertebrates in having a non-segmented body as well as a distinctive mode of development that involves asymmetric early cleavages and invariant cell lineages. Here we report that, despite these differences, Drosophila Hox proteins expressed in C. elegans can substitute for C. elegans Hox proteins in the control of three different cell-fate decisions: the regulation of cell migration, the specification of serotonergic neurons, and the specification of a sensory structure. We also show that the specificity of one C. elegans Hox protein is partly determined by two amino acids that have been implicated in sequence-specific DNA binding. Together these findings suggest that factors important for target recognition by specific Hox proteins have been conserved throughout much of the animal kingdom.			HUNTER, CP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MALICKI J, 1993, MECH DEVELOP, V42, P139, DOI 10.1016/0925-4773(93)90003-G; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLO CC, 1991, EMBO J, V12, P3959; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SALSER SJ, 1994, TRENDS GENET, V10, P159, DOI 10.1016/0168-9525(94)90092-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; ZENG WL, 1993, DEVELOPMENT, V118, P339; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	23	40	43	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					229	232		10.1038/377229a0	http://dx.doi.org/10.1038/377229a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675107				2022-12-24	WOS:A1995RV87200039
J	DECOCK, KM; WILKINSON, D				DECOCK, KM; WILKINSON, D			TUBERCULOSIS-CONTROL IN RESOURCE-POOR COUNTRIES - ALTERNATIVE APPROACHES IN THE ERA OF HIV	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY; CHEMOTHERAPY; INFECTION; THERAPY; AFRICA		CTR EPIDEMIOL RES S AFRICA,HLABISA 3937,SOUTH AFRICA; HLABISA HOSP,HLABISA 3937,SOUTH AFRICA		DECOCK, KM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Wilkinson, David/A-6207-2008	Wilkinson, David/0000-0002-7265-9846				ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; CROFTON J, 1992, CLIN TUBERCULOSIS; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; ENARSON DA, 1994, TUBERCULOSIS GUIDE L; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; KUMARESAN JA, 1992, BRIT MED J, V305, P340, DOI 10.1136/bmj.305.6849.340; NUNN P, 1991, LANCET, V377, P627; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; POZNIAK AL, 1992, AIDS, V6, P809, DOI 10.1097/00002030-199208000-00007; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; 1995, MMWR-MORBID MORTAL W, V44, P387; 1993, TREATMENT TUBERCULOS; 1995, WHOTB95183 REP; 1993, INVESTING HLTH; 1994, AM J RESP CRIT CARE, V149, P1359; 1992, MMWR-MORBID MORTAL W, V41, P1	28	62	62	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					675	677		10.1016/S0140-6736(95)92284-9	http://dx.doi.org/10.1016/S0140-6736(95)92284-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658822				2022-12-24	WOS:A1995RU04800013
J	ZHANG, YH; EMMONS, SW				ZHANG, YH; EMMONS, SW			SPECIFICATION OF SENSE-ORGAN IDENTITY BY A CAENORHABDITIS-ELEGANS PAX-6 HOMOLOG	NATURE			English	Article							C-ELEGANS; NEMATODE; GENE; EXPRESSION; SEQUENCE; PATTERN; MUTANTS; VECTORS; CELL	The Pax-6 transcription-factor gene, containing a paired domain and a paired-type homeodomain, is conserved in structure and ubiquitously present among Metazoa(1-5). It is required for development of the central nervous system, and is mutated in human aniridia, mouse and rat small eye and Drosophila eyeless(6). We identified the Pax-6 gene of the nematode Caenorhabditis elegans in genetic studies of male tail morphology(7,8). C. elegans Pax-6 encodes at least two independent genetic functions. One, like other Pax-6 genes, contains paired and homeodomains; this constitutes the genetic locus vab-3 (ref. 9). The other, described here, is expressed from an internal promoter and contains only the homeodomain portion; this constitutes the genetic locus mab-18 (ref. 7), The mab-18 form of the gene is expressed in a peripheral sense organ and is necessary for specification of sense-organ identity. Its function in this context could be to regulate the expression of cell recognition and adhesion proteins required for sense-organ assembly.			ZHANG, YH (corresponding author), ALBERT EINSTEIN COLL MED, DEPT MOLEC GENET, 1300 MORRIS PK AVE, NEW YORK, NY 10461 USA.			Zhang, Yinhua/0000-0003-0592-9153				BAIRD SE, 1991, DEVELOPMENT, V113, P515; BURR AH, 1985, PHOTOCHEM PHOTOBIOL, V41, P577, DOI 10.1111/j.1751-1097.1985.tb03529.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAMBERLIN HM, 1995, DEV BIOL, V170, P679, DOI 10.1006/dbio.1995.1246; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CHOW KL, 1994, DEVELOPMENT, V120, P2579; CHOW KL, IN PRESS DEVELOPMENT; CLARK SG, 1994, GENETICS, V137, P987; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HEDGECOCK EM, 1985, TRENDS NEUROSCI, V8, P288, DOI 10.1016/0166-2236(85)90104-3; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WALTHER C, 1991, DEVELOPMENT, V113, P1435	24	125	127	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					55	59		10.1038/377055a0	http://dx.doi.org/10.1038/377055a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659160				2022-12-24	WOS:A1995RT72500054
J	WOLFEL, T; HAUER, M; SCHNEIDER, J; SERRANO, M; WOLFEL, C; KLEHMANNHIEB, E; DEPLAEN, E; HANKELN, T; ZUMBUSCHENFELDE, KHM; BEACH, D				WOLFEL, T; HAUER, M; SCHNEIDER, J; SERRANO, M; WOLFEL, C; KLEHMANNHIEB, E; DEPLAEN, E; HANKELN, T; ZUMBUSCHENFELDE, KHM; BEACH, D			A P16(INK4A)-INSENSITIVE CDK4 MUTANT TARGETED BY CYTOLYTIC T-LYMPHOCYTES IN A HUMAN-MELANOMA	SCIENCE			English	Article							MALIGNANT-MELANOMA; PEPTIDE; CELLS; ANTIGENS; GENE; IDENTIFICATION; INHIBITION; MOLECULES; SUBUNIT; BINDING	A mutated cyclin-dependent kinase 4 (CDK4) was identified as a tumor-specific antigen recognized by HL4-A2.1-restricted autologous cytolytic T lymphocytes (CTLs) in a human melanoma. The mutated CDK4 allele was present in autologous cultured melanoma cells and metastasis tissue, but not in the patient's lymphocytes. The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16(INK4a), but not of p21 or of p27(KIP1). The same mutation was found in one additional melanoma among 28 melanomas analyzed. These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16(INK4a).	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; CATHOLIC UNIV LEUVEN,LUDWIG INST CANC RES,B-1200 BRUSSELS,BELGIUM; UNIV MAINZ,INST MOLEK GENET,D-55099 MAINZ,GERMANY	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; KU Leuven; Ludwig Institute for Cancer Research; Johannes Gutenberg University of Mainz	WOLFEL, T (corresponding author), UNIV MAINZ,MED KLIN & POLIKLIN 1,LANGENBECKSTR 1,D-55101 MAINZ,GERMANY.		Serrano, Manuel/H-2634-2015; Wölfel, Thomas/G-6519-2012	Serrano, Manuel/0000-0001-7177-9312; 				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; DEBERGEYCK V, 1994, EUR J IMMUNOL, V24, P2203, DOI 10.1002/eji.1830240941; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNUTH A, 1984, P NATL ACAD SCI-BIOL, V81, P3511, DOI 10.1073/pnas.81.11.3511; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIVINGSTON PO, 1979, INT J CANCER, V24, P34, DOI 10.1002/ijc.2910240107; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI T, 1994, CANCER RES, V54, P3396; NIJMAN HW, 1993, EUR J IMMUNOL, V23, P1215, DOI 10.1002/eji.1830230603; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PREHN RT, 1957, J NATL CANCER I, V18, P769; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SRIVASTAVA PK, 1987, P NATL ACAD SCI USA, V84, P3807, DOI 10.1073/pnas.84.11.3807; SZIKORA JP, 1993, IMMUNOGENETICS, V37, P135, DOI 10.1007/BF00216837; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VOLKENANDT M, 1991, J CUTAN PATHOL, V18, P210, DOI 10.1111/j.1600-0560.1991.tb00155.x; WARD PL, 1989, J EXP MED, V170, P217, DOI 10.1084/jem.170.1.217; WOLFEL T, 1993, INT J CANCER, V55, P237, DOI 10.1002/ijc.2910550212; WOLFEL T, 1994, EUR J IMMUNOL, V24, P759, DOI 10.1002/eji.1830240340; XIONG Y, 1993, CELL, V75, P817	50	866	918	1	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1281	1284		10.1126/science.7652577	http://dx.doi.org/10.1126/science.7652577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652577				2022-12-24	WOS:A1995RR84200039
J	BECHARA, A; TRANEL, D; DAMASIO, H; ADOLPHS, R; ROCKLAND, C; DAMASIO, AR				BECHARA, A; TRANEL, D; DAMASIO, H; ADOLPHS, R; ROCKLAND, C; DAMASIO, AR			DOUBLE DISSOCIATION OF CONDITIONING AND DECLARATIVE KNOWLEDGE RELATIVE TO THE AMYGDALA AND HIPPOCAMPUS IN HUMANS	SCIENCE			English	Article							MEMORY; FEAR; AMNESIA; SYSTEMS; DAMAGE	A patient with selective bilateral damage to the amygdala did not acquire conditioned autonomic responses to visual or auditory stimuli but did acquire the declarative facts about which visual or auditory stimuli were paired with the unconditioned stimulus. By contrast, a patient with selective bilateral damage to the hippocampus failed to acquire the facts but did acquire the conditioning. Finally, a patient with bilateral damage to both amygdala and hippocampal formation acquired neither the conditioning nor the facts. These findings demonstrate a double dissociation of conditioning and declarative knowledge relative to the human amygdala and hippocampus.	UNIV IOWA, COLL MED, DEPT NEUROL, DIV BEHAV NEUROL & COGNIT NEUROSCI, IOWA CITY, IA 52242 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA; MIT, INFORMAT & DECIS SYST LAB, CAMBRIDGE, MA 02139 USA	University of Iowa; Salk Institute; Massachusetts Institute of Technology (MIT)			Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS019632] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS19632] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; ADOLPHS R, IN PRESS J NEUROSCI; Amaral D. G., 1987, HDB PHYSL NERVOUS SY, P211; [Anonymous], 1987, HDB PHYSL 1 NERVOUS; BERGER TW, 1983, BEHAV BRAIN RES, V8, P49, DOI 10.1016/0166-4328(83)90171-7; Damasio A. R., 1994, DESCARTES ERROR EMOT; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEBAR KS, IN PRESS J NEUROSCI; LEBAR KS, 1994, SOC NEUR ABSTR, V20, P360; LEDOUX JE, 1994, SCI AM, V270, P50, DOI 10.1038/scientificamerican0694-50; LEE GP, 1988, NEUROPSY NEUROPSY BE, V1, P119; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MISHKIN M, 1994, CURR OPIN NEUROBIOL, V4, P200, DOI 10.1016/0959-4388(94)90073-6; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; TRANEL D, 1994, PSYCHOPHYSIOLOGY, V31, P427, DOI 10.1111/j.1469-8986.1994.tb01046.x; TRANEL D, 1989, NEUROPSYCHOLOGIA, V27, P381, DOI 10.1016/0028-3932(89)90046-8; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; VANHOESEN GW, 1985, ANN NY ACAD SCI, V444, P97; Wechsler D., 1987, WMS R WECHSLER MEMOR; Wechsler D., 1991, WECHSLER ADULT INTEL; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	27	905	921	0	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1115	1118		10.1126/science.7652558	http://dx.doi.org/10.1126/science.7652558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RQ748	7652558				2022-12-24	WOS:A1995RQ74800048
J	HENNING, KA; LI, L; IYER, N; MCDANIEL, LD; REAGAN, MS; LEGERSKI, R; SCHULTZ, RA; STEFANINI, M; LEHMANN, AR; MAYNE, LV; FRIEDBERG, EC				HENNING, KA; LI, L; IYER, N; MCDANIEL, LD; REAGAN, MS; LEGERSKI, R; SCHULTZ, RA; STEFANINI, M; LEHMANN, AR; MAYNE, LV; FRIEDBERG, EC			THE COCKAYNE-SYNDROME GROUP-A GENE ENCODES A WD REPEAT PROTEIN THAT INTERACTS WITH CSB PROTEIN AND A SUBUNIT OF RNA-POLYMERASE-II TFIIH	CELL			English	Article							DNA-REPAIR; XERODERMA-PIGMENTOSUM; INCREASED SENSITIVITY; CELLULAR-SENSITIVITY; ULTRAVIOLET-LIGHT; UV IRRADIATION; CELLS; FIBROBLASTS; TRANSFORMATION; TRANSCRIPTION	The hereditary disease Cockayne syndrome (CS) is characterized by a complex clinical phenotype, CS cells are abnormally sensitive to ultraviolet radiation and are defective in the repair of transcriptionally active genes, The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/Snf, We report the cloning of the CSA cDNA, which can encode a WD repeat protein, Mutations in the cDNA have been identified in CS-A cell lines, CSA protein. interacts with CSB protein and with p44 protein, a subunit of the human RNA polymerase II transcription factor IIH. These observations suggest that the products of the CSA and CSB genes are involved in transcription.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; INST GENET BIOCHEM & EVOLUTIONIST,I-27100 PAVIA,ITALY; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND; UNIV SUSSEX,TRAFFORD CTR MED RES,BRIGHTON BN1 9RY,E SUSSEX,ENGLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Sussex; University of Brighton; University of Sussex					NATIONAL CANCER INSTITUTE [R01CA052461, P30CA016672, R01CA044247] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44247, CA-52461, CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; BRUMBACK RA, 1978, ARCH NEUROL-CHICAGO, V35, P337, DOI 10.1001/archneur.1978.00500300011002; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FRIEDBERG EC, 1994, MUTAT RES, V307, P5, DOI 10.1016/0027-5107(94)90272-0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P655; HOAR DI, 1978, AM J HUM GENET, V30, P590; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KENNEDY RM, 1980, NEUROLOGY, V30, P1268, DOI 10.1212/WNL.30.12.1268; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEHMANN AR, 1979, CANCER RES, V39, P4237; LEHMANN AR, 1993, J MED GENET, V30, P679, DOI 10.1136/jmg.30.8.679; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LEHMANN AR, 1994, MUTAT RES, V315, P41, DOI 10.1016/0921-8777(94)90026-4; MARSHALL RR, 1980, MUTAT RES, V69, P107, DOI 10.1016/0027-5107(80)90180-3; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MAYNE LV, 1982, CANCER RES, V42, P1473; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MULLENDERS LHF, 1992, DNA REPAIR MECHANISM, P247; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OTSUKA F, 1984, J INVEST DERMATOL, V82, P480, DOI 10.1111/1523-1747.ep12260999; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHMICKEL RD, 1977, PEDIATRICS, V60, P135; SCHWEIGER M, 1987, EUR J BIOCHEM, V165, P235, DOI 10.1111/j.1432-1033.1987.tb11433.x; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; SUGITA K, 1987, PEDIATR RES, V21, P34, DOI 10.1203/00006450-198701000-00009; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Swirski Richard A., 1992, Methods (Orlando), V4, P133, DOI 10.1016/1046-2023(92)90045-A; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4704; VERMEULEN W, 1995, COLD SPRING HARB SYM, V59, P317; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5	50	383	392	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					555	564		10.1016/0092-8674(95)90028-4	http://dx.doi.org/10.1016/0092-8674(95)90028-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664335	Bronze			2022-12-24	WOS:A1995RR73400007
J	GEDDES, JR; JUSZCZAK, E				GEDDES, JR; JUSZCZAK, E			PERIOD TRENDS IN RATE OF SUICIDE IN FIRST 28 DAYS AFTER-DISCHARGE FROM PSYCHIATRIC-HOSPITAL IN SCOTLAND, 1968-92	BRITISH MEDICAL JOURNAL			English	Article							AFTER-DISCHARGE; INPATIENT CARE; PREVENTION; RISK	Objective-To examine period trends in the rate of suicide in the first 28 days after discharge from psychiatric hospital. Design-Cohort study of patients discharged from psychiatric hospital. Setting-Scotland. Subjects-Ah patients aged 15-84 who were discharged from Scottish psychiatric hospitals during 1968 to 1992. Outcome measure-The rate of suicide (classified as codes E950-9 and E980-9 according to the International Classification of Diseases, Ninth Revision) within 28 days of discharge per 100 000 person years at risk for five year periods during 1968 to 1992. Crude, within cohort rates and externally standardised rates were calculated. Results-Overall, 196 male patients committed suicide in 20 520 person years at risk, and 171 female patients committed suicide in 24 114 person years at risk. A significant Linear trend was seen in period effect on externally standardised mortality ratios in both sexes: a decrease in male patients (P=0.008) and an increase in female patients (P=0.0001). The adjusted standardised mortality ratio in 1988-92 compared with 1968-72 was 0.62 (95% confidence interval 0.39 to 0.98) in male patients and 2.73 (1.64 to 4.56) in female patients. Conclusion-The increase in the rate of suicide in the 28 days after discharge in female psychiatric patients makes this an increasingly important period to target. The rise has occurred against the background of a reduction of 60% in the number of psychiatric beds for adults.	ROYAL EDINBURGH & ASSOCIATED HOSP,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND; NATL HLTH SERV SCOTLAND,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; NHS National Services Scotland				Geddes, John/0000-0002-5281-5960				ALLEBECK P, 1987, ACTA PSYCHIAT SCAND, V76, P414, DOI 10.1111/j.1600-0447.1987.tb05626.x; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; BAKER RJ, 1978, GLIM SYSTEM; Breslow N. E., 1987, STATISTICAL METHODS, VII; Charlton J., 1992, Population Trends, P10; Clayton DHM, 1993, STATISTICAL METHODS; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P1347; DIEKSTRA RFW, 1993, ACTA PSYCHIATR SCA S, V371, P9; ENGBERG M, 1994, ACTA PSYCHIAT SCAND, V89, P35, DOI 10.1111/j.1600-0447.1994.tb01482.x; FLOOD RA, 1968, BRIT J PSYCHIAT, V114, P443, DOI 10.1192/bjp.114.509.443; FULLEN I, 1993, BRIT MED J, V306, P710; GEDDES JR, 1994, BRIT J PSYCHIAT, V164, P564, DOI 10.1192/S0007125000051989; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; ISOMETSA E, 1993, LANCET, V342, P1055, DOI 10.1016/0140-6736(93)92913-E; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; KING E, 1994, BRIT J PSYCHIAT, V165, P658, DOI 10.1192/bjp.165.5.658; KING EA, 1993, LANCET, V342, P744; KREITMAN N, 1994, HLTH B EDINB, V52, P300; MCGONIGAL G, 1992, Health Bulletin (Edinburgh), V50, P309; MORGAN HG, 1992, BRIT J PSYCHIAT, V160, P149, DOI 10.1192/bjp.160.2.149; VASSILAS CA, 1993, BRIT MED J, V307, P300, DOI 10.1136/bmj.307.6899.300; 1978, MENTAL DISORDERS GLO; 1986, MAKING REALITY COMMU; 1992, HLTH NATION STRATEGY; 1991, EGRET EPIDEMIOLOGICA	26	50	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					357	360		10.1136/bmj.311.7001.357	http://dx.doi.org/10.1136/bmj.311.7001.357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640540	Green Published			2022-12-24	WOS:A1995RN46900014
J	SHAMOO, Y; FRIEDMAN, AM; PARSONS, MR; KONIGSBERG, WH; STEITZ, TA				SHAMOO, Y; FRIEDMAN, AM; PARSONS, MR; KONIGSBERG, WH; STEITZ, TA			CRYSTAL-STRUCTURE OF A REPLICATION FORK SINGLE-STRANDED-DNA BINDING-PROTEIN (T4 GP32) COMPLEXED TO DNA	NATURE			English	Article							GENE 32 PROTEIN; H-1-NMR 500 MHZ; ESCHERICHIA-COLI; BACTERIOPHAGE-T4; SITE; IDENTIFICATION; MUTAGENESIS; RESIDUES	THE single-stranded DNA (ssDNA) binding protein gp32 from bacteriophage T4 is essential for T4 DNA replication, recombination and repair. In vivo gp32 binds ssDNA as the replication fork advances and stimulates repulsion processivity and accuracy by a factor of several hundred(1). Gp32 binding affects nearly every major aspect of DNA metabolism. Among its important functions are: (1) configuring ssDNA templates for efficient use by the replisome including DNA polymerase; (2) melting out adventitious secondary structures; (3) protecting exposed ssDNA from nucleases; and (4) facilitating homologous recombination by binding ssDNA during strand displacement. We have determined the crystal structure of the gp32 DNA binding domain complexed to ssDNA at 2.2 Angstrom resolution. The ssDNA binding cleft comprises regions from three structural subdomains and includes a positively charged surface that runs parallel to a series of hydrophobic pockets formed bg clusters of aromatic side chains. Although only weak electron density is seen for the ssDNA, it indicates that the phosphate backbone contacts an electropositive cleft of the protein, placing the bases in contact with the hydrophobic pockets. The DNA mobility implied by the weak electron density may reflect the role of gp32 as a sequence-independent ssDNA chaperone allowing the largely unstructured ssDNA to slide freely through the cleft.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University	SHAMOO, Y (corresponding author), YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA.		Friedman, Alan M/J-2696-2012; Steitz, Thomas A./C-6559-2009	Shamoo, Yousif/0000-0001-9241-8962				ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, X PLOR VERSION 2 2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; DELIUS H, 1972, J MOL BIOL, V67, P341, DOI 10.1016/0022-2836(72)90454-8; GIEDROC DP, 1987, BIOCHEMISTRY-US, V26, P5251, DOI 10.1021/bi00391a007; GIEDROC DP, 1989, BIOCHEMISTRY-US, V28, P2410, DOI 10.1021/bi00432a011; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KHAMIS MI, 1986, BIOCHEMISTRY-US, V25, P5865, DOI 10.1021/bi00368a005; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P50; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAN T, 1989, BIOCHEMISTRY-US, V28, P8833, DOI 10.1021/bi00448a023; PRIGODICH RV, 1984, BIOCHEMISTRY-US, V23, P522, DOI 10.1021/bi00298a019; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; SHAMOO Y, 1988, PROTEINS, V4, P1, DOI 10.1002/prot.340040103; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; SPICER EK, 1979, J BIOL CHEM, V254, P6433; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VANAMERONGEN H, 1990, BIOCHEMISTRY-US, V29, P5619, DOI 10.1021/bi00475a029; YANG W, 1990, J BIOL CHEM, V265, P13553; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	29	222	231	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 27	1995	376	6538					362	366		10.1038/376362a0	http://dx.doi.org/10.1038/376362a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630406				2022-12-24	WOS:A1995RL44300053
J	KOBAYASHI, S; AMIKURA, R; OKADA, M				KOBAYASHI, S; AMIKURA, R; OKADA, M			PRESENCE OF MITOCHONDRIAL LARGE RIBOSOMAL-RNA OUTSIDE MITOCHONDRIA IN GERM PLASM OF DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							MATERNAL-EFFECT MUTATIONS; INSITU HYBRIDIZATION; POLAR GRANULES; EMBRYOS; GENE; CELLS; SEGMENTATION; LOCALIZATION; PATTERN; NANOS	Mitochondrial large ribosomal RNA (mtlrRNA) has been identified as a cytoplasmic factor that induces pole cell formation in embryos whose ability to form a germ line has been abolished by treatment with ultraviolet light. In situ hybridization analyses reveal that mtlrRNA is enriched in germ plasm and is tightly associated with polar granules, the distinctive organelles of germ plasm, which supports the idea that mtlrRNA functions in pole cell formation. This suggests that a product from the mitochondrial genome, along with nuclear products, participates in a key event in embryonic development: determination of the germ line.			KOBAYASHI, S (corresponding author), UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN.							BINDER M, 1986, J CELL BIOL, V102, P1646, DOI 10.1083/jcb.102.5.1646; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; CLARY DO, 1985, NUCLEIC ACIDS RES, V13, P4029, DOI 10.1093/nar/13.11.4029; DING DF, COMMUNICATION; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; HAY B, 1988, DEVELOPMENT, V103, P625; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KOBAYASHI S, 1990, NUCLEIC ACIDS RES, V18, P4592, DOI 10.1093/nar/18.15.4592; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; KOBAYASHI S, UNPUB; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1992, SCIENCE, V255, P1216, DOI 10.1126/science.1372132; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; OKADA M, 1974, DEV BIOL, V37, P43, DOI 10.1016/0012-1606(74)90168-7; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; UNDERWOOD EM, 1980, DEV BIOL, V77, P303, DOI 10.1016/0012-1606(80)90476-5; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	24	135	138	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1521	1524		10.1126/science.7684857	http://dx.doi.org/10.1126/science.7684857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	7684857				2022-12-24	WOS:A1993LF05800042
J	NAKANE, H; TAKEUCHI, S; YUBA, S; SAIJO, M; NAKATSU, Y; MURAI, H; NAKATSURU, Y; ISHIKAWA, T; HIROTA, S; KITAMURA, Y; KATO, Y; TSUNODA, Y; MIYAUCHI, H; HORIO, T; TOKUNAGA, T; MATSUNAGA, T; NIKAIDO, O; NISHIMUNE, Y; OKADA, Y; TANAKA, K				NAKANE, H; TAKEUCHI, S; YUBA, S; SAIJO, M; NAKATSU, Y; MURAI, H; NAKATSURU, Y; ISHIKAWA, T; HIROTA, S; KITAMURA, Y; KATO, Y; TSUNODA, Y; MIYAUCHI, H; HORIO, T; TOKUNAGA, T; MATSUNAGA, T; NIKAIDO, O; NISHIMUNE, Y; OKADA, Y; TANAKA, K			HIGH-INCIDENCE OF ULTRAVIOLET-B-INDUCED OR CHEMICAL-CARCINOGEN-INDUCED SKIN TUMORS IN MICE LACKING THE XERODERMA-PIGMENTOSUM GROUP-A GENE	NATURE			English	Article							REPAIR GENE; DAMAGED DNA; PROTEIN; BINDING; CELLS	XERODERMA pigmentosum (XP) is an autosomal recessive disorder characterized by a high frequency of skin cancer on sun-exposed areas, and neurological complications, XP has a defect in the early step(s) of nucleotide-excision repair (NER) and consists of eight different genetic complementation groups (groups A-G and a variant)(1). We established XPA (group-A XP) gene-deficient mice by gene targeting of mouse embryonic stem (ES) cells. The XPA-deficient mice showed neither obvious physical abnormalities nor pathological alterations, but were defective in NER and highly susceptible to ultraviolet-B- or 9,10-dimethyl-1,2-benz[a]anthracene-induced skin carcinogenesis. These findings provide is vivo evidence that the XPA protein protects mice from carcinogenesis initiated by ultraviolet or chemical carcinogen, The XPA-deficient mice may provide a good in vivo model to study the high incidence of skin carcinogenesis in group A XP patients.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC MED,DEPT PATHOL,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,OSAKA 565,JAPAN; KINKI UNIV,COLL AGR,ANIM REPROD LAB,NARA 631,JAPAN; KANSAI MED UNIV,DEPT DERMATOL,OSAKA 570,JAPAN; NATL INST ANIM IND,REPROD BIOCHEM LAB,TSUKUBA,IBARAKI 305,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,DIV RADIAT BIOL,KANAZAWA,ISHIKAWA 920,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,OSAKA 565,JAPAN	Osaka University; University of Tokyo; Osaka University; Kindai University (Kinki University); Kansai Medical University; National Agriculture & Food Research Organization - Japan; Kanazawa University; Osaka University			中根, 裕信/V-9816-2019	Nakatsu, Yoshimichi/0000-0001-7408-7071				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; BRADLEY A, 1992, BIO-TECHNOL, V10, P534, DOI 10.1038/nbt0592-534; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; IKAI K, 1986, ARCH DERMATOL RES, V278, P445, DOI 10.1007/BF00455161; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUNAGA T, 1990, MUTAT RES, V235, P187, DOI 10.1016/0921-8777(90)90073-E; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; TANAKA K, 1980, SOMAT CELL GENET, V6, P739, DOI 10.1007/BF01538973; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561	17	247	251	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					165	168		10.1038/377165a0	http://dx.doi.org/10.1038/377165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675085				2022-12-24	WOS:A1995RU75400053
J	CAMACHO, P; LECHLEITER, JD				CAMACHO, P; LECHLEITER, JD			CALRETICULIN INHIBITS REPETITIVE INTRACELLULAR CA2+ WAVES	CELL			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; XENOPUS-LAEVIS OOCYTES; CALCIUM-BINDING PROTEIN; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; RELEASE; STORES; IDENTIFICATION; CALSEQUESTRIN; CHANNELS	Inositol 1,4,5-trisphosphate (IP3)-mediated calcium (Ca2+) signaling is subject to cytosolic and luminal regulatory mechanisms. In Xenopus oocytes, Ca2+-sensitive gating of the IP3 receptor (IP(3)R) produces repetitive waves of Ca2+ release. We examined the role of the luminal Ca2+-binding protein calreticulin (CRT) in IP3-mediated Ca2+ signaling by using Ca2+ wave activity as a sensitive Ca2+ release assay. Overexpression of CRT inhibited repetitive IP3-induced Ca2+ waves. Deletion mutagenesis demonstrated that CRT inhibition was mediated by the high affinity-low capacity Ca2+-binding domain, which contributes little to Ca2+ storage. This novel function of CRT in intracellular Ca2+ signaling may be regulated by Ca2+ occupancy of the high affinity binding site.			CAMACHO, P (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048451] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CALLAMARAS N, 1994, CELL CALCIUM, V15, P66, DOI 10.1016/0143-4160(94)90105-8; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; ENYEDI P, 1993, CELL CALCIUM, V14, P485, DOI 10.1016/0143-4160(93)90007-S; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HAUSEN P, 1981, STAIN TECHNOL, V56, P287, DOI 10.3109/10520298109067329; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LIU NG, 1994, J BIOL CHEM, V269, P28635; LONGIN A, 1993, J HISTOCHEM CYTOCHEM, V41, P1833, DOI 10.1177/41.12.8245431; LYTTON J, 1991, HEART CARDIOVASCULAR, P1203; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OSBORN M, 1982, METHOD CELL BIOL, V24, P97; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	41	198	202	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					765	771		10.1016/0092-8674(95)90473-5	http://dx.doi.org/10.1016/0092-8674(95)90473-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671304	Bronze			2022-12-24	WOS:A1995RU75500011
J	VOGEL, KS; BRANNAN, CI; JENKINS, NA; COPELAND, NG; PARADA, LF				VOGEL, KS; BRANNAN, CI; JENKINS, NA; COPELAND, NG; PARADA, LF			LOSS OF NEUROFIBROMIN RESULTS IN NEUROTROPHIN-INDEPENDENT SURVIVAL OF EMBRYONIC SENSORY AND SYMPATHETIC NEURONS	CELL			English	Article							NERVE GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; TRK PROTOONCOGENE PRODUCT; DORSAL-ROOT-GANGLIA; TYPE-1 GENE; CAENORHABDITIS-ELEGANS; PROTEIN PRODUCT; TYROSINE KINASE; RAS P21; MOUSE	Mutations at the neurofibromatosis 1 (NF1) locus in humans and mice result in abnormal growth of neural crest-derived cells, including melanocytes and Schwann cells. We have exploited a targeted disruption of the NF1 gene in mice to examine the role of neurofibromin in the acquisition of neurotrophin dependence in embryonic neurons. We show that both neural crest- and placode-derived sensory neurons isolated from NF1 (-/-) embryos develop, extend neurites, and survive in the absence of neurotrophins, whereas their wild-type counterparts die rapidly unless nerve growth factor (NGF) or brain-derived neurotrophic factor (BDNF) is added to the culture medium. Moreover, NF1 (-/-) sympathetic neurons survive for extended periods and acquire mature morphology in the presence of NGF-blocking antibodies. Our results are consistent with a model wherein neurofibromin acts as a negative regulator of neurotrophin-mediated signaling for survival of embryonic peripheral neurons.	NCI,FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	VOGEL, KS (corresponding author), UNIV TEXAS,SW MED CTR,CTR DEV BIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Parada, luis F/B-9400-2014		NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COUGHLIN MD, 1985, DEV BIOL, V110, P392, DOI 10.1016/0012-1606(85)90098-3; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; DAVIES A, 1984, J COMP NEUROL, V223, P124, DOI 10.1002/cne.902230110; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DEDOUARIN NM, 1992, SENSORY NEURONS DIVE, P143; DICICCOBLOOM E, 1990, J CELL BIOL, V110, P2073, DOI 10.1083/jcb.110.6.2073; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ERNSBERGER U, 1988, DEV BIOL, V126, P420, DOI 10.1016/0012-1606(88)90151-0; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HAN M, 1990, GENETICS, V126, P899; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAWSON SN, 1979, J NEUROCYTOL, V8, P265, DOI 10.1007/BF01236122; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NG NFL, 1993, J BIOL CHEM, V268, P25329; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; ROHRER H, 1988, DEVELOPMENT, V103, P545; RUBIN E, 1985, J NEUROSCI, V5, P673; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; THEILER K, 1989, HOUSE MOUSE; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; Vogel Kristine S., 1992, P171; VOGEL KS, 1991, NEURON, V7, P819, DOI 10.1016/0896-6273(91)90284-7; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weston J A, 1970, Adv Morphog, V8, P41; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	58	132	133	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					733	742		10.1016/0092-8674(95)90470-0	http://dx.doi.org/10.1016/0092-8674(95)90470-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671302	Bronze			2022-12-24	WOS:A1995RU75500008
J	DARBY, SC; EWART, DW; GIANGRANDE, PLF; DOLIN, PJ; SPOONER, RJD; RIZZA, CR				DARBY, SC; EWART, DW; GIANGRANDE, PLF; DOLIN, PJ; SPOONER, RJD; RIZZA, CR			MORTALITY BEFORE AND AFTER HIV-INFECTION IN THE COMPLETE UK POPULATION OF HEMOPHILIACS	NATURE			English	Article							HEMOPHILIA CENTERS; UNITED-KINGDOM; AIDS; COHORT; DIRECTORS; BRITAIN; BEHALF; STATES; DEATH	DURING 1977-91, 6,278 males diagnosed with haemophilia were living in the UK. During 1979-86, 1,227 were infected with the human immunodeficiency virus (HIV-1) as a result of transfusion therapy (median estimated seroconversion date, October 1982). Among 2,448 with severe haemophilia, the annual death rate was stable at 8 per 1,000 during 1977-84; during 1985-92 death rates remained at 8 per 1,000 among HIV-seronegative patients but rose steeply in seropositive patients, reaching 81 per 1,000 in 1991-92. Among 3,830 with mild or moderate haemophilia, the pattern was similar, with an initial death rate of 4 per 1,000 in 1977-84, rising to 85 per 1,000 in 1991-92 in seropositive patients. During 1985-92, there were 403 deaths in HIV seropositive patients, whereas 60 would have been predicted from rates in seronegatives, suggesting that 85% of the deaths in seropositive patients were due to HIV infection. Most of the excess deaths were certified as due to AIDS or to conditions recognized as being associated with AIDS.	CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND	University of Oxford	DARBY, SC (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.		Semple, Malcolm Gracie/A-8790-2008	Semple, Malcolm Gracie/0000-0001-9700-0418; Laffan, Michael/0000-0002-8268-3268				ARONSON DL, 1988, AM J HEMATOL, V27, P7, DOI 10.1002/ajh.2830270103; ARONSTAM A, 1993, ARCH DIS CHILD, V68, P521, DOI 10.1136/adc.68.4.521; CHEINSONGPOPOV R, 1986, BRIT MED J, V293, P168, DOI 10.1136/bmj.293.6540.168; CHORBA TL, 1994, AM J HEMATOL, V45, P112, DOI 10.1002/ajh.2830450204; COLOMBO M, 1991, AM J HEMATOL, V37, P243, DOI 10.1002/ajh.2830370406; CUTHBERT RJG, 1990, BMJ-BRIT MED J, V301, P956, DOI 10.1136/bmj.301.6758.956; DARBY SC, 1990, STAT MED, V9, P681, DOI 10.1002/sim.4780090615; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOEDERT JJ, 1994, LANCET, V344, P791, DOI 10.1016/S0140-6736(94)92345-0; JOHNSON RE, 1985, AM J EPIDEMIOL, V121, P797, DOI 10.1093/oxfordjournals.aje.a114051; JONES P, 1985, BRIT MED J, V291, P695, DOI 10.1136/bmj.291.6497.695; KOUMBARELIS E, 1994, THROMB HAEMOSTASIS, V72, P808; LEE CA, 1991, BMJ-BRIT MED J, V303, P1093, DOI 10.1136/bmj.303.6810.1093; MCCORMICK A, 1994, POPULATION TRENDS, V76, P1; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; SMITH GM, 1991, CLIN LAB HAEMATOL, V13, P115; TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x; WILLIAMS MD, 1988, THROMB HAEMOSTASIS, V60, P97; 1994, LANCET, V343, P871; 1989, MORBIDITY MORTALITY, V38, P1; 1971, MANUAL INT STATISTIC; 1989, PHIL T R SOC LOND B, V325, P179	24	103	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					79	82		10.1038/377079a0	http://dx.doi.org/10.1038/377079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659168				2022-12-24	WOS:A1995RT72500061
J	PEKKANEN, J; TUOMILEHTO, J; UUTELA, A; VARTIAINEN, E; NISSINEN, A				PEKKANEN, J; TUOMILEHTO, J; UUTELA, A; VARTIAINEN, E; NISSINEN, A			SOCIAL-CLASS, HEALTH BEHAVIOR, AND MORTALITY AMONG MEN AND WOMEN IN EASTERN FINLAND	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; INEQUALITIES; ASSOCIATION; MAGNITUDE; EDUCATION; SMOKING; DEATH; OSLO	Objective-To evaluate the associations between social class as defined by occupation, health behaviour, and mortality from all causes and coronary heart disease among middle aged men and women in eastern Finland. Design-Prospective observational study of two independent, random population samples examined in 1972 and 1977. Setting-North Karelia and Kuopio, Finland. Subjects-8967 men and 9694 women aged 30-64 years at the beginning of the follow up study. The subjects were followed up for mortality up till 1987 by using the National Death Registry. Measurements and main results-Altogether 1429 men and 620 women died during the follow up, 603 men and 164 women of coronary heart disease. Among both sexes, compared with white collar workers unskilled blue collar workers had more adverse risk factors and also higher mortality due to coronary heart disease, other cardiovascular diseases, cancer, violent causes, and all other causes. Among men the age adjusted relative risk for all cause mortality in unskilled blue collar workers v white collar workers was reduced from 1.85 (95% confidence interval 1.55 to 2.22) to 1.47 (1.23 to 1.77) when adjusted for smoking, serum cholesterol concentration, hypertension, body mass index, and physical activity in leisure time. Among women the corresponding reduction in hazard ratio was from 1.49 (1.15 to 1.92) to 1.39 (1.07 to 1.81). The respective hazard ratios for coronary heart disease were 1.54 (1.16 to 2.02) and 1.22 (0.92 to 1.61) among men and 1.74 (1.05 to 2.90) and 1.66 (0.99 to 2.79) among women. Conclusions-Unfavourable cardiovascular risk factors and high mortality are concentrated among lower social classes in Finland. Among men about half of the excess coronary and all cause,mortality among unskilled blue collar workers was associated with their unfavourable risk factor profile. The association was smaller in women.	NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,SF-00300 HELSINKI,FINLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,SF-70211 KUOPIO,FINLAND	Finland National Institute for Health & Welfare; University of Eastern Finland	PEKKANEN, J (corresponding author), NATL PUBL HLTH INST,DEPT ENVIRONM EPIDEMIOL,POB 95,SF-70701 KUOPIO,FINLAND.							ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ARBER S, 1990, NEW DIRECTIONS SOCIO; COX DR, 1972, J R STAT SOC B, V34, P187; CROUSE JR, 1989, LANCET, V1, P318, DOI 10.1016/S0140-6736(89)91320-2; DENNIS BH, 1993, INT J EPIDEMIOL, V22, P420, DOI 10.1093/ije/22.3.420; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; HEIN HO, 1992, J INTERN MED, V231, P477, DOI 10.1111/j.1365-2796.1992.tb00963.x; HOLME I, 1976, LANCET, V2, P1396; HOLME I, 1980, J EPIDEMIOL COMMUN H, V34, P48, DOI 10.1136/jech.34.1.48; KUNST AE, 1994, INT J EPIDEMIOL, V23, P742, DOI 10.1093/ije/23.4.742; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; LIU K, 1982, CIRCULATION, V66, P1308, DOI 10.1161/01.CIR.66.6.1308; LUOTO R, 1994, J EPIDEMIOL COMMUN H, V48, P348, DOI 10.1136/jech.48.4.348; MACKENBACH JP, 1995, BRIT MED J, V310, P1152, DOI 10.1136/bmj.310.6988.1152; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; MARTIKAINEN P, IN PRESS SOCIOLOGY H; PEKKANEN J, 1995, J EPIDEMIOL COMMUN H, V49, P144, DOI 10.1136/jech.49.2.144; POCOCK SJ, 1987, LANCET, V2, P197; PUSKA P, 1981, N KARELIA PROJECT EV; ROSENGREN A, 1988, BRIT MED J, V297, P1497, DOI 10.1136/bmj.297.6662.1497; SALONEN JT, 1982, J EPIDEMIOL COMMUN H, V36, P294, DOI 10.1136/jech.36.4.294; SALONEN JT, 1980, 11980 SER OR REP; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1062, DOI 10.1093/oxfordjournals.aje.a115210; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1991, SOC SCI MED, V32, P1297, DOI 10.1016/0277-9536(91)90046-F; Townsend P., 1988, BLACK REPORT HLTH DI; Valkonen T, 1992, Int J Health Sci, V3, P157; VALKONEN T, 1990, SOCIOECONOMIC MORTAL; WING S, 1987, LANCET, V2, P1067; WOODWARD M, 1992, PREV MED, V21, P136, DOI 10.1016/0091-7435(92)90013-8; 1987, HLTH ALL YEAR 2000 F; 1973, OFFICIAL STATISTIC C, V6, P104	35	150	151	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					589	593		10.1136/bmj.311.7005.589	http://dx.doi.org/10.1136/bmj.311.7005.589			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663252	Green Published			2022-12-24	WOS:A1995RT72300015
J	HAYLLAR, J; BJARNASON, I				HAYLLAR, J; BJARNASON, I			NSAIDS, COX-2 INHIBITORS, AND THE GUT	LANCET			English	Editorial Material							RISK		UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	HAYLLAR, J (corresponding author), MT ISA BASE HOSP,MT ISA,QLD,AUSTRALIA.							AKARASEREENONT P, 1994, BRIT J PHARMACOL, V110, pP183; ASLANIAN R, 1994, EXPERT OPIN INV DRUG, V3, P1323; Bjarnason I., 1994, Gastroenterology, V106, pA53; EVERSMEYER W, 1993, AM J MED S2A, V95, P10; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEWIS AJ, 1994, NONSTEROIDAL ANTIINF, P1; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SAVAGE RL, 1993, ARTHRITIS RHEUM, V36, P84, DOI 10.1002/art.1780360114; SOMASUNDARAM S, 1995, SCAND J GASTROENTERO, V30, P289, DOI 10.3109/00365529509093280; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0	13	85	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					521	522		10.1016/S0140-6736(95)91378-5	http://dx.doi.org/10.1016/S0140-6736(95)91378-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658776				2022-12-24	WOS:A1995RQ98600006
J	BARANGER, AM; PALMER, CR; HAMM, MK; GIEBLER, HA; BRAUWEILER, A; NYBORG, JK; SCHEPARTZ, A				BARANGER, AM; PALMER, CR; HAMM, MK; GIEBLER, HA; BRAUWEILER, A; NYBORG, JK; SCHEPARTZ, A			MECHANISM OF DNA-BINDING ENHANCEMENT BY THE HUMAN T-CELL LEUKEMIA-VIRUS TRANSACTIVATOR TAX	NATURE			English	Article							TRANSCRIPTION FACTOR-II; PROTEIN; LEUKEMIA; DIMERIZATION; FLEXIBILITY; TRANSITION; SEQUENCE; ELEMENTS; REPEATS; HELICES	Tax protein activates transcription of the human T-cell leukaemia virus type I (HTLV-I) genome through three imperfect cyclic AMP-responsive element (CRE) target sites located within the viral promoter(1). Previous work has shown that Tax interacts with the bZIP element of proteins that bind the CRE target site(2-4) to promote peptide dimerization(3,5), suggesting an association between Tax and the bZIP coiled coil. Here we show that the site of interaction with Tax is not the coiled coil, but the basic segment. This interaction increases tbe stability of the GCN4 bZIP dimer by 1.7 kcal mol(-1) and tbe DNA affinity of the dimer by 1.9 kcal mol(-1). The differential effect of Tax on several bZIP-DNA complexes that differ in peptide sequence or DNA conformation suggests a model for Tax action based on stabilization of a distinct DNA-bound protein structure. This model may explain how Tax interacts with transcription factors of considerable sequence diversity to alter patterns of gene expression.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523	Yale University; Yale University; Colorado State University								ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; CUENOUD B, 1993, SCIENCE, V259, P510, DOI 10.1126/science.8424173; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRANKLIN AA, 1995, J BIOMED SCI, V1, P17; GLOVER I, 1983, BIOPOLYMERS, V22, P293, DOI 10.1002/bip.360220138; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; Metallo S J, 1994, Chem Biol, V1, P143, DOI 10.1016/1074-5521(94)90004-3; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; O'NEIL KT, 1990, SCIENCE, V249, P774; PAOLELLA DN, 1994, SCIENCE, V264, P110; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	26	159	161	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					606	608		10.1038/376606a0	http://dx.doi.org/10.1038/376606a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637812				2022-12-24	WOS:A1995RP75600055
J	MACILWAIN, C				MACILWAIN, C			LAST-MINUTE LIFELINE FOR PRINCETON TOKAMAK TESTS	NATURE			English	Editorial Material																		1995, NATURE, V375, P713; 1995, NATURE, V375, P622	2	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					541	541						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637791				2022-12-24	WOS:A1995RP75600005
J	SU, Y; DOSTMANN, WRG; HERBERG, FW; DURICK, K; XUONG, NH; TENEYCK, L; TAYLOR, SS; VARUGHESE, KI				SU, Y; DOSTMANN, WRG; HERBERG, FW; DURICK, K; XUONG, NH; TENEYCK, L; TAYLOR, SS; VARUGHESE, KI			REGULATORY SUBUNIT OF PROTEIN-KINASE-A - STRUCTURE OF DELETION MUTANT WITH CAMP BINDING DOMAINS	SCIENCE			English	Article							CYCLIC-NUCLEOTIDE ANALOGS; CATALYTIC SUBUNIT; 8-AZIDOADENOSINE 3',5'-MONOPHOSPHATE; ADENOSINE 3'-5'-MONOPHOSPHATE; COVALENT MODIFICATION; R-SUBUNIT; SITE-A; ACTIVATION; AMP; PHOSPHOROTHIOATES	In the molecular scheme of living organisms, adenosine 3',5'-monophosphate (cyclic AMP or cAMP) has been a universal second messenger. In eukaryotic cells, the primary receptors for cAMP are the regulatory subunits of cAMP-dependent protein kinase. The crystal structure of a 1-91 deletion mutant of the type I alpha regulatory subunit was refined to 2.8 Angstrom resolution. Each of the two tandem cAMP binding domains provides an extensive network of hydrogen bonds that buries the cyclic phosphate and the ribose between two beta strands that are linked by a short alpha helix. Each adenine base stacks against an aromatic ring that lies outside the beta barrel. This structure provides a molecular basis for understanding how cAMP binds cooperatively to its receptor protein, thus mediating activation of the kinase.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; SAN DIEGO SUPERCOMP CTR, LA JOLLA, CA 92186 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01644] Funding Source: Medline; NIGMS NIH HHS [GM34921, GM07313] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDRIDGE K, UNPUB; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1985, BIOCHEMISTRY-US, V24, P2163, DOI 10.1021/bi00330a009; BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CORBIN JD, 1982, EUR J BIOCHEM, V125, P259, DOI 10.1111/j.1432-1033.1982.tb06677.x; CREIGHTON TE, 1984, PROTEINS, P139; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DUPREZ E, 1993, J BIOL CHEM, V268, P8332; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P301, DOI 10.1007/BF02254719; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; JASTORFF B, 1979, EUR J BIOCHEM, V101, P555, DOI 10.1111/j.1432-1033.1979.tb19750.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERLAVAGE AR, 1980, J BIOL CHEM, V255, P8483; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KREBS EG, 1993, BIOSCIENCE REP, V13, P127, DOI 10.1007/BF01149958; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCCP4 ESF EACM; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; NELSON NC, 1983, J BIOL CHEM, V258, P981; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHABB JB, 1991, J BIOL CHEM, V266, P24320; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; SU Y, 1993, J MOL BIOL, V230, P1091, DOI 10.1006/jmbi.1993.1224; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WOODFORD TA, 1987, J BIOL CHEM, V262, P13321; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; YAGURA TS, 1981, BIOCHEMISTRY-US, V20, P879, DOI 10.1021/bi00507a035	60	327	334	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					807	813		10.1126/science.7638597	http://dx.doi.org/10.1126/science.7638597			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638597				2022-12-24	WOS:A1995RN65000036
J	CULLEN, PJ; HSUAN, JJ; TRUONG, O; LETCHER, AJ; JACKSON, TR; DAWSON, AP; IRVINE, RF				CULLEN, PJ; HSUAN, JJ; TRUONG, O; LETCHER, AJ; JACKSON, TR; DAWSON, AP; IRVINE, RF			IDENTIFICATION OF A SPECIFIC INS(1,3,4,5)P-4-BINDING PROTEIN AS A MEMBER OF THE GAP1 FAMILY	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; BUD-SITE-SELECTION; YEAST	INOSITOL 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4) is produced rapidly from inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) in stimulated cells(1,2). Despite extensive experimentation, no clearly defined cellular function has yet been described for this inositol phosphate. Binding sites specific for Ins(1,3,4,5)P-4 have been identified in several tissues(3,4), and we have purified one such protein to homogeneity(5). Its high affinity for Ins(1,3,4,5)P-4, and its exquisite specificity for this isomeric configuration(5,6), suggest it may be an Ins(1,3,4,5)P-4 receptor. Here we report the cloning and characterization of this protein as a GTPase-activating protein, specifically a member of the GAP family. In vitro it shows GAP activity against both Rap and Ras, but only the Ras GAP activity is inhibited by phospholipids and is specifically stimulated by Ins(1,3,4,5)P-4.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV CAMBRIDGE, BABRAHAM INST, DEPT ZOOL, MOLEC SIGNALLING LAB, CAMBRIDGE CB2 3EJ, ENGLAND	University of East Anglia; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	CULLEN, PJ (corresponding author), BABRAHAM INST, INOSITIDE LAB, BABRAHAM HALL, CAMBRIDGE CB2 4AT, ENGLAND.		Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Cullen, Peter/0000-0002-9070-8349				BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; CORVAZIER E, 1991, BIOCHEM J, V281, P323; CULLEN PJ, 1994, BIOCHEM J, V298, P739, DOI 10.1042/bj2980739; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1992, BIOCHEM J, V288, P149, DOI 10.1042/bj2880149; CULLEN PJ, 1995, FEBS LETT, V358, P240, DOI 10.1016/0014-5793(94)01435-4; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HASHII M, 1993, J BIOL CHEM, V268, P19403; IRVINE RF, 1993, CURR BIOL, V3, P540, DOI 10.1016/0960-9822(93)90052-P; IRVINE RF, 1992, INOSITOL PHOSPHATE C, P161; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MANNING DR, 1991, THROMB HAEMOSTASIS, V66, P393; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8846; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914	21	287	289	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					527	530		10.1038/376527a0	http://dx.doi.org/10.1038/376527a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637787				2022-12-24	WOS:A1995RN62200049
J	GURDON, JB; MITCHELL, A; MAHONY, D				GURDON, JB; MITCHELL, A; MAHONY, D			DIRECT AND CONTINUOUS ASSESSMENT BY CELLS OF THEIR POSITION IN A MORPHOGEN GRADIENT	NATURE			English	Article							MESODERM INDUCTION; XENOPUS; RESPONSES; ACTIVIN; HOMOLOG	ACCORDING to the morphogen gradient concept(1-5), cells in one part of an embryo secrete diffusible molecules (morphogens) that spread to other nearby cells and activate genes at different threshold concentrations, Strong support for the operation of a morphogen gradient mechanism in vertebrate development has come from the biochemical experiments of Green and Smith(6,7), who induced different kinds of gene expression in amphibian blastula cells exposed to small changes in activin concentration, But the interpretation of these experiments has been complicated by recent reports that cells tested for gene expression 3 hours after exposure to activin fail to show the graded response previously reported at 15 hours(6,7), a result suggesting that cells recognize their position in a gradient by an indirect mechanism, Here we conclude from the in situ analysis of blastula tissue containing activin-loaded beads(11) that cells respond directly to changing morphogen concentrations, in a way that resembles a ratchet-like process.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE,ENGLAND	University of Cambridge	GURDON, JB (corresponding author), CANC RES CAMPAIGN,WELLCOME INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRICKELL PM, 1989, BIOESSAYS, V11, P145, DOI 10.1002/bies.950110508; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1995, BIOESSAYS, V17, P93, DOI 10.1002/bies.950170202; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1994, DEVELOPMENT, V120, P2271; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JONES EA, 1987, DEVELOPMENT, V101, P557; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SYMES K, 1987, DEVELOPMENT, V101, P339; SYMES K, 1994, DEVELOPMENT, V120, P2339; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VIZE PD, 1994, TRENDS GENET, V10, P371, DOI 10.1016/0168-9525(94)90134-1; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOLPERT L, 1989, DEVELOPMENT, V107, P3	22	133	133	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					520	521		10.1038/376520a0	http://dx.doi.org/10.1038/376520a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637784				2022-12-24	WOS:A1995RN62200046
J	JEFFREY, PD; RUSO, AA; POLYAK, K; GIBBS, E; HURWITZ, J; MASSAGUE, J; PAVLETICH, NP				JEFFREY, PD; RUSO, AA; POLYAK, K; GIBBS, E; HURWITZ, J; MASSAGUE, J; PAVLETICH, NP			MECHANISM OF CDK ACTIVATION REVEALED BY THE STRUCTURE OF A CYCLINA-CDK2 COMPLEX	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; PHOSPHORYLATION; CYCLINS; BINDING; YEAST; LOCALIZATION; INVITRO; PROGRAM	The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 Angstrom resolution. CyclinA binds to one side of CDK2's catalytic cleft, inducing large conformational changes in its PSTAIRE helix and T-loop. These changes activate the kinase by realigning active site residues and relieving the steric blockade at the entrance of the catalytic cleft.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	JEFFREY, PD (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Jeffrey, Philip/0000-0002-4351-5341; Massague, Joan/0000-0001-9324-8408				BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P273; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STANDART N, 1990, GENE DEV, V4, P1257; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; 1979, SERC4 DAR LAB COLL C	50	1190	1227	2	109	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					313	320		10.1038/376313a0	http://dx.doi.org/10.1038/376313a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630397				2022-12-24	WOS:A1995RL44300040
J	MORI, I; OHSHIMA, Y				MORI, I; OHSHIMA, Y			NEURAL REGULATION OF THERMOTAXIS IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							C-ELEGANS; CHEMOSENSORY NEURONS; CELL LINEAGE; MUTANT; CHEMOTAXIS	THERMAL stimulus is an important environmental factor influencing animal behaviour(1). However, the mechanisms underlying thermosensation and thermal adaptation are poorly understood. The nematode Caenorhabditis elegans can sense a range of environmental temperatures and migrate towards the cultivation temperature on a thermal gradient(2). This modifiable thermotactic response provides an ideal system for studying the cellular and molecular processes involved in thermosensation and thermal information storage. We have identified neurons critical for thermotaxis by killing individual cells in live animals. The results indicate that an amphid sensory neuron, AFD, is a major thermosensory neuron. Some of the genetically defined cryophilic and thermophilic mutant phenotypes were mimicked when amphid interneurons AIY and AIZ, respectively, were killed, indicating that AIY is responsible for thermophilic movement and AIZ for cryophilic movement. We propose a neural model in which regulation of the activities of the two interneurons in opposite directions, depending on the cultivation temperature, is essential for thermotaxis.			MORI, I (corresponding author), KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN.							AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BRENNER S, 1974, GENETICS, V77, P71; Eckert R, 1988, ANIMAL PHYSL; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1975, P NATL ACAD SCI USA, V72, P4061, DOI 10.1073/pnas.72.10.4061; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	14	397	413	1	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					344	348		10.1038/376344a0	http://dx.doi.org/10.1038/376344a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630402				2022-12-24	WOS:A1995RL44300048
J	DEMATTEIS, MA; SANTINI, G; KAHN, RA; DITULLIO, G; LUINI, A				DEMATTEIS, MA; SANTINI, G; KAHN, RA; DITULLIO, G; LUINI, A			RECEPTOR AND PROTEIN KINASE-C-MEDIATED REGULATION OF ARF BINDING TO THE GOLGI-COMPLEX	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; GUANINE-NUCLEOTIDE; COATED VESICLES; CELL-SURFACE; BETA-COP; SECRETION; INHIBITION; TRANSPORT; MEMBRANES	THE formation of constitutive transport vesicles involves the association of non-clathrin coat proteins to transport organelles1,2 . Here we report that IgE receptors and protein kinase C (PKC) regulate the GTP-dependent binding of the two coat proteins ADP-ribosylation factor (ARF) and beta-COP3-5 to Golgi membranes in rat basophilic leukaemia cells. Activation of IgE receptors and PKC prevented the ARF and beta-COP dissociation from Golgi membranes that occurs in permeabilized cells in the absence of GTP and potentiated the association-promoting effects of GTP and the G protein activator fluoroaluminate. In contrast, PKC downregulation and PKC inhibition abolished the activity of GTP and fluoro-luminate in promoting ARF binding to the Golgi complex. Studies of ARF binding to isolated Golgi membranes gave similiar results. These findings suggest that coat assembly on Golgi membranes, and thus possibly constitutive secretory traffic, is modulated by membrane receptors and second messengers.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,MOLEC NEUROBIOL LAB,I-66030 SANTA MARIA IMBAR,ITALY; NCI,DIV CANC TREATMENT,BIOL CHEM LAB,BETHESDA,MD 20892	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	DEMATTEIS, MA (corresponding author), IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,PHYSIOPATHOL SECRET UNIT,I-66030 SANTA MARIA IMBAR,ITALY.		Kahn, Richard/ABD-2666-2020; Luini, Alberto/L-1372-2013; De Matteis, Maria Antonietta/AHE-5161-2022	Kahn, Richard/0000-0002-0259-0601; Luini, Alberto/0000-0002-8729-2549; De Matteis, Maria Antonietta/0000-0003-0053-3061				ALI H, 1989, J IMMUNOL, V143, P2626; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LOW SH, 1991, J BIOL CHEM, V266, P17729; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Melancon P, 1991, Trends Cell Biol, V1, P165, DOI 10.1016/0962-8924(91)90018-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; ORCI L, 1991, CELL, V64, P1183; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STROUS GJ, 1993, J BIOL CHEM, V268, P2341	36	140	143	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					818	821		10.1038/364818a0	http://dx.doi.org/10.1038/364818a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689177				2022-12-24	WOS:A1993LU58100060
J	KURAHASHI, T; YAU, KW				KURAHASHI, T; YAU, KW			COEXISTENCE OF CATIONIC AND CHLORIDE COMPONENTS IN ODORANT-INDUCED CURRENT OF VERTEBRATE OLFACTORY RECEPTOR-CELLS	NATURE			English	Article							CYCLIC-NUCLEOTIDES; ADENYLATE-CYCLASE; GATED CHANNELS; NEURONS; CILIA; ACTIVATION; MEMBRANE; CONDUCTANCE; NEWT; TRANSDUCTION	ODORANT stimulation leads to a depolarization of olfactory receptor neurons1-3. A mechanism underlying this transduction, which occurs in the sensory cilia3-6, involves a G-protein-mediated increase in adenylyl cyclase activity7-10, and therefore a rise in internal cyclic AMP and consequent opening of a cAMP-gated cation channel on the plasma membrane11-22. Another mechanism, not as well established, involves the opening of an inositol trisphosphate-activated cation channel on the plasma membrane23 as a result of phospholipase C activity24,25. In both cases, an influx of cations is thought to generate the depolarizing receptor potential. We now report, however, that the mechanism is actually more complex. The odorant-induced current appears to contain an inward chloride component also, which is triggered by calcium influx through the cation-selective channel. This newly found chloride component can be as large as the cationic component. The co-existence of cationic and chloride components in the odorant response, possibly unique among sensory transduction mechanisms, may serve to reduce variations in the transduction current resulting from changes in external ionic concentrations around the olfactory cilia. Our finding can explain the long-standing puzzle of why removal of most mucosal cations still does not diminish the amplitude of the olfactory receptor cell response26-28.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University								ALVAREZLEEFMANS FJ, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P109; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; DIONNE VE, 1992, J GEN PHYSIOL, V99, P415, DOI 10.1085/jgp.99.3.415; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FIRESTEIN S, 1991, NEURON, V6, P825, DOI 10.1016/0896-6273(91)90178-3; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GETCHELL TV, 1986, PHYSIOL REV, V66, P772, DOI 10.1152/physrev.1986.66.3.772; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; KLEENE SJ, 1991, J MEMBRANE BIOL, V120, P75, DOI 10.1007/BF01868593; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KOLESNIKOV SS, 1990, FEBS LETT, V266, P96, DOI 10.1016/0014-5793(90)81515-P; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1989, P NATL ACAD SCI USA, V86, P5641, DOI 10.1073/pnas.86.14.5641; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SUZUKI N, 1978, COMP BIOCHEM PHYS A, V61, P461; SUZUKI N, 1989, CHEM SENSES, V1, P469; TUCKER D, 1965, COLD SPRING HARB SYM, V30, P207, DOI 10.1101/SQB.1965.030.01.023; YAMASHITA M, 1991, VISUAL NEUROSCI, V6, P399, DOI 10.1017/S0952523800006635; YOSHII K, 1983, BRAIN RES, V274, P239, DOI 10.1016/0006-8993(83)90701-1; ZUFALL F, 1991, J NEUROSCI, V11, P3573	33	264	266	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					71	74		10.1038/363071a0	http://dx.doi.org/10.1038/363071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	7683113				2022-12-24	WOS:A1993LA68200061
J	ARUFFO, A; FARRINGTON, M; HOLLENBAUGH, D; LI, X; MILATOVICH, A; NONOYAMA, S; BAJORATH, J; GROSMAIRE, LS; STENKAMP, R; NEUBAUER, M; ROBERTS, RL; NOELLE, RJ; LEDBETTER, JA; FRANCKE, U; OCHS, HD				ARUFFO, A; FARRINGTON, M; HOLLENBAUGH, D; LI, X; MILATOVICH, A; NONOYAMA, S; BAJORATH, J; GROSMAIRE, LS; STENKAMP, R; NEUBAUER, M; ROBERTS, RL; NOELLE, RJ; LEDBETTER, JA; FRANCKE, U; OCHS, HD			THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME	CELL			English	Article							HUMAN B-CELLS; TUMOR NECROSIS FACTOR; HYPERIMMUNOGLOBULINEMIA-M; LYMPHOCYTES-B; RECEPTOR; IMMUNODEFICIENCY; SEQUENCES; INTERLEUKIN-4; CARCINOMAS; ANTIBODY	The prominent role of the CD40 receptor in B cell responses led us to investigate the role of the gp39-CD40 interaction in a group of primary immunodeficient patients with defective antibody production. Here we report that patients with hyper-IgM syndrome (HIM) have a defective gp39-CD40 interaction. B cells from HIM patients express functional CD40, but their T cells do not bind CD40-Ig. These patients expressed normal levels of gp39 mRNA, but these mRNAs encode defective gp39 proteins owing to mutations in the extracellular domain of gp39. Soluble recombinant forms of gp39 containing these mutations were unable to bind CD40 and drive normal B cell proliferation. The gene encoding gp39 was mapped to Xq26, the X chromosome region where the gene responsible for HIM had previously been mapped. These data suggest that a defect in gp39 is the basis of X-linked HIM.	UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA; STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV CALIF LOS ANGELES, MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; DARTMOUTH COLL, SCH MED, DEPT MICROBIOL, LEBANON, NH 03756 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University; Howard Hughes Medical Institute; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Dartmouth College	ARUFFO, A (corresponding author), BRISTOL MEYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA.		Bajorath, Jürgen/F-7493-2014		NHGRI NIH HHS [R01 HG00298] Funding Source: Medline; NIAID NIH HHS [AI26296] Funding Source: Medline; NICHD NIH HHS [HD17427] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026296, R37AI026296] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; BURTIN P, 1961, REV FR ETUD CLIN BIO, V6, P286; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; GALY AHM, 1992, J IMMUNOL, V149, P775; GASCAN H, 1991, J IMMUNOL, V147, P8; GIACALONE J, 1992, NAT GENET, V1, P137, DOI 10.1038/ng0592-137; GORDON J, 1987, EUR J IMMUNOL, V17, P1535, DOI 10.1002/eji.1830171026; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; MOLLER P, 1989, LEUCOCYTE TYPING, V4, P175; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; OCHS HD, 1989, IMMUNOLOGIC DISORDER, P226; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; PELTZ GA, 1988, J IMMUNOL, V141, P1891; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; Sambrook J., 1989, MOL CLONING LAB MANU; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WEDGWOOD RJ, 1980, INSERM S, V16, P69; WIEACKER P, 1984, AM J HUM GENET, V36, P265; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679; ZHANG K, 1991, J IMMUNOL, V146, P1836; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	47	768	801	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 29	1993	72	2					291	300		10.1016/0092-8674(93)90668-G	http://dx.doi.org/10.1016/0092-8674(93)90668-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678782				2022-12-24	WOS:A1993KK03800013
J	BARNARD, MR; MICHELSON, AD				BARNARD, MR; MICHELSON, AD			A MORPHOLOGIC QUESTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BARNARD, MR (corresponding author), UNIV MASSACHUSETTS,MED CTR,WORCESTER,MA 01655, USA.		Michelson, Alan/ABE-8487-2021	Michelson, Alan/0000-0002-1746-4819					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1051	1051		10.1056/NEJM199510193331605	http://dx.doi.org/10.1056/NEJM199510193331605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675048				2022-12-24	WOS:A1995RZ34000005
J	FRETTS, RC; SCHMITTDIEL, J; MCLEAN, FH; USHER, RH; GOLDMAN, MB				FRETTS, RC; SCHMITTDIEL, J; MCLEAN, FH; USHER, RH; GOLDMAN, MB			INCREASED MATERNAL AGE AND THE RISK OF FETAL DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DELAYED CHILDBEARING; PREGNANCY; BIRTH	Background. Although the fetal death rate has declined over the past 30 years among women of all ages, ii is unknown whether particular characteristics of the mother, such as age, still affect the risk of fetal death. We undertook a study to determine whether older age, having a first child (nulliparity), or other characteristics of the mother are risk factors for fetal death. Methods. We used data from the McGill Obstetrical Neonatal Database to evaluate risk factors for fetal death among all deliveries at the Royal Victoria Hospital in Montreal (n=94,346) from 1961 through 1993, Data were available for two time periods (1961 through 1974 and 1978 through 1993); data for 1975 through 1977 have not been entered into the data base and were therefore not included. Using logistic regression, we estimated the effect of specific maternal characteristics and complications of pregnancy on the risk of fetal death. Results. The fetal death rate decreased significantly from 11.5 per 1000 total births (including live births and stillbirths) in the 1960s to 3.2 per 1000 in 1990 through 1993 (P<0,001), Between these periods, the average maternal age at delivery increased from 27 to 30 years (P<0.001), and the frequency of the diagnosis of diabetes and hypertension during pregnancy increased fivefold (P<0.001), Nevertheless, after we controlled for these and other maternal characteristics, women 35 years of age or older continued to have a significantly higher rate of fetal death than their younger counterparts (odds ratio for women 35 to 39 years of age as compared with women <30 years of age, 1.9; 95 percent confidence interval, 1.3 to 2.7; for those 40 or older, 2.4; 95 percent confidence interval, 1.3 to 4.5). Conclusions. Changes in maternal health and obstetrical practice have resulted in a 70 percent decline in the rate of fetal death among pregnant women of all ages since the 1960s. Advancing maternal age, however, continues to be a risk factor for fetal death.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; ROYAL VICTORIA HOSP, DEPT OBSTET & GYNECOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, MONTREAL, PQ, CANADA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; McGill University; Royal Victoria Hospital; McGill University	FRETTS, RC (corresponding author), BETH ISRAEL HOSP, DEPT OBSTET & GYNECOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ALES KL, 1990, SURG GYNECOL OBSTET, V171, P209; BARKAN SE, 1987, AM J EPIDEMIOL, V125, P101, DOI 10.1093/oxfordjournals.aje.a114491; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CNATTINGIUS S, 1992, Journal of the American Medical Association, V268, P886, DOI 10.1001/jama.268.7.886; CNATTINGIUS S, 1993, OBSTET GYNECOL, V81, P512; CUNNINGHAM FG, 1990, NEW ENGL J MED, V323, P414; EDGE V, 1993, AM J OBSTET GYNECOL, V168, P1881, DOI 10.1016/0002-9378(93)90706-O; FORMAN MR, 1984, JAMA-J AM MED ASSOC, V252, P3135, DOI 10.1001/jama.252.22.3135; FRETTS RC, 1992, OBSTET GYNECOL, V79, P35; KIELY JL, 1986, AM J EPIDEMIOL, V123, P444, DOI 10.1093/oxfordjournals.aje.a114259; KIRZ DS, 1985, AM J OBSTET GYNECOL, V152, P7, DOI 10.1016/S0002-9378(85)80166-6; LEYLAND AH, 1990, NEW ENGL J MED, V323, P413; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; PITKIN RM, 1991, AM J OBSTET GYNECOL, V164, P1045, DOI 10.1016/0002-9378(91)90584-E; PRYSAK M, 1995, OBSTET GYNECOL, V85, P65, DOI 10.1016/0029-7844(94)00330-G; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P285; SLUTSKER L, 1992, OBSTET GYNECOL, V79, P778; 1990, SAS USERS GUIDE STAT; 1989, VITAL HLTH STATIS 21, V47; 1979, LANCET, V1, P142	21	293	306	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					953	957		10.1056/NEJM199510123331501	http://dx.doi.org/10.1056/NEJM199510123331501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666913				2022-12-24	WOS:A1995RY58600001
J	BRAHE, C; SERVIDEI, S; ZAPPATA, S; RICCI, E; TONALI, P; NERI, G				BRAHE, C; SERVIDEI, S; ZAPPATA, S; RICCI, E; TONALI, P; NERI, G			GENETIC HOMOGENEITY BETWEEN CHILDHOOD-ONSET AND ADULT-ONSET AUTOSOMAL RECESSIVE SPINAL MUSCULAR-ATROPHY	LANCET			English	Note								Molecular diagnosis of childhood proximal spinal muscular atrophy has been enhanced by the discovery of the survival motor neuron (SMN) gene, which is absent or truncated in 98.6% of patients. To determine whether deletion analysis of the SMN gene may also be diagnostic for adult-onset disease, we studied six patients and found deletions in all. This finding will facilitate the diagnosis of adult-onset spinal muscular atrophy, and provides evidence for genetic homogeneity between the clinically diverse adult and childhood forms of the disease.	UNIV CATTOLICA SACRO CUORE, A GEMELLI SCH MED, NEUROL INST, I-00168 ROME, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	BRAHE, C (corresponding author), UNIV CATTOLICA SACRO CUORE, A GEMELLI SCH MED, INST MED GENET, I-00168 ROME, ITALY.		Servidei, Serenella/ABC-4262-2021; Ricci, Enzo/AAC-4448-2020	SERVIDEI, Serenella/0000-0001-8478-2799; RICCI, Enzo/0000-0003-3092-3597	Telethon [517] Funding Source: Medline	Telethon(Fondazione Telethon)		KAUSCH K, 1991, HUM GENET, V86, P317; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; PEARN J, 1980, LANCET, V1, P919; PEARN JH, 1978, BRAIN, V101, P591, DOI 10.1093/brain/101.4.591; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1	5	88	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					741	742		10.1016/S0140-6736(95)91507-9	http://dx.doi.org/10.1016/S0140-6736(95)91507-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658877				2022-12-24	WOS:A1995RU81000013
J	COX, JT				COX, JT			HPV DNA TESTING - CLINICAL BOON OR BOONDOGGLE	LANCET			English	Editorial Material							CYTOLOGY; SMEARS				COX, JT (corresponding author), UNIV CALIF SANTA BARBARA, STUDENT HLTH SERV, SANTA BARBARA, CA 93106 USA.							[Anonymous], 1993, ACTA CYTOL, V37, P115; COX JT, 1992, OBSTET GYNECOL, V80, P389; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1067, DOI 10.1111/j.1471-0528.1989.tb03382.x; HATCH KD, 1995, AM J OBSTET GYNECOL, V172, P1150, DOI 10.1016/0002-9378(95)91473-0; HUTCHINSON ML, 1992, ACTA CYTOL, V36, P499; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LUNGU O, 1995, OBSTET GYNECOL, V85, P337, DOI 10.1016/0029-7844(94)00399-X; Meijer C. J., 1992, EPIDEMIOLOGY CERVICA, P271; SCHIFFMAN MH, 1994, CANCER RES, V54, pS1944; SCHIFFMAN MH, 1993, J NATL CANCER I, V85, P1868, DOI 10.1093/jnci/85.22.1868-a; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L	15	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 16	1995	346	8977					717	719						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658868				2022-12-24	WOS:A1995RU81000004
J	JACKSON, LA; HILSDON, R; FARLEY, MM; HARRISON, LH; REINGOLD, AL; PLIKAYTIS, BD; WENGER, JD; SCHUCHAT, A				JACKSON, LA; HILSDON, R; FARLEY, MM; HARRISON, LH; REINGOLD, AL; PLIKAYTIS, BD; WENGER, JD; SCHUCHAT, A			RISK-FACTORS FOR GROUP-B STREPTOCOCCAL DISEASE IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						RISK FACTORS; CROSS INFECTION; COMMUNITY-ACQUIRED INFECTIONS; STREPTOCOCCAL INFECTION; STREPTOCOCCUS AGALACTIAE	TOXOID CONJUGATE VACCINE; NONPREGNANT ADULTS; III POLYSACCHARIDE; INFECTION; BACTEREMIA; ANTIBODY; INFANTS; WOMEN	Objective: To determine risk factors for community-acquired and nosocomial group B streptococcal disease in adults. Design: Case-control study. Setting: 3 metropolitan areas in the United States with an aggregate population of 6.6 million persons. Patients: 219 nonpregnant adults with invasive group B streptococcal infection identified by a population-based surveillance in 1991 and 1992 and 645 hospital-matched controls. Results: The following conditions were associated with a significantly increased risk for community-acquired group B streptococcal infection after controlling for age in multivariate analysis: cirrhosis (odds ratio, 9.7 [95% CI, 3.5 to 26.9]; P <0.001), diabetes (odds ratio, 3.0 [CI, 1.9 to 4.7]; P <0.001), stroke (odds ratio, 3.5 [CI, 1.9 to 6.4]; P <0.001), breast cancer (odds ratio, 4.0 [CI, 1.6 to 9.8]; P =0.002), decubitus ulcer (odds ratio, 4.0 [CI, 1.6 to 9.8]; P =0.002), and neurogenic bladder (odds ratio, 4.6 [CI, 1.4 to 15.1]; P =0.01). Sixty-three percent of community case-patients had at least one of these conditions. Nosocomial infection (48 cases [22%]) was independently associated with the placement of a central venous line (odds ratio, 30.9 [CI, 5.2 to 184.1]; P <0.001), diabetes, congestive heart failure, and seizure disorder. Conclusions: Several chronic conditions were independently associated with group B streptococcal disease, and most case-patients had at least one of these conditions. If group B streptococcal vaccines being developed for prevention of neonatal disease are protective in adults, a vaccination strategy targeting those at highest risk has the potential to substantially reduce the burden of invasive group B streptococcal infection in adults.	CTR DIS CONTROL & PREVENT, CHILDHOOD & RESP DIS BRANCH, ATLANTA, GA 30333 USA; EMORY UNIV, SCH MED, ATLANTA, GA USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA; UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA	Centers for Disease Control & Prevention - USA; Emory University; Johns Hopkins University; University of California System; University of California Berkeley								[Anonymous], 1993, MMWR Recomm Rep, V42, P1; ANTHONY BF, 1983, J INFECT DIS, V147, P776, DOI 10.1093/infdis/147.4.776; BAKER CJ, 1981, PEDIATRICS, V68, P544; BAKER CJ, 1986, J INFECT DIS, V154, P47, DOI 10.1093/infdis/154.1.47; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BAKER CJ, 1990, NEW ENGL J MED, V322, P1857, DOI 10.1056/NEJM199006283222606; BAYER AS, 1976, AM J MED, V61, P498, DOI 10.1016/0002-9343(76)90329-6; BERKOWITZ K, 1990, J CLIN MICROBIOL, V28, P5, DOI 10.1128/JCM.28.1.5-7.1990; BLUMBERG HM, 1994, CLIN RES, V42, pA298; Breslow NE, 1980, IARC SCI PUBL, V32, P248; CASEY JI, 1982, AM J EPIDEMIOL, V116, P704, DOI 10.1093/oxfordjournals.aje.a113453; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P64; DILLON HC, 1982, J INFECT DIS, V145, P794, DOI 10.1093/infdis/145.6.794; DWORZACK DL, 1979, AM J MED SCI, V277, P67, DOI 10.1097/00000441-197901000-00008; Edwards MS, 1995, PRINCIPLES PRACTICE, V4, P1835; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; FINNEGAN OC, 1981, POSTGRAD MED J, V57, P202, DOI 10.1136/pgmj.57.665.202; GALLAGHER PG, 1985, AM J MED, V78, P795, DOI 10.1016/0002-9343(85)90285-2; GALLAGHER PG, 1986, REV INFECT DIS, V8, P175; HARRISON LH, 1995, J INFECT DIS, V171, P513, DOI 10.1093/infdis/171.2.513; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LERNER PI, 1977, MEDICINE, V56, P457, DOI 10.1097/00005792-197711000-00001; MADOFF LC, 1994, J CLIN INVEST, V94, P286, DOI 10.1172/JCI117319; MATHEW P, 1993, NEW ENGL J MED, V329, P1658; MILLER JD, 1982, SOUTHERN MED J, V75, P76, DOI 10.1097/00007611-198201000-00021; MUNOZ P, 1992, CLIN INFECT DIS, V14, P492, DOI 10.1093/clinids/14.2.492; OPAL SM, 1988, ARCH INTERN MED, V148, P641, DOI 10.1001/archinte.148.3.641; PAOLETTI LC, 1994, INFECT IMMUN, V62, P3236, DOI 10.1128/IAI.62.8.3236-3243.1994; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; PAOLETTI LC, 1992, INFECT IMMUN, V60, P4009, DOI 10.1128/IAI.60.10.4009-4014.1992; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; SMALL CB, 1984, AM J MED, V76, P367, DOI 10.1016/0002-9343(84)90653-3; VERGHESE A, 1986, REV INFECT DIS, V8, P912; WESSELS MR, 1993, INFECT IMMUN, V61, P4760, DOI 10.1128/IAI.61.11.4760-4766.1993; WESSELS MR, 1995, J INFECT DIS, V171, P879, DOI 10.1093/infdis/171.4.879; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; 1992, SAS P229 SAS I TECHN	37	196	198	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					415	420		10.7326/0003-4819-123-6-199509150-00003	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639440				2022-12-24	WOS:A1995RU43700003
J	POTTS, M				POTTS, M			NONSURGICAL ABORTION - WHOS FOR METHOTREXATE	LANCET			English	Editorial Material											POTTS, M (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720, USA.							CREININ MD, 1993, CONTRACEPTION, V48, P339, DOI 10.1016/0010-7824(93)90079-M; CREININ MD, 1994, JAMA-J AM MED ASSOC, V272, P1190, DOI 10.1001/jama.272.15.1190; CREININ MD, 1993, CONTRACEPTION, V48, P519, DOI 10.1016/0010-7824(93)90114-M; DONNENFELD AE, 1994, TERATOLOGY, V49, P79, DOI 10.1002/tera.1420490202; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; TANAKA T, 1982, FERTIL STERIL, V37, P851; THIERSCH JB, 1952, AM J OBSTET GYNECOL, V63, P1398; WINIKOFF B, 1995, FAM PLANN PERSPECT, V27, P142, DOI 10.2307/2136257	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					655	656		10.1016/S0140-6736(95)92276-8	http://dx.doi.org/10.1016/S0140-6736(95)92276-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658816				2022-12-24	WOS:A1995RU04800005
J	VAINIO, A; OLLILA, J; MATIKAINEN, E; ROSENBERG, P; KALSO, E				VAINIO, A; OLLILA, J; MATIKAINEN, E; ROSENBERG, P; KALSO, E			DRIVING ABILITY IN CANCER-PATIENTS RECEIVING LONG-TERM MORPHINE ANALGESIA	LANCET			English	Article							PAIN; BUPRENORPHINE; PSYCHOMOTOR; OPIOIDS	When given in single doses to healthy volunteers, opioid analgesics impair reaction time, muscle coordination, attention, and short-term memory sufficiently to affect driving and other skilled activities. Despite the increasing use of oral morphine daily, little is known about the effect of long-term opioid therapy on psychomotor performance. To examine the effects of continuous morphine medication, psychological and neurological tests originally designed for professional motor vehicle drivers were conducted in two groups of cancer patients who were similar apart from experience of pain, 24 were on continuous morphine (mean 209 mg oral morphine daily) for cancer pain; and 25 were pain-free without regular analgesics. Though the results were a little worse in the patients taking morphine, there were no significant differences between the groups in intelligence, vigilance. concentration, fluency of motor reactions, or division of attention. Of the neural function tests, reaction times (auditory, visual, associative), thermal discrimination, and body sway with eyes open were similar in the two groups; only balancing ability with closed eyes was worse in the morphine group. These results indicate that, in cancer patients receiving long-term morphine treatment with stable doses, morphine has only a slight and selective effect on functions related to driving.	UNIV HELSINKI,CENT HOSP,DEPT ANAESTHESIA,SF-00290 HELSINKI,FINLAND; FINNISH INST OCCUPAT HLTH,HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital; Finnish Institute of Occupational Health								BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; BUKASA B, 1985, VERKEHRSPSYCHOLOGISC, V23; Bukasa B, 1990, DIAGNOSTICA, V36, P148; Gardziella M., 1985, WARTEGG PIIRUSTUSTES; GORDON N, 1976, PSYCHOPHARMACOLOGIA, V16, P337; HAKKINEN S, 1979, ACCIDENT ANAL PREV, V11, P7, DOI 10.1016/0001-4575(79)90033-2; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; JOO S, 1994, J TRAFFIC MED, V22, P101; KERR B, 1991, NEUROPSYCHOPHARMACOL, V5, P157; LEQUESNE PM, 1990, J NEUROL NEUROSUR PS, V53, P558, DOI 10.1136/jnnp.53.7.558; LINNOILA M, 1986, DRUGS DRIVING, P29; LOMBARDO WK, 1976, INT J ADDICT, V11, P389, DOI 10.3109/10826087609056158; MACDONALD FC, 1989, BRIT J CLIN PHARMACO, V27, P453, DOI 10.1111/j.1365-2125.1989.tb05393.x; OHANLON JF, 1986, DRUGS DRIVING; OJALA M, 1989, ACTA NEUROL SCAND, V80, P118, DOI 10.1111/j.1600-0404.1989.tb03852.x; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; ROTHENBERG S, 1977, PSYCHOPHARMACOLOGY, V52, P299, DOI 10.1007/BF00426715; SAARIALHOKERE U, 1987, EUR J CLIN PHARMACOL, V33, P139, DOI 10.1007/BF00544557; SJOGREN P, 1989, PAIN, V39, P5, DOI 10.1016/0304-3959(89)90168-1; SVENSSON JO, 1982, J CHROMATOGR, V230, P427, DOI 10.1016/S0378-4347(00)80494-6; TREAT JR, 1977, DOTHS03453577TAC IND; VAINIO A, 1988, ACTA ANAESTH SCAND, V32, P179, DOI 10.1111/j.1399-6576.1988.tb02711.x; WARTEGG E, 1955, TESTS KLINISCHEN PSY, V2, P520; YATES IW, 1980, CANCER, V45, P228	24	152	156	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					667	670		10.1016/S0140-6736(95)92281-4	http://dx.doi.org/10.1016/S0140-6736(95)92281-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658820				2022-12-24	WOS:A1995RU04800010
J	DUAN, DR; PAUSE, A; BURGESS, WH; ASO, T; CHEN, DYT; GARRETT, KP; CONAWAY, RC; CONAWAY, JW; LINEHAN, WM; KLAUSNER, RD				DUAN, DR; PAUSE, A; BURGESS, WH; ASO, T; CHEN, DYT; GARRETT, KP; CONAWAY, RC; CONAWAY, JW; LINEHAN, WM; KLAUSNER, RD			INHIBITION OF TRANSCRIPTION ELONGATION BY THE VHL TUMOR-SUPPRESSOR PROTEIN	SCIENCE			English	Article							FACTOR-SIII; IDENTIFICATION	Germline mutations in the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of tumors, including renal carcinoma, hemangioblastoma of the central nervous system, and pheochromocytoma. Here, a cellular transcription factor, Elongin (SIII), is identified as a functional target of the VHL protein. Elongin (SIII) is a heterotrimer consisting of a transcriptionally active subunit (A) and two regulatory subunits (B and C) that activate transcription elongation by RNA polymerase II. The VHL protein was shown to bind tightly and specifically to the Elongin B and C subunits and to inhibit Elongin (SIII) transcriptional activity in vitro. These findings reveal a potentially important transcriptional regulatory network in which the VHL protein may play a key role.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; NCI, SURG BRANCH, UROL ONCOL SECT, BETHESDA, MD 20892 USA; AMER RED CROSS, JEROME H HOLLAND LAB, DEPT BIOL MOLEC, ROCKVILLE, MD 20855 USA; OKLAHOMA MED RES FDN, PROGRAM MOLEC BIOL, OKLAHOMA CITY, OK 73104 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American Red Cross; Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, UNPUB; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Chen D.-Y., UNPUB; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GAO JZ, 1995, CANCER RES, V55, P743; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lis JT, 1994, TRANSCRIPTION MECH R, P459; SHUIN T, 1994, CANCER RES, V54, P2852; TAN SY, 1994, J BIOL CHEM, V269, P25684; TORY K, 1981, JNCI-J NATL CANCER I, V81, P1079; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	26	476	492	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1402	1406		10.1126/science.7660122	http://dx.doi.org/10.1126/science.7660122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660122	Green Submitted			2022-12-24	WOS:A1995RT80600038
J	HARI, KL; SANTERRE, A; SEKELSKY, JJ; MCKIM, KS; BOYD, JB; HAWLEY, RS				HARI, KL; SANTERRE, A; SEKELSKY, JJ; MCKIM, KS; BOYD, JB; HAWLEY, RS			THE MEI-41 GENE OF DROSOPHILA-MELANOGASTER IS A STRUCTURAL AND FUNCTIONAL HOMOLOG OF THE HUMAN ATAXIA-TELANGIECTASIA GENE	CELL			English	Article							CELL-CYCLE CHECKPOINT; X-LINKED MUTANTS; DROSOPHILA-MELANOGASTER; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; DNA DAMAGE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-ABERRATIONS; CHROMATID INTERCHANGES; SOMATIC-CELLS	The D. melanogaster mei-41 gene is required for DNA repair, mitotic chromosome stability, and normal levels of meiotic recombination in oocytes. Here we show that the predicted mei-41 protein is similar in sequence to the ATM (ataxia telangiectasia) protein from humans and to the yeast rad3 and Mec1p proteins. There is also extensive functional overlap between mei-41 and ATM. Like ATM-deficient cells, mei-41 cells are exquisitely sensitive to ionizing radiation and display high levels of mitotic chromosome instability. We also demonstrate that mei-41 cells, like ATM-deficient cells, fail to show an irradiation-induced delay in the entry into mitosis that is characteristic of normal cells. Thus, the mei-41 gene of Drosophila may be considered to be a functional homolog of the human ATM gene.			HARI, KL (corresponding author), UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616, USA.			Sekelsky, Jeff/0000-0002-4424-677X; Hawley, R. Scott/0000-0002-6478-0494				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARLETT CF, 1985, ATAXIA TELANGIECTASI, P1; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1976, P NATL ACAD SCI USA, V73, P4140, DOI 10.1073/pnas.73.11.4140; BAKER BS, 1978, GENETICS, V90, P531; BAKER BS, 1972, GENETICS, V71, P255; Baker BS, 1976, GENETICS BIOL DROS B, P351; BANGA SS, 1986, MUTAT RES, V163, P157, DOI 10.1016/0027-5107(86)90044-8; BANGA SS, 1995, MOL GEN GENET, V246, P148, DOI 10.1007/BF00294677; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BOYD JB, 1976, GENETICS, V84, P485; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CALVI BR, 1994, EMBO J, V13, P1636, DOI 10.1002/j.1460-2075.1994.tb06427.x; CARPENTER AT, 1974, GENETICS, V76, P453; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRIEDBERG EC, 1995, DNA REPAIR; GATTI M, 1980, P NATL ACAD SCI-BIOL, V77, P1575, DOI 10.1073/pnas.77.3.1575; GATTI M, 1974, GENETICS, V77, P701; GATTI M, 1979, P NATL ACAD SCI USA, V76, P1377, DOI 10.1073/pnas.76.3.1377; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAWLEY RS, 1989, ANNU REV GENET, V23, P87, DOI 10.1146/annurev.ge.23.120189.000511; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NGUYEN TD, 1979, MUTAT RES, V63, P67, DOI 10.1016/0027-5107(79)90104-0; PIMPINELLI S, 1976, MUTAT RES, V35, P101, DOI 10.1016/0027-5107(76)90172-X; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YAMAMOTO AH, 1990, MUTAT RES, V29, P17	47	248	259	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					815	821		10.1016/0092-8674(95)90478-6	http://dx.doi.org/10.1016/0092-8674(95)90478-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671309	Bronze			2022-12-24	WOS:A1995RU75500016
J	KIM, J; IRVINE, KD; CARROLL, SB				KIM, J; IRVINE, KD; CARROLL, SB			CELL RECOGNITION, SIGNAL INDUCTION, AND SYMMETRICAL GENE ACTIVATION AT THE DORSAL-VENTRAL BOUNDARY OF THE DEVELOPING DROSOPHILA WING	CELL			English	Article							IMAGINAL DISK; ENCODES; SERRATE	Appendage formation in insects and vertebrates depends upon signals from both the anterior-posterior and dorsal-ventral (DV) axes. In Drosophila, wing formation is organized symmetrically around the DV boundary of the growing wing imaginal disc and requires interactions between dorsal and ventral cells. Compartmentalization of the wing disc, dorsal cell behavior, and the expression of two dorsally expressed putative signaling molecules, fringe (fng) and Serrate (Ser), are regulated by the apterous selector gene. Here, we demonstrate that fng and Ser have distinct roles in a novel cell recognition and signal induction process. fng serves as a boundary-determining molecule such that Ser is induced wherever cells expressing fng and cells not expressing fng are juxtaposed. Ser in turn triggers the expression of genes involved in wing growth and patterning on both sides of the DV boundary.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	KIM, J (corresponding author), UNIV WISCONSIN, MOLEC BIOL LAB, HOWARD HUGHES MED INST, MADISON, WI 53706 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER; NICHD NIH HHS [5R01-HD22780] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1995, DEVELOPMENT, V121, P619; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; HIZN U, 1994, CELL, V76, P77; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; LABORDA J, 1993, J BIOL CHEM, V268, P3817; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; Meinhardt H., 1991, Seminars in Developmental Biology, V2, P129; MORATA G, 1979, DEV BIOL, V70, P355, DOI 10.1016/0012-1606(79)90033-2; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PADDOCK SW, 1993, BIOTECHNIQUES, V14, P42; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANICOLA M, 1995, GENETICS, V139, P745; SPREICHER S, 1994, DEVELOPMENT, V120, P535; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; TIONG SYK, 1995, DEVELOPMENT, V121, P1649; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223	39	243	245	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					795	802		10.1016/0092-8674(95)90476-X	http://dx.doi.org/10.1016/0092-8674(95)90476-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671307	Bronze			2022-12-24	WOS:A1995RU75500014
J	LEVIN, M; JOHNSON, RL; STERN, CD; KUEHN, M; TABIN, C				LEVIN, M; JOHNSON, RL; STERN, CD; KUEHN, M; TABIN, C			A MOLECULAR PATHWAY DETERMINING LEFT-RIGHT ASYMMETRY IN CHICK EMBRYOGENESIS	CELL			English	Article							AXIAL STRUCTURES; BODY ASYMMETRY; EMBRYO; PATTERN; ACTIVIN; BLASTODERM; EXPRESSION; INDUCTION; MUTATION; HEART	While significant progress has been made in understanding the molecular events underlying the early specification of the antero-posterior and dorso-ventral axes, little information is available regarding the cellular or molecular basis for left-right (LR) differences in animal morphogenesis. We describe the expression patterns of three genes involved in LR determination in chick embryos: activin receptor IIa, Sonic hedgehog (Shh), and cNR-1 (related to the mouse gene nodal). These genes are expressed asymmetrically during and after gastrulation and regulate the expression of one another in a sequential pathway. Moreover, manipulation of the sidedness of either activin protein or Shh expression alters heart situs. Together, these observations identify a cascade of molecular asymmetry that determines morphological LR asymmetry in the chick embryo.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; NIH,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	Columbia University; National Institutes of Health (NIH) - USA	LEVIN, M (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.		Stern, Claudio D/C-6265-2008; Levin, Michael/A-5918-2011; Stern, Claudio/AAZ-7381-2021; Kuehn, Michael R/A-4573-2014	Stern, Claudio D/0000-0002-9907-889X; Levin, Michael/0000-0001-7292-8084; Stern, Claudio/0000-0002-9907-889X; Kuehn, Michael R/0000-0002-7703-9160				BROWN NA, 1991, CIBA F SYMP, V162, P182; CONLON FL, 1994, DEVELOPMENT, V120, P1919; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; DANOS MC, 1995, DEVELOPMENT, V121, P1467; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELDER FF, 1993, SCIENCE, V260, P679; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; FUJINAGA M, 1991, DEV BIOL, V143, P203, DOI 10.1016/0012-1606(91)90067-D; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARA K, 1978, ORG MILESTONE HALF C, P221; HOYLE C, 1992, DEVELOPMENT, V115, P1071; Hummel K. P., 1959, Journal of Heredity, V50, P9; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KAUFMAN MH, 1981, J ANAT, V133, P235; KINOSHITA K, 1993, DEV BIOL, V160, P276, DOI 10.1006/dbio.1993.1305; KLAR AJS, 1994, TRENDS GENET, V10, P292; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAYTON WM, 1993, TERATOLOGY, V47, P595, DOI 10.1002/tera.1420470611; MCCAIN ER, 1994, DEVELOPMENT, V120, P395; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROSLINK H, 1994, CELL, V76, P761; SALAZAR DEL RIO J, 1974, Journal of Embryology and Experimental Morphology, V31, P199; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHREINER CM, 1993, DEV BIOL, V158, P560, DOI 10.1006/dbio.1993.1214; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; STALSBER.H, 1969, DEV BIOL, V19, P109, DOI 10.1016/0012-1606(69)90051-7; STEIN S, 1995, MECH DEVELOP, V49, P37, DOI 10.1016/0925-4773(94)00300-C; Stern CD, 1993, ESSENTIAL DEV BIOL P; STERN CD, 1995, IN PRESS DEV BIOL; STOREY KG, 1992, DEVELOPMENT, V114, P729; STREIT A, 1994, TRENDS GENET, V10, P181, DOI 10.1016/0168-9525(94)90240-2; TOYAMA R, 1995, DEVELOPMENT, V121, P383; VIRAGH S, 1989, J MOL CELL CARDIOL, V21, P123, DOI 10.1016/0022-2828(89)90856-0; Waddington CH, 1933, J EXP BIOL, V10, P38; WADDINGTON CH, 1932, PHILOS T ROY SOC B, V13, P221; Wilhelmi H, 1921, ARCH ENTWICKLUNG ORG, V48, P517, DOI 10.1007/BF02554577; YOKOTA C, 1995, BIOCHEM BIOPH RES CO, V207, P1, DOI 10.1006/bbrc.1995.1144; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; YOST HJ, 1991, CIBA F SYMP, V162, P165; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0; ZIV T, 1992, DEVELOPMENT, V115, P689	53	638	656	0	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					803	814		10.1016/0092-8674(95)90477-8	http://dx.doi.org/10.1016/0092-8674(95)90477-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671308	Bronze			2022-12-24	WOS:A1995RU75500015
J	GOLDBERG, J; HUANG, HB; KWON, YG; GREENGARD, P; NAIRN, AC; KURIYAN, J				GOLDBERG, J; HUANG, HB; KWON, YG; GREENGARD, P; NAIRN, AC; KURIYAN, J			3-DIMENSIONAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN SERINE/THREONINE PHOSPHATASE-1	NATURE			English	Article							MICROCYSTIN-LR; CALCINEURIN; IDENTIFICATION; MECHANISM; DOMAIN; HYDROLYSIS; REFINEMENT; ISOFORMS; ENZYME; ACID	The crystal structure of mammalian protein phosphatase-1, complexed with the toxin microcystin and determined at 2.1 Angstrom resolution, reveals that it is a metalloenzyme unrelated in architecture to the tyrosine phosphatases. Two metal ions are positioned by a central beta-alpha-beta-alpha-beta scaffold at the active site, from which emanate three surface grooves that are potential binding sites for substrates and inhibitors. The carboxy terminus is positioned at the end of one of the grooves such that regulatory sequences following the domain might modulate function. The fold of the catalytic domain is expected to be closely preserved in protein phosphatases 2A and 2B (calcineurin).	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University				Nairn, Angus/0000-0002-7075-0195				ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAGY JR, 1995, NAT STRUCT BIOL, V2, P114, DOI 10.1038/nsb0295-114; BARFORD D, 1994, J MOL BIOL, V235, P763, DOI 10.1006/jmbi.1994.1027; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; COHEN P, 1989, REV BIOCH, V58, P453; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; FISCHER EH, 1982, TRENDS BIOCHEM SCI, V7, P3, DOI 10.1016/0968-0004(82)90051-2; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEMMINGS HCJ, 1995, MOL CELLUAR MECHANIS, P279; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JENNY TF, 1995, PROTEINS, V21, P1, DOI 10.1002/prot.340210102; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM YH, 1993, J BIOL CHEM, V268, P18513; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KING MM, 1984, J BIOL CHEM, V259, P8847; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KOONIN EV, 1994, PROTEIN SCI, V3, P356; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIWAKIMATSUSHIMA R, 1992, J CANCER RES CLIN, V118, P420, DOI 10.1007/BF01629424; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; STONE RL, 1994, J BIOL CHEM, V269, P31323; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; VINCENT JB, 1991, J BIOL CHEM, V266, P17737; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997; ZHANG ZJ, 1993, MOL CELL BIOCHEM, V128, P113, DOI 10.1007/BF01076762; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	50	730	746	4	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					745	753		10.1038/376745a0	http://dx.doi.org/10.1038/376745a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651533				2022-12-24	WOS:A1995RR83600032
J	KHARBANDA, S; REN, RB; PANDEY, P; SHAFMAN, TD; FELLER, SM; WEICHSELBAUM, RR; KUFE, DW				KHARBANDA, S; REN, RB; PANDEY, P; SHAFMAN, TD; FELLER, SM; WEICHSELBAUM, RR; KUFE, DW			ACTIVATION OF THE C-ABL TYROSINE KINASE IN THE STRESS-RESPONSE TO DNA-DAMAGING AGENTS	NATURE			English	Article							CELL-CYCLE; PHOSPHORYLATION; BINDING	THE product of the c-abl gene is a non-receptor tyrosine kinase that is localized to the nucleus and cytoplasm. The precise function of c-Abl is unknown. Here we show that ionizing radiation activates c-Abl. Similar results were obtained with the alkylating agents cis-platinum and mitomycin C. We also demonstrate that cells deficient in c-Abl fail to activate Jun kinase (JNK/SAP kinase) after ionizing radiation or alkylating agent exposure and that reconstitution of c-Abl in these cells restores that response. In contrast, the stress response to tumour-necrosis factor is stimulated by a c-Abl-independent mechanism. These findings indicate that c-abl is involved in the stress response to DNA-damaging agents.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,DEPT BIOL,WALTHAM,MA 02254; UNIV WURZBURG,INST RADIOBIOL & CELL BIOL,MOLEC ONCOL LAB,D-97078 WURZBURG,GERMANY; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115	Brandeis University; University of Wurzburg; University of Chicago; Harvard University; Harvard Medical School	KHARBANDA, S (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CAN PHARMACOL,BOSTON,MA 02115, USA.							DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MATTIONI T, 1995, ONCOGENE, V10, P1325; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SALEEM A, 1995, J IMMUNOL, V154, P4150; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TOMASZ M, 1988, BIOCHEMISTRY-US, V27, P3182, DOI 10.1021/bi00409a009; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	19	454	470	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					785	788		10.1038/376785a0	http://dx.doi.org/10.1038/376785a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651539				2022-12-24	WOS:A1995RR83600043
J	LOVE, JJ; LI, XA; CASE, DA; GIESE, K; GROSSCHEDL, R; WRIGHT, PE				LOVE, JJ; LI, XA; CASE, DA; GIESE, K; GROSSCHEDL, R; WRIGHT, PE			STRUCTURAL BASIS FOR DNA BENDING BY THE ARCHITECTURAL TRANSCRIPTION FACTOR LEF-1	NATURE			English	Article							ALPHA-ENHANCER; NUCLEOPROTEIN STRUCTURES; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; MINOR-GROOVE; HMG DOMAIN; PROTEINS; BINDING; COMPLEX; TCF-1	LYMPHOID enhancer-binding factor (LEF-1) and the closely related T-cell factor 1 (TCF-1) are sequence-specific and cell-type-specific DNA-binding proteins that play important regulatory roles in organogenesis and thymocyte differentiation(1-5). LEF-1 participates in regulation of the enhancer associated with the T cell receptor (TCR)-alpha gene by inducing a sharp bend in the DNA and facilitating interactions between Ets-1, PEBP2-alpha, and ATF/CREB transcription factors bound at sites flanking the LEF-1 site(1,2,6,7). It seems that LEF-1 plays an architectural role in the assembly and function of this regulatory nucleoprotein complex(7,8). LEF-1 recognizes a specific nucleotide sequence through a high-mobilty-group (HMG) domain(1,2). Proteins containing HMG domains bind DNA in the minor groove, bend the double helix(6,9,10), and recognize four-way junctions and other irregular DNA structures(9,11). Here we report the solution structure of a complex of the LEF-1 HMG domain and adjacent basic region with its cognate DNA. The structure reveals the HMG domain bound in the widened minor groove of a markedly distorted and bent double helix. The basic region binds across the narrowed major groove and contributes to DNA recognition.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, SAN DIEGO, CA 92037 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Wright, Peter/0000-0002-1368-0223				CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GLESE K, 1991, GENE DEV, V5, P2567; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETERS R, 1995, BIOCHEMISTRY-US, V34, P4569, DOI 10.1021/bi00014a009; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SEIP S, 1994, J MAGN RESON SER B, V104, P172, DOI 10.1006/jmrb.1994.1072; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	31	527	536	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					791	795		10.1038/376791a0	http://dx.doi.org/10.1038/376791a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651541				2022-12-24	WOS:A1995RR83600045
J	REEVE, MA; FULLER, CW				REEVE, MA; FULLER, CW			A NOVEL THERMOSTABLE POLYMERASE FOR DNA-SEQUENCING	NATURE			English	Article							DOUBLE-STRANDED DNA; TAQ POLYMERASE; EXONUCLEASE ACTIVITY; GENE; PCR		AMERSHAM LIFE SCI INC,CLEVELAND,OH 44128		REEVE, MA (corresponding author), AMERSHAM INT PLC,AMERSHAM RES LABS,WHITE LION RD,AMERSHAM HP7 9LL,BUCKS,ENGLAND.			Fuller, Carl/0000-0003-2277-2119; Reeve, Michael/0000-0002-0747-9902				AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P498; JOYCE CM, 1982, J BIOL CHEM, V257, P1958; KLENOW H, 1971, EUR J BIOCHEM, V22, P371, DOI 10.1111/j.1432-1033.1971.tb01554.x; Lawyer F C, 1993, PCR Methods Appl, V2, P275; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LEVEDAKOU EN, 1989, BIOTECHNIQUES, V7, P438; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; SAMOLS SB, 1995, COMMENTS, V21, P57; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339	13	59	90	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					796	797		10.1038/376796a0	http://dx.doi.org/10.1038/376796a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651542				2022-12-24	WOS:A1995RR83600046
J	LANE, RJM; BURGESS, AP; FLINT, J; RICCIO, M; ARCHARD, LC				LANE, RJM; BURGESS, AP; FLINT, J; RICCIO, M; ARCHARD, LC			EXERCISE RESPONSES AND PSYCHIATRIC-DISORDER IN CHRONIC FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article									CHARING CROSS & WESTMINSTER MED SCH,DEPT PSYCHIAT,LONDON W6 8RF,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT BIOCHEM,LONDON W6 8RF,ENGLAND	Imperial College London; Imperial College London	LANE, RJM (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT NEUROSCI,LONDON W6 8RF,ENGLAND.			Burgess, Adrian P/0000-0002-0977-8105				DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; LANE RJM, 1994, J NEUROL NEUROSUR PS, V57, P662, DOI 10.1136/jnnp.57.5.662-a; NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Wing J. K. C., 1974, MEASUREMENT CLASSIFI	5	18	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					544	545		10.1136/bmj.311.7004.544	http://dx.doi.org/10.1136/bmj.311.7004.544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663210	Green Published			2022-12-24	WOS:A1995RR73700020
J	THORLACIUS, S; TRYGGVADOTTIR, L; OLAFSDOTTIR, GH; JONASSON, JG; OGMUNDSDOTTIR, HM; TULINIUS, H; EYFJORD, JE				THORLACIUS, S; TRYGGVADOTTIR, L; OLAFSDOTTIR, GH; JONASSON, JG; OGMUNDSDOTTIR, HM; TULINIUS, H; EYFJORD, JE			LINKAGE TO BRCA2 REGION IN HEREDITARY MALE BREAST-CANCER	LANCET			English	Note							ANDROGEN RECEPTOR GENE; FAMILIES; RISKS	Breast cancer is rare in men, and family history of the disease is a risk factor. The recently discovered BRCA2 gene on chromosome 13q is thought to account for some families with increased risk of breast cancer, including male breast cancer. We descibe a family with multiple cases of male breast cancer but, interestingly, no increase in female breast cancer. Linkage to the BRCA2 region is demonstrated and all the affected men share the same haplotype for the BCRA2 markers and loss of the other alleles in their tumours.	ICELAND CANC SOC, MOLED & CELL BIOL RES LAB, IS-125 REYKJAVIK, ICELAND; ICELAND CANC SOC, ICELAND CANC REGISTRY, IS-125 REYKJAVIK, ICELAND; UNIV HOSP REYKJAVIK, DEPT PATHOL, REYKJAVIK, ICELAND	Landspitali National University Hospital			Ögmundsdóttir, Helga M/L-6970-2015	Tryggvadottir, Laufey/0000-0001-8067-9030; Jonasson, Jon G./0000-0002-2635-5032				ANDERSON DE, 1992, J NATL CANCER I, V84, P1114, DOI 10.1093/jnci/84.14.1114; BORRESEN AL, 1992, CANCER RES, V52, P3234; COLLINS N, 1995, ONCOGENE, V10, P1673; EASTON DF, 1993, AM J HUM GENET, V52, P678; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LOBACCARO JM, 1993, NAT GENET, V5, P109, DOI 10.1038/ng1093-109; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; TULINIUS H, 1992, J MED GENET, V29, P158, DOI 10.1136/jmg.29.3.158; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	10	80	84	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 26	1995	346	8974					544	545		10.1016/S0140-6736(95)91383-1	http://dx.doi.org/10.1016/S0140-6736(95)91383-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658781				2022-12-24	WOS:A1995RQ98600011
J	LEAKEY, MG; FEIBEL, CS; MCDOUGALL, I; WALKER, A				LEAKEY, MG; FEIBEL, CS; MCDOUGALL, I; WALKER, A			NEW 4-MILLION-YEAR-OLD HOMINID SPECIES FROM KANAPOI AND ALLIA BAY, KENYA	NATURE			English	Article							HADAR FORMATION; ETHIOPIA; AUSTRALOPITHECUS; MORPHOLOGY; TURKANA	Nine hominid dental, cranial and postcranial specimens from Kanapoi, Henya, and 12 specimens from Allia Bay, Kenya, are described here as a new species of Australopithecus dating from between about 3.9 million and 4.2 million years ago. The mosaic of primitive and derived features shows this species to be a possible ancestor to Australopithecus afarensis and suggests that Ardipithecus ramidus is a sister species to this and all later hominids. A tibia establishes that hominids were bipedal at least half a million years before the previous earliest evidence showed.	RUTGERS STATE UNIV, DEPT ANTHROPOL, NEW BRUNSWICK, NJ 08903 USA; AUSTRALIAN NATL UNIV, RES SCH EARTH SCI, CANBERRA, ACT 0200, AUSTRALIA; PENN STATE UNIV, DEPT ANTHROPOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT BIOL, UNIVERSITY PK, PA 16802 USA	Rutgers State University New Brunswick; Australian National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	LEAKEY, MG (corresponding author), NATL MUSEUMS KENYA, POB 40658, NAIROBI, KENYA.		Klein, Richard G/B-5910-2009					Aiello L, 1990, INTRO HUMAN EVOLUTIO; Brown F. H., 1991, KOOBI FORA RES PROJE, V3, P1; Cebula G. T., 1986, TERRA COGNITA, V6, P139; COFFING K, 1994, AM J PHYS ANTHROPOL, V93, P55, DOI 10.1002/ajpa.1330930104; Day M.H., 1978, EARLY HOMINIDAFRIC, P311; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; Harris J.M., 1987, P524; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; KOHLLARSON L, 1942, SPUREN VORMENSCHEN F; LATIMER B, 1987, AM J PHYS ANTHROPOL, V74, P155, DOI 10.1002/ajpa.1330740204; MCDOUGALL I, 1985, GEOL SOC AM BULL, V96, P159, DOI 10.1130/0016-7606(1985)96<159:KAADOT>2.0.CO;2; MCDOUGALL I, 1988, GEOCHRONOLOGY THERMO; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; NAMWAMBA F, 1983, THESIS U UTAH; PATTERSON B, 1967, SCIENCE, V156, P64, DOI 10.1126/science.156.3771.64; PUECH PF, 1986, J HUM EVOL, V15, P325, DOI 10.1016/S0047-2484(86)80015-X; SENUT B, 1980, COLLEGIUM ANTROPOL, V4, P87; Senut B., 1985, P193; STEVEN TA, 1967, US GEOL SURV PROF D, V575, P47; WARD SC, 1982, AM J PHYS ANTHROPOL, V57, P605, DOI 10.1002/ajpa.1330570407; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	25	343	354	1	56	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					565	571		10.1038/376565a0	http://dx.doi.org/10.1038/376565a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP756	7637803				2022-12-24	WOS:A1995RP75600043
J	MACILWAIN, C				MACILWAIN, C			GENE PATENT STUDY DROWNED AS OTA SINKS	NATURE			English	Editorial Material																		1995, NATURE, V375, P711	1	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					541	541						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637791				2022-12-24	WOS:A1995RP75600004
J	PERINI, G; WAGNER, S; GREEN, MR				PERINI, G; WAGNER, S; GREEN, MR			RECOGNITION OF BZIP PROTEINS BY THE HUMAN T-CELL LEUKEMIA-VIRUS TRANSACTIVATOR TAX	NATURE			English	Article							DNA-BINDING SPECIFICITY; LEUCINE ZIPPER MOTIF; ZTA TRANSACTIVATOR; YEAST GCN4; DOMAIN; DIMERIZATION; ACTIVATOR; FAMILY; CREB; AP-1	HUMAN T-cell leukaemia virus type I(HTLV-I) Tax protein increases the DNA binding of many cellular transcription factors that contain a basic region-leucine zipper (bZIP) DNA-binding domain(1-3). bZIP domains comprise a leucine-rich dimerization motif and a basic region that mediates DNA contact. How Tax recognizes diverse bZIPs is not understood. Here we show that no specific sequence of the leucine zipper is required for a Tax response. In contrast, the basic region is essential for the Tax-mediated DNA-binding increase, which can be eliminated by single substitutions of several conserved amino acids. Surprisingly, Tax alters the relative affinity of a bZIP for different DNA binding sites. Thus, through recognition of the conserved basic region, Tax increases DNA binding and modifies DNA site selection. Tax provides a model for how a single auxiliary factor can regulate multiple sequence-specific DNA-binding proteins.			PERINI, G (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605, USA.							ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEI D, 1994, P NATL ACAD SCI USA, V91, P11318; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	16	136	136	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					602	605		10.1038/376602a0	http://dx.doi.org/10.1038/376602a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637811				2022-12-24	WOS:A1995RP75600054
J	WEN, W; MEINKOTH, JL; TSIEN, RY; TAYLOR, SS				WEN, W; MEINKOTH, JL; TSIEN, RY; TAYLOR, SS			IDENTIFICATION OF A SIGNAL FOR RAPID EXPORT OF PROTEINS FROM THE NUCLEUS	CELL			English	Article							SV40 T-ANTIGEN; ESCHERICHIA-COLI; MESSENGER-RNA; PORE COMPLEX; CYCLIC-AMP; 2 STEPS; TRANSPORT; TRANSLOCATION; IMPORT; KINASE	Active nuclear import of protein is controlled by nuclear localization signals (NLSs), but nuclear export is not understood well. Nuclear trafficking of the catalytic (C) subunit of cAMP-dependent protein kinase (cAPK) is critical for regulation of gene expression. The heat-stable inhibitor (PKI) of cAPK contains a nuclear export signal (NES) that triggers rapid, active net extrusion of the C-PKI complex from the nucleus. This NES (residues 35-49), fused or conjugated to heterologous proteins, was sufficient for rapid nuclear export. Hydrophobic residues were critical. The NES is a slightly weaker signal than the SV40 NLS. A sequence containing only residues 37-46, LALKLAGLDI, is also sufficient for nuclear export. This is an example of a protein-based NES having no obvious association with RNA. A similar sequence, LQLPPLERLTL, from Rev, an RNA-binding protein of HIV-1, also is an NES.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of Pennsylvania; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	WEN, W (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.		Meinkoth, Judy L/G-2900-2010		NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BOHNLEIN E, 1991, J VIROL, V65, P7051; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB D S, 1991, Current Biology, V1, P212, DOI 10.1016/0960-9822(91)90059-6; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUIOCHON MA, 1994, P NATL ACAD SCI USA, V91, P7179; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; THOMAS J, 1991, J BIOL CHEM, V266, P10906; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEN W, 1994, J BIOL CHEM, V269, P8423; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; WEN W, 1994, J BIOL CHEM, V269, P32214; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	60	1000	1023	0	44	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					463	473		10.1016/0092-8674(95)90435-2	http://dx.doi.org/10.1016/0092-8674(95)90435-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634336	hybrid			2022-12-24	WOS:A1995RP24200016
J	FRITZ, CC; ZAPP, ML; GREEN, MR				FRITZ, CC; ZAPP, ML; GREEN, MR			A HUMAN NUCLEOPORIN-LIKE PROTEIN THAT SPECIFICALLY INTERACTS WITH HIV REV	NATURE			English	Article							VIRUS TYPE-1 REV; PORE COMPLEX PROTEIN; ACTIVATION DOMAIN; I REX; DEFINITION; MOTIF	THE Rev protein of human immunodeficiency virus type I (HIV-1) facilitates the nuclear export of unspliced and partly spliced viral RNAs. Rev contains an RNA binding domain, required for interaction with HIV-1 RNA, and an effector domain, required for RNA-bound Rev to function. The Rev effector domain is believed to interact with a cellular cofactor required for the Rev response and thus HIV-1 replication(1,2). Here we report the use of a yeast two-hybrid screen to clone human Rev interacting protein (hRIP), which specifically interacts with the Rev effector domain. This hRIP protein has hemology with nucleoporins, a class of proteins that mediate nucleocytoplasmic transport(3,4). These and other properties of hRIP are those expected of a Rev cellular cofactor.			FRITZ, CC (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,SUITE 309,WORCESTER,MA 01605, USA.		Williamson, James R/B-2891-2009	Williamson, James R/0000-0002-8772-468X				CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GORSCH LC, 1995, CELL BIOL, V129, P939; Green MR, 1993, AIDS RES REV, V3, P41; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; ZHANG GH, 1994, NATURE, V372, P809	20	238	243	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					530	533		10.1038/376530a0	http://dx.doi.org/10.1038/376530a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637788				2022-12-24	WOS:A1995RN62200050
J	MADDOX, J				MADDOX, J			DIRECTORY TO THE HUMAN GENOME	NATURE			English	Article																			0	7	7	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					459	460		10.1038/376459a0	http://dx.doi.org/10.1038/376459a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637774				2022-12-24	WOS:A1995RN62200017
J	AVERY, AC; ZHAO, ZS; RODRIGUEZ, A; BIKOFF, EK; SOHEILIAN, M; FOSTER, CS; CANTOR, H				AVERY, AC; ZHAO, ZS; RODRIGUEZ, A; BIKOFF, EK; SOHEILIAN, M; FOSTER, CS; CANTOR, H			RESISTANCE TO HERPES STROMAL KERATITIS CONFERRED BY AN IGG2A-DERIVED PEPTIDE	NATURE			English	Article							T-CELL CLONES; SIMPLEX KERATITIS; ANTIGEN; MICE; MHC; UNRESPONSIVENESS; SUSCEPTIBILITY; DETERMINANTS; LYMPHOCYTES; ALLOTYPE	NOT all peripheral tissue antigens enter the thymus and it is unclear how the immune system remains tolerant to this class of self antigen. As tolerance to self peptides can generate gaps in the T-cell repertoire for cross-reactive foreign antigens(1,2), we investigated whether this mechanism might also diminish autoimmune reactions to similar peptides expressed by peripheral tissues. Herpes stromal keratitis (HSK) is a virally induced autoimmune reaction against corneal tissues mediated by T cells(3-5), and is a leading cause of human blindness(6). Resistance to HSK in mice is associated with allotypic variation in immunoglobulin genes(7,8), possibly because circulating immunoglobin-derived peptides can cross-tolerize T cells specific for corneal tissue autoantigens. Here we show that HSK is mediated by T-cell clones specific for corneal self antigens which also recognize an allotype-bearing peptide derived from IgG2a, and that exposure of HSK-susceptible mice to a soluble form of this peptide confers resistance to HSK. Shared expression of peptide subsequences between sequestered tissue proteins and circulating proteins may be important for maintenance of self-tolerance and prevention of autoimmunity.	HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM,SCH MED, DEPT OPHTHALMOL,HILLES IMMUNOL LAB, BOSTON, MA 02114 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University	AVERY, AC (corresponding author), HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT PATHOL, IMMUNOPATHOL LAB, 44 BINNEY ST, BOSTON, MA 02115 USA.		Soheilian, Masoud/AAW-4743-2020; Rodriguez-Garcia, Alejandro/AAI-1045-2019; Avery, Anne/J-8405-2017	Rodriguez-Garcia, Alejandro/0000-0002-1419-2109; Soheilian, Masoud/0000-0001-7508-426X				ABROMSONLEEMAN S, 1995, J IMMUNOL, V154, P388; AKOVA YA, 1993, CURR EYE RES, V12, P1093, DOI 10.3109/02713689309033507; ALEXANDER RJ, 1981, EXP EYE RES, V32, P205, DOI 10.1016/0014-4835(81)90009-9; BARTNES K, 1991, EUR J IMMUNOL, V21, P2365, DOI 10.1002/eji.1830211011; BIKOFF E, 1986, J IMMUNOL, V137, P28; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1411, DOI 10.1002/eji.1830210613; BIKOFF EK, 1989, EUR J IMMUNOL, V19, P1903, DOI 10.1002/eji.1830191022; CALLANAN D, 1988, TRANSPLANTATION, V45, P437, DOI 10.1097/00007890-198802000-00039; CLAVERIE JM, 1988, EUR J IMMUNOL, V18, P1547, DOI 10.1002/eji.1830181012; DAWSON C, 1976, SURV OPHTHALMOL, V21, P11; DEWIT D, 1992, J EXP MED, V175, P9, DOI 10.1084/jem.175.1.9; FELLER DC, 1991, NATURE, V349, P720, DOI 10.1038/349720a0; FOSTER CS, 1986, CLIN IMMUNOL IMMUNOP, V40, P313, DOI 10.1016/0090-1229(86)90036-X; FRIEDMAN S, 1987, IMMUNOGENETICS, V26, P193, DOI 10.1007/BF00346512; GARCHON HJ, 1991, HUM IMMUNOL, V32, P1, DOI 10.1016/0198-8859(91)90113-N; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; MARSHAKROTHSTEIN A, 1980, P NATL ACAD SCI-BIOL, V77, P1120, DOI 10.1073/pnas.77.2.1120; MATZINGER P, 1981, NATURE, V292, P497, DOI 10.1038/292497a0; MERCADAL CM, 1993, J VIROL, V67, P3404, DOI 10.1128/JVI.67.6.3404-3408.1993; METCALF JF, 1979, INFECT IMMUN, V26, P1164, DOI 10.1128/IAI.26.3.1164-1171.1979; MOUDGIL KD, 1993, J EXP MED, V178, P2131, DOI 10.1084/jem.178.6.2131; Niederkorn J Y, 1990, Adv Immunol, V48, P191, DOI 10.1016/S0065-2776(08)60755-5; OPREMCAK EM, 1990, INVEST OPHTH VIS SCI, V31, P305; OPREMCAK EM, 1988, INVEST OPHTH VIS SCI, V29, P749; ROSS J, 1989, Investigative Ophthalmology and Visual Science, V30, P442; RUSSELL RG, 1984, INVEST OPHTH VIS SCI, V25, P938; VIDOVIC D, 1988, NATURE, V336, P222, DOI 10.1038/336222a0	27	99	101	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					431	434		10.1038/376431a0	http://dx.doi.org/10.1038/376431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630419				2022-12-24	WOS:A1995RM63900053
J	SCHILLER, PH				SCHILLER, PH			EFFECT OF LESIONS IN VISUAL CORTICAL AREA V4 ON THE RECOGNITION OF TRANSFORMED OBJECTS	NATURE			English	Article							STATE DEPENDENT ACTIVITY; BROAD-BAND CHANNELS; COLOR-OPPONENT; RHESUS-MONKEY; CORTEX; MACAQUE; DISCRIMINATION; PERCEPTION; VISION; DEPTH	THE primate visual system has a remarkable capability for recognizing objects irrespective of the multitude of images they form on the retinal surface by virtue of changes in size, perspective, contrast, colour and partial obstruction by other stimuli in the visual scene. There is increasing evidence that this remarkable capacity is brought about by processes that occur earlier in the visual system than had previously been thought(1-14). Here I show that after ablation of area V4 in the rhesus monkey, major deficits arise in the recognition of objects that have been transformed in size, in the degree of occlusion, and in the amount of contour information provided. The ability to detect these objects when presented individually was unaffected by these lesions.			SCHILLER, PH (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-634,CAMBRIDGE,MA 02139, USA.							DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1992, NATURE, V358, P756, DOI 10.1038/358756a0; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; HAENNY PE, 1988, EXP BRAIN RES, V69, P245, DOI 10.1007/BF00247570; HEYWOOD CA, 1992, J NEUROSCI, V12, P4056; HEYWOOD CA, 1987, J NEUROSCI, V7, P2601; HUBEL DH, 1970, NATURE, V225, P41, DOI 10.1038/225041a0; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2190; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SCHILLER PH, 1991, SCIENCE, V251, P1251, DOI 10.1126/science.2006413; SCHILLER PH, 1993, VISUAL NEUROSCI, V10, P717, DOI 10.1017/S0952523800005423; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; SCHILLER PH, IN PRESS BEHAV BRAIN; WALSH V, 1992, BEHAV BRAIN RES, V50, P115, DOI 10.1016/S0166-4328(05)80293-1; WEISKRANTZ L, 1984, BRAIN, V107, P1033, DOI 10.1093/brain/107.4.1033; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0; ZEKI SM, 1973, BRAIN RES, V53, P422, DOI 10.1016/0006-8993(73)90227-8	20	64	64	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					342	344		10.1038/376342a0	http://dx.doi.org/10.1038/376342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630401				2022-12-24	WOS:A1995RL44300047
J	ZHU, N; LIGGITT, D; LIU, Y; DEBS, R				ZHU, N; LIGGITT, D; LIU, Y; DEBS, R			SYSTEMIC GENE-EXPRESSION AFTER INTRAVENOUS DNA DELIVERY INTO ADULT MICE	SCIENCE			English	Article							TRANSGENIC ANIMALS; HIGHLY EFFICIENT; TRANSFECTION; INVIVO; LIPOFECTION	Direct gene transfer into adult animals resulting in generalized or tissue-specific expression would facilitate rapid analysis of transgene effects and allow precise in vivo manipulation of biologic processes at the molecular level. A single intravenous injection of expression plasmid:cationic liposome complexes into adult mice efficiently transfected virtually all tissues. In addition to vascular endothelial cells, most of the extravascular parenchymal cells present in many tissues including the lung, spleen, lymph nodes, and bone marrow expressed the transgene without any apparent treatment-related toxicity. The transgene was still expressed in large numbers of cells in multiple tissues for at least 9 weeks after a single injection. Expression could be targeted to specific tissues and cell types, depending on the promoter element used.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,SCH MED,DEPT COMPARAT MED,SEATTLE,WA 98195	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle								ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; DEBS R, 1992, AM J RESP CELL MOL, V7, P406, DOI 10.1165/ajrcmb/7.4.406; DEBS RJ, 1987, BIOCHIM BIOPHYS ACTA, V901, P183, DOI 10.1016/0005-2736(87)90114-3; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JARNAGIN WR, 1992, NUCLEIC ACIDS RES, V20, P4205, DOI 10.1093/nar/20.16.4205; JULIANO RL, 1983, LIPOSOMES, P53; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MARUYAMA K, 1990, P NATL ACAD SCI USA, V87, P5744, DOI 10.1073/pnas.87.15.5744; MERLINO GT, 1991, FASEB J, V5, P2996, DOI 10.1096/fasebj.5.14.1752364; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZHU N, UNPUB	24	683	864	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					209	211		10.1126/science.7687073	http://dx.doi.org/10.1126/science.7687073			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	7687073				2022-12-24	WOS:A1993LL59600040
J	FOULKES, NS; SCHLOTTER, F; PEVET, P; SASSONECORSI, P				FOULKES, NS; SCHLOTTER, F; PEVET, P; SASSONECORSI, P			PITUITARY-HORMONE FSH DIRECTS THE CREM FUNCTIONAL SWITCH DURING SPERMATOGENESIS	NATURE			English	Article							GOLDEN-HAMSTERS; GENE; TRANSCRIPTION; SEQUENCE	THE CREM (cyclic AMP-responsive element modulator) gene encodes multiple regulators of the cAMP-transcriptional response by alternative splicing1. A developmental switch in CREM expression occurs during spermatogenesis, whereby CREM function is converted from an antagonist to an activator (CREMtau; ref. 2) which accumulates to extremely high levels from the premeiotic spermatocyte stage onwards. To define the physiological mechanisms controlling the CREM developmental switch, we have hypophysectomized rats and observed the extinction of CREMtau expression in testis, thereby demonstrating a central role of the pituitary-hypothalamic axis. We then used the seasonal-dependent modulation of spermatogenesis in hamsters to dissect the hormonal programme controlling this developmental process. By this approach, combined with direct administration of pituitary-derived hormones, we have established that follicle-stimulating hormone (FSH) is responsible for the CREM switch. FSH appears to regulate CREM expression by alternative polyadenylation, which results in a dramatic enhancement of transcript stability.	CNRS, URA 1332, F-67000 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS)	SASSONECORSI, P (corresponding author), FAC MED STRASBOURG, CNRS, GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891				Bartke A., 1985, The hamster - reproduction and behavior., P73; CROWLEY WF, 1991, RECENT PROG HORM RES, V47, P27; DESJARDINS C, 1971, ENDOCRINOLOGY, V89, P791, DOI 10.1210/endo-89-3-791; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; JEGOU B, 1992, SCHERING F WORKSHOP, V4, P57; JETTON AE, 1991, ENDOCRINOLOGY, V129, P1025, DOI 10.1210/endo-129-2-1025; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; KLEMCKE HG, 1987, BIOL REPROD, V37, P356, DOI 10.1095/biolreprod37.2.356; MAZLUFF WF, 1986, TRANSCRIPTION TRANSL; PEVET P, 1988, REPROD NUTR DEV, V28, P575; RAYNAUD F, 1991, J NEURAL TRANSM-GEN, V83, P235, DOI 10.1007/BF01253393; Reiter R J, 1980, Endocr Rev, V1, P109; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; Santen R. J., 1987, ENDOCRINOL METAB, P821; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; VULLIAMY TJ, 1988, P NATL ACAD SCI USA, V85, P5171, DOI 10.1073/pnas.85.14.5171	19	233	236	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1993	362	6417					264	267		10.1038/362264a0	http://dx.doi.org/10.1038/362264a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	7681549				2022-12-24	WOS:A1993KT02600062
J	WAKSMAN, G; SHOELSON, SE; PANT, N; COWBURN, D; KURIYAN, J				WAKSMAN, G; SHOELSON, SE; PANT, N; COWBURN, D; KURIYAN, J			BINDING OF A HIGH-AFFINITY PHOSPHOTYROSYL PEPTIDE TO THE SRC SH2 DOMAIN - CRYSTAL-STRUCTURES OF THE COMPLEXED AND PEPTIDE-FREE FORMS	CELL			English	Article							SIGNAL TRANSDUCTION; PROTEIN; REFINEMENT	The crystal structure of the Src SH2 domain complexed with a high affinity 11-residue phosphopeptide has been determined at 2.7 angstrom resolution by X-ray diffraction. The peptide binds in an extended conformation and makes primary interactions with the SH2 domain at six central residues: PQ(pY)EEI. The phosphotyrosine and the isoleucine are tightly bound by two well-defined pockets on the protein surface, resulting in a complex that resembles a two-pronged plug engaging a two-holed socket. The glutamate residues are in solvent-exposed environments in the vicinity of basic side chains of the SH2 domain, and the two N-terminal residues cap the phosphotyrosine-binding site. The crystal structure of Src SH2 in the absence of peptide has been determined at 2.5 angstrom resolution, and comparison with the structure of the high affinity complex reveals only localized and relatively small changes.	HOWARD HUGHES MED INST,NEW YORK,NY 10021; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115	Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.	WAKSMAN, G (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.		Cowburn, David/A-8448-2008	Cowburn, David/0000-0001-6770-7172				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1988, XPLOR VERSION 2 2 MA; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; ECK M, 1993, IN PRESS; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, IN PRESS MOL CELL BI; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIU X, 1993, IN PRESS ONCOGENE; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, IN PRESS; PAYNE G, 1993, IN PRESS P NATL ACAD; PICCIONE E, 1993, IN PRESS BIOCHEMISTR; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROSSMANN MG, 1972, INT SCI REV SERIES, V13; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHOELSON SE, 1993, IN PRESS EMBO J, V6; SONGYANG Z, 1993, CELL, V72; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WILLIAMS KP, 1993, IN PRESS J BIOL CHEM; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	45	699	726	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					779	790		10.1016/0092-8674(93)90405-F	http://dx.doi.org/10.1016/0092-8674(93)90405-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680960				2022-12-24	WOS:A1993KR43600013
J	ZHOU, SY; SHOELSON, SE; CHAUDHURI, M; GISH, G; PAWSON, T; HASER, WG; KING, F; ROBERTS, T; RATNOFSKY, S; LECHLEIDER, RJ; NEEL, BG; BIRGE, RB; FAJARDO, JE; CHOU, MM; HANAFUSA, H; SCHAFFHAUSEN, B; CANTLEY, LC				ZHOU, SY; SHOELSON, SE; CHAUDHURI, M; GISH, G; PAWSON, T; HASER, WG; KING, F; ROBERTS, T; RATNOFSKY, S; LECHLEIDER, RJ; NEEL, BG; BIRGE, RB; FAJARDO, JE; CHOU, MM; HANAFUSA, H; SCHAFFHAUSEN, B; CANTLEY, LC			SH2 DOMAINS RECOGNIZE SPECIFIC PHOSPHOPEPTIDE SEQUENCES	CELL			English	Article							MIDDLE-T-ANTIGEN; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; BINDING; POLYOMAVIRUS; PP60C-SRC; GAP; SRC	A phosphopeptide library was used to determine the sequence specificity of the peptide-binding sites of SH2 domains. One group of SH2 domains (Src, Fyn, Lck, Fgr, Abl, Crk, and Nck) preferred sequences with the general motif pTyr-hydrophilic-hydrophilic-Ile/Pro while another group (SH2 domains of p85, phospholipase C-gamma, and SHPTP2) selected the general motif pTyr-hydrophobic-X-hydrophobic. Individual members of these groups selected unique sequences, except the Src subfamily (Src, Fyn, Lck, and Fgr), which all selected the sequence pTyr-Glu-Glu-Ile. The variability in SH2 domain sequences at likely sites of contact provides a structural basis for the phosphopeptide selectivity of these families. Possible in vivo binding sites of the SH2 domains are discussed.	BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; BASF CORP, CAMBRIDGE, MA 02139 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Harvard University; Beth Israel Deaconess Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; BASF; Rockefeller University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tufts University	ZHOU, SY (corresponding author), HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014; Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Cantley, Lewis C/0000-0002-1298-7653; 				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, IN PRESS J BIOL CHEM; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; DOMCHEK S, 1993, BIOCHEMISTRY-US, V31, P9865; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LIU X, 1993, IN PRESS ONCOGENE; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHUMACHER TNM, 1992, EUR J IMMUNOL, V22, P1405, DOI 10.1002/eji.1830220612; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	41	2487	2701	0	38	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					767	778		10.1016/0092-8674(93)90404-E	http://dx.doi.org/10.1016/0092-8674(93)90404-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680959				2022-12-24	WOS:A1993KR43600012
J	MIYATA, T; TAKEDA, J; IIDA, Y; YAMADA, N; INOUE, N; TAKAHASHI, M; MAEDA, K; KITANI, T; KINOSHITA, T				MIYATA, T; TAKEDA, J; IIDA, Y; YAMADA, N; INOUE, N; TAKAHASHI, M; MAEDA, K; KITANI, T; KINOSHITA, T			THE CLONING OF PIG-A, A COMPONENT IN THE EARLY STEP OF GPI-ANCHOR BIOSYNTHESIS	SCIENCE			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; VARIANT SURFACE GLYCOPROTEIN; THY-1 GLYCOPROTEIN; MEMBRANE-PROTEIN; CELLS; EXPRESSION; MUTANTS; VECTOR	The glycosylphosphatidylinositol (GPI) anchor is a membrane attachment structure of many proteins and occurs in a wide variety of eukaryotes from yeasts to mammals. The structure of the core of the GPI anchor is conserved in protozoa and mammals and so is its biosynthetic pathway. A complementary DNA encoding a human protein termed PIG-A (phosphatidylinositol glycan-class A) was cloned. PIG-A was necessary for synthesis of N-acetylglucosaminyl-phosphatidylinositol, the very early intermediate in GPI-anchor biosynthesis.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,BRANCH HOSP,SCH MED,DEPT INTERNAL MED,NAGOYA 461,JAPAN; GIFU UNIV,SCH MED,DEPT PEDIAT,GIFU 500,JAPAN	Osaka University; Nagoya University; Gifu University			Kinoshita, Taroh/C-7353-2009; Miyata, Toshio/A-4872-2010; Takahashi, Minoru/G-4748-2011					ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; INOUE N, UNPUB; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAHASHI M, UNPUB; UETSUKI T, 1989, J BIOL CHEM, V264, P5791	29	422	430	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1318	1321		10.1126/science.7680492	http://dx.doi.org/10.1126/science.7680492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	7680492				2022-12-24	WOS:A1993KN88300029
J	LINDSLEY, JE; WANG, JC				LINDSLEY, JE; WANG, JC			STUDY OF ALLOSTERIC COMMUNICATION BETWEEN PROTOMERS BY IMMUNOTAGGING	NATURE			English	Article							TOPOISOMERASE-II; TRANSITION; DNA	LIGAND-INDUCED allosteric changes in proteins are important in their cellular functions and regulation1,2, and both concerted and sequential examples are known3-5. The distinction has entailed elaborate analysis, however, and only a few systems have been unequivocally analysed. We have investigated the coupling between ATP usage and DNA transport by type II DNA topoisomerases6,7, and one key question concerning allostery in these dyadic enzymes is whether ATP binding to one protomer can induce a concerted conformational change in the entire enzyme. Here we use an enzyme with one immunotagged subunit defective in ATP binding and one wild-type subunit to show that it can. Our approach should be generally applicable in the study of allostery and communication between members of a macromolecular assembly.			LINDSLEY, JE (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							DEPEW RE, 1978, J BIOL CHEM, V253, P511; FERSHT A, 1984, ENZYME STRUCTURE MEC, P263; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583	9	61	62	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					749	750		10.1038/361749a0	http://dx.doi.org/10.1038/361749a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680110				2022-12-24	WOS:A1993KN78900064
J	ALLEN, RC; ARMITAGE, RJ; CONLEY, ME; ROSENBLATT, H; JENKINS, NA; COPELAND, NG; BEDELL, MA; EDELHOFF, S; DISTECHE, CM; SIMONEAUX, DK; FANSLOW, WC; BELMONT, J; SPRIGGS, MK				ALLEN, RC; ARMITAGE, RJ; CONLEY, ME; ROSENBLATT, H; JENKINS, NA; COPELAND, NG; BEDELL, MA; EDELHOFF, S; DISTECHE, CM; SIMONEAUX, DK; FANSLOW, WC; BELMONT, J; SPRIGGS, MK			CD40 LIGAND GENE DEFECTS RESPONSIBLE FOR X-LINKED HYPER-IGM SYNDROME	SCIENCE			English	Article							HUMAN B-CELLS; HYPERIMMUNOGLOBULINEMIA-M; T-CELLS; IMMUNODEFICIENCY; INTERLEUKIN-4; DIFFERENTIATION; SWITCH; PROLIFERATION; LOCALIZATION; ACTIVATION	The ligand for CD40 (CD40L) is a membrane glycoprotein on activated T cells that induces B cell proliferation and immunoglobulin secretion. Abnormalities in the CD40L gene were associated with an X-linked immunodeficiency in humans [hyper-IgM (immunoglobulin M) syndrome]. This disease is characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. CD40L complementary DNAs from three of four patients with this syndrome contained distinct point mutations. Recombinant expression of two of the mutant CD40L complementary DNAs resulted in proteins incapable of binding to CD40 and unable to induce proliferation or IgE secretion from normal B cells. Activated T cells from the four affected patients failed to express wild-type CD40L, although their B cells responded normally to wild-type CD40L. Thus, these CD40L defects lead to a T cell abnormality that results in the failure of patient B cells to undergo immunoglobulin class switching.	IMMUNEX RES & DEV CORP, DEPT MOLEC BIOL, SEATTLE, WA 98101 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC GENET, HOUSTON, TX 77030 USA; IMMUNEX RES & DEV CORP, DEPT IMMUNOL, SEATTLE, WA 98101 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; Baylor College of Medicine			Belmont, John W/AAI-2494-2019; Belmont, John/AAH-6084-2021	Belmont, John W/0000-0001-7409-3578; 	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; PHS HHS [A125129] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE RJ, 1990, INT IMMUNOL, V2, P1039, DOI 10.1093/intimm/2.11.1039; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1990, J IMMUNOL, V144, P938; ARMITAGE RJ, UNPUB; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BRAHMI Z, 1983, J CLIN IMMUNOL, V3, P127, DOI 10.1007/BF00915483; CLAASSEN JL, 1990, J IMMUNOL METHODS, V126, P213, DOI 10.1016/0022-1759(90)90153-M; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GALY AHM, 1992, J IMMUNOL, V149, P775; GEHA RS, 1979, J CLIN INVEST, V64, P385, DOI 10.1172/JCI109473; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GREEN EL, 1992, GENETICS PROBABILITY, P77; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JAMIESON WM, 1962, ARCH DIS CHILD, V37, P330, DOI 10.1136/adc.37.193.330; KYONG CU, 1978, PEDIATR RES, V12, P1024, DOI 10.1203/00006450-197810000-00015; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LEVITT D, 1983, J CLIN INVEST, V72, P1650, DOI 10.1172/JCI111124; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MALISZEWSKI CR, UNPUB; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WINFIELD JB, 1982, CLIN IMMUNOL IMMUNOP, V23, P58, DOI 10.1016/0090-1229(82)90070-8; ZHANG K, 1991, J IMMUNOL, V146, P1836	40	738	766	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1993	259	5097					990	993		10.1126/science.7679801	http://dx.doi.org/10.1126/science.7679801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	7679801				2022-12-24	WOS:A1993KL80000049
J	HORTON, R				HORTON, R			ESOPHAGEAL CANCER - LASER PALLIATION OF MALIGNANT DYSPHAGIA	LANCET			English	Editorial Material							CARCINOMA						Gandevia, Simon/D-5009-2011	Gandevia, Simon/0000-0002-1345-3821				BARR H, 1991, CANCER, V68, P1660, DOI 10.1002/1097-0142(19911001)68:7<1660::AID-CNCR2820680733>3.0.CO;2-L; GATZINSKY P, 1985, J THORAC CARDIOV SUR, V89, P71; LOIZOU LA, 1992, CANCER, V70, P386, DOI 10.1002/1097-0142(19920715)70:2<386::AID-CNCR2820700203>3.0.CO;2-H; MAUNOURY V, 1992, GUT, V33, P1602, DOI 10.1136/gut.33.12.1602; NAKAYAMA K, 1964, Clin Radiol, V15, P232, DOI 10.1016/S0009-9260(64)80073-8; SARGEANT IR, 1992, GUT, V33, P1597, DOI 10.1136/gut.33.12.1597; SKINNER DB, 1986, ANN SURG, V204, P391, DOI 10.1097/00000658-198610000-00007; WANG M, 1989, INT J RADIAT ONCOL, V16, P325; ZENONE T, 1992, EUR J CANCER, V28A, P1380, DOI 10.1016/0959-8049(92)90525-7	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					348	348		10.1016/0140-6736(93)90145-7	http://dx.doi.org/10.1016/0140-6736(93)90145-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	7679176				2022-12-24	WOS:A1993KK93900013
J	DUCHESNE, M; SCHWEIGHOFFER, F; PARKER, F; CLERC, F; FROBERT, Y; THANG, MN; TOCQUE, B				DUCHESNE, M; SCHWEIGHOFFER, F; PARKER, F; CLERC, F; FROBERT, Y; THANG, MN; TOCQUE, B			IDENTIFICATION OF THE SH3 DOMAIN OF GAP AS AN ESSENTIAL SEQUENCE FOR RAS-GAP MEDIATED SIGNALING	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C; P21 GTPASE; BINDING; PHOSPHORYLATION; PURIFICATION; RECEPTORS; INDUCTION	Guanosine triphosphatase activating protein (GAP) is an essential component of Ras signaling pathways. GAP functions in different cell types as a deactivator and a transmitter of cellular Ras signals. A domain (amino acids 275 to 351) encompassing the Src homology region 3 (SH3) of GAP was found to be essential for GAP signaling. A monoclonal antibody was used to block germinal vesicle breakdown (GVBD) induced by the oncogenic protein Ha-ras Lys12 in Xenopus oocytes. The monoclonal antibody, which was found to recognize the peptide containing amino acids 275 to 351 within the amino-terminal domain of GAP, did not modify the stimulation of the Ha-Ras-GTPase by GAP. Injection of peptides corresponding to amino acids 275 to 351 and 317 to 326 blocked GVBD induced by insulin or by Ha-Ras Lys12 but not that induced by progesterone. These findings confirm that GAP is an effector for Ras in Xenopus oocytes and that the SH3 domain is essential for signal transduction.	RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,13 QUAI JULES GUESDE,BP 14,F-94403 VITRY,FRANCE; CEA,CTR ETUD SACLAY,DRIPP,SERV PHARMACOL & IMMUNOL,F-91191 GIF SUR YVETTE,FRANCE; HOP ST ANTOINE,INSERM,U245,F-75571 PARIS 11,FRANCE	Sanofi-Aventis; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HIRAI S, 1984, DEV BIOL, V100, P214; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	25	135	147	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					525	528		10.1126/science.7678707	http://dx.doi.org/10.1126/science.7678707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	7678707				2022-12-24	WOS:A1993KJ07900038
J	COOPER, HM; HERBIN, M; NEVO, E				COOPER, HM; HERBIN, M; NEVO, E			OCULAR REGRESSION CONCEALS ADAPTIVE PROGRESSION OF THE VISUAL-SYSTEM IN A BLIND SUBTERRANEAN MAMMAL	NATURE			English	Article							MOLE RAT; RETINAL PROJECTIONS; SPALAX-EHRENBERGI; ALBINO-RAT; NUCLEUS; MELATONIN; VASOPRESSIN; PATHWAY; HAMSTER; BRAIN	THE mole rat, Spalax ehrenberghi, is an extreme example of natural visual degeneration in mammals: visual pathways are regressed and incomplete1, and the absence of visual cortical potentials or an overt behavioural response to light have led to the conclusion that Spalax is completely blind2-4. But structural and molecular investigations of the atrophied, subcutaneous eye suggest a functional role for the retina in light perception5,6, and entrainment of circadian locomotor and thermoregulatory rhythms by ambient light demonstrates a capacity for photoperiodic detection2,7-9. We report here that severe regression of thalamic and tectal structures involved in form and motion perception is coupled to a selective hypertrophy of structures subserving photoperiodic functions. As an alternative to the prevalent view that ocular regression results from negative or nonselective evolutionary processes10-12, the differential reduction and expansion of visual structures in Spalax can be explained as an adaptive response to the underground environment.	MUSEUM NATL HIST NAT, ANAT COMPAREE LAB, F-75005 PARIS, FRANCE; UNIV HAIFA, INST EVOLUT, HAIFA, ISRAEL	Museum National d'Histoire Naturelle (MNHN); University of Haifa	COOPER, HM (corresponding author), INSERM, U371, F-69500 BRON, FRANCE.		COOPER, HOWARD/M-7304-2014					BALKEMA GW, 1990, VISUAL NEUROSCI, V4, P593; BELTRAMINO C, 1980, NEUROENDOCRINOLOGY, V30, P238, DOI 10.1159/000123007; BRACE CL, 1963, AM NAT, V97, P39, DOI 10.1086/282252; BRONCHTI G, 1991, DEV BRAIN RES, V58, P159, DOI 10.1016/0165-3806(91)90002-Z; Cassone VM, 1988, J BIOL RHYTHM, V3, P71, DOI 10.1177/074873048800300106; Cei G., 1946, MONITORE ZOOL ITALIANO, V55, P69; COLLIN JP, 1981, PINEAL GLAND, V1, P27; COOPER AM, 1990, NEUROSCIENCE, V35, P335, DOI 10.1016/0306-4522(90)90087-K; COOPER HM, 1989, BRAIN RES, V477, P350, DOI 10.1016/0006-8993(89)91426-1; COOPER HM, IN PRESS J COMP NEUR; COOPER KE, 1979, J PHYSIOL-LONDON, V295, P33, DOI 10.1113/jphysiol.1979.sp012953; DEJONG WW, 1990, PROG CLIN BIOL RES, V335, P383; HAIM A, 1983, J EXP BIOL, V107, P59; HEIL P, 1991, NEUROREPORT, V2, P735, DOI 10.1097/00001756-199112000-00001; HETH G, 1986, J EXP ZOOL, V238, P1, DOI 10.1002/jez.1402380102; KASTING NW, 1983, BRAIN RES, V258, P127, DOI 10.1016/0006-8993(83)91237-4; KUDO M, 1988, NEUROSCI LETT, V93, P176, DOI 10.1016/0304-3940(88)90077-8; LEVINE JD, 1991, J COMP NEUROL, V306, P344, DOI 10.1002/cne.903060210; LUND RD, 1965, EXP NEUROL, V13, P302, DOI 10.1016/0014-4886(65)90118-4; MAGNIN M, 1989, BRAIN RES, V488, P390, DOI 10.1016/0006-8993(89)90737-3; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; NECKER R, 1992, NEUROREPORT, V3, P505, DOI 10.1097/00001756-199206000-00012; NELSON DE, 1991, J PHYSIOL-LONDON, V439, P115, DOI 10.1113/jphysiol.1991.sp018660; NEVO E, 1991, EVOLUTIONARY BIOL, V1, P1; PEVET P, 1984, J EXP ZOOL, V232, P41, DOI 10.1002/jez.1402320106; PEVET P, 1987, FUNDAMENTALS CLIN PI, P221; PICKARD GE, 1982, J COMP NEUROL, V211, P65, DOI 10.1002/cne.902110107; RADO R, 1988, ISR J ZOOL, V35, P105; SANYAL S, 1990, INVEST OPHTH VIS SCI, V31, P1398; SUGITA S, 1983, EXP NEUROL, V82, P413, DOI 10.1016/0014-4886(83)90413-2; TOGA AW, 1981, J COMP NEUROL, V199, P443, DOI 10.1002/cne.901990402; WEAVER DR, 1989, J NEUROSCI, V9, P2581; WILKENS H, 1971, EVOLUTION, V25, P530, DOI 10.1111/j.1558-5646.1971.tb01913.x; WRIGHT S, 1964, AM NAT, V98, P65, DOI 10.1086/282301	34	166	169	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					156	159		10.1038/361156a0	http://dx.doi.org/10.1038/361156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	7678449				2022-12-24	WOS:A1993KG46600060
J	WALD, TG; SHULT, P; KRAUSE, P; MILLER, BA; DRINKA, P; GRAVENSTEIN, S				WALD, TG; SHULT, P; KRAUSE, P; MILLER, BA; DRINKA, P; GRAVENSTEIN, S			A RHINOVIRUS OUTBREAK AMONG RESIDENTS OF A LONG-TERM-CARE FACILITY	ANNALS OF INTERNAL MEDICINE			English	Article						RHINOVIRUS; NURSING HOMES; RESPIRATORY TRACT INFECTIONS; DISEASE OUTBREAKS; LUNG DISEASES, OBSTRUCTIVE	ILLNESS; INFECTIONS; PRECIPITANTS; VIRUSES; ASTHMA	Objective: To describe the epidemiology of and clinical findings associated with a rhinovirus outbreak that occurred among institutionalized elderly persons. Design: Retrospective review of medical records and nursing surveillance reports. Setting: A 685-bed, long-term care facility for veterans and their spouses. Patients: 33 persons from whom rhinovirus was cultured. Measurements: Throat and nasopharyngeal virus culture; review of medical records to determine under-lying diseases, signs and symptoms of respiratory illness, illness duration, and interventions during illness; and review of nursing surveillance reports to determine room locations of ill persons. Results: Between 14 August and 2 September 1993, the number of respiratory illnesses increased. Throat and nasopharyngeal virus cultures were taken from 67 ill residents; 33 cultures yielded rhinovirus, and no other respiratory virus was isolated. Geographic clustering of persons infected with rhinovirus was observed. Of those persons with rhinovirus infections, 100% had upper respiratory symptoms, 34% had gastrointestinal symptoms, 71% had systemic symptoms, 66% had lower respiratory symptoms (including productive cough), and 52% had new abnormalities on lung auscultation. The 17 persons with rhinovirus infection who had chronic obstructive pulmonary disease had more severe illnesses: Five (29%) required glucocorticoid or bronchodilator therapy for illness-associated bronchospasm; 2 required transfer out of the facility; 1 developed a radiographically documented infiltrate; and 1 died of respiratory failure. Conclusions: Rhinovirus may cause epidemic, clinically important respiratory illness in nursing home residents. A large proportion of residents may become ill, and infection may be severe in persons with underlying lung disease.	UNIV WISCONSIN, SCH MED, INST AGING, MADISON, WI 53706 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, MADISON, WI USA; UNIV WISCONSIN, WISCONSIN STATE LAB HYG, MADISON, WI 53706 USA; WISCONSIN VET HOME, KING, WI 54946 USA	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison			Gravenstein, Stefan/O-1809-2019; Gravenstein, Stefan/G-1681-2011	Gravenstein, Stefan/0000-0001-6000-6859; 	NIA NIH HHS [AG00213, AG09632, AG00548] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000548, R01AG009632] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DALESSIO DJ, 1976, J INFECT DIS, V133, P28, DOI 10.1093/infdis/133.1.28; DICK EC, 1967, AM J EPIDEMIOL, V86, P386, DOI 10.1093/oxfordjournals.aje.a120749; DICK EC, 1992, TXB PEDIATRIC INFECT, P1507; DOUGLAS RG, 1966, AM REV RESPIR DIS, V94, P159; EADIE MB, 1966, BMJ-BRIT MED J, V2, P671, DOI 10.1136/bmj.2.5515.671; FALSEY AR, 1992, J AM GERIATR SOC, V40, P115, DOI 10.1111/j.1532-5415.1992.tb01929.x; FOX JP, 1985, AM J EPIDEMIOL, V122, P830, DOI 10.1093/oxfordjournals.aje.a114166; HENDLEY JO, 1969, AM J EPIDEMIOL, V89, P184, DOI 10.1093/oxfordjournals.aje.a120928; MCMILLAN JA, 1993, PEDIATR INFECT DIS J, V12, P321, DOI 10.1097/00006454-199304000-00011; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; OSTERWEIL D, 1990, J AM GERIATR SOC, V38, P659, DOI 10.1111/j.1532-5415.1990.tb01425.x; STENHOUSE AC, 1967, BMJ-BRIT MED J, V3, P461, DOI 10.1136/bmj.3.5563.461; VALENTI WM, 1982, J PEDIATR-US, V100, P722, DOI 10.1016/S0022-3476(82)80571-4; 1993, MMWR-MORBID MORTAL W, V42, P689	18	75	76	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					588	593		10.7326/0003-4819-123-8-199510150-00004	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677299				2022-12-24	WOS:A1995RY82800004
J	GOLDSTEIN, AM; FRASER, MC; STRUEWING, JP; HUSSUSSIAN, CJ; RANADE, K; ZAMETKIN, DP; FONTAINE, LS; ORGANIC, SM; DRACOPOLI, NC; CLARK, WH; TUCKER, MA				GOLDSTEIN, AM; FRASER, MC; STRUEWING, JP; HUSSUSSIAN, CJ; RANADE, K; ZAMETKIN, DP; FONTAINE, LS; ORGANIC, SM; DRACOPOLI, NC; CLARK, WH; TUCKER, MA			INCREASED RISK OF PANCREATIC-CANCER IN MELANOMA-PRONE KINDREDS WITH P16(INK4) MUTATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANT-MELANOMA; FAMMM SYNDROME; FAMILIAL MELANOMA; DYSPLASTIC NEVUS; PROGRESSION; LINKAGE; LOCUS	Background. A gene on chromosome 9p, p16(INK4), has been implicated in the pathogenesis of cutaneous malignant melanoma in 19 melanoma-prone families. In 10 of these kindreds mutations that impaired the function of the p16(INK4) protein (p16M alleles) cosegregated with the disease. By contrast, in the other nine kindreds the mutation did not alter the function of p16(INK4) (p16W alleles). We looked for differences in clinical and genetic epidemiologic features in these two groups of families. Methods. We compared the median ages at diagnosis of melanoma, number of melanomas, thickness of the tumors, and number of nevi in the kindreds. We estimated prospectively the risks of melanoma or other cancers in families followed for 6 to 18 years and the risks of other cancers since 1925 (the entire period) by comparing the number of cancer cases observed with the number expected. Results. The risk of invasive melanoma was increased by a factor of 75 in kindreds with p16W alleles and a factor of 38 in kindreds with p16W alleles. Although this difference was not significant (P=0.14), there was a striking difference in the risk of other tumors. In kindreds with p16M alleles, the risk of pancreatic cancer was increased by a factor of 13 in the prospective period (2 cases observed, 0.15 expected; standardized incidence ratio, 13.1; 95 percent confidence interval, 1.5 to 47.4) and by a factor of 22 in the entire period (7 cases observed, 0.32 expected; standardized incidence ratio, 21.8; 95 percent confidence interval, 8.7 to 44.8). In contrast, we found no cases of pancreatic cancer in kindreds with p16W alleles. Conclusions. The development of pancreatic cancer in kindreds prone to melanoma may require a p16M mutation. Genetic factors, such as the kind of mutation found in p16(INK4), may explain the inconsistent occurrence of other cancers in these kindreds.	NIH, WARREN G MAGNUSON CLIN CTR, DEPT NURSING, BETHESDA, MD 20892 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA; WESTAT CORP, ROCKVILLE, MD USA; WASHINGTON UNIV, SCH MED, DEPT SURG, ST LOUIS, MO 63110 USA; BATTELLE SRA, ROCKVILLE, MD USA; SEQUANA THERAPEUT INC, LA JOLLA, CA USA; UNIV PENN, SCH MED, PIGMENTED LES STUDY GRP, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Westat; Washington University (WUSTL); University of Pennsylvania; University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	GOLDSTEIN, AM (corresponding author), NCI, GENET EPIDEMIL BRANCH,EXECUT PLAZA N,RM 439, 6130 EXECUT BLVD, MSC 7372, BETHESDA, MD 20892 USA.		Tucker, Margaret A/B-4297-2015; Struewing, Jeffery P/I-7502-2013; Struewing, Jeffery P/C-3221-2008	Struewing, Jeffery P/0000-0002-4848-3334; Dracopoli, Nicholas/0000-0003-3962-4059				BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BERGMAN W, 1990, BRIT J CANCER, V61, P932, DOI 10.1038/bjc.1990.209; BOICE JD, 1991, NIH913180 PUBL; CALDAS C, 1994, NAT GENET, V8, P410, DOI 10.1038/ng1294-410c; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIXON WJ, 1992, BMDP STATISTICAL SOF; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1993, MELANOMA RES, V3, P271; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P40; KOPF A W, 1986, Journal of the American Medical Association, V256, P1915, DOI 10.1001/jama.256.14.1915; LI FP, 1988, CANCER RES, V48, P5358; LYNCH HT, 1981, BRIT J CANCER, V44, P553, DOI 10.1038/bjc.1981.225; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MILLER BA, 1993, NIH932789 PUBL; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PETTY EM, 1993, AM J HUM GENET, V53, P96; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SWERDLOW AJ, 1995, INT J CANCER, V61, P773, DOI 10.1002/ijc.2910610606; TUCKER MA, 1993, J INVEST DERMATOL, V100, pS350, DOI 10.1111/1523-1747.ep12470264; Walker G. J., 1994, American Journal of Human Genetics, V55, pA73; YOUNG JL, 1981, NCI MONOGRAPH, V57	32	477	486	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					970	974		10.1056/NEJM199510123331504	http://dx.doi.org/10.1056/NEJM199510123331504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666916	Bronze			2022-12-24	WOS:A1995RY58600004
J	POSTMA, DS; BLEECKER, ER; AMELUNG, PJ; HOLROYD, KJ; XU, JF; PANHUYSEN, CIM; MEYERS, DA; LEVITT, RC				POSTMA, DS; BLEECKER, ER; AMELUNG, PJ; HOLROYD, KJ; XU, JF; PANHUYSEN, CIM; MEYERS, DA; LEVITT, RC			GENETIC SUSCEPTIBILITY TO ASTHMA - BRONCHIAL, HYPERRESPONSIVENESS COINHERITED WITH A MAJOR GENE FOR ATOPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIRWAY RESPONSIVENESS; PULMONARY-FUNCTION; POPULATION-SAMPLE; SERUM IGE; METHACHOLINE; EXPRESSION; LINKAGE; HYPERREACTIVITY; CHROMOSOME-11Q; INTERLEUKIN-5	Background. Bronchial hyperresponsiveness, a risk factor for asthma, consists of a heightened bronchoconstrictor response to a variety of stimuli. The condition has a heritable component and is closely related to serum IgE levels and airway inflammation. The basis for these relations is unknown, as is the mechanism of genetic susceptibility to bronchial hyperresponsiveness. We attempted to define the interrelation between atopy and bronchial hyperresponsiveness and to investigate the chromosomal location of this component of asthma. Methods. We studied 303 children and grandchildren of 84 probands with asthma selected from a homogeneous population in the Netherlands. Ventilatory function, bronchial responsiveness to histamine, and serum total IgE were measured. The association between the last two variables was evaluated. Using analyses involving pairs of siblings, we tested for linkage between bronchial hyperresponsiveness and genetic markers on chromosome 5q31-q33, previously shown to be linked to a genetic locus regulating serum total IgE levels. Results. Serum total IgE levels were strongly correlated (r=0.65, P<0.01) in pairs of siblings concordant for bronchial hyperresponsiveness (defined as a greater than or equal to 20 percent decrease in the forced expiratory volume in one second produced by histamine [threshold dose, less than or equal to 16 mg per milliliter]), suggesting that these traits are coinherited. However, bronchial hyperresponsiveness was not correlated with serum IgE levels (r=0.04, P>0.10). Analyses of pairs of siblings showed linkage of bronchial hyperresponsiveness with several genetic markers on chromosome 5q, including D5S436 (P<0.001 for a histamine threshold value of less than or equal to 16 mg per milliliter). Conclusions. This study demonstrates that a trait for an elevated level of serum total IgE is coinherited with a trait for bronchial hyperresponsiveness and that a gene governing bronchial hyperresponsiveness is located near a major locus that regulates serum IgE levels on chromosome 5q. These findings are consistent with the existence of one or more genes on chromosome 5q31-q33 causing susceptibility to asthma.	UNIV GRONINGEN HOSP,GRONINGEN,NETHERLANDS; UNIV MARYLAND,SCH MED,BALTIMORE,MD; ASTHMA CTR,HAREN,NETHERLANDS; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	University of Groningen; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University				Holroyd, Kenneth/0000-0001-6050-3935	NHLBI NIH HHS [HL-48341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; CAULFIELD M, 1994, NEW ENGL J MED, V300, P1629; CHANDRASEKHARAP.SC, 1990, GENOMICS, V6, P94; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66, DOI 10.1136/adc.62.1.66; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COOKSON WOCM, 1989, LANCET, V1, P1292; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HOPP RJ, 1988, ANN ALLERGY, V61, P184; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; KATZ MF, 1993, ADV INTERNAL MED, V38, P189; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KELLEHER K, 1991, BLOOD, V77, P1436; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KONIG P, 1974, J ALLERGY CLIN IMMUN, V54, P280, DOI 10.1016/0091-6749(74)90014-1; LANDER ES, 1994, SCIENCE, V266, P1584; LEVITT RC, 1989, J APPL PHYSIOL, V67, P1125, DOI 10.1152/jappl.1989.67.3.1125; LEVITT RC, 1990, AM J PHYSIOL, V258, pL157, DOI 10.1152/ajplung.1990.258.4.L157; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; LNADER ES, 1994, SCIENCE, V265, P2037; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; Orie NGM, 1961, BRONCHITIS INT S; Ott J., 1991, ANAL HUMAN GENETIC L; PAUWELS R, 1985, EUR J RESPIR DIS, V66, P98; POSTMA DS, 1989, AM REV RESPIR DIS, V140, pS100, DOI 10.1164/ajrccm/140.3_Pt_2.S100; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P277; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1992, SAGE STATISTICAL ANA	53	635	662	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					894	900		10.1056/NEJM199510053331402	http://dx.doi.org/10.1056/NEJM199510053331402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666875	Bronze			2022-12-24	WOS:A1995RX19900002
J	GUPTA, JK; CAVE, M; LILFORD, RJ; FARRELL, TA; IRVING, HC; MASON, G; HAU, CM				GUPTA, JK; CAVE, M; LILFORD, RJ; FARRELL, TA; IRVING, HC; MASON, G; HAU, CM			CLINICAL-SIGNIFICANCE OF FETAL CHOROID-PLEXUS CYSTS	LANCET			English	Article							PRENATAL-DIAGNOSIS; LATERAL VENTRICLE; DOWNS-SYNDROME; AMNIOCENTESIS; FETUSES; TRISOMY-18; PREGNANCY; RISK	Choroid plexus (CP) cysts are commonly detected on routine mid-trimester ultrasound scan. When associated anomalies are detected, the risk is sufficient to justify an invasive diagnostic test such as amniocentesis. However, the risk when no associated anomalies are detected is much less well defined. This information is required to determine the appropriate management in cases of apparently isolated CP cysts. We thought the only way to resolve the difficulties in counselling prospective parents was to conduct a prospective study in a large unselected population. A registry of fetal CP cysts detected over 3 years in the Yorkshire Region was compiled and we identified 524 CP cysts. These cases were then amalgamated and analysed with 1361 cases from prospective studies reported in the world English literature and a further 71 unpublished cases identified from a 2 year prospective series from Ninewells Hospital, Dundee. The risk of chromosomal abnormalities was 1 in 150 (95% CI 1 in 85, 1 in 261) when no fetal anatomic abnormalities, apart from the CP cysts themselves, were detected antenatally. The risk increased to approximately 1 in 3 if any other associated ultrasound abnormalities were detected antenatally. The risk did not appear to be related to whether or not cyst size diminished as gestation progresses, whether they were unilateral or bilateral, and whether they were small or large in size (60-80% <10 mm). 76% of aneuploidic cases were trisomy 18 and 17% were trisomy 21. The risk of Down's syndrome in fetuses with CP cysts but no other anomalies detected antenatally is 1 in 880. The probability of a chromosomal abnormality is high when CP cysts are associated with any other antenatally detected anomaly, indicating a clear need to offering amniocentesis. The predictive value is much lower when no other anomalies are detected. In such cases, it is probably advisable to regard CP cysts as an indication for detailed ultrasound assessment, rather than invasive testing.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV LEEDS,INST EPIDEMIOL & HLTH SERV RES,LEEDS,W YORKSHIRE,ENGLAND; ST JAMES UNIV HOSP,DEPT DIAGNOST RADIOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; LEEDS GEN INFIRM,DEPT OBSTET & GYNAECOL,LEEDS,W YORKSHIRE,ENGLAND	University of Dundee; University of Leeds; Saint James's University Hospital; Leeds General Infirmary; University of Leeds	GUPTA, JK (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT OBSTET & GYNAECOL,DUNDEE DD1 9SY,SCOTLAND.			Farrell, Thomas/0000-0001-7775-2866				ACHIRON R, 1991, OBSTET GYNECOL, V78, P815; ANDREUSSI L, 1979, SURG NEUROL, V12, P53; BARKAI G, 1993, PRENATAL DIAG, V13, P843, DOI 10.1002/pd.1970130908; BENACERRAF BR, 1988, AM J OBSTET GYNECOL, V158, P404, DOI 10.1016/0002-9378(88)90165-2; BENACERRAF BR, 1990, AM J OBSTET GYNECOL, V162, P1001, DOI 10.1016/0002-9378(90)91304-U; CAMURRI L, 1989, PRENATAL DIAG, V9, P742, DOI 10.1002/pd.1970091011; CHAN L, 1989, OBSTET GYNECOL, V73, P703; CHINN DH, 1991, J ULTRAS MED, V10, P255; CHITKARA U, 1988, OBSTET GYNECOL, V72, P185; CHITTY LS, 1993, BR MED ULTRASOUND SO, V1, P40; CHUDLEIGH P, 1984, PRENATAL DIAG, V4, P135, DOI 10.1002/pd.1970040207; CLARK SL, 1988, OBSTET GYNECOL, V72, P585; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; FAKHRY J, 1985, J ULTRAS MED, V4, P561, DOI 10.7863/jum.1985.4.10.561; FITZSIMMONS J, 1989, OBSTET GYNECOL, V73, P257; GABRIELLI S, 1989, AM J OBSTET GYNECOL, V160, P1207, DOI 10.1016/0002-9378(89)90192-0; Gupta J. K., 1995, P231; HOWARD RJ, 1992, PRENATAL DIAG, V12, P685, DOI 10.1002/pd.1970120809; LILFORD RJ, 1994, BRIT J OBSTET GYNAEC, V101, P291, DOI 10.1111/j.1471-0528.1994.tb13612.x; NADEL AS, 1992, RADIOLOGY, V185, P545, DOI 10.1148/radiology.185.2.1410370; NYBERG DA, 1993, J ULTRAS MED, V12, P103; OSTLERE SJ, 1990, RADIOLOGY, V175, P753, DOI 10.1148/radiology.175.3.2188298; OSTLERE SJ, 1989, PRENATAL DIAG, V9, P205, DOI 10.1002/pd.1970090310; OSTLERE SJ, 1987, LANCET, V1, P1491; PLATT LD, 1991, AM J OBSTET GYNECOL, V164, P1652, DOI 10.1016/0002-9378(91)91451-2; PORTO M, 1993, J CLIN ULTRASOUND, V21, P103, DOI 10.1002/jcu.1870210205; ROOT S, 1994, AM J MED GENET, V49, P170, DOI 10.1002/ajmg.1320490203; SHUANGSH.S, 1965, ARCH PATHOL, V80, P214; SHUANGSHOTI S, 1966, NEUROLOGY, V16, P887, DOI 10.1212/WNL.16.9.887; TWINING P, 1991, BRIT J RADIOL, V64, P98, DOI 10.1259/0007-1285-64-758-98; WALKINSHAW SA, 1994, PRENATAL DIAG, V14, P663, DOI 10.1002/pd.1970140804; ZERRES K, 1992, HUM GENET, V89, P301	32	63	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					724	729		10.1016/S0140-6736(95)91502-8	http://dx.doi.org/10.1016/S0140-6736(95)91502-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658872				2022-12-24	WOS:A1995RU81000008
J	CHEN, BM; GRINNELL, AD				CHEN, BM; GRINNELL, AD			INTEGRINS AND MODULATION OF TRANSMITTER RELEASE FROM MOTOR-NERVE TERMINALS BY STRETCH	SCIENCE			English	Article							CELL-ADHESION; EXTRACELLULAR-MATRIX; SYNAPTIC STRENGTH; CALCIUM; CHANNELS; FIBRONECTIN; GADOLINIUM; JUNCTIONS; RECEPTORS; BLOCK	The stretch of a frog muscle within the physiological range can more than double the spontaneous and evoked release of neurotransmitter from its motor nerve terminals. Here, stretch enhancement of release was suppressed by peptides containing the sequence arginine-glycine-aspartic acid (RGD), which blocks integrin binding. Integrin antibodies also inhibited the enhancement obtained by stretching. Stretch enhancement depended on intraterminal calcium derived both from external calcium and from internal stores. Muscle stretch thus might enhance the release of neurotransmitters either by elevating internal calcium concentrations or by increasing the sensitivity of transmitter release to calcium in the nerve terminal.	UNIV CALIF LOS ANGELES, SCH MED, JERRY LEWIS NEUROMUSCULAR RES CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, AHMANSON LAB NEUROBIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030673] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30673, NS06232] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; [Anonymous], UNPUB; Chen B.-M., 1994, Society for Neuroscience Abstracts, V20, P58; CHEN BM, 1994, ADV SEC MESS PHOSPH, V29, P383; CRUZ LJ, 1985, J BIOL CHEM, V260, P9280; CYBULSKY AV, 1993, AM J PHYSIOL, V264, pC323, DOI 10.1152/ajpcell.1993.264.2.C323; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DIPOLO R, 1983, ANNU REV PHYSIOL, V45, P313, DOI 10.1146/annurev.ph.45.030183.001525; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GRINNELL AD, 1983, J PHYSIOL-LONDON, V338, P221, DOI 10.1113/jphysiol.1983.sp014670; GRINNELL AD, 1989, J PHYSIOL-LONDON, V418, P397, DOI 10.1113/jphysiol.1989.sp017848; GRINNELL AD, 1980, J PHYSIOL-LONDON, V307, P301, DOI 10.1113/jphysiol.1980.sp013436; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; HUTTER OF, 1956, J PHYSIOL-LONDON, V133, P610, DOI 10.1113/jphysiol.1956.sp005613; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KORNBERG L, 1992, TRENDS PHARMACOL SCI, V13, P93, DOI 10.1016/0165-6147(92)90034-4; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; SWERUP C, 1991, ACTA PHYSIOL SCAND, V143, P21, DOI 10.1111/j.1748-1716.1991.tb09197.x; TURKANIS SA, 1973, J PHYSIOL-LONDON, V230, P391, DOI 10.1113/jphysiol.1973.sp010194; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	31	106	108	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1578	1580		10.1126/science.7667637	http://dx.doi.org/10.1126/science.7667637			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667637				2022-12-24	WOS:A1995RU81300042
J	SKEHEL, PA; MARTIN, KC; KANDEL, ER; BARTSCH, D				SKEHEL, PA; MARTIN, KC; KANDEL, ER; BARTSCH, D			A VAMP-BINDING PROTEIN FROM APLYSIA REQUIRED FOR NEUROTRANSMITTER RELEASE	SCIENCE			English	Article							SYNAPTIC PLASTICITY; FUSION; VESICLES; DOCKING; FAMILY	Before the fusion of synaptic vesicles with the plasma membrane, a protein complex is thought to form between VAMP-an integral membrane protein of the vesicle-and two proteins associated with the plasma membrane, SNAP-25 and syntaxin. The yeast two-hybrid interaction cloning system has now been used to identify additional proteins from Aplysia that interact directly with VAMP. A 33-kilodalton membrane protein, termed VAP-33 (VAMP-associated protein of 33 kilodaltons), was identified whose corresponding messenger RNA was detected only in the central nervous system and the gill of Aplysia. Presynaptic injection of antibodies specific for VAP-33 inhibited synaptic transmission, which suggests that VAP-33 is required for the exocytosis of neurotransmitter.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	SKEHEL, PA (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, 722 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH045923] Funding Source: NIH RePORTER; NIMH NIH HHS [R37 MH45923-06] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARTSCH D, UNPUB; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHIN GJ, 1989, J NEUROSCI, V9, P38; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1993, J CELL SCI, P75; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; KLASS MR, 1984, MOL CELL BIOL, V4, P529, DOI 10.1128/MCB.4.3.529; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; MARTIN KH, UNPUB; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; RAYPORT SG, 1986, J NEUROSCI, V6, P759; REICHARDT LF, 1983, ANNU REV BIOCHEM, V52, P871, DOI 10.1146/annurev.bi.52.070183.004255; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SKEHEL PA, UNPUB; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; YAMASAKI S, 1994, P NATL ACAD SCI USA, V91, P4688, DOI 10.1073/pnas.91.11.4688	24	142	148	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1580	1583		10.1126/science.7667638	http://dx.doi.org/10.1126/science.7667638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667638				2022-12-24	WOS:A1995RU81300043
J	KARNI, A; MEYER, G; JEZZARD, P; ADAMS, MM; TURNER, R; UNGERLEIDER, LG				KARNI, A; MEYER, G; JEZZARD, P; ADAMS, MM; TURNER, R; UNGERLEIDER, LG			FUNCTIONAL MRI EVIDENCE FOR ADULT MOTOR CORTEX PLASTICITY DURING MOTOR SKILL LEARNING	NATURE			English	Article							CEREBRAL BLOOD-FLOW; SENSORY STIMULATION; TIME-COURSE; REPRESENTATION; HABITUATION; TASK	PERFORMANCE of complex motor tasks, such as rapid sequences of finger movements, can be improved in terms of speed and accuracy over several weeks by daily practice sessions, This improvement does not generalize to a matched sequence of identical component movements, nor to the contralateral hand, Here we report a study of the neural changes underlying this learning using functional magnetic resonance imaging (MRI) of local blood oxygenation level-dependent (BOLD)(1-4) signals evoked in primary motor cortex (Mi). Before training, a comparable extent of M1 was activated by both sequences, However, two ordering effects were observed: repeating a sequence within a brief time window initially resulted in a smaller area of activation (habituation), but later in a larger area of activation (enhancement), suggesting a switch in M1 processing mode within the first session (fast learning), By week 4 of training, concurrent with asymptotic performance, the extent of cortex activated by the practised sequence enlarged compared with the unpractised sequence, irrespective of order (slow learning), These changes persisted for several months, The results suggest a slowly evolving, long-term, experience-dependent reorganization of the adult M1, which may underlie the acquisition and retention of the motor skill.	NHLBI,CARDIAC ENERGET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	KARNI, A (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 49,ROOM 1B80,BETHESDA,MD 20892, USA.		Li, Chong/F-4265-2015; Turner, Robert/C-1820-2008	Turner, Robert/0000-0001-5055-9644; Jezzard, Peter/0000-0001-7912-2251; Meyer, Gundela/0000-0002-5730-828X				ASANUMA H, 1991, NEUROREPORT, V2, P217, DOI 10.1097/00001756-199105000-00001; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; Friston K.J., 1994, HUM BRAIN MAPP, V1, P153, DOI DOI 10.1002/HBM.460010207; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; JENKINS IH, 1994, J NEUROSCI, V14, P3775; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KAWASHIMA R, 1994, J NEUROSCI, V14, P3462; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEBIHAN D, 1993, P SOC MAGN RESON MED, V1, P11; MILLER EK, 1991, VISUAL NEUROSCI, V7, P357, DOI 10.1017/S0952523800004843; Milliken G. W., 1992, Society for Neuroscience Abstracts, V18, P506; MISHKIN M, 1984, NEUROBIOLOGY LEARNIN, P64; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PASCUALLEONE A, 1993, NEUROLOGY, V43, pA157; RADEMACHER J, 1993, CEREB CORTEX, V3, P313, DOI 10.1093/cercor/3.4.313; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; SANES JN, 1992, CEREB CORTEX, V2, P141, DOI 10.1093/cercor/2.2.141; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; STERLING MK, 1991, SCIENCE, V254, P716; WARACH S, 1992, J CEREBR BLOOD F MET, V12, P546, DOI 10.1038/jcbfm.1992.78	25	1347	1366	4	124	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					155	158						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675082				2022-12-24	WOS:A1995RU75400050
J	SUN, XJ; WANG, LM; ZHANG, YT; YENUSH, L; MYERS, MG; GLASHEEN, E; LANE, WS; PIERCE, JH; WHITE, MF				SUN, XJ; WANG, LM; ZHANG, YT; YENUSH, L; MYERS, MG; GLASHEEN, E; LANE, WS; PIERCE, JH; WHITE, MF			ROLE OF IRS-2 IN INSULIN AND CYTOKINE SIGNALING	NATURE			English	Article							HEMATOPOIETIC-CELLS; RECEPTOR; PROTEIN; PHOSPHORYLATION; TRANSMISSION; SEQUENCE	THE protein IRS-1 acts as an interface between signalling proteins with Src-homology-2 domains (SH2 proteins) and the receptors for insulin, IGF-1, growth hormone, several interleukins (IL-4, IL-9, IL-13) and other cytokines(1-7). It regulates gene expression acid stimulates mitogenesis, and appears to mediate insulin/IGF-1-stimulated glucose transport(8). Thus, survival of the IRS-1(-/-) mouse with only mild resistance to insulin was surprising(9,10). This dilemma is provisionally resolved with our discovery of a second IRS-signalling protein, We purified and cloned a likely candidate called 4PS from myeloid progenitor cells and, because of its resemblance to IRS-1, we designate it IRS-2. Alignment of the sequences of IRS-2 acid IRS-1 revealed a highly conserved amino terminus containing a pleckstrin-homology domain and a phosphotyrosine-binding domain, and a poorly conserved carboxy terminus containing several tyrosine phosphorylation motifs. IRS-2 is expressed in many cells, including tissues from IRS-1(-/-) mice(11), and may be essential for signalling by several receptor systems.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; NIH,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; Harvard University			Yenush, Lynne/J-8815-2014	Yenush, Lynne/0000-0001-8589-7002				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIU XJ, IN PRESS MOL CELL BI; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PATTI ME, 1995, DIABETES, V44, pA31; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITFIELD K, 1991, INT J FORECASTING, V7, P65, DOI 10.1016/0169-2070(91)90034-S; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	36	746	766	1	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					173	177		10.1038/377173a0	http://dx.doi.org/10.1038/377173a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675087				2022-12-24	WOS:A1995RU75400055
J	HATADA, MH; LU, XD; LAIRD, ER; GREEN, J; MORGENSTERN, JP; LOU, MZ; MARR, CS; PHILLIPS, TB; RAM, MK; THERIAULT, K; ZOLLER, MJ; KARAS, JL				HATADA, MH; LU, XD; LAIRD, ER; GREEN, J; MORGENSTERN, JP; LOU, MZ; MARR, CS; PHILLIPS, TB; RAM, MK; THERIAULT, K; ZOLLER, MJ; KARAS, JL			MOLECULAR-BASIS FOR INTERACTION OF THE PROTEIN-TYROSINE KINASE ZAP-70 WITH THE T-CELL RECEPTOR	NATURE			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; SRC HOMOLOGY-2 DOMAIN; CYCLOSPORINE-A; SH2 DOMAINS; ZETA-CHAIN; RECOGNITION; CALCINEURIN; COMPLEXES; SUBUNIT; TAIL	The crystal structure of the tandem SH2 domains of human ZAP-70 in complex with a peptide derived from the zeta-subunit of the T-cell receptor reveals an unanticipated interaction between the two domains. A coiled coil of a-helices connects the two SH2 domains, producing apr interface that constitutes one of the two critical phosphotyrosine binding sites. These and other unique features provide the molecular basis for highly selective association of ZAP-70 with the T-cell receptor.			HATADA, MH (corresponding author), ARIAD PHARMACEUT INC,26 LANDSDOWNE ST,CAMBRIDGE,MA 02139, USA.			Green, Jeremy/0000-0003-4544-6412				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CCP4, 1979, CCP4 SUITE PROGRAMS; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MIKOL V, 1995, J MOL BIOL, V246, P344, DOI 10.1006/jmbi.1994.0089; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; TANIGUCHI T, 1991, J BIOL CHEM, V268, P15790; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	47	301	311	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					32	38		10.1038/377032a0	http://dx.doi.org/10.1038/377032a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659156				2022-12-24	WOS:A1995RT72500047
J	HORTON, R				HORTON, R			SPINNING THE RISKS AND BENEFITS OF CALCIUM-ANTAGONISTS	LANCET			English	Editorial Material																		BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620	2	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					586	587		10.1016/S0140-6736(95)91429-3	http://dx.doi.org/10.1016/S0140-6736(95)91429-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7650997				2022-12-24	WOS:A1995RT18800002
J	SEPKOWITZ, KA; ARMSTRONG, D				SEPKOWITZ, KA; ARMSTRONG, D			TREATMENT OF OPPORTUNISTIC INFECTIONS IN AIDS	LANCET			English	Editorial Material									NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	SEPKOWITZ, KA (corresponding author), MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,NEW YORK,NY 10021, USA.							BROWN AE, 1985, INFECTIOUS COMPLICAT; GLATT AE, 1994, INFECT DIS CLIN N AM, P8; 1993, HIV AIDS SURVEILLANC	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					588	589		10.1016/S0140-6736(95)91432-3	http://dx.doi.org/10.1016/S0140-6736(95)91432-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651000				2022-12-24	WOS:A1995RT18800005
J	SAUNDERS, P; HERXHEIMER, A				SAUNDERS, P; HERXHEIMER, A			WHO MODEL LIST OF ESSENTIAL DRUGS - A BEACON THROUGH 2 DECADES	LANCET			English	Editorial Material									UNITED KINGDOM COCHRANE CTR,OXFORD,ENGLAND	Cochrane Centre	SAUNDERS, P (corresponding author), ESSENTIAL DRUGS PROJECT,LONDON,ENGLAND.		Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380				[Anonymous], 1977, WHO TECH REP SER, V615; 1990, LANCET, V335, P1003; 1995, WHO TECH REP SER, V850; WHODAP901, P13	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					519	519		10.1016/S0140-6736(95)91375-0	http://dx.doi.org/10.1016/S0140-6736(95)91375-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658773				2022-12-24	WOS:A1995RQ98600003
J	SICINSKI, P; DONAHER, JL; PARKER, SB; LI, TS; GARDNER, H; HASLAM, SZ; BRONSON, RT; ELLEDGE, SJ; WEINBERG, RA				SICINSKI, P; DONAHER, JL; PARKER, SB; LI, TS; GARDNER, H; HASLAM, SZ; BRONSON, RT; ELLEDGE, SJ; WEINBERG, RA			CYCLIN D1 PROVIDES A LINK BETWEEN DEVELOPMENT AND ONCOGENESIS IN THE RETINA AND BREAST	CELL			English	Article							MOUSE MAMMARY-GLAND; GENOMIC ORGANIZATION; CELL-CYCLE; GENES; AMPLIFICATION; EXPRESSION; ONTOGENY; CANCER; PROTOONCOGENE; PIGMENTOSA	Mice lacking cyclin D1 have been generated by gene targeting in embryonic stem cells. Cyclin D1-deficient animals develop to term but show reduced body size, reduced viability, and symptoms of neurological impairment. Their retinas display a striking reduction in cell number due to proliferative failure during embryonic development. In situ hybridization studies of normal mouse embryos revealed an extremely high level of cyclin al in the retina, suggesting a special dependence of this tissue on cyclin D1. In adult mutant females, the breast epithelial compartment fails to undergo the massive proliferative changes associated with pregnancy despite normal levels of ovarian steroid hormones, thus, steroid-induced proliferation of mammary epithelium during pregnancy may be driven through cyclin D1.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOWARD HUGHES MED INST,HOUSTON,TX 77030; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB STUDY RETINAL DEGENERAT,BOSTON,MA 02114; MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Baylor College of Medicine; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Michigan State University; Tufts University; Tufts University	SICINSKI, P (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA39826] Funding Source: Medline; NIA NIH HHS [AG11085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADNANE J, 1989, ONCOGENE, V4, P1389; BACUS S, 1988, AM J CLIN PATHOL, V90, P233, DOI 10.1093/ajcp/90.3.233; BARKLEY MS, 1979, BIOL REPROD, V20, P733, DOI 10.1095/biolreprod20.4.733; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRESCIANI FRANCESCO, 1968, CELL TISSUE KINET, V1, P51, DOI 10.1111/j.1365-2184.1968.tb00193.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HALL JE, 1992, J CLIN ENDOCR METAB, V74, P600, DOI 10.1210/jc.74.3.600; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; HASLAM SZ, 1992, J STEROID BIOCHEM, V42, P589, DOI 10.1016/0960-0760(92)90449-S; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HASLAM SZ, 1988, J STEROID BIOCHEM, V31, P9, DOI 10.1016/0022-4731(88)90199-9; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIESS M, 1995, ONCOGENE, V10, P159; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nandi S., 1958, J NATL CANCER I, V21, P1040; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SCHUURING E, 1992, CANCER RES, V52, P5229; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINBERG RH, 1991, PROGR RETINAL RES, P121; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; SUTHERLAND RL, 1993, J STEROID BIOCHEM, V47, P99, DOI 10.1016/0960-0760(93)90062-2; TAMARU T, 1993, NEUROSCI LETT, V153, P169, DOI 10.1016/0304-3940(93)90314-B; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E	51	895	910	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					621	630		10.1016/0092-8674(95)90034-9	http://dx.doi.org/10.1016/0092-8674(95)90034-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664341	Bronze			2022-12-24	WOS:A1995RR73400013
J	WOLOSHIN, P; SONG, KN; DEGNIN, C; KILLARY, AM; GOLDHAMER, DJ; SASSOON, D; THAYER, MJ				WOLOSHIN, P; SONG, KN; DEGNIN, C; KILLARY, AM; GOLDHAMER, DJ; SASSOON, D; THAYER, MJ			MSX1 INHIBITS MYOD EXPRESSION IN FIBROBLAST X 10T1/2 CELL HYBRIDS	CELL			English	Article							REGULATORY ELEMENTS; MOUSE EMBRYOGENESIS; HUMAN-CHROMOSOMES; MYOGENIN GENE; HOMEOBOX GENE; NEURAL-TUBE; MUSCLE; DIFFERENTIATION; 5-AZACYTIDINE; MYOBLASTS	Transfer of human chromosome 11, which contains the myoD locus, from primary fibroblasts into 10T(1/2) cells results in activation of myoD. In contrast, hybrids that retain human chromosome 11 and additional human chromosomes fail to activate myoD. We show that human chromosome 4 inhibits myoD activation. myoD enhancer/promoter reporter constructs show that repression is at the transcriptional level. Chromosome fragment-containing hybrids localize the repressing activity to the region of 4p that contains the homeobox gene MSX1. MSX1 is expressed in primary human fibroblasts and in 10T(1/2) cells containing human chromosome 4, while parental 10T(1/2) cells do not express Msx1, Forced expression of Msx1 represses myoD enhancer activity. Msx1 protein binds to the myoD enhancer and likely represses myoD transcription directly, Antisense MSX1 relieves repression mediated by chromosome 4. We conclude that MSX1 inhibits transcription of myoD and that myoD is a target for homeobox gene regulation.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77030; UNIV PENN,SCH MED,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	Boston University; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Icahn School of Medicine at Mount Sinai	WOLOSHIN, P (corresponding author), OREGON HLTH SCI UNIV,DEPT MED & MOLEC GENET,PORTLAND,OR 97201, USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X	NIAMS NIH HHS [AR42644] Funding Source: Medline; NICHD NIH HHS [HD27585] Funding Source: Medline; NIGMS NIH HHS [GM49334] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042644] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOBER E, 1994, DEVELOPMENT, V120, P603; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Favaloro J, 1980, Methods Enzymol, V65, P718; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEWITT JE, 1991, GENOMICS, V11, P670, DOI 10.1016/0888-7543(91)90074-O; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HSIAO WLW, 1986, J VIROL, V57, P1119, DOI 10.1128/JVI.57.3.1119-1126.1986; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; OTT MO, 1991, DEVELOPMENT, V111, P1097; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RONG PM, 1992, DEVELOPMENT, V115, P657; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785	43	127	129	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					611	620		10.1016/0092-8674(95)90033-0	http://dx.doi.org/10.1016/0092-8674(95)90033-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664340	Bronze			2022-12-24	WOS:A1995RR73400012
J	LIN, CT; ROBERTSON, DE; AHMAD, M; RAIBEKAS, AA; JORNS, MS; DUTTON, PL; CASHMORE, AR				LIN, CT; ROBERTSON, DE; AHMAD, M; RAIBEKAS, AA; JORNS, MS; DUTTON, PL; CASHMORE, AR			ASSOCIATION OF FLAVIN ADENINE-DINUCLEOTIDE WITH THE ARABIDOPSIS BLUE-LIGHT RECEPTOR CRY1	SCIENCE			English	Article							COLI DNA PHOTOLYASE; THALIANA; IDENTIFICATION; CHROMOPHORE; ENZYME	The Arabidopsis thaliana HY4 gene encodes CRY1, a 75-kilodalton flavoprotein mediating blue light-dependent regulation of seedling development. CRY1 is demonstrated here to noncovalently bind stoichiometric amounts of flavin adenine dinucleotide (FAD). The redox properties of FAD bound by CRY1 include an unexpected stability of the neutral radical flavosemiquinone (FADH .). The absorption properties of this flavosemiquinone provide a likely explanation for the additional sensitivity exhibited by CRY1-mediated responses in the green region of the visible spectrum, Despite the sequence homology to microbial DNA photolyases, CRY1 was found to have no detectable photolyase activity.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,JOHNSON FDN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; HAHNEMANN UNIV,SCH MED,DEPT BIOL CHEM,PHILADELPHIA,PA 19102	University of Pennsylvania; University of Pennsylvania; Drexel University				Ahmad, Margaret/0000-0003-4524-5813	NIGMS NIH HHS [GM31704, GM38409, GM51956] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038409, R01GM051956, R01GM031704] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Briggs W. R., 1976, Light and plant development. [Smith, H.]., P7; DARWIN C, 1881, POWER MOVEMENT PLANT, P462; Dutton P L, 1978, Methods Enzymol, V54, P411; EKER APM, 1990, J BIOL CHEM, V265, P8009; Galland Paul, 1991, P65; GALSTON AW, 1950, SCIENCE, V111, P619, DOI 10.1126/science.111.2893.619; GRESSEL J, 1979, PHOTOCHEM PHOTOBIOL, V30, P749, DOI 10.1111/j.1751-1097.1979.tb07209.x; HANGARTER R, COMMUNICATION; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; KONJEVIC R, 1989, P NATL ACAD SCI USA, V86, P9876, DOI 10.1073/pnas.86.24.9876; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LIN C, IN PRESS P NATL ACAD; Lin C. H., UNPUB; LIPSON ED, 1991, SENSORY RECEPTORS SI, P1; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P1, DOI 10.1021/bi00594a001; Palmer G., 1971, FLAVINS FLAVOPROTEIN, P123; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; TAKAO M, 1989, J BACTERIOL, V171, P6323, DOI 10.1128/jb.171.11.6323-6329.1989; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	26	354	382	0	53	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					968	970		10.1126/science.7638620	http://dx.doi.org/10.1126/science.7638620			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638620				2022-12-24	WOS:A1995RP73800033
J	KIM, Y; EOM, SH; WANG, JM; LEE, DS; SUH, SW; STEITZ, TA				KIM, Y; EOM, SH; WANG, JM; LEE, DS; SUH, SW; STEITZ, TA			CRYSTAL-STRUCTURE OF THERMUS-AQUATICUS DNA-POLYMERASE	NATURE			English	Article							ESCHERICHIA-COLI; PROTEIN STRUCTURES; 3'-5' EXONUCLEASE; MECHANISM; FRAGMENT; DOMAIN; SITE	THE DNA polymerase from Thermus aquaticus (Taq polymerase), famous for its use in the polymerase chain reaction, is homologous to Escherichia coli DNA polymerase I (pol I) (ref. 1). Like pol I, Tag polymerase has a domain at its amino terminus (residues 1-290) that has 5' nuclease activity and a domain at its carboxy terminus that catalyses the polymerase reaction. Unlike pol I, the intervening domain in Taq polymerase has lost the editing 3'-5' exonuclease activity. Although the structure of the Klenow fragment of pol I has been known for ten years(2), that of the intact pol I has proved more elusive. The structure of Tag polymerase determined here at 2.4 Angstrom resolution shows that the structures of the polymerase domains of the thermostable enzyme and of the Klenow fragment are nearly identical, whereas the catalytically critical carboxylate residues that bind two metal ions are missing from the remnants of the 3'-5'-exonuclease active site of Taq polymerase. The first view of the 5' nuclease domain, responsible for excising the Okazaki RNA in lagging-strand DNA replication, shows a cluster of conserved divalent metal-ion-binding carboxylates at the bottom of a cleft. The location of this 5'-nuclease active site some 70 Angstrom from the polymerase active site in this crystal form highlights the unanswered question of how this domain works in concert with the polymerase domain to produce a duplex DNA product that contains only a nick.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; SEOUL NATL UNIV,CTR MOLEC CATALYSIS,DEPT CHEM,SEOUL 151742,SOUTH KOREA; KOREAN INST SCI & TECHNOL,KOREA RES INST BIOSCI & BIOTECHNOL,TAEJON 305333,SOUTH KOREA	Yale University; Howard Hughes Medical Institute; Yale University; Seoul National University (SNU); Korea Institute of Science & Technology (KIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB)			Kim, Youngsoo/D-6046-2012; Suh, Won/H-8306-2013; Steitz, Thomas A./C-6559-2009	Suh, Won/0000-0002-1768-4635; 				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1992, E COMMUNICATION; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EOM SH, IN PRESS ACTA CRYS D, V51; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; JONES TA, 1993, E COMMUNICATION; KANKARE J, 1994, PROTEIN ENG, V7, P823, DOI 10.1093/protein/7.7.823; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TEPLYAKOV A, 1994, PROTEIN SCI, V7, P1098; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	29	337	370	2	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					612	616		10.1038/376612a0	http://dx.doi.org/10.1038/376612a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637814				2022-12-24	WOS:A1995RP75600057
J	PRENTICE, AM; JEBB, SA				PRENTICE, AM; JEBB, SA			OBESITY IN BRITAIN - GLUTTONY OR SLOTH	BRITISH MEDICAL JOURNAL			English	Article							DIETARY-FAT; ENERGY-INTAKE; WEIGHT; HUMANS	The prevalence of clinical obesity in Britain has doubled in the past decade. The Health of the Nation initiative has set ambitious targets for reversing the trend in recognition of the serious health burden which will accrue, but efforts to develop prevention and treatment strategies are handicapped by uncertainty as to the aetiology of the problem. It is generally assumed that ready access to highly palatable foods induces excess consumption and that obesity is caused by simple gluttony. There is evidence that a high fat diet does override normal satiety mechanisms, However, average recorded energy intake in Britain has declined substantially as obesity rates have escalated. The implication is that levels of physical activity, and hence energy needs, have declined even faster. Evidence suggests that modern inactive lifestyles are at least as important as diet in the aetiology of obesity and possibly represent the dominant factor.			PRENTICE, AM (corresponding author), MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 2DH,ENGLAND.		Prentice, Andrew/AAG-1961-2019	Jebb, Susan/0000-0001-9190-2920				Bennett N, 1995, HLTH SURVEY ENGLAND; Blundell John E., 1993, American Journal of Clinical Nutrition, V57, p772S, DOI 10.1093/ajcn/57.5.772S; BOLTONSMITH C, 1994, INT J OBESITY, V18, P820; Colditz G A, 1992, Am J Clin Nutr, V55, p503S, DOI 10.1093/ajcn/55.2.503s; DIETZ WH, 1985, PEDIATRICS, V75, P807; FLATT JP, 1987, ANN NY ACAD SCI, V499, P104, DOI 10.1111/j.1749-6632.1987.tb36202.x; GARROW JS, 1992, LANCET, V340, P409, DOI 10.1016/0140-6736(92)91481-M; GIBNEY M J, 1990, Journal of Human Nutrition and Dietetics, V3, P245, DOI 10.1111/j.1365-277X.1990.tb00064.x; Gregory F., 1990, DIETARY NUTR SURVEY; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HILL JO, IN PRESS AM J CLIN N; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LISSNER L, 1995, EUR J CLIN NUTR, V49, P79; LISSNER L, 1987, AM J CLIN NUTR, V46, P886, DOI 10.1093/ajcn/46.6.886; PRENTICE A M, 1989, Journal of Human Nutrition and Dietetics, V2, P95, DOI 10.1111/j.1365-277X.1989.tb00014.x; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; ROLLS BJ, 1994, AM J CLIN NUTR, V60, P476, DOI 10.1093/ajcn/60.4.476; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; Stubbs R. J., 1993, Proceedings of the Nutrition Society, V52, p35A; White A, 1993, HLTH SURVEY ENGLAND; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]; 1992, REPORT ACTIVITY PATT; 1994, SOCIAL TRENDS, V24; 1940, HOUSEHOLD FOOD CONSU; 1992, HOUSEHOLD FOOD CONSU	29	818	832	2	88	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					437	439		10.1136/bmj.311.7002.437	http://dx.doi.org/10.1136/bmj.311.7002.437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640595	Green Published			2022-12-24	WOS:A1995RP55400023
J	NEGISHI, I; MOTOYAMA, N; NAKAYAMA, K; NAKAYAMA, K; SENJU, S; HATAKEYAMA, S; ZHANG, Q; CHAN, AC; LOH, DY				NEGISHI, I; MOTOYAMA, N; NAKAYAMA, K; NAKAYAMA, K; SENJU, S; HATAKEYAMA, S; ZHANG, Q; CHAN, AC; LOH, DY			ESSENTIAL ROLE FOR ZAP-70 IN BOTH POSITIVE AND NEGATIVE SELECTION OF THYMOCYTES	NATURE			English	Article							PROTEIN-TYROSINE KINASE; KILLER-CELLS; T-CELLS; APOPTOSIS; COMPLEX; INVIVO; MICE	DURING thymic development, T cells that can recognize foreign antigen in association with self major histocompatibility complex (MHC) are selected for survival (positive selection) and autoreactive T cells are eliminated (negative selection). Both of these selective events are mediated by interaction between the T-cell receptor (TCR) and the peptid-MHC complex(1) But the signalling pathways that lead to cell survival or to cell death are still unclear. ZAP-70 is a protein tyrosine kinase (PTK) that is associated with the TCR signalling subunits (CD3 and zeta) and is expressed in T cells and natural killer cell(2). It has been shown that ZAP-70 plays a crucial role in T-cell activation(2-5) and development(6-8). Here we show that mice lacking ZAP-70 had neither CD4 nor CD8 single-positive T cells, but human ZAP-70 reconstituted both CD4 and CDS single-positive populations. Moreover, ZAP-70(-/-) thomocytes were not deleted by peptide antigens. Natural killer cell function was intact in the absence of ZAP-70. These data suggest that ZAP-70 is a central signalling molecule during thymic selection for CD4 and CD8 lineage.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV RHEUMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CONE JC, 1993, EUR J IMMUNOL, V23, P2488; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GUNJI Y, 1989, J IMMUNOL, V142, P1748; IWABUCHI K, 1992, P NATL ACAD SCI USA, V89, P9000, DOI 10.1073/pnas.89.19.9000; MADRENAS J, 1994, SCIENCE, V267, P515; MOMBAERTS P, 1994, INT IMMUNOL, V6, P1061, DOI 10.1093/intimm/6.7.1061; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURH CD, 1992, J EXP MED, V176, P611, DOI 10.1084/jem.176.2.611; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VIVLER E, 1993, EUR J IMMUNOL, V23, P1872	25	461	464	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					435	438		10.1038/376435a0	http://dx.doi.org/10.1038/376435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630421				2022-12-24	WOS:A1995RM63900055
J	JICK, SS; DEAN, AD; JICK, H				JICK, SS; DEAN, AD; JICK, H			ANTIDEPRESSANTS AND SUICIDE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To estimate the rate and means of suicide among people taking 10 commonly prescribed antidepressant drugs: dothiepin, amitriptyline, clomipramine, imipramine, flupenthixol, lofepramine, mianserin, fluoxetine, doxepin, and trazodone. Design-Open cohort study with a nested case-control analysis. Setting-General practices in the United Kingdom that used VAMP computers to maintain their patient records from January 1988 to February 1993. Subjects-172 598 people who had at least one prescription for one of the 10 antidepresssants during the study period. Main outcome measure-Suicide confirmed by general practitioner or on death certificate, or both. Results-143 people committed suicide. The overall rate of suicide was estimated to be 8.5 per 10 000 person years (95% confidence interval 7.2 to 10.0). Rates of suicide were higher in men than women (relative risk 2.8 (95% confidence interval 1.9 to 4.0)), people with a history of feeling suicidal (19.2 (9.5 to 38.7)), and people who had taken several different antidepressants (2.8 (1.8 to 4.3)). People who received high doses of antidepressants and those who had had a prescription in the 30 days before they committed suicide were also at higher risk than those who had received low doses and had had their prescriptions 30 or more days previously (2.3 (1.4 to 3.7) and 2.3 (1.6 to 3.4)) respectively. Rates of suicide were higher in patients who received fluoxetine, but this may be explained by selection biases which were present for those drug users. Conclusion-Several factors correlate with the risk of suicide in people taking antidepressants. After controlling for these factors, the risk of suicide was similar among the 10 study antidepressants. Overdose with antidepressants accounted for only 14% of the suicides.			JICK, SS (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				CASSIDY S, 1982, BRIT MED J, V295, P1021; DERBY LE, 1992, J CLIN PSYCHOPHARM, V12, P235; Henry J A, 1992, Eur J Med, V1, P343; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1992, PHARMACOTHERAPY, V12, P451; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; LEONARD BE, 1986, LANCET, V1, P1105; MONTGOMERY SA, 1992, INT CLIN PSYCHOPHARM, V95, P22; PAYNE CD, 1986, GENERALISED LINEAR I; Perry J, 1978, OXMIS PROBLEM CODES; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; TEICHER MN, 1991, J CLIN PSYCHIAT, V52, P108; 1993, EPILOG PLUS VERSION	15	205	208	2	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					215	218		10.1136/bmj.310.6974.215	http://dx.doi.org/10.1136/bmj.310.6974.215			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE496	7677826	Green Published			2022-12-24	WOS:A1995QE49600018
J	TSUBATA, T; WU, J; HONJO, T				TSUBATA, T; WU, J; HONJO, T			B-CELL APOPTOSIS INDUCED BY ANTIGEN RECEPTOR CROSS-LINKING IS BLOCKED BY A T-CELL SIGNAL THROUGH CD40	NATURE			English	Article							INVITRO TOLERANCE INDUCTION; LYMPHOCYTES-B; TRANSGENIC MOUSE; ACTIVATION; IMMUNOGLOBULIN; LIGAND; EXPRESSION; PROTEIN; DEATH; PROLIFERATION	IN mice transgenic for an autoantibody, self-reactive B cells have been shown to be eliminated upon interaction with membrane-bound self-antigens in the periphery1,2 as well as in the bone marrow3,5, suggesting that both immature and mature B cells are eliminated by multimerization of surface immunoglobulins (sIg). Activation of mature B cells by antigens may thus require a second signal that inhibits sIg-mediated apoptosis. Such a second signal is likely to be provided by T helper cells, because B-cell tolerance is more easily induced in the absence of T helper cells6-9. To assess the molecular nature of the signal that inhibits sIg-mediated apoptosis, we used anti-IgM-induced apoptotic death of WEHI-231 B lymphoma cells10,11 as a model system. Here we report that the signal for abrogating sIg-mediated apoptosis is generated by association of the CD40L molecule on T cells with the CD40 molecule on WEHI-231 cells. T-cell help through CD40 may thus determine whether B cells are eliminated or activated upon interaction with antigens.			TSUBATA, T (corresponding author), KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN.		Honjo, Tasuku/N-4470-2016; Tsubata, Takeshi/AAI-7489-2021	Tsubata, Takeshi/0000-0003-0760-1258				ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; METCALF ES, 1977, J IMMUNOL, V118, P2111; METCALF ES, 1976, J EXP MED, V143, P1327, DOI 10.1084/jem.143.6.1327; MOND JJ, 1981, J IMMUNOL, V127, P881; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; ODAKA C, 1990, J IMMUNOL, V144, P2096; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OZAKI S, 1988, J IMMUNOL, V141, P71; PAULIE S, 1989, J IMMUNOL, V142, P590; ROBB RJ, 1986, P NATL ACAD SCI USA, V83, P3992, DOI 10.1073/pnas.83.11.3992; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUBBARAO B, 1983, J IMMUNOL, V130, P2033; SUBBARAO B, 1984, J EXP MED, V159, P1796, DOI 10.1084/jem.159.6.1796; VAN DE VELDE H, 1991, NATURE, V351, P662	35	386	400	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 12	1993	364	6438					645	648		10.1038/364645a0	http://dx.doi.org/10.1038/364645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	7688865				2022-12-24	WOS:A1993LR77100058
J	BUTLER, A; TSUNODA, S; MCCOBB, DP; WEI, A; SALKOFF, L				BUTLER, A; TSUNODA, S; MCCOBB, DP; WEI, A; SALKOFF, L			MSLO, A COMPLEX MOUSE GENE ENCODING MAXI CALCIUM-ACTIVATED POTASSIUM CHANNELS	SCIENCE			English	Article							LIPID BILAYERS; ION CHANNELS; K+ CHANNELS; DROSOPHILA; SHAKER; COMPONENTS; PERMEATION; CURRENTS; BLOCKADE; PROTEIN	Complementary DNAs (cDNAs) from mSlo, a gene encoding calcium-activated potassium channels, were isolated from mouse brain and skeletal muscle, sequenced, and expressed in Xenopus oocytes. The mSlo-encoded channel resembled ''maxi'' or BK (high conductance) channel types; single channel conductance was 272 picosiemens with symmetrical potassium concentrations. Whole cell and single channel currents were blocked by charybdotoxin, iberiotoxin, and tetraethylammonium ion. A large number of variant mSlo cDNAs were isolated, indicating that several diverse mammalian BK channel types are produced by a single gene.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NINDS NIH HHS [R01 NS24785-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024785] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BUTLER AR, UNPUB; CAHALAN MD, 1991, CURR TOP MEMBR, V39, P357; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; ELKINS T, 1986, P NATL ACAD SCI USA, V83, P8415, DOI 10.1073/pnas.83.21.8415; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GHO M, 1992, J EXP BIOL, V170, P93; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1992, NEURON, V8, P483; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MEECH RW, 1978, ANNU REV BIOPHYS BIO, V7, P1, DOI 10.1146/annurev.bb.07.060178.000245; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; SAITO M, 1991, J NEUROSCI, V11, P2135; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SALKOFF L, 1987, SCIENCE, V237, P744, DOI 10.1126/science.2441469; SALKOFF L, 1985, J PHYSIOL-PARIS, V80, P275; SALKOFF L, 1983, NATURE, V302, P249, DOI 10.1038/302249a0; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; TORO L, 1991, AM J PHYSIOL, V260, pH1779, DOI 10.1152/ajpheart.1991.260.6.H1779; TORO L, 1990, J GEN PHYSIOL, V96, P373, DOI 10.1085/jgp.96.2.373; TORO L, 1990, AM J PHYSIOL, V258, P912; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157	35	571	588	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					221	224		10.1126/science.7687074	http://dx.doi.org/10.1126/science.7687074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	7687074				2022-12-24	WOS:A1993LL59600044
J	VALIUS, M; KAZLAUSKAS, A				VALIUS, M; KAZLAUSKAS, A			PHOSPHOLIPASE-C-GAMMA-1 AND PHOSPHATIDYLINOSITOL-3 KINASE ARE THE DOWNSTREAM MEDIATORS OF THE PDGF RECEPTORS MITOGENIC SIGNAL	CELL			English	Article							GROWTH-FACTOR RECEPTOR; GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; C-GAMMA; DNA-SYNTHESIS; BOVINE BRAIN; RAT-LIVER; ASSOCIATION; 3-KINASE	Upon ligand-induced tyrosine phosphorylation, the platelet-derived growth factor (PDGF) receptor (PDGFR) beta subunit associates with PLC-gamma1, RasGAP, PI3K, and a 64 kd protein. To determine the relative role of each of these associated proteins in PDGFR signaling, we constructed a PDGFR mutant (F5) unable to bind any of them and a panel of ''add-back'' mutants that could bind only one of the receptor-associated proteins. F5 PDGFR failed to activate PLC-gamma1, PI3K, or Ras and was unable to trigger DNA synthesis. Permitting association of F5 PDGFR with either PLC-gamma1 or PI3K restored Ras activation and a mitogenic response. Surprisingly, even though binding of the 64 kd protein almost fully restored Ras activation, it did not rescue the receptor's ability to trigger DNA synthesis. Thus Ras activation is insufficient to trigger PDGF-dependent DNA synthesis, and PLC-gamma1 and PI3K are independent downstream mediators of PDGFs mitogenic signal.	NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	National Jewish Health			Valius, Mindaugas/F-2734-2012; Valius, Mindaugas/N-1220-2019	Valius, Mindaugas/0000-0001-8478-8517	NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, IN PRESS MOL CELL BI; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLLOY CJ, 1989, CELL, V58, P649; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VALIUS M, 1993, MOL CELL BIOL, V13, P7266; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	68	627	632	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					321	334		10.1016/0092-8674(93)90232-F	http://dx.doi.org/10.1016/0092-8674(93)90232-F			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	7682895				2022-12-24	WOS:A1993KY50500013
J	VERMA, A; HIRSCH, DJ; GLATT, CE; RONNETT, GV; SNYDER, SH				VERMA, A; HIRSCH, DJ; GLATT, CE; RONNETT, GV; SNYDER, SH			CARBON-MONOXIDE - A PUTATIVE NEURAL MESSENGER	SCIENCE			English	Article							NITRIC-OXIDE SYNTHESIS; HEME OXYGENASE; RAT-BRAIN; GUANYLATE-CYCLASE; SMOOTH-MUSCLE; ACTIVATION; RELAXATION; MECHANISM; RNA; VASODILATION	Carbon monoxide, an activator of guanylyl cyclase, is formed by the action of the enzyme heme oxygenase. By in situ hybridization in brain slices, discrete neuronal localization of messenger RNA for the constitutive form of heme oxygenase throughout the brain has been demonstrated. This localization is essentially the same as that for soluble guanylyl cyclase messenger RNA, In primary cultures of olfactory neurons, zinc protoporphyrin-9, a potent selective inhibitor of heme oxygenase, depletes endogenous guanosine 3',5'-monophosphate (cGMP). Thus, carbon monoxide, like nitric oxide, may be a physiologic regulator of cGMP. These findings, together with the neuronal localizations of heme oxygenase, suggest that carbon monoxide may function as a neurotransmitter.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; WALTER REED ARMY MED CTR,DEPT NEUROL,WASHINGTON,DC 20307; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Verma, Ajay/0000-0001-7715-0443	NIDA NIH HHS [DA00266] Funding Source: Medline; NIMH NIH HHS [MH18501] Funding Source: Medline; NINDS NIH HHS [NS02131] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADEAGBO ASO, 1990, J PHARMACOL EXP THER, V252, P875; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1987, MOL PHARMACOL, V32, P497; CHERNICK RJ, 1989, HEPATOLOGY, V10, P365, DOI 10.1002/hep.1840100320; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6388; DIFIGLIA M, 1990, HUMAN NERVOUS SYSTEM, P1115; DIGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GRASER T, 1990, BIOMED BIOCHIM ACTA, V49, P293; HOKFELT T, 1984, SCIENCE, V225, P1326, DOI 10.1126/science.6147896; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KASA P, 1986, PROG NEUROBIOL, V26, P211, DOI 10.1016/0301-0082(86)90016-X; KOLBRIDE P, 1979, J GEN PHYSIOL, V79, P415; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MCFAUL SJ, 1987, TOXICOL APPL PHARM, V87, P464, DOI 10.1016/0041-008X(87)90252-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1983, BRAIN RES, V273, P9, DOI 10.1016/0006-8993(83)91088-0; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; RAMOS KS, 1989, BIOCHEM PHARMACOL, V38, P1368, DOI 10.1016/0006-2952(89)90347-X; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SUN Y, 1990, J BIOL CHEM, V265, P8212; SUNDERMAN FW, 1958, CLIN CHEM NY, V28, P2026; UTZ J, 1991, BIOCHEM PHARMACOL, V41, P1195, DOI 10.1016/0006-2952(91)90658-R; VEDERNIKOV YP, 1989, BIOMED BIOCHIM ACTA, V48, P601; Verma A., UNPUB; WEING JF, 1992, J NEUROCHEM, V58, P1140; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7794	43	1359	1434	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					381	384		10.1126/science.7678352	http://dx.doi.org/10.1126/science.7678352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	7678352				2022-12-24	WOS:A1993KG62400038
J	DEBELDER, AJ; RADOMSKI, MW; WHY, HJF; RICHARDSON, PJ; BUCKNALL, CA; SALAS, E; MARTIN, JF; MONCADA, S				DEBELDER, AJ; RADOMSKI, MW; WHY, HJF; RICHARDSON, PJ; BUCKNALL, CA; SALAS, E; MARTIN, JF; MONCADA, S			NITRIC-OXIDE SYNTHASE ACTIVITIES IN HUMAN MYOCARDIUM	LANCET			English	Note								Myocardial constitutive and inducible nitric oxide (NO) synthase activities were measured in right ventricular tissue from 17 patients with dilated cardiomyopathy (DCM). A significant activity of inducible enzyme was accompanied by a low activity of the constitutive NO synthase. Thus, the myocardium has the capacity to express both NO synthases. NO may have a physiological as well as a pathological role in the human myocardium.	WELLCOME RES LABS,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT CARDIOL,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London			Salas, Eduardo/AAL-4836-2020	Salas, Eduardo/0000-0002-6837-2471; bucknall, clifford/0000-0003-0662-5856				MONCADA S, 1991, PHARMACOL REV, V43, P109; OLSEN EGJ, 1979, AM HEART J, V98, P385, DOI 10.1016/0002-8703(79)90052-8; PALMER RMJ, 1992, BRIT J PHARMACOL, V105, P11, DOI 10.1111/j.1476-5381.1992.tb14202.x; RICHARDSON PJ, 1990, CURR OPIN CARDIOL, V5, P306, DOI 10.1097/00001573-199006000-00009; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SMITH JA, 1991, J PHYSIOL-LONDON, V439, P1; SMITH JC, 1992, CIRC RES, V70, P856	8	325	325	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					84	85		10.1016/0140-6736(93)92559-C	http://dx.doi.org/10.1016/0140-6736(93)92559-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	7678120				2022-12-24	WOS:A1993KF87000006
J	HOWARD, PK; SEFTON, BM; FIRTEL, RA				HOWARD, PK; SEFTON, BM; FIRTEL, RA			TYROSINE PHOSPHORYLATION OF ACTIN IN DICTYOSTELIUM ASSOCIATED WITH CELL-SHAPE CHANGES	SCIENCE			English	Article							BINDING PROTEINS; GENE-EXPRESSION; DISCOIDEUM; CHEMOTAXIS; IDENTIFICATION; POLYMERIZATION; MECHANISMS; MOTILITY; MULTIPLE; GROWTH	When Dictyostelium cells that have initiated their developmental program upon starvation are returned to growth medium, there is a rapid and transient de novo tyrosine phosphorylation of a 43-kilodalton protein. This protein was found to be actin. Most of the phosphorylation occurred in a single, minor acidic isoform of actin. Developing cells that had been returned to growth medium lost their pseudopod extensions, became round, and had reduced adhesion to the substratum. These effects occurred with kinetics that matched the increase in tyrosine phosphorylation of actin. In mutant cell lines in which the gene for the phosphotyrosine phosphatase PTP1 had been disrupted, tyrosine phosphorylation of actin was rapid and more prolonged. These cells responded with proportionally accelerated kinetics of cell rounding. Cell lines overexpressing PTP1 had diminished amplitude and duration of actin tyrosine phosphorylation and exhibited diminished cell-shape change and an accelerated return to the extended cell-shape morphology seen in starved cells.	UNIV CALIF SAN DIEGO, DEPT BIOL, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; SALK INST BIOL SCI, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92186 USA	University of California System; University of California San Diego; Salk Institute								AMATO PA, 1983, J CELL BIOL, V96, P750, DOI 10.1083/jcb.96.3.750; AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BURRIDGE K, 1986, Cancer Reviews, V4, P18; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; FARMER SR, 1989, CELL SHAPE DETERMINA, P173; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FUTRELLE RP, 1982, J CELL BIOL, V92, P807, DOI 10.1083/jcb.92.3.807; GARRELS JI, 1976, CELL, V9, P793, DOI 10.1016/0092-8674(76)90142-2; GERISCH G, 1982, ANNU REV PHYSIOL, V44, P535, DOI 10.1146/annurev.ph.44.030182.002535; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HOWARD P, UNPUB; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; MACLEOD C, 1980, DEV BIOL, V76, P263, DOI 10.1016/0012-1606(80)90378-4; MARIN FT, 1976, DEV BIOL, V48, P110, DOI 10.1016/0012-1606(76)90050-6; MCKEOWN M, 1981, J MOL BIOL, V151, P593, DOI 10.1016/0022-2836(81)90425-3; MCKEOWN M, 1981, COLD SPRING HARB SYM, V46, P495; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; MCROBBIE SJ, 1986, CRC CR REV MICROBIOL, V13, P335, DOI 10.3109/10408418609108742; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MELAMED I, 1991, BIOCHEM BIOPH RES CO, V176, P1424, DOI 10.1016/0006-291X(91)90445-D; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROMANS P, 1985, J MOL BIOL, V186, P337, DOI 10.1016/0022-2836(85)90109-3; SCHWEIGER A, 1992, J CELL SCI, V102, P601; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SIMPSON PA, 1984, J CELL BIOL, V99, P287, DOI 10.1083/jcb.99.1.287; SONOBE S, 1986, J BIOL CHEM, V261, P4837; WATTS RG, 1991, CELL MOTIL CYTOSKEL, V19, P159, DOI 10.1002/cm.970190304; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	35	108	109	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1993	259	5092					241	244		10.1126/science.7678470	http://dx.doi.org/10.1126/science.7678470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678470				2022-12-24	WOS:A1993KF71900035
J	HONG, CC; HASHIMOTO, C				HONG, CC; HASHIMOTO, C			AN UNUSUAL MOSAIC PROTEIN WITH A PROTEASE DOMAIN, ENCODED BY THE NUDEL GENE, IS INVOLVED IN DEFINING EMBRYONIC DORSOVENTRAL POLARITY IN DROSOPHILA	CELL			English	Article							DORSAL-VENTRAL PATTERN; SERINE PROTEASE; BLOOD-COAGULATION; MESSENGER-RNA; LDL-RECEPTOR; MELANOGASTER; SEQUENCE; LOCALIZATION; ACTIVATION; ZYMOGEN	Dorsoventral polarity of the Drosophila embryo is induced by a ventral extracellular signal, which is produced by a locally activated protease cascade within the extraembryonic perivitelline compartment. Local activation of the protease cascade depends on a positional cue that is laid down during oogenesis outside the oocyte. Here we present evidence that the nudel gene encodes an essential component of this cue. The nudel gene, which is expressed in follicle cells covering the oocyte, encodes an unusual mosaic protein resembling an extracellular matrix protein with a central serine protease domain. Our findings suggest that embryonic dorsoventral polarity is defined by a positional cue that requires the nudel protein to anchor and to trigger the protease cascade producing the polarity-inducing signal.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University	HONG, CC (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520, USA.		Hong, Charles/C-9989-2010		NICHD NIH HHS [HD-07149] Funding Source: Medline; NIGMS NIH HHS [GM-49370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049370] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; FARGNOLI J, 1982, DEV BIOL, V92, P306, DOI 10.1016/0012-1606(82)90177-4; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; GEHRING WJ, 1984, EMBO J, V3, P2077, DOI 10.1002/j.1460-2075.1984.tb02094.x; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAWLEY RJ, 1988, GENE DEV, V2, P341, DOI 10.1101/gad.2.3.341; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; KAY MA, 1985, MOL CELL BIOL, V5, P3583, DOI 10.1128/MCB.5.12.3583; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Merle J., 1968, DROSOPHILA INFORMATI, V43, P122; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MORISATO D, 1995, IN PRESS ANN REV GEN, V29; NEBES VL, 1991, J BIOL CHEM, V266, P22851; NECKAMEYER WS, 1989, NEURON, V2, P1167, DOI 10.1016/0896-6273(89)90183-9; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POPODI E, 1988, DEV BIOL, V127, P248, DOI 10.1016/0012-1606(88)90312-0; POWSNER J, 1935, PHYSIOL ZOOL, V8, P474; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERER LJ, 1988, DEV BIOL, V130, P786, DOI 10.1016/0012-1606(88)90367-3; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SMITH C, 1994, GENETICS, V136, P1355; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STJOHNSTON D, 1992, CELL, V68, P201; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wieschaus E., 1986, P199; WIGGINS RC, 1979, J EXP MED, V150, P1122, DOI 10.1084/jem.150.5.1122; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	57	92	96	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					785	794		10.1016/0092-8674(95)90475-1	http://dx.doi.org/10.1016/0092-8674(95)90475-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671306	hybrid			2022-12-24	WOS:A1995RU75500013
J	NEWMAN, LS; MCKEEVER, MO; OKANO, HJ; DARNELL, RB				NEWMAN, LS; MCKEEVER, MO; OKANO, HJ; DARNELL, RB			BETA-NAP, A CEREBELLAR DEGENERATION ANTIGEN, IS A NEURON-SPECIFIC VESICLE COAT PROTEIN	CELL			English	Article							STIFF-MAN SYNDROME; TRANSMITTER RELEASE; SYNAPTIC VESICLES; MEMBRANE-PROTEINS; BREAST-CANCER; CLATHRIN; SYNAPTOTAGMIN; COMPLEX; CELLS; PHOSPHORYLATION	We have identified a target antigen in autoimmune cerebellar degeneration, beta-NAP, that is closely related to the beta-adaptin and beta-COP coat proteins. beta-NAP is a non-clathrin-associated phosphoprotein expressed exclusively in neurons, from E12 through adulthood. beta-NAP is present in the neuronal soma and nerve terminal as soluble and membrane-bound pools and is associated with a discrete set of nerve-terminal vesicles. These results establish beta-NAP as a neuron-specific vesicle coat protein. We propose a model in which beta-NAP mediates vesicle transport between the soma and the axon terminus and suggest that beta-NAP may represent a general class of coat proteins that mediates apical transport in polarized cells.			NEWMAN, LS (corresponding author), ROCKEFELLER UNIV, NEUROONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Darnell, Robert B/B-9022-2008	Darnell, Robert B/0000-0002-5134-8088; Okano, Hirotaka James/0000-0003-4611-7098	NIGMS NIH HHS [5T32 GM07739] Funding Source: Medline; NINDS NIH HHS [K08 NS01461] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001461] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CAMIDGE DR, 1994, J CELL SCI, V107, P709; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; Curtis Rory, 1994, Trends in Cell Biology, V4, P383, DOI 10.1016/0962-8924(94)90045-0; DARNELL RB, 1993, NEUROLOGY, V43, P114, DOI 10.1212/WNL.43.1_Part_1.114; DARNELL RB, 1991, J NEUROSCI, V11, P1224, DOI 10.1523/jneurosci.11-05-01224.1991; DARNELL RB, 1994, CURRENT DIAGNOSIS NE, P137; DAVLETOV B, 1993, J BIOL CHEM, V268, P6816; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; GIBBS RB, 1994, J COMP NEUROL, V341, P324, DOI 10.1002/cne.903410304; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HOWARD FM, 1963, MAYO CLIN PROC, V38, P203; HURTLEY SM, 1993, TRENDS BIOCHEM SCI, V18, P453, DOI 10.1016/0968-0004(93)90001-4; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IKONEN E, 1993, CURR BIOL, V3, P635, DOI 10.1016/0960-9822(93)90061-R; JACOBSON M, 1991, DEV DEV NEUROBIOLOGY, P252; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KOENIG JH, 1989, J NEUROSCI, V9, P3844; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LIU JP, 1994, J BIOL CHEM, V269, P21043; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARTINMOUTOT N, 1993, J PHYSIOLOGY-PARIS, V87, P37, DOI 10.1016/0928-4257(93)90022-L; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEVSNER J, 1994, IN PRESS GENE; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; POSNER JB, 1990, RES P ARNMD, V68, P187; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIHRA TS, 1989, P NATL ACAD SCI USA, V86, P8108, DOI 10.1073/pnas.86.20.8108; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1993, NATURE, V366, P15, DOI 10.1038/366015a0; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	63	133	134	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					773	783		10.1016/0092-8674(95)90474-3	http://dx.doi.org/10.1016/0092-8674(95)90474-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671305	Bronze			2022-12-24	WOS:A1995RU75500012
J	HOPKINS, DR; AZAM, M; RUIZTIBEN, E; KAPPUS, KD				HOPKINS, DR; AZAM, M; RUIZTIBEN, E; KAPPUS, KD			ERADICATION OF DRACUNCULIASIS FROM PAKISTAN	LANCET			English	Article								In 1986 the World Health Organization targeted dracunculiasis (Guinea-worm disease), which seriously impairs socioeconomic development in 16 African countries, India, Pakistan, and Yemen, to be eradicated globally The target date for eradication by the end of 1995 was established in 1991. Pakistan eradicated dracunculiasis from the country in October, 1993, after a national campaign which began in 1987 with a nationwide village-by-village search for cases. The infection, which is transmitted by drinking water from ponds containing infected water fleas, was eradicated by using health education, cloth fillers, and the cyclopsicide, temephos; and in the later stages, by case containment. Methods pioneered in Pakistan's National Guinea Worm Eradication Program are now being applied in remaining endemic countries.	NATL INST HLTH,GUINEA WORM ERADICAT PROGRAM,ISLAMABAD,PAKISTAN; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	HOPKINS, DR (corresponding author), EMORY UNIV,CARTER CTR INC,1 COPENHILL,ATLANTA,GA 30307, USA.							HOPKINS DR, 1981, SCIENCE, V212, P495, DOI 10.1126/science.6451929; HOPKINS DR, 1991, B WORLD HEALTH ORGAN, V69, P533; KAPPUS K D, 1991, World Health Forum, V12, P220; PAUL JE, 1988, WASH231 WAT SAN HLTH; 1993, WKLY EPIDEMIOL REC, V68, P49; 1992, WKLY EPIDEMIOL REC, V67, P137; 1988, WKLY EPIDEMIOL REC, V63, P177; 1991, MMWR-MORBID MORTAL W, V40, P5; 1995, WKLY EPIDEMIOL REC, V70, P125	9	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					621	624		10.1016/S0140-6736(95)91442-0	http://dx.doi.org/10.1016/S0140-6736(95)91442-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651010				2022-12-24	WOS:A1995RT18800015
J	UDOLPH, G; LUER, K; BOSSING, T; TECHNAU, GM				UDOLPH, G; LUER, K; BOSSING, T; TECHNAU, GM			COMMITMENT OF CNS PROGENITORS ALONG THE DORSOVENTRAL AXIS OF DROSOPHILA NEUROECTODERM	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSPLANTED INDIVIDUAL CELLS; LINEAGE ANALYSIS; MIDLINE CELLS; SPINAL-CORD; EMBRYOS; MELANOGASTER; NEUROGENESIS; NEUROBLASTS; GUIDANCE	In the Drosophila embryo, the central nervous system (CNS) develops from a population of neural stem cells (neuroblasts) and midline progenitor cells, Here, the fate and extent of determination of CNS progenitors along the dorsoventral axis was assayed. Dorsal neuroectodermal cells transplanted into the ventral neuroectoderm or into the midline produced CNS lineages consistent with their new position. However, ventral neuroectodermal cells and midline cells transplanted to dorsal sites of the neuroectoderm migrated ventrally and produced CNS lineages consistent with their origin, Thus, inductive signals at the ventral midline and adjacent neuroectoderm may confer ventral identities to CNS progenitors as well as the ability to assume and maintain characteristic positions in the developing CNS. Furthermore, ectopic transplantations of wild-type midline cells into single minded (sim) mutant embryos suggest that the ventral midline is required for correct positioning of the cells.	UNIV MAINZ, INST GENET, D-55122 MAINZ, GERMANY	Johannes Gutenberg University of Mainz				Bossing, Torsten/0000-0002-3277-9130				BATE CM, 1976, J EMBRYOL EXP MORPH, V35, P107; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BOSSING T, UNPUB; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Campos-Ortega J. A., 1993, DEV DROSOPHILA MELAN, VII, P1091; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DOE CQ, 1992, DEVELOPMENT, V116, P855; Goodman C. S., 1993, DEV DROSOPHILA MELAN, VII, P1131; HALTER DA, 1995, DEVELOPMENT, V121, P317; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; NAMBU JR, 1993, COMP BIOCHEM PHYS A, V104, P399, DOI 10.1016/0300-9629(93)90439-B; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PACZEK M, 1993, DEVELOPMENT, V117, P205; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PROKOP A, 1994, DEVELOPMENT, V120, P2567; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SINK H, 1991, DEVELOPMENT, V112, P307; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P389, DOI 10.1007/BF00402872; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P445, DOI 10.1007/BF00375748; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; UDOLPH G, 1993, DEVELOPMENT, V118, P765; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	27	43	43	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	1995	269	5228					1278	1281		10.1126/science.7652576	http://dx.doi.org/10.1126/science.7652576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652576				2022-12-24	WOS:A1995RR84200038
J	SUDLOW, CM; RODGERS, H; KENNY, RA; THOMSON, RG				SUDLOW, CM; RODGERS, H; KENNY, RA; THOMSON, RG			SERVICE PROVISION AND USE OF ANTICOAGULANTS IN ATRIAL-FIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; MITRAL-STENOSIS; THROMBOEMBOLIC COMPLICATIONS; SYSTEMIC EMBOLIZATION; RANDOMIZED TRIAL; GENERAL-PRACTICE; STROKE; WARFARIN; PREVENTION; PREVALENCE	Several large trials have shown that the risk of stroke in patients with non-valvar atrial fibrillation is reduced by treatment with warfarin. Implementing this research evidence requires not only an understanding of the trials' results and of the changes that they imply for clinicians' treatment decisions but also an appreciation of the organisation, quantity, and quality of services required to support these changes. Understanding of these implications is crucial for developing services that allow changes in practice to produce reductions in stroke incidence while minimising the risks of treatment. This article considers the developments in service provision that will probably be required to support the changes in clinical practice suggested by the trials' results. These services will be provided largely by doctors, and their development has implications for doctors in both primary and secondary care.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	SUDLOW, CM (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Kenny, Rose Anne/0000-0002-9336-8124; Sudlow, Cathie/0000-0002-7725-7520				[Anonymous], 1994, ARCH INTERN MED, V154, P1449; [Anonymous], 1994, LANCET, V343, P687; ARONOW WS, 1989, AM J CARDIOL, V63, P366, DOI 10.1016/0002-9149(89)90349-4; BARNABY J, 1993, BRIT MED J, V306, P207, DOI 10.1136/bmj.306.6871.207-b; BATH PMW, 1993, BRIT MED J, V307, P1045, DOI 10.1136/bmj.307.6911.1045; BLACKSHEAR JL, 1993, AM J CARDIOL, V72, P840, DOI 10.1016/0002-9149(93)91079-W; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; CAMM AJ, 1980, AM HEART J, V99, P598, DOI 10.1016/0002-8703(80)90733-4; CAMPBELL A, 1974, BRIT HEART J, V36, P1005; CAPLAN LR, 1986, ANN NEUROL, V19, P158, DOI 10.1002/ana.410190208; CARO JJ, 1993, LANCET, V341, P1381, DOI 10.1016/0140-6736(93)90950-L; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CHIMOWITZ MI, 1993, STROKE, V24, P1015, DOI 10.1161/01.STR.24.7.1015; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CORBALAN R, 1992, AM HEART J, V124, P149, DOI 10.1016/0002-8703(92)90933-M; DOBLE N, 1987, J ROY SOC MED, V80, P627, DOI 10.1177/014107688708001009; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FLEGEL KM, 1991, J CLIN EPIDEMIOL, V44, P551, DOI 10.1016/0895-4356(91)90219-Y; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HILL JD, 1987, J ROY COLL GEN PRACT, V37, P172; KENNEDY RD, 1972, GERONTOL CLIN, V14, P5, DOI 10.1159/000245366; KITCHIN AH, 1977, BRIT HEART J, V39, P889, DOI 10.1136/hrt.39.8.889; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANDAHL S, 1984, EUR HEART J, V5, P326, DOI 10.1093/oxfordjournals.eurheartj.a061659; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; MCINNES GT, 1987, J ROY COLL PHYS LOND, V21, P42; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; NADEAU SE, 1993, STROKE, V24, P2128, DOI 10.1161/01.STR.24.12.2128; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; PELL JP, 1993, BRIT J GEN PRACT, V43, P152; PETERSEN P, 1990, ARCH INTERN MED, V150, P819, DOI 10.1001/archinte.150.4.819; PETERSEN P, 1989, LANCET, V1, P175; ROSE G, 1978, BRIT HEART J, V40, P636; RUOCCO NA, 1986, J AM COLL CARDIOL, V7, pA165; SHAKESPEARE J, 1994, BRIT MED J, V308, P415, DOI 10.1136/bmj.308.6925.415a; TAYLOR F, 1994, BRIT MED J, V307, P1493; TOHGI H, 1991, EUR NEUROL, V31, P126, DOI 10.1159/000116661; 1994, STROKE, V25, P1315; 1991, CIRCULATION, V84, P527; 1993, 1991 CENSUS; 1993, LANCET, V342, P1255; 1990, NEW ENGL J MED, V323, P1505; 1992, ANN INTERN MED, V116, P1	48	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					558	560		10.1136/bmj.311.7004.558	http://dx.doi.org/10.1136/bmj.311.7004.558			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663216	Green Published			2022-12-24	WOS:A1995RR73700029
J	HACHIYA, N; MIHARA, K; SUDA, K; HORST, M; SCHATZ, G; LITHGOW, T				HACHIYA, N; MIHARA, K; SUDA, K; HORST, M; SCHATZ, G; LITHGOW, T			RECONSTITUTION OF THE INITIAL STEPS OF MITOCHONDRIAL PROTEIN IMPORT	NATURE			English	Article							YEAST MITOCHONDRIA; RECEPTORS	WE have reconstituted the initial steps of mitochondrial protein import with a purified precursor protein, a purified, ATP-dependent, cytosolic chaperone selective for mitochondrial precursors (mitochondrial import stimulating factor; MSF), and either intact mitochondria or intact or solubilized mitochondrial outer membranes. We show that the precursor-MSF complex first binds to the Mas37p/Mas70p subunits of the mitochondrial import receptor. After ATP-dependent release of MSF, the precursor is transferred from Mas37p/Mas70p to the Mas20p/Mas22p subunits of the receptor, and finally delivered to the import channel in the outer membrane, Import in the absence of the MSF bypasses Mas37p/Mas70p. The ATP-mediated transfer of a precursor from MSF to specific subunits of the import receptor is similar to the GTP-mediated transfer of precursors from the signal recognition particle to its receptor on the endoplasmic reticulum.	UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	University of Basel; Kyushu University			Lithgow, Trevor J/H-5925-2017	Lithgow, Trevor J/0000-0002-0102-7884				ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAID A, 1983, METHOD ENZYMOL, V96, P192; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HONLINGER A, IN PRESS MOL CELL BI; KIEBLER M, 1994, J MEMBRANE BIOL, V135, P191; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465	17	154	156	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					705	709		10.1038/376705a0	http://dx.doi.org/10.1038/376705a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651521				2022-12-24	WOS:A1995RQ67200065
J	VALLESI, A; GIULI, G; BRADSHAW, RA; LUPORINI, P				VALLESI, A; GIULI, G; BRADSHAW, RA; LUPORINI, P			AUTOCRINE MITOGENIC ACTIVITY OF PHEROMONES PRODUCED BY THE PROTOZOAN CILIATE EUPLOTES-RAIKOVI	NATURE			English	Article							MATING PHEROMONE; STRUCTURAL CHARACTERIZATION; GROWTH-FACTOR; IDENTIFICATION; PURIFICATION; RECOGNITION; CELLS; ER-1	DIFFUSIBLE polypeptide pheromones (formerly referred to as mating-type factors, sex factors or gamones), which distinguish otherwise morphologically identical vegetative cell (mating) types from one another, are produced by some species of ciliates(1,2), Their most striking effect can be observed by exposing cells of one type to a pheromone secreted by another co-specific cell type(3). In the presence of this 'non-self' signal, these cells interrupt their vegetative life to unite temporarily in mating pairs, Thus ciliate pheromones have traditionally been associated only with mating induction(2,4), However, the identification of autocrine pheromone receptors(5,6) suggests a broader role, which is supported by the hypothesis that ciliates evolved their mating-type mechanism for pursuing self-recognition(1). We now report studies, in the cosmopolitan marine sand-dwelling protozoan ciliate Euplotes raikovi, demonstrating that these molecules promote the vegetative reproduction (mitogenic proliferation or growth) of the same cells from which they originate, As, understandably, such autocrine pheromone activity is primary to that of targeting and inducing a foreign cell to mate (paracrine functions), this finding provides an example of how the original function of a molecule can be obscured during evolution by the acquisition of a new one.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine	VALLESI, A (corresponding author), UNIV CAMERINO,DIPARTIMENTO BIOL MOLEC CELLULARE & ANIM,I-62032 CAMERINO MC,ITALY.		Bradshaw, Ralph A/K-1515-2013; Vallesi, Adriana/I-9933-2016	Vallesi, Adriana/0000-0002-4127-090X				BEALE G, 1990, TRENDS GENET, V6, P137, DOI 10.1016/0168-9525(90)90132-P; BROWN LR, 1993, J MOL BIOL, V231, P800, DOI 10.1006/jmbi.1993.1327; CONCETTI A, 1986, J BIOL CHEM, V261, P582; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KUHLMANN HW, 1989, J EXP ZOOL, V251, P316, DOI 10.1002/jez.1402510308; LUGINBUHL P, 1994, PROTEIN SCI, V3, P1537, DOI 10.1002/pro.5560030919; LUPORINI P, 1992, DEV GENET, V13, P9, DOI 10.1002/dvg.1020130103; LUPORINI P, 1994, ANN NY ACAD SCI, V712, P195, DOI 10.1111/j.1749-6632.1994.tb33573.x; LUPORINI P, 1986, P NATL ACAD SCI USA, V83, P2889, DOI 10.1073/pnas.83.9.2889; Luporini P., 1986, P263; MICELI C, 1991, EUR J BIOCHEM, V202, P759, DOI 10.1111/j.1432-1033.1991.tb16430.x; MICELI C, 1992, P NATL ACAD SCI USA, V89, P1988, DOI 10.1073/pnas.89.5.1988; Miyake A, 1981, BIOCH PHYSL PROTOZOA, P125; MRONGA S, 1994, PROTEIN SCI, V3, P1527, DOI 10.1002/pro.5560030918; OLINS DE, 1994, INT REV CYTOL, V153, P137, DOI 10.1016/S0074-7696(08)62190-7; ORTENZI C, 1990, J CELL BIOL, V111, P607, DOI 10.1083/jcb.111.2.607; ORTENZI C, 1995, J EUKARYOT MICROBIOL, V42, P242; OTTIGER M, 1994, PROTEIN SCI, V3, P1515, DOI 10.1002/pro.5560030917; PARFENOVA EV, 1989, ACTA PROTOZOOL, V28, P11; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P2071, DOI 10.1073/pnas.89.6.2071; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STEWART AE, 1992, PROTEIN SCI, V1, P777, DOI 10.1002/pro.5560010609; TAKAGI Y, 1994, ZOOL SCI, V10, P53; TANABE H, 1990, BIOCHEM BIOPH RES CO, V170, P786, DOI 10.1016/0006-291X(90)92160-2; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WHITBREAD JA, 1991, DEV GENET, V12, P78, DOI 10.1002/dvg.1020120114	26	64	66	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					522	524		10.1038/376522a0	http://dx.doi.org/10.1038/376522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637785	Green Submitted			2022-12-24	WOS:A1995RN62200047
J	QUILL, TE				QUILL, TE			THE AMBIGUITY OF CLINICAL INTENTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											QUILL, TE (corresponding author), UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14607 USA.							ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BRODY H, 1993, J CLIN ETHIC, V4, P112; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; VANDERMAAS PJ, 1992, HLTH POLICY MONOGRAP, V2; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1992, JAMA-J AM MED ASSOC, V267, P2229	9	137	138	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1039	1040		10.1056/NEJM199309303291414	http://dx.doi.org/10.1056/NEJM199309303291414			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	7690111				2022-12-24	WOS:A1993LY58700014
J	LOVE, PE; SHORES, EW; JOHNSON, MD; TREMBLAY, ML; LEE, EJ; GRINBERG, A; HUANG, SP; SINGER, A; WESTPHAL, H				LOVE, PE; SHORES, EW; JOHNSON, MD; TREMBLAY, ML; LEE, EJ; GRINBERG, A; HUANG, SP; SINGER, A; WESTPHAL, H			T-CELL DEVELOPMENT IN MICE THAT LACK THE ZETA-CHAIN OF THE T-CELL ANTIGEN RECEPTOR COMPLEX	SCIENCE			English	Article							ETA-CHAIN; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; EXPRESSION; THYMOCYTES; CD4; MUTATIONS; FAMILY; TCR	The zeta subunit of the T cell antigen receptor complex is required for targeting nascent receptor complexes to the cell surface and for receptor-mediated signal transduction. To examine the significance of the zeta subunit in T cell development, mice deficient for zeta expression were generated by gene targeting. These zeta-/- mice had few CD4+CD8+ thymocytes, and the generation of CD4+ and CD8+ single positive T cells was impaired but not completely abrogated. Peripheral T cells were present but were unusual in that they expressed small amounts of CD5 and few T cell receptors. Thus, zeta chain expression influences thymocyte differentiation but is not absolutely required for the generation of single positive T cells.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LOVE, PE (corresponding author), NICHHD,MAMMALIAN GENES & DEV LAB,BLDG 6B,ROOM 210,BETHESDA,MD 20892, USA.							Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISHI H, 1993, J IMMUNOL, V150, P1263; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LOVE PE, 1992, P NATL ACAD SCI USA, V89, P9929, DOI 10.1073/pnas.89.20.9929; LOVE PJ, UNPUB; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SHORTMAN K, 1988, CELL IMMUNOL, V113, P462, DOI 10.1016/0008-8749(88)90042-1; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; UNKLESS JC, 1979, J EXP MED, V150, P580; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	33	200	204	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					918	921		10.1126/science.7688481	http://dx.doi.org/10.1126/science.7688481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	7688481				2022-12-24	WOS:A1993LR89700040
J	GRANT, WE; HOPPER, C; MACROBERT, AJ; SPEIGHT, PM; BOWN, SG				GRANT, WE; HOPPER, C; MACROBERT, AJ; SPEIGHT, PM; BOWN, SG			PHOTODYNAMIC THERAPY OF ORAL-CANCER - PHOTOSENSITIZATION WITH SYSTEMIC AMINOLEVULINIC ACID	LANCET			English	Note								Photodynamic therapy with intravenous photosensitising drugs has been shown to be effective in the ablation of superficial cancers, but long-lasting photosensitivity is a serious disadvantage. Similar photosensitivity is a feature of certain types of porphyria. We present the first report of tumour necrosis brought about by photodynamic activation of a temporary endogenous porphyrin accumulation, after an oral dose of the haem precursor, 5-aminolaevulinic acid. In 4 patients, quantitative fluorescence microscopy showed that accumulation of the photoactive intermediate protoporphyrin IX peaked after 4-6 h in 4 oral cavity squamous cell carcinomas, returning to background in 24 h. Irradiation with non-thermal red laser light caused tumour necrosis in 3 patients.	UNIV LONDON UNIV COLL, SCH MED, DEPT SURG, DIV MAXILLOFACIAL SURG, LONDON WC1E 6JJ, ENGLAND; UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT ORAL PATHOL, LONDON WC1, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	GRANT, WE (corresponding author), UNIV LONDON UNIV COLL, SCH MED, DEPT SURG, NATL MED LASER CTR, LONDON WC1E 6JJ, ENGLAND.		Bown, Stephen G/C-5713-2009; Bown, Stephen/AAX-6573-2020					BARR H, 1987, BRIT J CANCER, V56, P111, DOI 10.1038/bjc.1987.166; BEDWELL J, 1992, BRIT J CANCER, V65, P818, DOI 10.1038/bjc.1992.175; DIVARIS DXG, 1990, AM J PATHOL, V136, P891; DOUGHERTY TJ, 1990, LASER SURG MED, V10, P485, DOI 10.1002/lsm.1900100514; DOUGHERTY TJ, 1966, ACTA MED SCAND, V179, P11; KENNEDY JC, 1992, J PHOTOCH PHOTOBIO B, V14, P275, DOI 10.1016/1011-1344(92)85108-7; LOH CS, 1993, BRIT J CANCER, V68, P41, DOI 10.1038/bjc.1993.284; LOH CS, 1992, BRIT J CANCER, V66, P452, DOI 10.1038/bjc.1992.295; MALIK Z, 1987, BRIT J CANCER, V56, P589, DOI 10.1038/bjc.1987.246; MEYER M, 1991, BRIT J CANCER, V64, P1093, DOI 10.1038/bjc.1991.470	10	228	235	1	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					147	148		10.1016/0140-6736(93)91347-O	http://dx.doi.org/10.1016/0140-6736(93)91347-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	7687318				2022-12-24	WOS:A1993LN04200013
J	HAYMAN, MJ; MEYER, S; MARTIN, F; STEINLEIN, P; BEUG, H				HAYMAN, MJ; MEYER, S; MARTIN, F; STEINLEIN, P; BEUG, H			SELF-RENEWAL AND DIFFERENTIATION OF NORMAL AVIAN ERYTHROID PROGENITOR CELLS - REGULATORY ROLES OF THE TGF-ALPHA/C-ERBB AND SCF/C-KIT RECEPTORS	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; TRANSFORMED ERYTHROBLASTS; MYELOID CELLS; EGF RECEPTOR; TS MUTANTS; VIRUS; ONCOGENE	The c-kit proto-oncogene product is a major regulator of early hematopoiesis in mice. We show here that the avian c-Kit protein, together with the c-erbB proto-oncogene product, regulates self-renewal and differentiation in two types of normal chick erythroid progenitors. A relatively frequent progenitor expressing only c-Kit transiently proliferated in response to avian c-Kit ligand (stem cell factor [SCF]). A second, rare progenitor coexpressed c-Kit and c-ErbB and was induced to long-term self-renewal by SCF or transforming growth factor alpha(TGFalpha), a c-ErbB ligand. In the absence of SFC or TGFalpha, both progenitors underwent erythropoietin (Epo)-dependent terminal differentiation with indistinguishable kinetics. Interestingly, Epo induced differentiation in the SCF progenitors even when SCF was present. In contrast, the c-ErbB-expressing, TGFalpha-induced progenitors continued to self-renew when treated with Epo plus the growth factors SCF, TGFalpha, or both. Expression of c-ErbB thus may be a dominant determinant for the sustained self-renewal of committed erythroid progenitors.	AMGEN CTR,THOUSAND OAKS,CA 91320; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Amgen; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	HAYMAN, MJ (corresponding author), SUNY,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BEUG H, 1992, NUCLEAR PROCESSES ON, P53; BEUG H, 1985, MODERN TRENDS HUMAN, V6, P284; BEUG H, 1987, ONCOGENES GROWTH CON, P85; BROXMEYER HE, 1991, BLOOD, V77, P2142; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1977, CANCER RES, V37, P59; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HAUNG E, 1990, CELL, V63, P225; KELLER G, 1992, CURR OPIN IMMUNOL, V4, P133, DOI 10.1016/0952-7915(92)90002-V; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KENNEDY M, 1992, BLOOD, V79, P180; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMAN, V7, P199; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Maniatis T., 1982, MOL CLONING; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	48	88	91	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					157	169		10.1016/0092-8674(93)90303-8	http://dx.doi.org/10.1016/0092-8674(93)90303-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687522				2022-12-24	WOS:A1993LN62500016
J	IMAMOTO, A				IMAMOTO, A			DISRUPTION OF THE CSK GENE, ENCODING A NEGATIVE REGULATOR OF SRC FAMILY TYROSINE KINASES, LEADS TO NEURAL-TUBE DEFECTS AND EMBRYONIC LETHALITY IN MICE	CELL			English	Article							HUMAN-COLON CARCINOMA; PP60C-SRC EXPRESSION; MOUSE-BRAIN; RAT-BRAIN; C-SRC; PHOSPHORYLATION; PROTEIN; ACTIVATION; P60C-SRC; PROTOONCOGENE	All Src family non-receptor tyrosine kinases are negatively regulated by phosphorylation at a carboxy-terminal tyrosine. To analyze the significance of this regulation during development, we have generated mice deficient in Csk, a kinase that phosphorylates this tyrosine, by gene targeting in embryonic stem cells. Homozygous mutant embryos exhibit a complex phenotype that includes defects in the neural tube and die between day 9 and day 10 of gestation. Cells derived from these embryos exhibit an order of magnitude increase in activity of Src and the related Fyn kinase. Phosphorylation at the carboxy-terminal tyrosine of Src was reduced but not eliminated and was accompanied by increased phosphorylation at another key tyrosine residue. These results demonstrate that Src family kinase activity is critically dependent on phosphorylation by Csk and suggest that the regulation of kinase activity may be essential during embryogenesis.	BAYLOR COLL MED, INST MOLEC GENET, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute			Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOULTER CA, 1991, DEVELOPMENT, V111, P357; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1987, ONCOGENE RES, V1, P297; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; Gluecksohn-Schoenheimer S, 1944, P NATL ACAD SCI USA, V30, P134, DOI 10.1073/pnas.30.6.134; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P424; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P124; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSTON JG, 1989, P NATL ACAD SCI USA, V86, P1066, DOI 10.1073/pnas.86.3.1066; Kaufman M.H., 1992, ATLAS MOUSE DEV; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LUMSDEN A, 1991, CELL, V64, P471, DOI 10.1016/0092-8674(91)90226-O; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MACAULEY A, 1993, ONCOGENE, V8, P117; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MARIN O, 1991, J BIOL CHEM, V266, P17798; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; OKADA M, 1991, J BIOL CHEM, V266, P24249; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; OUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SORIANO P, 1986, SCIENCE, V234, P1409, DOI 10.1126/science.3024318; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	62	366	373	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1117	1124		10.1016/0092-8674(93)90641-3	http://dx.doi.org/10.1016/0092-8674(93)90641-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	7685657				2022-12-24	WOS:A1993LH54800008
J	TUVESON, DA; CARTER, RH; SOLTOFF, SP; FEARON, DT				TUVESON, DA; CARTER, RH; SOLTOFF, SP; FEARON, DT			CD19 OF B-CELLS AS A SURROGATE KINASE INSERT REGION TO BIND PHOSPHATIDYLINOSITOL 3-KINASE	SCIENCE			English	Article							FACTOR-I RECEPTOR; PROTEIN TYROSINE PHOSPHORYLATION; GROWTH-FACTOR STIMULATION; LYMPHOCYTES-B; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; COMPLEMENT RECEPTOR; PDGF RECEPTOR; MIDDLE-T; ASSOCIATION	Antigen receptors on B and T lymphocytes transduce signals by activating nonreceptor protein tyrosine kinases (PTKs). A family of receptor PTKs contains kinase insert regions with the sequence tyrosine-X-X-methionine (where X is any amino acid) that when phosphorylated mediate the binding and activation of phosphatidylinositol 3-kinase (PI 3-kinase). The CD19 membrane protein of B cells enhances activation through membrane immunoglobulin M (mIgM) and was found to contain a functional analog of the kinase insert region. Ligation of mIgM induced phosphorylation of CD19 and association with PI 3-kinase. Thus, CD19 serves as a surrogate kinase insert region for mIgM by providing the means for PI 3-kinase activation by nonreceptor PTKs.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA	Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	TUVESON, DA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022833, R01AI028191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28191, AI22833] Funding Source: Medline; NIGMS NIH HHS [5T32GM07309] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; NADLER LM, 1983, J IMMUNOL, V131, P244; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TEDDER TF, 1989, J IMMUNOL, V143, P712; VANNOESEL CJM, 1991, J IMMUNOL, V146, P3881; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	54	292	298	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					986	989		10.1126/science.7684160	http://dx.doi.org/10.1126/science.7684160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	7684160				2022-12-24	WOS:A1993LB79100044
J	PIERCE, MA; JOHNSON, MD; MACIUNAS, RJ; MURRAY, MJ; ALLEN, GS; HARBISON, MA; CREASY, JL; KESSLER, RM				PIERCE, MA; JOHNSON, MD; MACIUNAS, RJ; MURRAY, MJ; ALLEN, GS; HARBISON, MA; CREASY, JL; KESSLER, RM			EVALUATING CONTRAST-ENHANCING BRAIN-LESIONS IN PATIENTS WITH AIDS BY USING POSITRON EMISSION TOMOGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; NERVOUS-SYSTEM LYMPHOMA; BIOPSY; NEUROPATHOLOGY; ENCEPHALITIS	Objective: To determine whether a noninvasive method for evaluating contrast-enhancing brain lesions in patients with the acquired immunodeficiency syndrome (AIDS) can accurately differentiate between lymphoma and nonlymphoma diagnoses. This method is based on Toxoplasma serologic testing and positron emission tomography. Design: Prospective, nonrandomized, criterion-standard clinical study. Setting: An academic center in the mid-southeastern United States. Patients: 20 patients with AIDS and contrast-enhancing brain lesions. Interventions: Positron emission tomographic scanning and Toxoplasma serologic testing. Main Outcome Measure: Diagnoses were confirmed by clinical response, autopsy, or brain biopsy. Results: Eight patients had a confirmed diagnosis of toxoplasmosis, six had lymphoma, four had other diagnoses, and two were not evaluable. Seven of eight patients with toxoplasmosis had positron emission tomographic scans; all of these scans showed hypometabolic lesions consistent with a nonlymphoma diagnosis. The six patients with lymphoma all had hypermetabolic lesions on positron emission tomographic scans. The difference between these two sets of results was statistically significant (P < 0.001, Fisher exact test, two-tailed). The anti-Toxoplasma titer was greater than or equal to 1:4 in all patients with confirmed toxoplasmosis who had serologic testing and in three of six patients with lymphoma. Conclusions: Evaluating contrast-enhancing brain lesions in patients with AIDS by using Toxoplasma serologic testing and positron emission tomography can accurately guide therapy and obviate the need for most brain biopsies in these patients. A larger, national, multicenter study is needed to confirm our findings and to determine the effect of earlier diagnosis and treatment on morbidity and mortality in patients with AIDS and primary central nervous system lymphoma.			PIERCE, MA (corresponding author), VANDERBILT UNIV, MED CTR,SCH MED,DIV INFECT DIS,1211 21ST AVE S, MED ARTS BLDG, SUITE 539, NASHVILLE, TN 37232 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR00095] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERS KH, 1986, AM J PATHOL, V124, P537; BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; CIMINO C, 1991, ARCH INTERN MED, V151, P1381, DOI 10.1001/archinte.151.7.1381; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DEGIROLAMI U, 1990, ARCH PATHOL LAB MED, V114, P643; GALETTO G, 1993, JAMA-J AM MED ASSOC, V269, P92, DOI 10.1001/jama.269.1.92; HOFFMAN JM, 1993, J NUCL MED, V34, P567; LEVY RM, 1992, NEUROSURGERY, V30, P186, DOI 10.1227/00006123-199202000-00006; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MOSKOWITZ LB, 1984, ARCH PATHOL LAB MED, V108, P368; ROSENBLUM ML, 1988, AIDS NERVOUS SYSTEM, P1; ROSENFELD SS, 1992, J NUCL MED, V33, P532; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; 1990, ARCH INTERN MED, V150, P735	16	71	73	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					594	598		10.7326/0003-4819-123-8-199510150-00005	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677300				2022-12-24	WOS:A1995RY82800005
J	BERTOLET, BD; MCMURTRIE, EB; HILL, JA; BELARDINELLI, L				BERTOLET, BD; MCMURTRIE, EB; HILL, JA; BELARDINELLI, L			THEOPHYLLINE FOR THE TREATMENT OF ATRIOVENTRICULAR-BLOCK AFTER MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Note							SICK SINUS SYNDROME; ENDOGENOUS ADENOSINE; ORAL THEOPHYLLINE; AMINOPHYLLINE; ANTAGONISM; ATROPINE	Objective: To show that second- or third-degree atrioventricular block occurring as an early complication of acute inferior myocardial infarction is mediated by adenosine. Setting: Cardiac care unit. Design: Uncontrolled, observational, hypothesis-driven study. Patients: Patients who developed clinically significant atrioventricular nodal blockade within 4 hours of admission for acute inferior myocardial infarction. Intervention: Theophylline, 100 mg/min intravenously to a maximum of 250 mg. Measurements: Continuous multilead electrocardiographic monitoring before and after administration of theophylline. Results: During a 6-month period, eight men who had had acute inferior myocardial infarction developed clinically significant atrioventricular block. Three had third-degree block, and five had high-grade second-degree block. In all patients, 1:1 atrioventricular nodal conduction was restored and normal sinus rhythm reappeared within 3 minutes of the administration of theophylline. All patients remained free of arrhythmia for at least 24 hours. Conclusions: Adenosine produced by the ischemic myocardium may induce atrioventricular nodal block. In our patients, atrioventricular nodal block was resistant to conventional therapy such as atropine, but it responded to the adenosine antagonist theophylline.	VET AFFAIRS MED CTR, GAINESVILLE, FL USA; UNIV FLORIDA, HLTH SCI CTR, GAINESVILLE, FL 32610 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University System of Florida; University of Florida	BERTOLET, BD (corresponding author), UNIV FLORIDA, J HILLIS MILLER HLTH CTR, BOX 100-277, GAINESVILLE, FL 32610 USA.							ALBONI P, 1991, AM HEART J, V122, P1361, DOI 10.1016/0002-8703(91)90578-6; [Anonymous], 1992, JAMA, V268, P2171; BELARDINELLI L, 1982, CIRC RES, V51, P569, DOI 10.1161/01.RES.51.5.569; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BELARDINELLI L, 1987, TOPICS PERSPECTIVES, P346; BERTOLET BD, 1994, J AM COLL CARDIOL, pA329; DIMARCO JP, 1985, J AM COLL CARDIOL, V6, P417, DOI 10.1016/S0735-1097(85)80181-9; ELLENHOGEN KA, 1988, AM HEART J 1, V16, P202; FREDHOLM BB, 1980, TRENDS PHARMACOL SCI, V1, P129; HAUGHT WH, 1994, AM HEART J, V128, P1255; ROFMAN M, 1972, CIRCULATION, V45, P703; SAITO D, 1993, J AM COLL CARDIOL, V21, P1199, DOI 10.1016/0735-1097(93)90246-W; SCLAROVSKY S, 1984, AM HEART J, V108, P19, DOI 10.1016/0002-8703(84)90539-8; SHAH PK, 1987, AM HEART J, V113, P194, DOI 10.1016/0002-8703(87)90029-9; VISKIN S, 1993, ANN INTERN MED, V118, P279, DOI 10.7326/0003-4819-118-4-199302150-00006; WESLEY RC, 1989, CIRCULATION, V80, P128, DOI 10.1161/01.CIR.80.1.128; WESLEY RC, 1986, J AM COLL CARDIOL, V8, P1232, DOI 10.1016/S0735-1097(86)80406-5	17	43	43	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					509	511		10.7326/0003-4819-123-7-199510010-00006	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661495				2022-12-24	WOS:A1995RW49500006
J	CHAISSON, RE; KERULY, JC; MOORE, RD				CHAISSON, RE; KERULY, JC; MOORE, RD			RACE, SEX, DRUG-USE, AND PROGRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL; AIDS; INFECTION; ZIDOVUDINE	Background. The rates of progression of human immunodeficiency virus (HIV) infection and survival have been reported to differ among sociodemographic groups, It is unclear whether these differences reflect biologic differences or differences in access to medical care. Methods. We measured disease progression and survival in a cohort of 1372 patients seropositive for HIV who were treated at a single urban center (median follow-up, 1.6 years). We calculated the rates of survival for the entire cohort and the rates of progression to the acquired immunodeficiency syndrome (AIDS) or death among the 740 patients who presented without AIDS. We used Cox proportional-hazards analysis to examine factors associated with progression to AIDS and death. Results. Progression to AIDS or death was associated with a CD4 cell count of 201 to 350 per cubic millimeter (relative risk, 2.0; P<0.001), the presence of symptoms at base line (relative risk, 2.0; P<0.001), prior antiretroviral therapy (relative risk, 1.7, P=0.003), and older age (relative risk per year of age, 1.02; P=0.03). However, there was no relation between disease progression and sex, race, injection-drug use, income, level of education, or insurance status. In the entire cohort, a lower CD4 cell count, a diagnosis of AIDS, older age, and the receipt of antiretroviral therapy before enrollment were associated with an increased risk of death, whereas the use of prophylaxis against pneumocystis pneumonia, zidovudine use after enrollment, and having a job at base line were associated with lower risks of death, There was no significant difference in survival between men and women, blacks and whites, injection-drug users and those who did not use drugs, or patients whose median annual incomes were $5,000 or less and those whose incomes were more than $5,000. Conclusions. Among patients with HIV infection who received medical care from a single urban center, there were no differences in disease progression or survival associated with sex, race, injection-drug use, or socioeconomic status. Differences found in other studies may reflect differences in the use of medical care.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University					AHRQ HHS [R01-HS0780902] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CHAISSON RE, 1991, AIDS, V5, P177, DOI 10.1097/00002030-199102000-00007; CHAISSON RE, 1993, AIDS, V7, P857, DOI 10.1097/00002030-199306000-00015; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; COX DR, 1972, J R STAT SOC B, V34, P187; EHMANN WC, 1994, J ACQ IMMUN DEF SYND, V7, P1095; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; HOGG RS, 1994, LANCET, V344, P1120, DOI 10.1016/S0140-6736(94)90631-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; Lee E.T., 1992, STATISTICAL METHODS; LEMP GF, 1992, J INFECT DIS, V166, P74, DOI 10.1093/infdis/166.1.74; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MELNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915, DOI 10.1001/jama.272.24.1915; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1994, JAMA-J AM MED ASSOC, V272, P1001, DOI 10.1001/jama.1994.03520130035018; MOORE RD, 1994, 34TH INT C ANT AG CH, P61; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SELIK RM, 1993, JAMA-J AM MED ASSOC, V270, P710; STANTON DL, 1994, J ACQ IMMUN DEF SYND, V7, P1050; TURNER BJ, 1994, J ACQ IMMUN DEF SYND, V7, P1250; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1994, MMWR-MORBID MORTAL W, V43, P644; 1994, LANCET, V343, P871; 1995, MMWR MORB MORTL WKLY, V44, P81; 1992, MMWR-MORBID MORTAL W, V41, P1	34	264	276	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					751	756		10.1056/NEJM199509213331202	http://dx.doi.org/10.1056/NEJM199509213331202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643881				2022-12-24	WOS:A1995RU80900002
J	FLINT, J; CORLEY, R; DEFRIES, JC; FULKER, DW; GRAY, JA; MILLER, S; COLLINS, AC				FLINT, J; CORLEY, R; DEFRIES, JC; FULKER, DW; GRAY, JA; MILLER, S; COLLINS, AC			A SIMPLE GENETIC-BASIS FOR A COMPLEX PSYCHOLOGICAL TRAIT IN LABORATORY MICE	SCIENCE			English	Article							ELEVATED PLUS-MAZE; ANXIETY; RAT; BEHAVIOR; DISORDER; LINKAGE	Psychological traits are commonly inferred from covariation in sets of behavioral measures that otherwise appear to have little in common. Emotionality in mice is such a trait, defined here by covariation in activity and defecation in a novel environment and emergence into the open arms of an elevated plus maze. Behavioral and quantitative trait analyses were conducted on four measures obtained from 879 mice from an F-2 intercross. Three loci, on murine chromosomes 1, 12, and 15, were mapped that influence emotionality. This trait, inferred from studies of strain, sex, and individual differences in rodents, may be related to human susceptibility to anxiety or neuroticism.	UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309; INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of Colorado System; University of Colorado Boulder; University of London; King's College London	FLINT, J (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.			Flint, Jonathan/0000-0002-9427-4429	NIDA NIH HHS [DA-00197, DA-05131] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000197] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; BROADHURST PL, 1960, EXPT PERSONALITY, V1, P3; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; Castle W E, 1921, Science, V54, P223, DOI 10.1126/science.54.1393.223; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEFRIES JC, 1978, BEHAV GENET, V8, P3, DOI 10.1007/BF01067700; DeFries JC, 1970, CONTRIBUTIONS BEHAVI, P23; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FANSELOW MS, 1991, MIDBRAIN PERIACQUEDU; GOLDSTEIN RB, 1994, ARCH GEN PSYCHIAT, V51, P383; GRAEFF FG, 1993, REV NEUROSCIENCE, V4, P181; Gray J.A., 1987, PSYCHOL FEAR STRESS, V2nd, P422; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; GREEN S, 1990, BEHAVIOURAL MODELS P; Hall CS, 1936, J COMP PSYCHOL, V22, P345, DOI 10.1037/h0059253; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P952; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P716; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LeDoux J E, 1992, Curr Opin Neurobiol, V2, P191, DOI 10.1016/0959-4388(92)90011-9; LINCOLN S, 1992, MAPPING GENES CONTRO; LIPP HP, 1989, EXPERIENTIA, V45, P845, DOI 10.1007/BF01954059; MAIER W, 1994, ARCH GEN PSYCHIAT, V51, P871; McGuffin P., 1994, SEMINARS PSYCHIATRIC; Montgomery KM, 1958, J COMP PHYSIOL PSYCH, V48, P254; Ott J., 1991, ANAL HUMAN GENETIC L; PANKSEPP J, 1982, BEHAV BRAIN SCI, V5, P407, DOI 10.1017/S0140525X00012759; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PAULS DL, 1993, NAT GENET, V3, P4, DOI 10.1038/ng0193-4; PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Plomin R, 1991, J Psychopharmacol, V5, P1, DOI 10.1177/026988119100500102; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; REDMOND DE, 1985, ANXIETY ANXIETY DISO, P530; TAYLOR MA, 1992, AM J PSYCHIAT, V149, P22; Wright S., 1968, EVOLUTION GENETICS P, V1; 1982, NEROPSYCHOLOGY ANXIE	41	327	334	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1432	1435		10.1126/science.7660127	http://dx.doi.org/10.1126/science.7660127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RT806	7660127				2022-12-24	WOS:A1995RT80600048
J	KIBEL, A; ILIOPOULOS, O; DECAPRIO, JA; KAELIN, WG				KIBEL, A; ILIOPOULOS, O; DECAPRIO, JA; KAELIN, WG			BINDING OF THE VONHIPPEL-LINDAU TUMOR-SUPPRESSOR PROTEIN TO ELONGIN-B AND ELONGIN-C	SCIENCE			English	Article							GENE; IDENTIFICATION; SEQUENCE; PRODUCT	Germ-line mutations of the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of human tumors, and somatic mutations of this gene have been identified in sporadic renal cell carcinomas and cerebellar hemangioblastomas. Two transcriptional elongation factors, Elongin B and C, were shown to bind in vitro and in vivo to a short, colinear region of the VHL protein (pVHL) that is frequently mutated in human tumors. A peptide replica of this region inhibited binding of pVHL to Elongin B and C, whereas a point-mutant derivative, corresponding to a naturally occurring VHL missense mutation, had no effect. These results suggest that the tumor suppression function of pVHL may be linked to its ability to bind to Elongin B and C.	CHILDRENS HOSP, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute								ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOSS K, 1987, GENE, V59, P285, DOI 10.1016/0378-1119(87)90336-2; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GARRETT KP, 1994, GENE, V150, P413, DOI 10.1016/0378-1119(94)90467-7; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, UNPUB; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; McKusick V.A., 1992, MENDELIAN INHERITANC; SHUIN T, 1994, CANCER RES, V54, P2852; WHALEY JM, 1994, AM J HUM GENET, V55, P1092	25	547	568	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1444	1446		10.1126/science.7660130	http://dx.doi.org/10.1126/science.7660130			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660130				2022-12-24	WOS:A1995RT80600051
J	CALANDRA, T; BERNHAGEN, J; METZ, CN; SPIEGEL, LA; BACHER, M; DONNELLY, T; CERAMI, A; BUCALA, R				CALANDRA, T; BERNHAGEN, J; METZ, CN; SPIEGEL, LA; BACHER, M; DONNELLY, T; CERAMI, A; BUCALA, R			MIF AS A GLUCOCORTICOID-INDUCED MODULATOR OF CYTOKINE PRODUCTION	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL GROWTH-FACTOR; CACHECTIN; ENDOTOXIN; MICE; INTERLEUKIN-1; INHIBITION; PITUITARY; STRESS; SHOCK	GLUCOCORTICOID hormones are important for vital functions and act to modulate inflammatory and immune responses(1,2). Yet, in contrast to other hormonal systems, no endogenous mediators have been identified that can directly counter-regulate their potent anti-inflammatory and immunosuppressive properties. Recent investigations of the protein macrophage migration inhibitory factor (MIF), which was discovered originally to be a T-lymphocyte-derived factor(3,4), have established it to be a pro-inflammatory pituitary and macrophage cytokine and a critical mediator of septic shock(5-7), Here we report the unexpected finding that low concentrations of glucocorticoids induce rather than inhibit MIF production from macrophages. MIF then acts to override glucocorticoid-mediated inhibition of cytokine secretion by lipopolysaccharide (LPS)-stimulated monocytes acid to overcome glucocorticoid protection against lethal endotoxaemia. These observations identify a unique counter-regulatory system that functions to control inflammatory and immune responses.	PICOWER INST MED RES,MANHASSET,NY 11030	Northwell Health			Donnelly, Thomas M/C-2717-2009; Calandra, Thierry/D-9017-2015	Donnelly, Thomas M/0000-0002-4399-2287; Calandra, Thierry/0000-0003-3051-1285; Christine, Metz/0000-0002-1013-1691				ABERNATHY RS, 1957, J LAB CLIN MED, V49, P708; ARYA SK, 1984, J IMMUNOL, V133, P273; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BERRY LJ, 1964, J EXP MED, V120, P721, DOI 10.1084/jem.120.5.721; BERTINI R, 1988, J EXP MED, V167, P1708, DOI 10.1084/jem.167.5.1708; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; GARTNER K, 1980, LAB ANIM, V14, P267, DOI 10.1258/002367780780937454; GELLER P, 1954, P SOC EXP BIOL MED, V86, P716; GILLIS S, 1979, J IMMUNOL, V123, P1624; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GOLDSTEIN RA, 1992, INFLAMMATION BASIC P, P1061; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LEW W, 1988, J IMMUNOL, V140, P1895; MITCHELL R, 1995, J IMMUNOL, V154, P3863; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; SILVERSTEIN R, 1991, J EXP MED, V173, P357, DOI 10.1084/jem.173.2.357; SPINK WW, 1954, J CLIN INVEST, V33, P540, DOI 10.1172/JCI102924; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; WEXLER BC, 1957, ENDOCRINOLOGY, V61, P300, DOI 10.1210/endo-61-3-300	25	989	1041	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					68	71		10.1038/377068a0	http://dx.doi.org/10.1038/377068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659164				2022-12-24	WOS:A1995RT72500058
J	ADAMSON, SJ; ALESSANDRI, LM; BADAWI, N; BURTON, PR; PEMBERTON, PJ; STANLEY, F				ADAMSON, SJ; ALESSANDRI, LM; BADAWI, N; BURTON, PR; PEMBERTON, PJ; STANLEY, F			PREDICTORS OF NEONATAL ENCEPHALOPATHY IN FULL-TERM INFANTS	BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL-PALSY; BIRTH ASPHYXIA	Objective-Preliminary investigation of the contribution of adverse antepartum and intrapartum factors to neonatal encephalopathy in singleton neonates born full term. Design-Matched case-control study based on incidence density sampling of controls. Setting-Two major teaching hospitals (one paediatric and one obstetric) and three peripheral maternity hospitals in Perth, Western Australia (population 1.2 million). Subjects-89 cases, all the full term singleton neonates born during an eight month period in 1992 who fulfilled one or more of six criteria during the first week of life (seizures, abnormal conscious state, persistent hypertonia or hypotonia, and feeding or respiratory difficulties of central origin). One full term control infant without neonatal encephalopathy was matched to each case by sex, hospital of delivery, time of day and day of the week of birth, and maternal health insurance status. Main outcome measures-Odds ratio estimates of relative risk of neonatal encephalopathy associated with antepartum and intrapartum factors. Results-Estimated incidence of moderate or severe encephalopathy in first week of life was 3.75 per 1000 full term live births. Thirteen cases and no controls had evidence suggestive of important intrapartum hypoxia, and in only five of these cases was the neurological condition at birth attributed to events during the intrapartum period. Univariate conditional logistic regression analysis identified significant differences between cases and controls for maternal vaginal bleeding in pregnancy, maternal thyroxine treatment, congenital abnormalities, induction of labour, interval from membrane rupture to delivery, maternal pyrexia in labour, augmentation of labour, abnormal intrapartum cardiotocograms, and meconium in labour. Family history of convulsions also approached significance. Conclusions-Our preliminary results suggest that intrapartum hypoxia, according to currently used criteria, was not the cause of neonatal encephalopathy in most cases in this population. Our findings suggest that many aetiologies of neonatal encephalopathy originate in the antepartum period.	INST CHILD HLTH RES,PERTH,WA 6872,AUSTRALIA; PRINCESS MARGARET HOSP CHILDREN,DEPT NEONATOL,SUBIACO,WA 6008,AUSTRALIA	Telethon Kids Institute; University of Western Australia			Badawi, Nadia/A-3179-2014; Burton, Paul R/H-7527-2016					ARMITAGE P, 1987, STATISTICAL METHODS; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P302, DOI 10.1111/j.1365-3016.1993.tb00406.x; BLAIR E, 1993, DEV MED CHILD NEUROL, V35, P449; Breslow N, 1980, STATISTICAL METHODS, V32; BURTON PR, 1994, STAT MED, V13, P1699, DOI 10.1002/sim.4780131702; COORSSEN EA, 1991, DEV MED CHILD NEUROL, V33, P730; COPAS J, 1984, J ROYAL STATISTICA A, V147, P35; DEESCOBAR GM, 1993, AM J CLIN NUTR, V57, pS280; DEMOTT RK, 1990, AM J OBSTET GYNECOL, V162, P1593, DOI 10.1016/0002-9378(90)90925-W; DEVLIN MM, 1990, J MED PRACTICE, V5, P215; ERGANDER U, 1983, ACTA PAEDIATR SCAND, V72, P321, DOI 10.1111/j.1651-2227.1983.tb09722.x; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; GLUCKMAN PD, 1992, DEV MED CHILD NEUROL, V34, P1010; HAGBERG G, 1976, ACTA PAEDIATR SCAND, V65, P403, DOI 10.1111/j.1651-2227.1976.tb04906.x; HENDERSONSMART D, 1991, MED J AUSTRALIA, V154, P576, DOI 10.5694/j.1326-5377.1991.tb121215.x; Joreskog K. G., 1989, LISREL; LEVENE MI, 1986, LANCET, V2, P67; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; MEYER BA, 1992, AM J OBSTET GYNECOL, V166, P612, DOI 10.1016/0002-9378(92)91685-4; MILLER G, 1989, ARCH DIS CHILD, V64, P557, DOI 10.1136/adc.64.4.557; MULLIGAN JC, 1980, J PEDIATR-US, V96, P903, DOI 10.1016/S0022-3476(80)80575-0; NELSON KB, 1984, JAMA-J AM MED ASSOC, V251, P1843, DOI 10.1001/jama.251.14.1843; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; PHAROAH POD, 1984, CLIN ENDOCRINOL, V21, P265, DOI 10.1111/j.1365-2265.1984.tb03468.x; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; STANLEY FJ, 1991, MED J AUSTRALIA, V154, P623, DOI 10.5694/j.1326-5377.1991.tb121226.x; STEER PJ, 1989, OBSTET GYNECOL, V64, P715; TUCKER JM, 1990, CLIN OBSTET GYNECOL, V33, P515, DOI 10.1097/00003081-199009000-00017; 1989, LANCET, V2, P1251	31	121	122	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					598	602		10.1136/bmj.311.7005.598	http://dx.doi.org/10.1136/bmj.311.7005.598			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663254	Green Published			2022-12-24	WOS:A1995RT72300017
J	YOON, CH; LEE, JH; JONGEWARD, GD; STERNBERG, PW				YOON, CH; LEE, JH; JONGEWARD, GD; STERNBERG, PW			SIMILARITY OF SLI-1, A REGULATOR OF VULVAR DEVELOPMENT IN C-ELEGANS, TO THE MAMMALIAN PROTOONCOGENE C-CBL	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; TYROSINE KINASE; SH3 DOMAINS; V-CBL; CELL FATES; GENE; INDUCTION; ENCODES; LET-60; TRUNCATION	Vulval induction during Caenorhabditis elegans development is mediated by LET-23, a homolog of the mammalian epidermal growth factor receptor tyrosine kinase. The sli-1 gene is a negative regulator of LET-23 and is shown here to encode a protein similar to c-Cbl, a mammalian proto-oncoprotein. SLI-1 and c-Cbl share approximately 55 percent amino acid identity over a stretch of 390 residues, which includes a C3HC4 zinc-binding motif known as the RING finger, and multiple consensus binding sites for Src homology 3 (SH3) domains. SLI-1 and c-Cbl may define a new class of proteins that modify receptor tyrosine kinase-mediated signal transduction.	CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL IMMUNOL & BIOCHEM, SAN FRANCISCO, CA 94143 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of California System; University of California Berkeley; University of California System; University of California San Francisco				Sternberg, Paul/0000-0002-7699-0173				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRENNER S, 1974, GENETICS, V77, P71; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; JONGEWARD GD, 1995, GENETICS, V139, P1553; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE JH, 1994, GENE DEV, V8, P60, DOI 10.1101/gad.8.1.60; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; VILLENEUVE AM, COMMUNICATION; WILLIAMS BD, 1992, GENETICS, V131, P609; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	277	288	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1102	1105		10.1126/science.7652556	http://dx.doi.org/10.1126/science.7652556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652556				2022-12-24	WOS:A1995RQ74800044
J	HAGEN, SJ; HOFRICHTER, J; EATON, WA				HAGEN, SJ; HOFRICHTER, J; EATON, WA			PROTEIN REACTION-KINETICS IN A ROOM-TEMPERATURE GLASS	SCIENCE			English	Article							GEMINATE RECOMBINATION; CONFORMATIONAL-CHANGES; NEUTRON-SCATTERING; HEME-PROTEINS; RELAXATION DYNAMICS; SOLVENT VISCOSITY; LIGAND-BINDING; CO BINDING; MYOGLOBIN; TRANSITION	Protein reaction kinetics in aqueous solution at room temperature are often simplified by the thermal averaging of conformational substates. These substates exhibit widely varying reaction rates that are usually exposed by trapping in a glass at low temperature. Here, it is shown that the solvent viscosity, rather than the low temperature, is primarily responsible for the trapping. this was demonstrated by placement of myoglobin in a glass at room temperature and subsequent observation of inhomogeneous reaction kinetics. The high solvent viscosity slowed the rate of crossing the energy barriers that separated the substates and also suppressed any change in the average protein conformation after ligand dissociation.			HAGEN, SJ (corresponding author), NIH,PHYS CHEM LAB,BLDG 5,BETHESDA,MD 20892, USA.		Hagen, Stephen J/E-9737-2015	Hagen, Stephen J/0000-0002-3373-5033				AGMON N, 1988, BIOCHEMISTRY-US, V27, P3507, DOI 10.1021/bi00409a057; AGMON N, 1990, J PHYS CHEM-US, V94, P2959, DOI 10.1021/j100370a041; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AGMON N, 1992, J CHEM PHYS, V97, P7270, DOI 10.1063/1.463500; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; CAMPBELL BF, 1987, SCIENCE, V238, P373, DOI 10.1126/science.3659921; CROWE JH, 1987, BIOCHEM J, V242, P1, DOI 10.1042/bj2420001; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Doster W., 1993, PROTEIN SOLVENT INTE, P375; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1994, PHYS TODAY, V47, P58, DOI 10.1063/1.881414; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; GREEN JL, 1994, J PHYS CHEM-US, V98, P13780, DOI 10.1021/j100102a052; GREEN JL, 1989, J PHYS CHEM-US, V93, P2880, DOI 10.1021/j100345a006; HAGEN SJ, UNPUB; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1983, HEMOGLOBINS STRUCTUR, P193; HOFRICHTER J, 1994, METHOD ENZYMOL, V232, P387; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; JACKLE J, 1986, REP PROG PHYS, V49, P171, DOI 10.1088/0034-4885/49/2/002; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; MAYER E, 1994, BIOPHYS J, V67, P862, DOI 10.1016/S0006-3495(94)80547-8; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SMITH J, 1990, P NATL ACAD SCI USA, V87, P1601, DOI 10.1073/pnas.87.4.1601; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; WOMERSLEY C, 1981, COMP BIOCHEM PHYS B, V70, P669, DOI 10.1016/0305-0491(81)90001-8	42	208	208	1	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					959	962		10.1126/science.7638618	http://dx.doi.org/10.1126/science.7638618			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638618				2022-12-24	WOS:A1995RP73800030
J	JOSHUATOR, L; XU, HE; JOHNSTON, SA; REES, DC				JOSHUATOR, L; XU, HE; JOHNSTON, SA; REES, DC			CRYSTAL-STRUCTURE OF A CONSERVED PROTEASE THAT BINDS DNA - THE BLEOMYCIN HYDROLASE, GAL6	SCIENCE			English	Article							CYSTEINE PROTEINASE; PAPAIN; RESOLUTION; YEAST; REFINEMENT; CLONING; AMINOPEPTIDASE; SPECIFICITY; COMPLEX; SUBUNIT	Bleomycin hydrolase is a cysteine protease that hydrolyzes the anticancer drug bleomycin. The homolog in yeast, Gal6, has recently been identified and found to bind DNA and to act as a repressor in the Gal4 regulatory system, The crystal structure of Gal6 at 2.2 Angstrom resolution reveals a hexameric structure with a prominent central channel, The papain-like active sites are situated within the central channel, in a manner resembling the organization of active sites in the proteasome. The Gal6 channel is lined with 60 lysine residues from the six subunits, suggesting a role in DNA binding, The carboxyl-terminal arm of Gal6 extends into the active site cleft and may serve a regulatory function. Rather than each residing in distinct, separable domains, the protease and DNA-binding activities appear structurally intertwined in the hexamer, implying a coupling of these two activities.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JOSHUATOR, L (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,147-75CH,PASADENA,CA 91125, USA.			Joshua-Tor, Leemor/0000-0001-8185-8049; Xu, H. Eric/0000-0002-6829-8144	NIGMS NIH HHS [GM45162, GM40700] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045162, R37GM045162, R01GM040700] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAPOTCHARTIER MP, 1994, EUR J BIOCHEM, V224, P497, DOI 10.1111/j.1432-1033.1994.00497.x; CHAPOTCHARTIER MP, 1993, APPL ENVIRON MICROB, V59, P330, DOI 10.1128/AEM.59.1.330-333.1993; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; FERNANDEZ L, 1994, APPL ENVIRON MICROB, V60, P333; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HEINEMANN U, 1982, J MOL BIOL, V161, P591, DOI 10.1016/0022-2836(82)90410-7; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KANE SA, 1994, PROG NUCLEIC ACID RE, V49, P313; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE G, 1971, BIOCHEM J, V124, P107, DOI 10.1042/bj1240107; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MISTOU MY, 1994, J MOL BIOL, V237, P160, DOI 10.1006/jmbi.1994.1215; MONDRAGON A, 1994, NATURE, V367, P138; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; MYLIN LM, 1990, METHOD ENZYMOL, V185, P297; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PICKERSGILL RW, 1991, ACTA CRYSTALLOGR B, V47, P766, DOI 10.1107/S0108768191003191; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rossmann M. G., 1972, MOL REPLACEMENT METH; SCHRODER E, 1993, FEBS LETT, V315, P38, DOI 10.1016/0014-5793(93)81128-M; SEBTI SM, 1991, CANCER RES, V51, P227; SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VESANTO E, 1994, EUR J BIOCHEM, V224, P991, DOI 10.1111/j.1432-1033.1994.00991.x; VRUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330; Wohlrab Y, 1993, INT DAIRY J, V3, P685, DOI 10.1016/0958-6946(93)90083-C; WU A, UNPUB; XU H, UNPUB; XU HE, 1994, J BIOL CHEM, V269, P21177; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; Zheng W., UNPUB	55	119	120	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					945	950		10.1126/science.7638617	http://dx.doi.org/10.1126/science.7638617			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638617				2022-12-24	WOS:A1995RP73800026
J	TAMURA, T; ISHIHARA, M; LAMPHIER, MS; TANAKA, N; OISHI, I; AIZAWA, S; MATSUYAMA, T; MAK, TW; TAKI, S; TANIGUCHI, T				TAMURA, T; ISHIHARA, M; LAMPHIER, MS; TANAKA, N; OISHI, I; AIZAWA, S; MATSUYAMA, T; MAK, TW; TAKI, S; TANIGUCHI, T			AN IRF-1-DEPENDENT PATHWAY OF DNA DAMAGE-INDUCED APOPTOSIS IN MITOGEN-ACTIVATED T-LYMPHOCYTES	NATURE			English	Article							REGULATORY FACTOR-I; PROGRAMMED CELL-DEATH; GENE CED-3; IRF-1; INDUCTION; HOMOLOG; ENZYME; SYSTEM; GROWTH; BCL-2	LYMPHOCYTES are particularly susceptible to DNA damage-induced apoptosis, a response which may serve as a form of 'altruistic suicide' to counter their intrinsic high potential for mutation and clonal expansion(1). The tumour suppressor p53 has been shown to regulate this type of apoptosis in thymocytes(2,3), but an as yet unknown, p53-independent pathway(s) appears to mediate the same event in mitogen-activated mature T lymphocytes(4). Here we show that DNA damage-induced apoptosis in these T lymphocytes is dependent on the antioncogenic transcription factor interferon regulatory factor (IRF)-1 (refs 5-7). Thus two different anti-oncogenic transcription factors, p53 and IRF-1, are required for distinct apoptotic pathways in T lymphocytes. We also show that mitogen induction of the interleukin-1 beta converting enzyme (ICE) gene(8-10), a mammalian homologue of the Caenorhabditis elegans cell death gene ced-3, is IRF-1-dependent. Ectopic overexpression of IRE-1 results in the activation of the endogenous gene for ICE and enhances the sensitivity of cells to radiation-induced apoptosis.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; RES DEV CORP JAPAN,PRECURSORY RES EMBRYON SCI & TECHNOL,KYOTO 61902,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 860,JAPAN; AMGEN INST,TORONTO,ON M4X 1K9,CANADA	Osaka University; Japan Science & Technology Agency (JST); Kumamoto University	TAMURA, T (corresponding author), UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,HONGO 7-3-1,TOKYO 113,JAPAN.		Oishi, Isao/L-8639-2018	Oishi, Isao/0000-0003-3682-5349; Tanaka, Nobuyuki/0000-0002-6373-2220; Taki, Shinsuke/0000-0001-5143-3496				CARRETTI DP, 1992, SCIENCE, V256, P97; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUKADA T, 1993, ONCOGENE, V8, P3313; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	414	422	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					596	599		10.1038/376596a0	http://dx.doi.org/10.1038/376596a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637809				2022-12-24	WOS:A1995RP75600052
J	CHENG, HJ; NAKAMOTO, M; BERGEMANN, AD; FLANAGAN, JG				CHENG, HJ; NAKAMOTO, M; BERGEMANN, AD; FLANAGAN, JG			COMPLEMENTARY GRADIENTS IN EXPRESSION AND BINDING OF ELF-1 AND MEK4 IN DEVELOPMENT OF THE TOPOGRAPHIC RETINOTECTAL PROJECTION MAP	CELL			English	Article							RETINAL AXONS; VISUAL-SYSTEM; CHICK; RECEPTOR; GUIDANCE; MOLECULE; POSITION; INVITRO; TECTUM; ORDER	Topographic maps with a defined spatial ordering of neuronal connections are a key feature of brain organization. Such maps are believed to develop in response to complementary position-specific labels in presynaptic and postsynaptic fields. However, the complementary labeling molecules are not known. In the well-studied visual map of retinal axons projecting to the tectum, the labels are hypothesized to be in gradients, without needing large numbers of cell-specific molecules. We recently cloned ELF-1 as a ligand for Eph family receptors. Here, RNA hybridization shows matching expression gradients for ELF-1 in the tectum and its receptor Mek4 in the retina. Binding activity detected with alkaline phosphatase fusions of ELF-1 and Mek4 also reveals gradients and provides direct evidence for molecular complementarity of gradients in reciprocal fields, ELF-1 and Mek4 may therefore play roles in retinotectal development and have properties predicted of topographic mapping labels.			CHENG, HJ (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Cheng, Hwai-Jong/AAY-5067-2021; Flanagan, John/AAM-2995-2020	Cheng, Hwai-Jong/0000-0003-0647-0567; Bergemann, Andrew/0000-0002-0027-7662; Nakamoto, Masaru/0000-0001-9356-1189	NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD029417, R01HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, IN PRESS MOL CELL BI; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COX EC, 1990, NEURON, V2, P31; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEITCHER DL, 1994, J NEUROSCI, V14, P486; Descartes R., 1664, TREATISE MAN; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; ITASAKI N, 1992, NEURON, V8, P787, DOI 10.1016/0896-6273(92)90099-Y; Jacobson M., 1991, DEV NEUROBIOLOGY; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAVAIL JH, 1971, BRAIN RES, V28, P391, DOI 10.1016/0006-8993(71)90053-9; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MEY J, 1992, J HIRNFORSCH, V33, P673; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NIETO MA, 1992, DEVELOPMENT, V116, P1137; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; SOANS C, 1994, ONCOGENE, V9, P3353; Sperry RW, 1943, J COMP NEUROL, V79, P33, DOI 10.1002/cne.900790104; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SPIRA AW, 1987, J COMP NEUROL, V260, P526, DOI 10.1002/cne.902600406; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VONBOXBERG Y, 1993, NEURON, V10, P345; WALTER J, 1987, DEVELOPMENT, V101, P685; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	43	630	642	1	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					371	381		10.1016/0092-8674(95)90426-3	http://dx.doi.org/10.1016/0092-8674(95)90426-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634327	Green Published, Bronze			2022-12-24	WOS:A1995RP24200007
J	CHEUNG, AY; WANG, H; WU, HM				CHEUNG, AY; WANG, H; WU, HM			A FLORAL TRANSMITTING TISSUE-SPECIFIC GLYCOPROTEIN ATTRACTS POLLEN TUBES AND STIMULATES THEIR GROWTH	CELL			English	Article							PROLINE-RICH PROTEIN; ARABINOGALACTAN-PROTEINS; NICOTIANA-ALATA; GENE-EXPRESSION; DAUCUS-CAROTA; EXTENSIN; STIGMA; AXONS; IDENTIFICATION; CHEMOTROPISM	Pollen tubes elongate directionally in the extracellular matrix of pistil tissues to transport the male gametes from the apically located stigma to the basally located ovary for fertilization. The molecular mechanisms underlying directional pollen tube growth in the pistil are poorly understood. We have purified a glycoprotein, TTS, from tobacco stylar transmitting tissue, which supports pollen tube growth between the stigma and the ovary. TTS proteins belong to the arabinogalactan protein family, and they polymerize readily in vitro in a head-to-tail fashion into oligomeric forms. TTS proteins stimulate pollen tube growth in vitro and attract pollen tubes grown in a semi-in vivo culture system. In vivo, the pollen tube growth rate is reduced in transgenic plants that have significantly reduced levels of TTS proteins as a result of either antisense suppression or sense cosuppression. These results identify TTS protein as a pistil component that positively contributes to pollen tube growth.			CHEUNG, AY (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.			Wang, Hong/0000-0003-4130-8741				BALDWIN TC, 1993, PLANT PHYSIOL, V103, P115, DOI 10.1104/pp.103.1.115; CHEN CG, 1993, PLANT MOL BIOL, V21, P391, DOI 10.1007/BF00019955; CHEN CG, 1994, P NATL ACAD SCI USA, V91, P10305, DOI 10.1073/pnas.91.22.10305; CHEN CG, 1992, PLANT CELL, V4, P1053, DOI 10.1105/tpc.4.9.1053; CHEUNG AY, 1995, P NATL ACAD SCI USA, V92, P3077, DOI 10.1073/pnas.92.8.3077; CHEUNG AY, 1993, PLANT J, V3, P151, DOI 10.1111/j.1365-313X.1993.tb00018.x; CLARKE A, 1979, P NATL ACAD SCI USA, V76, P3358, DOI 10.1073/pnas.76.7.3358; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; DU H, 1994, PLANT CELL, V6, P1643, DOI 10.1105/tpc.6.11.1643; FINCHER GB, 1983, ANNU REV PLANT PHYS, V34, P47, DOI 10.1146/annurev.pp.34.060183.000403; GLEESON PA, 1980, PHYTOCHEMISTRY, V19, P1777, DOI 10.1016/S0031-9422(00)83812-1; GOLDMAN MHD, 1992, PLANT CELL, V4, P1041, DOI 10.1105/tpc.4.9.1041; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HEATH IB, 1990, TIP GROWTH PLANT FUN; HESLOPHARRISON J, 1987, INT REV CYTOL, V107, P1, DOI 10.1016/S0074-7696(08)61072-4; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JEFFERIES CJ, 1974, STAIN TECHNOL, V49, P199, DOI 10.3109/10520297409116977; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; KANDASAMY MK, 1987, J PLANT PHYSIOL, V131, P495, DOI 10.1016/S0176-1617(87)80292-4; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KIELISZEWSKI MJ, 1992, PLANT PHYSIOL, V99, P538, DOI 10.1104/pp.99.2.538; Knox R. B., 1984, Cellular interactions, P508; KREUGER M, 1993, PLANTA, V189, P243, DOI 10.1007/BF00195083; LABARCA C, 1973, PLANT PHYSIOL, V52, P87, DOI 10.1104/pp.52.2.87; LIND JL, 1994, PLANT J, V6, P491, DOI 10.1046/j.1365-313X.1994.6040491.x; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; MASCARENHAS JP, 1975, BOT REV, V41, P259, DOI 10.1007/BF02860839; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MASCARENHAS JP, 1962, AM J BOT, V49, P482, DOI 10.2307/2439418; MASCARENHAS JP, 1962, NATURE, V196, P292, DOI 10.1038/196292a0; Mulcahy G. B., 1982, J PALYNOL, V18, P61; READ SM, 1993, PROTOPLASMA, V177, P1, DOI 10.1007/BF01403393; REGER BJ, 1992, SEX PLANT REPROD, V5, P201, DOI 10.1007/BF00189812; REGER BJ, 1992, SEX PLANT REPROD, V5, P47, DOI 10.1007/BF00714557; ROSEN WG, 1961, AM J BOT, V48, P889, DOI 10.2307/2439530; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SERPE MD, 1994, PLANTA, V193, P542, DOI 10.1007/BF02411560; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SHOWALTER AM, 1989, BIOCH PLANTS, V15, P485; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; SOMMERVILLE J, 1987, ELECTRON MICROSCOPY; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; Van Montagu M., 1986, METHOD ENZYMOL, V153, P277; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; VASIL IK, 1987, INT REV CYTOL, V107, P127, DOI 10.1016/S0074-7696(08)61075-X; WANG H, 1993, PLANT CELL, V5, P1639, DOI 10.1105/tpc.5.11.1639; WELK M, 1965, AM J BOT, V52, P774, DOI 10.2307/2439758; WU HM, 1995, CELL, V82, P395, DOI 10.1016/0092-8674(95)90428-X; YARIV J, 1967, BIOCHEM J, V105, P10; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	51	385	438	3	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					383	393		10.1016/0092-8674(95)90427-1	http://dx.doi.org/10.1016/0092-8674(95)90427-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634328	hybrid			2022-12-24	WOS:A1995RP24200008
J	STUTZ, F; NEVILLE, M; ROSBASH, M				STUTZ, F; NEVILLE, M; ROSBASH, M			IDENTIFICATION OF A NOVEL NUCLEAR PORE-ASSOCIATED PROTEIN AS A FUNCTIONAL TARGET OF THE HIV-1 REV PROTEIN IN YEAST	CELL			English	Article							VIRUS TYPE-1 REV; VIRAL MESSENGER-RNA; HTLV-I REX; TRANS-ACTIVATOR; MUTATIONAL ANALYSIS; COMPLEX PROTEINS; PREMESSENGER RNA; GENE; ENVELOPE; BINDING	The HIV-1 Rev protein increases the cytoplasm ic levels of unspliced and singly spliced target transcripts in metazoan systems. Based on experiments that indicate a similar function of Rev in the yeast S. cerevisiae, we have identified a yeast protein that interacts with the effector domain of Rev. The protein, Rip1p, is a novel small nucleoporin-like protein, some of which is associated with nuclear pores. Its closest known yeast relative is a nuclear pore component also implicated in mRNA transport from nucleus to cytoplasm. Analysis of strains that overexpress Rip1p or that are deleted for the RIP1 gene show that Rip1p is important for the effect of Rev on gene expression, indicating that the physical interaction is of functional significance in vivo. The results suggest that Rev directly promotes the cytoplasmic transport of suitable transcripts by targeting them to the nuclear pore.	BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA	Brandeis University	STUTZ, F (corresponding author), BRANDEIS UNIV, HOWARD HUGHES MED INST, WALTHAM, MA 02254 USA.		Stutz, Françoise C/N-4329-2017	Goodwin, Megan/0000-0001-8506-9944				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DINGWALL C, 1993, CURR BIOL, V3, P297, DOI 10.1016/0960-9822(93)90184-P; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P389; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LAGOSKY PA, 1987, NUCLEIC ACIDS RES, V15, P10355, DOI 10.1093/nar/15.24.10355; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LESSER CF, 1993, GENETICS, V133, P851; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Maniatis T., 1982, MOL CLONING; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	68	211	216	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					495	506		10.1016/0092-8674(95)90438-7	http://dx.doi.org/10.1016/0092-8674(95)90438-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634338	Bronze			2022-12-24	WOS:A1995RP24200019
J	OLIET, SHR; BOURQUE, CW				OLIET, SHR; BOURQUE, CW			MECHANOSENSITIVE CHANNELS TRANSDUCE OSMOSENSITIVITY IN SUPRAOPTIC NEURONS	NATURE			English	Article							ION CHANNELS; RAT; VASOPRESSIN; OXYTOCIN; ACTIVATION; NUCLEUS; STIMULI	VASOPRESSIN is a peptide hormone synthesized by neurons of the supraoptic and paraventricular nuclei, which project axon terminals to the neurohypophysis. Consistent with its antidiuretic properties, vasopressin release rises as a function of plasma osmolality1-3, a response that results from accelerated action potential discharge4-6. Previous studies have shown that increases in fluid osmolality depolarize supraoptic neurons in the absence of synaptic transmission7-9, suggesting that these cells behave as intrinsic osmoreceptors. The mechanism by which changes in osmolality are transduced into an electrical signal is unknown, however. Here we report that changes in cell volume accompany physiological variations in fluid osmolality and that these modulate the activity of mechanosensitive cation channels in a way that is consistent with the macroscopic regulation of membrane voltage and action potential discharge. These findings define a function for stretch-inactivated channels in mammalian central neurons.	MONTREAL GEN HOSP,CTR RES NEUROSCI,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University				Oliet, Stephane/0000-0003-0595-9029; Bourque, Charles/0000-0002-1594-742X				BOURQUE CW, 1989, J PHYSIOL-LONDON, V417, P263, DOI 10.1113/jphysiol.1989.sp017800; BRIMBLE MJ, 1977, J PHYSIOL-LONDON, V271, P253, DOI 10.1113/jphysiol.1977.sp011999; BRIMBLE MJ, 1978, J PHYSIOL-LONDON, V278, P69, DOI 10.1113/jphysiol.1978.sp012293; Darrow DC, 1935, J CLIN INVEST, V14, P266, DOI 10.1172/JCI100674; DUNN FL, 1973, J CLIN INVEST, V52, P3212, DOI 10.1172/JCI107521; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; FRIEDMAN JE, 1993, J NEUROSCI, V13, P63; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LAWRENCE D, 1985, BRAIN RES, V341, P176, DOI 10.1016/0006-8993(85)91486-6; LENG G, 1982, NEUROENDOCRINOLOGY, V34, P75, DOI 10.1159/000123280; MASON WT, 1980, NATURE, V287, P154, DOI 10.1038/287154a0; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; MORRIS CE, 1991, SCIENCE, V251, P1246, DOI 10.1126/science.1706535; OLIET SHR, 1992, J PHYSIOL-LONDON, V455, P291, DOI 10.1113/jphysiol.1992.sp019302; POULAIN DA, 1982, NEUROSCIENCE, V7, P773, DOI 10.1016/0306-4522(82)90044-6; ROBERTSON GL, 1976, KIDNEY INT, V10, P25, DOI 10.1038/ki.1976.76; SOKABE M, 1992, ADV COMP ENV PHYSL, V10, P55; VERNEY EB, 1947, PROC R SOC SER B-BIO, V135, P25, DOI 10.1098/rspb.1947.0037	19	272	275	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					341	343		10.1038/364341a0	http://dx.doi.org/10.1038/364341a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	7687327				2022-12-24	WOS:A1993LN57000058
J	JOHNSON, RJ; GRETCH, DR; YAMABE, H; HART, J; BACCHI, CE; HARTWELL, P; COUSER, WG; COREY, L; WENER, MH; ALPERS, CE; WILLSON, R				JOHNSON, RJ; GRETCH, DR; YAMABE, H; HART, J; BACCHI, CE; HARTWELL, P; COUSER, WG; COREY, L; WENER, MH; ALPERS, CE; WILLSON, R			MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS-C VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESSENTIAL MIXED CRYOGLOBULINEMIA; RECOMBINANT INTERFERON-ALFA; B VIRUS; ALPHA-INTERFERON; CONTROLLED TRIAL; NON-A; ANTIBODIES; CLONE	Background and Methods. Hepatitis C virus (HCV) infection causes both acute and chronic liver disease and is also associated with mixed cryoglobulinemia. Whether HCV is also associated with renal disease, as is the hepatitis B virus, is not known. We describe the clinical, pathologic, virologic, and immunologic features of eight patients with HCV infection who were referred to nephrologists for glomerulonephritis. Four patients were treated with interferon alfa. Results. All eight patients had proteinuria, and seven had decreased renal function. Renal biopsy in all patients revealed membranoproliferative glomerulonephritis, characterized by the deposition of IgG, IgM, and C3 in glomeruli. Electron microscopy of the biopsy specimens showed cryoglobulin-like structures in three of four patients. All eight patients had HCV RNA detected in their serum, elevated serum aminotransferase concentrations, and hypocomplementemia, and the majority had cryoglobulins and circulating immune complexes in their serum. Cryoprecipitates from the three patients who were tested contained HCV RNA and IgG anti-HCV antibodies to the nucleocapsid core antigen (HCVc or c22-3). IgM rheumatoid factors, present in all patients, bound anti-HCV IgG in all six patients tested. Four patients received interferon alfa for 2 to 12 months; all had evidence of decreased HCV replication and improvement of their renal and liver disease. Conclusions. Chronic HCV infection is associated with cryoglobulinemia and membranoproliferative glomerulonephritis. The pathogenesis is unknown, but may relate to deposition within glomeruli of immune complexes containing HCV, anti-HCV IgG, and IgM rheumatoid factors.	UNIV WASHINGTON,MED CTR,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT PATHOL,SEATTLE,WA 98195; HIROSAKI UNIV,SCH MED,DEPT MED,DIV NEPHROL,HIROSAKI,AOMORI 036,JAPAN	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Hirosaki University	JOHNSON, RJ (corresponding author), UNIV WASHINGTON,MED CTR,DEPT MED,DIV NEPHROL,BB-1257 HLTH SCI,SEATTLE,WA 98195, USA.		Wener, Mark/ABE-4491-2021	Johnson, Richard/0000-0003-3312-8193	NIDDK NIH HHS [DK 43422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK043422, R01DK043422] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; Berger J, 1977, Adv Nephrol Necker Hosp, V7, P3; BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; CACOUB P, 1992, ANN INTERN MED, V116, P605, DOI 10.7326/0003-4819-116-7-605_2; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAMMACCO F, 1992, CLIN EXP IMMUNOL, V87, P352, DOI 10.1111/j.1365-2249.1992.tb03001.x; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DEBANDT M, 1991, CLIN EXP RHEUMATOL, V9, P659; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DISDIER P, 1991, LANCET, V338, P1151, DOI 10.1016/0140-6736(91)92014-S; DRUET P, 1973, CLIN EXP IMMUNOL, V15, P483; DURAND JM, 1992, J INFECT DIS, V165, P778, DOI 10.1093/infdis/165.4.778; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P95; FIORINI G, 1986, CLIN EXP IMMUNOL, V64, P65; FLORINCH.A, 1974, CLIN EXP IMMUNOL, V16, P599; FRANKEL AH, 1992, Q J MED, V82, P101; GALLI M, 1992, LANCET, V339, P989, DOI 10.1016/0140-6736(92)91562-M; GRETCH D, 1992, J CLIN MICROBIOL, V30, P2145, DOI 10.1128/JCM.30.8.2145-2149.1992; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; JOHNSON RJ, 1990, KIDNEY INT, V37, P663, DOI 10.1038/ki.1990.32; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KNOX TA, 1991, AM J MED, V91, P554, DOI 10.1016/0002-9343(91)90196-5; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; Levo Y, 1977, Trans Assoc Am Physicians, V90, P167; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; NEGRO F, 1992, P NATL ACAD SCI USA, V89, P2247, DOI 10.1073/pnas.89.6.2247; NOBLEJAMIESON G, 1992, LANCET, V339, P706, DOI 10.1016/0140-6736(92)90600-8; OZAWA T, 1976, ARCH PATHOL LAB MED, V100, P484; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; PETERS M, 1989, SEMIN LIVER DIS, V9, P235, DOI 10.1055/s-2008-1040516; POPP JW, 1980, ANN INTERN MED, V92, P379, DOI 10.7326/0003-4819-92-3-379; RODRIGUEZITURBE B, 1984, KIDNEY INT, V25, P129, DOI 10.1038/ki.1984.19; ROLLINO C, 1991, NEPHRON, V59, P319, DOI 10.1159/000186573; 1990, NEW ENGL J MED, V323, P1756	38	792	806	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					465	470		10.1056/NEJM199302183280703	http://dx.doi.org/10.1056/NEJM199302183280703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	7678440				2022-12-24	WOS:A1993KM41700003
J	POPOV, S; BROWN, A; POO, MM				POPOV, S; BROWN, A; POO, MM			FORWARD PLASMA-MEMBRANE FLOW IN GROWING NERVE PROCESSES	SCIENCE			English	Article							NEURONS; GROWTH; ELONGATION; MOVEMENTS; CULTURE	Nerve growth requires addition of new plasma membrane material, which is generally believed to occur at the growth cone. Local incorporation of a fluorescent lipid analog into the plasma membrane of fast-growing Xenopus neurites revealed an anterograde bulk membrane flow that correlated with neurite elongation. The rate of membrane flow depended on the position of the labeled membrane segment along the neurite, increasing with distance from the soma. This result suggests that new membrane in growing Xenopus neurites is added not at the growth cone but at the cell body and along the neurite.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University			brown, abraham/R-8823-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts B., 2017, MOL BIOL CELL; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BRAY D, 1973, J CELL BIOL, V56, P702, DOI 10.1083/jcb.56.3.702; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; POPOV S, 1992, J NEUROSCI, V12, P77; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; TABTI N, 1991, CULTURING NERVE CELL; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TANK DW, 1982, J CELL BIOL, V92, P207, DOI 10.1083/jcb.92.1.207	16	68	69	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					244	246		10.1126/science.7678471	http://dx.doi.org/10.1126/science.7678471			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678471				2022-12-24	WOS:A1993KF71900036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CENTER FOR DRUGS INAUGURATES FAX-ON-DEMAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-24	WOS:A1995RV73400006
J	DECOSAS, J; KANE, F; ANARFI, JK; SODJI, KDR; WAGNER, HU				DECOSAS, J; KANE, F; ANARFI, JK; SODJI, KDR; WAGNER, HU			MIGRATION AND AIDS	LANCET			English	Editorial Material							INFECTION		CTR COOPERAT INT SANTE & DEV,ABIDJAN,COTE IVOIRE; UNIV GHANA,INST STAT SOCIAL & ECON RES,LEGON,GHANA; FORCES ACT MIEUX ETRE MERE & ENFANT,LOME,TOGO; GTZ,DIV HLTH POPULAT & NUTR,ESCHBORN,GERMANY	University of Ghana	DECOSAS, J (corresponding author), GTZ REG AIDS PROGRAMME W & CENT AFRICA,BOX 9698 KIA,ACCRA,GHANA.							ANARFI JK, 1982, THESIS REGIONAL I PO; ASHITEY GA, 1994, EPIDEMIOLOGY DISEASE; KALE K, 1994, ACTES S SIDA MIGRATI, P32; KANE F, 1993, AIDS, V7, P1261, DOI 10.1097/00002030-199309000-00017; LALOU R, 1994, MIGRATION SIDA AFRIQ; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; Odotei I., 1992, MARITIME ANTHR STUDI, V5, P88; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; RICH V, 1995, LANCET, V346, P432, DOI 10.1016/S0140-6736(95)92797-2; SUDARKASA N, 1977, SIGNS, V3, P178, DOI 10.1086/493450	10	177	178	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					826	828		10.1016/S0140-6736(95)91631-8	http://dx.doi.org/10.1016/S0140-6736(95)91631-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674750				2022-12-24	WOS:A1995RW25800022
J	GREENWELL, PW; KRONMAL, SL; PORTER, SE; GASSENHUBER, J; OBERMAIER, B; PETES, TD				GREENWELL, PW; KRONMAL, SL; PORTER, SE; GASSENHUBER, J; OBERMAIER, B; PETES, TD			TEL1, A GENE INVOLVED IN CONTROLLING TELOMERE LENGTH IN SACCHAROMYCES-CEREVISIAE, IS HOMOLOGOUS TO THE HUMAN ATAXIA-TELANGIECTASIA GENE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; SCHIZOSACCHAROMYCES-POMBE; SHUTTLE VECTORS; DNA-REPAIR; YEAST; RECOVERY; MUTANTS; VPS34	Yeast chromosomes terminate in tracts of simple repetitive DNA (poly[G(1-3)T]). Mutations in the gene TEL1 result in shortened telomeres. Sequence analysis of TEL1 indicates that it encodes a very large (322 kDa) protein with amio acid motifs found in phosphatidylinositol/protein kinases. The closest homolog to TEL1 is the human ataxia telangiectasia gene.	UNIV N CAROLINA, CURRICULUM GENET & CELL BIOL, CHAPEL HILL, NC 27599 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV MUNICH, INST BIOCHEM, D-81375 MUNICH, GERMANY	University of North Carolina; University of North Carolina Chapel Hill; University of Chicago; University of Munich	GREENWELL, PW (corresponding author), UNIV N CAROLINA, DEPT BIOL, CB 3280, CHAPEL HILL, NC 27599 USA.			Gassenhuber, johann/0000-0001-5338-8238	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024110] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24110, GM52319] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Guthrie C, 1991, GUIDE YEAST GENETICS; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEER RJ, 1984, NUCLEIC ACIDS RES, V12, P6685, DOI 10.1093/nar/12.17.6685; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; LUSTIG AJ, 1993, GENOME ANAL, V7, P79; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PANDITA RK, 1995, CYTOGENET CELL GENET, V71, P86; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; STACK JH, 1994, J BIOL CHEM, V269, P31552; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WALMSLEY RM, 1985, P NATL ACAD SCI USA, V82, P506, DOI 10.1073/pnas.82.2.506; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	46	352	362	1	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 8	1995	82	5					823	829		10.1016/0092-8674(95)90479-4	http://dx.doi.org/10.1016/0092-8674(95)90479-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671310	Bronze			2022-12-24	WOS:A1995RU75500017
J	SCHNITZER, JE; MCINTOSH, DP; DVORAK, AM; LIU, J; OH, P				SCHNITZER, JE; MCINTOSH, DP; DVORAK, AM; LIU, J; OH, P			SEPARATION OF CAVEOLAE FROM ASSOCIATED MICRODOMAINS OF GPI-ANCHORED PROTEINS	SCIENCE			English	Article							SIGNAL-TRANSDUCING MOLECULE; TRANS-GOLGI-NETWORK; T-CELL ACTIVATION; PLASMA-MEMBRANE; MDCK CELLS; EPITHELIAL-CELLS; TYROSINE KINASES; LINKED PROTEINS; PHOSPHATIDYLINOSITOL; RECEPTOR	In situ coating of the surface of endothelial cells in rat lung with cationic colloidal silica particles was used to separate caveolae from detergent-insoluble membranes rich in glycosyl phosphatidylinositol (GPI)-anchored proteins but devoid of caveolin. Immunogold electron microscopy showed that ganglioside G(M1)-enriched caveolae associated with an annular plasmalemmal domain enriched in GPI-anchored proteins. The purified caveolae contained molecular components required for regulated transport, including various lipid-anchored signaling molecules. Such specialized distinct microdomains may exist separately or together in the plasma membrane to organize signaling molecules and to process surface-bound ligands differentially.			SCHNITZER, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.				NHLBI NIH HHS [HL52766, HL43278] Funding Source: Medline; NIAID NIH HHS [AI33372] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052766, R29HL043278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033372] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BAMEZAI A, 1992, EUR J IMMUNOL, V22, P15, DOI 10.1002/eji.1830220104; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANEY LK, 1983, J BIOL CHEM, V258, P62; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CINEK T, 1992, J IMMUNOL, V149, P2262; DAVIS LS, 1988, J IMMUNOL, V141, P2246; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GARCIA M, 1993, J CELL SCI, V104, P1281; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; JACOBSON BS, 1992, EUR J CELL BIOL, V58, P296; KELLER EA, 1992, EMBO J, V3, P863; KORTY PE, 1991, J IMMUNOL, V146, P4092; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LETARTEMUIRHEAD M, 1974, BIOCHEM J, V143, P51, DOI 10.1042/bj1430051; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PATTON WF, 1990, ELECTROPHORESIS, V11, P79, DOI 10.1002/elps.1150110116; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; RYAN US, 1982, J APPL PHYSIOL, V53, P914, DOI 10.1152/jappl.1982.53.4.914; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P124, DOI 10.1016/1050-1738(93)90012-U; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1995, AM J PHYSIOL, V37, pH48; SCHNITZER JE, 1992, J BIOL CHEM, V264, P24544; SCHNITZER JE, UNPUB; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P21230; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SU B, 1991, J CELL BIOL, V112, P377, DOI 10.1083/jcb.112.3.377; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231; ZHANG F, 1991, J CELL BIOL, V115, P75, DOI 10.1083/jcb.115.1.75	61	439	449	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1435	1439		10.1126/science.7660128	http://dx.doi.org/10.1126/science.7660128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660128				2022-12-24	WOS:A1995RT80600049
J	LEE, S; HAHN, S				LEE, S; HAHN, S			MODEL FOR BINDING OF TRANSCRIPTION FACTOR TFIIB TO THE TBP-DNA COMPLEX	NATURE			English	Article							RNA POLYMERASE-II; CRYSTAL-STRUCTURE; MINOR-GROOVE; TATA-BOX; FUNCTIONAL DOMAINS; ELEMENT	TRANSCRIPTION factor TFIIB is essential for the formation of RNA polymerase II initiation complexes where it binds to the TATA-binding protein (TBP) complex with DNA and recruits RNA polymerase II. TFIIB is probably a target for various activators(1-4). Several models have been proposed for the position of TFIIB in the TFIIB-TBP-DNA complex(1,3,5,6). Here we examine the structure of this Complex using gel mobility-shift assays and hydroxylradical footprinting. TFIIB requires at least seven base pairs of DNA on either side of the TATA box to form a stable TFIIB-TBP-DNA complex. The sugar residues protected from hydroxylradial cleavage by the TFIIB-TBP complex were mapped on the crystal-structure model of the TBP-DNA complex. This analysis suggests that TFIIB binds beneath the concave surface of TBP, contacting DNA both upstream and downstream of the TATA box. Our model predicts that TFIIB binds close to the C-terminal stirrup of TBP and provides one explanation for why TBP needs to bend DNA.			LEE, S (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Hahn, Steven/0000-0001-7240-2533				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HA L, 1991, NATURE, V352, P689; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIMBALL AS, 1993, BIOCHEMISTRY-US, V32, P4698, DOI 10.1021/bi00069a002; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TULLIUS TD, 1988, NATURE, V332, P663, DOI 10.1038/332663a0; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911	24	81	81	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					609	612		10.1038/376609a0	http://dx.doi.org/10.1038/376609a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637813				2022-12-24	WOS:A1995RP75600056
J	BOGERD, HP; FRIDELL, RA; MADORE, S; CULLEN, BR				BOGERD, HP; FRIDELL, RA; MADORE, S; CULLEN, BR			IDENTIFICATION OF A NOVEL CELLULAR COFACTOR FOR THE REV/REX CLASS OF RETROVIRAL REGULATORY PROTEINS	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REV TRANS-ACTIVATOR; GENE-EXPRESSION REQUIRES; VIRAL MESSENGER-RNA; I REX; BINDING-SITE; NUCLEOLAR LOCALIZATION; TARGET SEQUENCE; DOMAIN; MUTANTS	HIV-1 Rev is the prototype of a class of retroviral regulatory proteins that induce the sequence-specific nuclear export of target RNAs. This function requires the Rev activation domain, which is believed to bind an essential cellular cofactor. We report the identification of a novel human gene product that binds to not only the HIV-1 Rev activation domain in vitro and in vivo but also to functionally equivalent domains in other Rev and Rex proteins. The Rev/Rex activation domain-binding (Rab) protein occupies a binding site on HIV-I Rev that precisely matches that predicted by genetic analysis. Rab binds the Rev activation domain when Rev is assembled onto its RNA target and can significantly enhance Rev activity when overexpressed. We conclude that Rab is the predicted activation domain-specific cofactor for the Rev/Rex class of RNA export factors.	DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710	Duke University	BOGERD, HP (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FRIDELL RA, 1993, J VIROL, V67, P7317, DOI 10.1128/JVI.67.12.7317-7323.1993; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HARPER JW, 1993, CELL, V75, P805; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HUANG JK, 1993, MOL CELL BIOL, V13, P7476, DOI 10.1128/MCB.13.12.7476; IVEYHOYLE M, 1990, MOL CELL BIOL, V10, P6152, DOI 10.1128/MCB.10.12.6152; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; KJERNS J, 1992, EMBO J, V11, P1119; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANCUSO VA, 1994, J VIROL, V68, P1998, DOI 10.1128/JVI.68.3.1998-2001.1994; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; TILEY LS, 1991, J VIROL, V65, P3877, DOI 10.1128/JVI.65.7.3877-3881.1991; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992	41	285	294	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					485	494		10.1016/0092-8674(95)90437-9	http://dx.doi.org/10.1016/0092-8674(95)90437-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634337	Bronze			2022-12-24	WOS:A1995RP24200018
J	FARNSWORTH, CL; FRESHNEY, NW; ROSEN, LB; GHOSH, A; GREENBERG, ME; FEIG, LA				FARNSWORTH, CL; FRESHNEY, NW; ROSEN, LB; GHOSH, A; GREENBERG, ME; FEIG, LA			CALCIUM ACTIVATION OF RAS MEDIATED BY NEURONAL EXCHANGE FACTOR RAS-GRF	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; PROTEIN; GENE; EXPRESSION; DOMAIN; CDC25; IDENTIFICATION; ASSOCIATION; INHIBITION	TYROSINE kinase receptors stimulate the Ras signalling pathway by enhancing the activity of the SOS nucleotide-exchange factor(1) This occurs, at least in part, by the recruitment of an SOS-GRB2 complex to Ras in the plasma membrane. Here we describe a different signalling pathway to Ras that involves activation of the Ras-GRF exchange factor(2-4) in response to Ca2+-influx, In particular, se show that the ability of Ras-CRF to activate Ras in vivo is markedly enhanced by raised Ca2+ concentrations. Activation is mediated by calmodulin binding to an IQ motif(5) in Ras-GRF, because substitutions in conserved amino acids in this motif prevent both calmodulin binding to Ras-CRF and Ras-GRF activation in vivo, So far, full-length Ras-GRF has been detected only in brain neurons(2,6,7), Our findings implicate Ras-GRF in the regulation of neuronal functions that are influenced by Ca2+ signals.	HARVARD UNIV,CHILDRENS HOSP,DEPT NEUROL,BOSTON,MA 02111; HARVARD UNIV,CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02111; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 01215	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	FARNSWORTH, CL (corresponding author), TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111, USA.		Farnsworth, Christine/Q-5617-2018	Farnsworth, Christine/0000-0001-7615-3749; Freshney, Norman/0000-0002-6342-341X				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1994, MOL CELL BIOL, V13, P7718; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cheney R. E., 1994, Molecular Biology of the Cell, V5, p21A; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D	28	379	386	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					524	527		10.1038/376524a0	http://dx.doi.org/10.1038/376524a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637786				2022-12-24	WOS:A1995RN62200048
J	BENTLEY, E; MACKIE, IC				BENTLEY, E; MACKIE, IC			TRENDS IN PRESCRIPTIONS OF PARACETAMOL FOR CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							MEDICINES		UNIV MANCHESTER,HOSP DENT,DEPT DENT MED & SURG,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester								BENTLEY EM, 1993, HEALTH EDUC RES, V8, P519, DOI 10.1093/her/8.4.519; MACKIE IC, 1993, BRIT DENT J, V175, P93, DOI 10.1038/sj.bdj.4808242; 1979, BRIT MED J, V1, P1231	3	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					362	362		10.1136/bmj.311.7001.362	http://dx.doi.org/10.1136/bmj.311.7001.362			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640543	Green Published			2022-12-24	WOS:A1995RN46900017
J	MCEACHERN, MJ; BLACKBURN, EH				MCEACHERN, MJ; BLACKBURN, EH			RUNAWAY TELOMERE ELONGATION CAUSED BY TELOMERASE RNA GENE-MUTATIONS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HUMAN FIBROBLASTS; BINDING-PROTEIN; YEAST; DNA; SENESCENCE; RAP1; IDENTIFICATION; SEQUENCES; STABILITY	The ribonucleoprotein enzyme telomerase adds telomeric DNA onto chromosome ends and is normally regulated so that telomeric DNA lengths are kept within defined bounds. In the telomerase RNA gene from the yeast Kluyveromyces lactis, specific mutations that alter telomeric DNA sequences result in telomeres elongating to up to 100 times their normal length and Impair cell growth. Some mutations cause immediate elongation whereas others behave like genetic time bombs, causing elongation only after a latent period of hundreds of generations.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	MCEACHERN, MJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, BOX 0414, SAN FRANCISCO, CA 94143 USA.							BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1993, MOL CELL BIOL, V13, P551, DOI 10.1128/MCB.13.1.551; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PARDUE ML, 1994, CURR OPIN GENET DEV, V4, P845, DOI 10.1016/0959-437X(94)90069-8; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; Sambrook J., 1989, MOL CLONING; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHAY JW, 1993, ONCOGENE, V8, P1407; SHIPPEN DE, 1994, P NATL ACAD SCI USA, V91, P405, DOI 10.1073/pnas.91.1.405; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; VESELKOV AG, 1993, NATURE, V364, P496, DOI 10.1038/364496a0; WILLIAMSON JR, 1994, REV BIOPHYS BIOMOL S, V23, P703; WRAY LV, 1987, MOL CELL BIOL, V7, P1111, DOI 10.1128/MCB.7.3.1111; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	43	305	316	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					403	409		10.1038/376403a0	http://dx.doi.org/10.1038/376403a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630414				2022-12-24	WOS:A1995RM63900045
J	OGASAWARA, J; WATANABEFUKUNAGA, R; ADACHI, M; MATSUZAWA, A; KASUGAI, T; KITAMURA, Y; ITOH, N; SUDA, T; NAGATA, S				OGASAWARA, J; WATANABEFUKUNAGA, R; ADACHI, M; MATSUZAWA, A; KASUGAI, T; KITAMURA, Y; ITOH, N; SUDA, T; NAGATA, S			LETHAL EFFECT OF THE ANTI-FAS ANTIBODY IN MICE	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; APOPTOSIS; EXPRESSION; RECEPTOR; CACHECTIN; DEATH; CDNA	DURING mammalian development, many cells are programmed to die1,2 most mediated by apoptosis3. The Fas antigen4 coded by the structural gene for mouse lymphoproliferation mutation (lpr)5,6, is a cell surface protein belonging to the tumour necrosis factor/nerve growth factor receptor family7,8, and mediates apoptosis7. The Fas antigen messenger RNA is expressed in the thymus, liver, heart, lung and ovary8. We prepared a monoclonal antibody against mouse Fas antigen, which immunoprecipitated the antigen (M(r) 45K) and had cytolytic activity against cell lines expressing mouse Fas antigen. We report here that staining of mouse thymocytes with the antibody indicated that thymocytes from the wild-type and lpr(cg) mice expressed the Fas antigen, whereas little expression of the Fas antigen was found in lpr mice. Intraperitoneal administration of the anti-Fas antibody into mice rapidly killed the wild-type mice but neither lpr nor lpr(cg) mice. Biochemical, histological and electron microscope analyses indicated severe damage of the liver by apoptosis. These findings suggest that the Fas antigen is important in programmed cell death in the liver, and may be involved in fulminant hepatitis in some cases.	OSAKA BIOSCI INST, 6-2-4 FURUEDAI, SUITA, OSAKA 565, JAPAN; OSAKA CITY INST PUBL HLTH & ENVIRONM SCI, TENNOJI KU, OSAKA 543, JAPAN; UNIV TOKYO, INST MED SCI, LAB ANIM RES CTR, TOKYO 108, JAPAN; OSAKA UNIV, SCH MED, DEPT PATHOL, SUITA, OSAKA 565, JAPAN	University of Tokyo; Osaka University			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; BENEDETTI A, 1988, J HEPATOL, V7, P319, DOI 10.1016/S0168-8278(88)80004-7; Chisari F V, 1992, Mol Genet Med, V2, P67; CLIGAN JE, 1991, CURRENT PROTOCOLS IM; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; FALK MH, 1992, BLOOD, V79, P3300; HIRATA Y, 1989, J IMMUNOL, V143, P2900; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KIMURA M, 1992, IMMUNOLOGY, V76, P498; KOBAYASHI N, 1990, P NATL ACAD SCI USA, V87, P9620, DOI 10.1073/pnas.87.24.9620; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; OEHM A, 1992, J BIOL CHEM, V267, P10709; POTTEN CS, 1992, CANCER METASTASIS RE, V11, P95; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SANCHEZMADRID F, 1983, J IMMUNOL, V130, P309; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WAAGE A, 1988, J EXP MED, V167, P1987, DOI 10.1084/jem.167.6.1987; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON J, 1977, J IMMUNOL, V120, P422; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	27	1799	1861	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	1993	364	6440					806	809		10.1038/364806a0	http://dx.doi.org/10.1038/364806a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689176				2022-12-24	WOS:A1993LU58100057
J	COTE, J; RUIZCARRILLO, A				COTE, J; RUIZCARRILLO, A			PRIMERS FOR MITOCHONDRIAL-DNA REPLICATION GENERATED BY ENDONUCLEASE-G	SCIENCE			English	Article							DISPLACEMENT LOOP REGION; CONSERVED SEQUENCE; NUCLEASE; CELLS; GENE; RNA; TRANSCRIPTION; INITIATION; PROTEIN; SITE	Endonuclease G (Endo G) is widely distributed among animals and cleaves DNA at double-stranded (dG)n.(dC)n and at single-stranded (dC)n tracts. Endo G is synthesized as a propeptide with an amino-terminal presequence that targets the nuclease to mitochondria. Endo G can also be detected in extranucleolar chromatin. In addition to deoxyribonuclease activities, Endo G also has ribonuclease (RNase) and RNase H activities and specifically cleaves mouse mitochondrial RNA and DNA-RNA substrates containing the origin of heavy-strand DNA replication (O(H)). The cleavage sites match those found in vivo, indicating that Endo G is capable of generating the RNA primers required by DNA polymerase gamma to initiate replication of mitochondrial DNA.	HOP HOTEL DIEU,LAVAL UNIV,SCH MED,CANC RES CTR,QUEBEC CITY G1R 2J6,QUEBEC,CANADA; HOP HOTEL DIEU,LAVAL UNIV,SCH MED,DEPT BIOCHEM,QUEBEC CITY G1R 2J6,QUEBEC,CANADA	Laval University; Laval University			Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445; BALL TK, 1987, GENE, V57, P183, DOI 10.1016/0378-1119(87)90121-1; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHOW TYK, 1983, J BIOL CHEM, V258, P2010; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; COTE J, 1989, J BIOL CHEM, V264, P3301; COTE J, UNPUB; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GILLUM AM, 1979, J MOL BIOL, V135, P353, DOI 10.1016/0022-2836(79)90441-8; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUSWIRTH WW, 1984, CELL, V37, P1001, DOI 10.1016/0092-8674(84)90434-3; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; KING TC, 1987, J BIOL CHEM, V262, P6214; KING TC, 1987, J BIOL CHEM, V262, P6204; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOW RL, 1987, J BIOL CHEM, V262, P16164; LOW RL, 1988, NUCLEIC ACIDS RES, V16, P6427, DOI 10.1093/nar/16.14.6427; MOOS M, 1988, J BIOL CHEM, V263, P6005; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PRATS E, 1989, NUCLEIC ACIDS RES, V17, P10097, DOI 10.1093/nar/17.23.10097; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; TOOPER JN, 1992, CELL, V70, P16; VINCENT RD, 1988, NUCLEIC ACIDS RES, V16, P3297, DOI 10.1093/nar/16.8.3297; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283	32	189	198	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					765	769		10.1126/science.7688144	http://dx.doi.org/10.1126/science.7688144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	7688144				2022-12-24	WOS:A1993LQ73000041
J	NOLAN, JM; BURKE, DH; PACE, NR				NOLAN, JM; BURKE, DH; PACE, NR			CIRCULARLY PERMUTED TRANSFER-RNAS AS SPECIFIC PHOTOAFFINITY PROBES OF RIBONUCLEASE-P RNA STRUCTURE	SCIENCE			English	Article							SUBSTRATE; ENZYME; SEQUENCE; CATALYSIS; MOIETY; SITE; DNA	Regions of Escherichia coli ribonuclease P (RNase P) RNA in proximity to a bound transfer RNA (tRNA) substrate were mapped by photoaffinity. A photoaffinity cross-linking reagent was introduced at specific sites in the interior of the native tRNA structure by modification of the 5' ends of circularly permuted tRNAs (cptRNAs). The polymerase chain reaction was used for the production of cptRNA templates. After the amplification of a segment of a tandemly duplicated tRNA gene, the cptRNA gene was transcribed in vitro to produce cptRNA. Modified cptRNAs were cross-linked to RNase P RNA, and the conjugation sites in RNase P RNA were determined by primer extension. These sites occur in phylogenetically conserved structures and sequences and identify regions of the ribozyme that form part of the tRNA binding site. The use of circularly permuted molecules to position specific modifications is applicable to the study of many inter- and intramolecular interactions.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	Indiana University System; Indiana University Bloomington; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034527, R01GM034527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BROWN JW, 1992, NUCLEIC ACIDS RES, V20, P1451, DOI 10.1093/nar/20.7.1451; BROWN JW, 1993, NUCLEIC ACIDS RES, V21, P671, DOI 10.1093/nar/21.3.671; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GAUSS DH, 1979, TRANSFER RNA STRUCTU, P518; GREEN CJ, 1988, J BIOL CHEM, V263, P652; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NOLAN JM, UNPUB; PACE NR, 1990, J BIOL CHEM, V265, P3587; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; REICH CI, 1988, THESIS U BUENOS AIRE; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH D, 1992, J BIOL CHEM, V267, P2429; THURLOW DL, 1991, NUCLEIC ACIDS RES, V19, P885, DOI 10.1093/nar/19.4.885; USMAN N, 1992, TRENDS BIOCHEM SCI, V17, P334, DOI 10.1016/0968-0004(92)90306-T; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671	28	113	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1993	261	5122					762	765		10.1126/science.7688143	http://dx.doi.org/10.1126/science.7688143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	7688143				2022-12-24	WOS:A1993LQ73000040
J	JUNTTIBERGGREN, L; LARSSON, O; RORSMAN, P; AMMALA, C; BOKVIST, K; WAHLANDER, K; NICOTERA, P; DYPBUKT, J; ORRENIUS, S; HALLBERG, A; BERGGREN, PO				JUNTTIBERGGREN, L; LARSSON, O; RORSMAN, P; AMMALA, C; BOKVIST, K; WAHLANDER, K; NICOTERA, P; DYPBUKT, J; ORRENIUS, S; HALLBERG, A; BERGGREN, PO			INCREASED ACTIVITY OF L-TYPE CA2+ CHANNELS EXPOSED TO SERUM FROM PATIENTS WITH TYPE-I DIABETES	SCIENCE			English	Article							KILLS IMMATURE THYMOCYTES; LIVER NUCLEI; CELL; CA-2+; ENDONUCLEASE; LINE	Type I diabetes [insulin-dependent diabetes mellitus (IDDM)] is an autoimmune disease associated with the destruction of pancreatic beta cells. Serum from patients with IDDM increased L-type calcium channel activity of insulin-producing cells and of GH3 cells derived from a pituitary tumor. The subsequent increase in the concentration of free cytoplasmic Ca2+ ([Ca2+]i) was associated with DNA fragmentation typical of programmed cell death or apoptosis. These effects of the serum were prevented by adding a blocker of voltage-activated L-type Ca2+ channels. When the serum was depleted of immunoglobulin M (IgM), it no longer affected [Ca2+]i. An IgM-mediated increase in Ca2+ influx may thus be part of the autoimmune reaction associated with IDDM and contribute to the destruction of beta cells in vivo.	KAROLINSKA INST,KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES,DEPT ENDOCRINOL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN; GOTHENBURG UNIV,DEPT MED PHYS,S-41390 GOTHENBURG,SWEDEN; KAROLINSKA INST,DEPT TOXICOL,S-10401 STOCKHOLM 60,SWEDEN; UNIV HOSP UPPSALA,DEPT INTERNAL MED,S-75185 UPPSALA,SWEDEN	Karolinska Institutet; Karolinska University Hospital; University of Gothenburg; Karolinska Institutet; Uppsala University; Uppsala University Hospital			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767				ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARKHAMMAR P, 1989, BIOCHEM BIOPH RES CO, V159, P223, DOI 10.1016/0006-291X(89)92426-1; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; ASHCROFT FM, 1990, PFLUG ARCH EUR J PHY, V415, P504, DOI 10.1007/BF00373633; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAEKKESKOV S, 1986, IMMUNOLOGY ENDOCRINE, P73; COOKE A, 1990, CURR TOP MICROBIOL I, V164, P126; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; HALLBERG A, UNPUB; HESS P, 1984, NATURE, V311, P588; JUNTTIBERGGREN L, UNPUB; KAMPE O, 1989, DIABETES, V38, P1326, DOI 10.2337/diabetes.38.10.1326; LARSSON O, UNPUB; LERNMARK A, 1985, DIABETOLOGIA, V28, P195; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RORSMAN P, 1986, AM J PHYSIOL, V251, pC912, DOI 10.1152/ajpcell.1986.251.6.C912; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SARA S, 1990, BIOPHYS J, V58, P567; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J	27	183	187	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					86	90		10.1126/science.7686306	http://dx.doi.org/10.1126/science.7686306			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	7686306				2022-12-24	WOS:A1993LK43400037
J	TSUKUMA, H; HIYAMA, T; TANAKA, S; NAKAO, M; YABUUCHI, T; KITAMURA, T; NAKANISHI, K; FUJIMOTO, I; INOUE, A; YAMAZAKI, H; KAWASHIMA, T				TSUKUMA, H; HIYAMA, T; TANAKA, S; NAKAO, M; YABUUCHI, T; KITAMURA, T; NAKANISHI, K; FUJIMOTO, I; INOUE, A; YAMAZAKI, H; KAWASHIMA, T			RISK-FACTORS FOR HEPATOCELLULAR-CARCINOMA AMONG PATIENTS WITH CHRONIC LIVER-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C VIRUS; NON-B HEPATITIS; NON-A; CIGARETTE-SMOKING; ITALIAN PATIENTS; BLOOD-DONORS; ANTIBODIES; PREVALENCE; CIRRHOSIS; CANCER	Background and Methods. To detect potentially curable cases of hepatocellular carcinoma, outpatients with chronic hepatitis or compensated liver cirrhosis who were seen at the Center for Adult Diseases (Osaka, Japan) were examined periodically by means of ultrasonography and measurement of serum alpha-fetoprotein. Risk factors for hepatocellular carcinoma were identified with a Cox proportional-hazards model. Results. A total of 917 patients, 40 to 69 years old, were registered from May 1987 to March 1991. By the end of September 1991, liver cancer had developed in 54. The three-year cumulative risk of liver cancer was 12.5 percent for 240 patients with liver cirrhosis at enrollment and 3.8 percent for 677 patients with chronic hepatitis. Cox regression analysis showed that the risk of liver cancer was increased almost sevenfold in patients with hepatitis B surface antigen (rate ratio, 6.92; 95 percent confidence interval, 2.92 to 16.39) and fourfold in patients with hepatitis C antibody (rate ratio, 4.09; 95 percent confidence interval, 1.30 to 12.85). A high alpha-fetoprotein value at enrollment was also a risk marker for liver cancer. Conclusions. Patients with hepatitis C virus infection have a greatly increased risk of liver cancer. Further studies are required to clarify the roles of other risk factors, including drinking and smoking habits.	CTR ADULT DIS,RES INST,OSAKA 537,JAPAN; CTR CANC DETECT & PREVENT,OSAKA,JAPAN		TSUKUMA, H (corresponding author), CTR ADULT DIS,DEPT FIELD RES,3-3 NAKAMICHI 1 CHOME,HIGASHINARI KU,OSAKA 537,JAPAN.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ADAMI HO, 1992, INT J CANCER, V51, P898, DOI 10.1002/ijc.2910510611; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1989, LANCET, V2, P1006; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; COX DR, 1972, J R STAT SOC B, V34, P187; HIRAYAMA T, 1989, CANCER CHEMOTH PHARM, V23, pS114, DOI 10.1007/BF00647254; HIRAYAMA T, 1981, BANBURY REPORT, V7, P409; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HSU HH, 1991, GASTROENTEROLOGY, V101, P1724, DOI 10.1016/0016-5085(91)90413-F; JOHNSON PJ, 1990, J NATL CANCER I, V82, P986, DOI 10.1093/jnci/82.12.986; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASUGAI H, 1985, AM J ROENTGENOL, V144, P243, DOI 10.2214/ajr.144.2.243; KATO N, 1989, P JPN ACAD B-PHYS, V65, P219, DOI 10.2183/pjab.65.219; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P1367; LOK ASF, 1991, HEPATOLOGY, V14, P756, DOI 10.1002/hep.1840140503; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; OSHIMA A, 1984, INT J CANCER, V34, P775, DOI 10.1002/ijc.2910340607; SHIBATA A, 1986, JPN J CANCER RES, V77, P287; TAKEUCHI K, 1990, GENE, V91, P287, DOI 10.1016/0378-1119(90)90102-W; TAKEUCHI K, 1990, NUCLEIC ACIDS RES, V18, P4626, DOI 10.1093/nar/18.15.4626; TANAKA K, 1991, CANCER RES, V51, P2842; TRICHOPOULOS D, 1980, JNCI-J NATL CANCER I, V65, P111; TSUKUMA H, 1990, INT J CANCER, V45, P231, DOI 10.1002/ijc.2910450205; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; YU MW, 1991, CANCER RES, V51, P5621; 1991, KOSEI NO SHIHYO, V38, P43; 1991, 5TH OS CANC REG PREF	30	982	1007	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1797	1801		10.1056/NEJM199306243282501	http://dx.doi.org/10.1056/NEJM199306243282501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	7684822	Green Published, Green Submitted			2022-12-24	WOS:A1993LH21000001
J	HERWALDT, BL; STOKES, SL; JURANEK, DD				HERWALDT, BL; STOKES, SL; JURANEK, DD			AMERICAN CUTANEOUS LEISHMANIASIS IN UNITED-STATES TRAVELERS	ANNALS OF INTERNAL MEDICINE			English	Article						LEISHMANIASIS, CUTANEOUS; TRAVEL; TREES; MEXICO; CENTRAL AMERICA	DIAGNOSIS; GUATEMALA; WORLD; ULCER	Objective: To characterize the exposures and practices of U.S. travelers who acquired cutaneous leishmaniasis in the Americas and to highlight problems they encountered in seeking medical care from U.S. physicians. Design: A retrospective review of Centers for Disease Control and Prevention Drug Service records and a telephone survey of patients. Patients: Fifty-nine civilian U.S. travelers with American cutaneous leishmaniasis for whom the Drug Service released sodium stibogluconate between 1 January 1985 and 30 April 1990; 58 travelers (98%) were interviewed. Main Measurements: Travel destination, exposure duration, knowledge about leishmaniasis, and time from noticing skin lesions to release of drug. Results: Overall, travelers acquired leishmaniasis in as many as 14 countries; 33 of 59 travelers (56%) were infected in Mexico or Central America. Twenty-seven travelers (46%) were conducting field studies and 23 (39%) were tourists, visitors, or tour guides. At least 15 persons (26% of the 58 interviewed travelers) were in forested areas for 1 week or less; at least 6 of these persons had a maximum exposure of 2 days. Ten persons (17%) were home at least 1 month before they noticed skin lesions. Patients consulted from one to seven physicians (mean, 2.1 physicians) before leishmaniasis was diagnosed. Overall, the median time from noticing lesions to the release of drug was 112 days (range, 13 to 1022 days); however, the median was only 55 days for 13 patients (22%) unusually knowledgeable about leishmaniasis and was a maximum of 60 days for 16 patients (28%) (including 7 of the 13 unusually knowledgeable patients) who generally consulted physicians exceptionally knowledgeable about infectious and tropical diseases. Conclusions: Travelers to forested areas in Central America and Texas and their physicians need to be educated about the risk for acquiring leishmaniasis even during short stays; effective preventive measures; and appropriate medical management.			HERWALDT, BL (corresponding author), CTR DIS CONTROL & PREVENT, PARASIT DIS BRANCH, 4770 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA.							ANDRADENARVAEZ FJ, 1990, T ROY SOC TROP MED H, V84, P219, DOI 10.1016/0035-9203(90)90262-D; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BERGER RS, 1987, J AM ACAD DERMATOL, V16, P1096, DOI 10.1016/S0190-9622(87)70142-X; BERMAN JD, 1988, REV INFECT DIS, V10, P560; Chulay J D, 1988, Rev Soc Bras Med Trop, V21, P165, DOI 10.1590/S0037-86821988000400002; COPELAND HW, 1990, AM J TROP MED HYG, V43, P257, DOI 10.4269/ajtmh.1990.43.257; DEDET JP, 1987, T ROY SOC TROP MED H, V81, P748, DOI 10.1016/0035-9203(87)90017-4; Desjeux P, 1991, WHOLEISH9130; GARNHAM P. C. C., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P12, DOI 10.1016/0035-9203(59)90080-X; GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270; GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687; HERWALDT BL, 1992, J INFECT DIS, V165, P518, DOI 10.1093/infdis/165.3.518; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; LAINSON R., 1963, TRANS ROY SOC TROP MED AND HYG, V57, P242, DOI 10.1016/0035-9203(63)90182-2; MAGUIRE JH, 1983, AM J MED SCI, V285, P32, DOI 10.1097/00000441-198303000-00005; MELBY PC, 1992, CLIN INFECT DIS, V15, P924, DOI 10.1093/clind/15.6.924; MERMEL LA, 1990, J AM ACAD DERMATOL, V23, P1178, DOI 10.1016/S0190-9622(08)80926-7; MORRISJONES SD, 1990, LANCET, V336, P691, DOI 10.1016/0140-6736(90)92187-M; NAVIN TR, 1990, AM J TROP MED HYG, V42, P36, DOI 10.4269/ajtmh.1990.42.36; PARKS A, 1987, J AM ACAD DERMATOL, V17, P855, DOI 10.1016/S0190-9622(87)80295-5; RODGERS MR, 1990, EXP PARASITOL, V71, P267, DOI 10.1016/0014-4894(90)90031-7; SANCHEZ JL, 1992, AM J TROP MED HYG, V47, P47, DOI 10.4269/ajtmh.1992.47.47; TAKAFUJI ET, 1980, AM J TROP MED HYG, V29, P516, DOI 10.4269/ajtmh.1980.29.516; WALTON BC, 1968, AM J TROP MED HYG, V17, P19, DOI 10.4269/ajtmh.1968.17.19; WEIGLE KA, 1987, AM J TROP MED HYG, V36, P489, DOI 10.4269/ajtmh.1987.36.489; 1989, YB TOURISM STATISTIC, V2; 1992, MMWR, V41, P131; 1991, NEW ENGL J MED, V324, P476; 1990, WHO TECHNICAL REPORT, V793; 1990, YB TOURISM STATISTIC, V2	30	68	71	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					779	784		10.7326/0003-4819-118-10-199305150-00004	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	7682386				2022-12-24	WOS:A1993LB64900004
J	BACSKAI, BJ; HOCHNER, B; MAHAUTSMITH, M; ADAMS, SR; KAANG, BK; KANDEL, ER; TSIEN, RY				BACSKAI, BJ; HOCHNER, B; MAHAUTSMITH, M; ADAMS, SR; KAANG, BK; KANDEL, ER; TSIEN, RY			SPATIALLY RESOLVED DYNAMICS OF CAMP AND PROTEIN KINASE-A SUBUNITS IN APLYSIA SENSORY NEURONS	SCIENCE			English	Article							ACTION-POTENTIAL DURATION; CYCLIC-AMP; BEHAVIORAL SENSITIZATION; ADENOSINE 3'=5'-MONOPHOSPHATE; TRANSMITTER RELEASE; REGULATORY SUBUNIT; WITHDRAWAL REFLEX; CATALYTIC SUBUNIT; FACILITATION; SEROTONIN	Cyclic adenosine monophosphate (cAMP)-dependent protein kinase, labeled with fluorescein and rhodamine on the catalytic and regulatory subunits, respectively, was injected into Aplysia sensory neurons either in culture or in intact cell clusters. Energy transfer between the subunits, a measure of cytosolic cAMP concentration ([cAMP]), and compartmentation of the dissociated subunits were monitored by confocal fluorescence microscopy. Bath application of serotonin produced a much greater elevation of [cAMP] in the processes than in the central bodies of the neurons. The resulting gradients must drive a sizable centripetal flux of cAMP because direct microinjection of cAMP showed that it diffused readily. Perinuclear increases in [cAMP] slowly caused the translocation of the freed catalytic subunit into the nucleus to an extent proportional to the percentage of its dissociation from the regulatory subunit.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Howard Hughes Medical Institute; University of California System; University of California San Diego; Columbia University			Bacskai, Brian/AAE-9583-2021					Adams S.R., 1993, FLUORESCENT PROBES B, P133; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BERNIER L, 1982, J NEUROSCI, V2, P1682; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CASTELLUCCI VF, 1980, P NATL ACAD SCI-BIOL, V77, P7492, DOI 10.1073/pnas.77.12.7492; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; COHEN MH, 1975, BIOPHYS J, V15, P753, DOI 10.1016/S0006-3495(75)85852-8; Crank J., 1956, MATH DIFFUSION; DALE N, 1987, J NEUROSCI, V7, P2232; DWORKIN M, 1977, J BIOL CHEM, V252, P864; FROST WN, 1985, P NATL ACAD SCI USA, V82, P9266; GREENBERG SM, 1987, J NEUROSCI, V7, P291; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HAYES JS, 1982, J CYCLIC NUCL PROT, V8, P1; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; HOCHNER B, UNPUB; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUANG RC, 1991, J GEN PHYSIOL, V98, P835, DOI 10.1085/jgp.98.4.835; KAANG BK, IN PRESS NEURON; KUPFERMANN I, 1970, SCIENCE, V167, P1743, DOI 10.1126/science.167.3926.1743; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORIMOTO BH, 1991, P NATL ACAD SCI USA, V88, P10835, DOI 10.1073/pnas.88.23.10835; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OCORR KA, 1985, NEUROSCI LETT, V55, P113, DOI 10.1016/0304-3940(85)90004-7; POTTER RL, 1979, J BIOL CHEM, V254, P2413; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; TERASAKI WL, 1977, J BIOL CHEM, V252, P1041; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1990, P R MICROSCOPICAL SO, V25, pS53	38	389	400	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					222	226		10.1126/science.7682336	http://dx.doi.org/10.1126/science.7682336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	7682336				2022-12-24	WOS:A1993KW45200041
J	DAVIS, SF; BYERS, RH; LINDEGREN, ML; CALDWELL, MB; KARON, JM; GWINN, M				DAVIS, SF; BYERS, RH; LINDEGREN, ML; CALDWELL, MB; KARON, JM; GWINN, M			PREVALENCE AND INCIDENCE OF VERTICALLY ACQUIRED HIV-INFECTION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS	Objective.-To estimate human immunodeficiency virus (HIV) type I prevalence among childbearing women, HIV incidence in infants, and the number of children living with HIV infection and acquired immunodeficiency syndrome as a result of transmission from mother to infant (vertical transmission). Design.-The national HIV serosurvey of childbearing women was used to estimate the incidence of vertically acquired HIV infection in children born between 1988 and 1993. Data from the national acquired immunodeficiency syndrome case surveillance system and a multicenter pediatric HIV surveillance project were modeled to estimate incidence in children born between 1978 and 1987. Setting.-Surveillance conducted by the Centers for Disease Control and Prevention, Atlanta, Ga, in collaboration with state and local health departments. Results.-Approximately 14920 HIV-infected infants were born in the United States between 1978 and 1993. Of these, an estimated 12240 children were living at the beginning of 1994; 26% were younger than 2 years, 35% were aged 2 to 4 years, and 39% were aged 5 years or older. Approximately 6530 HIV-infected women gave birth in the United States in 1993, and, based on a 25% vertical transmission rate, an estimated 1630 of their infants were HIV infected. Conclusions-These results provide a basis for estimating medical and other resource needs for HIV-infected women and their children and for measuring the impact of interventions to reduce vertical transmission of HIV.			DAVIS, SF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,E46,ATLANTA,GA 30333, USA.							AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; CALDWELL MB, 1992, PEDIATRICS, V90, P603; CALDWELL MB, 1992, PEDIATRICS, V90, P482; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; KARON JM, 1992, HIVNCID1092028 US DE; LINDSAY MK, 1991, OBSTET GYNECOL, V77, P599; LYON L, 1993, 9TH INT C AIDS BERL; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; SCHABLE B, 1995, PEDIATRICS, V95, P511; WANG MC, 1992, J AM STAT ASSOC, V87, P397, DOI 10.2307/2290270; 1989, MMWR MORB MORTAL SS7, V38, P1; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, HIV AIDS SURVEILLANC, V6, P1; IN PRESS VITAL STATI, V1; 1990, VITAL STATISTICS US, V1; 1994, VITAL STATISTICS US, V1; 1993, ANN SUMMARY BIRTHS M; 1993, VITAL STATISTICS US, V1; 1993, MMWR-MORBID MORTAL W, V42, P869	25	107	107	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					952	955		10.1001/jama.274.12.952	http://dx.doi.org/10.1001/jama.274.12.952			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674525				2022-12-24	WOS:A1995RV73400029
J	KUHEL, WI; WARD, RF				KUHEL, WI; WARD, RF			THYROID-CANCER IN CHILDREN	LANCET			English	Editorial Material											KUHEL, WI (corresponding author), CORNELL UNIV,COLL MED,DEPT CLIN OTOLARYNGOL,NEW YORK,NY 10021, USA.							Baverstock K F, 1993, World Health Stat Q, V46, P204; DEGROOT LJ, 1975, THYROID ITS DISEASES, P666; DUFFY BJ, 1950, J CLIN ENDOCR METAB, V101, P1296; HARNESS JK, 1971, ARCH SURG-CHICAGO, V10, P278; MAZZAFERRI EL, AM J MED; Winship T, 1970, CLIN P CHILDRENS HOS, V26, P327; ZIMMERMAN D, 1988, SURGERY, V10, P1157; ZIMMERMAN D, 1992, TREATMENT THYROID CA	8	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					719	720		10.1016/S0140-6736(95)91499-4	http://dx.doi.org/10.1016/S0140-6736(95)91499-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658869				2022-12-24	WOS:A1995RU81000005
J	KATZ, EB; STENBIT, AE; HATTON, K; DEPINHO, R; CHARRON, MJ				KATZ, EB; STENBIT, AE; HATTON, K; DEPINHO, R; CHARRON, MJ			CARDIAC AND ADIPOSE-TISSUE ABNORMALITIES BUT NOT DIABETES IN MICE DEFICIENT IN GLUT4	NATURE			English	Article							FACILITATIVE GLUCOSE TRANSPORTERS; LOCALIZATION; MUSCLE; RATS	THE insulin-sensitive glucose transporter, GLUT4, is the most abundant facilitative glucose transporter in muscle and adipose tissue, the major sites for postprandial glucose disposal, To assess the role of GLUT4 in glucose homeostasis, we have disrupted the murine GLUT4 gene. Because GLUT4 has been shown to be dysregulated in pathological states such as diabetes and obesity, it was expected that genetic ablation of GLUT4 would result in abnormal glucose homeostasis, The mice deficient in GLUT4 (GLUT4-null) are growth-retarded and exhibit decreased longevity associated with cardiac hypertrophy and severely reduced adipose tissue deposits, Blood glucose levels in female GLUT4-null mice are not significantly elevated in either the fasting or fed state; in contrast, male GLUT4-null mice have moderately reduced glycaemias in the fasted state and increased glycaemias in the fed state, However, both female and male GLUT4-null mice exhibit postprandial hyperinsulinaemia, indicating possible insulin resistance. Increased expression of other glucose transporters is observed in the liver (GLUT2) and heart (GLUT1) but not skeletal muscle. Oral glucose tolerance tests show that both female and male GLUT4-null mice clear glucose as efficiently as controls, but insulin tolerance tests indicate that these mice are less sensitive to insulin action, The GLUT4-null mice demonstrate that functional GLUT4 protein is not required for maintaining nearly normal glycaemia but that GLUT4 is absolutely essential for sustained growth, normal cellular glucose and fat metabolism, and expected longevity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BRESSLER R, 1993, CARDIOSCIENCE, V4, P133; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; DEFRONZO RA, 1991, DIABETES CARE, V4, P173; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; GARVEY WT, 1993, AM J PHYSIOL, V264, pH837, DOI 10.1152/ajpheart.1993.264.3.H837; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KRAEGEN EW, 1993, BIOCHEM J, V295, P387; LITWAN SE, 1990, AM J PHYSIOL, V258, pH551; LO CW, 1986, J CELL SCI, V81, P143; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MODAN M, 1991, DIABETES CARE, V14, P470, DOI 10.2337/diacare.14.6.470; OLEFSKY JM, 1993, EXPL MED BIOL, V334, P129; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Sambrook J., 1989, MOL CLONING LAB MANU; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SLIEKER LJ, 1992, DIABETES, V41, P187, DOI 10.2337/diabetes.41.2.187; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1990, DIABETES, V39, P712, DOI 10.2337/diabetes.39.6.712	23	342	352	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					151	155		10.1038/377151a0	http://dx.doi.org/10.1038/377151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675081				2022-12-24	WOS:A1995RU75400049
J	PATHMANATHAN, R; PRASAD, U; SADLER, R; FLYNN, K; RAABTRAUB, N				PATHMANATHAN, R; PRASAD, U; SADLER, R; FLYNN, K; RAABTRAUB, N			CLONAL PROLIFERATIONS OF CELLS INFECTED WITH EPSTEIN-BARR-VIRUS IN PREINVASIVE LESIONS RELATED TO NASOPHARYNGEAL CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EBV GENE-EXPRESSION; LYMPHOPROLIFERATIVE DISEASE; EPITHELIAL-CELLS; TRANSCRIPTION; INSITU; DNA; RNA; TRANSFORMATION; SPECIMENS; BIOPSIES	Background. The Epstein-Barr virus (EBV) is consistently detected in patients with nasopharyngeal carcinoma. To determine whether EBV infection is an early, initiating event in the development of this malignant tumor, we screened nasopharyngeal-biopsy samples, most of which were archival, for preinvasive lesions, including dysplasia and carcinoma in situ, Preinvasive lesions were found in 11 samples, which were tested for the presence of EBV. Methods. EBV infection was detected with in situ hybridization for EBV-encoded RNAs (EBERs) and by immunohistochemical staining for latent membrane protein 1 (LMP-1). The larger samples were also tested for the EBV genome with the use of Southern blotting. The expression of specific EBV RNAs was determined by the amplification of complementary DNA with the polymerase chain reaction. Results. Evidence of EBV infection was detected in all 11 tissue samples with dysplasia or carcinoma in situ, EBERs were identified in all eight samples tested, and LMP-1 was detected in all six of the tested samples. Six of the seven samples tested for the EBV termini contained clonal EBV DNA. Transcription of the latent EBV gene products, EBV nuclear antigen 1, LMP-1, LMP-2A, and the BamHI-A fragment, was detected in most of the samples. Viral proteins characteristic of lytic lesions were not detected. Conclusions. Preinvasive lesions of the nasopharynx are infected with EBV. The EBV DNA is clonal, indicating that the lesions represent a focal cellular growth that arose from a single EBV-infected cell and that EBV infection is an early, possibly initiating event in the development of nasopharyngeal carcinoma. Preinvasive lesions contain EBV RNAs that are characteristic of latent infection but not the viral proteins that are characteristic of lytic infection. The detection of the EBV-transforming gene, LMP-1, in all the neoplastic cells suggests that its expression is essential for preinvasive epithelial proliferations associated with nasopharyngeal carcinoma.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL,CHAPEL HILL,NC 27599; UNIV MALAYA,DEPT PATHOL,KUALA LUMPUR,MALAYSIA; UNIV MALAYA,DEPT OTORHINOLARYNGOL,KUALA LUMPUR,MALAYSIA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Universiti Malaya; Universiti Malaya			Rajadurai, Pathmanathan A/ L A/W-1817-2019		NCI NIH HHS [CA32979] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032979] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MC, 1987, HAINES TAYLOR OBSTET, P225; ARRAND JR, 1982, J VIROL, V41, P376, DOI 10.1128/JVI.41.2.376-389.1982; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; CRISSMAN JD, 1989, AM J SURG PATHOL, V13, P5; de-The G., 1982, HERPESVIRUSES, P25; DESGRANGES C, 1975, INT J CANCER, V16, P7, DOI 10.1002/ijc.2910160103; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GILLIGAN KJ, 1991, J VIROL, V65, P6252, DOI 10.1128/JVI.65.11.6252-6259.1991; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; LEE ES, 1995, NEW ENGL J MED, V332, P19, DOI 10.1056/NEJM199501053320104; LI ZQ, 1983, NASOPHARYNGEAL CARCI, P17; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RANDHAWA PS, 1992, NEW ENGL J MED, V327, P1710, DOI 10.1056/NEJM199212103272403; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; SAM CK, 1993, INT J CANCER, V53, P957; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; SUN Y, 1993, ONCOGENE, V8, P791; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WU TC, 1991, AM J PATHOL, V138, P1461; YEUNG WM, 1993, INT J CANCER, V53, P746, DOI 10.1002/ijc.2910530507; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	36	458	480	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					693	698		10.1056/NEJM199509143331103	http://dx.doi.org/10.1056/NEJM199509143331103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637746				2022-12-24	WOS:A1995RV22700003
J	HARTWIG, JH; BOKOCH, GM; CARPENTER, CL; JANMEY, PA; TAYLOR, LA; TOKER, A; STOSSEL, TP				HARTWIG, JH; BOKOCH, GM; CARPENTER, CL; JANMEY, PA; TAYLOR, LA; TOKER, A; STOSSEL, TP			THROMBIN RECEPTOR LIGATION AND ACTIVATED RAC UNCAP ACTIN FILAMENT BARBED ENDS THROUGH PHOSPHOINOSITIDE SYNTHESIS IN PERMEABILIZED HUMAN PLATELETS	CELL			English	Article							BINDING PROTEIN-RHO; PHOSPHATIDYLINOSITOL BISPHOSPHATE; STIMULATED PLATELETS; ALPHA-THROMBIN; GROWTH-FACTOR; GELSOLIN; POLYPHOSPHOINOSITIDES; 3-KINASE; PEPTIDE; CELLS	Cells respond to diverse external stimuli by polymerizing cytoplasmic actin, and recent evidence indicates that GTPases can specify where this polymerization takes place, Actin assembly in stimulated blood platelets occurs where sequestered monomers add onto the fast-growing (barbed) ends of actin filaments (F-actin), which are capped in the resting cells, We report that D3 and D4 polyphosphoinositides, PI(4)P, PI(4,5)P-2, PI(3,4)P-2, and PI(3,4,5)P-3, uncap F-actin in resting permeabilized platelets, The thrombin receptor-activating peptide (TRAP), GTP, and GTP gamma S, but not GDP beta S, also uncap F-actin in permeabilized platelets. GDP beta S inhibits TRAP-induced F-actin uncapping, and PI(4,5)P-2 overcomes this inhibition, Constitutively active mutant Rac, but not Rho, activates uncapping of F-actin, PI(4,5)P-2-binding peptides derived from gelsolin inhibit F-actin uncapping by TRAP, Rac, and GTP gamma S. TRAP and Rac induce rapid PI(4,5)P-2 synthesis in permeabilized platelets. The findings establish a signaling pathway for actin assembly involving Rac in which the final message is phosphoinositide-mediated F-actin uncapping.	Scripps Res Inst, DEPT IMMUNOL & CELL BIOL, LA JOLLA, CA 92037 USA; BETH ISRAEL HOSP, DEPT MED, DIV HEMATOL, SIGNAL TRANSDUCT LAB, BOSTON, MA 02115 USA	Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center	HARTWIG, JH (corresponding author), BRIGHAM & WOMENS HOSP, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.				NHLBI NIH HHS [HL19429] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NIGMS NIH HHS [GM4428] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRANOFF BW, 1983, J BIOL CHEM, V258, P2076; APGAR JR, 1995, MOL BIOL CELL, V6, P97, DOI 10.1091/mbc.6.1.97; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BRASS LF, 1986, J BIOL CHEM, V261, P6838; CARSON MR, 1992, AM J PHYSIOL, V263, pL664, DOI 10.1152/ajplung.1992.263.6.L664; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DAVIES TA, 1989, J BIOL CHEM, V264, P19600; FOX JEB, 1984, J CELL BIOL, V98, P1985, DOI 10.1083/jcb.98.6.1985; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; GAUDETTE DC, 1993, J BIOL CHEM, V268, P13773; GOU DM, 1994, J CHEM SOC CHEM COMM, P2125, DOI 10.1039/c39940002125; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HASLAM RJ, 1984, BIOCHEM J, V222, P351, DOI 10.1042/bj2220351; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; REDMOND T, 1994, J BIOL CHEM, V269, P21657; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SULTAN C, 1991, J BIOL CHEM, V266, P23554; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	46	589	602	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					643	653		10.1016/0092-8674(95)90036-5	http://dx.doi.org/10.1016/0092-8674(95)90036-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664343	Bronze			2022-12-24	WOS:A1995RR73400015
J	STALEY, KJ; SOLDO, BL; PROCTOR, WR				STALEY, KJ; SOLDO, BL; PROCTOR, WR			IONIC MECHANISMS OF NEURONAL EXCITATION BY INHIBITORY GABA(A) RECEPTORS	SCIENCE			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; GAMMA-AMINOBUTYRIC ACID; GYRUS GRANULE CELLS; SYNAPTIC POTENTIALS; MEDIATED RESPONSES; RAT HIPPOCAMPUS; PH; CONDUCTANCE; CHANNELS; SLICES	Gamma-aminobutyric acid A (GABA(A)) receptors are the principal mediators of synaptic inhibition, and yet when intensely activated, dendritic GABA(A) receptors excite rather than inhibit neurons. The membrane depolarization mediated by GABA(A) receptors is a result of the differential, activity-dependent collapse of the opposing concentration gradients of chloride and bicarbonate, the anions that permeate the GABA(A) ionophore. Because this depolarization diminishes the voltage-dependent block of the N-methyl-D-aspartate (NMDA) receptor by magnesium, the activity-dependent depolarization mediated by GABA is sufficient to account for frequency modulation of synaptic NMDA receptor activation. Anionic gradient shifts may represent a mechanism whereby the rate and coherence of synaptic activity determine whether bendritic GABA(A) receptor activation is excitatory or inhibitory.	UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	STALEY, KJ (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT NEUROL,B182,4200 E 9TH AVE,DENVER,CO 80262, USA.				NIAAA NIH HHS [AA03527] Funding Source: Medline; NICHD NIH HHS [HD27827] Funding Source: Medline; NINDS NIH HHS [NS01573] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003527] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ALVAREZLEEFMANS FJ, 1988, J PHYSIOL-LONDON, V406, P225, DOI 10.1113/jphysiol.1988.sp017378; AVOLI M, 1987, BRAIN RES, V400, P191, DOI 10.1016/0006-8993(87)90671-8; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; CHEN JCT, 1992, J NEUROPHYSIOL, V67, P29, DOI 10.1152/jn.1992.67.1.29; DAVIES CH, 1993, J PHYSIOL-LONDON, V472, P245, DOI 10.1113/jphysiol.1993.sp019945; DAVIES CH, 1992, NATURE, V349, P609; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; GROVER LM, 1993, J NEUROPHYSIOL, V69, P1541, DOI 10.1152/jn.1993.69.5.1541; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HUGENARD JR, 1986, J NEUROPHYSIOL, V56, P1; JAROLIMEK W, 1989, BRAIN RES, V505, P225, DOI 10.1016/0006-8993(89)91447-9; KAILA K, 1987, NATURE, V330, P163, DOI 10.1038/330163a0; KAILA K, 1993, J PHYSIOL-LONDON, V464, P273, DOI 10.1113/jphysiol.1993.sp019634; KAILA K, 1992, NEUROREPORT, V3, P105, DOI 10.1097/00001756-199201000-00028; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; LAMBERT NA, 1991, J NEUROPHYSIOL, V66, P1538, DOI 10.1152/jn.1991.66.5.1538; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; MOTT DD, 1992, SCIENCE, V252, P1718; MULLER W, 1991, J NEUROPHYSIOL, V65, P141, DOI 10.1152/jn.1991.65.1.141; MULLER W, 1989, BRAIN RES, V484, P184, DOI 10.1016/0006-8993(89)90361-2; NACHSHEN DA, 1988, J GEN PHYSIOL, V91, P289, DOI 10.1085/jgp.91.2.289; NICOLL RA, 1978, J PHYSIOL-LONDON, V283, P121, DOI 10.1113/jphysiol.1978.sp012491; PASTERNACK M, 1993, ACTA PHYSIOL SCAND, V148, P229, DOI 10.1111/j.1748-1716.1993.tb09553.x; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; Russell JM, 1990, CHLORIDE CHANNELS CA; SMITH RL, 1995, J NEUROSCI, V15, P4057; STALEY K, 1994, J NEUROPHYSIOL, V72, P273, DOI 10.1152/jn.1994.72.1.273; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; THALMANN RH, 1988, NEUROSCI LETT, V21, P319; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; TOLKOVSKY AM, 1987, NEUROSCIENCE, V22, P1093, DOI 10.1016/0306-4522(87)92984-8; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938; Woodbury D. M., 1982, ANTIEPILEPTIC DRUGS, P771; XIE XM, 1993, J PHYSIOL-LONDON, V460, P503, DOI 10.1113/jphysiol.1993.sp019484; [No title captured]	47	655	672	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					977	981		10.1126/science.7638623	http://dx.doi.org/10.1126/science.7638623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638623				2022-12-24	WOS:A1995RP73800036
J	GARCIAMORENO, C; TURMEN, T				GARCIAMORENO, C; TURMEN, T			INTERNATIONAL PERSPECTIVES ON WOMENS REPRODUCTIVE HEALTH	SCIENCE			English	Editorial Material											GARCIAMORENO, C (corresponding author), WHO,DIV FAMILY HLTH,CH-1211 GENEVA 27,SWITZERLAND.							ALTHAUS A, 1991, INT FAM PLAN PERSPEC, V17, P145; BONGAARTS J, 1995, STUD FAMILY PLANN, V26, P57, DOI 10.2307/2137932; ELIAS C, 1991, 5 POP COUNC WORK PAP; FONN S, COMMUNICATION; HEISE L, 1994, 255 WORLD BANK DISC; KAY B, 1991, QUALITY CALIDAD QUAL, V3; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232; 1994, WHOGPADIR944 REP; 1995, WHOFHE956; 1994, WHOGPASEF944 GLOB PR; 1994, 1994 INT C POP DEV C	11	8	8	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					790	792		10.1126/science.7638592	http://dx.doi.org/10.1126/science.7638592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN650	7638592				2022-12-24	WOS:A1995RN65000030
J	KARUPIAH, G; XIE, QW; BULLER, RML; NATHAN, C; DUARTE, C; MACMICKING, JD				KARUPIAH, G; XIE, QW; BULLER, RML; NATHAN, C; DUARTE, C; MACMICKING, JD			INHIBITION OF VIRAL REPLICATION BY INTERFERON-GAMMA-INDUCED NITRIC-OXIDE SYNTHASE	SCIENCE			English	Article							VACCINIA VIRUS; RIBONUCLEOTIDE REDUCTASE; PROTEIN-KINASE; CELLS; MACROPHAGES; BIOCHEMISTRY; MECHANISM; ARGINASE; PRODUCT; SYSTEM	Interferons (IFNs) induce antiviral activity in many cell types. The ability of IFN-gamma to inhibit replication of ectromelia, vaccinia, and herpes simplex-1 viruses in mouse macrophages correlated with the cells' production of nitric oxide (NO). Viral replication was restored in IFN-gamma-treated macrophages exposed to inhibitors of NO synthase. Conversely, epithelial cells with no detectable NO synthesis restricted viral replication when transfected with a complementary DNA encoding inducible NO synthase or treated with organic compounds that generate NO. In mice, an inhibitor of NO synthase converted resolving ectromelia virus infection into fulminant mousepox. Thus, induction of NO synthase can be necessary and sufficient for a substantial antiviral effect of IFN-gamma.	CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, BEATRICE & SAMUEL A SEAVER LAB, NEW YORK, NY 10021 USA	Cornell University	KARUPIAH, G (corresponding author), NIAID, VIRAL DIS LAB, BETHESDA, MD 20892 USA.		Karupiah, Gunasegaran/J-4707-2013	Karupiah, Gunasegaran/0000-0001-6306-4405	NCI NIH HHS [CA43610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CONSTANTOULAKIS P, 1993, SCIENCE, V259, P1314, DOI 10.1126/science.7680491; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DING AH, 1988, J IMMUNOL, V141, P2407; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; HECK DE, 1992, J BIOL CHEM, V267, P21277; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1990, INT CONGR SER, V897, P189; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KARUPIAH G, 1990, J EXP MED, V172, P1495, DOI 10.1084/jem.172.5.1495; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; KARUPIAH G, UNPUB; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1992, INFLAMMATION BASIC P, P265; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; RUBY J, 1991, LYMPHOKINE CYTOK RES, V10, P353; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1992, J BIOL CHEM, V267, P5017; SETHI KK, 1983, IMMUNOBIOLOGY, V165, P459, DOI 10.1016/S0171-2985(83)80069-2; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WILDY P, 1982, INFECT IMMUN, V37, P40, DOI 10.1128/IAI.37.1.40-45.1982; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; XIE Q, UNPUB; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	40	757	782	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1993	261	5127					1445	1448		10.1126/science.7690156	http://dx.doi.org/10.1126/science.7690156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	7690156				2022-12-24	WOS:A1993LW54900032
J	HAWKEN, M; NUNN, P; GATHUA, S; BRINDLE, R; GODFREYFAUSSETT, P; GITHUI, W; ODHIAMBO, J; BATCHELOR, B; GILKS, C; MORRIS, J; MCADAM, K				HAWKEN, M; NUNN, P; GATHUA, S; BRINDLE, R; GODFREYFAUSSETT, P; GITHUI, W; ODHIAMBO, J; BATCHELOR, B; GILKS, C; MORRIS, J; MCADAM, K			INCREASED RECURRENCE OF TUBERCULOSIS IN HIV-1-INFECTED PATIENTS IN KENYA	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; MORTALITY; KINSHASA; ZAIRE	There is evidence that in human immunodeficiency virus 1 (HIV-1) infected patients with tuberculosis the rate of recurrence of tuberculosis is increased in those patients treated with a standard thiacetazone-containing regimen. To assess the impact of HIV-1 on tuberculosis in Kenya, patients with tuberculosis were studied prospectively. After treatment with either a standard thiacetazone plus isoniazid regimen or a short-course thiacetazone-containing regimen, overall recurrence rate of tuberculosis was 34 times greater in 58 HIV-1-positive patients than in 138 HIV-1-negative patients (adjusted rate ratio 33.8, 95% CI 4.3-264). Recurrence in the HIV-1-positive group was strongly associated with a cutaneous hypersensitivity reaction due to thiacetazone during initial treatment (rate ratio 13.2, 95% CI 3.1-56.2). In all patients with a cutaneous hypersensitivity reaction ethambutol was substituted for thiacetazone. No significant association was found between recurrence among HIV-1-positive patients and initial resistance, initial treatment regimen, a diagnosis of AIDS (WHO definition), or poor compliance. DNA fingerprinting suggested that both relapse and new infection may have produced recurrence of tuberculosis. In patients who had a cutaneous hypersensitivity reaction, increased recurrence rate may have been related to interruption of treatment, subsequent poor compliance, or more advanced immunosuppression. Alternatively, a change to the combination of ethambutol and isoniazid in the continuation phase for 11 months only may not be adequate.	KENYA GOVT MED RES CTR,NAIROBI,KENYA; PUBL HLTH LAB,OXFORD,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; KENYATTA NATL HOSP,HOSP INFECT DIS,NAIROBI,KENYA	Kenya Medical Research Institute; University of London; London School of Hygiene & Tropical Medicine; Kenyatta National Hospital	HAWKEN, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CITRON KM, 1983, OXFORD TXB MED, V1; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; GODFREYFAUSSETT P, 1991, LANCET, V337, P176, DOI 10.1016/0140-6736(91)90840-L; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2052; NARAIN JP, IN PRESS TUBERC LUNG; NDINYAACHOLA JO, 1991, 7 INT C AIDS FLOR; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1991, LANCET, V337, P627; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; Slutkin G, 1988, Bull Int Union Tuberc Lung Dis, V63, P21; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SORIANO E, 1988, AIDS, V2, P429, DOI 10.1097/00002030-198812000-00003; 1992, WKLY EPIDEMIOL REC, V67, P1; 1990, NATIONAL LEPROSY TUB	17	125	127	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					332	337		10.1016/0140-6736(93)91474-Z	http://dx.doi.org/10.1016/0140-6736(93)91474-Z			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	7687729				2022-12-24	WOS:A1993LQ86800012
J	FALANGA, V; EAGLSTEIN, WH				FALANGA, V; EAGLSTEIN, WH			THE TRAP HYPOTHESIS OF VENOUS ULCERATION	LANCET			English	Article							PERICAPILLARY FIBRIN; SKIN CAPILLARIES; GROWTH; LIPODERMATOSCLEROSIS; FIBROBLAST; CELLS; LEG	The pathogenesis of venous ulceration is unknown. We propose that macromolecules leaking into the dermis as a result of venous hypertension bind to or ''trap'' growth factors and matrix material, which then become unavailable for tissue repair and for the maintenance of tissue integrity.			FALANGA, V (corresponding author), UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,POB 016250,MIAMI,FL 33101, USA.			Falanga, Vincent/0000-0003-2292-2017	NIA NIH HHS [AG 10998] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010998] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALSLEV E, 1992, BRIT J DERMATOL, V126, P582; BROWSE NL, 1982, LANCET, V2, P243; BUCALO B, 1989, J INVEST DERMATOL, V92, P539; BURNAND KG, 1982, BRIT J SURG, V69, P41, DOI 10.1002/bjs.1800690114; BURNAND KG, 1982, BMJ-BRIT MED J, V285, P1071, DOI 10.1136/bmj.285.6348.1071; CHRISTOPOULOS D, 1989, SURGERY, V106, P829; CLAUDY AL, DETECTIONUNDERGRADED; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DODD HJ, 1985, J ROY SOC MED, V78, P373, DOI 10.1177/014107688507800505; FALANGA V, 1987, ARCH DERMATOL, V123, P620, DOI 10.1001/archderm.123.5.620; FALANGA V, 1992, J DERMATOL SURG ONC, V18, P409, DOI 10.1111/j.1524-4725.1992.tb03694.x; FALANGA V, 1992, J DERMATOL SURG ONC, V18, P604, DOI 10.1111/j.1524-4725.1992.tb03514.x; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; Higley HR, 1992, WOUNDS, V4, P33; HOPKINS NFG, 1983, BRIT MED J, V286, P333, DOI 10.1136/bmj.286.6362.333; KATZ MH, 1991, J AM ACAD DERMATOL, V25, P1054, DOI 10.1016/0190-9622(91)70306-M; PARDES JB, 1990, J INVEST DERMATOL, V94, P563; PARTSCH H, 1984, BRIT J DERMATOL, V110, P249, DOI 10.1111/j.1365-2133.1984.tb07481.x; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SCOTT HJ, 1991, BRIT J SURG, V78, P210, DOI 10.1002/bjs.1800780226	20	208	213	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1006	1008		10.1016/0140-6736(93)91085-Z	http://dx.doi.org/10.1016/0140-6736(93)91085-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	7682272				2022-12-24	WOS:A1993KY36800016
J	VOGEL, W; LAMMERS, R; HUANG, JT; ULLRICH, A				VOGEL, W; LAMMERS, R; HUANG, JT; ULLRICH, A			ACTIVATION OF A PHOSPHOTYROSINE PHOSPHATASE BY TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							CHIMERIC RECEPTOR; KINASE; DOMAIN; MECHANISM; SUBSTRATE; PROTEINS; SH2	Regulation of cell proliferation, differentiation, and metabolic homeostasis is associated with the phosphorylation and dephosphorylation of specific tyrosine residues of key regulatory proteins. The phosphotyrosine phosphatase 1D (PTP 1D) contains two amino terminally located Src homology 2 (SH2) domains and is similar to the Drosophila corkscrew gene product, which positively regulates the torso tyrosine kinase signal transduction pathway. PTP activity was found to be regulated by physical interaction with a protein tyrosine kinase. PTP 1D did not dephosphorylate receptor tyrosine kinases, despite the fact that it associated with the epidermal growth factor receptor and chimeric receptors containing the extracellular domain of the epidermal growth factor receptor and the cytoplasmic domain of either the HER2-neu, kit-SCF, or platelet-derived growth factor beta (betaPDGF) receptors. PTP 1D was phosphorylated on tyrosine in cells overexpressing the betaPDGF receptor kinase and this tyrosine phosphorylation correlated with an enhancement of its catalytic activity. Thus, protein tyrosine kinases and phosphatases do not simply oppose each other's action; rather, they may work in concert to maintain a fine balance of effector activation needed for the regulation of cell growth and differentiation.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University								BURGESS WH, 1990, MOL CELL BIOL, V10, P4470; FENG GS, IN PRESS SCIENCE; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HERBST R, 1991, J BIOL CHEM, V266, P19908; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P1; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TUNG HYL, 1987, ANAL BIOCHEM, V161, P412; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, UNPUB; YI T, 1992, MOL CELL BIOL, V12, P826; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	27	562	586	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1611	1614		10.1126/science.7681217	http://dx.doi.org/10.1126/science.7681217			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	7681217				2022-12-24	WOS:A1993KR54300039
J	TROYANOVSKY, SM; ESHKIND, LG; TROYANOVSKY, RB; LEUBE, RE; FRANKE, WW				TROYANOVSKY, SM; ESHKIND, LG; TROYANOVSKY, RB; LEUBE, RE; FRANKE, WW			CONTRIBUTIONS OF CYTOPLASMIC DOMAINS OF DESMOSOMAL CADHERINS TO DESMOSOME ASSEMBLY AND INTERMEDIATE FILAMENT ANCHORAGE	CELL			English	Article							CELL-ADHESION MOLECULES; AMINO-ACID-SEQUENCE; JUNCTIONAL PLAQUE PROTEIN; KIDNEY EPITHELIAL-CELLS; MESSENGER-RNA; GLYCOPROTEIN-3 DESMOCOLLINS; PEMPHIGUS-VULGARIS; HUMAN PLAKOGLOBIN; GAP-JUNCTIONS; CLONED CDNA	To examine the potential of cytoplasmic portions (''tails'') of desmosomal cadherins for assembly of desmosome plaque structures and anchorage of intermediate filaments (IFs), we transfected cultured human A-431 carcinoma cells, abundant in desmosomes and cytokeratin IFs, with constructs encoding chimeric proteins in which the transmembranous region of connexin 32 had been fused with tails of desmocollin (Dsc) or desmoglein (Dsg). The results show that the tail of the long splice form a of Dsc, but not its shorter splice form b, contains sufficient information to recruit desmoplakin and plakoglobin to connexon membrane paracrystals (gap junctions) and to form a novel kind of plaque at which cytokeratin IFs attach. By contrast, chimeras containing a Dsg tail, which accumulated in the plasma membrane, showed a dominant-negative effect: they not only were unable to form gap junction structures and plaques but also led to the disappearance of all endogenous desmosomes and the detachment of IFs from the plasma membrane.			TROYANOVSKY, SM (corresponding author), GERMAN CANC RES CTR,DIV CELL BIOL,W-6900 HEIDELBERG,GERMANY.			Leube, Rudolf/0000-0002-5519-7379; Franke, Werner W./0000-0002-4873-8448				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BUXTON RS, 1993, IN PRESS J CELL BIOL; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1984, J CELL SCI, V70, P41; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Cowin P, 1985, CELL CONTACT, P427; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRANKE WW, 1987, VIRCHOWS ARCH A, V411, P137, DOI 10.1007/BF00712737; FRANKE WW, 1987, EXP CELL RES, V173, P17, DOI 10.1016/0014-4827(87)90328-4; FRANKE WW, 1984, CELL, V36, P813, DOI 10.1016/0092-8674(84)90031-X; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HORST M, 1991, P NATL ACAD SCI USA, V82, P4137; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KARTENBECK J, 1982, EMBO J, V1, P725, DOI 10.1002/j.1460-2075.1982.tb01237.x; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KEMLER R, 1990, MORPHOREGULATORY MOL, P41; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOCH PJ, 1991, DIFFERENTIATION, V47, P29, DOI 10.1111/j.1432-0436.1991.tb00218.x; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1991, EUR J CELL BIOL, V55, P200; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KREIS TE, 1983, CELL, V32, P1125, DOI 10.1016/0092-8674(83)90296-9; LARSEN WJ, 1985, MOD CELL BIOL, V4, P151; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1986, LAB INVEST, V54, P4; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NILLES LA, 1991, J CELL SCI, V99, P809; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PARRISH EP, 1990, J CELL SCI, V96, P239; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PENN EJ, 1987, J CELL BIOL, V105, P57, DOI 10.1083/jcb.105.1.57; RUPPERT S, 1984, NATURE, V308, P554, DOI 10.1038/308554a0; SCHMELZ M, 1986, EUR J CELL BIOL, V42, P184; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; SINGER SJ, 1992, NATURE, V255, P1671; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THEIS DG, 1993, IN PRESS INT J DEV T; TROYANOVSKY SM, 1989, J CELL SCI, V93, P419; TROYANOVSKY SM, 1992, EUR J CELL BIOL, V59, P127; TSUKITA S, 1990, CELL STRUCT FUNCT, V15, P7, DOI 10.1247/csf.15.7; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G	66	172	172	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					561	574		10.1016/0092-8674(93)90075-2	http://dx.doi.org/10.1016/0092-8674(93)90075-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679953				2022-12-24	WOS:A1993KP16500011
J	HOOVER, JE; STRICK, PL				HOOVER, JE; STRICK, PL			MULTIPLE OUTPUT CHANNELS IN THE BASAL GANGLIA	SCIENCE			English	Article							PRIMATE MOTOR CORTEX; FREE ARM MOVEMENTS; FRONTAL-LOBE; THALAMIC INPUTS; GLOBUS-PALLIDUS; CORTICOSPINAL PROJECTIONS; NEURONAL POPULATION; 3-DIMENSIONAL SPACE; ARCUATE PREMOTOR; VISUAL TARGETS	The neural circuits that link the basal ganglia with the cerebral cortex are critically involved in the generation and control of voluntary movement. Retrograde transneuronal transport of herpes simplex virus type 1 was used to examine the organization of connections in the cebus monkey between an output nucleus of the basal ganglia, the internal segment of the globus pallidus (GPi), and three cortical areas: the primary motor cortex, the supplementary motor area, and the ventral premotor area. Spatially separate regions of the GPi were labeled after virus injections into each cortical area. The GPi projects to multiple cortical motor areas, and this pallidal output is organized into discrete channels. This information provides a new anatomical framework for examining the function of the basal ganglia in skeletomotor control.	SUNY HLTH SCI CTR, VET ADM MED CTR, RES SERV, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24328, NS2957] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; Barbeau A., 1986, HDB CLIN NEUROLOGY, P87; BORTOFF GA, UNPUB; COOPER IS, 1958, J NEUROSURG, V15, P244, DOI 10.3171/jns.1958.15.3.0244; DeLong M. R., 1981, HDB PHYSL NERVOUS SY, P1017; DEVITO JL, 1982, EXP BRAIN RES, V46, P107; DUM RP, 1991, J NEUROSCI, V11, P667; EVARTS EV, 1984, TRENDS NEUROSCI, V7, P447, DOI 10.1016/S0166-2236(84)80151-4; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GIGUERE M, 1988, J COMP NEUROL, V277, P195, DOI 10.1002/cne.902770204; GOLDMANRAKIC PS, 1990, TRENDS NEUROSCI, V13, P241, DOI 10.1016/0166-2236(90)90103-H; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; HEINDEL WC, 1989, J NEUROSCI, V9, P582; HOLSAPPLE JW, 1991, J NEUROSCI, V11, P2644; HUMPHREY DR, 1991, DAHLEM WORKSHOP REPO, P413; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KEMP JM, 1970, BRAIN, V93, P525, DOI 10.1093/brain/93.3.525; KIM R, 1976, J COMP NEUROL, V169, P263, DOI 10.1002/cne.901690302; KUO JS, 1973, J COMP NEUROL, V151, P201, DOI 10.1002/cne.901510302; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Manocha S. L., 1968, STEREOTAXIC ATLAS BR; MARSDEN CD, 1982, NEUROLOGY, V32, P514, DOI 10.1212/WNL.32.5.514; MATELLI M, 1989, J COMP NEUROL, V280, P468, DOI 10.1002/cne.902800311; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; NAMBU A, 1991, EXP BRAIN RES, V84, P279; NAUTA WALLE J. H., 1966, BRAIN RES, V1, P3, DOI 10.1016/0006-8993(66)90103-X; SCHELL GR, 1984, J NEUROSCI, V4, P539; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; STRICK PL, IN PRESS EXPT NEUROA; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; UGOLINI G, 1989, SCIENCE, V243, P89, DOI 10.1126/science.2536188; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P91; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245; ZEMANICK MC, 1991, P NATL ACAD SCI USA, V88, P8048, DOI 10.1073/pnas.88.18.8048	38	467	472	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					819	821		10.1126/science.7679223	http://dx.doi.org/10.1126/science.7679223			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	7679223				2022-12-24	WOS:A1993KL11000035
J	KAYE, D				KAYE, D			DIPSTICKS FOR DIAGNOSIS OF URINARY-TRACT INFECTION IN THE NURSING-HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BACTERIURIA				KAYE, D (corresponding author), MED COLL PENN,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; BALDASSARRE JS, 1991, MED CLIN N AM, V75, P375, DOI 10.1016/S0025-7125(16)30460-6; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BOSCIA JA, 1989, ANN INTERN MED, V110, P404, DOI 10.7326/0003-4819-110-5-404; GLECKMAN R, 1982, SOUTHERN MED J, V75, P551, DOI 10.1097/00007611-198205000-00011; PAPPAS PG, 1991, MED CLIN N AM, V75, P313, DOI 10.1016/S0025-7125(16)30456-4	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					868	868		10.1001/jama.274.11.868	http://dx.doi.org/10.1001/jama.274.11.868			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674489				2022-12-24	WOS:A1995RU60300008
J	DODGE, JA				DODGE, JA			MALE-FERTILITY IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material											DODGE, JA (corresponding author), QUEENS UNIV BELFAST,NUFFIELD DEPT CHILD HLTH,BELFAST,ANTRIM,NORTH IRELAND.		Chotirmall, Sanjay Haresh/K-4127-2015	Chotirmall, Sanjay Haresh/0000-0003-0417-7607				ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; AUGARTEN A, 1994, LANCET, V344, P1473, DOI 10.1016/S0140-6736(94)90292-5; BARRETO C, 1991, J MED GENET, V28, P420, DOI 10.1136/jmg.28.6.420; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; DEAN M, 1994, HUM GENET, V93, P364; FOGDESTAM I, 1994, 19TH EUR CYST FIBR C; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; LIU J, 1994, JAMA-J AM MED ASSOC, V272, P1858, DOI 10.1001/jama.272.23.1858; OATES RD, 1992, J ASSIST REPROD GEN, V9, P36, DOI 10.1007/BF01204112; STERN RC, 1995, LANCET, V346, P274, DOI 10.1016/S0140-6736(95)92165-6; STERN RC, 1983, LANCET, V1, P1401; VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993; 1995, 1995 UK CYST FIBR SU; 1994, HUMAN FERTILISTION E	16	16	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					587	588		10.1016/S0140-6736(95)91431-5	http://dx.doi.org/10.1016/S0140-6736(95)91431-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7650999				2022-12-24	WOS:A1995RT18800004
J	[Anonymous]				[Anonymous]			CARE IN THE COMMUNITY	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					714	714						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651524				2022-12-24	WOS:A1995RR83600002
J	ZIMMERLY, S; GUO, HT; PERLMAN, PS; LAMBOWITZ, AM				ZIMMERLY, S; GUO, HT; PERLMAN, PS; LAMBOWITZ, AM			GROUP-II INTRON MOBILITY OCCURS BY TARGET DNA-PRIMED REVERSE TRANSCRIPTION	CELL			English	Article							EVOLUTIONARY RELATIONSHIPS; CYTOCHROME-OXIDASE; RNA; MATURASE; YEAST; GENE; RETROVIRUSES; PROTEINS	Mobile group II introns encode reverse transcriptases and insert site specifically into intronless alleles (homing). Here, in vitro experiments show that homing of the yeast mtDNA group II intron aI2 occurs by reverse transcription at a double-strand break in the recipient DNA. A site-specific endonuclease cleaves the antisense strand of recipient DNA at position +10 of exon 3 and the sense strand at the intron insertion site. Reverse transcription of aI2-containing pre-mRNA is primed by the antisense strand cleaved in exon 3 and results in cotransfer of the intron and flanking exon sequences. Remarkably, the DNA endonuclease that initiates homing requires both the aI2 reverse transcriptase protein and aI2 RNA. Parallels in their reverse transcription mechanisms raise the possibility that mobile group II introns were ancestors of nuclear non-long terminal repeat retrotransposons and telomerases.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZIMMERLY, S (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NIGMS NIH HHS [GM31480, GM37949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949, R01GM031480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; EICKBUSH TH, 1992, NEW BIOL, V4, P430; Eickbush Thomas H., 1994, P121; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MOHR G, 1993, NUCLEIC ACIDS RES, V21, P4991, DOI 10.1093/nar/21.22.4991; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; SAINSARDCHANET A, 1994, J MOL BIOL, V242, P630, DOI 10.1006/jmbi.1994.1613; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J., 1989, MOL CLONING LAB MANU; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	31	225	248	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					545	554		10.1016/0092-8674(95)90027-6	http://dx.doi.org/10.1016/0092-8674(95)90027-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664334	Bronze			2022-12-24	WOS:A1995RR73400006
J	CARTLIDGE, PHT; STEWART, JH				CARTLIDGE, PHT; STEWART, JH			EFFECT OF CHANGING THE STILLBIRTH DEFINITION ON EVALUATION OF PERINATAL-MORTALITY RATES	LANCET			English	Article							PRETERM INFANTS; ATTITUDES; VIABILITY	The perinatal mortality rate is widely used as a summary statistic for evaluating the effectiveness of perinatal care. Since October, 1992, it has been a legal requirement in England and Wales to register fetal deaths at 24-27 completed weeks of gestation as stillbirths (in addition to those after 28 weeks), thereby altering the definition of perinatal death. In a cohort analysis of all babies born to women resident in Wales during 1993, we assessed whether the revised definition of perinatal mortality rate more appropriately measures effectiveness of care. There were 36 793 births and 313 perinatal deaths (221 stillbirths, 92 early neonatal deaths). At 24-27 weeks' gestation there were 59 (39%) survivors and 93 deaths (52 stillbirths, 36 neonatal deaths [28 early, eight late], and 5 postneonatal deaths). 119 babies had a birthweight below 500 g; one survived and 24 were perinatal deaths. Of the 36 late neonatal deaths all were attributed to perinatally related events. Increased survival of infants at 24-27 weeks' gestation emphasises the importance of including all these infants in the perinatal mortality rate, but it would be a more useful measure of the effectiveness of perinatal care if it excluded babies below 500 g, and included late neonatal deaths.			CARTLIDGE, PHT (corresponding author), UNIV WALES COLL MED,DEPT CHILD HLTH,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							[Anonymous], 1978, INT CLASSIFICATION D; [Anonymous], 1988, REGISTRATION MODERN; CARTLIDGE PHT, 1995, BRIT MED J, V310, P155, DOI 10.1136/bmj.310.6973.155; CLARKE M, 1993, BRIT MED J, V306, P824, DOI 10.1136/bmj.306.6881.824; FENTON AC, 1990, BRIT MED J, V300, P434, DOI 10.1136/bmj.300.6722.434; KEELING JW, 1989, ARCH DIS CHILD, V64, P1345, DOI 10.1136/adc.64.10_Spec_No.1345; MACFARLANE A, 1990, BRIT MED J, V300, P942, DOI 10.1136/bmj.300.6729.942-a; Macfarlane A, 1980, HLTH TRENDS, V12, P45; Mallett R, 1979, Community Med, V1, P6, DOI 10.1007/BF02548737; MUTCH LMM, 1981, BRIT MED J, V282, P119, DOI 10.1136/bmj.282.6258.119; SCOTT MJ, 1981, BRIT MED J, V282, P707, DOI 10.1136/bmj.282.6265.707; WIGGLESWORTH JS, 1980, LANCET, V2, P684; 1993, CONFIDENTIAL ENQUIRY; 1990, REGISTRATION PROPOSA; 1991, LANCET, V337, P331; 1990, LANCET, V336, P782	16	55	60	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					486	488		10.1016/S0140-6736(95)91327-0	http://dx.doi.org/10.1016/S0140-6736(95)91327-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637485				2022-12-24	WOS:A1995RP85700015
J	SASAI, Y; LU, B; STEINBEISSER, H; DEROBERTIS, EM				SASAI, Y; LU, B; STEINBEISSER, H; DEROBERTIS, EM			REGULATION OF NEURAL INDUCTION BY THE CHD AND BMP-4 ANTAGONISTIC PATTERNING SIGNALS IN XENOPUS	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL PATTERN; MESODERM INDUCTION; DROSOPHILA EMBRYO; GENE-EXPRESSION; PLATE; LAEVIS	IN Drosophila the amount of neurogenic ectoderm, from which the central nervous system (CNS) derives, is regulated by a dorsal-ventral system of positional information in which two secreted molecules of antagonistic functions, decapentaplegic (dpp) and short-gastrulation (sog), play fundamental roles(1-4). The vertebrate homologue of dpp is either bmp-4 or bmp-2 (ref. 5), and the homologue of sog is chd(4,6,7) (s-chordin). In Xenopus the CNS is induced by signals emanating from the organizer(8), and two proteins secreted by the organizer, noggin(9) and follistatin(10), have been shown to induce neural tissue in animal-cap assays. Here we report that Chd, another organizer-specific secreted factor(6), has neuralizing activity and that this activity can be antagonized by Bmp-4. Inhibition of the function of the endogenous Bmp-4 present in the animal cap(1)1 also leads to neural differentiation. We suggest that conserved molecular mechanisms involving chd/sog and bmp-4/dpp gene products pattern the ectoderm in Xenopus and in Drosophila.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869				ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JAMRICH M, 1989, DEVELOPMENT, V105, P779; JONES CM, 1992, DEVELOPMENT, V115, P639; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; PADGETT RW, 1994, P NATL ACAD SCI USA, V90, P2905; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHARPE CR, 1989, DEVELOPMENT, V107, P701; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; ZARAISKY AG, 1992, DEV BIOL, V152, P373, DOI 10.1016/0012-1606(92)90144-6	28	542	566	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					333	336		10.1038/376333a0	http://dx.doi.org/10.1038/376333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630399				2022-12-24	WOS:A1995RL44300045
J	NORGARDSUMNICHT, KE; VARKI, NM; VARKI, A				NORGARDSUMNICHT, KE; VARKI, NM; VARKI, A			CALCIUM-DEPENDENT HEPARIN-LIKE LIGANDS FOR L-SELECTIN IN NONLYMPHOID ENDOTHELIAL-CELLS	SCIENCE			English	Article							LYMPHOCYTE HOMING RECEPTOR; ANTITHROMBIN-BINDING SEQUENCE; ADHESION MOLECULE-1 LAM-1; LEUKOCYTE ADHESION; BASEMENT-MEMBRANE; LINKED OLIGOSACCHARIDES; SULFATE PROTEOGLYCANS; VASCULAR ENDOTHELIUM; HUMAN-NEUTROPHILS; PASTEURELLA-HAEMOLYTICA	L-Selectin is a calcium-dependent mammalian lectin that mediates lymphocyte trafficking by recognizing sialylated ligands on high endothelial venules in lymph nodes. Although L-selectin probably mediates neutrophil extravasation into nonlymphoid tissues, no corresponding ligand has been characterized. Staining of cultured endothelial cells with an L-selectin chimera (LS-Rg) showed an internal pool of ligands. Metabolic labeling with sulfur-35-labeled sulfate revealed heparin lyase-sensitive ligands that bound LS-Rg in a calcium-dependent, sialic acid-independent manner. A fraction of commercial heparin bound to LS-Rg and LS-Rg bound to heparin-agarose, both in a calcium-dependent manner. Thus, L-selectin recognizes endothelial heparin-like chains, which could be physiological ligands mediating leucocyte trafficking.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA38701] Funding Source: Medline; NHLBI NIH HHS [HL07089] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BHAVANANDAN VP, 1992, GLYCOCONJUGATES COMP, P167; BRADBURY MG, 1991, IMMUNOLOGY, V72, P231; BRADBURY MG, 1989, IMMUNOLOGY, V66, P546; BRAUER PR, 1990, DEVELOPMENT, V110, P805; DAWSON J, 1992, EUR J IMMUNOL, V22, P1647, DOI 10.1002/eji.1830220646; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; FAKUDA M, 1985, J BIOL CHEM, V260, P12957; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HUANG K, 1991, J CLIN INVEST, V88, P1778, DOI 10.1172/JCI115498; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; INOUE S, 1989, J HISTOCHEM CYTOCHEM, V37, P597, DOI 10.1177/37.5.2522961; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEY K, 1991, AM J PHYSIOL, V260, pH1667, DOI 10.1152/ajpheart.1991.260.5.H1667; LEY K, 1991, BLOOD, V77, P2553; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; NORGARD KE, UNPUB; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROUX L, 1988, J BIOL CHEM, V263, P8879; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SIMONASSMANN P, 1989, J CELL BIOL, V109, P1837, DOI 10.1083/jcb.109.4.1837; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPERTINI O, 1991, J IMMUNOL, V147, P2565; STOOLMAN LM, 1989, J CLIN INVEST, V84, P1196, DOI 10.1172/JCI114285; STOOLMAN LM, 1992, CELL SURFACE CARBOHY, P71; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TANGELDER GJ, 1991, BLOOD, V77, P1565; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VANDENHEUVEL LPWJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P67, DOI 10.1016/0005-2736(90)90191-P; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WALENGA JM, 1988, THROMB RES, V52, P553, DOI 10.1016/0049-3848(88)90128-4; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	67	179	185	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					480	483		10.1126/science.7687382	http://dx.doi.org/10.1126/science.7687382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	7687382				2022-12-24	WOS:A1993LN62300039
J	JACKSON, RJ				JACKSON, RJ			CYTOPLASMIC REGULATION OF MESSENGER-RNA FUNCTION - THE IMPORTANCE OF THE 3' UNTRANSLATED REGION	CELL			English	Editorial Material							TRANSLATIONAL CONTROL; PICORNAVIRUS RNA; INITIATION; DEADENYLATION; PROTEIN; COMPLEX				JACKSON, RJ (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND.							BRAUN RE, 1991, ENZYME, V44, P120; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; HARFORD JB, 1991, ENZYME, V44, P28; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MACDONALD PM, 1992, SEMIN DEV BIOL, V3, P413; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SIMON R, 1992, GENE DEV, V6, P2580, DOI 10.1101/gad.6.12b.2580; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STRIPECKE R, 1992, NUCLEIC ACIDS RES, V20, P5555, DOI 10.1093/nar/20.21.5555; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; VARNUM SM, 1992, DEV BIOL, V153, P283, DOI 10.1016/0012-1606(92)90113-U; WICKENS M, 1992, SEM DEV BIOL, V3, P399	24	404	411	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					9	14		10.1016/0092-8674(93)90290-7	http://dx.doi.org/10.1016/0092-8674(93)90290-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687524				2022-12-24	WOS:A1993LN62500003
J	LU, B; FU, WM; GREENGARD, P; POO, MM				LU, B; FU, WM; GREENGARD, P; POO, MM			CALCITONIN GENE-RELATED PEPTIDE POTENTIATES SYNAPTIC RESPONSES AT DEVELOPING NEUROMUSCULAR-JUNCTION	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CHICK SKELETAL-MUSCLE; EMBRYONIC NEURON; RAPID INDUCTION; INITIAL EVENTS; SPINAL-CORD; PHOSPHORYLATION; MYOTUBES; DESENSITIZATION; CULTURE	PROTEIN phosphorylation is important in synaptic transmission and plasticity1. At the neuromuscular junction, phosphorylation of acetylcholine (ACh) receptor-channels increases the rate of agonist-induced channel desensitization2. In contrast, potentiation of ACh channel activity through protein phosphorylation has not been described. We report here that calcitonin gene-related peptide (CGRP), a neuropeptide present at presynaptic motor nerve terminals3,4, enhances the postsynaptic response at developing neuromuscular junctions by increasing the burst duration of embryonic ACh channels. The effect of CGRP on these ACh channels is mimicked by dibutyryl-cyclic AMP and by cAMP-dependent protein kinase (PKA) and prevented by a specific peptide inhibitor of PKA. Moreover, postsynaptic inhibition of PKA reduced the amplitude and decay time of spontaneous synaptic currents, suggesting that endogenous CGRP may act as a potentiating factor during the early phase of synaptogenesis.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University	LU, B (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021, USA.		Lu, Bai/A-4018-2012	FU, WEN-MEI/0000-0003-4157-8987; Lu, Bai/0000-0001-5418-9759				BREHM P, 1982, DEV BIOL, V91, P93, DOI 10.1016/0012-1606(82)90012-4; BREHM P, 1984, J PHYSIOL-LONDON, V357, P203, DOI 10.1113/jphysiol.1984.sp015497; BREHM P, 1988, ION CHANNEL MODULATO, P345; EUSEBI F, 1985, J CELL BIOL, V100, P1339, DOI 10.1083/jcb.100.4.1339; FERRERMONTIEL AV, 1991, P NATL ACAD SCI USA, V88, P10213, DOI 10.1073/pnas.88.22.10213; FONTAINE B, 1986, NEUROSCI LETT, V71, P59, DOI 10.1016/0304-3940(86)90257-0; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOPFIELD JF, 1988, NATURE, V336, P577; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JENNINGS CGB, 1989, BRAIN RES, V504, P199, DOI 10.1016/0006-8993(89)91357-7; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MASON RT, 1984, NATURE, V308, P653, DOI 10.1038/308653a0; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; PENG HB, 1989, J COMP NEUROL, V290, P533; POPPER P, 1989, BRAIN RES, V496, P180, DOI 10.1016/0006-8993(89)91064-0; ROA M, 1991, NEUROSCIENCE, V41, P563, DOI 10.1016/0306-4522(91)90349-S; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; TABTI N, 1991, CULTURES NERVE CELLS, P37; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V304, P161, DOI 10.1038/304161a0	28	105	105	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					76	79		10.1038/363076a0	http://dx.doi.org/10.1038/363076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	7683114				2022-12-24	WOS:A1993LA68200063
J	TEEM, JL; BERGER, HA; OSTEDGAARD, LS; RICH, DP; TSUI, LC; WELSH, MJ				TEEM, JL; BERGER, HA; OSTEDGAARD, LS; RICH, DP; TSUI, LC; WELSH, MJ			IDENTIFICATION OF REVERTANTS FOR THE CYSTIC-FIBROSIS DELTA-F508 MUTATION USING STE6-CFTR CHIMERAS IN YEAST	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR CHLORIDE CHANNEL; MULTIDRUG RESISTANCE; STRUCTURAL MODEL; GENE; CELLS; EXPRESSION; TRANSPORT; PROTEIN; PHOSPHORYLATION	Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis; the most common mutation is deletion of phenylalanine at position 508 (DELTAF508). We constructed STE6-CFTR chimeras with portions of the first nucleotide-binding domain (NBD1) of the yeast STE6 a-factor transporter replaced by portions of CFTR NBD1. The chimeras were functional in yeast, but mating efficiency decreased when DELTAF508 was introduced into NBD1. We isolated two DELTAF508 revertant mutations (R553M and R553Q) that restored mating; both were located within the CFTR NBD1 sequence. Introduction of these revertant mutations into human CFTR partially corrected the processing and Cl- channel gating defects caused by the DELTAF508 mutation. These results suggest that the NBD1s of CFTR and STE6 share a similar structure and function and that, in CFTR, the regions containing F508 and R553 interact. They also indicate that the abnormal conformation produced by DELTAF508 can be partially corrected by additional alterations in the protein.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA	Howard Hughes Medical Institute; University of Iowa; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	TEEM, JL (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Tsui, Lap-chee/A-1081-2010	Berger, Herbert/0000-0003-4383-2643; Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DORK T, 1991, HUM GENET, V87, P441; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	40	151	166	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					335	346		10.1016/0092-8674(93)90233-G	http://dx.doi.org/10.1016/0092-8674(93)90233-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	7682896				2022-12-24	WOS:A1993KY50500014
J	RODECK, CH				RODECK, CH			PRENATAL-DIAGNOSIS - FETAL DEVELOPMENT AFTER CHORIONIC VILLUS SAMPLING	LANCET			English	Editorial Material							DEFECTS				RODECK, CH (corresponding author), UNIV LONDON UNIV COLL,DEPT OBSTET & GYNAECOL,LONDON WC1E 6BT,ENGLAND.							BURTON BK, 1992, OBSTET GYNECOL, V79, P726; FABRIS C, 1992, PRENATAL DIAG, V12, P1074, DOI 10.1002/pd.1970121216; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; KULIEV AM, 1992, IN PRESS PRENAT DIAG; LIN SP, 1992, NOV M AM SOC HUM GEN; QUINTERO RA, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90272-5; WEBSTER WS, 1990, TERATOLOGY, V41, P689, DOI 10.1002/tera.1420410605; WEBSTER WS, 1987, TERATOLOGY, V35, P253, DOI 10.1002/tera.1420350212	9	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					468	469		10.1016/0140-6736(93)90213-Z	http://dx.doi.org/10.1016/0140-6736(93)90213-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	7679461				2022-12-24	WOS:A1993KN13700010
J	OESTERLING, JE; MARTIN, SK; BERGSTRALH, EJ; LOWE, FC				OESTERLING, JE; MARTIN, SK; BERGSTRALH, EJ; LOWE, FC			THE USE OF PROSTATE-SPECIFIC ANTIGEN IN STAGING PATIENTS WITH NEWLY DIAGNOSED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE; CARCINOMA; SCINTIGRAPHY; SCANS	Objective.-To assess the need for obtaining radionuclide bone scans in the staging evaluation of patients with newly diagnosed, untreated prostate cancer. This determination was made on the basis of presenting prostate-specific antigen (PSA) levels. Design.-Retrospective review. Participants.-The medical records of 2064 consecutive patients with prostate cancer who were evaluated at the Mayo Clinic in Rochester, Minn, from January 1989 through December 1990 were reviewed. Eight hundred fifty-two patients with newly diagnosed, untreated disease and a serum PSA concentration less than 20.0 mug/L at presentation comprised the study population. Main Outcome Measure.-The rate of false-negative results associated with using the serum PSA concentration to predict bone scan findings. Results.-Five hundred sixty-one patients had a serum PSA concentration of 10.0 mug/L or less; only three had an abnormal bone scan result, and one had an indeterminate scan result. Of the 467 men whose PSA value was 8.0 mug/L or less (two times the upper limit of the reference range), none had bone scan results that were either abnormal or indeterminate. The rate of false-negative results for an abnormal bone scan result was 0% with a serum PSA value of 8.0 mug/L or less and 0.5% with a cutoff level of 10.0 mug/L. The 95% upper confidence limit for the rate of false-negative results for all PSA cutoff levels less than 20.0 mug/L was less than 2%. Conclusions.-For patients with newly diagnosed, untreated prostate cancer, a serum PSA concentration of 10.0 mug/L or less, and no skeletal symptoms, a staging radionuclide bone scan does not appear to be necessary. This clinical situation applies to 39% of all patients presenting with newly diagnosed prostate cancer. Since more than 130 000 new cases are diagnosed each year, approximately 50 000 patients are affected annually. If the $600 staging bone scan were eliminated for these patients, a significant economic savings to the health care system in this country would be effected.	MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905; ST LUKES ROOSEVELT HOSP,DEPT UROL,NEW YORK,NY; COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,NEW YORK,NY 10032	Mayo Clinic; Mount Sinai St. Luke's; Mount Sinai West; Columbia University	OESTERLING, JE (corresponding author), MAYO CLIN & MAYO FDN,DEPT UROL,200 1ST ST SW,ROCHESTER,MN 55905, USA.							BERGER GL, 1981, J UROLOGY, V125, P637, DOI 10.1016/S0022-5347(17)55144-7; CATALONA WJ, 1984, PROSTATE CANCER; CHYBOWSKI FM, 1991, J UROLOGY, V145, P313, DOI 10.1016/S0022-5347(17)38325-8; LINDNER A, 1982, J UROLOGY, V128, P1181, DOI 10.1016/S0022-5347(17)53412-6; MCGREGOR B, 1978, BRIT J UROL, V50, P178, DOI 10.1111/j.1464-410X.1978.tb02798.x; MERRICK MV, 1985, BRIT J UROL, V57, P715, DOI 10.1111/j.1464-410X.1985.tb07039.x; ODONOGHUE EPN, 1978, BRIT J UROL, V50, P172, DOI 10.1111/j.1464-410X.1978.tb02797.x; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PAULSON DF, 1988, DIAGNOSIS MANAGEMENT, P417; ROCK RC, 1987, CLIN CHEM, V33, P2257; ROSEN PR, 1984, J NUCL MED, V25, P289; SCHAFFER DL, 1976, RADIOLOGY, V121, P431, DOI 10.1148/121.2.431; UTZ DC, 1969, J AMER MED ASSOC, V209, P1701, DOI 10.1001/jama.209.11.1701; 1992, CANCER FACTS FIGURES	14	185	191	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					57	60						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	7677962				2022-12-24	WOS:A1993KF02600027
J	DOBRESCU, D; URSEA, B; POPE, M; ASCH, AS; POSNETT, DN				DOBRESCU, D; URSEA, B; POPE, M; ASCH, AS; POSNETT, DN			ENHANCED HIV-1 REPLICATION IN V-BETA-12 T-CELLS DUE TO HUMAN CYTOMEGALOVIRUS IN MONOCYTES - EVIDENCE FOR A PUTATIVE HERPESVIRUS SUPERANTIGEN	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; ENDOGENOUS SUPERANTIGENS; MICROBIAL SUPERANTIGENS; DENDRITIC CELLS; INFECTION; EXPRESSION; AIDS; STIMULATION	HIV-1 replicates more efficiently in cultured IL-2-dependent CD4 T cells expressing V beta 12 T cell receptors (TCRs) rather than other TCRs (Laurence et al., 1992). A viral reservoir is frequently established in V beta 12 T cells in HIV-1-infected patients. Here we show that cytomegalovirus (CMV) is responsible for V beta 12-selective HIV-1 replication that is indistinguishable from the effect of known superantigens (SAGs). This effect is dependent on direct contact of T cells with CMV-infected monocytes. CMV infection, but not ie1 or ie2 transfection, reproduces this effect in a monocytoid cell line (U937). In HIV-infected patients, the presence of CMV antibodies correlates with an HIV-1 viral load preferentially skewed to the V beta 12 subset. Together, these data suggest that a CMV gene product is responsible for a SAG-driven V beta 12-selective HIV-1 reservoir in vivo.	CORNELL UNIV,GRAD SCH MED SCI,HUMAN MOLEC IMMUNOBIOL LAB,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,DIV HEMATOL & ONCOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT CELL BIOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University; Rockefeller University					NIAID NIH HHS [AI33322] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033322] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1993, IMMUNOL REV, V131, P5, DOI 10.1111/j.1600-065X.1993.tb01527.x; BACCALA R, 1992, RES IMMUNOL, V143, P288, DOI 10.1016/S0923-2494(92)80122-2; BHARDWAJ N, 1992, J EXP MED, V175, P267, DOI 10.1084/jem.175.1.267; BHARDWAJ N, 1994, INFECT IMMUN, V62, P135, DOI 10.1128/IAI.62.1.135-144.1994; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CHATILA T, 1993, IMMUNOL REV, V131, P43, DOI 10.1111/j.1600-065X.1993.tb01529.x; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CLOUSE KA, 1989, J IMMUNOL, V143, P470; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COFFIN JM, 1992, SCIENCE, V255, P411, DOI 10.1126/science.1310360; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DOBRESCU D, 1995, P NATL ACAD SCI USA, V92, P5563, DOI 10.1073/pnas.92.12.5563; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; HELD W, 1994, J EXP MED, V180, P2347, DOI 10.1084/jem.180.6.2347; HIRSCH MS, 1984, REV INFECT DIS, V6, P726; HO WZ, 1991, AIDS RES HUM RETROV, V7, P689, DOI 10.1089/aid.1991.7.689; HOBER D, 1992, CLIN IMMUNOL IMMUNOP, V62, P168, DOI 10.1016/0090-1229(92)90069-Z; IBANEZ CE, 1991, J VIROL, V65, P6581, DOI 10.1128/JVI.65.12.6581-6588.1991; JENKINS DE, 1994, J GEN VIROL, V75, P2337, DOI 10.1099/0022-1317-75-9-2337; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KORMAN AJ, 1992, EMBO J, V11, P1901, DOI 10.1002/j.1460-2075.1992.tb05242.x; LABRECQUE N, 1993, J EXP MED, V177, P1735, DOI 10.1084/jem.177.6.1735; LAFON M, 1994, J EXP MED, V180, P1207, DOI 10.1084/jem.180.4.1207; LAFON M, 1992, NATURE, V358, P507, DOI 10.1038/358507a0; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; Mocarski Edward S. Jr., 1993, P173; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NUMAZAKI K, 1992, MED MICROBIOL IMMUN, V181, P323; OKSENHENDLER E, 1993, AIDS, V7, P1023, DOI 10.1097/00002030-199307000-00023; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POSNETT DN, 1993, AIDS, V7, P625, DOI 10.1097/00002030-199305000-00003; POSNETT DN, 1993, SUPERANTIGENS PATHOG, P163; POSNETT DN, 1995, IN PRESS ANN NY ACAD, V1017; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; SKOLNIK PR, 1994, J INFECT DIS, V157, P508; SMITH LR, 1992, EUR J IMMUNOL, V22, P641, DOI 10.1002/eji.1830220305; SMITH PD, 1992, J CLIN INVEST, V90, P1642, DOI 10.1172/JCI116035; SMITH TJ, 1993, BLOOD, V81, P1521; SODERBERG C, 1993, TRANSPLANT P, V25, P1416; STINSKI MF, 1978, J VIROL, V26, P686, DOI 10.1128/JVI.26.3.686-701.1978; TAYLORWIEDEMAN J, 1994, J VIROL, V68, P1597, DOI 10.1128/JVI.68.3.1597-1604.1994; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; WEBSTER A, 1989, LANCET, V2, P63	51	81	83	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					753	763		10.1016/0092-8674(95)90472-7	http://dx.doi.org/10.1016/0092-8674(95)90472-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671303	Bronze			2022-12-24	WOS:A1995RU75500010
J	BENNETT, PB; YAZAWA, K; MAKITA, N; GEORGE, AL				BENNETT, PB; YAZAWA, K; MAKITA, N; GEORGE, AL			MOLECULAR MECHANISM FOR AN INHERITED CARDIAC-ARRHYTHMIA	NATURE			English	Article							LONG QT SYNDROME; NA+-CHANNEL INACTIVATION; FREE MEMBRANE PATCHES; SODIUM-CHANNELS; CURRENTS	IN the congenital long-QT syndrome, prolongation of the cardiac action potential occurs by an unknown mechanism(1,2) and predisposes individuals to syncope and sudden death as a result of ventricular arrhythmias(3), Genetic heterogeneity has been demonstrated for autosomal dominant long-QT syndrome by the identification of multiple distinct loci(4,5), associated mutations in two candidate genes have recently been reported(6,7). One form of hereditary long QT (LQT3) has been linked to a mutation(7) in the gene encoding the human heart voltage-gated sodium-channel alpha-subunit (SCN5A on chromosome 3p21)(8). Here we characterize this mutation using heterologous expression of recombinant human heart sodium channels, Mutant channels show a sustained inward current during membrane depolarization, Single-channel recordings indicate that mutant channels fluctuate between normal and non-inactivating gating modes. Persistent inward sodium current explains prolongation of cardiac action potentials, and provides a molecular mechanism for this form of congenital long-QT syndrome.	VANDERBILT UNIV, MED CTR, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University	BENNETT, PB (corresponding author), VANDERBILT UNIV, MED CTR, DEPT PHARMACOL, NASHVILLE, TN 37232 USA.							ALZHEIMER C, 1993, J NEUROSCI, V13, P660; ATTWELL D, 1988, LANCET, V1, P1136; CARMELIET E, 1993, EUR HEART J, V14, P3, DOI 10.1093/eurheartj/14.suppl_H.3; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1995, CYTOGENET CELL GENET, V68, P67; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Higuchi R., 1989, PCR TECHNOLOGY, P61; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; JU YK, 1994, P ROY SOC B-BIOL SCI, V256, P163, DOI 10.1098/rspb.1994.0065; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KIYOSUE T, 1989, CIRC RES, V64, P389, DOI 10.1161/01.RES.64.2.389; MAKITA N, 1994, J BIOL CHEM, V269, P7571; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; NILIUS B, 1988, BIOPHYS J, V53, P857, DOI 10.1016/S0006-3495(88)83166-7; PATLAK J, 1991, PHYSIOL REV, V71, P1047, DOI 10.1152/physrev.1991.71.4.1047; PATLAK JB, 1986, J GEN PHYSIOL, V87, P305, DOI 10.1085/jgp.87.2.305; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHWARTZ PJ, 1992, ANN NY ACAD SCI, V644, P112, DOI 10.1111/j.1749-6632.1992.tb31007.x; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VALENZUELA C, 1994, BIOPHYS J, V67, P161, DOI 10.1016/S0006-3495(94)80465-5; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910	25	704	720	1	14	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					683	685		10.1038/376683a0	http://dx.doi.org/10.1038/376683a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651517				2022-12-24	WOS:A1995RQ67200059
J	ALBERTSEN, PC; FRYBACK, DG; STORER, BE; KOLON, TF; FINE, J				ALBERTSEN, PC; FRYBACK, DG; STORER, BE; KOLON, TF; FINE, J			LONG-TERM SURVIVAL AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECISION-ANALYSIS; CO-MORBIDITY; COMORBIDITY; OUTCOMES; DISEASE	Objective.-To determine age-specific, all-cause mortality, disease-specific mortality, and life expectancy for men aged 65 to 75 years who are treated only with immediate or delayed hormonal therapy for newly diagnosed, clinically localized prostate cancer. Design.-A population-based, retrospective cohort study. Setting.-Patient records were abstracted from 37 acute care hospitals and two Veterans Affairs medical centers in Connecticut. Original pathology slides were sent to a referee pathologist who was blinded to case outcomes. Subjects.-All men identified by the Connecticut Tumor Registry with clinically localized prostate cancer diagnosed in 1971 to 1976 who were aged 65 to 75 years at the time of diagnosis and were untreated or treated with immediate or delayed hormonal therapy. Main Outcome Measures.-Parametric proportional hazards models incorporating tumor histologic findings, comorbidity, and age at the time of diagnosis to compare cohort survival with that of men in the general population. Results.-After a mean follow-up of 15.5 years, the age-adjusted survival for men with Gleason score 2 to 4 tumors was not significantly different from that of the general population. Maximum estimated lost life expectancy for men with Gleason score 5 to 7 tumors was 4 to 5 years and for men with Gleason score 8 to 10 tumors was 6 to 8 years. Tumor histologic findings and patient comorbidities were powerful independent predictors of survival. Conclusions.-Compared with the general population, men aged 65 to 75 years with conservatively treated low-grade prostate cancer incur no loss of life expectancy. Men with higher-grade tumors (Gleason scores 5 to 10) experience a progressively increasing loss of life expectancy. Case series reports of survival/ mortality experienced by men with clinically localized prostate cancer that fail to control for age, tumor histologic features, and comorbidities risk significant bias.	UNIV WISCONSIN,DEPT PREVENT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOSTAT,MADISON,WI 53706; YALE UNIV,CTR CANC,NEW HAVEN,CT	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Yale University	ALBERTSEN, PC (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT SURG,DIV UROL,263 FARMINGTON AVE,FARMINGTON,CT 06030, USA.			Kolon, Thomas/0000-0002-8740-5021	AHRQ HHS [HS06770] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BECK JR, 1994, J UROLOGY, V152, P1894, DOI 10.1016/S0022-5347(17)32409-6; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CATALONA WJ, 1989, J UROLOGY, V142, P1302, DOI 10.1016/S0022-5347(17)39066-3; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; COWEN ME, 1994, J CLIN EPIDEMIOL, V47, P3, DOI 10.1016/0895-4356(94)90029-9; Elandt-Johnson R C, 1980, SURVIVAL MODELS DATA; Fleming C, 1993, JAMA, V269, P2650; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KAPLAN MH, 1974, J CHRON DIS, V27, P387, DOI 10.1016/0021-9681(74)90017-4; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; MOLD JW, 1992, J FAM PRACTICE, V34, P561; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487	21	369	374	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					626	631		10.1001/jama.274.8.626	http://dx.doi.org/10.1001/jama.274.8.626			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637143				2022-12-24	WOS:A1995RP70200030
J	FEIGENSPAN, A; WASSLE, H; BORMANN, J				FEIGENSPAN, A; WASSLE, H; BORMANN, J			PHARMACOLOGY OF GABA RECEPTOR CL- CHANNELS IN RAT RETINAL BIPOLAR CELLS	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; GLYCINE RECEPTOR; PATCH-CLAMP; FUNCTIONAL EXPRESSION; MEMBRANE PATCHES; XENOPUS OOCYTES; SUBUNIT; CURRENTS; BICUCULLINE; STRYCHNINE	Gamma-AMINOBUTYRIC acid (GABA), a major inhibitory neurotransmitter in the mammalian nervous system, is known to operate bicuculline-sensitive Cl- channels through GABA(A) receptors and bicuculline-insensitive cation channels through GABA(B) receptors1,2. Recent observations indicate that the retina may contain GABA receptors with unusual pharmacological properties3-5. Here we report that GABA gates bicuculline-insensitive Cl- channels in rod bipolar cells of the rat retina, which were not modulated by flunitrazepam, pentobarbital and alphaxalone and were only slightly blocked by picrotoxinin. Moreover, the GABA(B) receptor agonist baclofen, and the antagonist 2-hydroxysaclofen had no effect. The underlying single-channel conductance was 7 pS and the open time 150 ms. These values are clearly different from those obtained for GABA(A) receptor channels recorded in other neurons of the same preparation, and in other parts of the brain1,6-8. The bicuculline- and baclofen-insensitive GABA receptors were activated selectively by the GABA analogue cis-4-aminocrotonic acid (CACA)9. Hence they may be similar to those receptors termed GABA(C) receptors10.	MAX PLANCK INST HIRNFORSCH,DEUTSCHORDENSTR 46,W-6000 FRANKFURT 71,GERMANY	Max Planck Society			Bormann, Joachim/E-6214-2011					Becker C.-M., 1992, HDB EXPT PHARM, V102, P539; BORMANN J, 1985, P NATL ACAD SCI USA, V82, P2168, DOI 10.1073/pnas.82.7.2168; BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DREW CA, 1984, NEUROSCI LETT, V52, P317, DOI 10.1016/0304-3940(84)90181-2; FEIGENSPAN A, IN PRESS VISUAL NEUR; GAHWILER BH, 1984, NEUROSCIENCE, V11, P751, DOI 10.1016/0306-4522(84)90192-1; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JOHNSTON GA, 1975, J NEUROCHEM, V24, P157, DOI 10.1111/j.1471-4159.1975.tb07642.x; KARSCHIN A, 1990, J NEUROPHYSIOL, V63, P860, DOI 10.1152/jn.1990.63.4.860; LIPTON SA, 1989, VISUAL NEUROSCI, V3, P275, DOI 10.1017/S0952523800010026; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; PRIBILLA I, IN PRESS EMBO J; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SHIRASAKI T, 1991, BRAIN RES, V561, P77, DOI 10.1016/0006-8993(91)90751-G; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; YEH HH, 1990, VISUAL NEUROSCI, V4, P349, DOI 10.1017/S0952523800004557	26	360	365	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					159	162		10.1038/361159a0	http://dx.doi.org/10.1038/361159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	7678450				2022-12-24	WOS:A1993KG46600061
J	ASCHERIO, A; BIELLIK, R; EPSTEIN, A; SNETRO, G; GLOYD, S; AYOTTE, B; EPSTEIN, PR				ASCHERIO, A; BIELLIK, R; EPSTEIN, A; SNETRO, G; GLOYD, S; AYOTTE, B; EPSTEIN, PR			DEATHS AND INJURIES CAUSED BY LAND MINES IN MOZAMBIQUE	LANCET			English	Article							EXPERIENCE; HEALTH	Land mines in Mozambique are still causing death and injuries years after the initial dispute. Since 1980, 3400 people have had an amputation because of land mine injuries, However, there are no direct estimates of the number of deaths or casualties which are not treated in hospitals. In March, 1994, a medical team assembled by Physicians for Human Rights (PHR) conducted household surveys in the province of Manica and in the sub-district of Metuchira, province of Sofala. The object was to assess the frequency and severity of injuries and mortality caused by land mines in the civilian population. We found ratios of 8.1 and 16.7 casualties per 1000 living people in Manica and Metuchira, respectively. The prevalence of amputees was 3.2 per 1000 in Manica, and 2.3 in Metuchira. These figures are several folds higher than suggested by hospital data. The case fatality rate was 48%. Most of the victims were civilians (68%) and were injured by antipersonnel mines (81%). 16% of victims were women, and 7% were under 15 years of age. Our results suggest that the impact of land mines is substantially higher than originally thought.	PHYSICIANS HUMAN RIGHTS,BOSTON,MA 02116; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; WHO,HARARE,ZIMBABWE; MASSACHUSETTS DEPT PUBL HLTH,BOSTON,MA 02116; SAVE THE CHILDREN,WESTPORT,CT; UNIV WASHINGTON,SCH PUBL HLTH,SEATTLE,WA 98195; HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138	Harvard University; Harvard T.H. Chan School of Public Health; World Health Organization; Massachusetts Department of Public Health; University of Washington; University of Washington Seattle; Harvard University								Anderson K, 1993, LANDMINES DEADLY LEG; BLAGDEN P, 1993, APR INT COMM RED CRO; BLAGDEN P, 1993, DEFENSE WEEK    0913, P11; CLIFF J, 1993, SOC SCI MED, V36, P843, DOI 10.1016/0277-9536(93)90076-G; CLIFF J, 1988, SOC SCI MED, V27, P717, DOI 10.1016/0277-9536(87)90331-5; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P63; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; SHEEHAN E, 1993, LANDMINE CASUALTIES; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P331, DOI 10.1001/jama.272.5.331; VINES A, 1944, LANDMINES MOZAMBIQUE, P42; 1993, HIDDEN KILLERS GLOBA	12	53	55	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					721	724		10.1016/S0140-6736(95)91501-X	http://dx.doi.org/10.1016/S0140-6736(95)91501-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658871				2022-12-24	WOS:A1995RU81000007
J	KUHN, R; SCHWENK, F; AGUET, M; RAJEWSKY, K				KUHN, R; SCHWENK, F; AGUET, M; RAJEWSKY, K			INDUCIBLE GENE TARGETING IN MICE	SCIENCE			English	Article							INVIVO EXPRESSION; MX GENE; INTERFERON; RECOMBINATION; BACTERIOPHAGE-P1; CELLS; VIRUS	A method of gene targeting that allows the inducible inactivation of a target gene in mice is presented. The method uses an interferon-responsive promoter to control the expression of Cre recombinase, Here, Cre was used to delete a segment of the DNA polymerase beta gene flanked by loxP recombinase recognition sites. Deletion was complete in liver and nearly complete in lymphocytes within a few days, whereas partial deletion was obtained in other tissues. This method can be used for the inducible inactivation of any other gene in vivo.	UNIV ZURICH, INST MOLEC BIOL 1, CH-8093 ZURICH, SWITZERLAND	University of Zurich	KUHN, R (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, D-50931 COLOGNE, GERMANY.		Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Rajewsky, Klaus/0000-0002-6633-6370				ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHANG KC, 1990, ARCH VIROL, V110, P151, DOI 10.1007/BF01311285; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; de Clercq E, 1980, Antibiot Chemother (1971), V27, P251; DOUGHERTY TF, 1952, PHYSIOL REV, V32, P379, DOI 10.1152/physrev.1952.32.4.379; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; GRESSER I, 1977, CELL IMMUNOL, V34, P406, DOI 10.1016/0008-8749(77)90262-3; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; KUHN R, UNPUB; LOHLER J, UNPUB; MELTON DW, 1994, BIOESSAYS, V16, P633, DOI 10.1002/bies.950160907; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STAEHELI P, 1986, MOL CELL BIOL, V6, P4770, DOI 10.1128/MCB.6.12.4770; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	21	1485	1552	1	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1427	1429		10.1126/science.7660125	http://dx.doi.org/10.1126/science.7660125			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660125				2022-12-24	WOS:A1995RT80600046
J	RHODES, J; CHEN, H; HALL, SR; BEESLEY, JE; JENKINS, DC; COLLINS, P; ZHENG, B				RHODES, J; CHEN, H; HALL, SR; BEESLEY, JE; JENKINS, DC; COLLINS, P; ZHENG, B			THERAPEUTIC POTENTIATION OF THE IMMUNE-SYSTEM BY COSTIMULATORY SCHIFF-BASE-FORMING DRUGS	NATURE			English	Article							T-CELL ACTIVATION; ANTIGEN; LYMPHOCYTES; EXPRESSION; RESPONSES; RECEPTOR; CLONING; ACID	IMMUNE responses are orchestrated by CD4 T lymphocytes, which receive a cognitive signal when clonally distributed receptors are occupied by major histocompatibility complex (MHC) class II-bound peptides on antigen-presenting cells (APCs)(1,2). The APCs provide costimulatory signals, through macromolecules such as CD80, that regulate outcomes in terms of T-cell activation or anergy(3-6). We have studied essential complementary chemical events in the form of Schiff base formation between carbonyls and amines that are constitutively expressed on presenting cell and T-cell surfaces(7-9) and provide a new target for manipulation of immune responses(10,11). Here we show that small Schiff base-forming molecules can substitute for the physiological donor of carbonyl groups and provide a costimulatory signal to CD4 Th-cells through a mechanism that activates clofilium-sensitive K+ and Na+ transport. One such molecule, tucaresol, enhances CD4 Th-cell responses, selectively favouring a Th1-type profile of cytokine production, in vivo tucaresol potently enhances CD4 Th-cell priming and CD8 cytotoxic T-cell priming to viral antigens, and has substantial therapeutic activity in murine models of disease.	WELLCOME RES LABS,CORE SUPPORT GRP,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,EXPTL BIOL GRP,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories	RHODES, J (corresponding author), WELLCOME RES LABS,MOLEC IMMUNOL GRP,BECKENHAM BR3 3BS,KENT,ENGLAND.							AMARAL MC, 1993, IMMUNOLOGY, V79, P24; ATTALI B, 1992, J BIOL CHEM, V267, P8650; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GAO XM, 1990, J IMMUNOL, V144, P2883; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; Hall T.A., 1986, PRINCIPLES ANAL ELEC, P219; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Hedrick Stephen M., 1993, P383; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MOSMANN TR, 1992, ANNU REV IMMUNOL, V7, P145; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; RHODES J, 1995, ANN NY ACAD SCI, V754, P169, DOI 10.1111/j.1749-6632.1995.tb44450.x; RHODES J, 1990, J IMMUNOL, V145, P463; RHODES J, 1989, J IMMUNOL, V143, P1482; ROLAN PE, 1993, BRIT J CLIN PHARMACO, V35, P419, DOI 10.1111/j.1365-2125.1993.tb04160.x; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELGRADE MK, 1984, J GEN VIROL, V65, P515, DOI 10.1099/0022-1317-65-3-515; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Weiss Arthur, 1993, P467; Wroblewski Joanna, 1993, P317, DOI 10.1017/CBO9780511600371.023; ZHENG B, 1992, SCIENCE, V256, P1560, DOI 10.1126/science.1598588	25	118	130	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					71	75		10.1038/377071a0	http://dx.doi.org/10.1038/377071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659167				2022-12-24	WOS:A1995RT72500059
J	SCHARSCHMIDT, BF				SCHARSCHMIDT, BF			HEPATITIS-E - A VIRUS IN WAITING	LANCET			English	Editorial Material							NON-B HEPATITIS; NON-A		UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SCHARSCHMIDT, BF (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.							BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KHUROO MS, 1995, LANCET, V315, P1025; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525; LOK ASF, 1994, J HEPATOL, V20, P567, DOI 10.1016/S0168-8278(05)80341-1; NANDA SK, 1995, GASTROENTEROLOGY, V108, P225, DOI 10.1016/0016-5085(95)90028-4; PAUL DA, 1994, J INFECT DIS, V169, P801, DOI 10.1093/infdis/169.4.801; PURDY MA, 1994, GASTROENTEROL CLIN N, V23, P537; REYES GR, 1990, SCIENCE, V24, P1335; VASHWANATHAN R, 1957, INDIAN J MED RES S, V45, P1; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L	11	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					519	520		10.1016/S0140-6736(95)91376-9	http://dx.doi.org/10.1016/S0140-6736(95)91376-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658774				2022-12-24	WOS:A1995RQ98600004
J	SIMON, MN; DEVIRGILIO, C; SOUZA, B; PRINGLE, JR; ABO, A; REED, SI				SIMON, MN; DEVIRGILIO, C; SOUZA, B; PRINGLE, JR; ABO, A; REED, SI			ROLE FOR THE RHO-FAMILY GTPASE CDC42 IN YEAST MATING-PHEROMONE SIGNAL PATHWAY	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE GENE; CELL-DIVISION-CYCLE; MOLECULAR-CLONING; BINDING PROTEIN; HUMAN HOMOLOG; POLARITY; ENCODES; KINASE; G25K	IN the budding yeast Saccharomyces cerevisiae, the process of conjugation of haploid cells of genotype MAT alpha and MAT alpha to form MAT alpha/alpha diploids is triggered by pheromones produced by each mating type. These pheromones stimulate a cellular response by interaction with receptors linked to a heterotrimeric G protein. Although genetic analysis indicates that the pheromone signal is transmitted through the G beta gamma dimer, the initial target(s) of G protein activation remain to be determined. Temperature-sensitive cells with mutations of the CDC24 and CDC42 genes, which are incapable of budding and of generating cell polarity at the restrictive temperature(1-3), are also unable to mate(4). Cdc24 acts as a guanylyl-nucleotide-exchange factor for the Rho-type GTPase Cdc42(5), which has been shown to be a fundamental component of the molecular machinery controlling morphogenesis in eukaryotic cells(6-10). Therefore, the inability of cdc24 and cdc42 mutants to mate has been presumed to be due to a requirement for generation of cell polarity and related morphogenetic events during conjugation, But here we show that Cdc42 has a direct signalling role in the mating-pheromone response between the G protein and the downstream protein kinase cascade.	SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill			De Virgilio, Claudio/B-4707-2012	De Virgilio, Claudio/0000-0001-8826-4323				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BENDER A, 1992, YEAST, V8, P315, DOI 10.1002/yea.320080409; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEN WN, 1993, J BIOL CHEM, V268, P13280; EIBLE R, 1989, BIOTECHNIQUES, V13, P18; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1973, GENETICS, V74, P267; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	30	189	190	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					702	705		10.1038/376702a0	http://dx.doi.org/10.1038/376702a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651520				2022-12-24	WOS:A1995RQ67200064
J	RICHARDSON, R; HURWITZ, B				RICHARDSON, R; HURWITZ, B			DONORS ATTITUDES TOWARDS BODY DONATION FOR DISSECTION	LANCET			English	Article								We report a survey in the UK of potential whole-body donors for dissection. 218 people (age range 19-97 years) answered a postal questionnaire, giving information about themselves, their reasons for donation, attitudes towards the dead body, funeral preferences and medical giving and receiving. In addition to altruism, motives included the wish to avoid funeral ceremonies, to avoid waste, and in a few cases, to evade the expense of a funeral. 44% understood that their bodies would be used as teaching material, 42% for experiments. Whilst 69% believed in one or more supernatural phenomena, only 39% said they were religious. 69% requested cremation after dissection; 2% wanted to be buried. The notion of money incentives to promote donation was overwhelmingly rejected.	ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON, ENGLAND	Imperial College London	RICHARDSON, R (corresponding author), UCL, DEPT ANAT, LONDON WC1 6BT, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Dooley D, 1973, Ann R Coll Surg Engl, V53, P13; Druce M, 1994, CLIN ANAT, V7, P42, DOI [DOI 10.1002/CA.980070108, 10.1002/ca.980070108]; FENNELL S, 1992, NEW ZEAL MED J, V105, P472; HORNE DJD, 1990, ACAD MED, V65, P645, DOI 10.1097/00001888-199010000-00011; HUMPHREY DC, 1973, B NEW YORK ACAD MED, V49, P819; MURRAY TH, 1994, JAMA-J AM MED ASSOC, V272, P814, DOI 10.1001/jama.272.10.814; MURRAY TH, 1987, HASTINGS CENT REP, V17, P30, DOI 10.2307/3562041; RICHARDSON R, 1989, DEATH DISSECTION DES, P95	8	86	86	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 29	1995	346	8970					277	279		10.1016/S0140-6736(95)92166-4	http://dx.doi.org/10.1016/S0140-6736(95)92166-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630248				2022-12-24	WOS:A1995RL75700011
J	HAMILTON, SR; LIU, B; PARSONS, RE; PAPADOPOULOS, N; JEN, J; POWELL, SM; KRUSH, AJ; BERK, T; COHEN, Z; TETU, B; BURGER, PC; WOOD, PA; TAQI, F; BOOKER, SV; PETERSEN, GM; OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; VOGELSTEIN, B; KINZLER, KW				HAMILTON, SR; LIU, B; PARSONS, RE; PAPADOPOULOS, N; JEN, J; POWELL, SM; KRUSH, AJ; BERK, T; COHEN, Z; TETU, B; BURGER, PC; WOOD, PA; TAQI, F; BOOKER, SV; PETERSEN, GM; OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; VOGELSTEIN, B; KINZLER, KW			THE MOLECULAR-BASIS OF TURCOTS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; NONPOLYPOSIS COLORECTAL-CANCER; AUTOSOMAL DOMINANT; GARDNERS-SYNDROME; COLON-CANCER; BRAIN-TUMORS; MUTATIONS; GENE; LOCUS; IDENTIFICATION	Background. Turcot's syndrome is characterized clinically by the concurrence of a primary brain tumor and multiple colorectal adenomas. We attempted to define the syndrome at the molecular level. Methods. Fourteen families with Turcot's syndrome identified in two registries and the family originally described by Turcot and colleagues were studied. Germ-line mutations in the adenomatous polyposis coli (APC) gene characteristic of familial adenomatous polyposis were evaluated, as well as DNA replication errors and germline mutations in nucleotide mismatch-repair genes characteristic of hereditary nonpolyposis colorectal cancer. In addition, a formal risk analysis for brain tumors in familial adenomatous polyposis was performed with a registry data base. Results. Genetic abnormalities were identified in 13 of the 14 registry families. Germ-line APC mutations were detected in 10. The predominant brain tumor in these 10 families was medulloblastoma (11 of 14 patients, or 79 percent), and the relative risk of cerebellar medulloblastoma in patients with familial adenomatous polyposis was 92 times that in the general population (95 percent confidence interval, 29 to 269; P<0.001). In contrast, the type of brain tumor in the other four families was glioblastoma multiforme. The glioblastomas and colorectal tumors in three of these families and in the original family studied by Turcot had replication errors characteristic of hereditary nonpolyposis colorectal cancer. In addition, germ-line mutations in the mismatch-repair gene hMLH1 or hPMS2 were found in two families. Conclusions. The association between brain tumors and multiple colorectal adenomas can result from two distinct types of germ-line defects: mutation of the APC gene or mutation of a mismatch-repair gene. Molecular diagnosis may contribute to the appropriate care of affected patients.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV MED GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,DIV NEUROPATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; MT SINAI HOSP,FAMILIAL GASTROINTESTINAL CANC REGISTRY,TORONTO,ON M5G 1X5,CANADA; HOTEL DIEU QUEBEC,ANAT PATHOL LAB,QUEBEC CITY,PQ,CANADA; STRATTON VET AFFAIRS MED CTR,DEPT MED,DIV MED ONCOL,ALBANY,NY; ALBANY MED COLL,ALBANY,NY	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Laval University; Albany Medical College	HAMILTON, SR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,DIV GASTROINTESTINAL & LIVER PATHOL,ROSS BLDG,RM 632,BALTIMORE,MD 21205, USA.		Papadopoulos, Nickolas/K-7272-2012	Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345, R01CA045831, R01CA047527] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345, CA47527, CA45831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAUGHMAN FA, 1969, NEW ENGL J MED, V281, P1345, DOI 10.1056/NEJM196912112812407; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BLAIR NP, 1980, AM J OPHTHALMOL, V90, P661, DOI 10.1016/S0002-9394(14)75133-5; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUSSEY HJR, 1975, FAMILIAL POLYPOSIS C, P23; BUSSEY HJR, 1975, FAMILIAL POLYPOSIS C, P10; COHEN SB, 1982, J MED GENET, V19, P193, DOI 10.1136/jmg.19.3.193; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COSTA OL, 1987, DIS COLON RECTUM, V30, P391, DOI 10.1007/BF02555461; CRAIL H W, 1949, U S Nav Med Bull, V49, P123; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, CELL, V77, pA166; GIARDIELLO FM, 1991, J PEDIATR-US, V119, P766, DOI 10.1016/S0022-3476(05)80297-5; GIARDIELLO FM, 1993, GUT, V34, P1394, DOI 10.1136/gut.34.10.1394; GIARDIELLO FM, 1993, GASTROENTEROLOGY, V105, P1550, DOI 10.1016/0016-5085(93)90164-8; GIARDIELLO FM, 1991, GUT, V32, P1170, DOI 10.1136/gut.32.10.1170; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GURBUZ AK, 1994, GUT, V35, P377, DOI 10.1136/gut.35.3.377; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; HAMILTON SR, 1979, GASTROENTEROLOGY, V77, P1252; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ITOH H, 1993, INT J COLORECTAL DIS, V8, P87, DOI 10.1007/BF00299334; JARVIS L, 1988, DIS COLON RECTUM, V31, P907, DOI 10.1007/BF02554859; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KIKUCHI T, 1993, CANCER RES, V53, P957; KIM HG, 1994, AM J PATHOL, V145, P148; KINGSTON JE, 1983, ARCH DIS CHILD, V58, P959, DOI 10.1136/adc.58.12.959; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KROPILAK M, 1989, DIS COLON RECTUM, V32, P778, DOI 10.1007/BF02562128; LASSER DM, 1994, NEUROLOGY, V44, P1083, DOI 10.1212/WNL.44.6.1083; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEWIS JH, 1983, CANCER, V51, P524, DOI 10.1002/1097-0142(19830201)51:3<524::AID-CNCR2820510326>3.0.CO;2-I; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MCKUSICK VA, 1962, JAMA-J AM MED ASSOC, V182, P271, DOI 10.1001/jama.1962.03050420047012; MINAMI T, 1990, JPN J MED, V29, P391; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NEWTON HB, 1991, CANCER, V68, P1633, DOI 10.1002/1097-0142(19911001)68:7<1633::AID-CNCR2820680728>3.0.CO;2-1; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARAF F, 1994, GASTROEN CLIN BIOL, V18, P297; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PIERCE E R, 1970, Clinical Genetics, V1, P65; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RADIN DR, 1984, AM J ROENTGENOL, V142, P475, DOI 10.2214/ajr.142.3.475; ROCHLITZ CF, 1993, BRIT J CANCER, V68, P519, DOI 10.1038/bjc.1993.379; ROSENFELD M, 1991, Neurology, V41, P304; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; RUTZ HP, 1991, J NEUROSURG, V74, P813, DOI 10.3171/jns.1991.74.5.0813; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TITHECOTT GA, 1989, J PEDIATR SURG, V24, P1189, DOI 10.1016/S0022-3468(89)80117-4; TOPS CMJ, 1992, AM J MED GENET, V43, P888, DOI 10.1002/ajmg.1320430528; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; TURCOT J, 1959, Dis Colon Rectum, V2, P465, DOI 10.1007/BF02616938; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#	72	781	821	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					839	847		10.1056/NEJM199503303321302	http://dx.doi.org/10.1056/NEJM199503303321302			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7661930				2022-12-24	WOS:A1995QP22800002
J	BERBERIAN, L; GOODGLICK, L; KIPPS, TJ; BRAUN, J				BERBERIAN, L; GOODGLICK, L; KIPPS, TJ; BRAUN, J			IMMUNOGLOBULIN-V(H)3 GENE-PRODUCTS - NATURAL LIGANDS FOR HIV GP120	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CROSS-REACTIVE IDIOTYPE; B-CELL ACTIVATION; STAPHYLOCOCCAL PROTEIN; T-CELLS; CD4 RECEPTOR; INFECTION; ANTIGEN; ANTIBODY; AUTOANTIBODIES	Infection with human immunodeficiency virus-type 1 (HIV-1) depletes T cells expressing CD4 and B cells expressing immunoglobulin (Ig) V(H)3 gene products. A subpopulation of normal B cells from non-HIV-infected individuals was shown to bind to HIV gp120 by means of membrane Ig; most of these B cells expressed V(H)3 family Ig. Serum V(H)3 IgM from uninfected individuals also avidly bound gp120. Finally, gp120 selectively induced Ig secretion by V(H)3 B cells, indicating that the binding of gp120 functionally activated these cells. These results indicate that naturally occurring V(H)3 Ig is a second ligand for gp120 and a candidate superantigen for V(H)3 B cells.	UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Diego				Braun, Jonathan/0000-0003-1646-2974	NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER; NCI NIH HHS [CA12800] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; NIGMS NIH HHS [GM08375] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; AULT KA, 1977, J IMMUNOL, V119, P327; AXELROD O, 1991, BLOOD, V77, P1484; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BASS HZ, 1992, CLIN IMMUNOL IMMUNOP, V64, P63, DOI 10.1016/0090-1229(92)90060-2; BERBERIAN L, 1991, BLOOD, V78, P175; BRAUN J, 1992, J CLIN INVEST, V89, P1395, DOI 10.1172/JCI115728; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; CASALI P, 1989, IMMUNOL TODAY, V10, P364, DOI 10.1016/0167-5699(89)90268-5; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CROWLEY JJ, 1990, MOL IMMUNOL, V27, P87, DOI 10.1016/0161-5890(90)90063-6; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GOODGLICK L, UNPUB; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HAIGWOOD NL, 1990, VACCINES 90, P313; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; JEFFERIES LC, 1992, CLIN IMMUNOL IMMUNOP, V65, P119, DOI 10.1016/0090-1229(92)90214-9; JORDAN CA, 1991, J VIROL, V65, P736, DOI 10.1128/JVI.65.2.736-742.1991; KIRKHAM PM, 1992, EMBO J, V11, P603, DOI 10.1002/j.1460-2075.1992.tb05092.x; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LYDYARD PM, 1990, SCAND J IMMUNOL, V32, P709, DOI 10.1111/j.1365-3083.1990.tb03214.x; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARTIN T, 1992, J EXP MED, V175, P983, DOI 10.1084/jem.175.4.983; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; OLEE T, 1991, J CLIN INVEST, V88, P193, DOI 10.1172/JCI115277; PASCUAL V, 1991, Current Biology, V1, P315, DOI 10.1016/0960-9822(91)90097-G; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SASSO EH, 1989, J IMMUNOL, V142, P2778; SASSO EH, 1991, J IMMUNOL, V147, P1877; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; SHOKRI F, 1991, J IMMUNOL, V146, P936; STEIMER KS, 1988, VACCINES, V88, P347; SUTOR GC, 1992, J IMMUNOL, V149, P1452; VALLESAYOUB Y, 1990, BLOOD, V76, P17; WALTER MA, 1991, J EXP MED, V174, P335, DOI 10.1084/jem.174.2.335; YOUNG F, 1990, J IMMUNOL, V145, P2545	45	261	271	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1993	261	5128					1588	1591		10.1126/science.7690497	http://dx.doi.org/10.1126/science.7690497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	7690497				2022-12-24	WOS:A1993LX47400033
J	NGUYEN, M; STRUBEL, NA; BISCHOFF, J				NGUYEN, M; STRUBEL, NA; BISCHOFF, J			A ROLE FOR SIALYL LEWIS-X/A GLYCOCONJUGATES IN CAPILLARY MORPHOGENESIS	NATURE			English	Article							LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE LIGAND; CELL-ADHESION; ACTIVATION ANTIGEN; E-SELECTIN; ELAM-1; ENDOTHELIUM; RECOGNITION; INDUCTION; INVITRO	To identify cell adhesion molecules required for angiogenesis, we used an in vitro model in which bovine capillary endothelial cells can be induced to form capillary-like tubes. Monoclonal antibodies directed against the carbohydrate epitopes sialyl Lewis-X and sialyl Lewis-A inhibited capillary formation. We postulated that a member of the selectin family of adhesion molecules may be involved in capillary formation because these proteins bind to sialyl Lewis-X/A-containing ligands. We isolated a 2.8-kilobase complementary DNA from a bovine capillary endothelial cell cDNA library which encodes a polypeptide with 71% identity to human E-selectin. We report here that antibody directed against the bovine E-selectin inhibited capillary formation, suggesting that in addition to its role in leukocyte adhesion to endothelium, a form of E-selectin is involved in capillary morphogenesis.	CHILDRENS HOSP MED CTR,SURG RES LAB,300 LONGWOOD AVE,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974; Strubel, Naomi/0000-0002-4394-2108				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; Heusser C H, 1981, Methods Enzymol, V73, P406; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MESSADI DV, 1987, J IMMUNOL, V139, P1557; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STRUBEL NA, 1993, BIOCHEM BIOPH RES CO, V192, P338, DOI 10.1006/bbrc.1993.1420; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	27	207	214	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					267	269		10.1038/365267a0	http://dx.doi.org/10.1038/365267a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	7690465				2022-12-24	WOS:A1993LX47100059
J	KETCHEM, RR; HU, W; CROSS, TA				KETCHEM, RR; HU, W; CROSS, TA			HIGH-RESOLUTION CONFORMATION OF GRAMICIDIN-A IN A LIPID BILAYER BY SOLID-STATE NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRANSMEMBRANE ION-CHANNEL; PHASE PEPTIDE-SYNTHESIS; C-13 CHEMICAL-SHIFT; RIGHT-HANDED HELIX; PHOSPHOLIPID-BILAYERS; MEMBRANE-PROTEINS; SIDE-CHAINS; TRYPTOPHAN; SPECTROSCOPY	Solid-state nuclear magnetic resonance spectroscopy of uniformly aligned preparations of gramicidin A in lipid bilayers has been used to elucidate a high-resolution dimeric structure of the cation channel conformation solely on the basis of the amino acid sequence and 144 orientational constraints. This initial structure defines the helical pitch as single-stranded, fixes the number of residues per turn at six to seven, specifies the helix sense as right-handed, and identifies the hydrogen bonds. Refinement of this initial structure yields reasonable hydrogen-bonding distances with only minimal changes in the torsion angles.	FLORIDA STATE UNIV,INST MOLEC BIOPHYS,NATL HIGH MAGNET FIELD LAB,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University			Ketchem, Randal/AAB-4372-2020; Ketchem, Randal R/K-2258-2017	Ketchem, Randal/0000-0002-7821-2682; Ketchem, Randal R/0000-0002-7821-2682; Cross, Timothy/0000-0002-9413-0505	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023007] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER MD, 1991, BIOCHEMISTRY-US, V30, P8830, DOI 10.1021/bi00100a015; BOUCHARD M, 1993, BIOPHYS J, V64, pA61; BYSTROV VF, 1987, B MAGN RESON, V8, P84; CHIU SW, 1993, BIOPHYS J, V64, P98, DOI 10.1016/S0006-3495(93)81344-4; CORNELL BA, 1988, BIOPHYS J, V53, P67, DOI 10.1016/S0006-3495(88)83066-2; Deisenhofer, 1990, CURRENT TOPICS MEMBR, V36, P53; FIELDS CG, 1989, INT J PEPT PROT RES, V33, P298; FIELDS CG, 1989, THESIS FLORIDA STATE; FIELDS GB, 1988, P NATL ACAD SCI USA, V85, P1384, DOI 10.1073/pnas.85.5.1384; GARBOW JR, 1993, J AM CHEM SOC, V115, P238, DOI 10.1021/ja00054a034; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HING AW, 1990, BIOCHEMISTRY-US, V29, P4144, DOI 10.1021/bi00469a018; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; KATSARAS J, 1992, BIOPHYS J, V61, P827, DOI 10.1016/S0006-3495(92)81888-X; KILLIAN JA, 1992, BIOCHEMISTRY-US, V31, P11283, DOI 10.1021/bi00161a004; KINSEY RA, 1981, J BIOL CHEM, V256, P9028; KVICK A, 1977, ACTA CRYSTALLOGR B, V33, P3796, DOI 10.1107/S0567740877012102; LANGS DA, 1991, P NATL ACAD SCI USA, V88, P5345, DOI 10.1073/pnas.88.12.5345; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LEE KC, IN PRESS BIOPHYS J; LOGRASSO PV, 1989, J AM CHEM SOC, V111, P1910, DOI 10.1021/ja00187a072; LOMIZE AL, 1992, BIOORG KHIM+, V18, P182; MAI W, 1993, PROTEIN SCI, V2, P532; NICHOLSON LK, 1989, BIOCHEMISTRY-US, V28, P9379, DOI 10.1021/bi00450a019; PROSSER RS, 1991, BIOCHEMISTRY-US, V30, P4687, DOI 10.1021/bi00233a008; ROUX B, 1988, BIOPHYS J, V53, P297, DOI 10.1016/S0006-3495(88)83107-2; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; SEPAROVIC F, 1991, CHEM PHYS LETT, V181, P157, DOI 10.1016/0009-2614(91)90348-D; SMITH R, 1989, BIOPHYS J, V56, P307, DOI 10.1016/S0006-3495(89)82677-3; TAKEUCHI H, 1990, BIOCHEMISTRY-US, V29, P1572, DOI 10.1021/bi00458a031; TENG Q, 1992, J AM CHEM SOC, V114, P5312, DOI 10.1021/ja00039a048; TENG Q, 1991, J MOL BIOL, V218, P607, DOI 10.1016/0022-2836(91)90705-B; THOMPSON LK, 1992, BIOCHEMISTRY-US, V31, P7931, DOI 10.1021/bi00149a026; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WEINSTEIN S, 1979, P NATL ACAD SCI USA, V76, P4230, DOI 10.1073/pnas.76.9.4230; ZHANG ZL, 1992, BIOCHEMISTRY-US, V31, P8822, DOI 10.1021/bi00152a019	37	624	628	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1457	1460		10.1126/science.7690158	http://dx.doi.org/10.1126/science.7690158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	7690158				2022-12-24	WOS:A1993LW54900036
J	BOUGHTONSMITH, NK; EVANS, SM; HAWKEY, CJ; COLE, AT; BALSITIS, M; WHITTLE, BJR; MONCADA, S				BOUGHTONSMITH, NK; EVANS, SM; HAWKEY, CJ; COLE, AT; BALSITIS, M; WHITTLE, BJR; MONCADA, S			NITRIC-OXIDE SYNTHASE ACTIVITY IN ULCERATIVE-COLITIS AND CROHNS-DISEASE	LANCET			English	Note								Excessive nitric oxide (NO) production by an isoform of NO synthase that can be induced by inflammatory stimuli leads to changes in vascular permeability and to tissue injury. We measured NO synthase activities in mucosa and muscle from the colons of control patients (n=11) and patients with ulcerative colitis (6) or Crohn's disease (4). NO synthase activity in colonic mucosa of ulcerative colitis patients was 0.55 (median interquartile range 0.32-0.57) nmol/min per g tissue, which was about eightfold higher than the value in control mucosa, with no individual overlap (p<0.001). With colonic muscle there was no difference in NO synthase activity between ulcerative colitis patients and controls. In the patients with Crohn's disease, mucosal NO synthase activity did not differ from control values and activity in the colonic muscle was low. Thus, induction of colonic NO synthase may be involved in the mucosal vasodilation and increased vascular permeability of active ulcerative colitis, and could also contribute to the impaired motility that accompanies toxic dilation.	WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; University of Nottingham								BOUGHTONSMITH NK, 1992, BRIT J PHARMACOL, V107, pP79; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; JENKINS D, 1990, GUT, V31, P426, DOI 10.1136/gut.31.4.426; MAHIDA YR, 1989, GUT, V30, P835, DOI 10.1136/gut.30.6.835; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; WAKEFIELD AJ, 1989, LANCET, V2, P1057	10	414	426	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					338	340		10.1016/0140-6736(93)91476-3	http://dx.doi.org/10.1016/0140-6736(93)91476-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	7687730				2022-12-24	WOS:A1993LQ86800014
J	CHEN, TY; PENG, YW; DHALLAN, RS; AHAMED, B; REED, RR; YAU, KW				CHEN, TY; PENG, YW; DHALLAN, RS; AHAMED, B; REED, RR; YAU, KW			A NEW SUBUNIT OF THE CYCLIC NUCLEOTIDE-GATED CATION CHANNEL IN RETINAL RODS	NATURE			English	Article							VERTEBRATE PHOTORECEPTORS; ACTIVATED CONDUCTANCE; FUNCTIONAL EXPRESSION; ION CHANNELS; TEA BLOCKADE; K+ CHANNELS; GMP; EXCITATION; SEGMENTS; CALCIUM	RETINAL rods respond to light with a membrane hyperpolarization produced by a G-protein-mediated signalling cascade that leads to cyclic GMP hydrolysis and the consequent closure of a cGMP-gated channel that is open in darkness1-7. A protein that forms this channel has recently been purified from bovine retina8 and molecularly cloned9, suggesting that the native cGMP-gated channel might be a homo-oligomer10. Here we report the cloning of another protein from human retina which has only about 30% overall identity to the rod channel subunit. This protein, immunocytochemically localized to rod outer segments, does not form functional channels by itself. However, when co-expressed with the cloned human rod channel protein'', it introduces rapid flickers to the channel openings that are characteristic of the native channel12-16. The hetero-oligomeric channel is also highly sensitive to the blocker L-CiS-diltiazem, like the native channel15,17,18. This new protein thus seems to be another subunit of the native rod channel. The hetero-oligomeric nature of the rod channel means that it is no exception to a common motif shared by other ligand-gated channels.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOMED ENGN, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								BEAN BP, 1990, J NEUROSCI, V10, P11; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAYNES LW, 1992, J GEN PHYSIOL, V100, P783, DOI 10.1085/jgp.100.5.783; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KAUPP UB, 1992, REV PHYSL, V54, P153; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LUHRING H, 1990, NATO ADV SCI I A-LIF, V194, P169; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATTHEWS G, 1986, J NEUROSCI, V6, P2521; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; QUANDT FN, 1991, NEUROSCIENCE, V42, P629, DOI 10.1016/0306-4522(91)90032-J; SHIELLS RA, 1992, P ROY SOC B-BIOL SCI, V247, P21, DOI 10.1098/rspb.1992.0004; STERN JH, 1986, P NATL ACAD SCI USA, V83, P1163, DOI 10.1073/pnas.83.4.1163; STRYER L, 1991, J BIOL CHEM, V266, P10711; TORRE V, 1992, P ROY SOC B-BIOL SCI, V250, P209, DOI 10.1098/rspb.1992.0151; WOHLFART P, 1992, J BIOL CHEM, V267, P644; Yau K W, 1991, Curr Opin Neurobiol, V1, P252, DOI 10.1016/0959-4388(91)90086-M; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1986, MEMBRANE CONTROL CEL, P343; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	38	299	305	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1993	362	6422					764	767		10.1038/362764a0	http://dx.doi.org/10.1038/362764a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	7682292				2022-12-24	WOS:A1993KY45000061
J	OKSENBERG, JR; PANZARA, MA; BEGOVICH, AB; MITCHELL, D; ERLICH, HA; MURRAY, RS; SHIMONKEVITZ, R; SHERRITT, M; ROTHBARD, J; BERNARD, CCA; STEINMAN, L				OKSENBERG, JR; PANZARA, MA; BEGOVICH, AB; MITCHELL, D; ERLICH, HA; MURRAY, RS; SHIMONKEVITZ, R; SHERRITT, M; ROTHBARD, J; BERNARD, CCA; STEINMAN, L			SELECTION FOR T-CELL RECEPTOR V-BETA-D-BETA-J-BETA GENE REARRANGEMENTS WITH SPECIFICITY FOR A MYELIN BASIC-PROTEIN PEPTIDE IN BRAIN-LESIONS OF MULTIPLE-SCLEROSIS	NATURE			English	Article							NONRADIOACTIVE OLIGONUCLEOTIDE PROBES; AMPLIFIED DNA; SEQUENCE; POLYMORPHISM	MULTIPLE sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system in which a restricted cellular immune response has been observed. In order to establish whether such T cell responses are likely to be antigen-specific particularly with regard to myelin basic protein (MBP), we analysed T-cell receptor (TCR) gene rearrangements directly from MS brain plaques, using the polymerase chain reaction on reverse transcribed messenger RNA, and compared these with TCR of previously described MBP-specific T cell clones from MS and the rat model experimental allergic encephalomyelitis. Rearranged Vbeta5.2 genes were detected in the brains of all patients who were HLA DRB1*1501, DQA1*0102, DQB1*0602, DPB1*0401. The Vbeta5.2-Dbeta-Jbeta sequences in these MS brain plaques revealed five motifs. One of the common motifs was identical to that described for the VDJ region of a Vbeta5.2 T-cell clone. This clone was from an MS patient who was HLA DRB1*1501, DQB1*0602, DPB1*0401, and it was cytotoxic towards targets containing the MBP peptide 89-106 (ref. 1). The deduced amino-acid sequence of this VDJ rearrangement, Leu-Arg-Gly, has also been described in rat T cells cloned from experimental allergic encephalomyelitis lesions, which are specific for MBP peptide 87-99 (ref. 2). VDJ sequences with specificity for this MBP epitope constitute a large fraction (40%) of the TCR Vbeta5.2 N(D)N rearrangements in MS lesions. The capacity of rat T cells with these VDJ sequences to cause experimental allergic encephalomyelitis2 and the prevalence of such sequences in demyelinated human lesions indicate that T cells with this rearranged TCR may be critical in MS.	ROCHE MOLEC SYST,DEPT HUMAN GENET,EMERYVILLE,CA 94608; ROCKY MT MS CTR,ENGLEWOOD,CO 80150; LA TROBE UNIV,NEUROIMMUNOL LAB,BUNDOORA,VIC 3083,AUSTRALIA; IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304	La Trobe University	OKSENBERG, JR (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305, USA.			Steinman, Lawrence/0000-0002-2437-2250; Panzara, Michael/0000-0003-2810-4832				BEGOVICH AB, 1992, J IMMUNOL, V148, P249; BUGAWAN TL, 1991, IMMUNOGENETICS, V33, P163, DOI 10.1007/BF01719235; BUGAWAN TL, 1990, IMMUNOGENETICS, V32, P231; GAUTAM AM, 1992, J EXP MED, V176, P605, DOI 10.1084/jem.176.2.605; GIEGERICH G, 1992, EUR J IMMUNOL, V22, P753, DOI 10.1002/eji.1830220319; GOLD DP, 1992, J IMMUNOL, V148, P1712; HELMUTH R, 1990, AM J HUM GENET, V47, P515; JAHNKE U, 1985, SCIENCE, V229, P282, DOI 10.1126/science.2409602; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; MORAHAN G, 1989, IMMUNOGENETICS, V30, P311, DOI 10.1007/BF02421337; OKSENBERG JR, 1990, CURR OPIN IMMUNOL, V2, P619, DOI 10.1016/0952-7915(90)90021-8; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; PANZARA MA, 1992, BIOTECHNIQUES, V12, P728; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; TERASAKI PI, 1986, SCIENCE, V193, P1245; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549	18	422	433	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					68	70		10.1038/362068a0	http://dx.doi.org/10.1038/362068a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	7680433				2022-12-24	WOS:A1993KP97600062
J	HOEY, T; WEINZIERL, ROJ; GILL, G; CHEN, JL; DYNLACHT, BD; TJIAN, R				HOEY, T; WEINZIERL, ROJ; GILL, G; CHEN, JL; DYNLACHT, BD; TJIAN, R			MOLECULAR-CLONING AND FUNCTIONAL-ANALYSIS OF DROSOPHILA TAF110 REVEAL PROPERTIES EXPECTED OF COACTIVATORS	CELL			English	Article							TRANSCRIPTION FACTOR; SYNERGISTIC ACTIVATION; PREINITIATION COMPLEX; BINDING-PROTEIN; TFIID COMPLEX; GENE; SP1; INVITRO; EXPRESSION; MECHANISM	The general transcription factor TFIID is a multiprotein complex containing the TATA-binding protein and several associated factors (TAFs), some of which may function as coactivators that are essential for activated, but not basal, transcription. Here we describe the isolation and characterization of the first gene encoding a TAF protein. The deduced amino acid sequence of TAF110 revealed the presence of several glutamine- and serine/threonine-rich regions reminiscent of the protein-protein interaction domains of the regulatory transcription factor Spl that are involved in transcription activation and multimerization. In both Drosophila cells and yeast, TAF110 specifically interacts with the glutamine-rich activation domains of Sp1. Moreover, purified Spl selectively binds recombinant TAF110 in vitro. These findings taken together suggest that TAF110 may function as a coactivator by serving as a site of protein-protein contact between activators like Sp1 and the TFIID complex.			HOEY, T (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Weinzierl, Robert/0000-0003-4095-9921				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; DYNLACHT BD, 1991, GENE DEV, V66, P563; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SKELLY S, 1987, P NATL ACAD SCI USA, V84, P8365, DOI 10.1073/pnas.84.23.8365; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	53	551	563	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					247	260		10.1016/0092-8674(93)90664-C	http://dx.doi.org/10.1016/0092-8674(93)90664-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678780				2022-12-24	WOS:A1993KK03800009
J	NODWELL, JR; GREENBLATT, J				NODWELL, JR; GREENBLATT, J			RECOGNITION OF BOXA ANTITERMINATOR RNA BY THE ESCHERICHIA-COLI ANTITERMINATION FACTORS NUSB AND RIBOSOMAL-PROTEIN S10	CELL			English	Article							ESCHERICHIA-COLI; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; ANTI-TERMINATION; NUCLEOTIDE-SEQUENCE; GENE PROTEIN; TRANSCRIPTION; REGION; SITE; OPERON	The boxA sequences of the E. coli ribosomal RNA (rrn) operons are sufficient to cause RNA polymerase to read through Rho-dependent transcriptional terminators. We show that a complex of the transcription antitermination factors NusB and ribosomal protein S10 interacts specifically with box A RNA. Neither Nus B nor S10 binds boxA RNA on its own, and neither NusA nor NusG affects the interaction of the NusB-S10 complex with boxA RNA. Mutations in boxA that impair its anti-termination activity compromise its interaction with NusB and S10, suggesting that ribosomal protein S10 regulates the synthesis of ribosomal RNA in bacteria. RNA containing the closely related boxA sequence from the bacteriophage lambda nutR site is not stably bound by NusB and S10. This probably explains why antitermination in phage lambda depends on the phage lambda N protein and the boxB component of the nut site, in addition to boxA.			NODWELL, JR (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA.							ALBRECHTSEN B, 1990, J MOL BIOL, V213, P123, DOI 10.1016/S0022-2836(05)80125-1; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; BREWSTER JM, 1981, J BACTERIOL, V148, P897, DOI 10.1128/JB.148.3.897-903.1981; DOELLING JH, 1989, NUCLEIC ACIDS RES, V17, P5565, DOI 10.1093/nar/17.14.5565; FRANKLIN NC, 1985, J MOL BIOL, V181, P75, DOI 10.1016/0022-2836(85)90325-0; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; FRIEDMAN DI, 1983, CELL, V34, P143, DOI 10.1016/0092-8674(83)90144-7; FRIEDMAN DI, 1976, VIROLOGY, V73, P119, DOI 10.1016/0042-6822(76)90066-0; GEORGOPOULOS CP, 1980, MOL GEN GENET, V179, P55, DOI 10.1007/BF00268446; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1984, CAN J BIOCHEM CELL B, V62, P79, DOI 10.1139/o84-012; GREENBLATT J, 1987, RNA POLYM REGULATION, P357; HOLBEN WE, 1984, P NATL ACAD SCI-BIOL, V81, P6789, DOI 10.1073/pnas.81.21.6789; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LI J, 1992, J BIOL CHEM, V267, P6012; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; MASON S, 1992, IN PRESS J BIOL CHEM; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MORGAN EA, 1986, J BACTERIOL, V168, P1; MORGAN EA, 1980, CELL, V21, P257, DOI 10.1016/0092-8674(80)90133-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OLINS PO, 1981, CELL, V26, P205, DOI 10.1016/0092-8674(81)90303-2; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; OLSON ER, 1982, CELL, V31, P61, DOI 10.1016/0092-8674(82)90405-6; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SCHAUER AT, 1987, J MOL BIOL, V194, P679, DOI 10.1016/0022-2836(87)90245-2; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SHARROCK RA, 1984, J BACTERIOL, V163, P704; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; WHALEN W A, 1990, New Biologist, V2, P975; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4515	42	132	135	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					261	268		10.1016/0092-8674(93)90665-D	http://dx.doi.org/10.1016/0092-8674(93)90665-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678781				2022-12-24	WOS:A1993KK03800010
J	PFEIFER, JD; WICK, MJ; ROBERTS, RL; FINDLAY, K; NORMARK, SJ; HARDING, CV				PFEIFER, JD; WICK, MJ; ROBERTS, RL; FINDLAY, K; NORMARK, SJ; HARDING, CV			PHAGOCYTIC PROCESSING OF BACTERIAL-ANTIGENS FOR CLASS-I MHC PRESENTATION TO T-CELLS	NATURE			English	Article							MEMBRANE PROTEIN; LYMPHOCYTES-T; SALMONELLA; INDUCTION; MOLECULES; TOPOLOGY; SURFACE; EPITOPE; INVIVO	CLASS I major histocompatibility complex (MHC) molecules present antigens that are produced within the presenting cell or penetrate from the vacuolar system into the cytosol for processing. Most studies of exogenous antigen processing have used soluble antigens, which are not efficiently presented by class I MHC molecules1 and do not elicit CD8 T-cell responses in vivo. But particulate antigen preparations with no known mechanism for cytosolic penetration can also elicit CD8 T-cell responses in vivo2-7. We report here that phagocytosis of bacteria with no mechanism for cytosolic penetration also results in presentation of bacterial antigens by class I MHC molecules. Moreover, this mechanism is resistant to cycloheximide and Brefeldin A, which block the classical class I processing pathway. These results suggest a novel vacuolar class I processing pathway for exogenous phagocytic antigens.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; ARNQVIST A, 1992, MOL MICROBIOL, V6, P2443; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRUNT LM, 1990, J IMMUNOL, V145, P3540; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHARBIT A, 1986, EMBO J, V5, P3029, DOI 10.1002/j.1460-2075.1986.tb04602.x; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; COLLINS DS, 1992, J IMMUNOL, V148, P3336; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FARRELL JP, 1989, J IMMUNOL, V142, P2052; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; GAO XM, 1992, INFECT IMMUN, V60, P3780, DOI 10.1128/IAI.60.9.3780-3789.1992; GOODING LR, 1980, J IMMUNOL, V124, P1258; GRANT EP, 1992, J IMMUNOL, V148, P13; HARDING CV, 1992, EUR J IMMUNOL, V22, P1865, DOI 10.1002/eji.1830220728; HARDING CV, 1991, J IMMUNOL, V147, P2860; HARDING CV, 1991, J IMMUNOL, V147, P767; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MISRA R, 1988, J BACTERIOL, V170, P528, DOI 10.1128/jb.170.2.528-533.1988; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; PFEIFER JD, 1992, J IMMUNOL, V149, P2576; REDDY R, 1992, J IMMUNOL, V148, P1585; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; SARMIENTO M, 1982, IMMUNOL REV, V68, P133; SMITH JD, 1992, P NATL ACAD SCI USA, V89, P7767, DOI 10.1073/pnas.89.16.7767	31	561	586	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					359	362		10.1038/361359a0	http://dx.doi.org/10.1038/361359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	7678924				2022-12-24	WOS:A1993KJ59000060
J	NISHIZAKA, T; MIYATA, H; YOSHIKAWA, H; ISHIWATA, S; KINOSITA, K				NISHIZAKA, T; MIYATA, H; YOSHIKAWA, H; ISHIWATA, S; KINOSITA, K			UNBINDING FORCE OF A SINGLE MOTOR MOLECULE OF MUSCLE MEASURED USING OPTICAL TWEEZERS	NATURE			English	Article							ACTIN FILAMENT; DIRECTION; MYOSIN; INVITRO; RIGOR; SPEED	THE unbinding and rebinding of motor proteins and their substrate filaments are the main components of sliding movement(1). We have measured the unbinding force between an actin filament and a single motor molecule of muscle, myosin, in the absence of ATP, by pulling the filament with optical tweezers(2). The unbinding force could be measured repeatedly on the same molecule, and was independent of the number of measurements and the direction of the imposed loads within a range of +/-90 degrees. The average unbinding force was 9.2 +/- 4.4 pN, only a few times larger than the sliding force(3-5) but an order of magnitude smaller than other intermolecular forces(6,7). From its kinetics(8) we suggest that unbinding occurs sequentially at the molecular interface, which is an inherent property of motor molecules.	WASEDA UNIV,SCH SCI & ENGN,DEPT PHYS,SHINJUKU KU,TOKYO 169,JAPAN; WASEDA UNIV,ADV RES CTR SCI & ENGN,SHINJUKU KU,TOKYO 169,JAPAN	Waseda University; Waseda University								ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; ISHIWATA S, 1993, PHASE TRANSIT, V45, P105, DOI 10.1080/01411599308223720; KINOSITA K, 1991, J CELL BIOL, V115, P67, DOI 10.1083/jcb.115.1.67; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; MARSTON SB, 1982, BIOCHEM J, V203, P453, DOI 10.1042/bj2030453; MIYATA H, 1995, BIOPHYS J, V68, pS286; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; NISHIZAKA T, 1993, NATURE, V361, P269, DOI 10.1038/361269a0; NISHIZAKA T, 1995, BIOPHYS J, V68, pS75; SCHOENBERG M, 1985, BIOPHYS J, V48, P863, DOI 10.1016/S0006-3495(85)83847-9; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; TAWADA K, 1986, J MUSCLE RES CELL M, V7, P339, DOI 10.1007/BF01753655; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; YAMADA A, 1990, J BIOCHEM-TOKYO, V108, P341, DOI 10.1093/oxfordjournals.jbchem.a123203	22	202	204	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					251	254		10.1038/377251a0	http://dx.doi.org/10.1038/377251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675112				2022-12-24	WOS:A1995RV87200046
J	SHANER, A; ECKMAN, TA; ROBERTS, LJ; WILKINS, JN; TUCKER, DE; TSUANG, JW; MINTZ, J				SHANER, A; ECKMAN, TA; ROBERTS, LJ; WILKINS, JN; TUCKER, DE; TSUANG, JW; MINTZ, J			DISABILITY INCOME, COCAINE USE, AND REPEATED HOSPITALIZATION AMONG SCHIZOPHRENIC COCAINE ABUSERS - A GOVERNMENT-SPONSORED REVOLVING-DOOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADDICTION SEVERITY INDEX; SUBSTANCE-ABUSE; DRUG-ABUSE; PSYCHIATRIC-PATIENTS; URINE; CHROMATOGRAPHY; VALIDITY	Background. Many patients with serious mental illness are addicted to drugs and alcohol. This comorbidity creates additional problems for the patients and for the clinicians, health care systems, and social-service agencies that provide services to this population. One problem is that disability income, which many people with serious mental illness receive to pay for basic needs, may facilitate drug abuse. In this study, we assessed the temporal patterns of cocaine use, psychiatric symptoms, and psychiatric hospitalization in a sample of schizophrenic patients receiving disability income. Methods. We evaluated 105 male patients with schizophrenia and cocaine dependence at the time of their admission to the hospital. They had severe mental illness and a long-term dependence on cocaine, with repeated admissions to psychiatric hospitals; many were homeless. The severity of psychiatric symptoms and urinary concentrations of the cocaine metabolite benzoylecgonine were evaluated weekly for 15 weeks. Results. Cocaine use, psychiatric symptoms, and hospital admissions all peaked during the first week of the month, shortly after the arrival of the disability payment, on the first day. The average patient spent nearly half his total income on illegal drugs. Conclusions. Among cocaine-abusing schizophrenic persons, the cyclic pattern of drug use strongly suggests that it is influenced by the monthly receipt of disability payments. The consequences of this cycle include the depletion of funds needed for housing and food, exacerbation of psychiatric symptoms, more frequent psychiatric hospitalization, and a high rate of homelessness. The troubling irony is that income intended to compensate for the disabling effects of severe mental illness may have the opposite effect.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SHANER, A (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,116A,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA.		Mintz, Jim/N-7385-2014	Mintz, Jim/0000-0002-8299-5851	NIMH NIH HHS [R01 MH48081] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048081] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTERMAN AI, 1983, J PSYCHIAT TREAT EV, V5, P377; BRADY K, 1990, AM J PSYCHIAT, V147, P1164; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COHEN J, 1992, MENTALLY ILL CHEM AB; CONE EJ, 1989, J FORENSIC SCI, V34, P15; DIXON L, 1991, AM J PSYCHIAT, V148, P224; DRAKE RE, 1991, NEW DIR MENT HLTH SE, V50, P3; FARRELL M, 1992, MENT PHYS DISABIL LA, V16, P236; FERRARA SD, 1992, J ANAL TOXICOL, V16, P217, DOI 10.1093/jat/16.4.217; GALANTER M, 1988, AM J DRUG ALCOHOL AB, V14, P211, DOI 10.3109/00952999809001548; HARTZ D, 1994, HOSP COMMUNITY PSYCH, V45, P491; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; Lukoff D, 1986, SCHIZOPHRENIA B, V12, P594, DOI DOI 10.1093/SCHBUL/12.4.578; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MELTZER HY, 1976, SCHIZOPHRENIA BULL, V2, P19, DOI 10.1093/schbul/2.1.19; OVERALL JE, 1962, PSYCHOL REP, V10, P799; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; RICHARD ML, 1985, J CLIN PSYCHIAT, V46, P79; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBERTS LJ, 1992, NEW DIR MENT HLTH SE, V53, P55; SAFER DJ, 1987, HOSP COMMUNITY PSYCH, V38, P511; SATEL S, 1994, NEW REPUBLIC    0530, P18; SEALE JP, 1993, PRIMARY CARE, V20, P167; SHANER A, 1993, AM J PSYCHIAT, V150, P758; SPITZER RL, 1990, USERS GUIDE STRUTURE; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; SVENSSON JO, 1986, J ANAL TOXICOL, V10, P122, DOI 10.1093/jat/10.3.122; VENTURA J, 1993, INT J METH PSYCH RES, V3, P221; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; WATTS VW, 1986, J ANAL TOXICOL, V10, P198, DOI 10.1093/jat/10.5.198; YESAVAGE JA, 1983, J CLIN PSYCHIAT, V44, P259; ZISOOK S, 1992, AM J PSYCHIAT, V149, P552; 1993, DHHS SSA65008 SOC SE, P353; 1987, DIAGNOSTIC STATISTIC; 1994, WALL STREET J   0208, pA18; 1993, WALL STREET J   0128, pA18	39	163	163	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					777	783		10.1056/NEJM199509213331207	http://dx.doi.org/10.1056/NEJM199509213331207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU809	7643886				2022-12-24	WOS:A1995RU80900007
J	MILLER, RW				MILLER, RW			LOOKING FOR ADVERSE REPRODUCTIVE OUTCOMES IN ATOMIC VETERANS - ARE SUCH STUDIES FEASIBLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MILLER, RW (corresponding author), INST MED,COMM STUDY FEASIBIL & NEED EPIDEMIOL STUDIES ADVE,WASHINGTON,DC 20418, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					865	865						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674486				2022-12-24	WOS:A1995RU60300004
J	COOK, DN; BECK, MA; COFFMAN, TM; KIRBY, SL; SHERIDAN, JF; PRAGNELL, IB; SMITHIES, O				COOK, DN; BECK, MA; COFFMAN, TM; KIRBY, SL; SHERIDAN, JF; PRAGNELL, IB; SMITHIES, O			REQUIREMENT OF MIP-1-ALPHA FOR AN INFLAMMATORY RESPONSE TO VIRAL-INFECTION	SCIENCE			English	Article							STEM-CELL PROLIFERATION; LYMPHOCYTES; CHEMOKINES; MIP-1-BETA; EXPRESSION	Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is a chemokine that has pro-inflammatory and stem cell inhibitory activities in vitro. Its biologic role in vivo was examined in mice in which the gene encoding MIP-1 alpha had been disrupted. Homozygous MIP-1 alpha mutant (-/-) mice were resistant to Coxsackievirus-induced myocarditis seen in infected wildtype (+/+) mice. Influenza virus-infected -/- mice had reduced pneumonitis and delayed clearance of the virus compared with infected +/+ mice. The -/- mice had no overt hematopoietic abnormalities. These results demonstrate that MIP-1 alpha is an important mediator of virus-induced inflammation in vivo.	UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; VET AFFAIRS MED CTR,DEPT INTERNAL MED,DURHAM,NC 27710; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; OHIO STATE UNIV,HLTH SCI CTR,DEPT ORAL BIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,HLTH SCI CTR,DEPT MED MICROBIOL & IMMUNOL,COLUMBUS,OH 43210; CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	University of North Carolina; University of North Carolina Chapel Hill; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Beatson Institute	COOK, DN (corresponding author), UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.		Cook, Donald/E-5079-2019	Cook, Donald/0000-0002-0052-3755; Sheridan, John/0000-0002-6927-0266	NHLBI NIH HHS [R29HL46195, HL37001] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046195, R01HL037001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK MA, 1994, J NUTR, V124, P345, DOI 10.1093/jn/124.3.345; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; GILL BM, 1995, DIABETES, V44, P614, DOI 10.2337/diabetes.44.6.614; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HERMANN G, 1995, J NEUROIMMUNOL, V56, P179, DOI 10.1016/0165-5728(94)00145-E; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KARPUS W, 1994, J IMMUNOL, V8, P1148; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KIM HS, 1988, NUCLEIC ACIDS RES, V18, P8887; MALTMAN J, 1994, J EXP MED, V178, P925; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PRAGNELL IB, 1988, BLOOD, V72, P196; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; WOODRUFF JF, 1974, J IMMUNOL, V113, P1726; WOODRUFF JF, 1980, AM J PATHOL, V101, P425	17	529	548	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1583	1585		10.1126/science.7667639	http://dx.doi.org/10.1126/science.7667639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667639				2022-12-24	WOS:A1995RU81300044
J	POWERS, T; WALTER, P				POWERS, T; WALTER, P			RECIPROCAL STIMULATION OF GTP HYDROLYSIS BY 2 DIRECTLY INTERACTING GTPASES	SCIENCE			English	Article							SIGNAL RECOGNITION PARTICLE; ELONGATION FACTOR-TU; 4.5S RNA; RIBONUCLEOPROTEIN; SUBUNIT; MODEL	The Escherichia coli guanosine triphosphate (GTP)-binding proteins Ffh and FtsY have been proposed to catalyze the cotranslational targeting of proteins to the bacterial plasma membrane. A mutation was introduced into the GTP-binding domain of FtsY that altered its nucleotide specificity from GTP to xanthosine triphosphate (XTP). The mutant FtsY protein stimulated GTP hydrolysis by a ribonucleoprotein consisting of Ffh and 4.5S RNA in a reaction that required XTP, and it hydrolyzed XTP in a reaction that required both the Ffh-4.5S ribonucleoprotein and GTP. Thus, nucleotide triphosphate hydrolysis by Ffh and FtsY is likely to occur in reciprocally coupled reactions in which the two interacting guanosine triphosphatases act as regulatory proteins for each other.			POWERS, T (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; Evnin L B, 1988, Ann N Y Acad Sci, V542, P61, DOI 10.1111/j.1749-6632.1988.tb25808.x; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; HWANG YW, 1987, J BIOL CHEM, V262, P13081; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P482; SEGEL IH, 1975, ENZYME; SEGEL IH, COMMUNICATION; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	21	181	182	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1422	1424		10.1126/science.7660124	http://dx.doi.org/10.1126/science.7660124			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660124				2022-12-24	WOS:A1995RT80600044
J	CANNON, J; CULLINAN, P; TAYLOR, AN				CANNON, J; CULLINAN, P; TAYLOR, AN			CONSEQUENCES OF OCCUPATIONAL ASTHMA	BRITISH MEDICAL JOURNAL			English	Article											CANNON, J (corresponding author), NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,DOVEHOUSE ST,LONDON SW3 6LR,ENGLAND.							[Anonymous], 1980, CLASSIFICATION OCCUP; GANNON PFG, 1993, BRIT J IND MED, V50, P491; MERIDITH S, 1993, J EPIDEMIOL COMMUNIT, V47, P459; VENABLES KM, 1989, RESP MED, V83, P437, DOI 10.1016/S0954-6111(89)80078-2	4	60	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					602	603		10.1136/bmj.311.7005.602	http://dx.doi.org/10.1136/bmj.311.7005.602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663255	Green Published			2022-12-24	WOS:A1995RT72300018
J	LEHMANN, ED; HOPKINS, KD; GOSLING, RG				LEHMANN, ED; HOPKINS, KD; GOSLING, RG			ATHEROSCLEROSIS IN THE ASCENDING AORTA AND RISK OF ISCHEMIC STROKE	LANCET			English	Editorial Material							MAGNETIC-RESONANCE; WAVE VELOCITY		WHITTINGTON HOSP, ACAD DEPT MED, LONDON N19 5NF, ENGLAND; UNIV S BANK, SCH APPL SCI, LONDON, ENGLAND	University of London; University College London; London South Bank University	LEHMANN, ED (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, DEPT NEUROL, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BOGREN HG, 1989, AM HEART J, V118, P234, DOI 10.1016/0002-8703(89)90181-6; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; HOPKINS KD, 1994, LANCET, V343, P1447, DOI 10.1016/S0140-6736(94)92577-1; KISTLER JP, 1994, NEW ENGL J MED, V331, P1517, DOI 10.1056/NEJM199412013312211; LANNE T, 1992, ULTRASOUND MED BIOL, V18, P451, DOI 10.1016/0301-5629(92)90084-N; LEHMANN ED, 1993, ULTRASOUND MED BIOL, V19, P683, DOI 10.1016/0301-5629(93)90087-5; LEHMANN ED, 1994, LANCET, V344, P1763, DOI 10.1016/S0140-6736(94)92901-7; LEHMANN ED, IN PRESS CLIN SCI; MOHIADDIN RH, 1993, J APPL PHYSIOL, V74, P492, DOI 10.1152/jappl.1993.74.1.492; OGREN M, 1995, BMJ-BRIT MED J, V310, P1294, DOI 10.1136/bmj.310.6990.1294; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WADA T, 1994, ARTERIOSCLER THROMB, V14, P479, DOI 10.1161/01.ATV.14.3.479	15	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 2	1995	346	8975					589	590		10.1016/S0140-6736(95)91433-1	http://dx.doi.org/10.1016/S0140-6736(95)91433-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651001				2022-12-24	WOS:A1995RT18800006
J	BERGGREN, KK; BARD, A; WILBUR, JL; GILLASPY, JD; HELG, AG; MCCLELLAND, JJ; ROLSTON, SL; PHILLIPS, WD; PRENTISS, M; WHITESIDES, GM				BERGGREN, KK; BARD, A; WILBUR, JL; GILLASPY, JD; HELG, AG; MCCLELLAND, JJ; ROLSTON, SL; PHILLIPS, WD; PRENTISS, M; WHITESIDES, GM			MICROLITHOGRAPHY BY USING NEUTRAL METASTABLE ATOMS AND SELF-ASSEMBLED MONOLAYERS	SCIENCE			English	Article							BEAM; SURFACES	Lithography can be performed with beams of neutral atoms in metastable excited states to pattern self-assembled monolayers (SAMs) of alkanethiolates on gold. An estimated exposure of a SAM of dodecanethiolate (DDT) to 15 to 20 metastable argon atoms per DDT molecule damaged the SAM sufficiently to allow penetration of an aqueous solution of ferricyanide to the surface of the gold. This solution etched the gold and transformed the patterns in the SAMs into structures of gold; these structures had edge resolution of less than 100 nanometers. Regions of SAMs as large as 2 square centimeters were patterned by exposure to a beam of metastable argon atoms. these observations suggest that this system may be useful in new forms of micro- and nanolithography.	HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138; NATL INST STAND & TECHNOL,DIV ATOM PHYS,GAITHERSBURG,MD 20899; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; NATL INST STAND & TECHNOL,ELECTRON PHYS GRP,GAITHERSBURG,MD 20899	Harvard University; National Institute of Standards & Technology (NIST) - USA; Harvard University; National Institute of Standards & Technology (NIST) - USA			rolston, steven l/L-5175-2013; Sano, Michael/E-1715-2011; Prentiss, Mara/AAU-2940-2021; McClelland, Jabez/A-2358-2015	rolston, steven l/0000-0003-1671-4190; McClelland, Jabez/0000-0001-5672-5965	NIGMS NIH HHS [1-F32 GM16511-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016511] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT NL, 1992, SCIENCE, V257, P1380, DOI 10.1126/science.257.5075.1380; ADAMS CS, 1994, PHYS REP, V240, P143, DOI 10.1016/0370-1573(94)90066-3; BEHRINGER RE, 1994, J OPT SOC AM B, V11, P1166; BOZCO F, 1983, J CHEM PHYS, V78, P4256; BRAIN CD, 1987, J AM CHEM SOC, V114, P7155; BRAND JA, 1992, REV SCI INSTRUM, V63, P163, DOI 10.1063/1.1143000; CALVERT JM, 1992, THIN SOLID FILMS, V211, P359; CONRAD H, 1979, PHYS REV LETT, V42, P1082, DOI 10.1103/PhysRevLett.42.1082; DULCEY CS, 1991, SCIENCE, V252, P551, DOI 10.1126/science.2020853; DUNNING FB, 1971, J PHYS PT B ATOM M P, V4, P1696, DOI 10.1088/0022-3700/4/12/018; FAHEY DW, 1980, J PHYS E SCI INSTRUM, V13, P381, DOI 10.1088/0022-3735/13/4/004; HUANG JY, 1994, LANGMUIR, V10, P626, DOI 10.1021/la00015a005; KIM E, 1995, J ELECTROCHEM SOC, V142, P628, DOI 10.1149/1.2044112; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; LOPEZ GP, 1993, J AM CHEM SOC, V115, P10774, DOI 10.1021/ja00076a038; MCCLELLAND JJ, 1993, SCIENCE, V262, P877, DOI 10.1126/science.262.5135.877; MCCLELLAND JJ, IN PRESS J OPT SOC B; NUZZO RG, 1987, J AM CHEM SOC, V114, P1990; TIBERIO RC, 1993, APPL PHYS LETT, V62, P476, DOI 10.1063/1.108938; TIMP G, 1992, PHYS REV LETT, V69, P1636, DOI 10.1103/PhysRevLett.69.1636; Webb HW, 1924, PHYS REV, V24, P113, DOI 10.1103/PhysRev.24.113; WHITESIDE GM, IN PRESS HDB SURFACE; WILBUR JL, UNPUB; WILBUR JL, 1994, ADV MATER, V7, P600; WILBUR JL, IN PRESS ADV MATER; XIA Y, UNPUB	26	203	212	1	42	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1255	1257		10.1126/science.7652572	http://dx.doi.org/10.1126/science.7652572			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652572				2022-12-24	WOS:A1995RR84200030
J	YU, HT; SCHREIBER, SL				YU, HT; SCHREIBER, SL			STRUCTURE OF GUANINE-NUCLEOTIDE-EXCTRANGE FACTOR HUMAN MSS4 AND IDENTIFICATION OF ITS RAB-INTERACTING SURFACE	NATURE			English	Article							BINDING DOMAIN; PROTEIN; P21	GUANINE-NUCLEOTIDE-EXCHANGE factors (GEFs) promote the exchange of GDP for GTP in Ras GTPases, and thereby positively regulate their functions(1,2). Members of the Sec4/Ypt1/Rab branch of the Ras superfamily are essential for vesicular transport(3-6). A GEF for a subset of Rab proteins, termed mammalian suppressor of Sec4 (Mss4), has been identified(7). Here we use multidimensional NMR to determine the structure of human Mss4 (hMss4), which is the first tertiary structure established for a protein with GEF activity. Mss4 contains a central beta-sheet sandwiched between two small sheets. It also binds a Zn ion through Cys 23, Cys 26, Cys 94 and Cys 97. The Rab-binding surface of hMss4 has subsequently been delineated using chemical-shift perturbation experiments and site-directed mutagenesis. The active site of hMss4 involves the Zn2+-binding region and a neighbouring loop.	HARVARD UNIV, DEPT CHEM, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute				Yu, Hongtao/0000-0002-8861-049X				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; LAL CC, 1993, MOL CELL BIOL, V13, P1345; LIAN LY, 1994, METHOD ENZYMOL, V239, P657; MITSOU MY, 1992, EMBO J, V11, P2391; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WATENPAUGH KD, 1980, J MOL BIOL, V138, P615, DOI 10.1016/S0022-2836(80)80020-9; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YU HT, 1995, BIOCHEMISTRY-US, V34, P9103, DOI 10.1021/bi00028a020	29	51	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					788	791		10.1038/376788a0	http://dx.doi.org/10.1038/376788a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651540				2022-12-24	WOS:A1995RR83600044
J	IWATA, S; OSTERMEIER, C; LUDWIG, B; MICHEL, H				IWATA, S; OSTERMEIER, C; LUDWIG, B; MICHEL, H			STRUCTURE AT 2.8-ANGSTROM RESOLUTION OF CYTOCHROME-C-OXIDASE FROM PARACOCCUS-DENITRIFICANS	NATURE			English	Article							CRYSTAL-STRUCTURES; PROTEIN STRUCTURES; SUBUNIT; REFINEMENT; 2-SUBUNIT; FEATURES; ACCURACY; COMPLEX; ENERGY; ENZYME	The crystal structure at 2.8 Angstrom resolution of the four protein subunits containing cytochrome c oxidase from the soil bacterium Paracoccus denitrificans, complexed with an antibody F-v fragment, is described. Subunit I contains 12 membrane-spanning, primarily helical segments and binds haem a and the haem a(3)-copper B binuclear centre where molecular oxygen Is reduced to water. Two proton transfer pathways, one for protons consumed in water formation and one for 'proton pumping', could be identified. Mechanisms for proton pumping are discussed.	MAX PLANCK INST BIOPHYS,D-60528 FRANKFURT,GERMANY; UNIV FRANKFURT,BIOZENTRUM,INST BIOCHEM,D-60439 FRANKFURT,GERMANY	Max Planck Society; Goethe University Frankfurt								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; ESSEN LO, 1995, THESIS J WOLFGANG GO; GARCIAHORSMAN JA, 1995, BIOCHEMISTRY-US, V34, P4428, DOI 10.1021/bi00013a035; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HALTIA T, 1990, BIOCHEMISTRY-US, V33, P9731; HALTIA T, 1991, EMBO J, V8, P2015; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HOSLER JP, 1993, BIOENERG BIOMEMBR, V25, P136; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P896; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; MORGAN JE, 1994, BIOENERG BIOMEMBR, V26, P599; OTWINOWSKI Z, 1991, 1991 P CCP4 STUD WEE, P80; OTWINOWSKI Z, 1993, 1991 P CCP4 STUD WEE, P56; PASCHER I, 1992, BIOCHIM BIOPHYS ACTA, V1113, P339, DOI 10.1016/0304-4157(92)90006-V; RAITIO M, 1990, FEBS LETT, V261, P431, DOI 10.1016/0014-5793(90)80609-M; RICH PR, 1994, AUST J PL PHYSL, V22, P479; RIEDER R, 1980, J BIOL CHEM, V255, P4732; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; STEFFENS GJ, 1979, H-S Z PHYSIOL CHEM, V360, P613; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TURBA A, 1995, EUR J BIOCHEM, V231, P259, DOI 10.1111/j.1432-1033.1995.0259f.x; VANDEROOST J, 1992, EMBO J, V11, P3209, DOI 10.1002/j.1460-2075.1992.tb05398.x; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM M, 1996, BIOCHIM BIOPHYS ACTA, V1187, P106	46	1952	1977	4	156	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					660	669		10.1038/376660a0	http://dx.doi.org/10.1038/376660a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651515				2022-12-24	WOS:A1995RQ67200053
J	MOHLEBOETANI, JC; MILLER, B; HALPERN, M; TRIVEDI, A; TESSLER, J; SOLOMON, SL; FENSTERSHEIB, M				MOHLEBOETANI, JC; MILLER, B; HALPERN, M; TRIVEDI, A; TESSLER, J; SOLOMON, SL; FENSTERSHEIB, M			SCHOOL-BASED SCREENING FOR TUBERCULOUS INFECTION - A COST-BENEFIT-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECISION-ANALYSIS; PROGNOSIS; CHILDREN; REACTORS	Objective.-To compare tuberculin screening of all kindergartners and high school entrants (screen-all strategy) vs screening limited to high-risk children (targeted screening). Design.-Decision, cost-effectiveness, and cost-benefit analyses. Setting and Subjects.-Students in a large urban and rural county. Definitions.-High risk of tuberculous infection was defined as birth in a country with a high prevalence of tuberculosis. Low risk was defined as birth in the United States. Outcome Measures.-Tuberculosis cases prevented per 10 000 children screened. Net costs, net cost per case prevented, benefit-cost ratio, and incremental cost-effectiveness. Results.-The screen-all strategy would prevent 14.9 cases per 10 000 children screened; targeted screening would prevent 84.9 cases per 10 000 children screened. The screen-all strategy is more costly than no screening; the benefit-cost ratio is 0.58. Targeted screening would result in a net savings; the benefit-cost ratio is 1.2. Screening all children is cost saving only if the reactor rate is 20% or greater. The cost per additional case prevented for screening all children compared with targeted screening ($34 666) is more than twice as high as treatment and contact tracing for a case of tuberculosis ($16 392). Conclusions.-Targeted screening of schoolchildren is much less costly than mass screening and is more efficient in prevention of tuberculosis.	CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,CLIN RES BRANCH,PREVENT EFFECTIVENESS STUDIES UNIT,ATLANTA,GA 30333; CTY SANTA CLARA PUBL HLTH DEPT,DIV DIS CONTROL & PREVENT,SAN JOSE,CA; CTR DIS CONTROL & PREVENT,PREVENT MED RESIDENCY,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,SPECIAL STUDIES ACT,ATLANTA,GA 30333; BATTELLE CTR PUBL HLTH RES & EVALUAT,ARLINGTON,VA; BATTELLE CTR PUBL HLTH RES & EVALUAT,DURHAM,NC	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Mohle-Boetani, Janet/AAH-4221-2019					BARRY MA, 1990, AM J PUBLIC HEALTH, V80, P439, DOI 10.2105/AJPH.80.4.439; BASS JB, 1993, TUBERCULOSIS COMPREH, P139; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; COMSTOCK GW, 1986, JAMA-J AM MED ASSOC, V256, P2729, DOI 10.1001/jama.256.19.2729; COMSTOCK GW, 1975, AM REV RESPIR DIS, V11, P573; DAVIDSON P T, 1990, American Review of Respiratory Disease, V141, pA336; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P161; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GRZYBOWSKI S, 1964, AM REV RESPIR DIS, V90, P707; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; KOPLAN JP, 1980, JAMA-J AM MED ASSOC, V2442, P736; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; SCHECHTER Y, 1990, DIABETES, V39, P1; SHAW BV, 1993, PROFESSIONAL SOFTWAR; SNIDER DE, 1984, AM J PUBLIC HEALTH, V74, P1353, DOI 10.2105/AJPH.74.12.1353; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STEINER P, 1980, AM J DIS CHILD, V134, P747, DOI 10.1001/archpedi.1980.02130200017007; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; 1991, LOTUS 1 2 3 DOS; 1993, ADV REPORT FINAL MOR, V41, P22; 1993, DATA MATTERS; 1982, B WORLD HEALTH ORGAN, V60, P555; 1988, MMWR-MORBID MORTAL W, V37, P663; 1994, AM J RESP CRIT CARE, V149, P1359; 1990, MMWR-MORBID MORTAL W, V39, P10; 1989, CDC898322 US DEP HLT; 1990, PERSONS AGE PLACE BI; 1994, PEDIATRICS, V93, P131; 1991, REPORT COMMITTEE INF, P487	34	78	78	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					613	619						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637141				2022-12-24	WOS:A1995RP70200028
J	WYNN, TA; CHEEVER, AW; JANKOVIC, D; POINDEXTER, RW; CASPAR, P; LEWIS, FA; SHER, A				WYNN, TA; CHEEVER, AW; JANKOVIC, D; POINDEXTER, RW; CASPAR, P; LEWIS, FA; SHER, A			AN IL-12-BASED VACCINATION METHOD FOR PREVENTING FIBROSIS INDUCED BY SCHISTOSOME INFECTION	NATURE			English	Article							TUMOR NECROSIS FACTOR; MURINE SCHISTOSOMIASIS; IMMUNE-RESPONSE; MESSENGER-RNA; MANSONI; MICE; INFLAMMATION; INDUCTION; INVIVO; BETA	THE harmful fibrosis which often occurs in the context of infectious. disease involves the excessive deposition of connective tissue matrix, particularly collagen, and is mostly resistant to pharmacological and immunological intervention(1). In schistosomiasis, fibrosis is associated with the granulomatous response to parasite eggs trapped in the liver(2). We have previously shown that interleukin (IL)-12 administered peritoneally with eggs prevents subsequent pulmonary granuloma formation on intravenous challenge with eggs(3). Here we show that sensitization with eggs plus IL-12 partly inhibits granuloma formation and dramatically reduces the tissue fibrosis induced by natural infection with Schistosoma mansoni worms. These results are an example of a vaccine against parasites which acts by preventing pathology rather than infection. IL-12, is known to favour the priming of Th1 rather than Th2 cells, and the effects on fibrosis are accompanied by replacement of the Th2-dominated pattern of cytokine expression characteristic of S. mansoni infection with one dominated by Th1 cytokines. Elevated Th2 cytokine expression and fibrosis are common manifestations of a wide variety of infectious diseases and atopic disorders which might be ameliorated by vaccination with antigen and IL-12.	NIAID,PARASIT DIS LAB,HOST PARASITE SECT,BETHESDA,MD 20892; BIOMED RES INST,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	WYNN, TA (corresponding author), NIAID,PARASITOL LAB,IMMUNOBIOL SECT,BETHESDA,MD 20892, USA.		Wynn, Thomas A/AAO-3523-2021; Wynn, Thomas A/C-2797-2011	Wynn, Thomas A/0000-0002-7244-8731; 				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; BERGQUIST NR, 1994, IMMUNOLOGIST, V2, P131; BUTTERWORTH AE, 1992, T ROY SOC TROP MED H, V86, P1, DOI 10.1016/0035-9203(92)90411-5; CAPRON AR, 1992, CURR OPIN IMMUNOL, V4, P419, DOI 10.1016/S0952-7915(06)80033-6; CHEEVER AW, 1992, J IMMUNOL, V148, P3244; CHEEVER AW, 1994, J IMMUNOL, V153, P753; CZAJA MJ, 1989, HEPATOLOGY, V10, P795, DOI 10.1002/hep.1840100508; DOMINGO EO, 1968, AM J PATHOL, V52, P369; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HENDERSON GS, 1992, J IMMUNOL, V148, P2261; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; OSWALD IP, 1994, J IMMUNOL, V153, P1707; PEARCE EJ, 1995, MOL APPROACHES PARAS, V12, P497; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; PLAYFAIR JHL, 1991, ACT LEIDENS, V60, P157; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SHER A, 1991, J IMMUNOL, V147, P2713; SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; WYNN TA, 1993, J IMMUNOL, V151, P1430; WYNN TA, 1995, J IMMUNOL, V154, P4701; WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551; YAMASHITA T, 1992, J IMMUNOL, V149, P3659; ZWINGENBERGER K, 1990, SCAND J IMMUNOL, V31, P205, DOI 10.1111/j.1365-3083.1990.tb02761.x	27	356	376	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					594	596		10.1038/376594a0	http://dx.doi.org/10.1038/376594a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637808				2022-12-24	WOS:A1995RP75600051
J	PETERSEN, RC; SMITH, GE; IVNIK, RJ; TANGALOS, EG; SCHAID, DJ; THIBODEAU, SN; KOKMEN, E; WARING, SC; KURLAND, LT				PETERSEN, RC; SMITH, GE; IVNIK, RJ; TANGALOS, EG; SCHAID, DJ; THIBODEAU, SN; KOKMEN, E; WARING, SC; KURLAND, LT			APOLIPOPROTEIN-E STATUS AS A PREDICTOR OF THE DEVELOPMENT OF ALZHEIMERS-DISEASE IN MEMORY-IMPAIRED INDIVIDUALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TYPE-4 ALLELE; MENTAL STATUS; DEMENTIA; DIAGNOSIS	Objective.-The outcome of patients with mild cognitive impairment is not known, yet these patients present a difficult dilemma for the clinician. This study was designed to characterize the outcome of a group of patients with mild cognitive impairment and to determine whether the presence of the epsilon 4 allele on the apolipoprotein E gene (APOE) is a predictor of that outcome. Design.-A prospective, longitudinal inception cohort. Setting.-General community clinic. Participants.-A consecutive sample of 66 patients who met criteria for a diagnosis of a mild cognitive impairment and who had at least one clinical reevaluation was identified from the Mayo Clinic Alzheimer's Disease Center/Alzheimer's Disease Patient Registry. Interventions.-We evaluated patients initially and at 12- to 18-month intervals up to 54 months using standard neurological and neuropsychological measures such as the Mini-Mental State Examination, the Dementia Rating Scale, the Wechsler Adult Intelligence Scale-Revised, the Wechsler Memory Scale-Revised, and the Free and Cued Selective Reminding Test. The APOE status of study patients was determined. Main Outcome Measure.-The development of dementia as determined by the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition and the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria. Results.-Sixty-six individuals had been reevaluated once (mean of 18 months), 36 individuals twice (mean of 36 months), and 22 individuals on three occasions (mean of 54 months), with conversion rates to dementia at these intervals of 24%, 44%, and 55%, respectively. A multivariate Cox regression model demonstrated that possession of an APOE epsilon 4 allele was the strongest predictor of clinical outcome. Conclusions.-These data suggest the following: (1) patients with mild cognitive impairment can be clinically defined, (2) many members of this group progress to Alzheimer's disease, and (3) APOE epsilon 4 allele status appears to be a strong predictor of clinical progression.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PSYCHIAT & PSYCHOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV COMMUNITY INTERNAL MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL & LAB MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	PETERSEN, RC (corresponding author), MAYO CLIN & MAYO FDN, DEPT NEUROL, ROCHESTER, MN 55905 USA.		Waring, Stephen/AAR-6870-2021	Waring, Stephen/0000-0002-9674-0083; Smith, Glenn/0000-0003-1506-9484	NIA NIH HHS [AG06786, AG08031] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG008031, U01AG006786] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; ARRIAGADA PV, 1992, NEUROLOGY, V42, P1681, DOI 10.1212/WNL.42.9.1681; Benton A.L., 1989, MULTILINGUAL APHASIA; BENTON AL, 1988, CONTRIBUTIONS NEUROP; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUSCHKE H, 1984, J CLIN NEUROPSYCHOL, V6, P433, DOI 10.1080/01688638408401233; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; HIXSON JE, 1990, J LIPID RES, V31, P545; Ivnik R., 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; IVNIK RJ, 1990, PSYCHOL ASSESSMENT, V2, P804; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; Jastak J.J., 1984, MANUAL WIDE RANGE AC; Kaplan E, 1978, BOSTON NAMING TEST; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karusu T.B., 1976, GERIATRIC PSYCHIAT, P77; KOKMEN E, 1987, MAYO CLIN PROC, V62, P281, DOI 10.1016/S0025-6196(12)61905-3; KOKMEN E, 1991, ARCH NEUROL-CHICAGO, V48, P725, DOI 10.1001/archneur.1991.00530190071018; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; MALEC JF, 1991, PSYCHOL ASSESSMENT J, V3, P82; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Petersen R C, 1990, Aging (Milano), V2, P408; PETERSEN RC, 1992, NEUROLOGY, V42, P396, DOI 10.1212/WNL.42.2.396; PETERSEN RC, 1994, NEUROLOGY, V44, P867, DOI 10.1212/WNL.44.5.867; PETERSEN RC, 1993, ANN NEUROL, V34, P292; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; Rey A, 1964, LEXAMEN CLINIQUE PSY; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; TSAI MS, 1994, AM J HUM GENET, V54, P643; Wechsler D., 1987, WMS R WECHSLER MEMOR; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; Weintraub S, 1982, ALZHEIMERS DIS REPOR, P189; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555; 1987, DIAGNOSTIC STATISTIC	45	632	656	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1274	1278		10.1001/jama.273.16.1274	http://dx.doi.org/10.1001/jama.273.16.1274			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7646655				2022-12-24	WOS:A1995QU57100030
J	HORUK, R; CHITNIS, CE; DARBONNE, WC; COLBY, TJ; RYBICKI, A; HADLEY, TJ; MILLER, LH				HORUK, R; CHITNIS, CE; DARBONNE, WC; COLBY, TJ; RYBICKI, A; HADLEY, TJ; MILLER, LH			A RECEPTOR FOR THE MALARIAL PARASITE PLASMODIUM-VIVAX - THE ERYTHROCYTE CHEMOKINE RECEPTOR	SCIENCE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; KNOWLESI MALARIA; CYTOKINE FAMILY; SPECIFICITY; ANTIGEN; PROTEIN	Plasmodium vivax and P. falciparum are the major causes of human malaria, except in sub-Saharan Africa where people lack the Duffy blood group antigen, the erythrocyte receptor for P. vivax. Duffy negative human erythrocytes are resistant to invasion by P. vivax and the related monkey malaria, P. knowlesi. Several lines of evidence in the present study indicate that the Duffy blood group antigen is the erythrocyte receptor for the chemokines interleukin-8 (IL-8) and melanoma growth stimulatory activity (MGSA). First, IL-8 binds minimally to Duffy negative erythrocytes. Second, a monoclonal antibody to the Duffy blood group antigen blocked binding of IL-8 and other chemokines to Duffy positive erythrocytes. Third, both MGSA and IL-8 blocked the binding of the parasite ligand and the invasion of human erythrocytes by P. knowlesi, suggesting the possibility of receptor blockade for anti-malarial therapy.	NIH,MALARIA RES LAB,BETHESDA,MD 20892; MONTEFIORE MED CTR,BRONX,NY 10467; JG BROWN CANC CTR,DIV MED ONCOL HEMATOL,LOUISVILLE,KY 40292	National Institutes of Health (NIH) - USA; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	HORUK, R (corresponding author), GENENTECH INC,S SAN FRANCISCO,CA 94080, USA.			Chitnis, Chetan/0000-0002-8773-9865	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041382] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41382] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARINAGA M, 1992, SCIENCE, V258, P1730, DOI 10.1126/science.1334571; BRADLEY DJ, 1987, OXFORD TXB MED, V1, pCH5; BROUN GO, 1966, NEW ENGL J MED, V275, P1410, DOI 10.1056/NEJM196612222752504; CHAUDHURI A, 1989, J BIOL CHEM, V264, P13770; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DARBONNE WC, UNPUB; GOODING LR, 1992, CELL, V71, P5; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HADLEY TJ, 1984, SCIENCE, V223, P597, DOI 10.1126/science.6695171; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1993, J BIOL CHEM, V268, P541; HORUK R, UNPUB; LEE J, 1992, J BIOL CHEM, V267, P16283; MARSH W L, 1975, Critical Reviews in Clinical Laboratory Sciences, V5, P387, DOI 10.3109/10408367509107049; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; MURPHY GS, 1993, LANCET, V341, P96, DOI 10.1016/0140-6736(93)92568-E; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; WASNIOWSKA K, 1993, BIOCHEM BIOPH RES CO, V192, P366, DOI 10.1006/bbrc.1993.1424	27	479	497	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1182	1184		10.1126/science.7689250	http://dx.doi.org/10.1126/science.7689250			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	7689250	Green Submitted			2022-12-24	WOS:A1993LU58600036
J	DESAI, SA; KROGSTAD, DJ; MCCLESKEY, EW				DESAI, SA; KROGSTAD, DJ; MCCLESKEY, EW			A NUTRIENT-PERMEABLE CHANNEL ON THE INTRAERYTHROCYTIC MALARIA PARASITE	NATURE			English	Article							HOST-CELL MEMBRANE; PLASMODIUM-FALCIPARUM; MITOCHONDRIAL-MEMBRANE; ERYTHROCYTIC STAGES; PRECURSORS; TRANSPORT; PATHWAY; CULTURE	DURING its 48-hour cycle inside the red blood cell, the human malaria parasite, Plasmodium falciparum, increases its volume 25-fold and divides asexually. This rapid growth demands large amounts of nutrients, a problem exacerbated by the lower metabolic rate and relative ionic impermeability of the host red blood cell. Direct passage of small nutrients across the two membranes that separate the parasite from the erythrocyte cytosol may be important for parasite development, and has been demonstrated for radiolabelled glucose2, amino acids3,4 and purine nucleosides4-6. Flux studies on plasmodia are limited, however, to suspensions of erythrocyte-free parasites and so cannot be used to examine the individual transport properties of the two membranes involved. Here we use the cell-attached patch clamp method7 to overcome this limitation. After removing the intervening red blood cell membrane and forming gigaohm seals on the small (3-5 mum) parasite, we studied transport across the parasitophorous vacuole membrane (PVM), the outer of the two membranes that separate the parasite from the erythrocyte cytosol. A 140-pS channel which is permeable to both cations and anions was identified on the PVM. This channel is present at high density, is open more than 98 per cent of the time at the resting potential of the PVM, and is permeable to lysine and glucuronate. The channel can readily transport amino acids and monosaccharides across the PVM and may be essential for fulfilling the parasite's metabolic demands.	WASHINGTON UNIV,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT MECH ENGN,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Desai, Sanjay A/B-7110-2009	Desai, Sanjay/0000-0003-2150-2483				BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; GERO AM, 1991, ADV EXP MED BIOL, V309, P169; GINSBERG H, 1990, COMP BIOCHEM PHYS A, V95, P31, DOI 10.1016/0300-9629(90)90006-E; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; HALDAR K, 1992, MOL BIOCHEM PARASIT, V50, P161, DOI 10.1016/0166-6851(92)90253-G; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN BD, 1980, J PARASITOL, V66, P205, DOI 10.2307/3280805; HUNTER M, 1987, NATURE, V327, P522, DOI 10.1038/327522a0; IZUMO A, 1988, COMP BIOCHEM PHYS B, V91, P735, DOI 10.1016/0305-0491(88)90201-5; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; KANAANI J, 1989, J BIOL CHEM, V264, P3194; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LANGRETH SG, 1977, B WORLD HEALTH ORGAN, V55, P171; LEE P, 1988, AM J TROP MED HYG, V39, P157, DOI 10.4269/ajtmh.1988.39.157; MIKKELSEN RB, 1986, MOL BIOCHEM PARASIT, V21, P83, DOI 10.1016/0166-6851(86)90082-4; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; SCHROEDER JE, 1991, NEURON, V6, P13, DOI 10.1016/0896-6273(91)90117-I; SHERMAN IW, 1977, B WORLD HEALTH ORGAN, V55, P211; SHERMAN IW, 1988, PARASITOLOGY, V96, pS57, DOI 10.1017/S003118200008598X; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; TANABE K, 1990, PARASITOL TODAY, V6, P225, DOI 10.1016/0169-4758(90)90199-E; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRAGER W, 1971, J PROTOZOOL, V18, P392, DOI 10.1111/j.1550-7408.1971.tb03341.x; WIBO M, 1981, J CELL BIOL, V89, P456, DOI 10.1083/jcb.89.3.456; YAMADA KA, 1981, MOL BIOCHEM PARASIT, V3, P253, DOI 10.1016/0166-6851(81)90056-6	29	174	181	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					643	646		10.1038/362643a0	http://dx.doi.org/10.1038/362643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	7681937				2022-12-24	WOS:A1993KX43800052
J	WHITE, RE; LEE, AB; SHCHERBATKO, AD; LINCOLN, TM; SCHONBRUNN, A; ARMSTRONG, DL				WHITE, RE; LEE, AB; SHCHERBATKO, AD; LINCOLN, TM; SCHONBRUNN, A; ARMSTRONG, DL			POTASSIUM CHANNEL STIMULATION BY NATRIURETIC PEPTIDES THROUGH CGMP-DEPENDENT DEPHOSPHORYLATION	NATURE			English	Article							CA-2+-ACTIVATED K+ CHANNELS; ANTERIOR-PITUITARY-CELLS; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; CALCIUM CHANNELS; CYCLIC-GMP; MODULATION; PHOSPHATASES; RECEPTOR; CYCLASE	NATRIURETIC peptides inhibit the release and action of many hormones through cyclic guanosine monophosphate (cGMp)1,2, but the mechanism of cGMP action is unclear3. In frog ventricular muscle and guinea-pig hippocampal neurons, cGMP inhibits voltage-activated Ca2+ currents by stimulating phosphodiesterase activity and reducing intracellular cyclic AMP4,5; however, this mechanism is not involved in the action of cGMP on other channels6 or on Ca2+ channels in other cells7,8. Natriuretic peptide receptors in the rat pituitary also stimulate guanylyl cyclase activity but inhibit secretion by increasing membrane conductance to potassium9,10. In an electrophysiological study on rat pituitary tumour cells11, we identified the large-conductance, calcium- and voltage-activated potassium channels (BK) as the primary target of another inhibitory neuropeptide, somatostatin. Here we report that atrial natriuretic peptide also stimulates BK channel activity in GH4C1 cells through protein dephosphorylation. Unlike somatostatin, however, the effect of atrial natriuretic peptide on BK channel activity is preceded by a rapid and potent stimulation of cGMP production and requires cGMP-dependent protein kinase activity. Protein phosphatase activation by cGMP-dependent kinase could explain the inhibitory effects of natriuretic peptides on electrical excitability and the antagonism of cGMP and cAMP in many systems12.	NIEHS, CELLULAR & MOLEC PHARMACOL LAB, RES TRIANGLE PK, NC 27709 USA; UNIV ALABAMA, DEPT PATHOL, BIRMINGHAM, AL 35294 USA; UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77225 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Alabama System; University of Alabama Birmingham; University of Texas System								ANTONI FA, 1990, J ENDOCRINOL, V126, P183, DOI 10.1677/joe.0.1260183; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DAYANITHI G, 1990, J ENDOCRINOL, V125, P39, DOI 10.1677/joe.0.1250039; DOERNER D, 1988, NEURON, V1, P693, DOI 10.1016/0896-6273(88)90168-7; DORFINGER LJ, 1983, ENDOCRINOLOGY, V13, P1541; FISCHMEISTER R, 1987, J PHYSIOL-LONDON, V387, P453, DOI 10.1113/jphysiol.1987.sp016584; Goldberg N D, 1973, Adv Cyclic Nucleotide Res, V3, P155; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; HESCHELER J, 1987, EUR J BIOCHEM, V165, P261, DOI 10.1111/j.1432-1033.1987.tb11436.x; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; OHYA Y, 1989, PFLUG ARCH EUR J PHY, V414, P257, DOI 10.1007/BF00584624; ONO K, 1992, J PHYSIOL-LONDON, V454, P673, DOI 10.1113/jphysiol.1992.sp019286; REINHART PH, 1991, J NEUROSCI, V11, P1627; SCHONBRUNN A, 1990, METABOLISM, V39, P96, DOI 10.1016/0026-0495(90)90221-W; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; STEINER AL, 1979, METHOD HORM RADIOIMM, P3; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; TOHSE N, 1991, CIRC RES, V69, P325, DOI 10.1161/01.RES.69.2.325; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WILLIAMS DL, 1988, P NATL ACAD SCI USA, V85, P9360, DOI 10.1073/pnas.85.23.9360	31	241	252	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					263	266		10.1038/361263a0	http://dx.doi.org/10.1038/361263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	7678699				2022-12-24	WOS:A1993KH61400061
J	ZAGHOUANI, H; STEINMAN, R; NONACS, R; SHAH, H; GERHARD, W; BONA, C				ZAGHOUANI, H; STEINMAN, R; NONACS, R; SHAH, H; GERHARD, W; BONA, C			PRESENTATION OF A VIRAL T-CELL EPITOPE EXPRESSED IN THE CDR3 REGION OF A SELF IMMUNOGLOBULIN MOLECULE	SCIENCE			English	Article							DENDRITIC CELLS; LYMPHOCYTES-T; GENE SEGMENTS; FC-RECEPTORS; ANTIGEN; CHAIN; RECOGNITION; SURFACE	Synthetic peptides corresponding to microbial epitopes stimulate T cell immunity but their immunogenicity is poor and their half-lives are short. A viral epitope inserted into the complementarity-determining region 3 (CDR3) loop of the heavy chain of a self immunoglobulin (Ig) molecule was generated from the Ig context and was presented by I-E(d) class II molecules to virus-specific, CD4+ T cells. Chimeric Ig-peptide was presented 100 to 1000 times more efficiently than free synthetic peptide and was able to prime virus-specific T cells in vivo. These features suggest that antigenized Ig can provide an improved and safe vaccine for the presentation of microbial and other peptides.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021; WISTAR INST,PHILADELPHIA,PA 19104	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; The Wistar Institute			Steinman, Ralph/F-7729-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013013, R01AI018316, R01AI013013, P01AI024460] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24460, AI13013, AI18316] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTEGAY M, 1992, J VIROL, V66, P1199, DOI 10.1128/JVI.66.2.1199-1201.1992; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; CHIMINI G, 1989, J EXP MED, V169, P297, DOI 10.1084/jem.169.1.297; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; FREIMUTH P, 1990, RES MICROBIOL, V141, P995, DOI 10.1016/0923-2508(90)90139-H; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; HABERMAN AM, 1990, J IMMUNOL, V145, P3087; HAN YS, 1991, J EXP MED, V174, P733; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; MOSMANN TJ, 1983, IMMUNOL METHODS, V66, P55; NUSSENZWEIG MC, 1980, J EXP MED, V151, P1196, DOI 10.1084/jem.151.5.1196; NUSSENZWEIG MC, 1981, J EXP MED, V154, P168, DOI 10.1084/jem.154.1.168; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; RATHBUN GA, 1988, J MOL BIOL, V202, P383, DOI 10.1016/0022-2836(88)90272-0; ROMANI N, 1989, J EXP MED, V169, P1153, DOI 10.1084/jem.169.3.1153; SANZ I, 1987, P NATL ACAD SCI USA, V84, P1085, DOI 10.1073/pnas.84.4.1085; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; UNKELESS JC, 1981, ADV IMMUNOL, V31, P247, DOI 10.1016/S0065-2776(08)60922-0; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; ZAGHOUANI H, 1992, J IMMUNOL, V148, P3604; ZAGHOUANI H, UNPUB	25	112	127	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					224	227		10.1126/science.7678469	http://dx.doi.org/10.1126/science.7678469			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678469				2022-12-24	WOS:A1993KF71900030
J	WINN, WC; WESTENFELD, FW				WINN, WC; WESTENFELD, FW			INFLUENZA-A VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											WINN, WC (corresponding author), UNIV VERMONT,COLL MED,BURLINGTON,VT 05405, USA.								0	5	5	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					912	912		10.1056/NEJM199510053331405	http://dx.doi.org/10.1056/NEJM199510053331405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666877				2022-12-24	WOS:A1995RX19900005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW SAFETY STANDARD FOR MEDICAL DEVICE WIRES PROPOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-24	WOS:A1995RV73400005
J	WIJGERDE, M; GROSVELD, F; FRASER, P				WIJGERDE, M; GROSVELD, F; FRASER, P			TRANSCRIPTION COMPLEX STABILITY AND CHROMATIN DYNAMICS IN-VIVO	NATURE			English	Article							BETA-GLOBIN GENE; DOMINANT CONTROL REGION; LOCUS-CONTROL REGION; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITE; ACTIVATION-REGION; ERYTHROID-CELLS; EXPRESSION; ENHANCER	Distant regulatory sequences affect transcription through long-range chromatin interactions. Visualization of transcriptional activity of genes that compete for distant elements, using the globin locus as a model, has revealed the dynamics of chromatin Interactions in vivo. Multiple genes appear to be transcribed alternately rather than at the same time to generate several messenger RNAs in one cell. The regulator may stably complex with one gene at a time and switch back and forth between genes in a flip-flop mechanism.	NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	WIJGERDE, M (corresponding author), ERASMUS UNIV ROTTERDAM,MGC DEPT CELL BIOL & GENET,3015 GE ROTTERDAM,NETHERLANDS.		Fraser, Peter/B-7549-2009	Fraser, Peter/0000-0002-0041-1227				ARNDTJOVIN D, 1985, J HISTOCHEM CYTOCHEM, V25, P585; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; CURTIS PJ, 1977, COLD SPRING HARB SYM, V42, P971; DEVILLIERS J, 1982, COLD SPRING HARB SYM, V47, P911; DILLON N, 1990, NATURE, V350, P252; DIRKS RW, 1993, J CELL SCI, V104, P1187; DRISCOLL MC, 1989, P NATL ACAD SCI USA, V86, P7470, DOI 10.1073/pnas.86.19.7470; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FRASER P, 1987, GENE DEV, V1, P885; FURUKAWA T, 1994, BLOOD, V83, P1412; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; STROUBOULIS J, 1994, THESIS OPEN U UK; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TERASIMA T, 1963, EXP CELL RES, V30, P344, DOI 10.1016/0014-4827(63)90306-9; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WASYLYK B, 1983, CELL, V32, P503, DOI 10.1016/0092-8674(83)90470-1; ZHANG G, 1994, NATURE, V372, P22	36	420	429	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					209	213		10.1038/377209a0	http://dx.doi.org/10.1038/377209a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675106	Green Submitted			2022-12-24	WOS:A1995RV87200031
J	COHEN, BM; RENSHAW, PF; STOLL, AL; WURTMAN, RJ; YURGELUNTODD, D; BABB, SM				COHEN, BM; RENSHAW, PF; STOLL, AL; WURTMAN, RJ; YURGELUNTODD, D; BABB, SM			DECREASED BRAIN CHOLINE UPTAKE IN OLDER ADULTS - AN IN-VIVO PROTON MAGNETIC-RESONANCE SPECTROSCOPY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAT-BRAIN; CEREBROSPINAL-FLUID; H-1-NMR SPECTROSCOPY; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; BARRIER TRANSPORT; CELL-MEMBRANES; METABOLISM; NEURONS; ACETYLCHOLINE	Objective.-To test the hypothesis that uptake of circulating choline into the brain decreases with age, because alterations in metabolism of choline may be a factor contributing to age-related degenerative changes in the brain. Design.-Cohort comparison in younger and older adults. Participants.-Subjects were chosen consecutively from lists of healthy volunteers screened by medical and psychiatric interviews and laboratory tests. Younger adults (n=12) were between the ages of 20 and 40 years (mean age, 32 years), and older adults (n=16) were between the ages of 60 and 85 years (mean age, 73 years). Interventions.-After fasting overnight, subjects received choline, as the bitartrate, to yield free choline equal to 50 mg/kg of body weight. Blood was drawn for determination of plasma choline concentration by high-performance liquid chromatography, and proton magnetic resonance spectroscopy (H-1-MRS) was performed to determine the relative concentration of cytosolic choline-containing compounds in the brain at baseline and after ingestion of choline. Main Outcome Measures.-Plasma choline and cytosolic choline-containing compounds in the brain, estimated as the ratio of the choline resonance to the creatine resonance on H-1-MRS scans of the basal ganglia, were compared following blinded analyses of data from subject cohorts studied at baseline and 3 hours after choline ingestion. Results.-Levels of plasma choline and cytosolic choline-containing compounds in brain were similar at baseline in younger and older subjects. Following ingestion of choline, plasma choline concentration increased by similar proportions (76% and 80%) in both younger and older subjects. Brain cytosolic choline-containing compounds increased substantially in younger subjects (mean increase, 60%; P<.001 vs baseline). Older subjects showed a much smaller increase in brain choline-containing compounds (mean, 16%, P<.001 vs the increase in younger subjects). Conclusion.-Uptake of circulating choline into the brain decreases with age. Given the key role of choline in neuronal structure and function, this change may be a contributing factor in onset in late life of neurodegenerative, particularly dementing, illnesses in which cholinergic neurons show particular susceptibility to loss.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; MIT,CLIN RES CTR,CAMBRIDGE,MA 02139; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,PSYCHOPHARMACOL UNIT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital	COHEN, BM (corresponding author), MCLEAN HOSP,CTR BRAIN IMAGING,115 MILL ST,BELMONT,MA 02178, USA.		Renshaw, Perry/O-1384-2018; Cohen, Bruce M./AAZ-4986-2020		NIMH NIH HHS [MH28783, MH31154, MH38313] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH028783, P01MH031154, R01MH028783] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ansell G B, 1977, Int Rev Neurobiol, V20, P1, DOI 10.1016/S0074-7742(08)60649-2; ARMSTRONG DM, 1993, NEUROBIOL AGING, V14, P457, DOI 10.1016/0197-4580(93)90104-J; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BARTUS RT, 1984, NUTRITION GERONTOLOG, P191; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BRINKMAN SD, 1982, J CLIN PSYCHOPHARM, V2, P281; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P799, DOI 10.1016/0730-725X(93)90197-L; COHEN BM, 1985, LIFE SCI, V37, P1403, DOI 10.1016/0024-3205(85)90079-7; COHEN BM, 1982, AM J PSYCHIAT, V139, P1162; CORNFORD EM, 1978, J NEUROCHEM, V30, P299, DOI 10.1111/j.1471-4159.1978.tb06530.x; FISCHER W, 1992, NEUROBIOL AGING, V13, P9, DOI 10.1016/0197-4580(92)90003-G; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; GRIFFEY RH, 1990, J MAGN RESON, V88, P161, DOI 10.1016/0022-2364(90)90120-X; GRINNA LS, 1977, GERONTOLOGY, V23, P452, DOI 10.1159/000212222; GROWDON JH, 1977, J NEUROCHEM, V28, P229, DOI 10.1111/j.1471-4159.1977.tb07732.x; GROWDON JH, 1977, ANN NEUROL, V1, P418, DOI 10.1002/ana.410010503; GROWDON JH, 1977, NEW ENGL J MED, V297, P524, DOI 10.1056/NEJM197709082971002; GUZE BH, 1991, PSYCHIAT RES-NEUROIM, V40, P195, DOI 10.1016/0165-1781(91)90158-L; HETHERINGTON HP, 1994, MAGNET RESON MED, V32, P565, DOI 10.1002/mrm.1910320504; HOLLISTER LE, 1978, LIFE SCI, V23, P17, DOI 10.1016/0024-3205(78)90319-3; ISHIMARU H, 1991, J PHARMACOBIO-DYNAM, V14, P321, DOI 10.1248/bpb1978.14.321; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P55, DOI 10.1016/0006-3223(91)90210-D; JERNIGAN TL, 1993, ARCH NEUROL-CHICAGO, V47, P27; JOPE RS, 1979, J NEUROSCI RES, V4, P69, DOI 10.1002/jnr.490040110; KANG YS, 1990, J PHARMACOBIO-DYNAM, V13, P353, DOI 10.1248/bpb1978.13.353; KAYE WH, 1982, BIOL PSYCHIAT, V17, P275; KIKINIS R, 1992, JMRI-J MAGN RESON IM, V2, P619, DOI 10.1002/jmri.1880020603; KLEIN J, 1990, J NEUROCHEM, V55, P1231, DOI 10.1111/j.1471-4159.1990.tb03129.x; KLEIN J, 1992, J NEUROCHEM, V58, P870, DOI 10.1111/j.1471-4159.1992.tb09337.x; KLEIN J, 1991, J NEUROCHEM, V57, P370, DOI 10.1111/j.1471-4159.1991.tb03762.x; KLEIN J, 1993, NEUROCHEM INT, V22, P293, DOI 10.1016/0197-0186(93)90058-D; LOFFELHOLZ K, 1993, PROG BRAIN RES, V98, P197; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; MILLER LG, 1990, BIOCHEM PHARMACOL, V40, P1179, DOI 10.1016/0006-2952(90)90381-T; MILLINGTON WR, 1982, J NEUROCHEM, V38, P1748, DOI 10.1111/j.1471-4159.1982.tb06658.x; MOHS RC, 1979, AM J PSYCHIAT, V136, P1275; MOORADIAN AD, 1988, BRAIN RES, V440, P328, DOI 10.1016/0006-8993(88)91002-5; MURPHY DGM, 1992, ARCH NEUROL-CHICAGO, V49, P839, DOI 10.1001/archneur.1992.00530320063013; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; PARDRIDGE WM, 1986, FASEB J, V45, P2047; PERRY EK, 1980, AGE AGEING, V9, P1, DOI 10.1093/ageing/9.1.1; PERRY EK, 1992, NEUROBIOL AGING, V13, P393, DOI 10.1016/0197-4580(92)90113-C; PETROFF OAC, 1988, COMP BIOCHEM PHYS B, V90, P249, DOI 10.1016/0305-0491(88)90069-7; PETROFF OAC, 1988, J NEUROCHEM, V51, P163, DOI 10.1111/j.1471-4159.1988.tb04850.x; PETROFF OAC, 1989, NEUROLOGY, V39, P1197, DOI 10.1212/WNL.39.9.1197; Rinn W E, 1988, J Geriatr Psychiatry Neurol, V1, P144, DOI 10.1177/089198878800100304; ROUSER G, 1968, LIPIDS, V3, P284, DOI 10.1007/BF02531202; SCHMIDT DE, 1981, NEUROPHARMACOLOGY, V20, P535, DOI 10.1016/0028-3908(81)90205-7; SCREMIN OU, 1993, PROG BRAIN RES, V98, P191; SHENTON ME, 1991, SCHIZOPHR RES, V5, P103, DOI 10.1016/0920-9964(91)90037-R; SPECTOR R, 1989, J NEUROCHEM, V53, P1667, DOI 10.1111/j.1471-4159.1989.tb09229.x; STOLL AL, 1995, BIOL PSYCHIAT, V37, P170, DOI 10.1016/0006-3223(94)00120-R; THAL LJ, 1983, ANN NEUROL, V13, P491, DOI 10.1002/ana.410130504; TROMMER BA, 1982, J NEUROCHEM, V39, P1704, DOI 10.1111/j.1471-4159.1982.tb08006.x; TUCEK S, 1984, PROG BIOPHYS MOL BIO, V44, P1, DOI 10.1016/0079-6107(84)90011-7; ULUS IH, 1976, SCIENCE, V194, P1060, DOI 10.1126/science.10629; WECKER L, 1978, SCIENCE, V199, P86, DOI 10.1126/science.199.4324.86; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8; WURTMAN RJ, 1977, LANCET, V2, P68; WURTMAN RJ, 1985, NEUROCHEM INT, V7, P869; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1992, J AM COLL NUTR, V11, P473	62	116	121	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					902	907		10.1001/jama.274.11.902	http://dx.doi.org/10.1001/jama.274.11.902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674505				2022-12-24	WOS:A1995RU60300030
J	IRIBARREN, C; SHARP, DS; BURCHFIEL, CM; PETROVITCH, H				IRIBARREN, C; SHARP, DS; BURCHFIEL, CM; PETROVITCH, H			ASSOCIATION OF WEIGHT-LOSS AND WEIGHT FLUCTUATION WITH MORTALITY AMONG JAPANESE-AMERICAN MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ALL-CAUSE MORTALITY; BODY-WEIGHT; METABOLIC-RATE; HEALTH; RISK; VARIABILITY; LONGEVITY; STROKE; HAWAII	Background. Weight loss and fluctuations in weight have been associated with increased risks of death from cardiovascular disease and from all causes. The clinical and public health implications of these associations are unclear. Methods. We examined the long-term relation of weight change and fluctuation in weight with mortality over a 6-year period in 6537 middle-aged Japanese American men enrolled in the Honolulu Heart Program, a prospective study (mean follow-up, 14.5 years). Results. Men who had a weight loss of 4.5 kg or more or who had large fluctuations in weight (or both) over a six-year period were, on average, in poorer health than their peers whose weight was more stable. After the exclusion of subjects who died during the first five years of follow-up and after adjustment for confounding factors, a weight loss of more than 4.5 kg was associated with the risk of death from all causes, with the exception of death from cancer. The subjects whose weight fluctuated the most had a significantly higher risk of death from cardiovascular causes (relative risk, 1.41; 95 percent confidence interval, 1.03 to 1.93), death from noncardiovascular and noncancerous causes (relative risk, 1.53; 95 percent confidence interval, 1.12 to 2.10), and death from all causes (relative risk, 1.25; 95 percent confidence interval, 1.05 to 1.48). However, the associations of weight loss and variation in weight with death from cardiovascular causes and from noncardiovascular and noncancerous causes were not found among healthy men who had never smoked. Conclusions. The associations between weight loss or fluctuation and mortality were partially explained by confounding factors and by the presence of preexisting disease. However, weight loss and weight fluctuation were unrelated to death among healthy men who had never smoked. Thus, concern about the health hazards of weight loss and variation may not be applicable to otherwise healthy people.	NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, HONOLULU EPIDEMIOL RES UNIT, BETHESDA, MD 20892 USA; UNIV HAWAII MANOA, JOHN A BURNS SCH MED, DEPT MED, HONOLULU, HI 96822 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Hawaii System; University of Hawaii Manoa	IRIBARREN, C (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.				NHLBI NIH HHS [N01-HV-02901, N01-HC-02901] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC002901] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; ARCHAMBAULT CM, 1989, PHYSIOL BEHAV, V46, P417, DOI 10.1016/0031-9384(89)90013-9; BELSKY JL, 1971, 1271 AT BOMB CAS COM; BLAIR SN, 1993, ANN INTERN MED, V119, P749, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00024; BROWNELL KD, 1986, PHYSIOL BEHAV, V38, P459, DOI 10.1016/0031-9384(86)90411-7; COX DR, 1972, J R STAT SOC B, V34, P187; DRAPER NR, 1981, APPLIED REGRESSION A, P19; FRENCH SA, 1995, INT J OBESITY, V19, P22; GORDON T, 1975, AM J CLIN NUTR, V28, P304, DOI 10.1093/ajcn/28.4.304; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARRIS TB, 1993, AM J EPIDEMIOL, V137, P1318, DOI 10.1093/oxfordjournals.aje.a116641; HO SC, 1994, J GERONTOL, V49, pM269, DOI 10.1093/geronj/49.6.M269; JEBB SA, 1991, INT J OBESITY, V15, P367; JEFFERY RW, 1992, AM J CLIN NUTR, V55, P641, DOI 10.1093/ajcn/55.3.641; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KRAEMER H C, 1990, Annals of Behavioral Medicine, V12, P119, DOI 10.1207/s15324796abm1203_4; KULLER L, 1993, ANN INTERN MED, V119, P630, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00015; KUSHNER RF, 1993, NUTR REV, V51, P127, DOI 10.1111/j.1753-4887.1993.tb03089.x; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; LISSNER L, 1990, INT J OBESITY, V14, P373; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; Reed G W, 1993, Obes Res, V1, P392; RHOADS GG, 1983, LANCET, V1, P492; Rumpel C, 1993, Ann Epidemiol, V3, P343, DOI 10.1016/1047-2797(93)90060-H; RUMPEL C, 1994, INT J OBESITY, V18, P179; SCHOTTE DE, 1990, HEALTH PSYCHOL, V9, P599, DOI 10.1037/0278-6133.9.5.599; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STEVENS J, 1990, INT J OBESITY, V14, P385; TAYLOR CB, 1995, AM J EPIDEMIOL, V141, P461, DOI 10.1093/oxfordjournals.aje.a117448; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WATT BK, 1963, DEP AGR HDB, V8; Wing R R, 1993, Obes Res, V1, P390; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; 1994, JAMA-J AM MED ASSOC, V272, P1196; 1987, SAS STAT SOFTWARE VE; 1971, 1970 CENSUS POPULATI	41	109	109	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					686	692		10.1056/NEJM199509143331102	http://dx.doi.org/10.1056/NEJM199509143331102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637745				2022-12-24	WOS:A1995RV22700002
J	LILLIEN, L				LILLIEN, L			CHANGES IN RETINAL CELL FATE INDUCED BY OVEREXPRESSION OF EGF RECEPTOR	NATURE			English	Article							TGF-ALPHA; DIFFERENTIATION; GENE; PROLIFERATION; CULTURES; LINEAGE; INVITRO; PROTEIN; MOUSE; ENTRY	THE differentiation of multipotential progenitor cells in the vertebrate retina into photoreceptors, neurons and glial cells is regulated in part by cell-cell signalling(1-11). Transforming growth factor (TGF)-alpha is one of the extracellular signals implicated in the control of several aspects of retinal development, including proliferation and cell fate(5,6,11-13). The way cells interpret pleiotropic signals such as TGF-alpha is influenced by the level of expression of epidermal growth factor receptor (EGF-R) in some cell lines(14,15). To address the influence of receptor level on responses of retinal progenitor cells to TGF-alpha, additional copies of EGF-Rs were introduced in vitro and in vivo with a retrovirus. Normally irt vitro, low concentrations of TGF-alpha stimulated proliferation whereas high concentrations biased choice of cell fate, inhibiting differentiation into rod photoreceptors while promoting differentiation into Muller glial cells, We report here that introduction of extra EGF-Rs into progenitor cells in vitro reduced the concentration of TGF-alpha required for changes in rod and Muller cell differentiation but did not enhance proliferation, Introduction of extra EGF-Rs in vivo increased the proportion of clones that contained Muller glial cells, suggesting that receptor level is normally limiting, These findings demonstrate that responsiveness to extracellular signals during development can be modulated by the introduction of additional receptors, and suggest that the level of expression of receptors for these signals contributes to the regulation of cell fate.			LILLIEN, L (corresponding author), MED COLL PENN, DEPT ANAT & NEUROBIOL, 3200 HENRY AVE, PHILADELPHIA, PA 19072 USA.							ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; AKAGAWA K, 1986, BRAIN RES, V383, P110, DOI 10.1016/0006-8993(86)90012-0; ALTSHULER D, 1992, DEVELOPMENT, V114, P947; ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BJORKLUND H, 1985, NEUROSCI LETT, V54, P363, DOI 10.1016/S0304-3940(85)80061-6; FERRI RT, 1995, DEVELOPMENT, V121, P1151; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HUNTER DD, 1992, NEURON, V8, P399, DOI 10.1016/0896-6273(92)90269-J; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; LEUTTEKE NC, 1993, CELL, V73, P263; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LINSER P, 1984, ANN NY ACAD SCI, V429, P430, DOI 10.1111/j.1749-6632.1984.tb12369.x; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; REH TA, 1992, J NEUROBIOL, V23, P1067, DOI 10.1002/neu.480230811; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SPARROW JR, 1990, DEV BRAIN RES, V51, P69, DOI 10.1016/0165-3806(90)90259-2; TAYLOR M, 1990, J NEUROBIOL, V21, P470, DOI 10.1002/neu.480210308; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; WATANABE T, 1990, NEURON, V3, P461; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	30	222	226	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					158	162		10.1038/377158a0	http://dx.doi.org/10.1038/377158a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675083				2022-12-24	WOS:A1995RU75400051
J	BRUNS, D; JAHN, R				BRUNS, D; JAHN, R			REAL-TIME MEASUREMENT OF TRANSMITTER RELEASE FROM SINGLE SYNAPTIC VESICLES	NATURE			English	Article							IDENTIFIED LEECH NEURONS; NEUROTRANSMITTER RELEASE; CHROMAFFIN CELLS; TRANSMISSION; CULTURE; FUSION; SYNAPTOBREVIN; ACETYLCHOLINE; TETANUS	NEUROTRANSMITTER release is mediated by Ca2+ dependent exocytosis of synaptic vesicles', Neither the amount of transmitter released from individual synaptic vesicles nor the kinetics of this process have yet been directly determined, Using carbon fibres as electrochemical detectors(2,3), we have measured release of the neurotransmitter serotonin from cultured neurons of the leech(4). This technique allowed us to monitor transmitter discharge from single synaptic vesicles as spike-like oxidation currents at high time resolution, providing new insight into the mechanism of neuronal exocytosis, Two types of signals were characterized, corresponding to exocytosis of small clear and large dense core vesicles present in these cells, A small vesicle discharges about 4,700 transmitter molecules with a time constant in the region of 260 mu s, whereas large vesicles release their content of approximately 80,000 molecules with a time constant of about 1.3 ms, Release from both vesicle types is initiated rapidly, with a rise time of less than 60 mu s, suggesting an abrupt opening of a preassembled fusion pore.	YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University	BRUNS, D (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA.			Jahn, Reinhard/0000-0003-1542-3498				ADLER EM, 1991, J NEUROSCI, V11, P1496; ALMERS W, 1989, SECRETION ITS CONTRO, P269; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BARTFAI T, 1988, ANNU REV PHARMACOL, V28, P285, DOI 10.1146/annurev.pa.28.040188.001441; BEAUDET A, 1981, J PHYSIOLOGY PARIS, V77, P193; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FUCHS PA, 1982, J PHYSIOL-LONDON, V323, P195, DOI 10.1113/jphysiol.1982.sp014068; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HENDERSON L, 1983, J PHYSL, V399, P309; HENDERSON LP, 1983, J PHYSIOL-LONDON, V340, P347, DOI 10.1113/jphysiol.1983.sp014766; KUFFLER DP, 1987, J COMP NEUROL, V256, P516, DOI 10.1002/cne.902560404; KUFFLER SW, 1975, J PHYSIOL-LONDON, V251, P465, DOI 10.1113/jphysiol.1975.sp011103; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WRONA MZ, 1990, BIOORG CHEM, V18, P291, DOI 10.1016/0045-2068(90)90005-P	21	337	344	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					62	65		10.1038/377062a0	http://dx.doi.org/10.1038/377062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659162				2022-12-24	WOS:A1995RT72500056
J	EYPASCH, E; LEFERING, R; KUM, CK; TROIDL, H				EYPASCH, E; LEFERING, R; KUM, CK; TROIDL, H			PROBABILITY OF ADVERSE EVENTS THAT HAVE NOT YET OCCURRED - A STATISTICAL REMINDER	BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE RANDOMIZED TRIAL; LAPAROSCOPIC CHOLECYSTECTOMY; OPEN APPENDECTOMY; SAFETY	The probability of adverse and undesirable events during and after operations that have not yet occurred in a finite number of patients (n) can be estimated with Hanley's simple formula, which gives the upper limit of the 95% confidence interval of the probability of such an event: upper limit of 95% confidence interval=maximum risk=3/n (for n>30). Doctors and surgeons should keep this simple rule in mind when complication rates of zero are reported in the literature and when they have not (yet) experienced a disastrous complication in a procedure.			EYPASCH, E (corresponding author), UNIV COLOGNE,KLINIKEN STADT KOLN,DEPT SURG 2,OSTMERHEIMER STR 200,D-51109 COLOGNE,GERMANY.							ATTWOOD SEA, 1992, SURGERY, V112, P497; COLLET D, 1993, SURG ENDOSC-ULTRAS, V7, P334, DOI 10.1007/BF00725952; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; FRAZEE RC, 1994, ANN SURG, V219, P725, DOI 10.1097/00000658-199406000-00017; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V259, P1743; HEBEBRAND D, 1994, CHIRURG, V65, P112; KUM CK, 1993, BRIT J SURG, V80, P1599, DOI 10.1002/bjs.1800801236; LARSON GM, 1992, AM J SURG, V163, P221, DOI 10.1016/0002-9610(92)90105-Z; MCANENA OJ, 1991, LANCET, V338, P693, DOI 10.1016/0140-6736(91)91267-X; PETERS JH, 1991, ANN SURG, V213, P3, DOI 10.1097/00000658-199101000-00002; Pier A, 1991, Surg Laparosc Endosc, V1, P8; TATE JJT, 1993, LANCET, V342, P633, DOI 10.1016/0140-6736(93)91757-D; TROIDL H, 1992, ENDOSCOPY, V24, P252, DOI 10.1055/s-2007-1010477; TROIDL H, 1993, LANGENBECKS ARCH C S, P59; 1991, NEW ENGL J MED, V324, P1073	15	226	229	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					619	620		10.1136/bmj.311.7005.619	http://dx.doi.org/10.1136/bmj.311.7005.619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663258	Green Published			2022-12-24	WOS:A1995RT72300025
J	ZHOU, XJ; BENSON, KF; ASHAR, HR; CHADA, K				ZHOU, XJ; BENSON, KF; ASHAR, HR; CHADA, K			MUTATION RESPONSIBLE FOR THE MOUSE PYGMY PHENOTYPE IN THE DEVELOPMENTALLY-REGULATED FACTOR HMGI-C	NATURE			English	Article							GROUP PROTEIN HMG-I(Y); GENE; EXPRESSION; DOMAIN; LOCUS	GROWTH is one of the fundamental aspects in the development of an organism. Classical genetic studies have isolated four viable, spontaneous mouse mutants' disrupted in growth, leading to dwarfism. Pygmy is unique among these mutants because its phenotype cannot be explained by aberrations in the growth hormone-insulin-like growth factor endocrine pathway(2-5). Here we show that the pygmy phenotype arises from the inactivation of Hmgi-c (ref. 6), a member of the Hmgi family(7) which function as architectural factors in the nuclear scaffolds and are critical in the assembly of stereospecific transcriptional complexes(9). Hmgi-c and another Hmgi family member, Hmgi(y) (ref. 10), were found to be expressed predominantly during embryogenesis. The HMGI proteins are known to be regulated by cell cycle-dependent phosphorylation which alters their DNA binding affinity(11). These results demonstrate the important role of HMGI proteins in mammalian growth and development.			ZHOU, XJ (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854, USA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; Green MC., 1989, GENETIC VARIANTS STR, P12; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KING J, 1955, GENETICS, V53, P487; LEHRACH H., 1990, GENOME ANAL, P39; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; NISSLEY SP, 1980, HORM METAB RES, V12, P158, DOI 10.1055/s-2007-996230; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SINHA YN, 1979, P SOC EXP BIOL MED, V162, P221, DOI 10.3181/00379727-162-40651; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; XIANG X, 1990, SCIENCE, V247, P967, DOI 10.1126/science.2305264	24	531	554	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					771	774		10.1038/376771a0	http://dx.doi.org/10.1038/376771a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651535				2022-12-24	WOS:A1995RR83600039
J	PARISH, S; COLLINS, R; PETO, R; YOUNGMAN, L; BARTON, J; JAYNE, K; CLARKE, R; APPLEBY, P; LYON, V; CEDERHOLMWILLIAMS, S; MARSHALL, J; SLEIGHT, P				PARISH, S; COLLINS, R; PETO, R; YOUNGMAN, L; BARTON, J; JAYNE, K; CLARKE, R; APPLEBY, P; LYON, V; CEDERHOLMWILLIAMS, S; MARSHALL, J; SLEIGHT, P			CIGARETTE-SMOKING, TAR YIELDS, AND NONFATAL MYOCARDIAL-INFARCTION - 14000 CASES AND 32000 CONTROLS IN THE UNITED-KINGDOM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SCOTTISH-HEART-HEALTH; FILTER CIGARETTE; LUNG-CANCER; NICOTINE; RISK; SMOKERS; COTININE	Objectives-To assess the effects of cigarette smoking on the incidence of non-fatal myocardial infarction, and to compare tar in different types of manufactured cigarettes. Methods-In the early 1990s responses to a postal questionnaire were obtained from 13 926 survivors of myocardial infarction (cases) recently discharged from hospitals in the United Kingdom and 32 389 of their relatives (controls). Blood had been obtained from cases soon after admission for the index myocardial infarction and was also sought from the controls. 4923 cases and 6880 controls were current smokers of manufactured cigarettes with known tar yields. Almost all tar yields were 7-9 or 12-15 mg/cigarette (mean 7.5 mg for low tar (<10 mg) and 13.3 for medium tar (greater than or equal to 10 mg)). The cited risk ratios were standardised for age and sex and compared myocardial infarction rates in current cigarette smokers with those in non-smokers who had not smoked cigarettes regularly in the past 10 years. Results-At ages 30-49 the rates of myocardial infarction in smokers were about five times those in non-smokers (as defined); at ages 50-59 they were three times those in non-smokers, and even at ages 60-79 they were twice as great as in non-smokers (risk ratio 6.3, 4.7, 3.1, 2.5, and 1.9 at 30-39, 40-49, 50-59, 60-69, 70-79 respectively; each 2P<0.00001). After standardisation for age, sex, and amount smoked, the rate of non-fatal myocardial infarction was 10.4% (SD 5.4) higher in medium tar than in low tar cigarette smokers (2P=0.06). This percentage was not significantly greater at ages 30-59 (16.6% (7.1)) than at 60-79 (1.0% (8.5)). In both age ranges the difference in risk between cigarette smokers and non-smokers was much larger than the difference between one type of cigarette and another (risk ratio 3.39 and 3.95 at ages 30-59 for smokers of similar numbers of low and of medium tar cigarettes, and risk ratio 2.35 and 2.37 at ages 60-79). Most possible confounding factors that could be tested for were similar in low and medium tar users, with no significant differences in blood lipid or albumin concentrations. Conclusion-The present study indicates that the imminent change of tar yields in the European Union to comply with an upper limit of 12 mg/cigarette will not increase (and may somewhat decrease) the incidence of myocardial infarction, unless they indirectly help perpetuate tobacco use. Even low tar cigarettes still greatly increase rates of myocardial infarction, however, especially among people in their 30s, 40s, and 50s, and far more risk is avoided by not smoking than by changing from one type of cigarette to another.	RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, EPIDEMIOL STUDIES UNIT, OXFORD OX2 6HE, ENGLAND; JOHN RADCLIFFE HOSP, DEPT CARDIAC, OXFORD OX3 9DU, ENGLAND; OXFORD BIORES LAB, OXFORD OX4 4GA, ENGLAND	Radcliffe Infirmary; University of Oxford; University of Oxford	PARISH, S (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; CASTELLI WP, 1981, LANCET, V2, P109, DOI 10.1016/S0140-6736(81)90297-X; COLLINS R, 1995, LANCET, V345, P669; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; HAMMOND EC, 1976, ENVIRON RES, V12, P263, DOI 10.1016/0013-9351(76)90036-0; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HIGENBOTTAM T, 1982, J EPIDEMIOL COMMUN H, V36, P113, DOI 10.1136/jech.36.2.113; HUNT D, 1992, LANCET, V339, P753; KAUFMAN DW, 1983, NEW ENGL J MED, V308, P409, DOI 10.1056/NEJM198302243080801; KAUFMAN DW, 1989, AM J EPIDEMIOL, V129, P703, DOI 10.1093/oxfordjournals.aje.a115185; KNIGHT GJ, 1985, CLIN CHEM, V31, P118; LEE PN, 1981, J EPIDEMIOL COMMUN H, V35, P16, DOI 10.1136/jech.35.1.16; NEGRI E, 1993, BRIT MED J, V306, P1567, DOI 10.1136/bmj.306.6892.1567; PALMER JR, 1989, NEW ENGL J MED, V320, P1569, DOI 10.1056/NEJM198906153202401; PETITTI DB, 1985, J CHRON DIS, V38, P581, DOI 10.1016/0021-9681(85)90047-5; Peto R, 1994, MORTALITY SMOKING DE; STELLMAN SD, 1989, PREV MED, V18, P518, DOI 10.1016/0091-7435(89)90010-8; VUTUC C, 1983, J NATL CANCER I, V71, P435; WALD N, 1991, UK SMOKING STATISTIC; Wald N, 1989, NICOTINE SMOKING LOW; WOODWARD M, 1993, ADDICTION, V88, P821, DOI 10.1111/j.1360-0443.1993.tb02096.x; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, BRIT J ADDICT, V87, P921; WYNDER EL, 1979, NEW ENGL J MED, V300, P894, DOI 10.1056/NEJM197904193001605; WYNDER EL, 1979, J NATL CANCER I, V62, P471, DOI 10.1093/jnci/62.3.471; ZARIDZE D, 1986, IARC SCI PUBLICATION, V74; 1994, STATISTICAL B DEPT H, V14	29	159	162	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	1995	311	7003					471	477		10.1136/bmj.311.7003.471	http://dx.doi.org/10.1136/bmj.311.7003.471			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647641	Green Published			2022-12-24	WOS:A1995RQ67000012
J	STROES, ESG; KOOMANS, HA; DEBRUIN, TWA; RABELINK, TJ				STROES, ESG; KOOMANS, HA; DEBRUIN, TWA; RABELINK, TJ			VASCULAR FUNCTION IN THE FOREARM OF HYPERCHOLESTEROLEMIC PATIENTS OFF AND ON LIPID-LOWERING MEDICATION	LANCET			English	Article							ENDOTHELIUM-DEPENDENT VASODILATION; RESISTANCE VESSELS; CORONARY-ARTERIES; NITRIC-OXIDE; L-ARGININE; RELEASE; CHOLESTEROL; HUMANS	To study whether vascular dysfunction in hypercholesterolaemia is reversible, we investigated patients without overt arterial disease who were taking maintenance treatment for hypercholesterolaemia. Medication was stopped for 2 weeks, reinstituted for 12 weeks, and again stopped for 6 weeks. During both maintenance treatment and the 12 weeks of step-up medication the lipid profile was improved but did not return to normal. Dose-response curves for serotonin-induced vasodilatation, an index of nitric oxide-dependent vasodilatation, showed a comparable and significant rightward shift. after a medication-free period of 2 and 6 weeks compared with control subjects, indicating endothelial dysfunction, which was already maximum after 2 weeks. After 12 weeks of lipid-lowering medication, the difference in endothelial function between controls and patients had disappeared. Go-infusion of L-arginine, the substrate for nitric oxide synthase, returned the impaired serotonin response during hypercholesterolaemia to normal, but had no effect on this response in controls or in patients while on lipid-lowering medication. Neither endothelium-independent vasorelaxation, assessed by sodium nitroprusside infusion, nor vasoconstriction induced by the nitric oxide blocker L-NMMA, were different between controls and patients, whether the latter were on or off lipid-lowering medication. Our results show an L-arginine-sensitive, impaired nitric-oxide-mediated vascular relaxation of forearm resistance vessels in hypercholesterolaemia which is reproducible, and reversible after short-term lipid-lowering therapy. Demonstration of such changes in this readily accessible vascular bed will allow larger trials assessing vascular function during lipid-lowering therapy to be done.	UNIV UTRECHT HOSP,DEPT MED,LIPID CLIN,3584 CX UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT HYPERTENS & NEPHROL,3584 CX UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center			Rabelink, Ton J./A-5316-2008	Rabelink, Ton J./0000-0001-6780-5186				ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; BRUNING TA, 1994, J CARDIOVASC PHARM, V24, P454, DOI 10.1097/00005344-199409000-00014; BRUNING TA, 1994, CIRC RES, V74, P912, DOI 10.1161/01.RES.74.5.912; BUSSE R, 1993, CIRCULATION, V87, P18; CALVER A, 1992, J CLIN INVEST, V90, P2448; CASINO PR, 1993, CIRCULATION, V88, P2541, DOI 10.1161/01.CIR.88.6.2541; CHANG PC, 1988, COMPUT BIOL MED, V18, P157, DOI 10.1016/0010-4825(88)90042-X; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CHOWIENCZYK PJ, 1992, LANCET, V340, P1430, DOI 10.1016/0140-6736(92)92621-L; CHOWIENCZYK PJ, 1995, CLIN SCI, V88, P111, DOI 10.1042/cs0880111; CHOWIENCZYK PJ, 1994, LANCET, V344, P305, DOI 10.1016/S0140-6736(94)91342-0; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DUBOISRANDE JL, 1992, J CARDIOVASC PHARM, V20, pA211; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; EGASHIRA K, 1993, J CLIN INVEST, V91, P29, DOI 10.1172/JCI116183; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Goldstein JL, 1983, METABOLIC BASIS INHE, P672; HARRISON DG, 1995, AM J CARDIOL, V75, pB75, DOI 10.1016/0002-9149(95)80018-N; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; PRITCHARD KA, 1995, ENDOTHELIUM S, V2, pS19; RABELINK AJ, 1988, LANCET, V2, P1335; SHIMOKAWA H, 1991, CIRCULATION, V83, P652, DOI 10.1161/01.CIR.83.2.652; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801	28	373	380	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					467	471		10.1016/S0140-6736(95)91322-X	http://dx.doi.org/10.1016/S0140-6736(95)91322-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637480				2022-12-24	WOS:A1995RP85700010
J	HELLER, BA; HOLTEN, D; KIRMAIER, C				HELLER, BA; HOLTEN, D; KIRMAIER, C			CONTROL OF ELECTRON-TRANSFER BETWEEN THE L-SIDE AND M-SIDE OF PHOTOSYNTHETIC REACTION CENTERS	SCIENCE			English	Article							RHODOBACTER-SPHAEROIDES R-26; INITIAL CHARGE SEPARATION; BACTERIAL REACTION CENTERS; STARK-EFFECT SPECTROSCOPY; RHODOPSEUDOMONAS-VIRIDIS; PROTEIN INTERACTIONS; TRANSFER DYNAMICS; TRANSIENT STATES; BACTERIOPHEOPHYTIN; MECHANISM	An aspartic acid residue has been introduced near ring V of the L-side accessory bacteriochlorophyll (BChl(L)) of the photosynthetic reaction center in a Rhodobacter capsulatus mutant in which a His also replaces Leu 212 on the M-polypeptide. The initial stage of charge separation in the G(M201)D/L(M212)H double mutant yields similar to 70 percent electron transfer to the L-side cofactors, similar to 15 percent rapid deactivation to the ground state, and similar to 15 percent electron transfer to the so-called inactive M-side bacteriopheophytin (BPh(M)). It is suggested here that the Asp introduced at M201 modulates the reduction potential of BChl(L), thereby changing the energetics of charge separation. The results demonstrate that an individual amino acid residue can, through its influence on the free energies of the charge-separated states, effectively dictate the balance between the forward electron transfer reactions on the L-side of the RC, the charge-recombination processes, and electron transfer to the M-side chromophores.			HELLER, BA (corresponding author), WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130, USA.							ARLT T, 1993, P NATL ACAD SCI USA, V90, P11757, DOI 10.1073/pnas.90.24.11757; BIXON M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P301, DOI 10.1016/S0005-2728(05)80062-3; BIXON M, 1989, BIOCHIM BIOPHYS ACTA, V977, P273, DOI 10.1016/S0005-2728(89)80081-7; BIXON M, 1992, PHOTOSYNTHETIC BACTE, V2, P291; Breton J., 1990, STRUCTURE FUNCTION B; BYLINA EJ, 1988, NATURE, V336, P182, DOI 10.1038/336182a0; CHAN CK, 1991, P NATL ACAD SCI USA, V88, P11202, DOI 10.1073/pnas.88.24.11202; CHEKALIN SV, 1987, FEBS LETT, V216, P245, DOI 10.1016/0014-5793(87)80698-1; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Deisenhofer J., 1993, PHOTOSYNTHETIC REACT, V2; ECCLES J, 1983, P NATL ACAD SCI-BIOL, V80, P4959, DOI 10.1073/pnas.80.16.4959; ELKABBANI O, 1991, BIOCHEMISTRY-US, V30, P5361, DOI 10.1021/bi00236a006; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; FINKELE U, 1990, BIOCHEMISTRY-US, V29, P8517, DOI 10.1021/bi00489a002; FRIESNER RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P99, DOI 10.1016/S0005-2728(89)80062-3; GOLDSTEIN RA, 1988, BIOCHIM BIOPHYS ACTA, V934, P253, DOI 10.1016/0005-2728(88)90189-2; GOTTFRIED DS, 1991, BIOCHIM BIOPHYS ACTA, V1059, P76, DOI 10.1016/S0005-2728(05)80189-6; GRAY KA, 1992, EUR J BIOCHEM, V207, P723, DOI 10.1111/j.1432-1033.1992.tb17102.x; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HANSON LK, 1987, J AM CHEM SOC, V109, P4728, DOI 10.1021/ja00249a050; HELLER B, UNPUB; HELLER BA, 1995, BIOCHEMISTRY-US, V34, P5294, DOI 10.1021/bi00015a045; JIA YW, 1993, J PHYS CHEM-US, V97, P13180, DOI 10.1021/j100152a024; KELLOGG EC, 1989, PHOTOSYNTH RES, V22, P47, DOI 10.1007/BF00114766; KIRMAIER C, 1991, SCIENCE, V251, P922, DOI 10.1126/science.2000491; KIRMAIER C, 1985, BIOCHIM BIOPHYS ACTA, V810, P49, DOI 10.1016/0005-2728(85)90205-1; KIRMAIER C, 1995, J PHYS CHEM-US, V99, P8903, DOI 10.1021/j100021a067; KIRMAIER C, 1995, J PHYS CHEM-US, V99, P8910, DOI 10.1021/j100021a068; KIRMAIER C, 1991, BIOCHEMISTRY-US, V30, P609, DOI 10.1021/bi00217a003; KIRMAIER C, 1988, P NATL ACAD SCI USA, V85, P7562, DOI 10.1073/pnas.85.20.7562; KORNIYA H, 1988, P NATL ACAD SCI USA, V85, P9012; LAPORTE L, 1993, CHEM PHYS, V176, P615, DOI 10.1016/0301-0104(93)80265-B; LAPORTE L, IN PRESS CHEM PHYS; LOCKHART DJ, 1988, P NATL ACAD SCI USA, V85, P107, DOI 10.1073/pnas.85.1.107; LOSCHE M, 1987, P NATL ACAD SCI USA, V84, P7537, DOI 10.1073/pnas.84.21.7537; MAITI S, 1994, P NATL ACAD SCI USA, V91, P10360, DOI 10.1073/pnas.91.22.10360; MARCHI M, 1993, J AM CHEM SOC, V115, P4178, DOI 10.1021/ja00063a041; MCDOWELL LM, 1991, BIOCHEMISTRY-US, V30, P8315, DOI 10.1021/bi00098a006; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHELBEYERLE ME, 1988, BIOCHIM BIOPHYS ACTA, V932, P52, DOI 10.1016/0005-2728(88)90139-9; MURCHISON HA, 1993, BIOCHEMISTRY-US, V32, P3498, DOI 10.1021/bi00064a038; NAGARAJAN V, 1993, BIOCHEMISTRY-US, V32, P12324, DOI 10.1021/bi00097a008; OGRODNIK A, 1994, J PHYS CHEM-US, V98, P3432, DOI 10.1021/j100064a026; PALANIAPPAN V, 1995, J AM CHEM SOC, V117, P3647, DOI 10.1021/ja00117a048; PARSON WW, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251, DOI 10.1016/0005-2728(90)90192-7; ROBERT B, 1985, FEBS LETT, V183, P326, DOI 10.1016/0014-5793(85)80803-6; SCHENCK CC, 1981, BIOCHIM BIOPHYS ACTA, V635, P383, DOI 10.1016/0005-2728(81)90036-0; SCHERER POJ, 1989, CHEM PHYS, V131, P115, DOI 10.1016/0301-0104(89)87084-3; SCHMIDT S, 1994, CHEM PHYS LETT, V223, P116, DOI 10.1016/0009-2614(94)00429-3; SHKUROPATOV AY, 1993, FEBS LETT, V322, P168, DOI 10.1016/0014-5793(93)81561-D; STEPHAN MA, 1994, SCIENCE, V264, P810; TAGUCHI AKW, 1992, BIOCHEMISTRY-US, V31, P10345, DOI 10.1021/bi00157a024; THOMPSON MA, 1991, J AM CHEM SOC, V113, P8210, DOI 10.1021/ja00022a003; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; WILLIAMS JC, 1992, BIOCHEMISTRY-US, V31, P11209; WOODBURY NW, 1994, BIOCHEMISTRY-US, V33, P8101, DOI 10.1021/bi00192a015; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	58	192	200	1	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					940	945		10.1126/science.7638616	http://dx.doi.org/10.1126/science.7638616			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638616				2022-12-24	WOS:A1995RP73800025
J	LEVYLAHAD, E; WIJSMAN, EM; NEMENS, E; ANDERSON, L; GODDARD, KAB; WEBER, JL; BIRD, TD; SCHELLENBERG, GD				LEVYLAHAD, E; WIJSMAN, EM; NEMENS, E; ANDERSON, L; GODDARD, KAB; WEBER, JL; BIRD, TD; SCHELLENBERG, GD			A FAMILIAL ALZHEIMERS-DISEASE LOCUS ON CHROMOSOME-1	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E; LINKAGE ANALYSIS; TYPE-4 ALLELE; BETA-PROTEIN; GENE; HETEROGENEITY; MARKERS; CONSTRUCTION; MUTATION	The Volga German kindreds are a group of seven related families with autosomal dominant early-onset Alzheimer's disease (AD). Linkage to known AD-related loci on chromosomes 21 and 14 has been excluded. Significant evidence for linkage to AD in these families was obtained with D1S479 and there was also positive evidence for linkage with other markers in the region. A 112-base pair allele of D1S479 co-segregated with the disease in five of seven families, which is consistent with a common genetic founder. This study demonstrates the presence of an AD locus on chromosome 1q31-42.	VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA 98108; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449; VET AFFAIRS MED CTR,DIV NEUROL,SEATTLE,WA 98108	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Levy-Lahad, Ephrat/F-2186-2018	Levy-Lahad, Ephrat/0000-0002-2637-1921	NHGRI NIH HHS [HG00835] Funding Source: Medline; NIA NIH HHS [F32 AG05635, AG05136] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG005635] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENJAMIN R, 1994, LANCET, V344, P473, DOI 10.1016/S0140-6736(94)91804-X; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BIRD TD, 1992, HETEROGENEITY ALZHEI, P118; BIRD TD, 1991, AM HIST SOC GERM RUS, V49; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BROUSSEAU T, 1994, NEUROLOGY, V342; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAVALLISFORZA LL, 1986, AM J HUM GENET, V38, P599; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HIXSON JE, 1990, J LIPID RES, V31, P545; HODGE SE, 1983, AM J HUM GENET, V35, P1139; KAMINO K, 1992, AM J HUM GENET, V51, P998; KONG A, 1993, GENET EPIDEMIOL, V10, P483, DOI 10.1002/gepi.1370100626; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LANNFELT L, 1993, NAT GENET, V4, P218, DOI 10.1038/ng0793-218; LEVYLAHAD E, IN PRESS ANN NEUROL; LIDDELL M, 1994, J MED GENET, V31, P197, DOI 10.1136/jmg.31.3.197; Lin S., 1994, American Journal of Human Genetics, V55, pA40; LIN SL, 1993, IMA J MATH APPL MED, V10, P1; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MORTON NE, 1955, AM J HUM GENET, V7, P277; OTT J, 1974, AM J HUM GENET, V26, P588; OTT J, 1992, AM J HUM GENET, V51, P283; Ott J., 1991, ANAL HUMAN GENETIC L; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; SCHELLENBERG GD, 1992, ANN NEUROL, V31, P223, DOI 10.1002/ana.410310214; SHERRINGTON, 1995, NATURE, V375, P754; SMITH AD, 1994, LANCET, V344, P473; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TSAI MS, 1994, AM J HUM GENET, V54, P643; VANDUIJN CM, 1994, AM J HUM GENET, V55, P714; YU CE, 1994, AM J HUM GENET, V54, P631; 1993, LANCET, V342, P737	49	629	652	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					970	973		10.1126/science.7638621	http://dx.doi.org/10.1126/science.7638621			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638621				2022-12-24	WOS:A1995RP73800034
J	VENANCE, L; PIOMELLI, D; GLOWINSKI, J; GIAUME, C				VENANCE, L; PIOMELLI, D; GLOWINSKI, J; GIAUME, C			INHIBITION BY ANANDAMIDE OF GAP-JUNCTIONS AND INTERCELLULAR CALCIUM SIGNALING IN STRIATAL ASTROCYTES	NATURE			English	Article							SINGLE-CHANNEL CURRENTS; CANNABINOID RECEPTOR; COMMUNICATION; WAVES; PROTEIN; BINDS; CELLS	ANANDAMIDE, an endogenous arachidonic acid derivative that is released from neurons and activates cannabinoid receptors(1), may act as a transcellular cannabimimetic messenger in the central nervous system(2-4). The biological actions of anandamide and the identity of its target cells are, however, still poorly documented(5). Here we show that anandamide is a potent inhibitor of gap-junction conductance and dye permeability in striatal astrocytes. This inhibitory effect is specific for anandamide as compared to coreleased congeners(4) or structural analogues, is sensitive to pertussis toxin and to protein-alkylating agents, and is neither mimicked by cannabinoid-receptor agonists nor prevented by a cannabinoid-receptor antagonist. Glutamate released from neurons evokes calcium waves in astrocytes(6) that propagate via gap junctions(7-9), and may, in turn, activate neurons distant from their initiation sites in astrocytes(10-12). We find that anandamide blocks the propagation of astrocyte calcium waves generated by either mechanical stimulation or local glutamate application. Thus, by regulating gap-junction permeability, anandamide may control intercellular communication in astrocytes and therefore neuron-glial interactions.	COLL FRANCE,INSERM,U114,F-75231 PARIS 05,FRANCE; INST NEUROSCI,LA JOLLA,CA 92037	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			Venance, Laurent/E-5840-2016	Venance, Laurent/0000-0003-0738-1662				CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; COMELLBELL AH, 1990, SCIENCE, V247, P470; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; DEVANE WA, 1994, TRENDS PHARMACOL SCI, V15, P40, DOI 10.1016/0165-6147(94)90106-6; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIAUME C, 1991, P NATL ACAD SCI USA, V88, P5577, DOI 10.1073/pnas.88.13.5577; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MURPHY NP, 1994, EUR J NEUROSCI, V6, P854, DOI 10.1111/j.1460-9568.1994.tb00995.x; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960-9822(00)00178-0	28	309	315	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					590	594		10.1038/376590a0	http://dx.doi.org/10.1038/376590a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637807	Green Submitted			2022-12-24	WOS:A1995RP75600050
J	DURING, MJ; NAEGELE, JR; OMALLEY, KL; GELLER, AI				DURING, MJ; NAEGELE, JR; OMALLEY, KL; GELLER, AI			LONG-TERM BEHAVIORAL RECOVERY IN PARKINSONIAN RATS BY AN HSV VECTOR EXPRESSING TYROSINE-HYDROXYLASE	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; AMINO-ACID DECARBOXYLASE; COLI BETA-GALACTOSIDASE; STRIATAL NEURONS; CEREBRAL-CORTEX; GENE-THERAPY; DOPAMINE; DISEASE; ORGANIZATION; INVIVO	One therapeutic approach to treating Parkinson's disease is to convert endogenous striatal cells into levo-3,4-dihydroxyphenylalanine (L-dopa)-producing cells. A defective herpes simplex virus type 1 vector expressing human tyrosine hydroxylase was delivered into the partially denervated striatum of 6-hydroxydopamine-lesioned rats, used as a model of Parkinson's disease. Efficient behavioral and biochemical recovery was maintained for 1 year after gene transfer. Biochemical recovery included increases in both striatal tyrosine hydroxylase enzyme activity and in extracellular dopamine concentrations. Persistence of human tyrosine hydroxylase was revealed by expression of RNA and immunoreactivity.	YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06510 USA; WESLEYAN UNIV, DEPT BIOL, MIDDLETOWN, CT 06457 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA	Yale University; Wesleyan University; Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	DURING, MJ (corresponding author), YALE UNIV, SCH MED, DEPT SURG, NEW HAVEN, CT 06510 USA.		Geller, Alfred/C-6469-2012; During, Matthew/AAC-1388-2020	Naegele, Janice Rae/0000-0001-5151-0543	NEI NIH HHS [EY09749] Funding Source: Medline; NINDS NIH HHS [NS06208, NS28227] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY009749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006208, R29NS028227] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RL, 1984, J PATHOL, V143, P241, DOI 10.1002/path.1711430403; BAKAY RAE, 1987, ANN NY ACAD SCI, V495, P623, DOI 10.1111/j.1749-6632.1987.tb23705.x; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; CASS WA, 1993, J NEUROCHEM, V61, P2269, DOI 10.1111/j.1471-4159.1993.tb07469.x; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COKER GT, 1990, MOL BRAIN RES, V8, P93, DOI 10.1016/0169-328X(90)90052-F; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; DUBACH M, 1987, NEUROSCI LETT, V75, P205, DOI 10.1016/0304-3940(87)90298-9; DURING MJ, 1992, EXP NEUROL, V115, P193, DOI 10.1016/0014-4886(92)90053-S; EMSON PC, 1990, EXP BRAIN RES, V79, P427, DOI 10.1007/BF00608254; FEDEROFF HJ, 1992, P NATL ACAD SCI USA, V89, P1636, DOI 10.1073/pnas.89.5.1636; FREED R, 1992, NEW ENGL J MED, V327, P1640; FREED WJ, 1980, ANN NEUROL, V8, P510, DOI 10.1002/ana.410080508; FREESE A, 1991, NUCLEIC ACIDS RES, V19, P7219, DOI 10.1093/nar/19.25.7219; GAGE FH, 1991, TRENDS NEUROSCI, V14, P328, DOI 10.1016/0166-2236(91)90156-O; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P1149, DOI 10.1073/pnas.87.3.1149; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P8950, DOI 10.1073/pnas.87.22.8950; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GELLER AI, IN PRESS J NEUROCHEM; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HAYCOCK JW, COMMUNICATION; HEFTI F, 1980, PHARMACOL BIOCHEM BE, V12, P185, DOI 10.1016/0091-3057(80)90353-6; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1; HORELLOU P, 1990, NEURON, V5, P393, DOI 10.1016/0896-6273(90)90078-T; JIAO SS, 1993, NATURE, V362, P450, DOI 10.1038/362450a0; KOSAKA T, 1987, EXP BRAIN RES, V68, P393; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LEWIS DA, 1993, NEUROSCIENCE, V54, P477, DOI 10.1016/0306-4522(93)90267-J; LI XM, 1992, J NEUROCHEM, V59, P1172, DOI 10.1111/j.1471-4159.1992.tb08363.x; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LOMBROSO PJ, 1993, J NEUROSCI, V13, P3064; MCGEOCH DJ, 1986, NUCLEIC ACIDS RES, V14, P1727, DOI 10.1093/nar/14.4.1727; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; MCGEORGE AJ, 1987, BRAIN RES, V423, P318, DOI 10.1016/0006-8993(87)90855-9; MOSCA JD, 1985, J VIROL, V56, P867, DOI 10.1128/JVI.56.3.867-878.1985; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P6910, DOI 10.1021/bi00396a007; PERESE DA, 1989, BRAIN RES, V494, P285, DOI 10.1016/0006-8993(89)90597-0; REDMOND DE, 1986, LANCET, V1, P1125; ROBERT F, 1993, J NEUROCHEM, V60, P721, DOI 10.1111/j.1471-4159.1993.tb03207.x; ROHRER H, 1986, J NEUROSCI, V6, P2616; SCHNEIDER JS, 1994, BRAIN RES, V643, P86, DOI 10.1016/0006-8993(94)90012-4; SLADEK JR, 1988, PROG BRAIN RES, V78, P497; SMITH RE, UNPUB, P54011; Song S., UNPUB; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STAINES WA, 1981, BRAIN RES, V206, P446, DOI 10.1016/0006-8993(81)90545-X; STEVENS JG, 1987, SCIENCE, V235, P1056, DOI 10.1126/science.2434993; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TASHIRO Y, 1989, NEUROSCI LETT, V97, P6, DOI 10.1016/0304-3940(89)90130-4; TASHIRO Y, 1989, NEUROSCI LETT, V100, P29, DOI 10.1016/0304-3940(89)90655-1; VANHORNE C, 1992, J PHARMACOL EXP THER, V263, P1285; VECSEI L, 1992, NEUROLOGICAL DISORDE, P223; WANG J, 1994, J NEUROSURG, V80, P484, DOI 10.3171/jns.1994.80.3.0484; WATSON K, 1980, J GEN VIROL, V49, P149, DOI 10.1099/0022-1317-49-1-149; WESTERINK BHC, 1990, J NEUROCHEM, V54, P381, DOI 10.1111/j.1471-4159.1990.tb01884.x; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; WILSON CJ, 1987, J COMP NEUROL, V263, P567, DOI 10.1002/cne.902630408; WOLFF JA, 1989, P NATL ACAD SCI USA, V86, P9011, DOI 10.1073/pnas.86.22.9011; YAHR MD, 1969, ARCH NEUROL-CHICAGO, V21, P343, DOI 10.1001/archneur.1969.00480160015001; YAHR MD, 1987, PARKINSONS DISEASE; YUREK DM, 1990, ANNU REV NEUROSCI, V13, P415, DOI 10.1146/annurev.neuro.13.1.415	62	314	336	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1399	1403		10.1126/science.266.5189.1399	http://dx.doi.org/10.1126/science.266.5189.1399			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7669103	Green Accepted			2022-12-24	WOS:A1994PT63200048
J	MUNRO, S; THOMAS, KL; ABUSHAAR, M				MUNRO, S; THOMAS, KL; ABUSHAAR, M			MOLECULAR CHARACTERIZATION OF A PERIPHERAL RECEPTOR FOR CANNABINOIDS	NATURE			English	Article							RAT-BRAIN; INSITU HYBRIDIZATION; CLONING; INVITRO; CDNA	THE major active ingredient of marijuana, DELTA9-tetrahydrocannabinol (DELTA9-THC), has been used as a psychoactive agent for thousands of years. Marijuana, and DELTA9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting1. The clinical application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochemical bases of their action. Progress stemmed initially from the synthesis of potent derivatives of DELTA9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids6. This receptor is expressed in the brain but not in the periphery, except for a low level in testes. It has been proposed that the non-psychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins1,7,8. Here we report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.			MUNRO, S (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Thomas, Kerrie L/A-6509-2010	Thomas, Kerrie L/0000-0003-3355-9583; Munro, Sean/0000-0001-6160-5773				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; COLLINS SJ, 1987, BLOOD, V70, P1233; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DALLMAN MJ, 1982, EUR J IMMUNOL, V12, P511, DOI 10.1002/eji.1830120612; DEVANE WA, 1992, J MED CHEM, V35, P2065, DOI 10.1021/jm00089a018; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOLLISTER LE, 1992, J PSYCHOACTIVE DRUGS, V24, P159, DOI 10.1080/02791072.1992.10471635; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; HOWLETT AC, 1990, TRENDS NEUROSCI, V13, P420, DOI 10.1016/0166-2236(90)90124-S; HUMPHREY JH, 1981, EUR J IMMUNOL, V11, P221, DOI 10.1002/eji.1830110311; JANSEN EM, 1992, BRAIN RES, V575, P93, DOI 10.1016/0006-8993(92)90428-C; KESHAV S, 1991, J EXP MED, V174, P1049, DOI 10.1084/jem.174.5.1049; KRAAL G, 1992, INT REV CYTOL, V132, P31, DOI 10.1016/S0074-7696(08)62453-5; LEE J, 1992, J BIOL CHEM, V267, P16283; LOPEZCEPERO M, 1986, J LEUKOCYTE BIOL, V39, P679, DOI 10.1002/jlb.39.6.679; MAILLEUX P, 1992, NEUROSCIENCE, V48, P655, DOI 10.1016/0306-4522(92)90409-U; MARTIN BR, 1986, PHARMACOL REV, V38, P45; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNSON AE, 1983, ADVERSE HLTH BEHAVIO, P257; RAZDAN RK, 1986, PHARMACOL REV, V38, P75; REICHMAN M, 1991, MOL PHARMACOL, V40, P547; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; SCHATZ AR, 1992, LIFE SCI, V51, P25; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIRASAWA T, 1992, NUCLEIC ACIDS RES, V20, P909, DOI 10.1093/nar/20.4.909; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	34	3811	4012	6	245	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					61	65		10.1038/365061a0	http://dx.doi.org/10.1038/365061a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	7689702				2022-12-24	WOS:A1993LV64600054
J	WANG, N; BUTLER, JP; INGBER, DE				WANG, N; BUTLER, JP; INGBER, DE			MECHANOTRANSDUCTION ACROSS THE CELL-SURFACE AND THROUGH THE CYTOSKELETON	SCIENCE			English	Article							VASCULAR ENDOTHELIAL-CELLS; RAT CARDIAC MYOCYTES; MECHANICAL FORCES; PC-12 NEURITES; SHEAR-STRESS; STRETCH; TENSION; MATRIX; ORGANIZATION; STIMULATION	Mechanical stresses were applied directly to cell surface receptors with a magnetic twisting device. The extracellular matrix receptor, integrin beta1, induced focal adhesion formation and supported a force-dependent stiffening response, whereas nonadhesion receptors did not. The cytoskeletal stiffness (ratio of stress to strain) increased in direct proportion to the applied stress and required intact microtubules and intermediate filaments as well as microfilaments. Tensegrity models that incorporate mechanically interdependent struts and strings that reorient globally in response to a localized stress mimicked this response. These results suggest that integrins act as mechanoreceptors and transmit mechanical signals to the cytoskeleton. Mechanotransduction, in turn, may be mediated simultaneously at multiple locations inside the cell through force-induced rearrangements within a tensionally integrated cytoskeleton.	CHILDRENS HOSP MED CTR,DEPT SURG,ENDERS 1007,300 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,RESP BIOL PROGRAM,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Ingber, Donald E/AAC-5894-2019; Wang, Ning/B-6966-2008		NCI NIH HHS [CA45548] Funding Source: Medline; NHLBI NIH HHS [HL-33009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; [Anonymous], 1956, MATH THEORY ELASTICI; BIZAL CL, 1991, J LEUKOCYTE BIOL, V50, P240, DOI 10.1002/jlb.50.3.240; BRODLAND GW, 1991, J BIOMECH ENG, V112, P319; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUXBAUM RE, 1988, J THEOR BIOL, V134, P379, DOI 10.1016/S0022-5193(88)80068-7; CIPRIANO LF, 1991, PHYSIOLOGIST, V34, P72; DEGROOT RP, 1990, J CELL SCI, V97, P33; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FOLKMAN J, 1989, CELL, V58, P803; FOLKMAN J, 1989, J CELL BIOL, V109, P317; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; Fuller B., 1961, PORTFOLIO ARTNEWS AN, V4, P112; FUNG YC, 1988, BIOMECHANICS; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532, DOI 10.1152/ajplegacy.1967.213.6.1532; HARRIS RC, 1992, LAB INVEST, V66, P548; HAY M, 1991, CELL MOTIL CYTOSKEL, V18, P63, DOI 10.1002/cm.970180107; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; Ingber D., 1993, PHYSICAL FORCES MAMM, P61; Ingber D. E, 1989, CELL SHAPE DETERMINA, P3; INGBER DE, 1993, J CELL SCI, V104, P613; Ingber DE., 1985, GENE EXPRESSION NORM, P13; INGBER DE, 1972, P NATL ACAD SCI USA, V69, P3579; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; KACAHR B, 1990, HEARING RES, V45, P179; Koch JC, 1917, AM J ANAT, V21, P177, DOI 10.1002/aja.1000210202; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; McMahon T.A., 1984, MUSCLES REFLEXES LOC; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NICKOLLS GH, 1992, J CELL SCI, V102, P753; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; PETERSEN NO, 1982, P NATL ACAD SCI-BIOL, V79, P5327, DOI 10.1073/pnas.79.17.5327; PIENTA KJ, 1991, MED HYPOTHESES, V34, P88, DOI 10.1016/0306-9877(91)90072-7; PINTO JG, 1973, J BIOMECH, V6, P597, DOI 10.1016/0021-9290(73)90017-1; RYAN TJ, 1989, J AM ACAD DERMATOL, V21, P115, DOI 10.1016/S0190-9622(89)70156-0; SAMUEL JL, 1990, IN VITRO CELL DEV B, V26, P905; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SIMS JR, 1992, J CELL SCI, V103, P1215; STAMENOVIC D, 1990, PHYSIOL REV, V70, P1117, DOI 10.1152/physrev.1990.70.4.1117; SUMPIO BE, 1988, ARCH SURG-CHICAGO, V123, P1233; TERRACIO L, 1988, IN VITRO CELL DEV B, V24, P53; VALBERG PA, 1984, SCIENCE, V224, P513, DOI 10.1126/science.6710153; VALBERG PA, 1985, J CELL BIOL, V101, P130, DOI 10.1083/jcb.101.1.130; VALBERG PA, 1987, BIOPHYS J, V52, P537, DOI 10.1016/S0006-3495(87)83243-5; WAGNER VT, 1992, P NATL ACAD SCI USA, V89, P3644, DOI 10.1073/pnas.89.8.3644; WARD IM, 1983, MECHANICAL PROPERTIE; WATSON PA, 1990, J BIOL CHEM, V265, P6569; WAYNE R, 1992, J CELL SCI, V101, P611; WILSON LJ, 1990, J COMP NEUROL, V296, P343, DOI 10.1002/cne.902960302; WIRTZ HRW, 1990, SCIENCE, V250, P1266, DOI 10.1126/science.2173861; WOLOSEWICK JJ, 1979, J CELL BIOL, V82, P114, DOI 10.1083/jcb.82.1.114; YAHARA I, 1972, P NATL ACAD SCI USA, V69, P608, DOI 10.1073/pnas.69.3.608; ZANER KS, 1989, J CELL BIOL, V109, P2233, DOI 10.1083/jcb.109.5.2233; [No title captured]; [No title captured]; [No title captured]	61	2330	2418	20	565	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1124	1127		10.1126/science.7684161	http://dx.doi.org/10.1126/science.7684161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	7684161				2022-12-24	WOS:A1993LC94200029
J	DECAMPOSLIMA, PO; GAVIOLI, R; ZHANG, QJ; WALLACE, LE; DOLCETTI, R; ROWE, M; RICKINSON, AB; MASUCCI, MG				DECAMPOSLIMA, PO; GAVIOLI, R; ZHANG, QJ; WALLACE, LE; DOLCETTI, R; ROWE, M; RICKINSON, AB; MASUCCI, MG			HLA-A11 EPITOPE LOSS ISOLATES OF EPSTEIN-BARR-VIRUS FROM A HIGHLY A11+ POPULATION	SCIENCE			English	Article							DETECTED MEMBRANE ANTIGEN; BURKITTS-LYMPHOMA CELLS; EBV LATENT GENES; RESTRICTED EXPRESSION; STRUCTURAL PROTEINS; BACTERIOPHAGE-T4; CLEAVAGE; LINES; HEAD	Cytotoxic T lymphocytes (CTLs) control viral infections by recognizing viral peptides presented by major histocompatibility complex (MHC) class I molecules. Human leukocyte antigen (HLA)-A11-restricted CTLs that recognize peptide residues 416 to 424 of the Epstein-Barr virus (EBV) nuclear antigen-4 frequently dominate EBV-induced responses in A11+ Caucasian donors. This epitope is conserved in type A EBV strains from Caucasians and central African populations, where A11 is relatively infrequent. However, strains from highly A11+ populations in New Guinea carry a lysine-to-threonine mutation at residue 424 that abrogates CTL recognition and binding of the peptide to nascent A11 molecules. The results suggest that evolution of a widespread and genetically stable virus such as EBV is influenced by pressure from MHC-restricted CTL responses.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN; UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	Karolinska Institutet; University of Birmingham			de Campos-Lima, Pedro Otavio/I-3495-2013; Gavioli, Riccardo/K-7594-2016; Masucci, Maria G/B-8588-2009; Dolcetti, Riccardo/O-3832-2015; Rowe, Martin/B-2880-2009; Masucci, Maria/AAC-6666-2019	de Campos-Lima, Pedro Otavio/0000-0001-8024-8628; Gavioli, Riccardo/0000-0002-7805-4290; Dolcetti, Riccardo/0000-0003-1625-9853; Rowe, Martin/0000-0003-4139-7326; Masucci, Maria/0000-0002-5541-2809	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA30264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1989, HUM BIOL, V61, P45; COLOMBANI J, 1982, TISSUE ANTIGENS, V20, P161; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DUMAS B, 1975, CLIN CHEM, V21, P1159; GAVIOLI R, 1992, P NATL ACAD SCI USA, V89, P5862, DOI 10.1073/pnas.89.13.5862; GAVIOLI R, 1993, J VIROL, V67, P1572, DOI 10.1128/JVI.67.3.1572-1578.1993; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HIRS C, 1977, ENZYME STRUCTURE, V47, P501; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; MASUCCI MG, 1992, INT IMMUNOL, V4, P1283, DOI 10.1093/intimm/4.11.1283; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; MORRIS PJ, 1973, HISTOCOMPATIBILITY T, P267; MOSS D, 1978, INT J CANCER, V23, P618; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIZZO PA, 1978, NATURE, V272, P629, DOI 10.1038/272629a0; POPE JH, 1968, AUST J EXP BIOL MED, V46, P643, DOI 10.1038/icb.1968.171; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SERJEANTSON S, 1989, COLONIZATION PACIFIC, V7, P120; TORSTEINSDOTTIR S, 1986, P NATL ACAD SCI USA, V83, P5620, DOI 10.1073/pnas.83.15.5620; WALLACE LE, 1982, NATURE, V297, P413, DOI 10.1038/297413a0; ZHANG QJ, 1993, P NATL ACAD SCI USA, V90, P2217, DOI 10.1073/pnas.90.6.2217; ZIMBER U, 1986, VIROLOGY, V154, P56, DOI 10.1016/0042-6822(86)90429-0	31	225	226	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					98	100		10.1126/science.7682013	http://dx.doi.org/10.1126/science.7682013			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682013				2022-12-24	WOS:A1993KV42300037
J	MACFARLANE, DE; DAHLE, CE				MACFARLANE, DE; DAHLE, CE			ISOLATING RNA FROM WHOLE-BLOOD - THE DAWN OF RNA-BASED DIAGNOSIS	NATURE			English	Article							POLYMERASE CHAIN-REACTION; BONE-MARROW TRANSPLANTATION; LEUKEMIA PATIENTS		UNIV IOWA,IOWA BIOTECHNOL CORP,INST TECHNOL INNOVAT,IOWA CITY,IA 52242	University of Iowa	MACFARLANE, DE (corresponding author), UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Macfarlane, Donald/0000-0001-8785-5690				AUBELSADRON G, 1961, BIOCHIM BIOPHYS ACTA, V53, P11, DOI 10.1016/0006-3002(61)90789-2; CHROMCZYNSKI P, 1991, CURRENT PROTOCOLS S, V14; DALLMAN MJ, 1991, IMMUNOL REV, V119, P163, DOI 10.1111/j.1600-065X.1991.tb00583.x; DELFAU MH, 1990, LEUKEMIA, V4, P1; Hayakawa K., 1991, CATIONIC SURFACTANTS; HIGUCHI R, 1989, PCR TECHNOLOGY; JONES AS, 1953, BIOCHIM BIOPHYS ACTA, V10, P607, DOI 10.1016/0006-3002(53)90304-7; KOWK S, 1992, PERKIN ELMER BIOTECH; MACFARLANE DE, 1989, ANAL BIOCHEM, V176, P457, DOI 10.1016/0003-2697(89)90342-4; MACFARLANE DE, 1991, Patent No. 5010183; NICHOLS J, 1992, BLOOD, V80, P2953; RALPH RK, 1984, BIOCHIM BIOPHYS ACTA, V87, P9; RECK RA, 1982, ENCY CHEM TECHNOLOGY, V19, P521; REDDI KK, 1976, P NATL ACAD SCI USA, V73, P2308, DOI 10.1073/pnas.73.7.2308; SAWYERS CL, 1990, P NATL ACAD SCI USA, V87, P563, DOI 10.1073/pnas.87.2.563; [No title captured]	16	49	58	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					186	188		10.1038/362186a0	http://dx.doi.org/10.1038/362186a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680772				2022-12-24	WOS:A1993KR02800069
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALPROSTADIL APPROVED AS IMPOTENCE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					935	935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674512				2022-12-24	WOS:A1995RV73400004
J	EKWALL, K; JAVERZAT, JP; LORENTZ, A; SCHMIDT, H; CRANSTON, G; ALLSHIRE, R				EKWALL, K; JAVERZAT, JP; LORENTZ, A; SCHMIDT, H; CRANSTON, G; ALLSHIRE, R			THE CHROMODOMAIN PROTEIN SWI6 - A KEY COMPONENT AT FISSION YEAST CENTROMERES	SCIENCE			English	Article							HETEROCHROMATIN-ASSOCIATED PROTEIN; POSITION-EFFECT VARIEGATION; DROSOPHILA-MELANOGASTER; ANTIBODIES; DOMAIN	Centromeres attach chromosomes to the spindle during mitosis, thereby ensuring the equal distribution of chromosomes into daughter cells. Transcriptionally silent heterochromatin of unknown function is associated with centromeres in many organisms. In the fission yeast Schizosaccharomyces pombe, the silent mating-type loci, centromeres, and telomeres are assembled into silent heterochromatin-like domains. The Swi6 chromodomain protein affects this silencing, and now it is shown that Swi6p localizes with these three chromosomal regions. In cells lacking Swi6p, centromeres lag on the spindle during anaphase and chromosomes are lost at high rates. Thus, Swi6p is located at fission yeast centromeres and is required for their proper function.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST GENET,D-38106 BRAUNSCHWEIG,GERMANY	University of Edinburgh; Braunschweig University of Technology				Allshire, Robin/0000-0002-8005-3625; Ekwall, Karl/0000-0002-3029-4041	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; HAGAN IM, 1988, J CELL SCI, V89, P343; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KELLUM R, 1995, J CELL SCI, V108, P1407; KELLUM R, 1995, J CELL SCI, V108, P1419; KLAR AJS, 1992, TRENDS GENET, V8, P208, DOI 10.1016/0168-9525(92)90100-I; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1982, CURR OPIN CELL BIOL, V5, P999; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; SAUNDERS WS, 1993, J CELL SCI, V104, P573; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; WOODS A, 1989, J CELL SCI, V93, P491; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	22	254	255	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1429	1431		10.1126/science.7660126	http://dx.doi.org/10.1126/science.7660126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660126				2022-12-24	WOS:A1995RT80600047
J	AHMED, AEH; NICHOLSON, KG; NGUYENVANTAM, JS				AHMED, AEH; NICHOLSON, KG; NGUYENVANTAM, JS			REDUCTION IN MORTALITY ASSOCIATED WITH INFLUENZA VACCINE DURING 1989-90 EPIDEMIC	LANCET			English	Article							VIRUS VACCINE; IMMUNIZATION; PREVENTION; INFECTION; EFFICACY; DISEASE; DEATHS	Influenza epidemics are associated with excess winter mortality Risk factors for influenza complications and death include chronic illness and living in residential care. In the UK uptake of influenza vaccine among high-risk groups is only 10-40%, partly because of scepticism about vaccine efficacy. We have assessed the efficacy of influenza vaccine in reducing mortality from certified influenza by a case-control study of subjects aged 16 years or older who died between Nov 4, 1989, and Feb 23, 1990, in 36 district health authorities in England. We reviewed general practitioners' records for 315 patients who died of influenza and 777 controls, matched for age, sex, and area of residence, who died a year after the epidemic. Information was collected on demography, the usual place of residence (institutional or noninstitutional), and the existence of chronic illness. Conditional logistic regression analysis for matched case-control studies showed that influenza vaccination reduced mortality by 41% (95% Cl 13-60) for all subjects. Further adjustments showed that among subjects who received the vaccine for the first time in 1989, Vaccination reduced mortality by 9% (0-59); however, among those who bad also been vaccinated previously, mortality was reduced by 75% (31-91). We detected no significant differences in the effect of vaccine between subjects who lived in institutions and in the community (p=0.16), or between subjects with high-risk medical conditions and those without (p=0.76). Influenza Vaccine is effective in reducing mortality from influenza, and efficacy seems to be greater after repeated annual vaccination than after first administration.	UNIV LEICESTER,SCH MED,DEPT MICROBIOL & IMMUNOL,LEICESTER LE1 9HN,LEICS,ENGLAND; UNIV NOTTINGHAM,QUEENS MED CTR,SCH MED,DEPT EPIDEMIOL & PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Leicester; University of Nottingham			Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655				ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; Ashley J., 1991, Population Trends, P16; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FEERY BJ, 1979, J INFECT DIS, V139, P237, DOI 10.1093/infdis/139.2.237; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GOVAERT TME, 1994, VACCINE, V12, P1185, DOI 10.1016/0264-410X(94)90241-0; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GUNDELFINGER BF, 1958, NEW ENGL J MED, V259, P1005, DOI 10.1056/NEJM195811202592103; HALL CB, 1987, PEDIATRICS, V80, P275; HOSKINS TW, 1979, LANCET, V1, P33; KEITEL WA, 1988, AM J EPIDEMIOL, V127, P353, DOI 10.1093/oxfordjournals.aje.a114809; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; LENNOX IM, 1990, AGE AGEING, V19, P169, DOI 10.1093/ageing/19.3.169; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; MORIO S, 1994, J EPIDEMIOL COMMUN H, V48, P46, DOI 10.1136/jech.48.1.46; NGUYENVANTAM JS, 1993, EPIDEMIOL INFECT, V111, P347, DOI 10.1017/S0950268800057058; NGUYENVANTAM JS, 1992, EPIDEMIOL INFECT, V108, P537, DOI 10.1017/S0950268800050032; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOLSON KG, 1987, VACCINE, V5, P302, DOI 10.1016/0264-410X(87)90156-3; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102; 1989, OPCS PP2892 MON; 1992, IMMUNISATION INFECTI	30	170	176	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					591	595		10.1016/S0140-6736(95)91434-X	http://dx.doi.org/10.1016/S0140-6736(95)91434-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651002				2022-12-24	WOS:A1995RT18800007
J	CROSLAND, A; JONES, R				CROSLAND, A; JONES, R			RECTAL BLEEDING - PREVALENCE AND CONSULTATION BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							IRRITABLE-BOWEL-SYNDROME; SYMPTOMS; DIAGNOSIS; DYSPEPSIA; DELAY	Objectives-To determine prevalence of rectal bleeding in the community and to examine factors that lead some patients to consult their general practitioner about rectal bleeding while others do not. Design-Questionnaire survey followed by semistructured interviews of sample of respondents with rectal bleeding. Setting-Two general practices on Tyneside. Subjects-2000 adult patients registered with the general practices were sent a validated questionnaire. Respondents with rectal bleeding were divided into consulters and non-consulters, and 30 patients from each group (matched for age, sex, and characteristics of bleeding) were interviewed. Main outcome measures-Prevalence of rectal bleeding, proportion of subjects with rectal bleeding who sought medical advice, and reasons for consulting or not consulting a doctor about rectal bleeding. Results-287 of the 1200 respondents to the questionnaire had noticed rectal bleeding at some time in their lives, and 231 had noticed it within previous 12 months. Only 118 (41%) of all respondents with rectal bleeding had ever sought medical advice for the problem. Those aged over 60 were most likely to have consulted, as were those who reported blood mixed with their stools. Main difference between those who had sought medical advice and those who had not was that consulters were more likely than non-consulters to perceive their symptoms as serious. Conclusions-Although rectal bleeding is common, only minority of patients seek medical advice for their bleeding. Perception of seriousness of symptoms seems to be most important factor in deciding whether to consult a doctor for rectal bleeding.	UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London	CROSLAND, A (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.							BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; BYLES JE, 1992, J EPIDEMIOL COMMUN H, V46, P241, DOI 10.1136/jech.46.3.241; DENT OF, 1990, DIS COLON RECTUM, V33, P851, DOI 10.1007/BF02051921; DENT OF, 1986, DIS COLON RECTUM, V29, P234; GOULSTON K, 1987, MED J AUSTRALIA, V146, P631, DOI 10.5694/j.1326-5377.1987.tb120441.x; GOULSTON KJ, 1986, LANCET, V2, P261; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; JONES RH, 1995, BRIT J CLIN PRACT, V49, P67; JONES RH, 1993, RECTAL BLEEDING GUID; KETTELL J, 1992, BRIT J GEN PRACT, V42, P459; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; MANT A, 1989, DIS COLON RECTUM, V32, P191, DOI 10.1007/BF02554525; RAFFERTY T, 1980, AM SURGEON, V46, P600; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; Strauss A., 1990, BASICS QUALITATIVE R; 1993, OPCS MONITOR     JUL	17	113	114	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					486	488		10.1136/bmj.311.7003.486	http://dx.doi.org/10.1136/bmj.311.7003.486			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647645	Green Published			2022-12-24	WOS:A1995RQ67000016
J	WEEKS, KM; CROTHERS, DM				WEEKS, KM; CROTHERS, DM			MAJOR GROOVE ACCESSIBILITY OF RNA	SCIENCE			English	Article							INTERNAL LOOPS; NUCLEIC-ACIDS; BINDING-SITE; FREE-ENERGY; RECOGNITION; SYNTHETASE; OLIGORIBONUCLEOTIDES; MISMATCHES	Chemical acylation experiments showed that the RNA major groove, often assumed to be too deep and narrow to permit recognition interactions, is accessible at duplex termini. Reactivity extended further into the helix in the 5' than in the 3' direction. Asymmetric and large loops between helices uncoupled them, which yielded both enhanced reactivity at terminal base pairs and weaker stabilization enthalpy compared to that in small loops or symmetric loops of the same size. Uncoupled helices have effective helix ends with accessible major grooves; such motifs are attractive contributors to protein recognition, tertiary folding, and catalysis.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University					NIGMS NIH HHS [GM21966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021966, R01GM021966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDEN CJ, 1979, J MOL BIOL, V132, P411, DOI 10.1016/0022-2836(79)90268-7; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; CANTOR CR, 1980, BIOPHYSICAL CHEM, P1205; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P3534, DOI 10.1021/bi00128a030; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRALLA J, 1973, J MOL BIOL, V78, P301, DOI 10.1016/0022-2836(73)90118-6; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HOLBROOK SR, 1983, BIOPOLYMERS, V22, P1145, DOI 10.1002/bip.360220410; JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547; Kim S H, 1976, Prog Nucleic Acid Res Mol Biol, V17, P181, DOI 10.1016/S0079-6603(08)60070-7; LONGFELLOW CE, 1990, BIOCHEMISTRY-US, V29, P278, DOI 10.1021/bi00453a038; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERITZ AE, 1991, BIOCHEMISTRY-US, V30, P6428, DOI 10.1021/bi00240a013; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; VINCZE A, 1973, J AM CHEM SOC, V95, P2677, DOI 10.1021/ja00789a045; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1992, CELL, V70, P1069; WEEKS KM, UNPUB; YARUS M, 1991, NUCLEIC ACIDS RES, V19, P1297, DOI 10.1093/nar/19.6.1297	28	191	197	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1574	1577		10.1126/science.7690496	http://dx.doi.org/10.1126/science.7690496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	7690496				2022-12-24	WOS:A1993LX47400029
J	VANDEUREN, M; VANDIJKE, B; KOOPMAN, RJJ; HORREVORTS, AM; MEIS, JFGM; SANTMAN, FW; VANDERMEER, JWM				VANDEUREN, M; VANDIJKE, B; KOOPMAN, RJJ; HORREVORTS, AM; MEIS, JFGM; SANTMAN, FW; VANDERMEER, JWM			RAPID DIAGNOSIS OF ACUTE MENINGOCOCCAL INFECTIONS BY NEEDLE ASPIRATION OR BIOPSY OF SKIN-LESIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BACTERIAL-MENINGITIS; PROGNOSIS; DISEASE; PURPURA; SHOCK	Objectives-To evaluate the usefulness of Gram staining and culture of skin lesions in patients with acute meningococcal infections. Design-Retrospective study. Setting-Community hospital and intensive care unit of a teaching hospital. Subjects-51 patients admitted from 1989 to 1993 with proved meningococcal infections and microbiological examination of specimens from skin lesions. Interventions-Needle aspiration of a skin lesion before start of antibiotic treatment in 26 patients in the community hospital; punch biopsy of skin lesion after start of antibiotic treatment in 25 patients in the teaching hospital. Main outcome measures-Detection of meningococci by Gram staining of specimens from skin lesions according to category of infection (meningococcaemia, meningitis, meningitis with shock, or septic shock without meningitis). Results-Bacteria were detected in the specimen from haemorrhagic skin lesions by culture or Gram staining, or both in 32 (63%) patients. The sensitivity of the Gram stain was 51% and did not differ significantly from its sensitivity in detecting bacteria in cerebrospinal fluid. In meningococcal sepsis, however, a Gram stained skin lesion was significantly more sensitive (72%) than Gram stained cerebrospinal fluid (22%). In patients with meningitis skin lesions gave positive results on staining more often if shock was present. The results for punch biopsy specimens were not affected by antibiotics as Gram staining gave positive results up to 45 hours after the start of treatment and culture gave positive results up to 13 hours. Conclusion-Microbiological examination of skin lesions is informative, especially in patients with sepsis and inconclusive results from cerebrospinal fluid, and may provide a diagnosis in such patients within 45 minutes. It differentiates well between meningitis with and without haemodynamic complications, and the result is not affected by previous antibiotic treatment.	UNIV HOSP NIJMEGEN, DEPT DERMATOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT MED MICROBIOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT INTENS CARE, 6500 HB NIJMEGEN, NETHERLANDS; ST LAURENTIUS HOSP, DEPT MED MICROBIOL, ROERMOND, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	VANDEUREN, M (corresponding author), UNIV HOSP NIJMEGEN, DEPT INTERNAL MED, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		van der Meer, Jos W.M./C-8521-2013; Meis, Jacques F/A-9241-2010	van der Meer, Jos W.M./0000-0001-5120-3690; Meis, Jacques F/0000-0003-3253-6080				[Anonymous], NIPH ANN; APICELLA MA, 1990, PRINCIPLES PRACTICE, P1600; ARGENBRIGHT LW, 1992, J CLIN INVEST, V89, P259, DOI 10.1172/JCI115570; BAXTER P, 1988, LANCET, V1, P1166; BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; Bernhard WG, 1944, J LAB CLIN MED, V29, P273; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BRANDTZAEG P, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P183; CAHALANE SF, 1975, LANCET, V2, P120; DAHLE J S, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P49; DAVIS CE, 1974, J EXP MED, V140, P159, DOI 10.1084/jem.140.1.159; EMPARANZA JI, 1988, CRIT CARE MED, V16, P168, DOI 10.1097/00003246-198802000-00015; GEDDEDAHL TW, 1990, REV INFECT DIS, V12, P359; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; HALSTENSEN A, 1987, SCAND J INFECT DIS, V19, P35, DOI 10.3109/00365548709032375; HILL WR, 1947, JAMA-J AM MED ASSOC, V134, P513, DOI 10.1001/jama.1947.02880230023006; HOALIN NI, 1992, LANCET, V340, P1432; HOYNE AL, 1948, ANN INTERN MED, V28, P248, DOI 10.7326/0003-4819-28-2-248; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; MANIOS S G, 1971, Scandinavian Journal of Infectious Diseases, V3, P127, DOI 10.3109/inf.1971.3.issue-2.06; MCGEJEE WG, 1967, ANN INTERN MED, V67, P250, DOI 10.7326/0003-4819-67-2-250; McLean S, 1931, AM J DIS CHILD, V42, P1053, DOI 10.1001/archpedi.42.5.1053; MERCIER JC, 1988, CRIT CARE MED, V16, P27, DOI 10.1097/00003246-198801000-00006; MOVAT HZ, 1985, HDB ENDOTOXIN, V3, P260; NETTER A, 1917, BRIT J CHILD DIS, V14, P101; NETTER A, 1917, BRIT J CHILD DIS, V14, P264; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; Rubenstein R, 1986, Pediatr Dermatol, V3, P414, DOI 10.1111/j.1525-1470.1986.tb00553.x; SINCLAIR JF, 1987, LANCET, V2, P38; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; TALAN DA, 1988, REV INFECT DIS, V10, P365; TOEWS WH, 1974, AM J DIS CHILD, V127, P173, DOI 10.1001/archpedi.1974.02110210023003; TOMPKINS LS, 1992, NEW ENGL J MED, V327, P1290; TOMPKINS V. N., 1943, Journal of the American Medical Association, V123, P31; TONJUM T, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P175; VANDEUREN M, 1992, CLIN INFECT DIS, V15, P424, DOI 10.1093/clind/15.3.424; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333	37	63	64	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	1993	306	6887					1229	1232		10.1136/bmj.306.6887.1229	http://dx.doi.org/10.1136/bmj.306.6887.1229			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	7684633	Green Published, Bronze			2022-12-24	WOS:A1993LB80400013
J	LUSSO, P; MALNATI, MS; GARZINODEMO, A; CROWLEY, RW; LONG, EO; GALLO, RC				LUSSO, P; MALNATI, MS; GARZINODEMO, A; CROWLEY, RW; LONG, EO; GALLO, RC			INFECTION OF NATURAL-KILLER-CELLS BY HUMAN HERPESVIRUS-6	NATURE			English	Article							CHRONIC FATIGUE SYNDROME; HUMAN-IMMUNODEFICIENCY-VIRUS; INVITRO; AIDS; DEFICIENCY; MECHANISM; ANTIGEN	NATURAL killer (NK) cells are a functionally defined subset of non-T, non-B lymphocytes of bone marrow origin, which induce lysis of selected target cells, including neoplastic and virus-infected cells1-3. The NK cell function provides an important mechanism of primary defence against viruses in vivo, as demonstrated by the occurrence of multiple herpesvirus infections in patients congenitally lacking NK cells4,5. Here we show that functionally competent CD3- NK clones can be productively infected by human herpesvirus 6 (HHV-6)6, a T-lymphotropic DNA virus7 that may play a role in the acquired immunodeficiency syndrome (AIDS)8 and in the chronic fatigue syndrome9, two disorders associated with a defective NK cell activity10-15. The infection is cytopathic and induces de novo expression of CD4, an antigen not expressed within the NK lineage16,17, thereby predisposing NK cells to infection by human immunodeficiency virus type 1 (HIV-1). These results provide evidence that a herpesvirus can directly target and kill NK cells, a potential strategy to suppress the natural anti-viral immunity of the host.	NIAID, IMMUNOGENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LUSSO, P (corresponding author), NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA.		Malnati, Mauro/AAN-4207-2020; Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728; Garzino-Demo, Alfredo/0000-0002-4095-6950; Malnati, mauro/0000-0001-5355-1680				AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BONAVIDA B, 1986, J IMMUNOL, V137, P1157; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CHEHIMI J, 1991, J VIROL, V65, P1812, DOI 10.1128/JVI.65.4.1812-1822.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FLEISHER G, 1982, J PEDIATR-US, V100, P727, DOI 10.1016/S0022-3476(82)80572-6; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; LANIER LL, 1986, LEUKOCYTE TYPING 2, V3, P157; LUSSO P, 1991, J IMMUNOL, V147, P685; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; LUSSO P, 1992, HUMAN HERPESVIRUS, V6, P121; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; MORETTA A, 1990, J EXP MED, V171, P695, DOI 10.1084/jem.171.3.695; OLDSTONE MBA, 1991, J VIROL, V65, P6381, DOI 10.1128/JVI.65.12.6381-6386.1991; RITZ J, 1988, ADV IMMUNOL, V42, P181, DOI 10.1016/S0065-2776(08)60845-7; ROBERTSON MJ, 1990, BLOOD, V76, P2421; ROBINSON WE, 1988, HUM PATHOL, V19, P535, DOI 10.1016/S0046-8177(88)80200-4; ROOK AH, 1983, J CLIN INVEST, V72, P398, DOI 10.1172/JCI110981; RUSCETTI FW, 1986, J IMMUNOL, V136, P3619; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SIRIANNI MC, 1988, J IMMUNOL, V140, P2565; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	29	172	174	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					458	462		10.1038/362458a0	http://dx.doi.org/10.1038/362458a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	7681936				2022-12-24	WOS:A1993KV42400087
J	HERRERO, C; VICENTE, A; BRUGUERA, M; ERCILLA, MG; BARRERA, JM; VIDAL, J; TERES, J; MASCARO, JM; RODES, J				HERRERO, C; VICENTE, A; BRUGUERA, M; ERCILLA, MG; BARRERA, JM; VIDAL, J; TERES, J; MASCARO, JM; RODES, J			IS HEPATITIS-C VIRUS-INFECTION A TRIGGER OF PORPHYRIA-CUTANEA-TARDA	LANCET			English	Note							HEPATOCELLULAR-CARCINOMA; PATHOLOGY; LIVER	The causes of liver disease, ranging from fatty changes to cirrhosis and hepatocellular carcinoma, in prophyria cutanea tarda (PCT) remain unclear. We tested 100 consecutive PCT patients for antibodies to hepatitis C virus (HCV) by enzyme-linked immunosorbent assay and a recombinant immunoblot assay. 75 (79%) patients with sporadic PCT but none of 5 with familial PCT were positive. HCV RNA was found in serum of all 18 anti-HCV-positive patients tested. There were no significant differences in the prevalence of anti-HCV between treated and untreated patients or between those with and without various HCV risk factors. The frequency of anti-HCV increased with the severity of liver histology. These findings implicate HCV in the aetiology of PCT-associated liver disease.	UNIV BARCELONA,HOSP CLIN,LIVER UNIT,VILLARROEL 170,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,SERV IMMUNOL,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,SERV MICROBIOL,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,DEPT DERMATOL,E-08036 BARCELONA,SPAIN	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona								BRUGUERA M, 1986, SEMIN DERMATOL, V5, P178; BRUIX J, 1989, LANCET, V2, P1004; CORTES JM, 1980, HISTOPATHOLOGY, V4, P471, DOI 10.1111/j.1365-2559.1980.tb02942.x; ELDER GH, 1990, RECENT ADV DERMATOLO, P55; LEEVY CM, 1979, DISEASES LIVER BILIA; LEFKOWITCH JH, 1983, LIVER, V3, P19; Lentner C, 1982, GEIGY SCI TABLES; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SALATA H, 1985, J HEPATOL, V1, P477, DOI 10.1016/S0168-8278(85)80746-7; SUAREZ M, 1992, GASTROENTEROL HEPATO, V15, P272	10	198	205	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					788	789		10.1016/0140-6736(93)90562-U	http://dx.doi.org/10.1016/0140-6736(93)90562-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	7681135				2022-12-24	WOS:A1993KU90000005
J	AZZOPARDI, P; COWEY, A				AZZOPARDI, P; COWEY, A			PREFERENTIAL REPRESENTATION OF THE FOVEA IN THE PRIMARY VISUAL-CORTEX	NATURE			English	Article							CORTICAL MAGNIFICATION FACTOR; LATERAL GENICULATE-NUCLEUS; GANGLION-CELL DENSITY; MACAQUE MONKEYS; STRIATE CORTEX; RETINA; FIELD; UNIFORMITY; NEURONS; VISION	THE retinal fovea, which corresponds to the central degree or so of vision, is spatially over-represented in the visual cortex. It is about 0.01% of retina area, but at least 8% of the striate cortex1-3. Does this simply reflect an equivalently uneven distribution of ganglion cells in the retina4-7, or is the cortical representation of the fovea preferentially expanded8-13? The answer hinges on the resolution of long-standing discrepancies between the retinal and cortical magnification factors. We approached the problem in a different way, using a retrograde transneuronal tracer from cortex to retina to relate directly the number of ganglion cells projecting to marked areas of striate cortex. We report here that ganglion cells near the fovea were allocated 3.3 to 5.9 times more cortical tissue than more peripheral ones, and conclude that the cortical representation of the most central retina is much greater than expected from the density of its ganglion cells.			AZZOPARDI, P (corresponding author), UNIV OXFORD,DEPT EXPTL PSYCHOL,S PARKS RD,OXFORD OX1 3UD,ENGLAND.		Azzopardi, Paul/C-5694-2013	Azzopardi, Paul/0000-0001-7386-8191				[Anonymous], 1941, AM J OPHTHALMOL, DOI [10.1016/S0002-9394(41)91363-6, DOI 10.1016/S0002-9394(41)91363-6]; CONNOLLY M, 1984, J COMP NEUROL, V226, P544, DOI 10.1002/cne.902260408; COWEY A, 1964, J NEUROPHYSIOL, V27, P366, DOI 10.1152/jn.1964.27.3.366; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DOW BM, 1981, EXP BRAIN RES, V44, P213; DRASDO N, 1977, NATURE, V266, P554, DOI 10.1038/266554a0; FENDICK M, 1983, VISION RES, V23, P145, DOI 10.1016/0042-6989(83)90137-2; HUBEL DH, 1974, J COMP NEUROL, V158, P295, DOI 10.1002/cne.901580305; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; Kulikowski J. J., 1989, SEEING CONTOUR COLOU, P274; LEVAY S, 1990, EXP BRAIN RES, V82, P77; LEVI DM, 1984, VISION RES, V24, P789, DOI 10.1016/0042-6989(84)90150-0; LEVI DM, 1987, VISION RES, V27, P581, DOI 10.1016/0042-6989(87)90044-7; MALPELI JG, 1975, J COMP NEUROL, V161, P569, DOI 10.1002/cne.901610407; MYERSON J, 1977, SCIENCE, V192, P855; OKUSKY J, 1982, J COMP NEUROL, V210, P278, DOI 10.1002/cne.902100307; PERRY VH, 1985, VISION RES, V25, P1795, DOI 10.1016/0042-6989(85)90004-5; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; PERRY VH, 1984, NEUROSCIENCE, V12, P1125, DOI 10.1016/0306-4522(84)90007-1; PERRY VH, 1988, NEUROSCIENCE, V25, P225, DOI 10.1016/0306-4522(88)90021-8; POTTS AM, 1972, INVEST OPHTH VISUAL, V11, P980; POWELL TPS, 1981, BRAIN RES, V216, P409, DOI 10.1016/0006-8993(81)90142-6; ROCKEL AJ, 1980, BRAIN, V103, P221, DOI 10.1093/brain/103.2.221; ROLLS ET, 1970, EXP BRAIN RES, V10, P298; ROVAMO J, 1979, EXP BRAIN RES, V37, P495, DOI 10.1007/bf00236819; SCHEIN SJ, 1988, J COMP NEUROL, V269, P479, DOI 10.1002/cne.902690403; SILVEIRA LCL, 1989, VISION RES, V29, P1471, DOI 10.1016/0042-6989(89)90131-4; STRASBURGER H, 1991, PERCEPT PSYCHOPHYS, V49, P495, DOI 10.3758/BF03212183; WASSLE H, 1989, NATURE, V341, P643, DOI 10.1038/341643a0; WASSLE H, 1990, VISION RES, V30, P1897, DOI 10.1016/0042-6989(90)90166-I	30	134	135	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					719	721		10.1038/361719a0	http://dx.doi.org/10.1038/361719a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680108				2022-12-24	WOS:A1993KN78900054
J	CHOW, YK; HIRSCH, MS; MERRILL, DP; BECHTEL, LJ; ERON, JJ; KAPLAN, JC; DAQUILA, RT				CHOW, YK; HIRSCH, MS; MERRILL, DP; BECHTEL, LJ; ERON, JJ; KAPLAN, JC; DAQUILA, RT			USE OF EVOLUTIONARY LIMITATIONS OF HIV-1 MULTIDRUG RESISTANCE TO OPTIMIZE THERAPY	NATURE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; VIRUS; REPLICATION; ZIDOVUDINE; DERIVATIVES; SENSITIVITY; INVITRO; MUTANTS; AZT	WILD-TYPE reverse transcriptase has evolved for the survival of human immunodeficiency virus type 1 (HIV-1) by natural selection1. In contrast, therapy relying on inhibitors of reverse transcriptase by nucleosides like zidovudine (AZT) or dideoxyinosine (ddI), and by non-nucleosides like pyridinones or nevirapine2-6, may exert different selection pressures on this enzyme. Therefore the acquisition of resistance to reverse transcriptase inhibitors by selection of mutations in the pol gene7-15 may require compromises in enzyme function that affect viral replication. As single mutations are unlikely to confer broad resistance when combinations of reverse transcriptase inhibitors are used, multiple mutations may occur that result in further compromises. Certain drug combinations may prevent the co-existence of adequate reverse transcription function and multi-drug resistance (MDR). Unlike bacterial or eukaryotic drug resistance, retroviral drug resistance is conferred only by mutations in its own genome16 and is limited by genome size. Combining drugs directed against the same essential viral protein may thus prevent HIV-1 MDR, whereas the conventional approach of targeting different HIV-1 proteins for combination therapy may not, because genomes with resistance mutations in different HIV-1 genes might recombine to develop MDR17. Here we show that several mutations in the HIV-1 reverse transcriptase gene that confer resistance to inhibitors of this enzyme can attenuate viral replication. We tested whether combinations of mutations giving rise to single-agent resistance might further compromise or even abolish viral replication, and if multidrug-resistant viruses could be constructed. Certain combinations of mutations conferring resistance to AZT, ddI and pyridinone are incompatible with viral replication. These results indicate that evolutionary limitations exist to restrict development of MDR. Furthermore, a therapeutic strategy exploiting these limitations by using selected multidrug regimens directed against the same target may prevent development of MDR. This approach, which we call convergent combination therapy, eliminated HIV-1 replication and virus breakthrough in vitro, and may be applicable to other viral targets. Moreover, elimination of reverse transcription by convergent combination therapy may also limit MDR.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	CHOW, YK (corresponding author), MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,GRAY 5,BOSTON,MA 02114, USA.							ALBERT J, 1992, J VIROL, V66, P5627, DOI 10.1128/JVI.66.9.5627-5630.1992; BALZARINI J, 1992, ANTIMICROB AGENTS CH, V36, P1073, DOI 10.1128/AAC.36.5.1073; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; COEN DM, 1986, J ANTIMICROB CHEMOTH, V18, P1; ERON JJ, 1992, P NATL ACAD SCI USA, V89, P3241, DOI 10.1073/pnas.89.8.3241; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Johnson V., 1990, TECHNIQUES HIV RES; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; JOHNSON VA, 1990, J INFECT DIS, V161, P1057; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KORNFELD H, 1987, NATURE, V326, P610, DOI 10.1038/326610a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND S, 1992, J INFECT DIS, V166, P1139, DOI 10.1093/infdis/166.5.1139; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TEMIN HM, 1989, J ACQ IMMUN DEF SYND, V2, P1; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	30	154	166	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					650	654		10.1038/361650a0	http://dx.doi.org/10.1038/361650a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	7679778				2022-12-24	WOS:A1993KM77600068
J	SEUBERT, P; OLTERSDORF, T; LEE, MG; BARBOUR, R; BLOMQUIST, C; DAVIS, DL; BRYANT, K; FRITZ, LC; GALASKO, D; THAL, LJ; LIEBERBURG, I; SCHENK, DB				SEUBERT, P; OLTERSDORF, T; LEE, MG; BARBOUR, R; BLOMQUIST, C; DAVIS, DL; BRYANT, K; FRITZ, LC; GALASKO, D; THAL, LJ; LIEBERBURG, I; SCHENK, DB			SECRETION OF BETA-AMYLOID PRECURSOR PROTEIN CLEAVED AT THE AMINO TERMINUS OF THE BETA-AMYLOID PEPTIDE	NATURE			English	Article							ALZHEIMERS-DISEASE; DOMAIN; IDENTIFICATION; MUTATION; GENE	THE accumulation in brain of senile plaques containing beta-amyloid protein (Abeta) is a defining feature of Alzheimer's disease1-3. The amyloid precursor protein (APP)4 from which Abeta is derived is subject to several genetic mutations which segregate with rare familial forms of the disease, resulting in early onset of dementia and plaque formation5-9, suggesting that APP metabolism plays a causal role in the disease. Various cell types have been shown to release a soluble form of Abeta, thus allowing for the in vitro study of Abeta generation10-12. We report here evidence that a substantial portion of the APP secreted by human mixed brain cell cultures, as well as that present in cerebrospinal fluid, is of a novel form cleaved precisely at the amino terminus of Abeta, suggesting that a secretory pathway is involved in Abeta genesis.	UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SEUBERT, P (corresponding author), ATHENA NEUROSCI INC,800F GATEWAY BLVD,SAN FRANCISCO,CA 94080, USA.							ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kennedy Hilary, 1992, Neurodegeneration, V1, P59; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PULLIAM L, 1984, J VIROL METHODS, V9, P301, DOI 10.1016/0166-0934(84)90056-9; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729	26	510	546	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					260	263		10.1038/361260a0	http://dx.doi.org/10.1038/361260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	7678698				2022-12-24	WOS:A1993KH61400060
J	WALD, A; ZEH, J; SELKE, S; ASHLEY, RL; COREY, L				WALD, A; ZEH, J; SELKE, S; ASHLEY, RL; COREY, L			VIROLOGICAL CHARACTERISTICS OF SUBCLINICAL AND SYMPTOMATIC GENITAL HERPES INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-2; VIRAL-ISOLATION; RISK-FACTORS; WOMEN; ACQUISITION; TRANSMISSION; FREQUENCY; LESIONS	Background. The frequency, pattern, and anatomical sites of subclinical shedding of herpes simplex virus (HSV) in the genital tract, along with factors that predict such shedding, have not been well characterized. Methods. We studied prospectively the clinical and virologic course of genital herpes in 110 women. The women kept symptom diaries and provided daily samples from the vulva, cervix, and rectum for viral culture. Results. During a median follow-up of 105 days, subclinical shedding of Virus was identified in 36 of 65 women (55 percent) with HSV type 2 (HSV-2), in 16 of 31 women (52 percent) with HSV type 1 (HSV-1) and HSV-2, and in 4 of 14 women (29 percent) with only HSV-1. Among women with genital HSV-2 infection, subclinical shedding occurred on a mean of 2 percent of the days. The mean duration of viral shedding during subclinical episodes was 1.5 days, as compared with 1.8 days during symptomatic episodes. HSV was isolated from several sites in the genital tract and rectum in 17 percent of subclinical episodes and 22 percent of symptomatic episodes. Half the episodes of subclinical shedding of HSV occurred within seven days of a symptomatic recurrence. The risk of subclinical shedding increased with the frequency of symptomatic recurrences, Subclinical shedding was more frequent among women with more than 12 recurrences per year than among those with no symptomatic recurrences (odds ratio, 3.3; 95 percent confidence interval, 1.4 to 7.9); it was also more frequent among women who had recently acquired genital herpes (odds ratio for women with HSV acquired in the past year as compared with those who had had the infection for a year or more, 1.85; 95 percent confidence interval, 1.1 to 3.1). Conclusions. Among women with a history of genital herpes infection, subclinical shedding of HSV is common and accounts for nearly one third of the total days of reactivation of HSV infection in the genital tract. Women with frequent symptomatic recurrences also have frequent subclinical shedding and may be at high risk for transmitting HSV.	WASHINGTON UNIV,DEPT MED,DIV VIROL,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT STAT,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT LAB MED,SEATTLE,WA 98144; WASHINGTON UNIV,DEPT MICROBIOL,SEATTLE,WA 98144				Wald, Anna/B-6272-2012; Corey, Lawrence/AAE-1796-2020	Wald, Anna/0000-0003-3486-6438; Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM E, 1979, OBSTET GYNECOL, V54, P171; ADAM E, 1980, AM J OBSTET GYNECOL, V137, P827, DOI 10.1016/0002-9378(80)90893-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON SE, 1986, GENITOURIN MED, V62, P181; BARTON SE, 1987, GENITOURIN MED, V63, P102; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Bowman C A, 1990, Int J STD AIDS, V1, P174; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1985, AM J OBSTET GYNECOL, V153, P24, DOI 10.1016/0002-9378(85)90584-8; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON Y, 1993, J INFECT DIS, V167, P942, DOI 10.1093/infdis/167.4.942; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; JOHNSON RE, 1990, NEW ENGL J MED, V321, P7; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; MCCULLAGH P, 1983, GEN LINEAR MODELS, P73; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; RATTRAY MC, 1978, BRIT J VENER DIS, V54, P262; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; STENZELPOORE MP, 1987, SEX TRANSM DIS, V14, P17, DOI 10.1097/00007435-198701000-00004; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107	24	413	421	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					770	775		10.1056/NEJM199509213331205	http://dx.doi.org/10.1056/NEJM199509213331205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU809	7643884	Bronze			2022-12-24	WOS:A1995RU80900005
J	DEREGE, PJF; WILLIAMS, SA; THERIEN, MJ				DEREGE, PJF; WILLIAMS, SA; THERIEN, MJ			DIRECT EVALUATION OF ELECTRONIC COUPLING MEDIATED BY HYDROGEN-BONDS - IMPLICATIONS FOR BIOLOGICAL ELECTRON-TRANSFER	SCIENCE			English	Article							PORPHYRIN-QUINONE COMPOUNDS; TUNNELING PATHWAYS; INTRAMOLECULAR ELECTRON; CYTOCHROME-C; DISTANCE DEPENDENCE; BENZENE-DERIVATIVES; CRYSTAL-STRUCTURE; FIXED-DISTANCE; ZINC PORPHYRIN; TRANSFER RATES	Three supramolecular bischromophoric systems featuring zinc(II) and iron(III) porphyrins have been synthesized to evaluate the relative magnitudes of electronic coupling provided by hydrogen, sigma, and pi bonds. Laser flash excitation generates the highly reducing singlet excited state of the (porphinato)zinc chromophore that can subsequently be electron transfer quenched by the (porphinato)iron(III) chloride moiety. Measurement of the photoinduced electron transfer rate constants enables a direct comparison of how well these three types of chemical interactions facilitate electron tunneling, In contrast to generally accepted theory, electronic coupling modulated by a hydrogen-bond interface is greater than that provided by an analogous interface composed entirely of carbon-carbon a bonds. These results bear considerably on the analysis of through-protein electron transfer rate data as well as on the power of theory to predict the path traversed by the tunneling electron in a biological matrix; moreover, they underscore the cardinal role played by hydrogen bonds in biological electron transfer processes.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	University of Pennsylvania			Williams, Scott/AAG-7029-2020					ALMARSSON O, 1993, J AM CHEM SOC, V115, P7093, DOI 10.1021/ja00069a005; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BERATAN DN, 1992, J PHYS CHEM-US, V96, P2852, DOI 10.1021/j100186a014; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BERATAN DN, 1986, J AM CHEM SOC, V108, P4321, DOI 10.1021/ja00275a014; BERATAN DN, 1991, ADV CHEM SER, V228, P71; BETTS JN, 1992, J AM CHEM SOC, V114, P4043, DOI 10.1021/ja00037a004; BOBROWSKI K, 1992, J PHYS CHEM-US, V96, P10036, DOI 10.1021/j100203a082; BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; CASIMIRO DR, 1993, J PHYS CHEM-US, V97, P13073, DOI 10.1021/j100152a007; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; COLAPIETRO M, 1982, ACTA CRYSTALLOGR B, V38, P1953, DOI 10.1107/S0567740882007651; COLAPIETRO M, 1978, ACTA CRYSTALLOGR B, V34, P3277, DOI 10.1107/S056774087801064X; DEREGE PJF, IN PRESS INORG CHIM; DIMAGNO SG, 1993, J ORG CHEM, V58, P5983, DOI 10.1021/jo00074a027; DIMAGNO SG, 1993, J AM CHEM SOC, V115, P2513, DOI 10.1021/ja00059a060; EATON SS, 1977, J AM CHEM SOC, V99, P6594, DOI 10.1021/ja00462a021; FARVER O, 1992, J AM CHEM SOC, V114, P5764, DOI 10.1021/ja00040a043; FRANZEN S, 1993, J PHYS CHEM-US, V97, P3040, DOI 10.1021/j100114a035; GAINES GL, 1991, J AM CHEM SOC, V113, P719, DOI 10.1021/ja00002a076; HARRIMAN A, 1992, J AM CHEM SOC, V114, P388, DOI 10.1021/ja00027a074; HELMS A, 1992, J AM CHEM SOC, V114, P6227, DOI 10.1021/ja00041a047; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; KHUNDKAR LR, 1994, J AM CHEM SOC, V116, P9700, DOI 10.1021/ja00100a040; KOBAYASHI H, 1975, ADV BIOPHYS, V8, P191; LHAYA Y, 1965, B CHEM SOC JPN, V38, P1144; LIN VSY, 1994, SCIENCE, V264, P1105, DOI 10.1126/science.8178169; LONGO FR, 1968, J HETEROCYCLIC CHEM, V6, P927; MARCUS RA, 1986, BIOCHIM BIOPHYS ACTA, V811, P265; MATAGA N, 1989, CHEM PHYS, V131, P473, DOI 10.1016/0301-0104(89)80192-2; MIKKELSEN KV, 1993, P NATL ACAD SCI USA, V90, P5443, DOI 10.1073/pnas.90.12.5443; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; OSUKA A, 1990, J AM CHEM SOC, V112, P4958, DOI 10.1021/ja00168a051; PAULSON BP, UNPUB; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PETERSONKENNEDY SE, 1986, J AM CHEM SOC, V108, P1739, DOI 10.1021/ja00268a004; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; RISSER SM, 1993, J AM CHEM SOC, V115, P2508, DOI 10.1021/ja00059a057; ROTHEMUND P, 1948, J AM CHEM SOC, V70, P1808, DOI 10.1021/ja01185a047; SAKATA Y, 1991, CHEM LETT, P1307, DOI 10.1246/cl.1991.1307; SAKATA Y, 1989, J AM CHEM SOC, V111, P8979, DOI 10.1021/ja00206a065; SCHAUER CK, 1985, INORG CHEM, V24, P4082, DOI 10.1021/ic00218a024; SESSLER JL, 1993, J AM CHEM SOC, V115, P10418, DOI 10.1021/ja00075a091; THERIEN MJ, 1991, ADV CHEM SER, V228, P191; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054; TURRO C, 1992, J AM CHEM SOC, V114, P4013, DOI 10.1021/ja00036a081; WASIELEWSKI MR, 1992, CHEM REV, V92, P435, DOI 10.1021/cr00011a005; WASIELEWSKI MR, 1985, J AM CHEM SOC, V107, P1080, DOI 10.1021/ja00290a066; WINKLER JR, 1992, CHEM REV, V92, P369, DOI 10.1021/cr00011a001; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007	53	339	342	3	60	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1409	1413		10.1126/science.7660123	http://dx.doi.org/10.1126/science.7660123			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660123				2022-12-24	WOS:A1995RT80600040
J	CHENN, A; MCCONNELL, SK				CHENN, A; MCCONNELL, SK			CLEAVAGE ORIENTATION AND THE ASYMMETRIC INHERITANCE OF NOTCH1 IMMUNOREACTIVITY IN MAMMALIAN NEUROGENESIS	CELL			English	Article							CEREBRAL-CORTEX; CELL LINEAGE; RADIAL GLIA; PATTERNS; MOUSE; MIGRATION; NEURONS; FATE; GENE	Neurons in the mammalian central nervous system are generated from progenitor cells near the lumen of the neural tube. Time-lapse microscopy of dividing cells in slices of developing cerebral cortex reveals that cleavage orientation predicts the fates of daughter cells. Vertical cleavages produce behaviorally and morphologically identical daughters that resemble precursor cells; these symmetric divisions may serve to expand or maintain the progenitor pool. In contrast, horizontally dividing cells produce basal daughters that behave like young migratory neurons and apical daughters that remain within the proliferative zone. Notch1 immunoreactivity is distributed asymmetrically in mitotic cells, with Notch1 inherited selectively by the basal (neuronal) daughter of horizontal divisions. These results provide cellular and molecular evidence that cortical neurons are generated from asymmetric divisions.			CHENN, A (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051864] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365] Funding Source: Medline; NIMH NIH HHS [MH51864] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; BERRY M, 1965, J ANAT, V99, P691; CAVINESS VS, 1995, IN PRESS TRENDS NEUR; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DAILEY ME, 1994, J NEUROSCI, V14, P1060, DOI 10.1523/JNEUROSCI.14-03-01060.1994; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FUJITA S, 1964, J COMP NEUROL, V122, P311, DOI 10.1002/cne.901220303; GRAY GE, 1992, DEVELOPMENT, V114, P271; HICKS SP, 1968, ANAT REC, V160, P619, DOI 10.1002/ar.1091600311; HINDS JW, 1971, Z ZELLFORSCH MIK ANA, V115, P226, DOI 10.1007/BF00391127; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEVINE SM, 1988, J COMP NEUROL, V277, P441, DOI 10.1002/cne.902770309; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MARTIN AH, 1967, NATURE, V215, P1133; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MILLER MW, 1985, DEV BRAIN RES, V23, P187, DOI 10.1016/0165-3806(85)90040-9; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; NYE JS, 1994, DEVELOPMENT, V120, P2421; OROURKE NA, 1992, SCIENCE, V258, P299, DOI 10.1126/science.1411527; PRICE J, 1988, DEVELOPMENT, V104, P473; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; ROBERTS JS, 1993, DEV BIOL, V155, P396, DOI 10.1006/dbio.1993.1038; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SMART IHM, 1973, J ANAT, V116, P67; SPANA EP, 1995, IN PRESS DEVELOPMENT; STENSAAS LJ, 1968, Z ZELLFORSCH MIK ANA, V91, P341, DOI 10.1007/BF00440763; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKAHASHI T, 1993, J NEUROSCI, V13, P820; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Woods D F, 1993, J Cell Sci Suppl, V17, P171; ZAMENHOF S, 1986, DEV BRAIN RES, V31, P143	41	609	621	0	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					631	641		10.1016/0092-8674(95)90035-7	http://dx.doi.org/10.1016/0092-8674(95)90035-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664342	Bronze			2022-12-24	WOS:A1995RR73400014
J	IZAURRALDE, E; LEWIS, J; GAMBERI, C; JARMOLOWSKI, A; MCGUIGAN, C; MATTAJ, IW				IZAURRALDE, E; LEWIS, J; GAMBERI, C; JARMOLOWSKI, A; MCGUIGAN, C; MATTAJ, IW			A CAP-BINDING PROTEIN COMPLEX MEDIATING U SNRNA EXPORT	NATURE			English	Article							MESSENGER-RNA PRECURSORS; RECOGNITION; INVITRO; NUCLEUS	CAP structures are added cotranscriptionally to all RNA polymerase II transcripts(1,2). They affect several processes including RNA stability(3-5), pre-messenger RNA splicing(6-11), RNA export from the nucleus(12-14) and translation initiation(15-17). The effect of the cap on translation is mediated by the initiation factor eIF-4F (refs 15-19), whereas the effect on pre-mRNA splicing involves a nuclear complex (CBC) composed of two cap binding proteins, CBP80 and CBP20(11). A role for CBC in the nuclear export of capped RNAs has also been proposed(11,13), We report here the characterization of human and Xenopus CBP20s. Antibodies against recombinant CBP20 prevent interaction of CBC with capped RNAs in vitro. Following microinjection into Xenopus oocytes, the antibodies inhibit both pre-mRNA splicing and export of U small nuclear RNAs to the cytoplasm, These results demonstrate that CBC mediates the effect of the cap structure in U snRNA export, and provide direct evidence for the involvement of a cellular RNA-binding factor in the transport of RNA to the cytoplasm.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Izaurralde, Elisa/G-3239-2012; Gamberi, Chiara/L-5740-2013	Gamberi, Chiara/0000-0002-7122-6491; Izaurralde, Elisa/0000-0001-7365-2649; Mattaj, Iain/0000-0002-5537-8284				BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LANG V, 1994, J BIOL CHEM, V269, P6117; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; PATZELT E, 1987, NUCLEIC ACIDS RES, V15, P1387, DOI 10.1093/nar/15.4.1387; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; SALDITTGEORGIEF.M, 1980, CELL, V19, P69; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; ZASLOFF M, 1982, NATURE, V300, P81, DOI 10.1038/300081a0	30	286	295	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					709	712		10.1038/376709a0	http://dx.doi.org/10.1038/376709a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651522				2022-12-24	WOS:A1995RQ67200066
J	SCHWEITZER, R; HOWES, R; SMITH, R; SHILO, BZ; FREEMAN, M				SCHWEITZER, R; HOWES, R; SMITH, R; SHILO, BZ; FREEMAN, M			INHIBITION OF DROSOPHILA EGF RECEPTOR ACTIVATION BY THE SECRETED PROTEIN ARGOS	NATURE			English	Article							FAINT-LITTLE-BALL; TYROSINE KINASE; GENE ENCODES; HOMOLOG; EXPRESSION; ANTAGONIST; TORPEDO; MELANOGASTER	THE Drosophila homologue of the mammalian epidermal growth factor (EGF) receptor (DER)(1,2) is a receptor tyrosine kinase involved in many stages of fly development, including photoreceptor determination, and wing-vein formation(3-9). Its primary activating ligand is the Spitz protein(10,11), which is similar to mammalian TGF-alpha (ref. 12), Argos is a secreted protein that, like Spitz, contains a single EGF motif(13-15). It is a repressor of cell determination in the eye, and acts in other tissues, including the wing(16-18) Because Argos has the opposite effects to DER in the eye (the former blocks photoreceptor determination, the latter promotes it) we have tested whether it acts by blocking the DER pathway, We show that Argos does indeed repress this pathway in vivo and find that, in vitro, Argos protein can inhibit the activation of DER by Spitz, Thus the determination of cells by the DER pathway is regulated by a balance between extracellular activating and inhibiting signals. This is the first in vivo example of an extracellular inhibitor of a receptor tyrosine kinase.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	MRC Laboratory Molecular Biology; Weizmann Institute of Science			Schweitzer, Ronen/AAY-2127-2020	Schweitzer, Ronen/0000-0002-7425-5028; Shilo, Ben Zion/0000-0003-4903-8889; Freeman, Matthew/0000-0003-0410-5451				BRUNNER A, 1994, MECH DEVELOP, V48, P175, DOI 10.1016/0925-4773(94)90058-2; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; CLIFFORD RJ, 1989, GENETICS, V123, P771; COCHET C, 1984, J BIOL CHEM, V259, P2553; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; XU T, 1993, DEVELOPMENT, V117, P1223; ZAK NB, 1990, ONCOGENE, V5, P1589	30	219	222	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					699	702		10.1038/376699a0	http://dx.doi.org/10.1038/376699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651519				2022-12-24	WOS:A1995RQ67200063
J	CARROLL, SB				CARROLL, SB			HOMEOTIC GENES AND THE EVOLUTION OF ARTHROPODS AND CHORDATES	NATURE			English	Review							BITHORAX-COMPLEX; HOMEOBOX GENES; LIMB DEVELOPMENT; FOSSIL RECORD; DISTAL-LESS; HOX GENES; WNT GENE; DROSOPHILA; ANTENNAPEDIA; ORIGIN	Clusters of homeotic genes sculpt the morphology of animal body plans and body parts. Different body patterns may evolve through changes in homeotic gene number, regulation or function. Recent evidence suggests that homeotic gene clusters were duplicated early in vertebrate evolution, but the generation of arthropod and tetrapod diversity has largely involved regulatory changes in the expression of conserved arrays of homeotic genes and the evolution of interactions between homeotic proteins and the genes they regulate.			CARROLL, SB (corresponding author), UNIV WISCONSIN, HOWARD HUGHES MED INST, RM BOCK LABS, 1525 LINDEN DR, MADISON, WI 53706 USA.							AHLBERG PE, 1991, NATURE, V354, P298, DOI 10.1038/354298a0; AKAM M, 1994, DEVELOPMENT, P209; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEEMAN RW, 1993, BIOESSAYS, V15, P439, DOI 10.1002/bies.950150702; BIRKETSMITH SJR, 1984, PROLEGS LEGS WINGS I; Bonner JT., 1988, EVOLUTION COMPLEXITY; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; Brower, 1991, DROSOPHILA INFORMATI, V70, P52; Brusca R.C., 1990, INVERTEBRATES; BURKE AC, 1995, DEVELOPMENT, V121, P333; Carroll RL, 1988, VERTEBRATE PALEONTOL; CARROLL SB, 1995, NATURE, V375, P58, DOI 10.1038/375058a0; CARTWRIGHT P, 1993, MOL PHYLOGENET EVOL, V2, P185, DOI 10.1006/mpev.1993.1019; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; DICKINSON WJ, 1991, EVOLUTIONARY BIOL, P127; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GANS C, 1975, AM ZOOL, V15, P455; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GINDHART JG, 1995, GENETICS, V139, P781; GOLDSCHMIDT RB, 1940, MATERIAL BASIS EVOLU; Gould S. J., 1977, ONTOGENY PHYLOGENY; GRAHAM A, 1994, CURR BIOL, V4, P1135, DOI 10.1016/S0960-9822(00)00256-6; HOGAN BLM, 1994, DEVELOPMENT, P53; HOLLAND PWH, 1994, DEVELOPMENT, P125; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JACOBS DK, 1990, P NATL ACAD SCI USA, V87, P4406, DOI 10.1073/pnas.87.11.4406; KAUFMAN T, 1990, GENETIC REGULATORY H; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOSTRIKEN R, 1992, DEV BIOL, V151, P225, DOI 10.1016/0012-1606(92)90229-A; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KUKALOVAPECK J, 1983, CAN J ZOOL, V61, P1618, DOI 10.1139/z83-217; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANN RS, 1994, DEVELOPMENT, V120, P3205; MASTICK GS, 1995, GENETICS, V139, P349; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1994, SCI AM, V270, P58, DOI 10.1038/scientificamerican0294-58; MCGINNIS W, 1994, GENETICS, V137, P607; MISOF B, 1995, CCE24 YAL U TECH REP; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; Nijhout H.F., 1991, DEV EVOLUTION BUTTER; Ohno S., 1970, EVOLUTION GENE DUPLI; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; Raff R.A., 1983, EMBRYOS GENES EVOLUT; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RUDDLE FH, 1994, DEVELOPMENT, P155; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SHANKLAND M, 1991, DEVELOPMENT, P29; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WALLACE B, 1985, Q REV BIOL, V60, P31, DOI 10.1086/414172; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; WHEELER WC, 1993, CLADISTICS, V9, P1, DOI 10.1111/j.1096-0031.1993.tb00207.x; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WILSON AC, 1985, SCI AM, V253, P164, DOI 10.1038/scientificamerican1085-164; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	76	528	545	4	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	1995	376	6540					479	485		10.1038/376479a0	http://dx.doi.org/10.1038/376479a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637779				2022-12-24	WOS:A1995RN62200036
J	SKEATH, JB; ZHANG, Y; HOLMGREN, R; CARROLL, SB; DOE, CQ				SKEATH, JB; ZHANG, Y; HOLMGREN, R; CARROLL, SB; DOE, CQ			SPECIFICATION OF NEUROBLAST IDENTITY IN THE DROSOPHILA EMBRYONIC CENTRAL-NERVOUS-SYSTEM BY GOOSEBERRY-DISTAL	NATURE			English	Article							GENES; EXPRESSION; ACHAETE; SEGREGATION; COMPLEX; REGION	THE Drosophila central nervous system develops from a segmentally reiterated array of 30 unique neural precursors, called neuroblasts. Each neuroblast goes through a stereotyped cell lineage to produce an invariant clone of neural progeny. It is critical to identify the genes that specify neuroblast identity as these genes control the time of formation, gene expression profile, and cell lineage characteristics of each neuroblast. Here we show that the Pax-type gooseberry-distal gene specifies row 5 neuroblast identity. Initially, four rows of neuroblasts form per segment (1, 3, 5, 7) and gooseberry-distal is expressed in row 5 neuroblasts(1-3). By using 10 molecular markers, and by following the number and orientation of neuroblast divisions, we show that lack of gooseberry-distal transforms row 5 neuroblasts into row 3 neuroblasts, whereas ubiquitous gooseberry-distal generates the reciprocal transformation. Thus, gooseberry-distal is necessary and sufficient to specify row 5 neuroblast identity autonomously, The 10 genes coordinately regulated by gooseberry-distal are prime candidates for controlling specific aspects of neuroblast identity.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI	University of Illinois System; University of Illinois Urbana-Champaign; Northwestern University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	SKEATH, JB (corresponding author), UNIV ILLINOIS,HOWARD HUGHES MED INST,URBANA,IL 61801, USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DOE CQ, 1988, SCIENCE, V239, P190; DOE CQ, 1992, DEVELOPMENT, V119, P855; Goodman Corey S., 1993, P1131; GUTJAHR T, 1993, DEVELOPMENT, V119, P21; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; MARTINBERMUDO MD, 1991, DEVELOPMENT, V119, P1003; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; SKEATH JB, 1992, DEVELOPMENT, V114, P939; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; ZHANG Y, 1994, DEVELOPMENT, V120, P1151	18	81	81	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					427	430		10.1038/376427a0	http://dx.doi.org/10.1038/376427a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630418				2022-12-24	WOS:A1995RM63900052
J	PARSONS, R; LI, GM; LONGLEY, M; MODRICH, P; LIU, B; BERK, T; HAMILTON, SR; KINZLER, KW; VOGELSTEIN, B				PARSONS, R; LI, GM; LONGLEY, M; MODRICH, P; LIU, B; BERK, T; HAMILTON, SR; KINZLER, KW; VOGELSTEIN, B			MISMATCH REPAIR DEFICIENCY IN PHENOTYPICALLY NORMAL HUMAN-CELLS	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; CARCINOGENESIS; MUTATIONS; LOCUS; MEMORIAL; HOMOLOG; LECTURE	Tumor cells in patients with hereditary nonpolyposis colorectal cancer (HNPCC) are characterized by a genetic hypermutability caused by defects in DNA mismatch repair. A subset of HNPCC patients was found to have widespread mutations not only in their tumors, but also in their non-neoplastic cells. Although these patients had numerous mutations in all tissues examined, they had very few tumors. The hypermutability was associated with a profound defect in mismatch repair at the biochemical level. These results have implications for the relation between mutagenesis and carcinogenesis, and they suggest that mismatch repair deficiency is compatible with normal human development.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; MT SINAI HOSP,FAMILIAL GI CANC REGISTRY,TORONTO,ON M5G 1X5,CANADA; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Duke University; Howard Hughes Medical Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Johns Hopkins University; Johns Hopkins University			Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885; Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [CA35494, CA62924] Funding Source: Medline; NIGMS NIH HHS [GM45190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035494, R37CA035494, P50CA062924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1992, GUT, V33, P783, DOI 10.1136/gut.33.6.783; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KNUDSON AG, 1985, CANCER RES, V45, P1437; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PARSONS R, UNPUB; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	33	301	326	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					738	740		10.1126/science.7632227	http://dx.doi.org/10.1126/science.7632227			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7632227				2022-12-24	WOS:A1995QW60300054
J	DOWELL, JS; SNADDEN, D; DUNBAR, JA				DOWELL, JS; SNADDEN, D; DUNBAR, JA			CHANGING TO GENERIC FORMULARY - HOW ONE FUNDHOLDING PRACTICE REDUCED PRESCRIBING COSTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To observe one general practice's attempt to reduce prescribing costs on becoming third wave fundholders through the introduction of a generic formulary applied to all new and repeat prescribing. To assess the impact on patients and prescribing patterns. Design-An observational study using interviews with patients and practitioners; questionnaires for patients and prescribing data. Setting-One urban general practice with five partners in Scotland. It became fundholding in April 1993. Subjects-71 searches of the register of repeat prescriptions identified 1274 potential changes in drugs. Questionnaires were sent to a stratified random sample of 280 patients four months after the changes were made; 33 interviews were conducted with 17 patients selected by local pharmacists to represent a wide range of opinion. Main outcome measures-Changes in prescribing and response and satisfaction of patients. Results-Of intended changes, 129 (70%) were in place after four months. Thirty three (20%) of the 167 patients who returned questionnaires were ''very unhappy,'' though interviews suggested that this was primarily with the communication they received rather than the change itself. Generic prescribing rose from one in three (37%) to over a half (58%). The volume of treatment dispensed (as treatment days) fell by 67 674 (10.7%), and the average cost per day's treatment fell by 3.1p from 32.3p per day in 1992 (9.4%), producing a total absolute saving of 24% (pound 137 712) over the first year. Conclusion-This practice has achieved a large reduction in prescribing costs rapidly. These were tolerated by patients, none of whom is thought to have left the practice for this reason. Great care must be taken to inform patients appropriately.	DOWNFIELD SURG,DUNDEE DD3 8NE,SCOTLAND		DOWELL, JS (corresponding author), WESTGATE HLTH CTR,TAYSIDE CTR GEN PRACTICE,DUNDEE DD2 4AD,SCOTLAND.		Dowell, Jonathan/M-6077-2019; Snadden, David/ABF-1586-2020; Dunbar, James A/G-3034-2012	Snadden, David/0000-0002-4818-1184; 				BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; PANTON R, 1993, BRIT MED J, V306, P310, DOI 10.1136/bmj.306.6873.310; Patton M. Q., 1990, QUALITATIVE EVALUATI, P280; 1994, PRESCRIPTION IMPROVE	7	71	71	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					505	508		10.1136/bmj.310.6978.505	http://dx.doi.org/10.1136/bmj.310.6978.505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7677830	Green Published			2022-12-24	WOS:A1995QJ59800028
J	FAIRBAIRN, LJ; COWLING, GJ; REIPERT, BM; DEXTER, TM				FAIRBAIRN, LJ; COWLING, GJ; REIPERT, BM; DEXTER, TM			SUPPRESSION OF APOPTOSIS ALLOWS DIFFERENTIATION AND DEVELOPMENT OF A MULTIPOTENT HEMATOPOIETIC-CELL LINE IN THE ABSENCE OF ADDED GROWTH-FACTORS	CELL			English	Article							COLONY-STIMULATING FACTORS; HEMATOPOIETIC PROGENITOR CELLS; SELF-RENEWAL; STEM-CELLS; GENE-EXPRESSION; NA+/H+ EXCHANGE; SURVIVAL; DEATH; BCL-2; PROTEIN	In the absence of growth factors, hemopoietic cells die rapidly by the process of apoptosis. Transfection of the human bcl-2 gene into an interleukin-3 (IL-3)-dependent, multipotent hemopoietic cell line allowed these cells to survive in the absence of IL-3, both in serum-containing and serum-deprived conditions, and this survival was accompanied by multilineage differentiation. Moreover, single cell experiments showed that differentiation could occur in the absence of cell division. While these data do not rule out the possibility that growth factors can influence the lineage choice of multipotent cells, they suggest that exposure to growth factors may not be obligatory for the differentiation of stem cells. The data also support the hypothesis that differentiation is intrinsically determined and that the role of the hemopoietic growth factors is enabling rather than inductive.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT BIOPHYS,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	FAIRBAIRN, LJ (corresponding author), CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT EXPTL HAEMATOL,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND.							BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BEGLEY CG, 1986, BLOOD, V68, P162; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BROXMEYER HE, 1992, AM J PEDIAT HEMATOL, V14, P22; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CURRY JL, 1967, SCIENCE, V236, P1229; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAIRBAIRN LJ, 1993, HAEMOPOIESIS PRACTIC, P175; FORD AM, 1992, P NATL ACAD SCI USA, V89, P3424, DOI 10.1073/pnas.89.8.3424; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HEBERLEIN C, 1990, ONCOGENE, V5, P1799; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; Heyworth C M, 1991, Growth Factors, V5, P87, DOI 10.3109/08977199109000274; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KAN O, 1993, HAEMOPOIESIS PRACTIC, P123; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; Maniatis T, 1989, DECONTAMINATION DILU; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1984, COLONY STIMULATING F; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDA T, 1984, P NATL ACAD SCI-BIOL, V81, P2520, DOI 10.1073/pnas.81.8.2520; TESTA NG, 1993, HAEMOPOIESIS PRACTIC; TESTA NG, 1991, CYTOKINES PRACTICAL, P229; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHETTON AD, 1988, BIOCHEM J, V256, P585, DOI 10.1042/bj2560585; WHETTON AD, 1988, BIOCHEM BIOPH RES CO, V152, P1173, DOI 10.1016/S0006-291X(88)80408-X; WHETTON AD, 1989, BIOCHIM BIOPHYS ACTA, V989, P11; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	57	357	359	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					823	832		10.1016/0092-8674(93)90462-Y	http://dx.doi.org/10.1016/0092-8674(93)90462-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	7690686				2022-12-24	WOS:A1993LX29200008
J	UTZ, U; BIDDISON, WE; MCFARLAND, HF; MCFARLIN, DE; FLERLAGE, M; MARTIN, R				UTZ, U; BIDDISON, WE; MCFARLAND, HF; MCFARLIN, DE; FLERLAGE, M; MARTIN, R			SKEWED T-CELL RECEPTOR REPERTOIRE IN GENETICALLY IDENTICAL-TWINS CORRELATES WITH MULTIPLE-SCLEROSIS	NATURE			English	Article							MYELIN BASIC-PROTEIN; GENES; GLYCOPROTEIN; INDIVIDUALS; DISEASE; CLONES; USAGE; ACID	ALTHOUGH the cause of multiple sclerosis (MS) is unknown, it is thought to involve a T cell-mediated autoimmune mechanism. Susceptibility to the disease is influenced by genetic factors such as genes of the HLA and T-cell receptor (TCR) complex1-6. Other evidence for a genetic influence includes the low incidence in certain ethnic groups7, the increased risk if there are affected family members8 and the increased concordance rate for disease in monozygotic twin pairs (26%)9, compared to dizygotic twins. Epidemiological studies indicate that there may be an additional role for envirommental factors. Although the target antigen(s) are not yet identified, several myelin or myelin-associated proteins have been suspected10-12, among them myelin basic protein. A lack of genetically comparable controls has impaired the analysis of the T-cell response in MS patients and caused disagreement on TCR usage in the disease13-15. Here we analyse the role of TCR genes in MS by comparing TCR usage in discordant versus concordant monozygotic twins in response to-self and foreign antigens. We find that after stimulation with myelin basic protein or tetanus toxoid, control twin sets as well as concordant twin sets select similar Valpha chains. Only the discordant twin sets select different TCRs after stimulation with antigens. Thus exogenous factors or the disease shape the TCR repertoire in MS patients, as seen by comparison with unaffected genetically identical individuals. This skewing of the TCR repertoire could contribute to the pathogenesis of MS and other T-cell-mediated diseases.	UNIV TUBINGEN,SCH MED,DEPT NEUROL,W-7400 TUBINGEN 1,GERMANY	Eberhard Karls University of Tubingen	UTZ, U (corresponding author), NINCDS,NEUROIMMUNOL BRANCH,BLDG 10,RM 5B-16,BETHESDA,MD 20892, USA.			Martin, Roland/0000-0002-0982-1329				ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; BEALL SS, 1989, J NEUROIMMUNOL, V21, P59, DOI 10.1016/0165-5728(89)90159-8; BENNUN A, 1991, P NATL ACAD SCI USA, V88, P2466, DOI 10.1073/pnas.88.6.2466; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN D, 1984, P NATL ACAD SCI-BIOL, V81, P1774, DOI 10.1073/pnas.81.6.1774; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; JOHNSON D, 1986, J NEUROIMMUNOL, V13, P99, DOI 10.1016/0165-5728(86)90053-6; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MALHOTRA U, 1992, J IMMUNOL, V149, P1802; MARTIN R, 1992, J IMMUNOL, V148, P1359; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SUN JB, 1991, J IMMUNOL, V146, P1490; Tiwari JL, 1985, HLA DIS ASS, P152; VARTDAL F, 1989, HUM IMMUNOL, V25, P103, DOI 10.1016/0198-8859(89)90074-8; WAKSMAN BH, 1984, P SOC EXP BIOL MED, V175, P282; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	22	124	126	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					243	247		10.1038/364243a0	http://dx.doi.org/10.1038/364243a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	7686632				2022-12-24	WOS:A1993LM68300059
J	GOULDING, EH; TIBBS, GR; LIU, D; SIEGELBAUM, SA				GOULDING, EH; TIBBS, GR; LIU, D; SIEGELBAUM, SA			ROLE OF H5 DOMAIN IN DETERMINING PORE DIAMETER AND ION PERMEATION THROUGH CYCLIC NUCLEOTIDE-GATED CHANNELS	NATURE			English	Article							K+ CHANNEL; TEA BLOCKADE; CHARYBDOTOXIN; INHIBITOR; RECEPTOR; REGION; MUSCLE; SITE	ION permeation through membrane channels is thought to be governed by a narrow region of the channel pore termed the selectivity filter1, which has been proposed to discriminate among ions by both specific binding and molecular sieving, as determined by pore diameter. Recent evidence suggests that a conserved domain (known as H5, P or SS1-SS2) in voltage-gated potassium2-8, sodium9-13 and calcium12channels contributes to the lining of the pore. Here we investigate whether the H5 domain determines pore diameter and examine the role of pore diameter in controlling ion permeation. These studies rely on differences in single channel conductance, ion selectivity and apparent pore diameter between cyclic nucleotide-gated channels cloned from bovine retina14 and catfish olfactory neurons15. Using chimaeric retinal-olfactory channels, we find that the H5 domain determines these differences in permeation properties, providing structural evidence that the cyclic nucleotide-gated channels are indeed members of the voltage-gated channel family15-17. Moreover, these results show directly that the H5 domain helps form the selectivity filter and that molecular sieving is important in controlling ion permeation.	COLUMBIA UNIV,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute	GOULDING, EH (corresponding author), COLUMBIA UNIV,DEPT PHYSIOL,CTR NEUROBIOL & BEHAV,722 W 168 ST,NEW YORK,NY 10032, USA.							BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEIGENBOTHAM L, 1992, SCIENCE, V258, P1152; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1991, IONIC CHANNELS EXCIT; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; NODDA M, 1989, FEBS LETT, V258, P213; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	22	108	108	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					61	64		10.1038/364061a0	http://dx.doi.org/10.1038/364061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	7686276				2022-12-24	WOS:A1993LK81800057
J	MACCHIA, D; ALMERIGOGNA, F; PARRONCHI, P; RAVINA, A; MAGGI, E; ROMAGNANI, S				MACCHIA, D; ALMERIGOGNA, F; PARRONCHI, P; RAVINA, A; MAGGI, E; ROMAGNANI, S			MEMBRANE TUMOR-NECROSIS-FACTOR-ALPHA IS INVOLVED IN THE POLYCLONAL B-CELL ACTIVATION-INDUCED BY HIV-INFECTED HUMAN T-CELLS	NATURE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; HOMOSEXUAL MEN; BINDING; CLONES	INFECTION of CD4+ T cells by human immune deficiency virus-1 (HIV-1) causes severe dysfunction of cellular immunity1-3, but paradoxically results in intense polyclonal activation of B cells, possibly accounting for both hypergammaglobulinaemia and frequent development of B-cell malignancies seen in HIV-infected patients4-7. We have reported that human CD4+ T-cell clones infected with HIV in vitro markedly stimulate immunoglobulin synthesis by B cells through a non-cognate, contact-dependent mechanism8. We show here that HIV-infected T-cell clones do not express the CD40 ligand (CD40L), a molecule critical for non-cognate B-cell activation9, but a small proportion of them do express membrane tumour-necrosis factor (TNF)-alpha. The ability of HIV-infected T-cell clones to induce polyclonal B-cell activation appears to be restricted to TNF-alpha-positive T blasts and is inhibited by antibodies against both TNF-alpha and TNF-alpha receptor. Freshly isolated CD4+ T cells from HIV-infected individuals express TNF-alpha on the cell membrane and induce TNF-alpha-mediated immunoglobulin production by B cells. Thus, membrane TNF-alpha seems to be involved in the polyclonal B-cell activation induced by HIV-infected T cells.	UNIV FLORENCE,DIV CLIN IMMUNOL & ALLERGOL,VIALE MORGAGNI 85,I-50134 FLORENCE,ITALY; UNIV PISA,POLICLIN SANTA CHIARA,IST CLIN MED 1,I-56100 PISA,ITALY	University of Florence; University of Pisa			Almerigogna, Fabio/AAL-4583-2020; Parronchi, Paola/AAE-5422-2022; Almerigogna, Fabio/A-4636-2012; Maggi, Enrico/AAA-8045-2019	Parronchi, Paola/0000-0002-9184-5089; Maggi, Enrico/0000-0002-1824-3583; Macchia, Donatella/0000-0001-9143-4186				AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; AMMANN AJ, 1983, CLIN IMMUNOL IMMUNOP, V27, P315, DOI 10.1016/0090-1229(83)90084-3; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EULER HH, 1985, CLIN EXP IMMUNOL, V59, P267; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; KINKHABWALA M, 1990, J EXP MED, V171, P941, DOI 10.1084/jem.171.3.941; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACCHIA D, 1991, J IMMUNOL, V146, P3413; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; TERPSTRA FG, 1989, EUR J IMMUNOL, V19, P667, DOI 10.1002/eji.1830190415	17	158	158	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					464	466		10.1038/363464a0	http://dx.doi.org/10.1038/363464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	7684824				2022-12-24	WOS:A1993LE93800063
J	LYAMICHEV, V; BROW, MAD; DAHLBERG, JE				LYAMICHEV, V; BROW, MAD; DAHLBERG, JE			STRUCTURE-SPECIFIC ENDONUCLEOLYTIC CLEAVAGE OF NUCLEIC-ACIDS BY EUBACTERIAL DNA-POLYMERASES	SCIENCE			English	Article							SINGLE-STRANDED-DNA; CHAIN-REACTION; THERMUS-AQUATICUS; 5'->3' EXONUCLEASE; AMPLIFICATION; PURIFICATION; GENERATION	Previously known 5' exonucleases of several eubacterial DNA polymerases have now been shown to be structure-specific endonucleases that cleave single-stranded DNA or RNA at the bifurcated end of a base-paired duplex. Cleavage was not coupled to synthesis, although primers accelerated the rate of cleavage considerably. The enzyme appeared to gain access to the cleavage site by moving from the free end of a 5' extension to the bifurcation of the duplex, where cleavage took place. Single-stranded 5' arms up to 200 nucleotides long were cleaved from such a duplex. Essentially any linear single-stranded nucleic acid can be targeted for specific cleavage by the 5' nuclease of DNA polymerase through hybridization with an oligonucleotide that converts the desired cleavage site into a substrate.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,1300 UNIV AVE,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					PHS HHS [30220] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BARGSEID M, 1991, STRATEGIES, V4, P34; CARBALLEIRA N, 1990, BIOTECHNIQUES, V9, P276; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hayashi K, 1991, PCR Methods Appl, V1, P34; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KALEDIN A S, 1981, Biokhimiya, V46, P1576; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEHMAN IR, 1978, ENZYME, V14, P15; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; LONGLEY MJ, 1990, NUCLEIC ACIDS RES, V18, P7317, DOI 10.1093/nar/18.24.7317; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, UNPUB; MATHUR EJ, 1991, NUCLEIC ACIDS RES, V19, P6952, DOI 10.1093/nar/19.24.6952; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEDRINI AM, 1983, J BIOL CHEM, V258, P1536; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SETLOW P, 1972, J BIOL CHEM, V247, P232; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377	31	306	382	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					778	783		10.1126/science.7683443	http://dx.doi.org/10.1126/science.7683443			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	7683443				2022-12-24	WOS:A1993LA74400021
J	LASSOUED, K; NUNEZ, CA; BILLIPS, L; KUBAGAWA, H; MONTEIRO, RC; LEBIEN, TW; COOPER, MD				LASSOUED, K; NUNEZ, CA; BILLIPS, L; KUBAGAWA, H; MONTEIRO, RC; LEBIEN, TW; COOPER, MD			EXPRESSION OF SURROGATE LIGHT CHAIN RECEPTORS IS RESTRICTED TO A LATE STAGE IN PRE-B CELL-DIFFERENTIATION	CELL			English	Article							LAMBDA-LIKE GENES; HEAVY-CHAIN; BONE-MARROW; BINDING-PROTEIN; MU-CHAIN; MONOCLONAL-ANTIBODY; SUPPRESSED MICE; LINEAGE CELLS; VPREB GENE; SURFACE	Surrogate light chain (psiLC) genes are transcriptionally active in progenitor B (pro-B) cells before immunoglobulin genes are rearranged. Current hypothetical models suggest that the psiLC proteins may couple with surrogate or conventional heavy chain proteins to form cell surface receptors that signal the progressive differentiation of pro-B, precursor B (pre-B), and immature B cells. Monoclonal antibodies were produced and used to examine the synthesis, expression, intermolecular interaction, and function of psiLC during B cell differentiation. The results indicate that, while psiLC production spans several developmental stages, cell surface expression is confined to a relatively late stage in normal pre-B cell differentiation, during which receptor cross-linkage does not impede cell growth or B cell differentiation.	UNIV ALABAMA, DEPT PEDIAT, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PATHOL, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MICROBIOL, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, HOWARD HUGHES MED INST, BIRMINGHAM, AL 35294 USA; UNIV MINNESOTA, SCH MED, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; University of Minnesota System; University of Minnesota Twin Cities	LASSOUED, K (corresponding author), UNIV ALABAMA, DEPT MED, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA.		Monteiro, Renato C/U-8633-2017	Monteiro, Renato C/0000-0001-5202-5646; LeBien, Tucker/0000-0001-5011-2199	NCI NIH HHS [CA13148, CA31685] Funding Source: Medline; NIAID NIH HHS [AI30879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA031685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BAUER SR, 1988, EMBO J, V7, P111, DOI 10.1002/j.1460-2075.1988.tb02789.x; BAUER SR, 1991, BLOOD, V78, P1581; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOSSY D, 1991, INT IMMUNOL, V3, P1081, DOI 10.1093/intimm/3.11.1081; Burrows P D, 1990, Semin Immunol, V2, P189; BURROWS PD, 1978, J IMMUNOL, V120, P1526; CHANG H, 1986, J EXP MED, V163, P425, DOI 10.1084/jem.163.2.425; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CIVIN CI, 1984, J IMMUNOL, V133, P157; COOPER MD, 1980, IMMUNOL REV, V52, P29, DOI 10.1111/j.1600-065X.1980.tb00329.x; COOPER MD, 1990, IMMUNOGLOBULIN GENES, P1; DEFRANCO AL, 1982, B T CELL TUMORS BIOL, P445; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P46; EWERT DL, 1984, J IMMUNOL, V132, P2524; FAHEY JL, 1971, ANN NY ACAD SCI, V190, P221, DOI 10.1111/j.1749-6632.1971.tb13537.x; FINDLEY HW, 1982, BLOOD, V60, P1305; FULOP GM, 1983, CELL IMMUNOL, V75, P91, DOI 10.1016/0008-8749(83)90308-8; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HOLLIS GF, 1989, P NATL ACAD SCI USA, V86, P5552, DOI 10.1073/pnas.86.14.5552; ISHIGAMI T, 1992, J IMMUNOL, V148, P360; Ishihara K, 1991, Dev Immunol, V1, P149, DOI 10.1155/1991/79721; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KIM KM, 1992, J IMMUNOL, V148, P29; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KIYOTAKI M, 1987, J IMMUNOL, V138, P4150; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIEN TW, 1990, LEUKEMIA, V4, P354; MARTIN D, 1991, J EXP MED, V173, P639, DOI 10.1084/jem.173.3.639; MARUYAMA S, 1985, J IMMUNOL, V135, P192; MASON DY, 1991, J IMMUNOL, V147, P2474; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; PULVERTAFT RJV, 1964, LANCET, V1, P238; RALPH P, 1973, J IMMUNOL, V110, P1470; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKAGUCHI N, 1986, EMBO J, V5, P2139, DOI 10.1002/j.1460-2075.1986.tb04477.x; SCHIFF C, 1991, BLOOD, V78, P1516; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SMITH RG, 1981, J IMMUNOL, V126, P596; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; TSUBATA T, 1992, INT IMMUNOL, V4, P637, DOI 10.1093/intimm/4.6.637; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; VILLABLANCA JG, 1990, J EXP MED, V172, P325, DOI 10.1084/jem.172.1.325; WORMANN B, 1989, J IMMUNOL, V142, P110; YELLEN AJ, 1991, J IMMUNOL, V146, P1446	71	156	157	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					73	86		10.1016/0092-8674(93)90161-I	http://dx.doi.org/10.1016/0092-8674(93)90161-I			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	7681728				2022-12-24	WOS:A1993KW75300009
J	SADOWSKI, HB; GILMAN, MZ				SADOWSKI, HB; GILMAN, MZ			CELL-FREE ACTIVATION OF A DNA-BINDING PROTEIN BY EPIDERMAL GROWTH-FACTOR	NATURE			English	Article							SERUM RESPONSE ELEMENT; SIGNAL TRANSDUCTION; 3T3 CELLS; FOS; TRANSCRIPTION; RECEPTORS; INSULIN; EXPRESSION; INDUCTION; COMPLEX	GROWTH factors such as platelet-derived growth factor and epidermal growth factor (EGF) bind to and activate cell-surface receptors with intrinsic tyrosine kinase activities1. Receptor activation elicits multiple physiological changes in target cells, including alterations in gene expression2-4. Receptor tyrosine kinase signalling involves recruitment of proteins into a signalling complex through interactions between receptor autophosphorylation sites and the src-homology region-2 (SH2) domains on these signalling proteins5-9. Diverse signals can subsequently be generated, depending on the specific receptor and Cell type 2,10. How such signals are transmitted to the nucleus is poorly understood, but because the transcriptional activation of many genes by growth factors occurs in the absence of new protein synthesis4, one or more signals emanating from growth factor receptors must directly affect transcription factors. We report here the activation by EGF of a DNA-binding protein in a cell-free system where activation of DNA binding requires ligand, receptor, ATP and phosphotyrosine-SH2 interactions.	COLD SPRING HARBOR LAB,BOX 100,1 BUNGTOWN RD,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KANAKURA Y, 1990, BLOOD, V76, P706; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; Treisman R, 1990, Semin Cancer Biol, V1, P47; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	30	246	252	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					79	83		10.1038/362079a0	http://dx.doi.org/10.1038/362079a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	7680434				2022-12-24	WOS:A1993KP97600066
J	HOES, AW; GROBBEE, DE; LUBSEN, J; TVELD, AJMI; VANDERDOES, E; HOFMAN, A				HOES, AW; GROBBEE, DE; LUBSEN, J; TVELD, AJMI; VANDERDOES, E; HOFMAN, A			DIURETICS, BETA-BLOCKERS, AND THE RISK FOR SUDDEN CARDIAC DEATH IN HYPERTENSIVE PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						DEATH, SUDDEN, CARDIAC; HYPERTENSION; ADRENERGIC BETA-ANTAGONISTS; DIURETICS; POTASSIUM	CORONARY HEART-DISEASE; BLOOD-PRESSURE; ABNORMALITIES; ARRHYTHMIAS; MANAGEMENT; STROKE; MEN	Objective: To determine whether the use of non-potassium-sparing diuretics and beta-blockers is associated with an excess risk for sudden cardiac death in hypertensive patients. Design: Case-control study. Setting: Rotterdam, the Netherlands. Patients: 257 case-patients who had died suddenly while receiving drug therapy for hypertension and 257 living controls also receiving drug therapy for hypertension. Measurements: Detailed information on medication use and clinical characteristics of all case-patients and controls was collected from the files of general practitioners. Additional information on medication use was obtained from computerized pharmacy records. Results: Patients receiving non-potassium-sparing diuretics had an increased risk for sudden cardiac death (relative risk, 1.8 [95% CI, 1.0 to 3.1]) compared with a reference group treated primarily with potassium-sparing diuretics. The corresponding relative risk for beta-blocker use was 1.7 (CI, 1.1 to 2.6). The use of non-potassium-sparing diuretics without beta-blockers was associated with a higher risk for sudden death (relative risk, 2.2 [CI, 1.1 to 4.6]) than was concomitant use of non-potassium-sparing diuretics and beta-blockers (relative risk, 1.4 [CI, 0.6 to 3.0]). The risk for sudden cardiac death among recipients of non-potassium-sparing diuretics was more pronounced in those who had been receiving the diuretic for less than 1 year and in those aged 75 years or younger. Conclusions: The use of non-potassium-sparing diuretics and beta-blockers is associated with an increased risk for sudden cardiac death. This association may offset part of the mortality benefit of these drugs in the treatment of hypertension.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT GEN PRACTICE, 3000 DR ROTTERDAM, NETHERLANDS; SOC RECH CARDIOL SA, CH-1261 GIVRINS, SWITZERLAND; ERASMUS UNIV ROTTERDAM, SCH MED, ACAD HOSP DIJKZIGT, DEPT INTERNAL MED 1, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	HOES, AW (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1970, JAMA, V213, P1143; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; Breslow N, 1980, STATISTICAL METHODS, V32; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUPPLES LA, 1992, CIRCULATION S1, V85; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HOES AW, 1994, DRUGS, V47, P711, DOI 10.2165/00003495-199447050-00002; HOLME I, 1984, JAMA-J AM MED ASSOC, V251, P1298, DOI 10.1001/jama.251.10.1298; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KULLER LH, 1986, CIRCULATION, V73, P114, DOI 10.1161/01.CIR.73.1.114; LOWN B, 1986, HEART DISEASE TXB CA; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MIALL WE, 1987, NEPHRON S1, V47; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; MYERBURG RJ, 1992, CIRCULATION, V85, P2; OLSSON G, 1991, AM J HYPERTENS, V4, P151, DOI 10.1093/ajh/4.2.151; PAPADEMETRIOU V, 1986, AM HEART J, V111, P1217, DOI 10.1016/0002-8703(86)90041-4; PITT B, 1992, CIRCULATION, V85, P107; POOLEWILSON PA, 1987, J HYPERTENS, V5, pS51; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SINGH S, 1984, CIRCULATION, V70, P996; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603	27	124	125	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					481	+		10.7326/0003-4819-123-7-199510010-00001	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661490				2022-12-24	WOS:A1995RW49500001
J	SAUNDERS, N; HAMMERSLEY, B				SAUNDERS, N; HAMMERSLEY, B			MAGNESIUM FOR ECLAMPSIA	LANCET			English	Editorial Material							PREECLAMPSIA-ECLAMPSIA; SULFATE				SAUNDERS, N (corresponding author), PRINCESS ANNE HOSP,SOUTHAMPTON,HANTS,ENGLAND.							BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; COTTON DB, 1992, AM J OBSTET GYNECOL, V166, P1127, DOI 10.1016/S0002-9378(11)90599-7; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; GOODWIN JS, 1984, JAMA-J AM MED ASSOC, V251, P2387, DOI 10.1001/jama.251.18.2387; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; SADEH M, 1989, STROKE, V20, P1273, DOI 10.1161/01.STR.20.9.1273; Sibai B M, 1992, Int J Obstet Anesth, V1, P167, DOI 10.1016/0959-289X(92)90024-X; SIBAI BM, 1984, AM J OBSTET GYNECOL, V150, P728, DOI 10.1016/0002-9378(84)90676-8; SIBAI BM, 1990, AM J OBSTET GYNECOL, V163, P1049, DOI 10.1016/0002-9378(90)91123-T; The Eclampsia Trial Collaborative Group, 1995, LANCET, V345, P1445	12	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					788	789		10.1016/S0140-6736(95)91614-8	http://dx.doi.org/10.1016/S0140-6736(95)91614-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674740				2022-12-24	WOS:A1995RW25800005
J	EBERS, GC; SADOVNICK, AD; RISCH, NJ; BULMAN, D; RICE, GPA; HASHIMOTO, SA; PATY, D; OGER, JJF; METZ, L; BELL, R; WARREN, S; HADER, W; AUTY, T; NATH, A; GRAY, T; OCONNOR, P; NELSON, R; FREEDMAN, M; BRUNET, D; PAULSETH, R; FRANCIS, G; DUQUETTE, P; MURRAY, TJ; BAHN, V; PRYSEPHILLIPS, W				EBERS, GC; SADOVNICK, AD; RISCH, NJ; BULMAN, D; RICE, GPA; HASHIMOTO, SA; PATY, D; OGER, JJF; METZ, L; BELL, R; WARREN, S; HADER, W; AUTY, T; NATH, A; GRAY, T; OCONNOR, P; NELSON, R; FREEDMAN, M; BRUNET, D; PAULSETH, R; FRANCIS, G; DUQUETTE, P; MURRAY, TJ; BAHN, V; PRYSEPHILLIPS, W			A GENETIC-BASIS FOR FAMILIAL AGGREGATION IN MULTIPLE-SCLEROSIS	NATURE			English	Article							TWINS; EPIDEMIOLOGY; CONCORDANCE	GENETIC-environmental interactions probably underlie spontaneous human autoimmune disorders, a category of complex traits thought to include multiple sclerosis (MS)(1). The geographical distribution and familiar aggregation of this disease have often been ascribed to the role of infectious agents(2), but there is no consensus, Increased family risks range from 300-fold(3,4) for monozygotic twins to 20-40-fold(5) for biological first-degree relatives over the general population prevalence of 0.1% (ref. 6). We screened a population-based sample of 15,000 individuals with MS by using standardized, personally administered questionnaires to identify adopted index cases and/or those who had adopted relatives, The frequency of MS among first-degree non-biological relatives living with the index case was no greater than expected from Canadian population prevalence data and significantly less than for biological relatives, These findings indicate that familial aggregation of MS is genetically determined: no effect of shared environment was detectable.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1W5,CANADA; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	University of British Columbia; Stanford University	EBERS, GC (corresponding author), UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON,ON N6A 5A5,CANADA.			Sadovnick, Dessa/0000-0003-2987-2008; Ebers, George/0000-0003-4771-4177				[Anonymous], 1968, INTRO PROBABILITY TH; BELLAMY N, 1992, ANN RHEUM DIS, V51, P588, DOI 10.1136/ard.51.5.588; DEAPEN D, 1992, ARTHRITIS RHEUM, V35, P311; EBERS G, 1987, NEW ENGL J MED, V315, P1638; EBERS GC, 1994, J NEUROIMMUNOL, V54, P117; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; KETY SS, 1976, BEHAV GENET, V6, P219, DOI 10.1007/BF01065721; KETY SS, 1994, ARCH GEN PSYCHIAT, V51, P442; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; LEITER EH, 1990, IMMUNOL TODAY, V11, P147, DOI 10.1016/0167-5699(90)90057-G; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; SADOVNICK AD, 1993, ANN NEUROL, V33, P281, DOI 10.1002/ana.410330309	14	478	485	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					150	151		10.1038/377150a0	http://dx.doi.org/10.1038/377150a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675080				2022-12-24	WOS:A1995RU75400048
J	LEIBOVICI, L; SAMRA, Z; KONIGSBERGER, H; DRUCKER, M; ASHKENAZI, S; PITLIK, SD				LEIBOVICI, L; SAMRA, Z; KONIGSBERGER, H; DRUCKER, M; ASHKENAZI, S; PITLIK, SD			LONG-TERM SURVIVAL FOLLOWING BACTEREMIA OR FUNGEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADULTS	Objective.-To delineate long-term survival after an episode of bacteremia or fungemia and risk factors for mortality. Design.-Cohort study. Setting.-A 900-bed university hospital in Israel. Patients.-Study group comprising 1991 patients 18 years of age or older in whom bacteremia or fungemia were detected between March 1988 and October 1992, and a control group comprising 1991 inpatients without any infectious diseases, matched for age, sex, department, date of admission, and underlying disorders. Interventions.-None. Measurements.-Interval from the date of the first positive blood culture (study group) or from date of the identical hospital day (in the matched control patient) to the date of death as recorded in the Israeli National Population registry or, if alive, to June 1, 1994. Results.-The median age of patients was 72 years. in the study group, the mortality rate was 26% at 1 month, 43% at 6 months, 48% at 1 year, and 63% at 4 years, and the median survival was 16.2 months. In the control group, the mortality rate was 7% at 1 month, 27% at 1 year, and 42% at 4 years, and the median survival was greater than 75 months (P<.001). Factors significantly and independently associated with mortality in bacteremic patients were functional class (median survival, 0.5 month in bedridden patients), septic shock (median survival, 0.2 month), serum albumin (median survival, 1.1 months in the lowest quartile), serum creatinine (median survival, 2.9 months in the highest quartile), age (median survival, 2.9 months in the highest quartile [age >80 years]), inappropriate empirical antibiotic treatment (median survival, 4.9 months), nosocomial infection (median survival, 9.6 months), and malignancy (median survival, 2.4 months). Conclusions.-Bacteremia is associated with high short-term mortality, but also a sign of severely curtailed long-term prognosis, especially in patients with low functional capacity, low serum albumin, high serum creatinine, nosocomial infections, malignancy, inappropriate antimicrobial treatment, and septic shock and in elderly patients.	BEILINSON MED CTR,MICROBIOL LAB,IL-49100 PETAH TIQWA,ISRAEL; BEILINSON MED CTR,INFECT DIS UNIT,IL-49100 PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,RAMAT AVIV,ISRAEL	Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	LEIBOVICI, L (corresponding author), BEILINSON MED CTR,DEPT MED B,IL-49100 PETAH TIQWA,ISRAEL.		Ashkenazi, Shai/V-7996-2019	Ashkenazi, Shai/0000-0001-7244-0679				AMIT M, 1994, SCAND J INFECT DIS, V26, P605, DOI 10.3109/00365549409011819; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; GEERDES HF, 1992, CLIN INFECT DIS, V15, P991, DOI 10.1093/clind/15.6.991; ISPAHANI P, 1987, Q J MED, V63, P427; LEIBOVICI L, 1991, ARCH INTERN MED, V151, P1801; LEIBOVICI L, 1992, CLIN INFECT DIS, V14, P436, DOI 10.1093/clinids/14.2.436; LEIBOVICI L, 1993, AGE AGEING, V22, P431, DOI 10.1093/ageing/22.6.431; MORIYAMA IM, 1989, AM J PUBLIC HEALTH, V79, P1349, DOI 10.2105/AJPH.79.10.1349; PHILLIPS A, 1989, LANCET, V2, P1434; WASUO Y, 1989, J CLIN EPIDEMIOL, V42, P577; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54; 1994, STAT ABSTR ISRAEL 19, P151; 1985, SAS USERS GUIDE STAT, P155	14	140	141	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					807	812		10.1001/jama.274.10.807	http://dx.doi.org/10.1001/jama.274.10.807			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650804				2022-12-24	WOS:A1995RU32400028
J	OLSON, MF; ASHWORTH, A; HALL, A				OLSON, MF; ASHWORTH, A; HALL, A			AN ESSENTIAL ROLE FOR RHO, RAC, AND CDC42 GTPASES IN CELL-CYCLE PROGRESSION THROUGH G(1)	SCIENCE			English	Article							C-JUN ACTIVITY; PROTEIN-KINASE; ACTIVATION DOMAIN; ADP-RIBOSYLATION; GROWTH-FACTORS; PHOSPHORYLATION; SERINE-63; PRODUCT; GENE	Members of the Rho family of small guanosine triphosphatases (GTPases) regulate the organization of the actin cytoskeleton; Rho controls the assembly of actin stress fibers and focal adhesion complexes, Rac regulates actin filament accumulation at the plasma membrane to produce lamellipodia and membrane ruffles, and Cdc42 stimulates the formation of filopodia, When microinjected into quiescent fibroblasts, Rho, Rac, and Cdc42 stimulated cell cycle progression through G(1) and subsequent DNA synthesis. Furthermore, microinjection of dominant negative forms of Rac and Cdc42 or of the Rho inhibitor C3 transferase blocked serum-induced DNA synthesis. Unlike Ras, none of the Rho GTPases activated the mitogen-activated protein kinase (MAPK) cascade that contains the protein kinases c-Raf1, MEK (MAPK or ERK kinase), and ERK (extracellular signal-regulated kinase). Instead, Rac and Cdc42, but not Rho, stimulated a distinct MAP kinase, the c-Jun kinase JNK/SAPK (Jun NH2-terminal kinase or stress-activated protein kinase). Rho, Rac, and Cdc42 control signal transduction pathways that are essential for cell growth.	UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	OLSON, MF (corresponding author), UCL, CRC, SIGNAL TRANSDUCT & ONCOGENE GRP, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND.		Olson, Michael F/A-3240-2011; Olson, Michael/ABA-4240-2021	Olson, Michael/0000-0003-3428-3507				BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QLU RG, 1995, NATURE, V374, P457; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YAN MH, 1994, NATURE, V372, P798	28	1036	1058	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1270	1272		10.1126/science.7652575	http://dx.doi.org/10.1126/science.7652575			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652575				2022-12-24	WOS:A1995RR84200036
J	BLADT, F; RIETHMACHER, D; ISENMANN, S; AGUZZI, A; BIRCHMEIER, C				BLADT, F; RIETHMACHER, D; ISENMANN, S; AGUZZI, A; BIRCHMEIER, C			ESSENTIAL ROLE FOR THE C-MET RECEPTOR IN THE MIGRATION OF MYOGENIC PRECURSOR CELLS INTO THE LIMB BUD	NATURE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; EPITHELIAL INTERACTIONS; TYROSINE KINASE; EXPRESSION; IDENTIFICATION; PROTOONCOGENE; MUSCULATURE; PROTEIN; ORIGIN	LIMB muscles develop from cells that migrate from the somites(1,2). The signal that induces migration of myogenic precursor cells to the limb emanates from the mesenchyme of the limb bud(2,3). Here we report that the c-met-encoded receptor tyrosine kinase is essential for migration of myogenic precursor cells into the limb anlage and for migration into diaphragm and tip of tongue. In c-met homozygous mutant (-/-) mouse embryos, the limb bud and diaphragm are not colonized by myogenic precursor cells and, as a consequence, skeletal muscles of the limb and diaphragm do not form. In contrast, development of the axial skeletal muscles proceeds in the absence of c-met signalling. The specific ligand of the c-met protein, the motility and growth factor scatter factor/hepatocyte growth factor(4-9), is expressed in limb mesenchyme and can thus provide the signal for migration which is received by c-met. We have therefore identified a paracrine signalling system that regulates migration of myogenic precursor cells.	MAX DELBRUCK CENTRUM MOLEK MED, D-13122 BERLIN, GERMANY; UNIV ZURICH, INST NEUROPATHOL, CH-8091 ZURICH, SWITZERLAND	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Zurich			Isenmann, Stefan/AAJ-3788-2020; Riethmacher, Dieter/AAB-8690-2022; Riethmacher, Dieter/A-6242-2010; Riethmacher, Dieter/AAP-2227-2021; Aguzzi, Adriano/A-3351-2008	Riethmacher, Dieter/0000-0002-4206-5529; Aguzzi, Adriano/0000-0002-0344-6708				BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOBER E, 1994, DEVELOPMENT, V120, P603; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GOULDING M, 1994, DEVELOPMENT, V120, P957; HAYASHI K, 1995, DEVELOPMENT, V121, P661; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; PAPAIOANNOU V, 1994, GENE TARGETING PRACT, P107; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZAMEGAR R, 1995, J CELL BIOL, V129, P1177	30	1042	1083	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	1995	376	6543					768	771		10.1038/376768a0	http://dx.doi.org/10.1038/376768a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651534				2022-12-24	WOS:A1995RR83600038
J	WAGNER, A				WAGNER, A			2ND CHILDHOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					606	606						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637134				2022-12-24	WOS:A1995RP70200009
J	DOUGLAS, RJ; KOCH, C; MAHOWALD, M; MARTIN, KAC; SUAREZ, HH				DOUGLAS, RJ; KOCH, C; MAHOWALD, M; MARTIN, KAC; SUAREZ, HH			RECURRENT EXCITATION IN NEOCORTICAL CIRCUITS	SCIENCE			English	Article							CAT VISUAL-CORTEX; INTRACORTICAL AXON COLLATERALS; LATERAL GENICULATE-NUCLEUS; RECEPTIVE-FIELD PROPERTIES; STRIATE CORTEX; SIMPLE CELLS; ORIENTATION SELECTIVITY; DIRECTIONAL SELECTIVITY; PYRAMIDAL CELLS; AREA 17	The majority of synapses in the mammalian cortex originate from cortical neurons. Indeed, the largest input to cortical cells comes from neighboring excitatory cells. However, most models of cortical development and processing do not reflect the anatomy and physiology of feedback excitation and are restricted to serial feedforward excitation. This report describes how populations of neurons in cat visual cortex can use excitatory feedback, characterized as an effective ''network conductance,'' to amplify their feedforward input signals and demonstrates how neuronal discharge can be kept proportional to stimulus strength despite strong, recurrent connections that threaten to cause runaway excitation. These principles are incorporated into models of cortical direction and orientation selectivity that emphasize the basic design principles of cortical architectures.	ETH ZURICH, CH-8006 ZURICH, SWITZERLAND; CALTECH, COMPUTAT & NEURAL SYST PROGRAM 13974, PASADENA, CA 91125 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, CTR BIOL & MED SYST, LONDON SW7 2BT, ENGLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; California Institute of Technology; Imperial College London	DOUGLAS, RJ (corresponding author), UNIV ZURICH, INST NEUROINFORMAT, CH-8006 ZURICH, SWITZERLAND.			Koch, Christof/0000-0001-6482-8067	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; AMIR Y, 1993, J COMP NEUROL, V334, P19, DOI 10.1002/cne.903340103; BERNANDER O, 1994, J NEUROPHYSIOL, V72, P2743, DOI 10.1152/jn.1994.72.6.2743; BISHOP PO, 1971, J PHYSIOL-LONDON, V219, P625, DOI 10.1113/jphysiol.1971.sp009681; Braitenberg V, 1991, ANATOMY CORTEX; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; Davis J., 1994, LARGE SCALE NEURONAL; DOUGLAS R, 1994, IEEE INT C NEUR NETW, P1848; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P217, DOI 10.1113/jphysiol.1985.sp015821; FERSTER D, 1987, J NEUROSCI, V7, P1780; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P233, DOI 10.1113/jphysiol.1985.sp015822; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; GANZ L, 1984, J NEUROPHYSIOL, V51, P294, DOI 10.1152/jn.1984.51.2.294; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRIEVE KL, 1991, EXP BRAIN RES, V87, P521; GROSSBERG S, 1988, NEURAL NETWORKS, V1, P17, DOI 10.1016/0893-6080(88)90021-4; GULYAS B, 1987, J NEUROPHYSIOL, V57, P1767, DOI 10.1152/jn.1987.57.6.1767; HEGGELUND P, 1981, EXP BRAIN RES, V42, P89; Hertz J, 1991, INTRO THEORY NEURAL; HOPFIELD JJ, 1984, P NATL ACAD SCI-BIOL, V81, P3088, DOI 10.1073/pnas.81.10.3088; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; KOCH C, 1990, J NEUROSCI, V10, P1728; LEVAY S, 1986, J NEUROSCI, V6, P3564; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAEX R, 1991, P NATL ACAD SCI USA, V88, P3549, DOI 10.1073/pnas.88.9.3549; MAEX R, 1995, THESIS LEUVEN U BELG; MARR D, 1970, PROC R SOC SER B-BIO, V176, P161, DOI 10.1098/rspb.1970.0040; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MASTRONARDE DN, 1987, J NEUROPHYSIOL, V57, P357, DOI 10.1152/jn.1987.57.2.357; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MCGUIRE BA, 1984, J NEUROSCI, V4, P3021; MCLEAN J, 1994, VISUAL NEUROSCI, V11, P271, DOI 10.1017/S0952523800001632; MEAD C, 1990, P IEEE, V78, P1629, DOI 10.1109/5.58356; MITCHISON G, 1992, TRENDS NEUROSCI, V15, P122, DOI 10.1016/0166-2236(92)90352-9; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; OHZAWA I, 1982, NATURE, V298, P266, DOI 10.1038/298266a0; PETERS A, 1994, CEREB CORTEX, V4, P215, DOI 10.1093/cercor/4.3.215; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1987, P NATL ACAD SCI USA, V84, P8740, DOI 10.1073/pnas.84.23.8740; SAUL AB, 1990, J NEUROPHYSIOL, V64, P206, DOI 10.1152/jn.1990.64.1.206; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SILLITO AM, 1977, J PHYSIOL-LONDON, V271, P699, DOI 10.1113/jphysiol.1977.sp012021; SOMERS D, 1995, P NATL ACAD SCI USA, V92, P3844; SUAREZ HH, IN PRESS J NEUROSCI; SUAREZ HH, 1995, THESIS CALTECH; Traub R.D., 1991, NEURONAL NETWORKS HI; VICTOR JD, 1987, J PHYSIOL-LONDON, V386, P219, DOI 10.1113/jphysiol.1987.sp016531; White E.L., 1989, CORTICAL CIRCUITS SY; WILLSHAW DJ, 1969, NATURE, V222, P960, DOI 10.1038/222960a0; WORGOTTER F, 1991, J NEUROSCI, V11, P1959; XING P, 1991, NEUROREPORT, V2, P485	60	732	735	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	1995	269	5226					981	985		10.1126/science.7638624	http://dx.doi.org/10.1126/science.7638624			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638624				2022-12-24	WOS:A1995RP73800037
J	FANKHAUSER, C; REYMOND, A; CERUTTI, L; UTZIG, S; HOFMANN, K; SIMANIS, V				FANKHAUSER, C; REYMOND, A; CERUTTI, L; UTZIG, S; HOFMANN, K; SIMANIS, V			THE S-POMBE CDC15 GENE IS A KEY ELEMENT IN THE REORGANIZATION OF F-ACTIN AT MITOSIS	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; CELL-DIVISION CYCLE; CYTOKINESIS; PROTEIN; CYTOSKELETON; COMPONENTS; SEPTATION; CLEAVAGE; DEFECTS; MYOSIN	The S. pombe cdc15 gene is essential for cell division, cdcl5(ts) mutants do not form a septum, but growth and nuclear division continue, leading to formation of multinucleate cells, The earliest step in septum formation and cytokinesis, rearrangement of actin to the center of the cell, is associated with appearance of hypophosphorylated cdc15p and formation of a cdc15p ring, which colocalizes with actin, Loss of cdc15p function impairs formation of the actin ring, The abundance of cdcl5 mRNA varies through the cell division cycle, peaking in early mitosis before septation, Expression of cdcl5 in G2-arrested cells induces actin rearrangement to the center of the cell, These data implicate cdc15p as a key element in mediating the cytoskeletal rearrangements required for cytokinesis.	SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND	Swiss Institute Experimental Cancer Research			Fankhauser, Christian/ABE-8757-2021; Hofmann, Kay/D-6714-2011; Fankhauser, Christian/C-4291-2018	Fankhauser, Christian/0000-0003-4719-5901; Hofmann, Kay/0000-0002-2289-9083; Fankhauser, Christian/0000-0003-4719-5901; Reymond, Alexandre/0000-0003-1030-8327				BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; FANKHAUSER C, 1993, MOL BIOL CELL, V4, P531, DOI 10.1091/mbc.4.5.531; Fankhauser Christian, 1994, Trends in Cell Biology, V4, P96, DOI 10.1016/0962-8924(94)90182-1; Fantes P.A., 1989, MOL BIOL FISSION YEA, P127; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; KANBE T, 1989, J CELL SCI, V94, P647; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KOHLI J, 1977, GENETICS, V87, P471; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARGOLIS RL, 1993, BIOESSAYS, V15, P201, DOI 10.1002/bies.950150310; MARKS J, 1992, J CELL SCI, V101, P801; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MARKS J, 1986, J CELL SCI, P229; MARKS J, 1987, SPEC PUBL SOC GEN MI, V23, P119; MCCOLLUM D, 1995, IN PRESS J CELL BIOL; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; NAKATSURU S, 1994, BIOCHEM BIOPH RES CO, V202, P82, DOI 10.1006/bbrc.1994.1896; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Robinow C, 1989, MOL BIOL FISSION YEA, P273; Sambrook J., 1989, MOL CLONING; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SIMANIS V, 1995, SEMIN CELL BIOL, V6, P79, DOI 10.1016/1043-4682(95)90004-7; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; WOODS A, 1989, J CELL SCI, V93, P491	44	218	221	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					435	444		10.1016/0092-8674(95)90432-8	http://dx.doi.org/10.1016/0092-8674(95)90432-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634333	Bronze			2022-12-24	WOS:A1995RP24200013
J	MITRAGOTRI, S; BLANKSCHTEIN, D; LANGER, R				MITRAGOTRI, S; BLANKSCHTEIN, D; LANGER, R			ULTRASOUND-MEDIATED TRANSDERMAL PROTEIN DELIVERY	SCIENCE			English	Article							INTERFERON-GAMMA; ERYTHROPOIETIN; PHONOPHORESIS; SKIN	Transdermal drug delivery offers a potential method of drug administration. However, its application has been limited to a few low molecular weight compounds because of the extremely low permeability of human skin. Low-frequency ultrasound was shown to increase the permeability of human skin to many drugs, including high molecular weight proteins, by several orders of magnitude, thus making transdermal administration of these molecules potentially feasible. It was possible to deliver and control therapeutic doses of proteins such as insulin, interferon gamma, and erythropoeitin across human skin. Low-frequency ultrasound is thus a potential noninvasive substitute for traditional methods of drug delivery, such as injections.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM44884] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APFEL RE, 1986, IEEE T ULTRASON FERR, P139; BOMMER J, 1988, LANCET, V2, P406; Bronaugh RL, 1989, PERCUTANEOUS ABSORPT, P27; BURNETTE RR, 1989, TRANSDERMAL DRUG DEL, P247; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P2633, DOI 10.1021/bi00383a034; ELIAS JJ, 1989, PERCUTANEOUS ABSORPT, P1; FRIDEMAN RM, 1981, INTERFERONS PRIMER; GAERTNER W, 1954, J ACOUST SOC AM, V26, P977, DOI 10.1121/1.1907464; GRUPS JW, 1989, BRIT J UROL, V64, P218, DOI 10.1111/j.1464-410X.1989.tb06000.x; Kost J, 1993, TOPICAL DRUG BIOAVAI, P91; KRALL LP, 1988, WORLD BOOK DIABETES, P160; MITRAGOTRI S, 1995, J PHARM SCI, V84, P697, DOI 10.1002/jps.2600840607; MORIMOTO Y, 1992, J PHARM PHARMACOL, V44, P634, DOI 10.1111/j.2042-7158.1992.tb05484.x; NEWMAN JT, 1992, J AM PODIAT MED ASSN, V82, P432, DOI 10.7547/87507315-82-8-432; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PISHKO MV, 1991, ANAL CHEM, V63, P2268, DOI 10.1021/ac00020a014; PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504; Quillen WS, 1980, ATHL TRAIN, V15, P109; ROSSEL J, 1988, IEEE T BIOMED ENG, V35, P649; SKAUEN DM, 1984, INT J PHARMACEUT, V20, P235, DOI 10.1016/0378-5173(84)90171-6; STRINGFELLOW D, 1986, CLIN APPLICATIONS IN, P1; TACHIBANA K, 1992, PHARMACEUT RES, V9, P952, DOI 10.1023/A:1015869420159; WALMSLEY AD, 1988, ULTRASOUND MED BIOL, V14; Walters KA., 1989, TRANSDERMAL DRUG DEL, P197; Wester R. C., 1993, TOPICAL DRUG BIOAVAI, P333	25	605	677	12	143	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					850	853		10.1126/science.7638603	http://dx.doi.org/10.1126/science.7638603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638603				2022-12-24	WOS:A1995RN65000048
J	WILSON, PA; HEMMATIBRIVANLOU, A				WILSON, PA; HEMMATIBRIVANLOU, A			INDUCTION OF EPIDERMIS AND INHIBITION OF NEURAL FATE BY BMP-4	NATURE			English	Article							XENOPUS-LAEVIS; MESODERM INDUCTION; DROSOPHILA EMBRYO; EARLY RESPONSE; EXPRESSION; ECTODERM; HOMOLOG; PATTERN; NOGGIN; RNA	DURING gastrulation in vertebrates, ectodermal cells choose between two fates, neural and epidermal. The nervous system forms in response to signals from the Spemann organizer(1,2); ectoderm that does not receive these signals becomes epidermis. Unexpectedly, however, in Xenopus, neural tissue also forms when cell-cell communication within the ectoderm is disrupted by cell dissociation(3,4) or by antagonists of the growth factor activin(5-7). These observations suggest that epidermal specification depends on local signalling, by activin or a close relative, and that neural tissue forms when this communication is blocked(6). Here we report that bone morphogenesis protein 4 (Bmp-4), a relative of activin that is expressed in the embryo at the time of ectodermal fate determination(8,9), is a potent epidermal inducer and neural inhibitor, the first reported in any vertebrate. Activin can inhibit neuralization by inducing mesoderm, but does not induce epidermis. Moreover, the dominant-negative activin receptor, which stimulates neuralization when expressed in the embryo(5,6), blocks Bmp-4 in our assay. Our findings demonstrate that epidermal fate can be induced, and thus provide further evidence that neural specification is under inhibitory control in vertebrates.			WILSON, PA (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							AKERS RM, 1986, SCIENCE, V231, P613, DOI 10.1126/science.3945801; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GODSAVE SF, 1989, DEV BIOL, V134, P486, DOI 10.1016/0012-1606(89)90122-X; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, IN PRESS DEV GENET; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; RAO Y, 1994, GENE DEV, V8, P939, DOI 10.1101/gad.8.8.939; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WITTA SE, 1995, DEVELOPMENT, V121, P721; YAMADA T, 1950, BIOL BULL-US, V98, P98, DOI 10.2307/1538572	31	629	655	4	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					331	333		10.1038/376331a0	http://dx.doi.org/10.1038/376331a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630398				2022-12-24	WOS:A1995RL44300044
J	SASSANFAR, M; SZOSTAK, JW				SASSANFAR, M; SZOSTAK, JW			AN RNA MOTIF THAT BINDS ATP	NATURE			English	Article							MOLECULAR RECOGNITION; RECEPTOR	RNAs that contain specific high-affinity binding sites for small molecule ligands immobilized on a solid support are present at a frequency of roughly one in 10(10)-10(11) in pools of random sequence RNA molecules1,2. Here we describe a new in vitro selection procedure designed to ensure the isolation of RNAs that bind the ligand of interest in solution as well as on a solid support. We have used this method to isolate a remarkably small RNA motif that binds ATP, a substrate in numerous biological reactions and the universal biological high-energy intermediate. The selected ATP-binding RNAs contain a consensus sequence, embedded in a common secondary structure. The binding properties of ATP analogues and modified RNAs show that the binding interaction is characterized by a large number of close contacts between the ATP and RNA, and by a change in the conformation of the RNA.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	SASSANFAR, M (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							ARNOLD FH, 1986, J CHROMATOGR, V355, P1, DOI 10.1016/S0021-9673(01)97299-1; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BRESLOW R, 1989, J AM CHEM SOC, V111, P8296, DOI 10.1021/ja00203a050; CARCANAGUE DR, 1992, J AM CHEM SOC, V114, P1515, DOI 10.1021/ja00030a077; CHANG SK, 1991, J AM CHEM SOC, V113, P7640, DOI 10.1021/ja00020a027; ECHAVARREN A, 1989, J AM CHEM SOC, V111, P4994, DOI 10.1021/ja00195a071; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAN E, 1993, J AM CHEM SOC, V115, P369, DOI 10.1021/ja00054a066; FERSHT A, 1985, ENZYME STRUCTURE MEC, P186; GOSWAMI S, 1989, J AM CHEM SOC, V111, P3425, DOI 10.1021/ja00191a048; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; REBEK J, 1987, SCIENCE, V235, P1478, DOI 10.1126/science.3823899; ROTELLO VM, 1993, J AM CHEM SOC, V115, P797, DOI 10.1021/ja00055a066; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; YOON SS, 1993, J AM CHEM SOC, V115, P823, DOI 10.1021/ja00055a083	17	500	541	5	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					550	553		10.1038/364550a0	http://dx.doi.org/10.1038/364550a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687750				2022-12-24	WOS:A1993LQ66700062
J	SPOHR, HL; WILLMS, J; STEINHAUSEN, HC				SPOHR, HL; WILLMS, J; STEINHAUSEN, HC			PRENATAL ALCOHOL EXPOSURE AND LONG-TERM DEVELOPMENTAL CONSEQUENCES	LANCET			English	Article							FOLLOW-UP; MATCHED CONTROLS; FETAL; CHILDREN; MOTHERS; IMPACT; GROWTH	Fetal alcohol syndrome (FAS) is a leading cause of congenital mental retardation but little is known about the long-term development and adolescent outcome of children with FAS. In a 10-year follow-up study of 60 patients diagnosed as having FAS in infancy and childhood, we investigated the long-term sequelae of intrauterine alcohol exposure. We found that the characteristic craniofacial malformations of FAS diminish with time, but microcephaly and, to a lesser degree, short stature and underweight (in boys) persist; in female adolescents body weight normalises. Persistent mental retardation is the major sequela of intrauterine alcohol exposure in many cases, and environmental and educational factors do not have strong compensatory effects on the intellectual development of affected children.	UNIV ZURICH,DEPT CHILD & ADOLESCENT PSYCHIAT,CH-8006 ZURICH,SWITZERLAND	University of Zurich	SPOHR, HL (corresponding author), GERMAN RED CROSS,RITTBERG HOSP,DEPT PEDIAT,CARSTENNSTR 58,W-1000 BERLIN 45,GERMANY.							Abel E. L., 1983, FETAL ALCOHOL SYNDRO; ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; ARONSON M, 1985, ACTA PAEDIATR SCAND, V74, P27, DOI 10.1111/j.1651-2227.1985.tb10916.x; CLARREN SK, 1978, NEW ENGL J MED, V298, P1036; DEHAENE P, 1977, REV ALCOOL, P145; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; KYLLERMAN M, 1985, ACTA PAEDIATR SCAND, V74, P20, DOI 10.1111/j.1651-2227.1985.tb10915.x; LANDESMANDWYER S, 1981, NEUROBEH TOXICOL TER, V3, P187; LARGO RH, 1980, HELV PAEDIATR ACTA, V35, P419; LEMOINE P, 1968, QUEST MED, V8, P476; Majewski F, 1976, MMW Munch Med Wochenschr, V118, P1635; NESTLER V, 1981, ALKOHOLEMBRYOPATHIE; QUELETTE EM, 1977, NEW ENGL J MED, V297, P528; SOKOL RJ, 1989, ALCOHOL CLIN EXP RES, V13, P597, DOI 10.1111/j.1530-0277.1989.tb00384.x; SPOHR HL, 1987, NEUROPEDIATRICS, V18, P13, DOI 10.1055/s-2008-1052428; STEINHAUSEN HC, 1982, J DEV BEHAV PEDIATR, V3, P49, DOI 10.1097/00004703-198206000-00001; STREISSGUTH AP, 1985, LANCET, V2, P85; STREISSGUTH AP, 1991, JAMA-J AM MED ASSOC, V265, P1961, DOI 10.1001/jama.265.15.1961; STREISSGUTH AP, 1991, J AM ACAD CHILD PSY, V30, P584, DOI 10.1097/00004583-199107000-00009	20	201	202	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					907	910		10.1016/0140-6736(93)91207-3	http://dx.doi.org/10.1016/0140-6736(93)91207-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	7681518				2022-12-24	WOS:A1993KW98100001
J	ZHOU, AM; HASSEL, BA; SILVERMAN, RH				ZHOU, AM; HASSEL, BA; SILVERMAN, RH			EXPRESSION CLONING OF 2-5A-DEPENDENT RNASE - A UNIQUELY REGULATED MEDIATOR OF INTERFERON ACTION	CELL			English	Article							ENCEPHALOMYOCARDITIS VIRUS-REPLICATION; ESCHERICHIA-COLI; MESSENGER-RNA; PROTEIN-SYNTHESIS; RIBOSOMAL-RNA; TREATED CELLS; 2'-5'-OLIGOADENYLATE SYNTHETASE; PPP(A2'P)NA-DEPENDENT RNASE; CONSTITUTIVE EXPRESSION; MOLECULAR-CLONING	2-5A-dependent RNAase, an interferon-induced enzyme that is activated by 5'-phosphorylated, 2',5'-linked oligoadenylates (2-SA), is implicated in both the molecular mechanisms of interferon action and the fundamental control of RNA stability in mammalian cells. Here we report the expression cloning and analysis of murine and human 2-5A-dependent RNAases. The 2-5A binding properties and RNAase activities of recombinant and naturally occurring forms of 2-5A-dependent RNAase were identical. Interferon induction of 2-5A-dependent RNAase expression was demonstrated by measuring the mRNA levels in cells treated with interferon and cycloheximide. Analysis of aligned murine and human 2-5A-dependent RNAase sequences revealed several intriguing features, including similarity to RNAase E, which is implicated in the control of mRNA stability in E. coli. Interestingly, a duplicated phosphate-binding loop motif was determined by deletion analysis and site-directed mutagenesis to function in the binding of 2-5A.	UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	ZHOU, AM (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195, USA.				NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA44059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APIRION D, 1978, J BIOL CHEM, V253, P1738; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; Brown R E, 1985, Prog Clin Biol Res, V202, P3; CAYLEY PJ, 1982, BIOCHEM BIOPH RES CO, V108, P1243, DOI 10.1016/0006-291X(82)92133-7; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; ETIENNESMEKENS M, 1983, P NATL ACAD SCI-BIOL, V80, P4609, DOI 10.1073/pnas.80.15.4609; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLOYDSMITH G, 1981, SCIENCE, V212, P1020; FLOYDSMITH G, 1988, J CELL BIOCHEM, V38, P12; GRIBAUDO G, 1991, J VIROL, V65, P1748, DOI 10.1128/JVI.65.4.1748-1757.1991; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; HOVANESSIAN AG, 1900, VIROLOGY, V101, P81; IMAI J, 1985, J BIOL CHEM, V260, P1390; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JACOBSEN H, 1983, VIROLOGY, V125, P496, DOI 10.1016/0042-6822(83)90222-2; JOHNSTON MI, 1987, J BIOL CHEM, V262, P8377; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; MARIE I, 1992, J BIOL CHEM, V267, P9933; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; Sambrook J., 1989, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1982, EUR J BIOCHEM, V126, P333; SILVERMAN RH, 1982, EUR J BIOCHEM, V124, P131, DOI 10.1111/j.1432-1033.1982.tb05915.x; SILVERMAN RH, 1987, LYMPHOKINES INTERFER, P149; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P581; TRUJILLO MA, 1987, EUR J BIOCHEM, V169, P167, DOI 10.1111/j.1432-1033.1987.tb13594.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATLING D, 1985, EMBO J, V4, P431, DOI 10.1002/j.1460-2075.1985.tb03647.x; WELLS JA, 1984, J BIOL CHEM, V259, P1363; WILLIAMS BRG, 1978, EUR J BIOCHEM, V92, P455, DOI 10.1111/j.1432-1033.1978.tb12767.x; WILLIAMS BRG, 1979, NATURE, V282, P582, DOI 10.1038/282582a0; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571; XIA ZG, 1990, J BIOL CHEM, V265, P6517	62	430	458	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					753	765		10.1016/0092-8674(93)90403-D	http://dx.doi.org/10.1016/0092-8674(93)90403-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680958	Bronze			2022-12-24	WOS:A1993KR43600011
J	FRAISE, AP				FRAISE, AP			DISINFECTION IN ENDOSCOPY	LANCET			English	Editorial Material							GLUTARALDEHYDE				FRAISE, AP (corresponding author), CITY HOSP,NHS TRUST,HOSP INFECT RES LAB,BIRMINGHAM,W MIDLANDS,ENGLAND.							BRADLEY CR, 1995, J HOSP INFECT, V29, P143, DOI 10.1016/0195-6701(95)90196-5; BROADLEY SJ, 1993, J HOSP INFECT, V23, P189, DOI 10.1016/0195-6701(93)90024-T; CALDER IM, 1992, LANCET, V339, P433, DOI 10.1016/0140-6736(92)90124-L; COATES D, 1992, J HOSP INFECT, V21, P241, DOI 10.1016/0195-6701(92)90135-9; COWAN RE, 1994, GUT, V35, P717, DOI 10.1136/gut.35.5.717-a; LYNAM PA, 1995, J HOSP INFECT, V30, P237, DOI 10.1016/S0195-6701(95)90322-4; LYNCH DA, 1994, ENDOSCOPY, V26, P351; TYLER R, 1990, J HOSP INFECT, V15, P339, DOI 10.1016/0195-6701(90)90090-B; VANKLINGEREN B, 1993, J HOSP INFECT, V25, P147, DOI 10.1016/0195-6701(93)90107-B	9	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					787	788		10.1016/S0140-6736(95)91613-X	http://dx.doi.org/10.1016/S0140-6736(95)91613-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674739				2022-12-24	WOS:A1995RW25800004
J	GAUTAM, M; NOAKES, PG; MUDD, J; NICHOL, M; CHU, GC; SANES, JR; MERLIE, JP				GAUTAM, M; NOAKES, PG; MUDD, J; NICHOL, M; CHU, GC; SANES, JR; MERLIE, JP			FAILURE OF POSTSYNAPTIC SPECIALIZATION TO DEVELOP AT NEUROMUSCULAR-JUNCTIONS OF RAPSYN-DEFICIENT MICE	NATURE			English	Article							DYSTROPHIN-RELATED PROTEIN; ADULT MUSCLE-FIBERS; ACETYLCHOLINE-RECEPTORS; 43K PROTEIN; CELLS; IDENTIFICATION; EXPRESSION; CLUSTERS	OF numerous synaptic components that have been identified, perhaps the best-studied are the nicotinic acetylcholine receptors (AChRs) of the vertebrate neuromuscular junction(1). AChRs are diffusely distributed on embryonic myotubes, but become highly concentrated (similar to 10,000 mu m(-2)) in the postsynaptic membrane as development proceeds. At least two distinct processes contribute to this accumulation. One is local synthesis: subsynaptic muscle nuclei transcribe AChR subunit genes at higher rates than extrasynaptic nuclei, so AChR messenger RNA is concentrated near synaptic sites(2,3). Second, once AChRs have been inserted in the membrane, they form high-density clusters by tethering to a subsynaptic cytoskeletal complex. A key component of this complex is rapsyn, a peripheral membrane protein of relative molecular mass 43K (refs 4, 5), which is precisely colocalized with AChRs at synaptic sites from the earliest stages of neuromuscular synaptogenesis(6). In heterologous systems, expression of recombinant rapsyn leads to clustering of diffusely distributed AChRs, suggesting that rapsyn may control formation of clusters(7,8). To assess the role of rapsyn in vivo, we generated and characterized mutant mice with a targeted disruption of the Rapsn gene. We report that rapsyn is essential for the formation of AChR clusters, but that synapse-specific transcription of AChR subunit genes can proceed in its absence.	UNIV WASHINGTON,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; UNIV WASHINGTON,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Noakes, Peter/X-9825-2019	Noakes, Peter/0000-0001-9821-8478; Gautam, Medha/0000-0002-5418-4322				APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; Chu Gerald C., 1995, Seminars in Developmental Biology, V6, P175, DOI 10.1016/S1044-5781(06)80027-7; CROWDER CM, 1988, MOL CELL BIOL, V8, P5257, DOI 10.1128/MCB.8.12.5257; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GAUTAM M, 1994, GENOMICS, V24, P366, DOI 10.1006/geno.1994.1629; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LAROCHELLE WJ, 1989, DEV BIOL, V132, P130, DOI 10.1016/0012-1606(89)90211-X; LUPA MT, 1989, J NEUROSCI, V9, P3937; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MERLIE JP, 1979, J BIOL CHEM, V254, P6320; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; MUSIL LS, 1989, J CELL BIOL, V108, P1833, DOI 10.1083/jcb.108.5.1833; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Sanes Joshua R., 1995, Seminars in Developmental Biology, V6, P163, DOI 10.1016/S1044-5781(06)80026-5; SANES JR, 1991, DEVELOPMENT, V113, P1181; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	30	456	464	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					232	236		10.1038/377232a0	http://dx.doi.org/10.1038/377232a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675108				2022-12-24	WOS:A1995RV87200040
J	HUANG, P; WEBER, JT; SOSIN, DM; GRIFFIN, PM; LONG, EG; MURPHY, JJ; KOCKA, F; PETERS, C; KALLICK, C				HUANG, P; WEBER, JT; SOSIN, DM; GRIFFIN, PM; LONG, EG; MURPHY, JJ; KOCKA, F; PETERS, C; KALLICK, C			THE FIRST REPORTED OUTBREAK OF DIARRHEAL ILLNESS ASSOCIATED WITH CYCLOSPORA IN THE UNITED-STATES	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; CYANOBACTERIA; CYCLOSPORA; WATER SUPPLY; DISEASE OUTBREAKS	ORGANISM; PATHOGEN	Objective: To investigate and characterize the epidemiology of a diarrheal outbreak associated with a potentially new pathogen, Cyclospora species (previously referred to as Cyanobacteria [blue-green algae]-like bodies). Design: Three retrospective cohort studies supported by laboratory studies, environmental investigation, and community surveillance. Setting: A hospital in Chicago. Participants: Housestaff physicians and hospital administrative staff. Measurements: Identification of clinical features associated with illness and potential risks for acquisition of infection. Results: Illness was characterized by watery diarrhea, abdominal cramping, decreased appetite, and low-grade fever. Symptoms typically occurred in a distinctive cycle of remissions and exacerbations lasting up to several weeks. Stool cultures and examinations for known ova and parasites were negative. Microscopic examination of stool specimens from 11 ill persons showed many spherical bodies, 8 to 10 mu m in diameter, that were identified as Cyclospora organisms. The organisms disappeared by 9 weeks after onset of illness in the 7 patients from whom follow-up specimens were obtained. Epidemiologic studies implicated tap water from a physicians' dormitory as the most likely source of the outbreak. Environmental investigation suggested that stagnant water in a storage tank may have contaminated the water supply after a pump failure. Conclusions: This is the first reported outbreak of diarrhea associated with Cyclospora in the United States. Cyclospora may be a human enteric pathogen able to produce bouts of acute and relapsing diarrhea, and it should be considered in assessments of patients with unexplained, prolonged diarrheal illness.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA								BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; BERLIN OGW, 1994, CLIN INFECT DIS, V18, P606, DOI 10.1093/clinids/18.4.606; CHIODINI PL, 1994, T ROY SOC TROP MED H, V88, P369, DOI 10.1016/0035-9203(94)90385-9; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; DEAU AG, 1990, EPI INFO VERSION 5 W; GUSTAFSON TL, 1991, TRUE EPISTAT; HALE D, 1994, JAMA-J AM MED ASSOC, V271, P144, DOI 10.1001/jama.271.2.144; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; MADICO G, 1993, LANCET, V342, P122, DOI 10.1016/0140-6736(93)91330-O; ORTEGA YR, 1994, J PARASITOL, V80, P625, DOI 10.2307/3283201; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; RABOLD JG, 1994, LANCET, V344, P1360, DOI 10.1016/S0140-6736(94)90716-1; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908; WURTZ R, 1994, CLIN INFECT DIS, V18, P620, DOI 10.1093/clinids/18.4.620; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; 1991, MMWR-MORBID MORTAL W, V40, P325	23	108	121	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					409	414		10.7326/0003-4819-123-6-199509150-00002	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639439				2022-12-24	WOS:A1995RU43700002
J	WANG, W; MEADOWS, LR; DENHAAN, JMM; SHERMAN, NE; CHEN, Y; BLOKLAND, E; SHABANOWITZ, J; AGULNIK, AI; HENDRICKSON, RC; BISHOP, CE; HUNT, DF; GOULMY, E; ENGELHARD, VH				WANG, W; MEADOWS, LR; DENHAAN, JMM; SHERMAN, NE; CHEN, Y; BLOKLAND, E; SHABANOWITZ, J; AGULNIK, AI; HENDRICKSON, RC; BISHOP, CE; HUNT, DF; GOULMY, E; ENGELHARD, VH			HUMAN H-Y - A MALE-SPECIFIC HISTOCOMPATIBILITY ANTIGEN DERIVED FROM THE SMCY PROTEIN	SCIENCE			English	Article							MASS-SPECTROMETRY; TRANSPLANTATION; HLA-A2.1; BINDING; GRAFT; HLA	H-Y is a transplantation antigen that can lead to rejection of male organ and bone marrow grafts by female recipients, even if the donor and recipient match at the major histocompatibility locus of humans, the HLA (human leukocyte antigen) locus, However, the origin and function of H-Y antigens has eluded researchers for 40 years. One human H-Y antigen presented by HLA-B7 was identified as an 11-residue peptide derived from SMCY, an evolutionarily conserved protein encoded on the Y chromosome, The protein from the homologous gene on the X chromosome, SMCX, differs by two amino acid residues in the same region. The identification of H-Y may aid in transplantation prognosis, prenatal diagnosis, and fertilization strategies.	LEIDEN UNIV HOSP, DEPT IMMUNOHAEMATOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, BLOOD BANK, 2333 AA LEIDEN, NETHERLANDS; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, BEIRNE CARTER CTR IMMUNOL RES, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA; PROMEGA CORP, MADISON, WI 53711 USA; BAYLOR COLL MED, DEPT OBSTET & GYNECOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT HUMAN MOLEC GENET, HOUSTON, TX 77030 USA; UNIV VIRGINIA, DEPT PATHOL, CHARLOTTESVILLE, VA 22903 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Virginia; University of Virginia; University of Virginia; Promega Corporation; Baylor College of Medicine; Baylor College of Medicine; University of Virginia			den Haan, Joke MM/A-4281-2010; Hunt, Donald F/I-6936-2012; Agoulnik, Alexander/AAK-3213-2020	den Haan, Joke MM/0000-0002-4421-6917; Hunt, Donald F/0000-0003-2815-6368; Agoulnik, Alexander/0000-0001-6587-6845; Sherman, Nicholas/0000-0003-3206-3113	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020963, R01AI020963, R01AI033993, R37AI033993] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33993, AI20963] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BILLINGHAM RE, 1960, J IMMUNOL, V85, P14; BORTIN MM, 1987, TRANSPLANT P, V19, P2655; CANTRELL MA, 1992, GENOMICS, V13, P1255, DOI 10.1016/0888-7543(92)90043-R; CHEN Y, 1994, J IMMUNOL, V152, P2874; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; EICHWALD EJ, 1955, TRANSPLAN B, V2, P121; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GOULMY E, 1976, LANCET, V2, P1206; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; GOULMY E, 1979, J EXP MED, V149, P545, DOI 10.1084/jem.149.2.545; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HOROWITZ MM, 1989, BONE MARROW TRANSPL, V4, P221; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; KING TR, 1994, GENOMICS, V24, P159, DOI 10.1006/geno.1994.1593; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; MEADOWS LR, UNPUB; PARHAM P, 1977, J BIOL CHEM, V252, P7555; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SCOTT DM, 1995, NATURE, V376, P695, DOI 10.1038/376695a0; SETTE A, 1994, J IMMUNOL, V153, P5586; SHAPIRO M, 1984, J IMMUNOGENET, V11, P209; TOKUDA S, 1977, NATURE, V267, P433, DOI 10.1038/267433a0; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; VANDERHARST D, 1994, BLOOD, V83, P1060; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WU JS, 1994, NAT GENET, V7, P491, DOI 10.1038/ng0894-491; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153	35	307	321	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1588	1590		10.1126/science.7667640	http://dx.doi.org/10.1126/science.7667640			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667640	Green Submitted			2022-12-24	WOS:A1995RU81300046
J	CHISHOLM, AD; HORVITZ, HR				CHISHOLM, AD; HORVITZ, HR			PATTERNING OF THE CAENORHABDITIS-ELEGANS HEAD REGION BY THE PAX-6 FAMILY MEMBER VAB-3	NATURE			English	Article							PAIRED BOX; C-ELEGANS; GENE; NEMATODE; ANIRIDIA; MUTATIONS; BODY	THE Pax-6 genes are important for eye development in both vertebrates and Drosophila. Mutations in the human PAX6 gene are found in patients with a variety of eye disorders, including aniridia and Peters' anomaly(1-3), and mutations in the Drosophila Pax-6 homologue cause the eyeless phenotype(4). In the nematode Caenorhabditis elegans, vab-3 mutants display many defects in head-region development, including aberrant morphogenesis, transformation of hypodermal (epidermal-like) cell fates to those of posterior homologues, and abnormal specification of neurons, Here we show that vab-3 is a member of the Pax-6 gene family and is expressed in head-region cells, This C. elegans Pax-6 locus can also encode proteins lacking the paired domain(5). Our results suggest: that. a primordial role of the Pax-6 gene family could have been to pattern part of the head region, and that Pax-6 genes subsequently evolved to be more specifically involved in eye development.			CHISHOLM, AD (corresponding author), MIT, DEPT BIOL, HOWARD HUGHES MED INST, 68-425, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.			Chisholm, Andrew/0000-0001-5091-0537				BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Burglin Thomas R., 1994, P25; BURR AH, 1985, PHOTOCHEM PHOTOBIOL, V41, P577, DOI 10.1111/j.1751-1097.1985.tb03529.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAMBERLIN HM, 1995, DEV BIOL, V170, P679, DOI 10.1006/dbio.1995.1246; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CLARK SG, 1994, GENETICS, V137, P987; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON IM, 1993, HUM MOL GENET, V2, P915; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; MARTIN P, 1992, ONCOGENE, V7, P1721; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0; ZUKER CS, 1994, SCIENCE, V265, P742, DOI 10.1126/science.8047881	31	134	136	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					52	55		10.1038/377052a0	http://dx.doi.org/10.1038/377052a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659159				2022-12-24	WOS:A1995RT72500053
J	MACCHI, P; VILLA, A; GILIANI, S; SACCO, MG; FRATTINI, A; PORTA, F; UGAZIO, AG; JOHNSTON, JA; CANDOTTI, F; O'SHEA, JJ; VEZZONI, P; NOTARANGELO, LD				MACCHI, P; VILLA, A; GILIANI, S; SACCO, MG; FRATTINI, A; PORTA, F; UGAZIO, AG; JOHNSTON, JA; CANDOTTI, F; O'SHEA, JJ; VEZZONI, P; NOTARANGELO, LD			MUTATIONS OF JAK-3 GENE IN PATIENTS WITH AUTOSOMAL SEVERE COMBINED IMMUNE-DEFICIENCY (SCID)	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; X-CHROMOSOME INACTIVATION; CARRIERS; CELLS	SEVERE combined immune deficiency (SCID) represents a heterogenous group of hereditary diseases. Mutations in the common gamma-chain (gamma(c)), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID1,2, which is usually(!ly associated with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID), The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown, The Jak-3 protein kinase(3,4) has been found to associate,vith the gamma(c)-chain-containing cytokine receptors(4-9). Therefore Jak-3 or other STAT proteins with which it interacts(10,11) are candidate genes for autosomal recessive T- B+ SCID7. Here we investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3. One patient carries a mutation (Tyr100-->Cys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes. The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination. Both mutations resulted in markedly reduced levels of Jak-3, These findings show that abnormalities in the Jak/STAT signalling pathway can account for SCID in humans.	CNR, IST TECNOL BIOMED AVANZATE, I-20131 MILAN, ITALY; UNIV BRESCIA, DIPARTIMENTO MATERNO INFANTILE, BRESCIA, ITALY; NIH, NATL CTR HUMAN GENOME RES, CLIN GENE THERAPY BRANCH, BETHESDA, MD 20892 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Brescia; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Vezzoni, Paolo/K-3197-2018; Frattini, Annalisa/B-7684-2015; Vezzoni, Paolo/R-3416-2019; Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016; Ugazio, Alberto/AAA-6092-2020	Frattini, Annalisa/0000-0002-1166-3091; Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Vezzoni, Paolo/0000-0002-6382-3923; Candotti, Fabio/0000-0001-6399-6042; Villa, Anna/0000-0003-4428-9013				BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONLEY ME, 1988, P NATL ACAD SCI USA, V85, P3090, DOI 10.1073/pnas.85.9.3090; DAMELL JE, 1994, SCIENCE, V264, P1415; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; GOUGEON ML, 1990, J IMMUNOL, V145, P2873; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHMALSTIEG FC, 1995, J CLIN INVEST, V95, P1169, DOI 10.1172/JCI117765; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; WENGLER GS, 1993, J IMMUNOL, V150, P700; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	19	680	776	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	1995	377	6544					65	68		10.1038/377065a0	http://dx.doi.org/10.1038/377065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659163				2022-12-24	WOS:A1995RT72500057
J	ALAVI, A; PARRINELLO, M; FRENKEL, D				ALAVI, A; PARRINELLO, M; FRENKEL, D			AB-INITIO CALCULATION OF THE SOUND-VELOCITY OF DENSE HYDROGEN - IMPLICATIONS FOR MODELS OF JUPITER	SCIENCE			English	Article							SOLID HYDROGEN; GROUND-STATE; OSCILLATIONS; EQUATION	First-priniciples molecular dynamics simulations were used to calculate the sound velocity of dense hydrogen, and the results were compared with extrapolations of experimental data that currently conflict with either astrophysical models or data obtained from recent global oscillation measurements of Jupiter. Excellent agreement with the extrapolated experimental data was obtained. These results strongly support the notion that the existing models for the jovian interior need to be revised.	MAX PLANCK INST FESTKORPERFORSCH,D-70569 STUTTGART,GERMANY; FOM,INST ATOM & MOLEC PHYS,1098 SJ AMSTERDAM,NETHERLANDS	Max Planck Society; AMOLF	ALAVI, A (corresponding author), UNIV CAMBRIDGE,DEPT CHEM,LENSFIELD RD,CAMBRIDGE CB2 1EW,ENGLAND.		Frenkel, Daan/G-2580-2014	Frenkel, Daan/0000-0002-6362-2021				ALVAI A, 1994, PHYS REV LETT, V73, P2599; ANSEN JP, 1986, THEORY SIMPLE LIQUID; BARBEE TW, 1989, PHYS REV LETT, V62, P1150, DOI 10.1103/PhysRevLett.62.1150; CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PhysRevLett.55.2471; CEPERLEY DM, 1980, PHYS REV LETT, V45, P566, DOI 10.1103/PhysRevLett.45.566; CEPERLEY DM, 1987, PHYS REV B, V36, P2092, DOI 10.1103/PhysRevB.36.2092; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; DUFFY TS, 1994, SCIENCE, V263, P1590, DOI 10.1126/science.263.5153.1590; GYGI F, 1993, PHYS REV B, V48, P11692, DOI 10.1103/PhysRevB.48.11692; HEMLEY RJ, 1990, PHYS REV B, V42, P6458, DOI 10.1103/PhysRevB.42.6458; KOHANOFF J, 1995, PHYS REV LETT, V74, P626, DOI 10.1103/PhysRevLett.74.626; MERMIN ND, 1993, PHYS REV, V137, pA1441; MOSSER B, 1993, ASTRON ASTROPHYS, V267, P604; MOSSER B, 1991, ASTRON ASTROPHYS, V251, P356; NATOLI V, 1993, PHYS REV LETT, V70, P1952, DOI 10.1103/PhysRevLett.70.1952; ROSS M, 1983, J CHEM PHYS, V79, P1487, DOI 10.1063/1.445939; Stanley HE., 1971, PHASE TRANSITIONS CR; 1994, CRC HDB CHEM PHYSICS, P6	18	42	43	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1252	1254		10.1126/science.7652571	http://dx.doi.org/10.1126/science.7652571			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652571	Green Submitted			2022-12-24	WOS:A1995RR84200029
J	ROGAEV, EI; SHERRINGTON, R; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; LIANG, Y; CHI, H; LIN, C; HOLMAN, K; TSUDA, T; MAR, L; SORBI, S; NACMIAS, B; PIACENTINI, S; AMADUCCI, L; CHUMAKOV, I; COHEN, D; LANNFELT, L; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH				ROGAEV, EI; SHERRINGTON, R; ROGAEVA, EA; LEVESQUE, G; IKEDA, M; LIANG, Y; CHI, H; LIN, C; HOLMAN, K; TSUDA, T; MAR, L; SORBI, S; NACMIAS, B; PIACENTINI, S; AMADUCCI, L; CHUMAKOV, I; COHEN, D; LANNFELT, L; FRASER, PE; ROMMENS, JM; STGEORGEHYSLOP, PH			FAMILIAL ALZHEIMERS-DISEASE IN KINDREDS WITH MISSENSE MUTATIONS IN A GENE ON CHROMOSOME-1 RELATED TO THE ALZHEIMERS-DISEASE TYPE-3 GENE	NATURE			English	Article							LINKAGE	WE report the cloning of a novel gene (E5-1) encoded on chromosome 1 which has substantial nucleotide and amino-acid sequence similarity to the S182 gene on chromosome 14q24.3. Mutations, including three new missense mutations in the S182 gene, are associated with the AD3 subtype of early-onset familial Alzheimer's disease (AD)(1). Both the E5-1 and the S182 proteins are predicted to be integral membrane proteins with seven membrane-spanning domains, and a large exposed loop between the sixth and seventh transmembrane domains. Analysis of the nucleotide sequence of the open reading frame (ORF) of the E5-1 gene led to the discovery of two missense substitutions at conserved amino-acid residues in affected members of pedigrees with a form of familial AD that has a later age of onset than the AD3 subtype (50-70 years versus 30-60 years for AD3). These observations imply that the E5-1 gene on chromosome 1 and the S182 gene on chromosome 14q24.3 are members of a family of genes (presenilins) with related functions, and indicates that mutations in conserved residues of E5-1 could also play a role in the genesis of AD. Our results also indicate that still other AD susceptibility genes exist.	UNIV TORONTO,CTR RES NEURODEGENERAT DIS,DEPT MED NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,DEPT MED BIOPHYS,TORONTO,ON M5S 1A8,CANADA; TORONTO HOSP,DEPT MED,DIV NEUROL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED & MOLEC GENET,TORONTO,ON M5S 1A8,CANADA; UNIV FLORENCE,DEPT NEUROL & PSYCHIAT,FLORENCE,ITALY; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN NEUROSCI GERIATR MED,S-14186 HUDDINGE,SWEDEN	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Florence; Karolinska Institutet			Rogaev, Evgeny/AAN-7662-2020; Nacmias, Benedetta/J-5084-2018	Nacmias, Benedetta/0000-0001-9338-9040; PIACENTINI, SILVIA/0000-0002-2749-6785; sorbi, sandro/0000-0002-0380-6670	Canadian Institutes of Health Research [37920] Funding Source: Medline; NIA NIH HHS [U24 AG021886, P30 AG10133] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133, U24AG021886] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; HOLLMANN N, 1994, ANNU REV NEUROSCI, V17, P31; Katzman Robert, 1994, P105; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANNFELT L, 1993, NAT GENET, V4, P218, DOI 10.1038/ng0793-218; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0	9	1654	1735	0	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					775	778		10.1038/376775a0	http://dx.doi.org/10.1038/376775a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651536				2022-12-24	WOS:A1995RR83600040
J	ANDERSON, FH				ANDERSON, FH			THE RECTAL APPROACH TO TREATMENT IN DISTAL ULCERATIVE-COLITIS	LANCET			English	Editorial Material							COLONIC MUCOSA		HLTH SCI CTR,VANCOUVER,BC,CANADA	University of British Columbia; University of Manitoba; Children's Hospital Research Institute of Manitoba	ANDERSON, FH (corresponding author), VANCOUVER HOSP,DIV GASTROENTEROL,VANCOUVER,BC,CANADA.							AZADKHAN AK, 1977, LANCET, V2, P892; BJORCK S, 1992, AGENTS ACTIONS, pC60; CEMPIERI M, 1995, GUT, V26, P400; CHAPMAN MAS, 1994, GUT, V35, P73, DOI 10.1136/gut.35.1.73; Fahey J, 1981, ADV INFLAMMAT RES, V2, P21; Grisham M, 1990, CAN J GASTROENTEROL, V4, P295, DOI 10.1155/1990/324287; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; NORDOY A, 1991, DRUGS, V42, P331, DOI 10.2165/00003495-199142030-00001; ROEDIGER WEW, 1980, LANCET, V2, P712; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; VERNIA P, 1995, DIGEST DIS SCI, V40, P305, DOI 10.1007/BF02065414	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					520	521		10.1016/S0140-6736(95)91377-7	http://dx.doi.org/10.1016/S0140-6736(95)91377-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658775				2022-12-24	WOS:A1995RQ98600005
J	SCHACTER, DL; REIMAN, E; UECKER, A; POLSTER, MR; YUN, LS; COOPER, LA				SCHACTER, DL; REIMAN, E; UECKER, A; POLSTER, MR; YUN, LS; COOPER, LA			BRAIN-REGIONS ASSOCIATED WITH RETRIEVAL OF STRUCTURALLY COHERENT VISUAL INFORMATION	NATURE			English	Article							MEMORY; OBJECTS; RECOGNITION; MECHANISMS; ACTIVATION; IMPLICIT	AN object's global, three-dimensional structure may be represented by a specialized brain system involving regions of inferior temporal cortex(1-3). This system's role in object representation can be understood by experiments in which people study drawings of novel objects with possible or impossible three-dimensional structures, and later make either possible/impossible object decisions or old/new recognition decisions about briefly flashed studied and nonstudied objects. Although object decisions about possible objects are facilitated by prior study, there is no corresponding facilitation for impossible objects, thereby implicating a system that is specifically involved in the representation of structurally coherent visual objects(4). Here we show, by positron emission tomography (PET), that increases in blood flow in inferior temporal regions are associated with object decisions about possible but not impossible objects, and that there are increases in the vicinity of the hippocampal formation associated with episodic recognition of possible objects.	UNIV ARIZONA,DEPT PSYCHIAT,TUCSON,AZ 85721; GOOD SAMARITAN REG MED CTR,CTR POSITRON EMISS TOMOG,PHOENIX,AZ 85006; UNIV ARIZONA,DIV NEURAL SYST MEMORY & AGING,TUCSON,AZ 85721; UNIV VICTORIA,DEPT PSYCHOL,WELLINGTON,NEW ZEALAND; ARIZONA STATE UNIV,DEPT COMP SCI & ENGN,TEMPE,AZ 85287; COLUMBIA UNIV,DEPT PSYCHOL,NEW YORK,NY 10027	University of Arizona; University of Arizona; Victoria University Wellington; Arizona State University; Arizona State University-Tempe; Columbia University	SCHACTER, DL (corresponding author), HARVARD UNIV,DEPT PSYCHOL,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.			Schacter, Daniel/0000-0002-2460-6061				ALLISON T, 1994, J NEUROPHYSIOL, V71, P821, DOI 10.1152/jn.1994.71.2.821; BUCKNER RL, 1995, J NEUROSCI, V15, P12; BUCKNER RL, 1995, HDB NEUROPSYCHOLOGY, P439; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; COOPER LA, 1992, J EXP PSYCHOL LEARN, V18, P43, DOI 10.1037/0278-7393.18.1.43; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; FRISTON KJ, 1991, J CEREB BLOOD FLOW M, V10, P458; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; Gray JA, 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; GROSS CG, 1992, PHIL T R SOC B, V335, P245; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Jones-Gotman M., 1993, Society for Neuroscience Abstracts, V19, P1002; KOSSLYN SM, IN PRESS BRAIN; MINTUN MA, 1991, J NUCL MED, V31, P816; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; ROBINSON DL, 1992, TRENDS NEUROSCI, V15, P127, DOI 10.1016/0166-2236(92)90354-B; SCHACTER DL, 1993, J EXP PSYCHOL LEARN, V19, P995, DOI 10.1037/0278-7393.19.5.995; SCHACTER DL, 1990, J EXP PSYCHOL GEN, V119, P5, DOI 10.1037/0096-3445.119.1.5; SCHACTER DL, 1991, J COGNITIVE NEUROSCI, V3, P118; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; STEM C, 1994, SOC NEUR ABSTR, V20, P530; Talairach J., 1988, COPLANAR STEREOTAXIC; TANAKA K, 1993, SCIENCE, V262, P685, DOI 10.1126/science.8235589; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; VINOGRADA OS, 1978, HIPPOCAMPUS, V2	29	261	261	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					587	590		10.1038/376587a0	http://dx.doi.org/10.1038/376587a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637806				2022-12-24	WOS:A1995RP75600049
J	WANNAMETHEE, G; SHAPER, AG; WHINCUP, PH; WALKER, M				WANNAMETHEE, G; SHAPER, AG; WHINCUP, PH; WALKER, M			LOW SERUM TOTAL CHOLESTEROL CONCENTRATIONS AND MORTALITY IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							FACTOR INTERVENTION TRIAL; CORONARY HEART-DISEASE; CANCER MORTALITY; FOLLOW-UP; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; BLOOD-LIPIDS; BODY-WEIGHT; EPIDEMIOLOGY; POPULATION	Objective-To examine the relation between low serum total cholesterol concentrations and causes of mortality. Design-Cohort study of men followed up for an average of 14.8 years (range 13.5-16.0 years). Setting-One general practice in each of 24 British towns. Subjects-7735 men aged 40-59 at screening selected at random from the 24 general practices. Main outcome measures-Deaths from all causes, cardiovascular causes, cancer, and non-cardiovascular, non-cancer causes. Results-During the mean follow up period of 14.8 years there were 1257 deaths from all causes, 640 cardiovascular deaths, 433 cancer deaths, and 184 deaths from other causes. Low serum cholesterol concentrations (<4.8 mmol/l), present in 5% (n=410) of the men, were associated with the highest mortality from all causes, largely due to a significant increase in cancer deaths (age adjusted relative risk 1.6 (95% confidence interval 1.1 to 2.3); <4.8 v 4.8-5.9 mmol/l) and in other non-cardiovascular deaths (age adjusted relative risk 1.9 (1.1 to 3.1)). Low serum cholesterol concentration was associated with an increased prevalence of several diseases and indicators of ill health and with lifestyle characteristics such as smoking and heavy drinking. After adjustment for these factors in the multivariate analysis the increased risk for cancer was attenuated (relative risk 1.4 (0.9 to 2.0)) and the inverse association with other non-cardiovascular, non-cancer causes was no longer significant (relative risk 1.5 (0.9 to 2.6); <4.8 v 4.8-5.9 mmol/l). The excess risks of cancer and of other non-cardiovascular deaths were most pronounced in the first five years and became attenuated and non-significant with longer follow up. By contrast, the positive association between serum total cholesterol concentration and cardiovascular mortality was seen even after more than 10 years of follow up. Conclusion-The association between comparatively low serum total cholesterol concentrations and excess mortality seemed to be due to preclinical cancer and other non-cardiovascular diseases. This suggests that public health programmes encouraging lower average concentrations of serum total cholesterol are unlikely to be associated with increased cancer or other non-cardiovascular mortality.			WANNAMETHEE, G (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977; Whincup, Peter/0000-0002-5589-4107				ALVAREZ C, 1986, CLIN CHEM, V32, P142; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; COX DR, 1972, J R STAT SOC B, V34, P187; DAVEYSMITH G, 1992, JAMA-J AM MED ASSOC, V267, P70; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; HARRIS T, 1994, J CLIN EPIDEMIOL, V45, P595; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HULLEY SB, 1992, CIRCULATION, V87, P1026; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1994, J CLIN EPIDEMIOL, V47, P961, DOI 10.1016/0895-4356(94)90110-4; JACOBS D, 1993, CIRCULATION, V86, P1046; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER MF, 1993, EUR HEART J, V14, P581, DOI 10.1093/eurheartj/14.5.581; PHILLIPS A, 1989, LANCET, V2, P1434; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SCHATZKIN A, 1987, LANCET, V2, P298; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1989, BRIT MED J, V298, P1381, DOI 10.1136/bmj.298.6684.1381; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WANNAMETHEE G, 1992, J EPIDEMIOL COMMUN H, V46, P197, DOI 10.1136/jech.46.3.197; WANNAMETHEE G, 1993, AM J EPIDEMIOL, V137, P735, DOI 10.1093/oxfordjournals.aje.a116734; 1982, JAMA-J AM MED ASSOC, V248, P2853	34	51	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					409	413		10.1136/bmj.311.7002.409	http://dx.doi.org/10.1136/bmj.311.7002.409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7640584	Green Published			2022-12-24	WOS:A1995RP55400011
J	AVEROF, M; AKAM, M				AVEROF, M; AKAM, M			HOX GENES AND THE DIVERSIFICATION OF INSECT AND CRUSTACEAN BODY PLANS	NATURE			English	Article							DROSOPHILA EMBRYO; HOMEOTIC GENES; EXPRESSION; COMPLEX; SEGMENT; ARTEMIA	CRUSTACEANS and insects share a common origin of segmentation(1,2), but the specialization of trunk segments appears to have arisen independently in insects and various crustacean subgroups(3'4). Such macroevolutionary changes in body architecture may be investigated by comparative studies of conserved genetic markers(5-7). The Hox genes are well suited for this purpose, as they determine positional identity along the body axis in a wide range of animals. Here we examine the expression of four Hox genes in the branchiopod crustacean Artemia franciscana, and compare this with Hox expression patterns from insects. In Artemia the three 'trunk' genes Antp, Ubx and abdA are expressed in largely overlapping domains in the uniform thoracic region, whereas in insects they specify distinct segment types within the thorax and abdomen. Our comparisons suggest a multistep process for the diversification of these Hox gene functions, involving early differences in tissue specificity and the later acquisition of a role in defining segmental differences within the trunk. We propose that the branchiopod thorax may be homologous to the entire pregenital (thoracic and abdominal) region of the insect trunk.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE,ENGLAND	University of Cambridge	AVEROF, M (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			Averof, Michalis/0000-0002-6803-7251	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1988, DEVELOPMENT, V104, P123; AKAM M, 1994, DEVELOPMENT S, V120, P209; ANDERSON D. T., 1967, AUST J ZOOL, V15, P47, DOI 10.1071/ZO9670047; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; BEEMAN RW, 1993, BIOESSAYS, V15, P439, DOI 10.1002/bies.950150702; CALMAN WT, 1909, CRUSTACEA; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; DOHLE W, 1988, DEVELOPMENT, V104, P147; DOHLE W, 1988, MYRIAPODA ANCESTRY I; Jurgens G., 1993, DEV DROSOPHILA MELAN, P687; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P567; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; MAHAFFEY JW, 1989, DEVELOPMENT, V105, P167; MANZANARES M, 1993, DEVELOPMENT, V118, P1209; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCNAMARA KJ, 1993, PALAEONTOLOGY, V36, P319; PATEL NH, 1989, DEVELOPMENT, V107, P201; RIEK E F, 1968, Records of the Australian Museum, V27, P313; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; Scourfield DJ, 1926, PHILOS T R SOC LON B, V214, P153, DOI 10.1098/rstb.1926.0005; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Snodgrass R. E., 1951, COMP STUDIES HEAD MA; TEAR G, 1990, DEVELOPMENT, V110, P915; UENO K, 1992, DEVELOPMENT, V114, P555; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Walossek Dieter, 1993, Fossils and Strata, V32, P1; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0	30	211	223	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					420	423		10.1038/376420a0	http://dx.doi.org/10.1038/376420a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630416				2022-12-24	WOS:A1995RM63900050
J	STERN, RC; DOERSHUK, CF; DRUMM, MI				STERN, RC; DOERSHUK, CF; DRUMM, MI			3849+10 KB C-]T MUTATION AND DISEASE SEVERITY IN CYSTIC-FIBROSIS	LANCET			English	Article							GENE; FORM; DNA	50% of patients with cystic fibrosis (CF) are homozygous for the Delta F508 mutation, but the remainder have at least one of many other less common mutations. The 3849+10 kb C-->T splice mutation seems to be associated with less severe disease. We report ten CF patients who are hemizygous for this mutation. Three male patients do not have azoospermia (sperm counts 12, 53, and 198x10(6)/mL). Another boy died before CF was diagnosed; his genital tract appeared normal at necropsy. All patients had clinically sufficient exocrine pancreatic function. Pulmonary disease was delayed in onset in most of these patients (range <1 to 16; median 9 years), but then became severe in some, progressing to death (in two) and need for transplantation in one. Sweat chloride concentration was abnormal (80 mmol/L) in one patient but in others was in the intermediate range (45-65 mmol/L). There was substantial variation in pulmonary disease severity within sibships. These observations suggest some dissociation in genetically determined severity between different organs. There was some evidence among these patients of a tendency for disease of the genital tract to become progressively more severe. Perhaps sperm banking should be offered to male patients. We speculate that some normal CF transmembrane conductance regulator is made in patients with this splice abnormality.	CASE WESTERN RESERVE UNIV,LEROY W MATTHEWS CYST FIBROSIS CTR,DEPT PEDIAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,LEROY W MATTHEWS CYST FIBROSIS CTR,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University	STERN, RC (corresponding author), UNIV CLEVELAND HOSP,RAINBOW BABIES & CHILDRENS HOSP,11100 EUCLID AVE,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; DEAN M, 1994, HUM GENET, V93, P364; GIBSON LE, 1959, PEDIATRICS, V23, P545; HANDELSMAN DJ, 1984, NEW ENGL J MED, V310, P3, DOI 10.1056/NEJM198401053100102; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KEREM BS, 1989, AM J HUM GENET, V44, P827; LANDING BH, 1969, ARCH PATHOL, V88, P569; LIEBERMAN J, 1990, INTERNAL MED, V11, P105; MERCIER B, 1995, AM J HUM GENET, V56, P272; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHUBER AP, 1993, HUM MOL GENET, V2, P153, DOI 10.1093/hmg/2.2.153; STERN RC, 1982, LANCET, V1, P1401; TAMAGNINI GP, 1983, BRIT J HAEMATOL, V54, P189, DOI 10.1111/j.1365-2141.1983.tb02087.x; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; 1994, HUM MUTAT, V4, P167	16	44	45	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					274	276		10.1016/S0140-6736(95)92165-6	http://dx.doi.org/10.1016/S0140-6736(95)92165-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630247				2022-12-24	WOS:A1995RL75700010
J	PETRIJ, F; GILES, RH; DAUWERSE, HG; SARIS, JJ; HENNEKAM, RCM; MASUNO, M; TOMMERUP, N; VANOMMEN, GJB; GOODMAN, RH; PETERS, DJM; BREUNING, MH				PETRIJ, F; GILES, RH; DAUWERSE, HG; SARIS, JJ; HENNEKAM, RCM; MASUNO, M; TOMMERUP, N; VANOMMEN, GJB; GOODMAN, RH; PETERS, DJM; BREUNING, MH			RUBINSTEIN-TAYBI SYNDROME CAUSED BY MUTATIONS IN THE TRANSCRIPTIONAL COACTIVATOR CBP	NATURE			English	Article							DENOVO RECIPROCAL TRANSLOCATION; PAIRED BOX GENE; CYCLIC-AMP; SHORT ARM; PROTEIN; DNA; 16P13.3	THE Rubinstein-Taybi syndrome (RTS) is a well-defined syndrome with facial abnormalities, broad thumbs, broad big toes and mental retardation as the main clinical features(1-3). Many patients with RTS have been shown to have breakpoints in, and microdeletions of, chromosome 16p13.3 (refs 4-8). Here we report that all these breakpoints are restricted to a region that contains the gene for the human CREB binding protein (CBP), a nuclear protein participating co-activator in cyclic-AMP-regulated gene expression(9-12). We show that RTS results not only from gross chromosomal rearrangements of chromosome 16p, but also from point mutations in the CBP gene itself. Because the patients are heterozygous for the mutations, we propose that the loss of one functional copy of the CBP gene underlies the developmental abnormalities in RTS and possibly the propensity for malignancy.	UNIV AMSTERDAM,ACAD MED CTR,DEPT HUMAN GENET,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT,1105 AZ AMSTERDAM,NETHERLANDS; KANAGAWA CHILDRENS MED CTR,DIV MED GENET,YOKOHAMA,KANAGAWA,JAPAN; JOHN F KENNEDY INST,DANISH CTR HUMAN GENOME RES,DK-2600 GLOSTRUP,DENMARK; ULLEVAL UNIV HOSP,DEPT MED GENET,OSLO,NORWAY; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Aarhus University; University of Oslo; Oregon Health & Science University	PETRIJ, F (corresponding author), LEIDEN UNIV,SYLVIUS LABS,DEPT HUMAN GENET,LEIDEN,NETHERLANDS.		Tommerup, Niels/T-8776-2017; Breuning, Martijn H/E-3429-2010; Peters, Dorien/AFH-8507-2022	Tommerup, Niels/0000-0003-2304-0112; Peters, Dorien/0000-0001-6974-7143; Giles, Rachel/0000-0001-9133-2008				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BREUNING MH, 1993, AM J HUM GENET, V52, P249; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAUWERSE JG, 1992, BLOOD, V79, P1299; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GFIBBONS RJ, 1995, CELL, V80, P837; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HENNEKAM RCM, 1990, AM J MED GENET S, V6, P17; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOTH CF, 1993, AM J HUM GENET, V52, P455; IMAIZUMI K, 1991, AM J MED GENET, V38, P636, DOI 10.1002/ajmg.1320380430; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LACOMBE D, 1992, AM J MED GENET, V44, P126; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MASUNO M, 1994, AM J MED GENET, V53, P352, DOI 10.1002/ajmg.1320530409; MICHAIL J, 1957, Rev Chir Orthop Reparatrice Appar Mot, V43, P142; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; RUBINSTEIN JH, 1963, AM J DIS CHILD, V105, P588, DOI 10.1001/archpedi.1963.02080040590010; SIRAGANIAN PA, 1989, MED PEDIATR ONCOL, V17, P485; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; TOMMERUP N, 1992, AM J MED GENET, V44, P237, DOI 10.1002/ajmg.1320440223; WESSELS JW, 1991, BLOOD, V77, P1555	28	929	964	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					348	351		10.1038/376348a0	http://dx.doi.org/10.1038/376348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630403				2022-12-24	WOS:A1995RL44300049
J	WILLETT, WC; MANSON, JE; STAMPFER, MJ; COLDITZ, GA; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				WILLETT, WC; MANSON, JE; STAMPFER, MJ; COLDITZ, GA; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			WEIGHT, WEIGHT CHANGE, AND CORONARY HEART-DISEASE IN WOMEN - RISK WITHIN THE NORMAL-WEIGHT RANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAT DISTRIBUTION; FOLLOW-UP; BODY; MORTALITY; OBESITY	Objective.-To assess the validity of the 1990 US weight guidelines for women that support a substantial gain in weight at approximately 35 years of age and recommend a range of body mass index (BMI) (defined as weight in kilograms divided by the square of height in meters) from 21 to 27 kg/m(2), in terms of coronary heart disease (CHD) risk in women. Design.-Prospective cohort study. Setting.-Female registered nurses in the United States. Participants.-A total of 115 818 women aged 30 to 55 years in 1976 and without a history of previous CHD. Main Outcome Measure.-Incidence of CHD defined as nonfatal myocardial infarction or fatal CHD. Results.-During 14 years of follow-up, 1292 cases of CHD were ascertained. After controlling for age, smoking, menopausal status, postmenopausal hormone use, and parental history of CHD and using as a reference women with a BMI of less than 21 kg/m(2), relative risks (RRs) and 95% confidence intervals (Cls) for CHD were 1.19 (0.97 to 1.44) for a BMI of 21 to 22.9 kg/m(2), 1.46 (1.20 to 1.77) for a BMI of 23 to 24.9 kg/m(2), 2.06 (1.72 to 2.48) for a BMI of 25 to 28.9 kg/m(2), and 3.56 (2.96 to 4.29) for a BMI of 29 kg/m(2) or more. Women who gained weight from 18 years of age were compared with those with stable weight (+/-5 kg) in analyses that controlled for the same variables as well as BMI at 18 years of age. The RRs and Cls were 1.25 (1.01 to 1.55) for a 5- to 7.9-kg gain, 1.64 (1.33 to 2.04) for an 8- to 10.9-kg gain, 1.92 (1.61 to 2.29) for an 11- to 19-kg gain, and 2.65 (2.17 to 3.22) for a gain of 20 kg or more. Among women within the BMI range of 18 to 25 kg/m(2), weight gain after 18 years of age remained a strong predictor of CHD risk. Conclusions.-Higher levels of body weight within the ''normal'' range, as well as modest weight gains after 18 years of age, appear to increase risks of CHD in middle-aged women. These data provide evidence that current US weight guidelines may be falsely reassuring to the large proportion of women of der than 35 years who are within the current guidelines but have potentially avoidable risks of CHD.	BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	WILLETT, WC (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 24074, HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLDITZ GA, 1990, AM J CLIN NUTR, V51, P1100, DOI 10.1093/ajcn/51.6.1100; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; GARRISON RJ, 1993, INT J OBESITY, V17, P417; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1994, AM J EPIDEMIOL, V139, pS46; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; RIMM EB, 1993, AM J EPIDEMIOL, V138, P601; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P303, DOI 10.1093/oxfordjournals.aje.a117252; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; WOOD PD, 1993, CRIT REV FOOD SCI, V33, P369, DOI 10.1080/10408399309527635; 1960, BUILD BLOOD PRESSURE, V1; 1985, NUTRITION YOUR HLTH; 1990, NUTRITION YOUR HLTH; 1960, BUILD BLOOD PRESSURE, V2; 1994, J NUTR, V124, P2240	23	745	760	1	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					461	465		10.1001/jama.273.6.461	http://dx.doi.org/10.1001/jama.273.6.461			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7654270				2022-12-24	WOS:A1995QE49800028
J	MUEGGE, K; VILA, MP; DURUM, SK				MUEGGE, K; VILA, MP; DURUM, SK			INTERLEUKIN-7 - A COFACTOR FOR V(D)J REARRANGEMENT OF THE T-CELL RECEPTOR BETA-GENE	SCIENCE			English	Article							MURINE INTERLEUKIN-7; RECOMBINATION; RAG-1; IL-7; THYMOCYTES; REGION	The diversity of the T cell receptor repertoire is generated by rearrangement of gene elements in immature thymocytes. To identify a thymic signal that induces this rearrangement, a variety of agents were tested for their ability to induce rearrangement of the T cell receptor beta gene in suspensions of thymocytes from mouse embryos at day 14 of gestation. Of 16 agents tested, only interleukin-7 (IL-7) induced V(D)J gene rearrangement and sustained expression of the RAG-1 and RAG-2 genes, which are known to control rearrangement. These data implicate IL-7, a cytokine that is abundantly expressed in embryonic thymus, in driving gene rearrangement during early T cell development.	NCI,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MUEGGE, K (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702, USA.			durum, scott/0000-0003-1307-9582				ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BORN W, 1985, P NATL ACAD SCI USA, V82, P2925, DOI 10.1073/pnas.82.9.2925; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; KAVALER J, 1984, NATURE, V310, P421, DOI 10.1038/310421a0; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MUEGGE K, UNPUB; MUEGGE K, IN PRESS P NATL ACAD; Murray R, 1989, Int Immunol, V1, P526, DOI 10.1093/intimm/1.5.526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SUDA T, 1991, J IMMUNOL, V146, P3068; WATSON JD, 1989, J IMMUNOL, V143, P1215; WILES MV, 1992, EUR J IMMUNOL, V22, P1037, DOI 10.1002/eji.1830220424; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	25	204	206	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					93	95		10.1126/science.7686307	http://dx.doi.org/10.1126/science.7686307			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	7686307	Green Submitted			2022-12-24	WOS:A1993LK43400039
J	WAGNER, RW; MATTEUCCI, MD; LEWIS, JG; GUTIERREZ, AJ; MOULDS, C; FROEHLER, BC				WAGNER, RW; MATTEUCCI, MD; LEWIS, JG; GUTIERREZ, AJ; MOULDS, C; FROEHLER, BC			ANTISENSE GENE INHIBITION BY OLIGONUCLEOTIDES CONTAINING C-5 PROPYNE PYRIMIDINES	SCIENCE			English	Article							EXPRESSION; RNA	Phosphorothioate oligodeoxynucleotides containing the C-5 propyne analogs of uridine and cytidine bind RNA with high affinity and are potent antisense inhibitors of gene expression. In a cellular assay, gene-specific antisense inhibition occurred at nanomolar concentrations of oligonucleotide, was dose-dependent and exquisitely sensitive to sequence mismatches, and was correlated with the melting temperature and length of oligonucleotide. Activity was independent of RNA target site and cell type but was detectable only when the oligonucleotides were microinjected or delivered with cell-permeabilizing agents. These oligonucleotides may have important applications in therapy and in studies of gene function.			WAGNER, RW (corresponding author), GILEAD SCI INC,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BISCHOFBERGER N, 1992, SEMIN VIROL, V3, P57; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; DRAPER KG, 1991, Patent No. 12811; FISEHR TL, IN PRESS NUCLEIC ACI; FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; FROEHLER BC, 1993, PROTOCOLS OLIGONUCLE, P63; GRAESSMANN M, 1991, NUCLEIC ACIDS RES, V19, P53, DOI 10.1093/nar/19.1.53; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; IRIBARREN AM, 1990, P NATL ACAD SCI USA, V87, P7747, DOI 10.1073/pnas.87.19.7747; ROSOLEN A, 1990, CANCER RES, V50, P6316; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H; TACK LC, 1989, J VIROL, V63, P3962; YOUNG S, 1991, NUCLEIC ACIDS RES, V19, P2463, DOI 10.1093/nar/19.9.2463	17	401	456	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1510	1513		10.1126/science.7684856	http://dx.doi.org/10.1126/science.7684856			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	7684856				2022-12-24	WOS:A1993LF05800038
J	MURGATROYD, FD; CAMM, AJ				MURGATROYD, FD; CAMM, AJ			ATRIAL ARRHYTHMIAS	LANCET			English	Article							SINUS RHYTHM; ANTIARRHYTHMIC DRUGS; VENTRICULAR RATE; FIBRILLATION; FLUTTER; FLECAINIDE; THERAPY; CARDIOVERSION; MAINTENANCE; FRAMINGHAM		ST GEORGE HOSP, SCH MED, DEPT CARDIOL SCI, CRANMER TERR, LONDON SW17 0RE, ENGLAND	St Georges University London								Allessie M, 1985, CARDIAC ELECTROPHYSI, P265, DOI DOI 10.1016/J.HRTHM.2012.03.008; ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; [Anonymous], 1989, NEW ENGL J MED, V321, P406; ANTMAN EM, 1990, J AM COLL CARDIOL, V15, P698, DOI 10.1016/0735-1097(90)90649-A; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; BAILY D, 1992, J AM COLL CARDIOL, V19, P41; BIGGER JT, 1985, AM J CARDIOL, V55, P623, DOI 10.1016/0002-9149(85)90125-0; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COUMEL P, 1978, ARCH MAL COEUR VAISS, V71, P645; COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; CRAWFORD W, 1989, AM J MED, V86, P663, DOI 10.1016/0002-9343(89)90440-3; FALK RH, 1991, ANN INTERN MED, V114, P573, DOI 10.7326/0003-4819-114-7-573; FISHER JD, 1990, ATRIAL ARRHYTHMIAS C, P400; FLEG JL, 1982, CHEST, V81, P302, DOI 10.1378/chest.81.3.302; GILLETTE PC, 1985, JAMA-J AM MED ASSOC, V253, P391, DOI 10.1001/jama.253.3.391; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MOE GK, 1962, ARCH INT PHARMACOD T, V140, P183; MURGATROYD FD, 1993, J AM COLL CARDIOL, V21, P380; MURGATROYD FD, 1993, J AM COLL CARDIOL, V21, P478; NATHAN AW, 1987, CLIN CARDIOL, V10, P317, DOI 10.1002/clc.4960100505; OLSHANSKY B, 1990, J AM COLL CARDIOL, V16, P1639, DOI 10.1016/0735-1097(90)90314-F; OLSHANSKY B, 1988, J AM COLL CARDIOL, V11, P359, DOI 10.1016/0735-1097(88)90102-7; PETERSEN P, 1989, LANCET, V1, P175; PRITCHETT ELC, 1991, AM J CARDIOL, V67, P976, DOI 10.1016/0002-9149(91)90170-P; RAWLES JM, 1990, BRIT HEART J, V63, P225; RAWLES JM, 1990, BRIT HEART J, V63, P157; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SUTTORP MJ, 1990, J AM COLL CARDIOL, V16, P1722, DOI 10.1016/0735-1097(90)90326-K; VANGELDER IC, 1991, AM J CARDIOL, V68, P41, DOI 10.1016/0002-9149(91)90707-R; WELLS JL, 1979, CIRCULATION, V60, P665, DOI 10.1161/01.CIR.60.3.665; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973	37	117	120	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1317	1322						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	7684105				2022-12-24	WOS:A1993LD25300012
J	TAUB, DD; CONLON, K; LLOYD, AR; OPPENHEIM, JJ; KELVIN, DJ				TAUB, DD; CONLON, K; LLOYD, AR; OPPENHEIM, JJ; KELVIN, DJ			PREFERENTIAL MIGRATION OF ACTIVATED CD4+ AND CD8+ T-CELLS IN RESPONSE TO MIP-1-ALPHA AND MIP-1-BETA	SCIENCE			English	Article							LANGERHANS CELLS; FLUORESCEIN ISOTHIOCYANATE; ADHESION RECEPTORS; CYTOKINE FAMILY; DENDRITIC CELLS; LYMPHOCYTES-T; ANTIGEN; INHIBITION; CHEMOTAXIS; SKIN	Recombinant human macrophage inflammatory protein-1alpha (rhMIP-1alpha) and rhMIP-1beta were potent chemoattractants of human T lymphocytes. These rhMIP-1 cytokines attracted only T cells activated by monoclonal antibody to CD3 and did not attract unstimulated lymphocytes. Phenotypic analysis revealed that CD4+ T cells were capable of migrating in response to rhMIP-1beta, whereas rhMIP-1alpha induced chemotaxis of predominantly CD8+ T lymphocytes. Activated naive and memory T cells also migrated in response to rhMIP-1 cytokines. Furthermore, these cytokines enhanced the ability of T cells to bind to an endothelial cell monolayer. These results suggest that rhMIP-1 cytokines preferentially recruit specific T cell subsets during the evolution of the immune response.	NCI,FCRDC,BIOL RESPONSE MODIFIER PROGRAM,EXPTL IMMUNOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAUB, DD (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIER PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702, USA.		Lloyd, Andrew/AAF-6071-2022; Lloyd, Andrew/AFJ-8960-2022; Lloyd, Andrew/E-7334-2017	Lloyd, Andrew/0000-0001-6277-8887; Lloyd, Andrew/0000-0001-6277-8887; 	PHS HHS [N01-C0-74102] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIBA S, 1990, J IMMUNOL, V145, P2791; BACON KB, 1989, BIOCHEM BIOPH RES CO, V165, P349, DOI 10.1016/0006-291X(89)91076-0; CENTER DM, 1983, J IMMUNOL, V128, P2563; CONLON KC, 1992, J IMMUNOL, V149, P3278; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HYENS RO, 1992, CELL, V69, P11; KORNFELD H, 1985, J IMMUNOL, V134, P3887; KUDO C, 1991, J IMMUNOL, V147, P2196; LARSEN C, 1990, PROG CLIN BIOL RES, V349, P419; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MACATONIA SE, 1986, IMMUNOLOGY, V59, P509; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; MIOSSEC P, 1984, J IMMUNOL, V133, P2007; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAPOLITANO M, 1990, J EXP MED, V173, P285; OH KO, 1991, J IMMUNOL, V147, P2978; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PILARO AM, 1990, J IMMUNOL METHODS, V135, P213, DOI 10.1016/0022-1759(90)90275-Z; RUSSELL RJ, 1975, NATURE, V256, P646, DOI 10.1038/256646a0; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SILBERBERGSINAKIN I, 1976, CELL IMMUNOL, V25, P137, DOI 10.1016/0008-8749(76)90105-2; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAUB DD, UNPUB; TURKA LA, 1990, J IMMUNOL, V144, P1646	28	742	752	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					355	358		10.1126/science.7682337	http://dx.doi.org/10.1126/science.7682337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	7682337				2022-12-24	WOS:A1993KX80000039
J	NURCOMBE, V; FORD, MD; WILDSCHUT, JA; BARTLETT, PF				NURCOMBE, V; FORD, MD; WILDSCHUT, JA; BARTLETT, PF			DEVELOPMENTAL REGULATION OF NEURAL RESPONSE TO FGF-1 AND FGF-2 BY HEPARAN-SULFATE PROTEOGLYCAN	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; CELL-SURFACE; BASEMENT-MEMBRANE; PRECURSOR CELLS; EXPRESSION; RECEPTOR; DIFFERENTIATION; NEURONS	Murine neural precursor cells and cell lines derived from them are stimulated by members of the heparin-binding fibroblast growth factor (FGF) family. The activity of FGF is regulated by heparan sulfate proteoglycans (HSPGs), and this interaction is an essential prerequisite for the binding of growth factor to the signal transducing receptors. Messenger RNA for FGF-2 was detectable in the neuroepithelium at embryonic day 9, and the HSPGs produced by these cells at this time preferentially bound FGF-2. However, at embryonic day 11, when messenger RNA for FGF-1 was first detectable, there was a switch in the binding specificity of the HSPG to FGF-1. Thus, a single species of HSPG undergoes a rapid, tightly controlled change in growth factor-binding specificity concomitant with the temporal expression of the FGFs.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute	NURCOMBE, V (corresponding author), UNIV MELBOURNE,DEPT ANAT & CELL BIOL,PARKVILLE,VIC 3052,AUSTRALIA.		Bartlett, Perry/F-3813-2012					ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ANY AH, 1990, BIOCHEM J, V265, P461; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BERNFIELD ME, 1992, ANN REV CELL BIOL, V8, P1; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; COLE GJ, 1989, EXP CELL RES, V182, P44, DOI 10.1016/0014-4827(89)90278-4; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FU YM, 1991, NEURON, V114, P1261; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KILPATRICK T, 1993, NEURON, V10, P1; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MATTHEW WD, 1985, J NEUROSCI, V5, P1842; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; NURCOMBE V, 1991, SOC NEUR ABSTR, V105, P553; NURCOMBE V, UNPUB; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHNURCH H, 1991, DEVELOPMENT, V111, P1143; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; THOMAS D, 1991, DEV BRAIN RES, V59, P117, DOI 10.1016/0165-3806(91)90091-V; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	386	406	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					103	106		10.1126/science.7682010	http://dx.doi.org/10.1126/science.7682010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682010				2022-12-24	WOS:A1993KV42300039
J	GETHER, U; JOHANSEN, TE; SNIDER, RM; LOWE, JA; NAKANISHI, S; SCHWARTZ, TW				GETHER, U; JOHANSEN, TE; SNIDER, RM; LOWE, JA; NAKANISHI, S; SCHWARTZ, TW			DIFFERENT BINDING EPITOPES ON THE NK1 RECEPTOR FOR SUBSTANCE-P AND A NONPEPTIDE ANTAGONIST	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; LIGAND-BINDING; SPECIFICITY; EXPRESSION; INHIBITORS; AGONIST; SITES; CDNA	NON-PEPTIDE ligands for peptide receptors have been discovered in several systems through file screening programs1-6, but the mechanism of action for these candidate drugs is obscure as they do not chemically resemble the native peptides. The compound CP 96345 is a high-affinity, non-peptide antagonist of the substance P (NK1) receptor4,5,7, which is important in pain perception and neurogenic inflammation8-11. Here we identify epitopes on the NK1 receptor responsible for the specific binding of CP 96345 by systematic exchange of corresponding segments between the NK1 receptor and the homologous NK3 (neurokinin B) receptor, which does not bind the non-peptide ligand. Non-conserved residues, in two epitopes around the top of transmembrane segment V and in one epitope at the top of transmembrane segment VI, are essential for the specific action of CP 96345 on the NK1 receptor, but are surprisingly not important for the binding of the natural peptide ligand, substance P. Susceptibility to the non-peptide antagonists can be conveyed to the previously unresponsive NK3 receptor by mutational transfer of this discontinuous epitope from the NK1 receptor.	PFIZER INC, DIV CENT RES, DEPT EXPLORATORY MED CHEM, GROTON, CT 06340 USA; KYOTO UNIV, FAC MED, INST IMMUNOL, KYOTO 606, JAPAN	Pfizer; Kyoto University	GETHER, U (corresponding author), UNIV COPENHAGEN, DEPT CLIN BIOCHEM, MOLEC ENDOCRINOL LAB, RIGSHOSP 6321, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.			Schwartz, Thue W./0000-0002-0261-6904; Gether, Ulrik/0000-0002-0020-3807				BUCK SH, 1986, TRENDS PHARMACOL SCI, V7, P65, DOI 10.1016/0165-6147(86)90256-7; CHANG RSL, 1990, MOL PHARMACOL, V37, P347; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHIMAWN HG, 1991, REV BIOCH, V60, P653; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ENGBERG G, 1981, NATURE, V293, P222, DOI 10.1038/293222a0; FONG TM, 1992, J BIOL CHEM, V267, P25664; FREIDINGER RM, 1990, ALFRED BENZON SYMP S, V29, P389; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; IVERSEN LL, 1990, ALFRED BENZON SYMP S, V29, P363; JOHANSEN TE, 1990, BIOCHEM BIOPH RES CO, V172, P1384, DOI 10.1016/0006-291X(90)91603-P; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAUFER R, 1985, P NATL ACAD SCI USA, V82, P7444, DOI 10.1073/pnas.82.21.7444; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; MCLEAN S, 1991, SCIENCE, V251, P437, DOI 10.1126/science.1703324; MIZRAHI J, 1984, EUR J PHARMACOL, V99, P193, DOI 10.1016/0014-2999(84)90241-3; PERNOW B, 1983, PHARMACOL REV, V35, P85; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; SNIDER RM, 1991, P NATL ACAD SCI USA, V88, P10042, DOI 10.1073/pnas.88.22.10042; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1988, J BIOL CHEM, V263, P10267; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1992, MOL PHARMACOL, V41, P369; YAMAMURA Y, 1991, SCIENCE, V252, P572, DOI 10.1126/science.1850553; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	28	235	235	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					345	348		10.1038/362345a0	http://dx.doi.org/10.1038/362345a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	7681152				2022-12-24	WOS:A1993KU17600061
J	HART, AC; KRAMER, H; ZIPURSKY, SL				HART, AC; KRAMER, H; ZIPURSKY, SL			EXTRACELLULAR DOMAIN OF THE BOSS TRANSMEMBRANE LIGAND ACTS AS AN ANTAGONIST OF THE SEV RECEPTOR	NATURE			English	Article							TYROSINE-KINASE RECEPTOR; DROSOPHILA RETINA; SEVENLESS PROTEIN; GROWTH-FACTOR; CELL FATE; SI-LOCUS; BRIDE; GENE; ENCODES; MOUSE	THE fate of the R7 photoreceptor cell in the Drosophila compound eye is established by a specific inductive interaction between the R8 photoreceptor neuron and the R7 precursor cell1. This induction is mediated by two cell-surface proteins: the ligand, bride of sevenless2 (boss), and sevenless (sev), a tyrosine-kinase receptor3-5 The structure of boss is unique for a ligand of a tyrosine-kinase receptor. It contains a large extracellular domain, seven transmembrane segments, and a carboxy-terminal cytoplasmic tail6,7. Here we report that: (1) boss activates tyrosine phosphorylation of the sev receptor; (2) the seven transmembrane domain of boss is necessary for its function; and (3) a soluble form of boss acts as an antagonist of the sev receptor both in vivo and in vitro.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT BIOL CHEM,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles				Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181				ANKELESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CAGAN RC, 1992, CELL, V69, P309; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JI I, 1991, J BIOL CHEM, V266, P13076; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	21	36	37	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					732	736		10.1038/361732a0	http://dx.doi.org/10.1038/361732a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680109				2022-12-24	WOS:A1993KN78900059
J	TANAKA, Y; ADAMS, DH; HUBSCHER, S; HIRANO, H; SIEBENLIST, U; SHAW, S				TANAKA, Y; ADAMS, DH; HUBSCHER, S; HIRANO, H; SIEBENLIST, U; SHAW, S			T-CELL ADHESION INDUCED BY PROTEOGLYCAN-IMMOBILIZED CYTOKINE MIP-1-BETA	NATURE			English	Article							LYMPHOCYTES-T; CD44; PROTEIN; ACTIVATION; RECEPTOR; FAMILY; GLYCOSAMINOGLYCANS; HYALURONATE; MOLECULE-1; ADHERENCE	LYMPHOCYTE migration from blood into tissue depends on integrin-mediated adhesion to endothelium1-4. Adhesion requires not only integrin ligands on the endothelium, but also activation signals because T-cell integrins cannot bind well until they are activated. The physiological 'triggers' for T-cell adhesion are unknown, but cytokines may be good candidates as they are released during inflammation and trigger adhesion in neutrophils and monocytes2,5,6. We have identified a cytokine, macrophage inflammatory protein-1beta (MIP-1beta),that induces both chemotaxis and adhesion of T cells; MIP-1beta is most effective at augmenting adhesion of CD8+ T cells to the vascular cell adhesion molecule VCAM-1. We reasoned that, as cytokines in vivo will be rapidly washed away, MIP-1beta might be bound to endothelial surfaces and so induce adhesion in its immobilized form. Here we show that: (1) MIP-1beta is present on lymph node endothelium; (2) immobilized MIP-1beta induces binding of T cells to VCAM-1 in vitro. MIP-1beta was immobilized by binding to proteoglycan: a conjugate of heparin with bovine serum albumin and cellular proteoglycan CD44 were both effective. We propose that MIP-1beta and other cytokines with glycosaminoglycan-binding sites will bind to and be presented by endothelial proteoglycans to trigger adhesion selectively not only of lymphocyte subsets, but also of other cell types.	UNIV BIRMINGHAM,DEPT PATHOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	TANAKA, Y (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.		Adams, David H/C-9092-2009	Adams, David H/0000-0001-6776-0336				ADAMS DH, 1991, J IMMUNOL, V147, P609; ADAMS DH, 1989, LANCET, V2, P1122; ARNAOUT MA, 1986, J CLIN INVEST, V78, P591; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HORGAN KJ, 1991, CURRENT PROTOCOLS IM; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALS ST, 1989, J IMMUNOL, V143, P851; PARDI R, 1992, IMMUNOL TODAY, V13, P224, DOI 10.1016/0167-5699(92)90159-5; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHAW LM, 1989, J EXP MED, V169, P303, DOI 10.1084/jem.169.1.303; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; TANAKA Y, IN PRESS IMMUN TODAY; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	40	801	814	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					79	82		10.1038/361079a0	http://dx.doi.org/10.1038/361079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7678446				2022-12-24	WOS:A1993KF71800053
J	DU, ZJ; LANG, SM; SASSEVILLE, VG; LACKNER, AA; ILYINSKII, PO; DANIEL, MD; JUNG, JU; DESROSIERS, RC				DU, ZJ; LANG, SM; SASSEVILLE, VG; LACKNER, AA; ILYINSKII, PO; DANIEL, MD; JUNG, JU; DESROSIERS, RC			IDENTIFICATION OF A NEF ALLELE THAT CAUSES LYMPHOCYTE-ACTIVATION AND ACUTE DISEASE IN MACAQUE MONKEYS	CELL			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELL ACTIVATION; MOLECULAR CLONE; RHESUS-MONKEYS; ANTIGEN; RETROVIRUS; AIDS; PHOSPHORYLATION; PATHOGENICITY; DETERMINANTS	Residues 17 and 18 in nef of SIVmac239 were changed from RQ to YE to create a translated sequence of SRPSGDLYERLLRARGETYGRLLGEVEDGYSQSP from residues 10-43. The YXXL motifs in this context match very well with consensus sequences for SH2 binding domains and are similar to ones present in nef of the acutely lethal pathogen SIVpbj14. The YE variant of SIVmac239, unlike SIVmac239 but like SIVpbj14, replicated well in resting peripheral blood mononuclear cell cultures, caused extensive T lymphocyte activation, and produced an acute disease in rhesus and pigtailed monkeys characterized by severe diarrhea, rash, and extensive lymphoid proliferation in the gastrointestinal tract. The YEnef gene transformed NIH 3T3 cells in culture. Both 239nef and YEnef were found to associate with src in cotransfected COS cells, and both 60 kDa src and 34 kDa nef were phosphorylated at tyrosine in these cells. The extent of tyrosine phosphorylation of 239nef was considerably less than that of YEnef in these assays. These findings identity an important determinant of the SIVpbj14 phenotype, and they provide evidence of a role for nef in signal transduction and cellular activation.			DU, ZJ (corresponding author), HARVARD UNIV, NEW ENGLAND REG PRIMATE RES CTR, SCH MED, SOUTHBOROUGH, MA 01772 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025328, R37AI025328] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168] Funding Source: Medline; NIAID NIH HHS [AI25328] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; BARBARESCHI M, 1994, AM J CLIN PATHOL, V102, P171, DOI 10.1093/ajcp/102.2.171; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DITTMAR MT, 1995, P NATL ACAD SCI USA, V92, P1362, DOI 10.1073/pnas.92.5.1362; DOLLARD SC, 1994, J VIROL, V68, P7800, DOI 10.1128/JVI.68.12.7800-7809.1994; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; FULTZ PN, 1994, VIRUS RES, V32, P205, DOI 10.1016/0168-1702(94)90042-6; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; ISRAEL ZR, 1993, AIDS RES HUM RETROV, V9, P277, DOI 10.1089/aid.1993.9.277; JUNG JU, 1995, IN PRESS J BIOL CHEM; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LANDBERG G, 1990, EXP CELL RES, V187, P111, DOI 10.1016/0014-4827(90)90124-S; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MORI K, 1992, J VIROL, V66, P2067, DOI 10.1128/JVI.66.4.2067-2075.1992; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NOVEMBRE FJ, 1993, J VIROL, V67, P2466, DOI 10.1128/JVI.67.5.2466-2474.1993; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	223	224	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 25	1995	82	4					665	674		10.1016/0092-8674(95)90038-1	http://dx.doi.org/10.1016/0092-8674(95)90038-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664345	Bronze			2022-12-24	WOS:A1995RR73400017
J	WANG, ND; FINEGOLD, MJ; BRADLEY, A; OU, CN; ABDELSAYED, SV; WILDE, MD; TAYLOR, LR; WILSON, DR; DARLINGTON, GJ				WANG, ND; FINEGOLD, MJ; BRADLEY, A; OU, CN; ABDELSAYED, SV; WILDE, MD; TAYLOR, LR; WILSON, DR; DARLINGTON, GJ			IMPAIRED ENERGY HOMEOSTASIS IN C/EBP-ALPHA KNOCKOUT MICE	SCIENCE			English	Article							ENHANCER-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; BROWN ADIPOSE-TISSUE; HEPATOMA-CELLS; GENE; LIVER; TRANSCRIPTION; EXPRESSION; METABOLISM; DISRUPTION	Mice homozygous for the targeted deletion of the c/ebp alpha gene, which expresses the CCAAT/enhancer-binding protein alpha (C/EBP alpha), did not store hepatic glycogen and died from hypoglycemia within 8 hours after birth. In these mutant mice, the amounts of glycogen synthase messenger RNA were 50 to 70 percent of normal and the transcriptional induction of the genes for two gluconeogenic enzymes, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, was delayed. The hepatocytes and adipocytes of the mutant mice failed to accumulate lipid and the expression of the gene for uncoupling protein, the defining marker of brown adipose tissue, was reduced. This study demonstrates that C/EBP alpha is critical for the establishment and maintenance of energy homeostasis in neonates.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839	NIDDK NIH HHS [DK 45285] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045285] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYNSLEYGREEN A, 1977, ARCH DIS CHILD, V52, P573, DOI 10.1136/adc.52.7.573; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DEVOS P, 1974, BIOCHEM J, V140, P331, DOI 10.1042/bj1400331; ERICKSON RP, 1968, P NATL ACAD SCI USA, V59, P437, DOI 10.1073/pnas.59.2.437; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; HAWDON JM, 1993, ARCH DIS CHILD-FETAL, V68, P280, DOI 10.1136/adc.68.3_Spec_No.280; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KOCHAN Z, 1992, COMP BIOCHEM PHYS B, V101, P283, DOI 10.1016/0305-0491(92)90191-S; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NEU J, 1990, EUR J PEDIATR, V150, P2, DOI 10.1007/BF01959470; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PHILIPPIDIS H, 1969, BIOCHEM J, V113, P651, DOI 10.1042/bj1130651; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang N., UNPUB; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	26	807	828	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	1995	269	5227					1108	1112		10.1126/science.7652557	http://dx.doi.org/10.1126/science.7652557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652557				2022-12-24	WOS:A1995RQ74800046
J	RIKLIN, A; KATZ, E; WILLNER, I; STOCKER, A; BUCKMANN, AF				RIKLIN, A; KATZ, E; WILLNER, I; STOCKER, A; BUCKMANN, AF			IMPROVING ENZYME-ELECTRODE CONTACTS BY REDOX MODIFICATION OF COFACTORS	NATURE			English	Article							GLUCOSE-OXIDASE; POLYMERS; CENTERS	EFFICIENT electron transfer of redox proteins to and from their environment is essential for the use of such proteins in biotechnological applications such as amperometric biosensors and photosynthetic biocatalysts(1-3). But most redox enzymes lack pathways that can transport an electron from their embedded redox site to an electrode(4,5) or a diffusing photoexcited species(6). Electrical communication between redox proteins and electrode surfaces has been improved by aligning proteins on chemically modified electrodes(7-9), by attaching electron-transporting groups(10,11) and by immobilizing proteins in polymer matrices tethered by redox groups(12-14). Generally these methods involve contacting the enzymes at random with electron relay units, Here we report an approach that allows site-specific positioning of electron-mediating units in redox proteins, We strip glucose oxidase of its flavin adenine dinucleotide (FAD) cofactors, modify tbe latter with redox-active ferrocene-containing groups, and then reconstitute the apoprotein with these modified cofactors, In this way, electrical contact between an electrode and the resulting enzyme in solution is greatly enhanced in a controlled and reproducible way.	HEBREW UNIV JERUSALEM, INST CHEM, IL-91904 JERUSALEM, ISRAEL; GESELL BIOTECHNOL FORSCH MBH, DEPT ENZYMOL, D-38124 BRAUNSCHWEIG, GERMANY	Hebrew University of Jerusalem; Gesellschaft fur Biotechnologische Forschung mbH			Stocker, Achim/O-5217-2017	Stocker, Achim/0000-0001-6862-7887				ARMSTRONG FA, 1988, ACCOUNTS CHEM RES, V21, P407, DOI 10.1021/ar00155a004; BLUM L, 1991, BIOSENSORS PRINCIPLE; BUCK RP, 1990, BIOSENSOR TECHNOLOGY; Buckmann AF, 1994, FLAVINS AND FLAVOPROTEINS 1993, P597; DEGANI Y, 1989, J AM CHEM SOC, V111, P2357, DOI 10.1021/ja00188a091; DEGANI Y, 1988, J AM CHEM SOC, V110, P2615, DOI 10.1021/ja00216a040; FOULDS NC, 1988, ANAL CHEM, V60, P2473, DOI 10.1021/ac00173a008; GORTON L, 1992, ANALYST, V117, P1235, DOI 10.1039/an9921701235; HELLER A, 1990, ACCOUNTS CHEM RES, V23, P128, DOI 10.1021/ar00173a002; HELLER A, 1992, J PHYS CHEM-US, V96, P3579, DOI 10.1021/j100188a007; LIONDAGAN M, 1994, J CHEM SOC CHEM COMM, P2741, DOI 10.1039/c39940002741; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MORRIS DL, 1983, METHOD ENZYMOL, V92, P413; SCHUHMANN W, 1991, J AM CHEM SOC, V113, P1394, DOI 10.1021/ja00004a048; WILLNER I, 1992, BIOELECTROCH BIOENER, V29, P29, DOI 10.1016/0302-4598(92)80051-H; WILLNER I, 1993, ADV MATER, V5, P912, DOI 10.1002/adma.19930051206; WILLNER I, 1991, TOP CURR CHEM, V159, P153; WILLNER I, 1994, J AM CHEM SOC, V116, P1428, DOI 10.1021/ja00083a031	18	208	216	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					672	675		10.1038/376672a0	http://dx.doi.org/10.1038/376672a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	RQ672	7651516				2022-12-24	WOS:A1995RQ67200055
J	AABY, P; SAMB, B; SIMONDON, F; SECK, AMC; KNUDSEN, K; WHITTLE, H				AABY, P; SAMB, B; SIMONDON, F; SECK, AMC; KNUDSEN, K; WHITTLE, H			NONSPECIFIC BENEFICIAL EFFECT OF MEASLES IMMUNIZATION - ANALYSIS OF MORTALITY STUDIES FROM DEVELOPING-COUNTRIES	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD MORTALITY; GUINEA-BISSAU; RURAL BANGLADESH; VACCINATION; COMMUNITY; SURVIVAL; SENEGAL; TITER; AGE	Objective-To examine whether the reduction in mortality after standard titre measles immunisation in developing countries can be explained simply by the prevention of acute measles and its long term consequences. Design-An analysis of all studies comparing mortality of unimmunised children and children immunised with standard titre measles vaccine in developing countries. Studies-10 cohort and two case-control studies from Bangladesh, Benin, Burundi, Guinea-Bissau, Haiti, Senegal, and Zaire. Main outcome measures-Protective efficacy of standard titre measles immunisation against all cause mortality. Extent to which difference in mortality between immunised and unimmunised children could be explained by prevention of measles disease. Results-Protective efficacy against death after measles immunisation ranged from 30% to 86%. Efficacy was highest in the studies with short follow up and when children were immunised in infancy (range 44-100%). Vaccine efficacy against death was much greater than the proportion of deaths attributed to acute measles disease. In four studies from Guinea-Bissau, Senegal, and Burundi vaccine efficacy against death remained almost unchanged when cases of measles were excluded from the analysis. Diphtheria-tetanus-pertussis and polio vaccinations were not associated with reduction in mortality. Conclusion-These observations suggest that standard titre measles vaccine may confer a beneficial effect which is unrelated to the specific protection against measles disease.	ORSTOM,DAKAR,SENEGAL; UNIV CHEIKH ANTA DIOP,DAKAR,SENEGAL; MRC LABS,BANJUL,GAMBIA	Institut de Recherche pour le Developpement (IRD); University Cheikh Anta Diop Dakar; MRC Laboratory Molecular Biology	AABY, P (corresponding author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,ARTILLERIVEJ 5,DK-2300 COPENHAGEN,DENMARK.			Aaby, Peter/0000-0001-8331-1389; Simondon, Francois/0000-0003-0395-1314				AABY P, 1993, BRIT MED J, V307, P1308, DOI 10.1136/bmj.307.6915.1308; AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1984, J TROP PEDIATRICS, V30, P164, DOI 10.1093/tropej/30.3.164; AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761; AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4; AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X; CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185; CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330, DOI 10.1093/oxfordjournals.aje.a115086; DULOU A, IN PRESS AM J EPIDEM; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; GARENNE M, 1986, ESTIMATION MORTALITE, P515; HARRIS MF, 1979, S AFR MED J, P38; HOLT EA, 1990, PEDIATRICS, V85, P188; HOLT EA, 1993, J INFECT DIS, V168, P1087, DOI 10.1093/infdis/168.5.1087; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474; 1981, LANCET, V1, P764	20	255	257	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 19	1995	311	7003					481	485		10.1136/bmj.311.7003.481	http://dx.doi.org/10.1136/bmj.311.7003.481			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647643	Green Published			2022-12-24	WOS:A1995RQ67000014
J	GRANT, MR; GODIARD, L; STRAUBE, E; ASHFIELD, T; LEWALD, J; SATTLER, A; INNES, RW; DANGL, JL				GRANT, MR; GODIARD, L; STRAUBE, E; ASHFIELD, T; LEWALD, J; SATTLER, A; INNES, RW; DANGL, JL			STRUCTURE OF THE ARABIDOPSIS RPM1 GENE ENABLING DUAL-SPECIFICITY DISEASE RESISTANCE	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; SYRINGAE PV GLYCINEA; YAC CLONES; IDENTIFICATION; AVIRULENCE; LOCUS; DNA; EXPRESSION; PROTEIN; WALKING	Plants can recognize pathogens through the action of disease resistance (R) genes, which confer resistance to pathogens expressing unique corresponding avirulence (avr) genes. The molecular basis of this gene-for-gene specificity is unknown. The Arabidopsis thaliana RPM1 gene enables dual specificity to pathogens expressing either of two unrelated Pseudomonas syringae avr genes. Despite this function, RPM1 encodes a protein sharing molecular features with recently described single-specificity R genes. Surprisingly, RPM1 is lacking from naturally occurring, disease-susceptible Arabidopsis accessions.	MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	Indiana University System; Indiana University Bloomington; University of North Carolina; University of North Carolina Chapel Hill			Innes, Roger/A-5244-2010		NIGMS NIH HHS [R29 GM 46451] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046451] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AUSUBEL FM, 1907, CURRENT PROTOCOLS MO; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Crute I, 1994, ARABIDOPSIS, P705; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DANGL JL, 1993, INT REV CYTOL, V144, P53, DOI 10.1016/S0074-7696(08)61513-2; DANGL JL, 1992, PLANT CELL, V4, P1359, DOI 10.1105/tpc.4.11.1359; DANGL JL, 1992, PLANT J, V2, P3, DOI 10.1111/j.1365-313X.1992.00003.x; DANGL JL, 1994, BACTERIAL PATHOGENES, V192, P99; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ELLIS JG, 1995, P NATL ACAD SCI USA, V92, P4185, DOI 10.1073/pnas.92.10.4185; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; INNES RW, 1993, PLANT J, V4, P813, DOI 10.1046/j.1365-313X.1993.04050813.x; INNES RW, UNPUB; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; LEWALD J, UNPUB; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; Matallana E., 1992, Methods in Arabidopsis research., P144; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MOWERY P, UNPUB; PUTTERILL J, 1993, MOL GEN GENET, V239, P145, DOI 10.1007/BF00281613; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMIDT R, 1994, PLANT J, V5, P735, DOI 10.1111/j.1365-313X.1994.00735.x; SCHMIDT R, 1992, GENOME ANAL, V4, P71; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; TAMAKI S, 1988, J BACTERIOL, V170, P4846, DOI 10.1128/jb.170.10.4846-4854.1988; TRAUT TW, 1994, EUR J BIOCHEM, V229, P9; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	42	722	781	2	60	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					843	846		10.1126/science.7638602	http://dx.doi.org/10.1126/science.7638602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638602				2022-12-24	WOS:A1995RN65000046
J	WU, HY; TAN, JY; FANG, M				WU, HY; TAN, JY; FANG, M			LONG-RANGE INTERACTION BETWEEN 2 PROMOTERS - ACTIVATION OF THE LEU-500 PROMOTER BY A DISTANT UPSTREAM PROMOTER	CELL			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; TOPOISOMERASE-I; DNA TOPOISOMERASES; TRANSCRIPTION; GENE; EXPRESSION; MUTATIONS; TEMPLATE; PLASMID	The leu-500 mutation can be suppressed in S. typhimurium topA. Previous studies have demonstrated that the plasmid-borne leu-500 minimal promoter cannot be activated in topA mutants unless adjacent (<250 bp) transcription occurs away from the leu-500 promoter (short-range promoter interaction). To search for a potential upstream promoter responsible for activation of leu-500 in the chromosomal context, we have identified the ilvlH promoter, located 1.9 kb upstream of leu-500 (long-range promoter interaction). Different from short-range promoter interaction, which is abolished by DNA sequence insertions, the long-range promoter interaction is mediated by the intervening DNA sequence. These studies suggest that the long-range interaction between a pair of divergently arrayed promoters is probably mediated by a complex process involving relay of DNA supercoiling by the DNA sequence located between the two promoters.			WU, HY (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201, USA.							BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; CALVO JM, 1969, J BACTERIOL, V97, P1272, DOI 10.1128/JB.97.3.1272-1282.1969; CAMPBELL CE, 1994, ONCOGENE, V9, P583; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; CHEN DR, 1993, BIOCHEMISTRY-US, V32, P13162, DOI 10.1021/bi00211a027; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DUBANAU E, 1972, MOL GEN GENET, V117, P91; ECCLES MR, 1994, ONCOGENE, V9, P2059; FRANCO RJ, 1989, J BACTERIOL, V171, P6573, DOI 10.1128/jb.171.12.6573-6579.1989; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GEMMILL RM, 1983, J MOL BIOL, V170, P39, DOI 10.1016/S0022-2836(83)80226-5; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MARGOLIN P, 1963, GENETICS, V48, P441; McKenney K, 1981, Gene Amplif Anal, V2, P383; MENZEL R, 1987, J BACTERIOL, V169, P1272, DOI 10.1128/jb.169.3.1272-1278.1987; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUKAI FH, 1963, P NATL ACAD SCI USA, V50, P140, DOI 10.1073/pnas.50.1.140; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; PLATKO JV, 1990, J BACTERIOL, V172, P4563, DOI 10.1128/jb.172.8.4563-4570.1990; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; SHINYA E, 1994, NUCLEIC ACIDS RES, V22, P2143, DOI 10.1093/nar/22.11.2143; SMITH GR, 1981, CELL, V24, P599, DOI 10.1016/0092-8674(81)90085-4; SQUIRES CH, 1983, J BACTERIOL, V154, P1054, DOI 10.1128/JB.154.3.1054-1063.1983; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; TRUCKSIS M, 1981, J BACTERIOL, V147, P679, DOI 10.1128/JB.147.2.679-681.1981; UMBARGER HE, 1987, ESCHERICHIA COLI SAL, V1, P352; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG Q, 1993, MOL MICROBIOL, V7, P883, DOI 10.1111/j.1365-2958.1993.tb01179.x; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	37	42	43	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					445	451		10.1016/0092-8674(95)90433-6	http://dx.doi.org/10.1016/0092-8674(95)90433-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634334	Bronze			2022-12-24	WOS:A1995RP24200014
J	CAI, H; LEVINE, V				CAI, H; LEVINE, V			MODULATION OF ENHANCER-PROMOTER INTERACTIONS BY INSULATORS IN THE DROSOPHILA EMBRYO	NATURE			English	Article							DOMAIN BOUNDARIES; PROTEIN; REPRESSION; EXPRESSION; CONVERSION; SILENCER; ELEMENT; ASSAY; GENE	INSULATOR DNAs, or boundary elements, functionally isolate neighbouring genes by blocking interactions between distal enhancers and inappropriate target promoters(1-5). The best-characterized insulators in Drosophila correspond to a 340-base-pair (bp) fragment from the gypsy retrotransposon(3), and the scs and scs' sequences flanking the 87A1 hsp70 locus(1,2). Here we demonstrate that both insulators block the interaction of defined even-skipped (eve) stripe enhancers(6,7) when positioned between the enhancer and the target promoter. The simultaneous use of two stripe enhancers (eve stripes 2 and 3) provides evidence that enhancers lying distal to the insulator are selectively blocked. The insertion of stripe- insulator-stripe sequences between two divergently transcribed promoters indicates that enhancers barred from acting on one basal promoter are fully accessible to appropriate regulatory factors for activating the other promoter. These results suggest that insulators do not propagate changes in chromatin structure. Finally, we present evidence that the gypsy insulator does not block interactions between a silencer element and a basal promoter, Taken together, these results suggest that insulators might not be restricted to the functional isolation of neighbouring genetic loci. Rather, they might function as flexible regulatory elements that modulate enhancer-promoter interactions within complex promoters and complex genetic loci.			CAI, H (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,PACIFIC HALL,LA JOLLA,CA 92093, USA.			Levine, Michael/0000-0001-7629-0081				CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GINDHART JG, 1995, GENETICS, V139, P781; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SMALL S, 1993, DEVELOPMENT, V119, P767; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1	16	188	190	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					533	536		10.1038/376533a0	http://dx.doi.org/10.1038/376533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637789				2022-12-24	WOS:A1995RN62200051
J	CHARNOV, EL; DOWNHOWER, JF				CHARNOV, EL; DOWNHOWER, JF			A TRADE-OFF-INVARIANT LIFE-HISTORY RULE FOR OPTIMAL OFFSPRING SIZE	NATURE			English	Article							NUMBER	OPTIMIZATION models have been widely and successfully used in evolutionary ecology to predict the attributes of organisms(1-6) Most such models maximize darwinian fitness (or a component of fitness) in the face of trade-offs and constraints; the numerical results usually depend on the exact form of the trade-offs/constraints. Here we report the first (to our knowledge) numerical optimum for life-history evolution which is independent of the details of the underlying trade-off, for a large array for trade-off forms. The rule is that at small litter sizes, the range in offspring size is inversely proportional to the size of the litter. Details of the offspring-survival/offspring-size trade-off(7-10) set the value of the proportionality constant, but the -1 exponent, the inverse proportionality itself, is universal. Studies of life histories have yielded many empirical examples of universality for various scaling exponents (for example, adult lifespan scales as approximate to 0.25 with adult body mass within many taxa); this is an example of the numerical value of an exponent (here -1) emerging from a life-history model as independent of all but a few general features of the underlying economic structure.	OHIO STATE UNIV, DEPT ZOOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University	CHARNOV, EL (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.							BEVERTON RJH, 1992, J FISH BIOL, V41, P137, DOI 10.1111/j.1095-8649.1992.tb03875.x; Bulmer M., 1994, THEORETICAL EVOLUTIO; CHARNOV E L, 1982; CHARNOV EL, 1995, EVOL ECOL, V9, P57, DOI 10.1007/BF01237697; CHARNOV EL, 1990, EVOL ECOL, V4, P273, DOI 10.1007/BF02214335; Charnov Eric L., 1993, P1; Clutton-Brock T, 1991, EVOLUTION PARENTAL C, DOI [10.1515/9780691206981, DOI 10.1515/9780691206981]; Gadgil M., 1975, ECOLOGY EVOLUTION CO, P142; Godfray H.C.J, 1994, PARASITOIDS; LLOYD DG, 1987, AM NAT, V129, P800, DOI 10.1086/284676; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; SHINE R, 1995, OIKOS, V72, P343, DOI 10.2307/3546119; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Stearns S.C., 1992, pi; Stephens D.W., 1986, pi; WOOTTON RJ, 1994, J FISH BIOL, V45, P1067	16	60	61	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					418	419		10.1038/376418a0	http://dx.doi.org/10.1038/376418a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630415	Green Submitted			2022-12-24	WOS:A1995RM63900049
J	FLEMING, DM; CHAKRAVERTY, P; SADLER, C; LITTON, P				FLEMING, DM; CHAKRAVERTY, P; SADLER, C; LITTON, P			COMBINED CLINICAL AND VIROLOGICAL SURVEILLANCE OF INFLUENZA IN WINTERS OF 1992-3 AND 1993-4	BRITISH MEDICAL JOURNAL			English	Article									CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,LONDON NW9 5EQ,ENGLAND	Public Health England	FLEMING, DM (corresponding author), ROYAL COLL GEN PRACTITIONERS,BIRMINGHAM RES UNIT,BIRMINGHAM B17 9DB,W MIDLANDS,ENGLAND.							DAISY JA, 1979, J CLIN MICROBIOL, V5, P688; HANNOUN C, 1989, EUR J EPIDEMIOL, V5, P285, DOI 10.1007/BF00144828; VANCASTEREN V, 1992, METHOD INFORM MED, V31, P147; WEBSTER RG, 1994, BRIT MED J, V309, P1179, DOI 10.1136/bmj.309.6963.1179; 1977, J R COLL GEN PRACT, V27, P544	5	47	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					290	291		10.1136/bmj.311.7000.290	http://dx.doi.org/10.1136/bmj.311.7000.290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633235	Green Published			2022-12-24	WOS:A1995RM71900022
J	FREY, PA; WHITT, SA; TOBIN, JB				FREY, PA; WHITT, SA; TOBIN, JB			A LOW-BARRIER HYDROGEN-BOND IN THE CATALYTIC TRIAD OF SERINE PROTEASES	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; ACTIVE-SITE; ALPHA-CHYMOTRYPSIN; HISTIDINE; PROTON; STABILIZATION; IMIDAZOLE; TRYPSIN; ENZYME; ACID	Spectroscopic properties of chymotrypsin and model compounds indicate that a low-barrier hydrogen bond participates in the mechanism of serine protease action. A low-barrier hydrogen bond between N delta 1 of His(57) and the beta-carboxyl group of Asp(102) in chymotrypsin can facilitate the formation of the tetrahedral adduct, and the nuclear magnetic resonance properties of this proton indicate that it is a low-barrier hydrogen bond. These conclusions are supported by the chemical shift of this proton, the deuterium isotope effect on the chemical shift, and the properties of hydrogen-bonded model compounds in organic solvents, including the hydrogen bond in cis-urocanic acid, in which the imidazole ring is internally hydrogen-bonded to the carboxyl group.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison	FREY, PA (corresponding author), UNIV WISCONSIN,GRAD SCH,INST ENZYME RES,MADISON,WI 53705, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028607, R01DK028607] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28607] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BREZINSKI B, 1981, ORG MAGN RESONANCE, V15, P78; CLARK JH, 1983, J CHEM SOC CHEM COMM, P136, DOI 10.1039/c39830000136; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; DEGASZAFRAN Z, 1981, ORG MAGN RESONANCE, V16, P214, DOI 10.1002/mrc.1270160310; EDELBACHER S, 1943, HOPPESEYLERS Z PHYSL, V279, P63; EMSLEY J, 1980, CHEM SOC REV, V9, P91, DOI 10.1039/cs9800900091; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GERIT JA, 1993, J AM CHEM SOC, V115, P11552; GUNNARSSON G, 1976, CHEM PHYS LETT, V38, P96, DOI 10.1016/0009-2614(76)80264-3; GUTHRIE JP, 1993, J AM CHEM SOC, V115, P11569, DOI 10.1021/ja00077a063; HALKIDES CJ, 1993, J AM CHEM SOC, V115, P3332, DOI 10.1021/ja00061a043; HENDERSON R, 1971, BIOCHEM J, V124, P13, DOI 10.1042/bj1240013; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; Jencks W. P., 1970, HDB BIOCH, pJ187; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; KOSSIAKOFF AA, 1981, BIOCHEMISTRY-US, V20, P6462, DOI 10.1021/bi00525a027; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P4627, DOI 10.1021/bi00615a008; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P46; MORRISON H, 1980, J CHROMATOGR, V183, P83, DOI 10.1016/S0378-4347(00)81402-4; MURTHY ASN, 1970, J CHEM SOC A, P1251, DOI 10.1039/j19700001251; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROBILLAR.G, 1974, J MOL BIOL, V86, P541, DOI 10.1016/0022-2836(74)90179-X; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; ROGERS GA, 1974, J AM CHEM SOC, V96, P2473, DOI 10.1021/ja00815a028; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; ZEEGERSHUYSKENS T, 1990, J MOL LIQ, V46, P263, DOI 10.1016/0167-7322(90)80059-S; ZIMMERMAN SC, 1991, TETRAHEDRON, V47, P2649, DOI 10.1016/S0040-4020(01)81797-X	32	706	718	6	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1927	1930		10.1126/science.7661899	http://dx.doi.org/10.1126/science.7661899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7661899				2022-12-24	WOS:A1994NT84700044
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			EFFICIENT CATALYSIS OF DISULFIDE BOND REARRANGEMENTS BY PROTEIN DISULFIDE-ISOMERASE	NATURE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DISULFIDE ISOMERASE; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; KINETIC ROLE; INTERMEDIATE; RESONANCE; BPTI	PROTEIN disulphide isomerase (PDI)1,2 is a highly abundant and ubiquitous eukaryotic protein that is essential for viability in yeast3,4. Although PDI is thought to catalyse disulphide bond formation and isomerization during protein biosynthesis, PDI has been found previously to have only moderate effects (approximately 25-fold) on the rate of oxidative folding of proteins in vitro. In addition, PDI has been implicated in several apparently unrelated cellular functions3. For example, PDI is the beta-subunit of prolyl 4-hydroxylase 5 and is part of the trigylceride transfer complex6. The oxidative folding of bovine pancreatic trypsin inhibitor (BPTI) is slow and inefficient in vitro7-11. Here we report that PDI increases by a factor of 3,000-6,000 the rates of folding of kinetically trapped BPTI folding intermediates, in which native structure impedes disulphide bond formation. By contrast, PDI has only small effects on the rate of disulphide bond formation in intermediates that are oxidized readily in the absence of PDI. These results suggest that an important function of PDI is to catalyse disulphide bond formation and rearrangements within kinetically trapped, structured folding intermediates.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), MIT,DEPT PHYS,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02139, USA.							CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1992, PROTEIN FOLDING, P481; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAJI EH, IN PRESS J BIOL CHEM; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MORJANA NA, 1993, P NATL ACAD SCI USA, V90, P2107, DOI 10.1073/pnas.90.6.2107; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; VANMIERLO CPM, 1991, J MOL BIOL, V222, P353, DOI 10.1016/0022-2836(91)90216-S; VENETIANER P, 1963, BIOCHIM BIOPHYS ACTA, V67, P166; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	28	191	195	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					185	188		10.1038/365185a0	http://dx.doi.org/10.1038/365185a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	7690463				2022-12-24	WOS:A1993LW44200055
J	MULLIGAN, MS; PAULSON, JC; DEFREES, S; ZHENG, ZL; LOWE, JB; WARD, PA				MULLIGAN, MS; PAULSON, JC; DEFREES, S; ZHENG, ZL; LOWE, JB; WARD, PA			PROTECTIVE EFFECTS OF OLIGOSACCHARIDES IN P-SELECTIN-DEPENDENT LUNG INJURY	NATURE			English	Article							ADHESION; NEUTROPHILS; GMP-140; ACTIVATION	NEUTROPHIL recruitment into tissues is a multistep process involving sequential engagement of adhesion molecules, including selectins (E,P,L), which are reactive with oligosaccharides, and the family of beta2 integrins which are reactive with endothelial intercellular adhesion molecules1-3. These processes result in the initial rolling of leukocytes along the endothelial surfaces, followed by the firm attachment of leukocytes to the endothelium. The intravenous infusion of cobra venom factor into rats results in acute lung injury that is neutrophil-dependent, oxygen radical mediated and P-selectin-dependent4,5. Here we report that infusion of sialyl-Lewis X, a ligand for P-selectin6-9, dramatically reduced lung injury and diminished the tissue accumulation of neutrophils, whereas irrelevant oligosaccharides had no such effects. These results suggest that sialyl-Lewis X carbohydrates maybe used as a new strategy for anti-inflammatory therapy.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,1301 CATHERINE RD,ANN ARBOR,MI 48109; CYTEL CORP,SAN DIEGO,CA 92121; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Paulson, James/AAG-3565-2019					BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; ICHIKAWA Y, IN PRESS J AM CHEM S; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; PAULSON JC, 1992, ADHESION ITS ROLE IN, P19; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SPRAGG RG, 1991, LUNG SCI F, P2003; TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	14	323	361	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					149	151		10.1038/364149a0	http://dx.doi.org/10.1038/364149a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	7686631	Green Published			2022-12-24	WOS:A1993LL36700050
J	NIKOLOV, DB; CHEN, H; HALAY, ED; USHEVA, AA; HISATAKE, K; LEE, DK; ROEDER, RG; BURLEY, SK				NIKOLOV, DB; CHEN, H; HALAY, ED; USHEVA, AA; HISATAKE, K; LEE, DK; ROEDER, RG; BURLEY, SK			CRYSTAL-STRUCTURE OF A TFIIB-TBP-TATA-ELEMENT TERNARY COMPLEX	NATURE			English	Article							TRANSCRIPTION FACTOR-TFIIB; RNA POLYMERASE-II; FUNCTIONAL DOMAINS; BINDING-PROTEIN; BOX COMPLEX; INITIATION; ACTIVATION	The crystal structure of the transcription factor IIB (TFIIB)/TATA box-binding protein (TBP)/TATA-element ternary complex is described at 2.7 Angstrom resolution, core TFIIB resembles cyclin A, and recognizes the preformed TBP-DNA complex through protein-protein and protein-DNA interactions. The amino-terminal domain of core TFIIB forms the downstream surface of the ternary complex, where it could fix the transcription start site. The remaining surfaces of TBP and the TFIIB can interact with TBP-associated factors, other class II initiation factors, and transcriptional activators and coactivators.	ROCKEFELLER UNIV,MOLEC BIOPHYS LABS,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Princeton University				Hisatake, Koji/0000-0002-5795-3115; Burley, Stephen K./0000-0002-2487-9713				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BRUNGER AT, 1992, XPLOR V 3 1 MANUAL; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRALAUKIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MOLDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PINTO I, 1994, J BIOL CHEM, V269, P30569; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P6077, DOI 10.1073/pnas.92.13.6077; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	478	487	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					119	128		10.1038/377119a0	http://dx.doi.org/10.1038/377119a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675079				2022-12-24	WOS:A1995RU75400039
J	CARPENTER, RHS; WILLIAMS, MLL				CARPENTER, RHS; WILLIAMS, MLL			NEURAL COMPUTATION OF LOG LIKELIHOOD IN CONTROL OF SACCADIC EYE-MOVEMENTS	NATURE			English	Article							SHORT REACTION-TIMES; EXPRESS SACCADES; LATENCIES; MONKEY; FIELD	THE latency between the appearance of a visual target and the start of the saccadic eye movement made to look at it varies from trial to trial to an extent that is inexplicable in terms of ordinary 'physiological' processes such as synaptic delays and conduction velocities. An alternative interpretation is that it represents the time needed to decide whether a target is in fact present: decision processes are necessarily stochastic, because they depend on extracting information from noisy sensory signals(1), In one such model(2), the presence of a target causes a signal in a decision unit to rise linearly at a rate r from its initial value s(0) until it reaches a fixed threshold theta, when a saccade is initiated, One can regard this decision signal as a neural estimate of the log likelihood of the hypothesis that the target is present, the threshold being the significance criterion or likelihood level at which the target is presumed to be present, Experiments manipulating the prior probability of the target's appearing confirm this notion: the latency distribution then changes in the way expected if s(0) simply reflects the prior log likelihood of the stimulus.			CARPENTER, RHS (corresponding author), UNIV CAMBRIDGE, PHYSIOL LAB, DOWNING ST, CAMBRIDGE CB2 3EG, ENGLAND.			Carpenter, Roger/0000-0003-2572-1448				BARLOW HB, 1980, PHILOS T ROY SOC B, V290, P71, DOI 10.1098/rstb.1980.0083; CARPENTER RHS, 1994, CONTEMPORARY OCULAR MOTOR AND VESTIBULAR RESEARCH: A TRIBUTE TO DAVID A. ROBINSON, P185; CARPENTER RHS, 1994, J PHYSIOL-LONDON, V488, pP4; Carpenter RHS, 1981, EYE MOVEMENTS COGNIT, P237; DALLOS PJ, 1963, IEEE T AUTOMAT CONTR, P218; EDWARDS Anthony William Fairbank, 1972, LIKELIHOOD; FISCHER B, 1984, EXP BRAIN RES, V57, P191; FISCHER B, 1983, BRAIN RES, V260, P21, DOI 10.1016/0006-8993(83)90760-6; Fisher R. A., 1921, METRON             4, V1, P3, DOI DOI 10.1093/BIOMET/9.1-2.22; FUCHS AF, 1967, J PHYSIOL-LONDON, V191, P609, DOI 10.1113/jphysiol.1967.sp008271; GRICE GR, 1968, PSYCHOL REV, V75, P359, DOI 10.1037/h0026287; HANES DP, 1995, EXP BRAIN RES, V103, P85; LYNCH JC, 1977, J NEUROPHYSIOL, V40, P362, DOI 10.1152/jn.1977.40.2.362; NAZIR TA, 1991, PSYCHOL RES-PSYCH FO, V53, P281, DOI 10.1007/BF00920481; RATCLIFF R, 1978, PSYCHOL REV, V85, P59, DOI 10.1037//0033-295X.85.2.59; ROBINSON DA, 1973, KYBERNETIK, V14, P71, DOI 10.1007/BF00288906; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; SCHILLER PH, 1987, J NEUROPHYSIOL, V57, P1033, DOI 10.1152/jn.1987.57.4.1033; WENBANSMITH MG, 1991, EXP BRAIN RES, V87, P218	19	639	641	2	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					59	62		10.1038/377059a0	http://dx.doi.org/10.1038/377059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7659161				2022-12-24	WOS:A1995RT72500055
J	NELLIS, WJ; ROSS, M; HOLMES, NC				NELLIS, WJ; ROSS, M; HOLMES, NC			TEMPERATURE-MEASUREMENTS OF SHOCK-COMPRESSED LIQUID-HYDROGEN - IMPLICATIONS FOR THE INTERIOR OF JUPITER	SCIENCE			English	Article							EQUATION-OF-STATE; MOLECULAR-HYDROGEN; FLUID NITROGEN; GIANT PLANETS; HIGH-DENSITY; DISSOCIATION; DEUTERIUM; KBAR	Shock temperatures of hydrogen up to 5200 kelvin were measured optically at pressures up to 83 gigapascals (830 kilobars). At highest pressures, the measured temperatures are substantially lower than predicted. These lower temperatures are caused by a continuous dissociative phase transition above 20 gigapascals. Because hydrogen is in thermal equilibrium in shock-compression experiments, the theory derived from the shock data can be applied to Jupiter. The planet's molecular envelope is cooler and has much less temperature variation than previously believed. The continuous dissociative phase transition suggests that there is no sharp boundary between Jupiter's molecular mantle and its metallic core. A possible convectively quiescent boundary layer might induce an additional layer in the molecular region, as has been predicted.	LAWRENCE LIVERMORE NATL LAB,DIV H,LIVERMORE,CA 94550	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	NELLIS, WJ (corresponding author), LAWRENCE LIVERMORE NATL LAB,INST GEOPHYS & PLANETARY PHYS,LIVERMORE,CA 94550, USA.							BARBEE TW, 1991, PHYS REV B, V44, P11563, DOI 10.1103/PhysRevB.44.11563; DICK RD, 1980, J CHEM PHYS, V73, P5264, DOI 10.1063/1.439955; DUFFY TS, 1994, SCIENCE, V263, P1590, DOI 10.1126/science.263.5153.1590; HOLMES N, UNPUB; HOLMES NC, 1995, REV SCI INSTRUM, V66, P2615, DOI 10.1063/1.1145597; HUBBARD WB, 1981, SCIENCE, V214, P145, DOI 10.1126/science.214.4517.145; HUBBARD WB, 1980, REV GEOPHYS, V18, P1, DOI 10.1029/RG018i001p00001; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; MAO HK, 1994, REV MOD PHYS, V66, P671, DOI 10.1103/RevModPhys.66.671; MITCHELL AC, 1981, REV SCI INSTRUM, V52, P347, DOI 10.1063/1.1136602; MOSSER B, 1991, ASTRON ASTROPHYS, V251, P356; NELLIS WJ, 1984, PHYS REV LETT, V53, P1248, DOI 10.1103/PhysRevLett.53.1248; NELLIS WJ, 1991, J CHEM PHYS, V94, P2244, DOI 10.1063/1.459895; NELLIS WJ, 1983, J CHEM PHYS, V79, P1480, DOI 10.1063/1.445938; NELLIS WJ, 1980, J CHEM PHYS, V73, P6137, DOI 10.1063/1.440105; RADOUSKY HB, 1986, PHYS REV LETT, V57, P2419, DOI 10.1103/PhysRevLett.57.2419; ROSS M, 1987, J CHEM PHYS, V86, P7110, DOI 10.1063/1.452360; ROSS M, 1983, J CHEM PHYS, V79, P1487, DOI 10.1063/1.445939; ROSS M, 1981, PHILOS T R SOC A, V303, P303, DOI 10.1098/rsta.1981.0204; SAUMON D, 1991, PHYS REV A, V44, P5122, DOI 10.1103/PhysRevA.44.5122; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; STEVENSON DJ, 1983, REP PROG PHYS, V46, P555, DOI 10.1088/0034-4885/46/5/001; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; VANTHIEL M, 1973, PHYS REV LETT, V31, P979, DOI 10.1103/PhysRevLett.31.979; Zharkov V. N., 1992, HIGH PRESSURE RES AP, P393; ZHARKOV VN, 1976, JUPITER, P135	26	87	89	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1249	1252		10.1126/science.7652570	http://dx.doi.org/10.1126/science.7652570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652570				2022-12-24	WOS:A1995RR84200028
J	DENG, CX; ZHANG, PM; HARPER, JW; ELLEDGE, SJ; LEDER, P				DENG, CX; ZHANG, PM; HARPER, JW; ELLEDGE, SJ; LEDER, P			MICE LACKING P21(C/P1/WAF1) UNDERGO NORMAL DEVELOPMENT, BUT ARE DEFECTIVE IN G1 CHECKPOINT CONTROL	CELL			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; GENE AMPLIFICATION; CDK2 ACTIVITY; APOPTOSIS; INHIBITOR; PROTEIN; IRRADIATION; EXPRESSION; DEFICIENT	p21(CIP1/WAF1) is a CDK inhibitor regulated by the tumor suppressor p53 and is hypothesized to mediate G1 arrest. p53 has been suggested to derive anti-oncogenic properties from this relationship. To test these notions, we created mice lacking p21(CIP1/WAF1). They develop normally and (unlike p53(-/-) mice) have not developed spontaneous malignancies during 7 months of observation. Nonetheless, p21(-/-) embryonic fibroblasts are significantly deficient in their ability to arrest in G1 in response to DNA damage and nucleotide pool perturbation. p21(-/-) cells also exhibit a significant growth alteration in vitro, achieving a saturation density as high as that observed In p53(-/-) cells. In contrast, other aspects of p53 function, such as thymocytic apoptosis and the mitotic spindle checkpoint, appear normal. These results establish the role of p21(CIP1/WAF1) in the G1 checkpoint, but suggest that the anti-apoptotic and the anti-oncogenic effects of p53 are more complex.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT HUMAN & MOLEC GENET,HOUSTON,TX 77030	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine			deng, chuxia/N-6713-2016	Harper, Jeffrey/0000-0002-6944-7236	NIA NIH HHS [AG11085] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1994, NAT GENET, V5, P225; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REOBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P71; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1993, ONCOGENE, V8, P1; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU F, 1995, P NATL ACAD SCI USA, V92, P1357; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	64	1916	1955	1	42	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					675	684		10.1016/0092-8674(95)90039-X	http://dx.doi.org/10.1016/0092-8674(95)90039-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664346	Bronze			2022-12-24	WOS:A1995RR73400018
J	RANTAKALLIO, P; LAARA, E; KOIRANEN, M				RANTAKALLIO, P; LAARA, E; KOIRANEN, M			A 28 YEAR FOLLOW-UP OF MORTALITY AMONG WOMEN WHO SMOKED DURING PREGNANCY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING	Objective-To investigate long term mortality among women who smoked during pregnancy and those who stopped smoking. Design-A follow up of a geographically defined cohort from 1966 through to 1993. Subjects-11 994 women in northern Finland expected to deliver in 1966, comprising 96% of all women giving birth in the area during that year. Smoking habits were recorded during pregnancy but not later. Main outcome measure-Mortality by cause (571 deaths). Results-The mortality ratio adjusted for age, place of residence, years of education and marital status was 2.3 (95% confidence interval 1.8 to 2.8) for the women who smoked during pregnancy and 1.6 (1.1 to 2.2) for those who stopped smoking before the second month of pregnancy, both compared with non-smokers. Among the smokers the relative mortality was higher for typical diseases related to tobacco intake, such as respiratory and oesophageal cancer and diseases of the cardiovascular and digestic organs and also for accidents and suicides. Conclusion-The risk of premature death seems to be higher in women who smoke during pregnancy than in other women who smoke. This may be explained either by the low proportion of those who stop later and the high proportion of heavy smokers or by other characteristics of these subjects that increase the risk.			RANTAKALLIO, P (corresponding author), UNIV OULU, DEPT PUBL HLTH SCI & GEN PRACTICE, AAPISTIE 1, SF-90220 OULU, FINLAND.							BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BUTLER NR, 1973, BRIT MED J, V4, P573, DOI 10.1136/bmj.4.5892.573; COLBY JP, 1994, SOC SCI MED, V38, P373, DOI 10.1016/0277-9536(94)90407-3; COX DR, 1972, J R STAT SOC B, V34, P187; Dixon W. J., 1990, BMDP STATISTICAL SOF; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; GRAHAM H, 1994, SOC SCI MED, V38, P691, DOI 10.1016/0277-9536(94)90459-6; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; PRITCHARD CW, 1994, J EPIDEMIOL COMMUN H, V48, P377, DOI 10.1136/jech.48.4.377; PUGH H, 1991, SOC SCI MED, V32, P1105, DOI 10.1016/0277-9536(91)90086-R; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; RANTAKALLIO P, 1969, ACTA PAEDIATR SC S, V0193; RANTAKALLIO P, 1983, ACTA PAEDIATR SCAND, V72, P747, DOI 10.1111/j.1651-2227.1983.tb09805.x; RANTAKALLIO P, 1983, PUBLIC HLTH REV, V11, P55; Rimpeld A., 1992, TOB CONTROL, V1, P285; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, LANCET, V340, P709; THORNTON A, 1994, J CLIN EPIDEMIOL, V47, P1143, DOI 10.1016/0895-4356(94)90101-5; TVERDAL A, 1993, J CLIN EPIDEMIOL, V46, P475, DOI 10.1016/0895-4356(93)90025-V; [No title captured]	21	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	1995	311	7003					477	480		10.1136/bmj.311.7003.477	http://dx.doi.org/10.1136/bmj.311.7003.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ670	7647642	Green Published			2022-12-24	WOS:A1995RQ67000013
J	WILLIAMS, GV; GOLDMANRAKIC, PS				WILLIAMS, GV; GOLDMANRAKIC, PS			MODULATION OF MEMORY FIELDS BY DOPAMINE D1 RECEPTORS IN PREFRONTAL CORTEX	NATURE			English	Article							PRIMATE CEREBRAL-CORTEX; WORKING MEMORY; PARKINSONS-DISEASE; TARGET-CELLS; NEURONS; RAT; SCHIZOPHRENIA; AMPHETAMINE; INVOLVEMENT; STIMULATION	Dopamine has been implicated in the cognitive process of working memory but the cellular basis of its action has yet to be revealed. By combining iontophoretic analysis of dopamine receptors with single-cell recording during behaviour, we found that D1 antagonists can selectively potentiate the 'memory fields' of prefrontal neurons which subserve working memory. The precision shown for D1 receptor modulation of mnemonic processing Indicates a direct gating of selective excitatory synaptic inputs to prefrontal neurons during cognition.			WILLIAMS, GV (corresponding author), YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA.							Amsten A. F., 1995, J NEUROSCI, V15, P3429; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; BAUER RH, 1978, PHARMACOL BIOCHEM BE, V8, P243, DOI 10.1016/0091-3057(78)90311-8; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BERGSON C, 1994, SOC NEUR ABSTR, V20, P275; BRADLEY VA, 1989, J NEUROL NEUROSUR PS, V52, P1228, DOI 10.1136/jnnp.52.11.1228; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; BUSHNELL PJ, 1983, PHARM BIOCH BEHAV, V45, P765; CALABRESI P, 1987, NEUROSCIENCE, V20, P757, DOI 10.1016/0306-4522(87)90239-9; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; CEPEDA C, 1992, SYNAPSE, V11, P330, DOI 10.1002/syn.890110408; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; DANIEL DG, 1991, J NEUROSCI, V11, P1907; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FUNAHASHI S, 1990, J NEUROPHYSIOL, V63, P814, DOI 10.1152/jn.1990.63.4.814; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster JM, 1989, PREFRONTAL CORTEX, P51; GODBOUT R, 1991, J PHARMACOL EXP THER, V258, P728; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; GOLDSTEIN LE, 1994, J NEUROSCI, V14, P4937; LANGE KW, 1992, PSYCHOPHARMACOLOGY, V107, P394, DOI 10.1007/BF02245167; LIDOW MS, 1991, NEUROSCIENCE, V40, P657, DOI 10.1016/0306-4522(91)90003-7; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; MALMBERG A, 1993, MOL PHARMACOL, V43, P749; MILLAR J, 1988, J NEUROSCI METH, V25, P59, DOI 10.1016/0165-0270(88)90120-3; MILLAR J, 1989, J COMP NEUROL, V287, P119, DOI 10.1002/cne.902870109; OSCALAIDHE SP, 1993, SOC NEUR ABSTR, V19, P800; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; SABATER R, 1993, EUR J PHARMACOL, V242, P205, DOI 10.1016/0014-2999(93)90082-S; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1401, DOI 10.1152/jn.1990.63.6.1401; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; SEGUELA P, 1988, BRAIN RES, V442, P11, DOI 10.1016/0006-8993(88)91427-8; SHURTLEFF D, 1994, PHARMACOL BIOCHEM BE, V47, P935, DOI 10.1016/0091-3057(94)90299-2; SMILEY JF, 1994, P NATL ACAD SCI USA, V91, P5720, DOI 10.1073/pnas.91.12.5720; TAYLOR LA, 1991, LIFE SCI, V49, P1505, DOI 10.1016/0024-3205(91)90051-C; THIERRY AM, 1988, ANN NY ACAD SCI, V537, P101, DOI 10.1111/j.1749-6632.1988.tb42099.x; VANEDEN CG, 1987, NEUROSCIENCE, V22, P849, DOI 10.1016/0306-4522(87)92964-2; WILSON FAW, 1994, P NATL ACAD SCI USA, V91, P4009, DOI 10.1073/pnas.91.9.4009; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4	45	1295	1311	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	1995	376	6541					572	575		10.1038/376572a0	http://dx.doi.org/10.1038/376572a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637804				2022-12-24	WOS:A1995RP75600044
J	TERADA, Y; TATSUKA, M; JINNO, S; OKAYAMA, H				TERADA, Y; TATSUKA, M; JINNO, S; OKAYAMA, H			REQUIREMENT FOR TYROSINE PHOSPHORYLATION OF CDK4 IN G1 ARREST INDUCED BY ULTRAVIOLET-IRRADIATION	NATURE			English	Article							ATAXIA TELANGIECTASIA; DNA-REPLICATION; PROTEIN-KINASE; CELLS; MITOSIS; INDUCTION; MUTATION; GENE	EXPOSURE to ultraviolet light arrests the function of mammalian fibroblasts in the G1 phase of the cell cycle, as well as the S and G2 phases. Although p21, an inhibitor of cyclin-dependent kinase (Cdk) that is induced by DNA damage mag partly account for the arrest in G1 (ref. 1), the mechanism is little understood. Here we show that tyrosine phosphorylation of Cdk4 is required for this arrest. In rat fibroblast, Cdk4 is tyrosine-phosphorylated during G1 progression, and its dephosphorylation is required for S phase. When cells are ultraviolet-irradiated, their arrest in G1 is accompanied by an increase in phosphorylation level. Conversely, cells expressing unphosphorylatable Cdk4(F17) fail to arrest in G1, and suffer significantly elevated chromosomal aberrations and cell death.	KANAZAWA UNIV, CANC RES INST, DEPT MOLEC ONCOL & VIROL, KANAZAWA, ISHIKAWA 920, JAPAN; UNIV TOKYO, FAC MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Kanazawa University; University of Tokyo	TERADA, Y (corresponding author), RES DEV CORP JAPAN, ERATO, OKAYAMA CELL SWITCHING PROJECT, SAKYO KU, KYOTO 606, JAPAN.			Terada, Yasuhiko/0000-0003-4784-5273				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NAGATA A, 1991, NEW BIOL, V3, P959; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TATSUKA M, 1989, MUTAT RES, V214, P321; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	27	169	169	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 27	1995	376	6538					358	362		10.1038/376358a0	http://dx.doi.org/10.1038/376358a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630405				2022-12-24	WOS:A1995RL44300052
J	SUSEK, RE; AUSUBEL, FM; CHORY, J				SUSEK, RE; AUSUBEL, FM; CHORY, J			SIGNAL-TRANSDUCTION MUTANTS OF ARABIDOPSIS UNCOUPLE NUCLEAR CAB AND RBCS GENE-EXPRESSION FROM CHLOROPLAST DEVELOPMENT	CELL			English	Article							MESSENGER-RNA ACCUMULATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PLANT-CELLS; LIGHT; THALIANA; CHLOROPHYLL; PROTEIN; BINDING; MAIZE	Chloroplast development requires coordinate nuclear and chloroplast gene expression. A putative signal from the chloroplast couples the transcription of certain nuclear genes encoding photosynthesis-related proteins with chloroplast function. We have identified at least three Arabidopsis nuclear genes (GUN1, GUN2, and GUN3) necessary for coupling the expression of some nuclear genes to the functional state of the chloroplast. Homozygous recessive gun mutations allow nuclear gene expression in the absence of chloroplast development and furthermore may interfere with the switch from dark-grown to light-grown development. Other reports suggest this intracellular cross-stalk also involves mitochondrial interactions. The GUN genes thus define steps in one specific branch of a complex interorganellar regulatory network.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT EXTRATERR PHYS,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	SUSEK, RE (corresponding author), SALK INST BIOL STUDIES,PLANT BIOL LAB,SAN DIEGO,CA 92186, USA.				NCRR NIH HHS [RR05595] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AN G, 1987, MOL GEN GENET, V270, P210; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BATSCHAUER A, 1986, EUR J BIOCHEM, V154, P625, DOI 10.1111/j.1432-1033.1986.tb09444.x; BURGESS DG, 1987, PLANTA, V170, P520, DOI 10.1007/BF00402986; CHAMOVITZ D, 1991, PLANT MOL BIOL, V16, P967, DOI 10.1007/BF00016069; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CHORY J, 1991, NEW BIOL, V3, P538; CHORY J, 1990, P NATL ACAD SCI USA, V87, P8776, DOI 10.1073/pnas.87.22.8776; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DATTA N, 1989, PLANT CELL, V1, P1069, DOI 10.1105/tpc.1.11.1069; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1987, CELL, V49, P379, DOI 10.1016/0092-8674(87)90290-X; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GOODWIN TW, 1985, INTRO PLANT BIOCH; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HA SB, 1988, P NATL ACAD SCI USA, V85, P8017, DOI 10.1073/pnas.85.21.8017; HARPSTER MH, 1984, PLANT MOL BIOL, V3, P59, DOI 10.1007/BF00040030; HERRERAESTRELLA L, 1983, EMBO J, V2, P987, DOI 10.1002/j.1460-2075.1983.tb01532.x; HOWE CJ, 1991, NATURE, V349, P109, DOI 10.1038/349109c0; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JOHANNINGMEIER U, 1984, J BIOL CHEM, V259, P3541; Kendrick RE., 2012, PHOTOMORPHOGENESIS P, P333; Kirk J., 1978, PLASTIDS THEIR CHEM, V2nd ed.; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; LAUER M, 1990, New Biologist, V2, P179; LEAVER CJ, 1980, GENOME ORG EXPRESSIO; LEUTWILER LS, 1986, NUCLEIC ACIDS RES, V14, P4051, DOI 10.1093/nar/14.10.4051; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MARTINEAU B, 1986, PLANT PHYSIOL, V78, P399; MARTINEZZAPATER JM, 1992, PLANT CELL, V4, P889, DOI 10.1105/tpc.4.8.889; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MAYFIELD SP, 1984, EUR J BIOCHEM, V144, P79, DOI 10.1111/j.1432-1033.1984.tb08433.x; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; MITRA A, 1989, PLANT MOL BIOL, V12, P169, DOI 10.1007/BF00020502; NGERNPRASIRTSIRI J, 1990, CELL STRUCT FUNCT, V15, P273, DOI 10.1247/csf.15.273; OELMULLER R, 1990, PLANT PHYSIOL, V92, P434, DOI 10.1104/pp.92.2.434; OELMULLER R, 1986, PLANTA, V168, P482, DOI 10.1007/BF00392267; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; OWEN J, 1987, PLANT MITOCHONDRIA S, P211; PLUMLEY FG, 1989, P NATL ACAD SCI USA, V86, P2678, DOI 10.1073/pnas.86.8.2678; RAPP JC, 1991, PLANT MOL BIOL, V17, P813, DOI 10.1007/BF00037063; RAPP JC, 1992, J BIOL CHEM, V267, P21404; REDEI G P, 1973, Mutation Research, V18, P149, DOI 10.1016/0027-5107(73)90031-6; ROUSSELL DL, 1991, PLANT PHYSIOL, V96, P232, DOI 10.1104/pp.96.1.232; SCHINDLER U, 1990, EMBO J, V9, P3415, DOI 10.1002/j.1460-2075.1990.tb07549.x; SCHWARTZ B W, 1991, Plant Physiology (Rockville), V96, P120; SIMPSON J, 1986, SCIENCE, V233, P34, DOI 10.1126/science.233.4759.34; STUMPF P, 1980, BIOCH PLANTS LIPIDS; SUSEK RE, 1992, AUST J PLANT PHYSIOL, V19, P387, DOI 10.1071/PP9920387; TAYLOR WC, 1987, DEV GENET, V8, P305, DOI 10.1002/dvg.1020080503; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; Taylor WC, 1986, CURRENT TOPICS PLANT, V5, P117; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WELLBURN A, 1984, CHLOROPLAST BIOGENES; WHITTAKER PA, 1978, MITOCHONDRIA STRUCTU	62	468	487	3	73	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					787	799		10.1016/0092-8674(93)90459-4	http://dx.doi.org/10.1016/0092-8674(93)90459-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	7690685				2022-12-24	WOS:A1993LX29200005
J	MACNICOL, AM; MUSLIN, AJ; WILLIAMS, LT				MACNICOL, AM; MUSLIN, AJ; WILLIAMS, LT			RAF-1 KINASE IS ESSENTIAL FOR EARLY XENOPUS DEVELOPMENT AND MEDIATES THE INDUCTION OF MESODERM BY FGF	CELL			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACTIVIN-A; C-RAF; ACTIVATION; EMBRYOS; RECEPTOR; HOMOLOG	Animal cap explants from Xenopus embryos injected with a dominant negative Raf-1 mutant, termed NAF (not a functional Raf), demonstrated a complete block to basic fibroblast growth factor (FGF)-stimulated mesoderm induction. Activin induction of mesoderm was normal in embryos that expressed NAF. Injection of NAF RNA into 2-cell stage embryos blocked normal development during neurula stages and caused severe posterior truncations in tadpoles. The phenotype induced by NAF could be rescued by coinjection of wild-type raf-I RNA. The NAF mutant functioned by specifically blocking the activation of endogenous Raf kinase activity. These findings suggest that Raf-1 mediates FGF, but not activin, receptor signaling during mesoderm induction and implicate Raf-1 as a key signaling molecule in the development of posterior structure.			MACNICOL, AM (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,PROGRAM EXCELLENCE MOLEC BIOL,SAN FRANCISCO,CA 94143, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002571, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43821, K11HL02571-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTABA AR, 1989, NATURE, V341, P33; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BRUDERJT, 1992, GENE DEV, V6, P545; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COUGHLIN SR, 1988, J BIOL CHEM, V263, P1; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HOPWOOD ND, 1990, BIOESSAYS, V12, P465, DOI 10.1002/bies.950121003; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEGUELLEC R, 1991, BIOL CELL, V72, P39, DOI 10.1016/0248-4900(91)90076-Y; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MATTHEWS LS, 1991, CELL, V65, P973; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAPP UR, 1991, ONCOGENE, V6, P495; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SYMES K, 1987, DEVELOPMENT, V101, P339; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; UENO H, 1992, J BIOL CHEM, V267, P1470; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	62	182	182	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					571	583		10.1016/0092-8674(93)90143-E	http://dx.doi.org/10.1016/0092-8674(93)90143-E			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	7683975				2022-12-24	WOS:A1993LA74300017
J	LONG, MY; LANGLEY, CH				LONG, MY; LANGLEY, CH			NATURAL-SELECTION AND THE ORIGIN OF JINGWEI, A CHIMERIC PROCESSED FUNCTIONAL GENE IN DROSOPHILA	SCIENCE			English	Article							MOLECULAR EVOLUTION; DNA; PSEUDOGENES; AMPLIFICATION; DUPLICATION; TRANSCRIPTS; RETROPOSONS; POLYMERASE; PRIMER	The origin of new genes includes both the initial molecular events and subsequent population dynamics. A processed Drosophila alcohol dehydrogenase (Adh) gene, previously thought to be a pseudogene, provided an opportunity to examine the two phases of the origin of a new gene. The sequence of the processed Adh messenger RNA became part of a new functional gene by capturing several upstream exons and introns of an unrelated gene. This novel chimeric gene, jingwei, differs from its parent Adh gene in both its pattern of expression and rate of molecular evolution. Natural selection participated in the origin and subsequent evolution of this gene.	UNIV CALIF DAVIS,EVOLUT & ECOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,CTR POPULAT BIOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis	LONG, MY (corresponding author), UNIV CALIF DAVIS,GENET SECT,DAVIS,CA 95616, USA.							ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; BANYAI L, 1983, FEBS LETT, V163, P37, DOI 10.1016/0014-5793(83)81157-0; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOLDBERG DA, 1982, CELL, V34, P59; Haldane J. B. S., 1932, CAUSES EVOLUTION; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOLLIS GF, 1982, NATURE, V296, P321, DOI 10.1038/296321a0; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1987, GENETICS, V116, P153; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JUKES T H, 1969, P21; Kimura M, 1985, NEUTRAL THEORY MOL E; KREITMAN M, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P204; LACHAISE D, 1988, EVOL BIOL, V22, P159; LANGLEY CH, 1982, P NATL ACAD SCI-BIOL, V79, P5631, DOI 10.1073/pnas.79.18.5631; LANGLEY CH, 1990, POPULATION BIOL GENE, P75; Li W.-H., 1983, P14; Li W-H., 1991, FUNDAMENTALS MOL EVO; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; LONG MW, UNPUB; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MORIYAMA EN, 1992, GENETICS, V130, P855; NEI M, 1981, GENETICS, V97, P145; NEI M, 1987, MOL EVOLUTIONARY GEN, P276; Ohno S., 1970, EVOLUTION GENE DUPLI; OHTA T, 1989, GENOME, V31, P304, DOI 10.1139/g89-048; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SULLIVAN DT, 1990, EVOL BIOL, V24, P107; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; [No title captured]	43	307	318	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					91	95		10.1126/science.7682012	http://dx.doi.org/10.1126/science.7682012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682012				2022-12-24	WOS:A1993KV42300035
J	GROVER, SA; COUPAL, L; HU, XF				GROVER, SA; COUPAL, L; HU, XF			IDENTIFYING ADULTS AT INCREASED RISK OF CORONARY-DISEASE - HOW WELL DO THE CURRENT CHOLESTEROL GUIDELINES WORK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESEARCH CLINICS PREVALENCE; HEART-DISEASE; LIPOPROTEIN-CHOLESTEROL; SERUM-CHOLESTEROL; FRAMINGHAM; MORTALITY; PREDICTION; LIPIDS; COST; MEN	Objective. To assess the accuracy of lipid screening strategies to identify individuals at increased risk of coronary heart disease mortality. Patients.-The 15% random sample of adults recruited into the Lipid Research Clinic Prevalence and Follow-up Studies, which included 3678 men and women aged 35 to 74 years. Total plasma cholesterol levels, lipoprotein fractions, and other coronary risk factors at study entry were compared with subsequent coronary heart disease mortality (mean follow-up, 12.2 years). Outcome Measures.-The areas under receiver operating characteristic curves for blood lipids, lipid ratios, the screening guidelines proposed by the National Cholesterol Education Program, those of the Canadian Consensus Conference on Cholesterol, and a coronary risk model that used Framingham data. Main Results.-The current National Cholesterol Education Program guidelines (area under the curve, 0.74) were significantly (P=.03) more accurate than the old National Cholesterol Education Program guidelines (area, 0.72). The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level (area, 0.72) was as accurate as current National Cholesterol Education Program guidelines. The coronary risk model (area, 0.85) was superior (P<.003) to all other screening maneuvers, Compared with the current National Cholesterol Education Program guidelines, the risk model demonstrated superior test sensitivity (70% vs 45%) with only slightly reduced specificity (82% vs 86%). Conclusion.-The ratio of total plasma cholesterol level to high-density lipoprotein cholesterol level is as accurate as current American screening guidelines, Future guidelines should better incorporate high-density lipoprotein cholesterol levels and nonlipid risk factors to target high-risk individuals accurately.	MONTREAL GEN HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DIV GEN INTERNAL MED,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOSTAT & EPIDEMIOL,MONTREAL,PQ,CANADA	McGill University; McGill University; McGill University; McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,1650 CEDAR AVE,MONTREAL,PQ H3G 1A4,CANADA.			Coupal, Louis/0000-0003-0828-9665				ABBOTT RD, 1982, PREV MED, V11, P131, DOI 10.1016/0091-7435(82)90013-5; ABBOTT RD, 1987, US DHEW NIH872284 PU; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BUSH TL, 1991, CIRCULATION, V83, P1287, DOI 10.1161/01.CIR.83.4.1287; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COOPER GR, 1992, JAMA-J AM MED ASSOC, V267, P1652, DOI 10.1001/jama.267.12.1652; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; HAMILTON VH, 1995, JAMA-J AM MED ASSOC, V273, P1032, DOI 10.1001/jama.273.13.1032; HANLEY JA, 1988, RADIOLOGY, V148, P889; HEISS G, 1980, CIRCULATION, V61, P302, DOI 10.1161/01.CIR.61.2.302; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; MARTIN MJ, 1986, LANCET, V2, P933; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; METZ CE, 1984, INFORMATION PROCESSI, P432; SIMONS LA, 1986, AM J CARDIOL, V57, pG5, DOI 10.1016/0002-9149(86)90659-4; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; WILSON PWF, 1987, AM J CARDIOL, V59, pG91, DOI 10.1016/0002-9149(87)90165-2; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; 1974, REFERENCE MANUAL LIP, V1; 1981, HLTH CANADIANS REPOR; 1988, CAN MED ASSOC J, V139, P1; 1974, REFERENCE MANUAL LIP, V2; 1978, CORONARY RISK HDB ES; 1988, ARCH INTERN MED, V148, P36; 1993, JAMA-J AM MED ASSOC, V269, P8015; 1989, LIFE TABLES CANADA P; 1974, MANUAL LABORATORY OP, V1; 1984, JAMA-J AM MED ASSOC, V251, P351; 1979, CIRCULATION, V60, P427	35	185	187	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					801	806		10.1001/jama.274.10.801	http://dx.doi.org/10.1001/jama.274.10.801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650803				2022-12-24	WOS:A1995RU32400027
J	GOODWIN, S				GOODWIN, S			HELICOBACTERS SHED NEW LIGHT ON CHAPERONINS	LANCET			English	Editorial Material							PYLORI; PROTEIN				GOODWIN, S (corresponding author), UNITED ARAB EMIRATES UNIV,FAC MED,DEPT MED MICROBIOL,AL AIN,U ARAB EMIRATES.							AUSTIN JW, 1992, J BACTERIOL, V174, P7470, DOI 10.1128/jb.174.22.7470-7473.1992; COATES ARM, 1993, MOL MICROBIOL, V8, P787, DOI 10.1111/j.1365-2958.1993.tb01624.x; COATES ARM, IN PRESS CHAPERONINS; DOIDGE C, 1994, LANCET, V343, P919; DUNN BE, 1992, INFECT IMMUN, V60, P1946, DOI 10.1128/IAI.60.5.1946-1951.1992; ESCHWEILER B, 1993, ZBL BAKT-INT J MED M, V280, P73, DOI 10.1016/S0934-8840(11)80942-4; Ferrero R. L., 1995, Gut, V37, pA51; Ghiara P., 1995, Gut, V37, pA51; GOODWIN CS, 1990, EUR J CLIN MICROBIOL, V9, P1, DOI 10.1007/BF01969526; Kansau Imad, 1995, Gut, V37, pA65; Monath T. P., 1995, Gut, V37, pA52; Phadnis S. H., 1995, Gut, V37, pA19; SUERBAUM S, 1994, MOL MICROBIOL, V14, P959, DOI 10.1111/j.1365-2958.1994.tb01331.x; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	14	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					653	655		10.1016/S0140-6736(95)92275-X	http://dx.doi.org/10.1016/S0140-6736(95)92275-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658815				2022-12-24	WOS:A1995RU04800004
J	KETCHUM, KA; JOINER, WJ; SELLERS, AJ; KACZMAREK, LK; GOLDSTEIN, SAN				KETCHUM, KA; JOINER, WJ; SELLERS, AJ; KACZMAREK, LK; GOLDSTEIN, SAN			A NEW FAMILY OF OUTWARDLY RECTIFYING POTASSIUM CHANNEL PROTEINS WITH 2 PORE DOMAINS IN TANDEM	NATURE			English	Article							EXPRESSION; K+	POTASSIUM channels catalyse the permeation of K+ ions across cellular membranes and are identified by a common structural moth, a highly conserved signature sequence of eight amino acids in the P domain of each channel's pore-forming alpha-subunit(1,2), Here we describe a novel K+ channel (TOK1) from Saccharomyces cerevisiae that contains two P domains within one continuous polypeptide, Xenopus laevis oocytes expressing the channel exhibit a unique, outwardly rectifying, K+-selective current. The channel is permeable to outward how of ions at membrane potentials above the K+ equilibrium potential; its conduction-voltage relationship is thus sensitive to extracellular K+ ion concentration. In excised membrane patches, external divalent cations block the channel in a voltage-dependent manner, and their removal in this configuration allows inward channel current, These attributes are similar to those described for inwardly rectifying K+ channels(3,4), but in the opposite direction, a previously uorecognized channel behaviour. Our results identify a new class of K+ channel which is distinctive in both its primary structure and functional properties. Structural homologues of the channel are present in the genome of Caenorhabditis elegans.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT GENET,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PHARMACOL,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06536	Yale University; Yale University; Yale University	KETCHUM, KA (corresponding author), YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PEDIAT,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.		Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MIOSGA T, 1994, YEAST, V10, P965, DOI 10.1002/yea.320100712; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	24	344	359	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					690	695		10.1038/376690a0	http://dx.doi.org/10.1038/376690a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7651518	Green Submitted			2022-12-24	WOS:A1995RQ67200061
J	ARCHER, JE; VEGA, LR; SOLOMON, F				ARCHER, JE; VEGA, LR; SOLOMON, F			RBL2P, A YEAST PROTEIN THAT BINDS TO BETA-TUBULIN AND PARTICIPATES IN MICROTUBULE FUNCTION IN-VIVO	CELL			English	Article							CONDITIONAL-LETHAL MUTATIONS; SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; ALPHA-TUBULIN; GAMMA-TUBULIN; ASPERGILLUS-NIDULANS; GENETIC-ANALYSIS; MESSENGER-RNAS; ACTIN; INHIBITION	Genetic configurations resulting in high ratios of beta-tubulin to alpha-tubulin are toxic in S. cerevisiae, causing microtubule disassembly and cell death, We identified three non-tubulin yeast genes that, when overexpressed, rescue cells from excess beta-tubulin, One, RBL2, rescues beta-tubulin lethality as efficiently as does alpha-tubulin. Rbl2p binds to beta-tubulin in vivo, Deficiencies or excesses of either Rbl2p or alpha-tubulin affect microtubule-dependent functions in a parallel fashion, Rbl2p has functional homology with murine cofactor A, a protein important for in vitro assays of beta-tubulin folding. The results suggest that Rbl2p participates in microtubule morphogenesis but not in the assembled polymer.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	ARCHER, JE (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		Vega, Leticia/AAF-4981-2021; Vega, Leticia/G-1984-2017	Vega, Leticia/0000-0001-7605-1048; 				ADAMS AEM, 1989, SCIENCE, V243, P231, DOI 10.1126/science.2643162; ADAMS AEM, 1989, GENETICS, V121, P675; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; FLOOR E, 1970, Journal of Molecular Biology, V47, P293, DOI 10.1016/0022-2836(70)90303-7; FULLER MT, 1987, J CELL BIOL, V104, P385, DOI 10.1083/jcb.104.3.385; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KATZ W, 1990, MOL CELL BIOL, V10, P2730; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; LIU HP, 1992, GENETICS, V132, P665; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; PASQUALONE D, 1994, J CELL BIOL, V127, P1973, DOI 10.1083/jcb.127.6.1973; ROUT MP, 1991, COLD SH Q B, V56, P687; SCHATZ PJ, 1988, GENETICS, V120, P681; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3722, DOI 10.1128/MCB.6.11.3722; SHERMAN F, 1986, LABORATOORY COURSE M; SKOUFIAS DA, 1992, BIOCHEMISTRY-US, V31, P738, DOI 10.1021/bi00118a015; SOLOMON F, 1992, METHODS STUDYING YEA; STERNBERG N, 1976, VIROLOGY, V71, P568, DOI 10.1016/0042-6822(76)90382-2; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WEINSTEIN B, 1992, MOL MICROBIOL, V6, P677, DOI 10.1111/j.1365-2958.1992.tb01515.x; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	38	76	79	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					425	434		10.1016/0092-8674(95)90431-X	http://dx.doi.org/10.1016/0092-8674(95)90431-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634332	Bronze			2022-12-24	WOS:A1995RP24200012
J	ENGEL, A; HAYERHARTL, MK; GOLDIE, KN; PFEIFER, G; HEGERL, R; MULLER, S; DASILVA, ACR; BAUMEISTER, W; HARTL, FU				ENGEL, A; HAYERHARTL, MK; GOLDIE, KN; PFEIFER, G; HEGERL, R; MULLER, S; DASILVA, ACR; BAUMEISTER, W; HARTL, FU			FUNCTIONAL-SIGNIFICANCE OF SYMMETRICAL VERSUS ASYMMETRICAL GROEL-GROES CHAPERONIN COMPLEXES	SCIENCE			English	Article							ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; CENTRAL CAVITY; PROTEIN; HYDROLYSIS; SURFACE; BINDING	The Escherichia coli chaperonin GroEL and its regulator GroES are thought to mediate adenosine triphosphate-dependent protein folding as an asymmetrical complex, with substrate protein bound within the GroEL cylinder. In contrast, a symmetrical complex formed between one GroEL and two GroES oligomers, with substrate protein binding to the outer surface of GroEL, was recently proposed to be the functional chaperonin unit. Electron microscopic and biochemical analyses have now shown that unphysiologically high magnesium concentrations and increased pH are required to assemble symmetrical complexes, the formation of which precludes the association of unfolded polypeptide. Thus, the functional significance of GroEL:(GroES)(2) particles remains to be demonstrated.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA; MAX PLANCK INST BIOCHEM, D-82150 MARTINSRIED, GERMANY	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Max Planck Society	ENGEL, A (corresponding author), UNIV BASEL, BIOZENTRUM, MAURICE E MULLER INST, CH-4056 BASEL, SWITZERLAND.		Hartl, F. Ulrich/Y-8206-2019; Hayer-Hartl, Manajit/V-8078-2017	Hayer-Hartl, Manajit/0000-0001-8213-6742	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050908] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50908] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BREMER A, 1992, ULTRAMICROSCOPY, V46, P85, DOI 10.1016/0304-3991(92)90008-8; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FRANK J, 1988, J MICROSC-OXFORD, V150, P99, DOI 10.1111/j.1365-2818.1988.tb04602.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5664	31	81	82	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					832	836		10.1126/science.7638600	http://dx.doi.org/10.1126/science.7638600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638600				2022-12-24	WOS:A1995RN65000043
J	HAJNOCZKY, G; ROBBGASPERS, LD; SEITZ, MB; THOMAS, AP				HAJNOCZKY, G; ROBBGASPERS, LD; SEITZ, MB; THOMAS, AP			DECODING OF CYTOSOLIC CALCIUM OSCILLATIONS IN THE MITOCHONDRIA	CELL			English	Article							MAMMALIAN MITOCHONDRIA; HEPATOCYTES; METABOLISM; CHANNELS; RECEPTOR; CELLS; IONS	Frequency-modulated oscillations of cytosolic Ca2+ ([Ca2+](c)) are believed to be important in signal transduction, but it has been difficult to correlate [Ca2+](c) oscillations directly with the activity of Ca2+-regulated targets. We have studied the control of Ca2+-sensitive mitochondrial dehydrogenases (CSMDHs) by monitoring mitochondrial Ca2+ ([Ca2+](m)) and the redox state of flavoproteins and pyridine nucleotides simultaneously with [Ca2+](c) in single hepatocytes. Oscillations of [Ca2+](c) induced by IP3-dependent hormones were efficiently transmitted to the mitochondria as [Ca2+](m) oscillations. Each [Ca2+](m) spike was sufficient to cause a maximal transient activation of the CSMDHs and [Ca2+](m) oscillations at frequencies above 0.5 per minute caused a sustained activation of mitochondrial metabolism. By contrast, sustained [Ca2+](c) increases yielded only transient CSMDH activation, and slow or partial [Ca2+](c) elevations were ineffective in increasing [Ca2+](m) or stimulating CSMDHs. We conclude that the mitochondria are tuned to oscillating [Ca2+](c) signals, the frequency of which can control the CSMDHs over the full range of potential activities.			HAJNOCZKY, G (corresponding author), THOMAS JEFFERSON UNIV, DEPT PATHOL ANAT & CELL BIOL, PHILADELPHIA, PA 19107 USA.		Thomas, Andrew/C-6755-2013; Gaspers, Lawrence/W-8766-2019	Gaspers, Lawrence/0000-0002-5620-3283; Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA00180, AA07215] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422, R29DK038422] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANWER MS, 1994, HEPATOLOGY, V20, P1309, DOI 10.1016/0270-9139(94)90773-0; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Hansford R.G., 1980, CURR TOP BIOENERG, VVolume 10, P217, DOI 10.1016/B978-0-12-152510-1.50012-2; HOEK JB, 1995, IN PRESS BIOCH BIOPH; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MIX TCH, 1994, BIOPHYS J, V66, pA97; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; NICHOLS BJ, 1994, BIOCHEM J, V303, P461, DOI 10.1042/bj3030461; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; RAPP PE, 1981, J EXP BIOL, V93, P119; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHOLZ R, 1969, J BIOL CHEM, V244, P2317; TAKEI K, 1992, J NEUROSCI, V12, P489; Thomas Andrew P., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P225; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	32	927	945	3	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					415	424		10.1016/0092-8674(95)90430-1	http://dx.doi.org/10.1016/0092-8674(95)90430-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634331	Bronze			2022-12-24	WOS:A1995RP24200011
J	WEISSMAN, MM; OLFSON, M				WEISSMAN, MM; OLFSON, M			DEPRESSION IN WOMEN - IMPLICATIONS FOR HEALTH-CARE RESEARCH	SCIENCE			English	Article							PSYCHIATRIC EPIDEMIOLOGY; PUERPERAL PSYCHOSES; MENTAL-DISORDERS; SOCIAL STRESS; PREGNANCY; POSTPARTUM; PREVALENCE; GENDER; PSYCHOTHERAPY; COMMUNITY	Epidemiologic data from around the world demonstrate that major depression is approximately twice as common in women than men and that its first onset peaks during the childbearing years. Progress has been made in understanding the epidemiology of depression and in developing effective treatments. Much remains to be learned about the basic pathogenesis of depression and the specific treatment needs of depressed women and their offspring, especially during the reproductive years.	NEW YORK STATE PSYCHIAT INST & HOSP, DIV CLIN & GENET EPIDEMIOL, NEW YORK, NY 10032 USA	New York State Psychiatry Institute	WEISSMAN, MM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA.		Olfson, Mark/AAA-8547-2021	Weissman, Myrna/0000-0003-3490-3075				[Anonymous], 1993, AM J PSYCHIAT, V150, P1; BALDWIN JA, 1989, ACTA PSYCHIAT SCAND, V80, P37, DOI 10.1111/j.1600-0447.1989.tb07167.x; BRESLAU N, IN PRESS PSYCHIATRY; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BROCKINGTON IF, 1990, BRIT J PSYCHIAT, V157, P331, DOI 10.1192/bjp.157.3.331; CANINO GJ, 1987, ARCH GEN PSYCHIAT, V44, P727; COHEN LS, 1992, CURR AFFECTIVE ILLNE, V11, P5; DAVIDSON J, 1985, ACTA PSYCHIAT SCAND, V71, P451, DOI 10.1111/j.1600-0447.1985.tb05057.x; DIMASCIO A, 1979, ARCH GEN PSYCHIAT, V36, P1450; DOWLATSHAHI D, 1990, PSYCHOL MED, V20, P655, DOI 10.1017/S0033291700017177; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FARAVELLI C, 1990, J AFFECT DISORDERS, V20, P135, DOI 10.1016/0165-0327(90)90127-T; FRANK E, 1988, AM J PSYCHIAT, V145, P41; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; GARVEY MJ, 1984, J REPROD MED, V29, P113; GLASSMAN AH, 1977, ARCH GEN PSYCHIAT, V34, P197; GOTLIB IH, 1989, J CONSULT CLIN PSYCH, V57, P269, DOI 10.1037/0022-006X.57.2.269; HOHMANN AA, 1989, MED CARE, V27, P478, DOI 10.1097/00005650-198905000-00004; KARAM E, 1991, OCT M INT TRAUM STRE; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KENDELL RE, 1985, J PSYCHOSOM RES, V29, P3, DOI 10.1016/0022-3999(85)90003-0; KERNS LL, 1986, J NERV MENT DIS, V174, P652, DOI 10.1097/00005053-198611000-00003; KESSLER RC, 1981, J HEALTH SOC BEHAV, V22, P49, DOI 10.2307/2136367; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KITAMURA T, 1993, PSYCHOL MED, V23, P967, DOI 10.1017/S003329170002643X; KLERMAN GL, 1974, AM J PSYCHIAT, V131, P186, DOI 10.1176/ajp.131.2.186; KUMAR R, 1993, PROG NEURO-PSYCHOPH, V17, P571, DOI 10.1016/0278-5846(93)90006-E; LEE CK, 1990, J NERV MENT DIS, V178, P242, DOI 10.1097/00005053-199004000-00004; LEPINE J P, 1989, Psychiatrie and Psychobiologie, V4, P267; MARTIN CJ, 1989, J AFFECT DISORDERS, V16, P283, DOI 10.1016/0165-0327(89)90083-9; Mastroianni AC, 1994, WOMEN HLTH RES ETHIC, VI; Miller L J, 1991, Psychiatr Med, V9, P275; Montgomery Stuart A., 1995, P1043; MORTOLA JF, 1989, PSYCHIAT CLIN N AM, V12, P69; OHARA MW, 1991, ARCH GEN PSYCHIAT, V48, P801; ORN H, 1988, ACTA PSYCHIAT SCAND, V77, P17, DOI 10.1111/j.1600-0447.1988.tb08543.x; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; ROBINS LN, 1991, PSYCHIATRIC DISORDER; ROHE GH, 1893, JAMA-J AM MED ASSOC, V21, P325; ROHE GH, 1993, JAMA-J AM MED ASSOC, V270, P1180; SARGEANT JK, 1990, ARCH GEN PSYCHIAT, V47, P519; SCHATZBERG AF, 1991, MANUAL CLIN PSYCHOPH, P315; SIMON G, 1995, AM J PSYCHIAT, V152, P352; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TUETH MJ, 1993, JAMA-J AM MED ASSOC, V270, P2177, DOI 10.1001/jama.1993.03510180047018; VIGGEDAL G, 1993, J CHILD PSYCHOL PSYC, V34, P295, DOI 10.1111/j.1469-7610.1993.tb00993.x; Weissman M.M., 1994, WORLD PSYCHIATR ASS, V2, P1; WEISSMAN MM, 1987, ARCH GEN PSYCHIAT, V44, P847; WEISSMAN MM, 1992, JAMA-J AM MED ASSOC, V268, P3098, DOI 10.1001/jama.1992.03490210080039; WELLS JE, 1989, AUST NZ J PSYCHIAT, V23, P315, DOI 10.3109/00048678909068289; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788; WISNER KL, 1993, AM J PSYCHIAT, V150, P1541; WITTCHEN HU, 1992, EUR ARCH PSY CLIN N, V241, P247, DOI 10.1007/BF02190261; WOLK SI, 1995, REV PSYCHIATRY, V14, pCH9; YONKERS KA, 1992, AM J PSYCHIAT, V149, P587; YONKERS KA, 1995, REV PSYCHIATRY, V2, P307; ZUCKERMAN B, 1990, J DEV BEHAV PEDIATR, V11, P190; 1993, 930551 US DEP HLTH H; 1980, DIAGNOSTIC STATISTIC	60	346	356	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					799	801		10.1126/science.7638596	http://dx.doi.org/10.1126/science.7638596			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RN650	7638596	Green Submitted			2022-12-24	WOS:A1995RN65000034
J	TATEISHI, J; BROWN, P; KITAMOTO, T; HOQUE, ZM; ROOS, R; WOLLMAN, R; CERVENAKOVA, L; GAJDUSEK, DC				TATEISHI, J; BROWN, P; KITAMOTO, T; HOQUE, ZM; ROOS, R; WOLLMAN, R; CERVENAKOVA, L; GAJDUSEK, DC			FIRST EXPERIMENTAL TRANSMISSION OF FATAL FAMILIAL INSOMNIA	NATURE			English	Article							CREUTZFELDT-JAKOB DISEASE; PRION PROTEIN ACCUMULATION; CODON-178; GENE; MICE	ORIGINALLY described by Lugaresi et al, in 1986 (ref. 1), fatal familial insomnia (FFI) is a rare inherited neurological disease characterized by the subacute progression of intractable insomnia and other autonomic abnormalities, cerebellar and pyramidal signs; myoclonus and dementia; neuropathologically, the major feature is severe neuronal loss with associated gliosis in the ventral and mediodorsal thalamic nuclei. The disease has been related to the group of spongiform encephalopathies by virtue of the presence of low levels of proteinase-resistant amyloid protein (PrPres) in the brain(2-4), and of a pathogenic single-allele mutation at codon 178 of the PRNP gene that encodes PrPres (refs 2, 5). Here rye report the successful transmission of the disease to experimental animals, placing FFI within the group of infectious cerebral amyloidoses.	NINCDS,CNS STUDIES LAB,BETHESDA,MD 20892; UNIV CHICAGO,MED CTR,DEPT NEUROL,CHICAGO,IL 60637; UNIV CHICAGO,MED CTR,DEPT PATHOL,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center	TATEISHI, J (corresponding author), KYUSHU UNIV,INST NEUROL,DEPT NEUROPATHOL,FUKUOKA 812,JAPAN.							BOSQUE PJ, 1992, NEUROLOGY, V42, P1864, DOI 10.1212/WNL.42.10.1864; BROWN P, 1995, ANN NEUROL, V38, P245, DOI 10.1002/ana.410380218; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; LITTLE BW, 1986, ANN NEUROL, V20, P231, DOI 10.1002/ana.410200209; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; MURAMOTO T, 1992, BRAIN RES, V599, P309, DOI 10.1016/0006-8993(92)90406-Y; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; TATEISHI J, 1981, ACTA NEUROPATHOL, V53, P161, DOI 10.1007/BF00689997	12	110	111	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					434	435		10.1038/376434a0	http://dx.doi.org/10.1038/376434a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630420				2022-12-24	WOS:A1995RM63900054
J	LAROSA, JC				LAROSA, JC			HAS HRT COME OF AGE	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; HORMONE-THERAPY; DISEASE				LAROSA, JC (corresponding author), TULANE UNIV,MED CTR,NEW ORLEANS,LA, USA.							BAR J, 1993, OBSTET GYNECOL, V81, P261; CLARKSON RB, 1994, DRUGS S2, V47, P42; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KUSHWAHA RS, 1992, CURR OPIN LIPIDOL, V3, P167; MENDOZA S, 1994, J LAB CLIN MED, V123, P837; SPAGNOLI LG, 1980, ATHEROSCLEROSIS, V82, P27; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; VANDERMOOREN MJ, 1994, METABOLISM, V43, P799, DOI 10.1016/0026-0495(94)90256-9; WAGNER JD, 1992, ARTERIOSCLER THROMB, V12, P717, DOI 10.1161/01.ATV.12.6.717; WHITCROFT SI, 1994, OBSTET GYNECOL, V84, P222; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; 1985, VITAL STATISTICS US, V2, P258	15	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					76	77		10.1016/S0140-6736(95)90056-X	http://dx.doi.org/10.1016/S0140-6736(95)90056-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7632206				2022-12-24	WOS:A1995QB80400003
J	CAPEL, B; SWAIN, A; NICOLIS, S; HACKER, A; WALTER, M; KOOPMAN, P; GOODFELLOW, P; LOVELLBADGE, R				CAPEL, B; SWAIN, A; NICOLIS, S; HACKER, A; WALTER, M; KOOPMAN, P; GOODFELLOW, P; LOVELLBADGE, R			CIRCULAR TRANSCRIPTS OF THE TESTIS-DETERMINING GENE SRY IN ADULT-MOUSE TESTIS	CELL			English	Article							SEX-DETERMINING REGION; MESSENGER-RNA; TRANSLATION; DROSOPHILA; EXPRESSION; ENCODES; PROTEIN; LETHAL; INITIATION; SEQUENCE	Sry is expressed at higher levels in the adult testis, where no function has been determined, than in the genital ridge, its critical site of action. cDNA and 5' RACE clones isolated from testis or from Sry-transfected cell lines have an unusual structure, with 3' sequences located in a 5' position. RNAase protection assays and reverse transcription polymerase chain reactions confirmed that these unusual RNA molecules represent the most abundant transcript in testis. Furthermore, oligonucleotide hybridization and RNAase H digestion proved that these Sry RNA molecules are circular. Similar transcripts were detected in the testes of mice with Mus musculus musculus, Mus musculus domesticus, and Mus spretus Sry genes. The circular RNA is found in the cytoplasm but is not substantially bound to polysomes. We suggest that the circles arise from normal splicing processes as a consequence of the unusual genomic structure surrounding the Sry locus in the mouse.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND	University of Cambridge	CAPEL, B (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND.		Koopman, Peter A/C-9416-2009	Koopman, Peter A/0000-0001-6939-0914; NICOLIS, SILVIA KIRSTEN/0000-0003-0378-3808; Lovell-Badge, Robin/0000-0001-9364-4179; Swain, Amanda/0000-0001-8666-1608	Medical Research Council [MC_U117562207] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BERTA P, 1990, NATURE, V348, P248; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLD P, 1981, BIOCHEMISTRY-US, V20, P4871; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; HAWKINS JR, 1992, AM J HUM GENET, V51, P979; HAYFLICK JS, 1989, NUCLEIC ACIDS RES, V17, P6403, DOI 10.1093/nar/17.15.6403; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAYTON MG, 1984, BRIT J CANCER, V49, P415, DOI 10.1038/bjc.1984.67; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RIO D C, 1992, Current Opinion in Cell Biology, V4, P444, DOI 10.1016/0955-0674(92)90010-A; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAFURI SR, 1993, IN PRESS J CELL BIOC; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	49	815	884	3	77	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					1019	1030		10.1016/0092-8674(93)90279-Y	http://dx.doi.org/10.1016/0092-8674(93)90279-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	7684656	Bronze			2022-12-24	WOS:A1993LF06100017
J	GABRIEL, SE; CLARKE, LL; BOUCHER, RC; STUTTS, MJ				GABRIEL, SE; CLARKE, LL; BOUCHER, RC; STUTTS, MJ			CFTR AND OUTWARD RECTIFYING CHLORIDE CHANNELS ARE DISTINCT PROTEINS WITH A REGULATORY RELATIONSHIP	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CL CHANNELS; KINASE-C; CONDUCTANCE; CELLS; CAMP; EXPRESSION; EPITHELIA; DISEASE	IN cystic fibrosis (CF), numerous epithelial cell functions are abnormal, including Cl- conductance, sodium absorption, mucin sulphation and enzyme secretion1-4. Although the CF gene product, the cystic fibrosis transmembrane conductance regulator (CFTR), functions as a small linear Cl- channel5-8, it is difficult to attribute such pleiotropic disease manifestations solely to a defect in Cl-conductance. This has led to speculation that CFTR regulates the activity of other proteins. One possible example is the protein kinase A activation of outward rectifying Cl- channels (ORCC), which is defective in membrane patches excised from CF cells9-16. Whether CFTR regulates the activity of an independent anion channel is debatable, because ORCC occur exclusively in excised membrane patches and could be an excision-induced molecular derivative of CFTR. 'Knockout' mice that lack CFTR17,18 provide a means to define the relationship between CFTR and ORCC. Here we report that ORCC are present in CFTR(-/-) mouse nasal epithelial cells and thus cannot be a derivative of the CFTR molecule. Also ORCC were regulated by protein kinase A in membrane patches from normal but not CFTR(-/-) cells. These observations are the first, to our knowledge definitive demonstration that CFTR regulates the activity of another protein.			GABRIEL, SE (corresponding author), UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599, USA.		Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FISCHER H, IN PRESS PFLUEGERS A; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; HAWS C, 1992, PEDIATR PULM S, V8, P253; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KRAUSS RD, 1992, EMBO J, V11, P875, DOI 10.1002/j.1460-2075.1992.tb05125.x; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LUCKACS GL, 1992, J BIOL CHEM, V267, P14568; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; MORRIS AP, 1992, PULMONOL S, V8, P247; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1991, AM J PHYSIOL-GASTR L, V261, P992; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277	32	253	260	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					263	266		10.1038/363263a0	http://dx.doi.org/10.1038/363263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	7683773				2022-12-24	WOS:A1993LC86600053
J	KIM, KJ; LI, B; WINER, J; ARMANINI, M; GILLETT, N; PHILLIPS, HS; FERRARA, N				KIM, KJ; LI, B; WINER, J; ARMANINI, M; GILLETT, N; PHILLIPS, HS; FERRARA, N			INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED ANGIOGENESIS SUPPRESSES TUMOR-GROWTH INVIVO	NATURE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN	THE development of new blood vessels (angiogenesis) is required for many physiological processes including embryogenesis, wound healing and corpus luteum formation1,2. Blood vessel neoformation is also important in the pathogenesis of many disorders1-5, particularly rapid growth and metastasis of solid tumours3-5. There are several potential mediators of tumour angiogenesis, including basic and acidic fibroblast growth factors, tumour necrosis factor-alpha and transforming factors-alpha and -beta1,2. But it is unclear whether any of these agents actually mediates angiogenesis and tumour growth in vivo. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and an angiogenesis inducer released by a variety of tumour cells and expressed in human tumours in situ. To test whether VEGF may be a tumour angiogenesis factor in vivo, we injected human rhabdomyosarcoma, glioblastoma multiforme or leiomyosarcoma cell lines into nude mice. We report here that treatment with a monoclonal antibody specific for VEGF inhibited the growth of the tumours, but had no effect on the growth rate of the tumour cells in vitro. The density of vessels was decreased in the antibody-treated tumours. These findings demonstrate that inhibition of the action of an angiogenic factor spontaneously produced by tumour cells may suppress tumour growth in vivo.	GENENTECH INC,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERMAN PW, 1989, J VIROL, V63, P3489, DOI 10.1128/JVI.63.8.3489-3498.1989; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1991, J NATL CANCER I, V82, P4; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIEBERMANN TA, 1987, EMBO J, V6, P1627; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254; RIZZINO A, 1987, METHOD ENZYMOL, V146, P341; ROSENTHAL R, 1990, J GROWTH FACTORS, V4, P53; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SENGER DR, 1986, CANCER RES, V46, P5629; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tisher E, 1991, J BIOL CHEM, V266, P11947; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WESTPHAL M, 1987, EXP CELL BIOL, V55, P152	32	3111	3562	4	205	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					841	844		10.1038/362841a0	http://dx.doi.org/10.1038/362841a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	7683111				2022-12-24	WOS:A1993KZ56300057
J	WANG, JF; DOWNS, WD; CECH, TR				WANG, JF; DOWNS, WD; CECH, TR			MOVEMENT OF THE GUIDE SEQUENCE DURING RNA CATALYSIS BY A GROUP-I RIBOZYME	SCIENCE			English	Article							SELF-SPLICING RNA; TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; ENDORIBONUCLEASE ACTIVITY; RIBONUCLEASE-P; RIBOSOMAL-RNA; SUBSTRATE; YEAST; CLEAVAGE; INVITRO	Ribozymes derived from the self-splicing pre-ribosomal RNA of Tetrahymena act as sequence-specific endonucleases. The reaction involves binding an RNA or DNA substrate by base pairing to the internal guide sequence (IGS) to form helix P1. Site-specific photo-crosslinking localized the 5' end of the IGS in helix P1 to the vicinity of conserved bases between helices P4 and P5, supporting a major feature of the Michel-Westhof three-dimensional structure model. The crosslinked ribozyme retained catalytic activity. When not base-paired, the IGS was still specifically crosslinked, but the major site was 37 angstrom distant from the reactive site in the experimentally supported three-dimensional model. The data indicate that a substantial induced-fit conformational change accompanies P1 formation, and they provide a physical basis for understanding the transport of oligonucleotides to the catalytic core of the ribozyme. The ability of RNA to orchestrate large-scale conformational changes may help explain why the ribosome and the spliceosome are RNA-based machines.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, COMMUNICATION; HERSCHLAG D, UNPUB; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P4411; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LECUYER KA, IN PRESS BIOCHEMISTR; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Quiocho F A, 1971, Adv Protein Chem, V25, P1, DOI 10.1016/S0065-3233(08)60278-8; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SCHUSTER GB, 1989, NATO ADV SCI I C-MAT, V272, P31; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; Williams K., COMMUNICATION; WILLIAMS KP, 1992, P NATL ACAD SCI USA, V89, P10400, DOI 10.1073/pnas.89.21.10400; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	48	101	106	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					504	508		10.1126/science.7682726	http://dx.doi.org/10.1126/science.7682726			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	7682726				2022-12-24	WOS:A1993KY50400022
J	KOHDA, D; HATANAKA, H; ODAKA, M; MANDIYAN, V; ULLRICH, A; SCHLESSINGER, J; INAGAKI, F				KOHDA, D; HATANAKA, H; ODAKA, M; MANDIYAN, V; ULLRICH, A; SCHLESSINGER, J; INAGAKI, F			SOLUTION STRUCTURE OF THE SH3 DOMAIN OF PHOSPHOLIPASE C-GAMMA	CELL			English	Article							SIGNAL TRANSDUCTION; PROTEIN-STRUCTURE; TYROSINE KINASE; VIRAL ONCOGENE; PC12 CELLS; GROWTH; DIFFERENTIATION; SPECTROSCOPY; REQUIREMENT; EXCHANGE	SH3 (Src homology 3) domains are found in many signaling proteins and appear to function as binding modules for cytoplasmic target proteins. The solution structure of the SH3 domain of human phospholipase C-gamma (PLC-gamma) was determined by two-dimensional H-1 NMR analysis. This SH3 domain is composed of eight antiparallel beta strands consisting of two successive ''Greek key'' motifs, which form a barrel-like structure. The conserved aliphatic and aromatic residues form a hydrophobic pocket on the molecular surface, and the conserved carboxylic residues are localized to the periphery. The hydrophobic pocket may serve as a binding site for target proteins. Analysis of the slowly exchanging amide protons by NMR measurements indicates that despite containing a high content of beta structure, the SH3 domain of PLC-gamma is flexible.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	New York University; Max Planck Society	KOHDA, D (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYS,18-22 HONKOMAGOME 3-CHOME,BUNKYO KU,TOKYO 113,JAPAN.		Odaka, Masafumi/C-2378-2013; Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776				BRUNGER AT, 1990, X PLOR VERSION 2 1 M; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAVANAGH J, 1992, J MAGN RESON, V96, P670, DOI 10.1016/0022-2364(92)90357-D; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLORE GM, 1986, J MOL BIOL, V191, P523, DOI 10.1016/0022-2836(86)90146-4; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	29	116	118	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					953	960		10.1016/0092-8674(93)90583-C	http://dx.doi.org/10.1016/0092-8674(93)90583-C			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7681365				2022-12-24	WOS:A1993KU17500015
J	ADAMS, SA; ROBSON, SC; GATHIRAM, V; JACKSON, TFHG; PILLAY, TS; KIRSCH, RE; MAKGOBA, MW				ADAMS, SA; ROBSON, SC; GATHIRAM, V; JACKSON, TFHG; PILLAY, TS; KIRSCH, RE; MAKGOBA, MW			IMMUNOLOGICAL SIMILARITY BETWEEN THE 170 KD AMEBIC ADHERENCE GLYCOPROTEIN AND HUMAN BETA-2 INTEGRINS	LANCET			English	Note							GALACTOSE-BINDING LECTIN; ENTAMOEBA-HISTOLYTICA; ANTIBODIES	Amoebiasis is an important cause of morbidity and mortality in developing countries. Virulence of Entamoeba histolytica depends on the trophozoite's being able to bind to colonic epithelium; binding is mediated by the 170 kD subunit of a 260 kD lectin. We found, by microcytofluorometry and western blotting studies, that this 170 kD subunit protein shares an epitope with human beta2 integrins-a subfamily of cell-surface glycoproteins expressed exclusively on leucocytes and involved in many adhesive and signalling interactions. The immunological similarity between these proteins may explain the trophozoite's ability to bind to and invade colonic epithelium.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,DIV MOLEC ENDOCRINOL,DU CANE RD,LONDON W12 0NN,ENGLAND; UNIV CAPE TOWN,SCH MED,MRC,LIVER RES CTR,CAPE TOWN,SOUTH AFRICA; UNIV NATAL,MRC,DURBAN,SOUTH AFRICA; UNIV NATAL,DEPT MED,DURBAN,SOUTH AFRICA	Imperial College London; University of Cape Town; University of Kwazulu Natal; University of Kwazulu Natal			Robson, Simon C./AAA-8537-2021	pillay, tahir/0000-0002-9982-9710	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHADEE K, 1987, J CLIN INVEST, V80, P1245, DOI 10.1172/JCI113199; JOYCE MP, 1988, AM J TROP MED HYG, V35, P159; MANN BJ, 1991, P NATL ACAD SCI USA, V88, P3248, DOI 10.1073/pnas.88.8.3248; PETRI WA, 1989, J BIOL CHEM, V264, P3007; PETRI WA, 1987, J CLIN INVEST, V80, P1238, DOI 10.1172/JCI113198; PETRI WA, 1990, J IMMUNOL, V144, P4803; RAVDIN JI, 1990, J INFECT DIS, V162, P768, DOI 10.1093/infdis/162.3.768; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Walsh J.A., 1988, P93	10	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					17	19		10.1016/0140-6736(93)92483-A	http://dx.doi.org/10.1016/0140-6736(93)92483-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	7678048				2022-12-24	WOS:A1993KF02700006
J	BEVERS, RFM; BAKKER, DJ; KURTH, KH				BEVERS, RFM; BAKKER, DJ; KURTH, KH			HYPERBARIC-OXYGEN TREATMENT FOR HEMORRHAGIC RADIATION CYSTITIS	LANCET			English	Article							THERAPY	Radiation-induced severe haemorrhagic cystitis is difficult to treat. Conventional treatments may decrease haematuria but do not affect the radiocystitis itself. Hyperbaric oxygen treatment has been reported to do both. We report the results of a prospective study of hyperbaric oxygen (20 sessions of 100% oxygen inhalation at 3 bar for 90 min in a multiplace hyperbaric chamber) to 40 patients with biopsy-proven radiation cystitis and severe haematuria. Haematuria disappeared completely or improved in 37 patients after treatment. Mean follow-up was 23.1 months (range 1-74); and the recurrence rate was 0.12/year. There were no adverse effects. Hyperbaric oxygen treatment should be considered for patients with severe radiation-induced haematuria.	UNIV AMSTERDAM,ACAD MED CTR,DEPT UROL,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam								Akiyama A, 1994, Nihon Hinyokika Gakkai Zasshi, V85, P1269; FELDMEIER JJ, 1994, UNDERSEA HYPERBAR M, V21, P467; GABB G, 1987, CHEST, V92, P1074, DOI 10.1378/chest.92.6.1074; GRIM PS, 1990, JAMA-J AM MED ASSOC, V263, P2216; KINDWALL EP, 1993, CLIN PLAST SURG, P589; LEE HC, 1994, UNDERSEA HYPERBAR M, V21, P321; MOSS WT, 1979, RAD ONCOLOGY RATIONA, P246; NAKADA T, 1992, EUR UROL, V22, P294; Noordzij JW., 1993, INT UROGYNECOL J, V4, P160; NORKOOL DM, 1993, J UROLOGY, V150, P332, DOI 10.1016/S0022-5347(17)35476-9; PARSONS CL, 1986, J UROLOGY, V136, P813, DOI 10.1016/S0022-5347(17)45087-7; RIJKMANS BG, 1989, EUR UROL, V16, P354; SCHOENROCK GJ, 1986, UROLOGY, V27, P271, DOI 10.1016/0090-4295(86)90289-X; WEISS JP, 1994, J UROLOGY, V151, P1514, DOI 10.1016/S0022-5347(17)35289-8	14	131	138	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					803	805		10.1016/S0140-6736(95)91620-2	http://dx.doi.org/10.1016/S0140-6736(95)91620-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674746				2022-12-24	WOS:A1995RW25800011
J	HESLOP, HE; BENAIM, E; BRENNER, MK; KRANCE, RA; STRICKLIN, LM; ROCHESTER, RJ; BILLING, R				HESLOP, HE; BENAIM, E; BRENNER, MK; KRANCE, RA; STRICKLIN, LM; ROCHESTER, RJ; BILLING, R			RESPONSE OF STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE TO LYMPHOBLAST ANTIBODY CBL1	LANCET			English	Note								Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN USA; CV CANC CTR, SAN MARCOS, CA USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	HESLOP, HE (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38101 USA.		Brenner, Malcolm/Y-2509-2019; Heslop, Helen/AAC-9500-2020		NCI NIH HHS [CA 20180, CA 21745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANASETTI C, 1994, BLOOD, V84, P1320; ANTIN JH, 1994, BLOOD, V84, P1342, DOI 10.1182/blood.V84.4.1342.bloodjournal8441342; BILLING R, 1982, HYBRIDOMA, V1, P303, DOI 10.1089/hyb.1.1982.1.303; BLAISE D, 1995, LANCET, V345, P1144, DOI 10.1016/S0140-6736(95)90978-8; BYERS VS, 1990, BLOOD, V75, P1426; CHAO NJ, 1993, NEW ENGL J MED, V329, P1225, DOI 10.1056/NEJM199310213291703; HERVE P, 1992, BLOOD, V79, P3362; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; PRENTICE HG, 1984, LANCET, V1, P472; TAKAHASHI H, 1983, LANCET, V2, P1155	10	25	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 23	1995	346	8978					805	806		10.1016/S0140-6736(95)91621-0	http://dx.doi.org/10.1016/S0140-6736(95)91621-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674747				2022-12-24	WOS:A1995RW25800012
J	GORLICH, D; VOGEL, F; MILLS, AD; HARTMANN, E; LASKEY, RA				GORLICH, D; VOGEL, F; MILLS, AD; HARTMANN, E; LASKEY, RA			DISTINCT FUNCTIONS FOR THE 2 IMPORTIN SUBUNITS IN NUCLEAR-PROTEIN IMPORT	NATURE			English	Article							GTP-BINDING PROTEIN; LOCATION; TRANSLOCATION; POLYPEPTIDE; MIGRATION; SEQUENCE; RAN/TC4; STEPS	THE import of nuclear proteins proceeds through the nuclear pore complex and requires nuclear localization signals (NLSs)(1,2), energy(3,4) and soluble factors(5), namely importin-alpha (M(r) 60K)(6-12,28), importin-beta (90K)(8-11,13) and Ran(14,15). Importin-alpha is primarily responsible for NLS recognition(6-12,29) and is a member of a protein family that includes the essential yeast nuclear pore protein SRP1p (ref. 16). As the first event, the complex of importin-alpha and importin-beta binds the import substrate in the cytosols(8,9). Here we show that this nuclear pore targeting complex initially docks as a single entity to the nuclear pore via importin-beta. Then the energy-dependent, Ran-mediated translocation through the pore results in the accumulation of import substrate and importin-alpha in the nucleus. In contrast, importin-beta accumulates at the nuclear envelope, but not in the nucleoplasm. Immunoelectron microscopy detects importin-beta on both sides of the nuclear pore. This suggests that the nuclear pore targeting complex might move as a single entity from its initial docking site through the central part of the nuclear pore before it disassembles on the nucleoplasmic side.	UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND; MAX DELBRUCK CENTRUM MOLEK MED, D-13122 BERLIN, GERMANY	University of Cambridge; Helmholtz Association; Max Delbruck Center for Molecular Medicine	GORLICH, D (corresponding author), WELLCOME CRC INST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		Görlich, Dirk/B-8296-2017; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P137; HARLOW E, 1988, ANTIBODIES LABORATOR; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	29	422	428	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 21	1995	377	6546					246	248		10.1038/377246a0	http://dx.doi.org/10.1038/377246a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675110				2022-12-24	WOS:A1995RV87200044
J	HOUETO, P; HOFFMAN, JR; IMBERT, M; LEVILLAIN, P; BAUD, FJ				HOUETO, P; HOFFMAN, JR; IMBERT, M; LEVILLAIN, P; BAUD, FJ			RELATION OF BLOOD CYANIDE TO PLASMA CYANOCOBALAMIN CONCENTRATION AFTER A FIXED-DOSE OF HYDROXOCOBALAMIN IN CYANIDE POISONING	LANCET			English	Article								Hydroxocobalamin combines with cyanide to form cyanocobalamin. We hypothesised that the amount of cyanocobalamin formed after a fixed dose of hydroxocobalamin given for cyanide poisoning would correlate with initial blood cyanide concentration. We determined blood cyanide concentration in 12 patients exposed to residential fires, and compared this with markers of the amount of cyanocobalamin formed after treatment with 5 g intravenous hydroxocobalamin. All relationships were highly correlated (r(2) 0.79-0.95), for the whole group, and there appeared to be an almost linear relationship for the 9 patients with initial cyanide concentration below 40 mu mol/L. Above this concentration, no further cyanocobalamin was formed from a single 5 g dose of hydroxocobalamin. In one patient with initial blood cyanide concentration of 96 mu mol/L, however, plasma cyanocobalamin concentration approximately doubled after a second 5 g dose of hydroxocobalamin. 5 g of hydroxocobalamin appears capable of binding all available cyanide ions for blood cyanide concentrations up to about 40 mu mol/L. Beyond this, more hydroxocobalamin must be given for remaining cyanide ions to be bound. This information will allow clinicians to use rapidly measurable plasma cyanocobalamin concentrations to gauge severity of exposure and evaluate adequacy of treatment.	UNIV PARIS 07,HOP FERNAND WIDAL,TOXICOL LAB,PARIS,FRANCE; BRIGADE SAPEURS POMPIERS,SERV MED,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite								BARTELHEIMER EW, 1962, ARCH INT PHARMACOD T, V139, P99; BRIGHT JE, 1988, HUM TOXICOL, V7, P183, DOI 10.1177/096032718800700214; EVANS CL, 1964, BRIT J PHARM CHEMOTH, V23, P455, DOI 10.1111/j.1476-5381.1964.tb01603.x; Favier C, 1993, CLIN INT CARE, V4, P69; HOUETO P, 1994, J ANAL TOXICOL, V18, P154, DOI 10.1093/jat/18.3.154; HOUETO P, 1994, THERAPIE, V49, P68; LINELL JC, 1987, CLIN EXPT TOXICOLOGY, P427; MOUREU H, 1957, Arch Mal Prof, V18, P116; RIEDERS F, 1975, METHODOLOGY ANAL TOX, P113; RIOU B, 1990, J NEUROSURG ANESTH, V2, P296, DOI 10.1097/00008506-199012000-00008; SCHWARTZ D, 1963, METHODES STATISTIQUE	11	42	46	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 2	1995	346	8975					605	608		10.1016/S0140-6736(95)91437-4	http://dx.doi.org/10.1016/S0140-6736(95)91437-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT188	7651005				2022-12-24	WOS:A1995RT18800010
J	WANG, CR; CASTANO, AR; PETERSON, PA; SLAUGHTER, C; LINDAHL, KF; DEISENHOFER, J				WANG, CR; CASTANO, AR; PETERSON, PA; SLAUGHTER, C; LINDAHL, KF; DEISENHOFER, J			NONCLASSICAL BINDING OF FORMYLATED PEPTIDE IN CRYSTAL-STRUCTURE OF THE MHC CLASS-IB MOLECULE H2-M3	CELL			English	Article							DROSOPHILA-MELANOGASTER CELLS; COMPLEX CLASS-I; HISTOCOMPATIBILITY ANTIGEN; VIRAL PEPTIDES; PROTEIN; RECOGNITION; SPECIFICITY; RESOLUTION; HLA-A2; H-2M3	H2-M3 is a class Ib MHC molecule of the mouse with a 10(4)-fold preference for binding N-formylated peptides. To elucidate the basis of this unusual specificity, we expressed and crystallized a soluble form of M3 with a formylated nonamer peptide, fMYFINILTL, and determined the structure by X-ray crystallography. M3, refined at 2.1 Angstrom resolution, resembles class ia MHC molecules in its overall structure, but differs in the peptide-binding groove. The A pocket, which usually accommodates the free N-terminus of a bound peptide, is closed, and the peptide is shifted one residue, such that the P1 side chain is lodged in the a pocket, The formyl group is coordinated by His-9 and a bound water on the floor of the groove.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute	WANG, CR (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.		Castaño, A. Raul/A-5905-2012	Castaño, A. Raul/0000-0003-2107-8862				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; CHEN W, 1993, J EXP MED, V177, P869, DOI 10.1084/jem.177.3.869; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HERMEL E, 1992, THESIS U TEXAS DALLA; HOGQUIST KA, 1993, EUR J IMMUNOL, V23, P3028, DOI 10.1002/eji.1830231145; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE S, 1994, J EXP MED, V179, P579, DOI 10.1084/jem.179.2.579; KURLANDER RJ, 1992, SCIENCE, V257, P678, DOI 10.1126/science.1496381; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MILLER JEW, 1994, J CELL BIOCHEM, V18, P292; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAMER EG, 1992, CELL, V70, P215, DOI 10.1016/0092-8674(92)90097-V; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROHREN EM, 1994, J IMMUNOL, V152, P5337; ROTZSCHKE O, 1993, NATURE, V361, P642, DOI 10.1038/361642a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; SMITH GP, 1994, INT IMMUNOL, V6, P1917, DOI 10.1093/intimm/6.12.1917; STROYNOWSKI I, 1994, CURR OPIN IMMUNOL, V6, P38, DOI 10.1016/0952-7915(94)90031-0; VYAS JM, 1995, J EXP MED, V181, P1817, DOI 10.1084/jem.181.5.1817; VYAS JM, 1992, J IMMUNOL, V149, P3605; WANG CR, 1993, P NATL ACAD SCI USA, V90, P2784, DOI 10.1073/pnas.90.7.2784; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; WANG CR, 1995, IMMUNOGENETICS, V42, P63, DOI 10.1007/BF00164989; YUNG ACM, 1994, CELL, V76, P39; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	51	128	129	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					655	664		10.1016/0092-8674(95)90037-3	http://dx.doi.org/10.1016/0092-8674(95)90037-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664344	Bronze			2022-12-24	WOS:A1995RR73400016
J	JONES, JK; GORKIN, L; LIAN, JF; STAFFA, JA; FLETCHER, AP				JONES, JK; GORKIN, L; LIAN, JF; STAFFA, JA; FLETCHER, AP			DISCONTINUATION OF AND CHANGES IN TREATMENT AFTER START OF NEW COURSES OF ANTIHYPERTENSIVE DRUGS - A STUDY OF A UNITED-KINGDOM POPULATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PATIENTS; HYPERTENSION	Objective-To evaluate the incidence of discontinuation of and changes in treatment after newly prescribed courses of antihypertensive drugs of the four primary therapeutic classes: beta blocker, calcium channel blocker, and angiotensin converting enzyme inhibitor. Design-A retrospective analysis of patients on an automated database of 1.2 million patients was conducted on visits between 1 October 1992 and 30 September 1993. Setting-General practices in the United Kingdom. Subjects-37 643 patients with hypertension receiving a relevant drug in the time period were identified. A new course of treatment in at least one of the four therapeutic classes, defined as a drug not prescribed in the previous four months, was observed in 10 222 patients aged greater than or equal to 40 years. Main outcome measures-Patients changing to other treatment or discontinuing after initiating a new course of treatment, defined as the absence of a refill prescription for the new drug or another in its category within a six month observation period. Results-Changes in or discontinuation of treatment were frequently observed, and by month six continuation rates ranged between 40% to 50% for all four classes of drugs. Conclusion-Low rates of continuation with a newly prescribed antihypertensive drug exist regardless of which drug is prescribed.	IMS INT, LONDON, ENGLAND		JONES, JK (corresponding author), DEGGE GRP, 1616 N FT MYER DR, SUITE 1430, ARLINGTON, VA 22209 USA.							[Anonymous], 1991, JAMA, V265, P3255; BLACK DM, 1987, J GERONTOL, V42, P552, DOI 10.1093/geronj/42.5.552; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAVIS CE, 1990, HDB HLTH BEHAVIOR CH; GORKIN L, 1990, HDB HLTH BEHAVIOR CH; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; MARONDE RF, 1989, MED CARE, V27, P1159, DOI 10.1097/00005650-198912000-00007; MCCOMBS JS, 1994, MED CARE, V32, P214, DOI 10.1097/00005650-199403000-00003; MOSS AJ, 1989, CIRCULATION, V80, P102; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; SHULMAN N, 1982, CONTROL CLIN TRIALS, V3, P13, DOI 10.1016/0197-2456(82)90016-2; SWALES JD, 1994, LANCET, V344, P380; 1979, JAMA-J AM MED ASSOC, V22, P2562	15	226	231	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 29	1995	311	7000					293	295		10.1136/bmj.311.7000.293	http://dx.doi.org/10.1136/bmj.311.7000.293			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633238	Green Published			2022-12-24	WOS:A1995RM71900026
J	WOOD, D; HALFON, N; SCARLATA, D; NEWACHECK, P; NESSIM, S				WOOD, D; HALFON, N; SCARLATA, D; NEWACHECK, P; NESSIM, S			IMPACT OF FAMILY RELOCATION ON CHILDRENS GROWTH, DEVELOPMENT, SCHOOL FUNCTION, AND BEHAVIOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIDIMENSIONAL ASSESSMENT; LIFE EVENTS; FOSTER-CARE; HEALTH; MORBIDITY; HOMELESS; POOR	Objective.-The United States is a highly mobile society, with family relocation rates double those of Great Britain and Germany. The objective of this study was to describe the impact of frequent family moves on reported rates of delay in growth or development, learning disorders, school failure, and frequent behavioral problems in US school-age children. Design and Setting.-We analyzed data on 9915 six- to 17-year-old children of families responding to the 1988 National Health Interview Survey, a nationally representative sample of families and children. Outcome Measures.-Parents were asked to report the total number of moves the index child had experienced during his or her lifetime. Total moves were adjusted for the child's age in years. Children were divided into two groups: never moved/infrequent relocation (below the 90th percentile for age-adjusted moves) and frequent relocation (above the 90th percentile for age-adjusted moves). The parent was asked if the child had ever had a learning disability or a delay in growth or development, had ever failed a grade, or had four or more frequently occurring behavioral problems as described by a behavioral problems checklist. Results.-The measures of both child dysfunction and family relocation were independently associated with multiple sociodemographic characteristics such as poverty, race, and family structure. Frequent relocation was associated with higher rates of all measures of child dysfunction; 23% of children who moved frequently had repeated a grade vs 12% of children who never or infrequently moved. Eighteen percent of children who moved frequently had four or more behavioral problems vs 7% of children who never or infrequently moved. Use of logistic regression to control for potential confounding covariates demonstrated that children who moved frequently were 77% more likely to be reported to have four or more behavioral problems (odds ratio, 1.77; 95% confidence interval, 1.37 to 2.29) and were 35% more likely to have failed a grade (odds ratio, 1.35; 95% confidence interval, 1.06 to 1.72), but no more likely to have had delays in growth or development or a learning disorder. Conclusions.-After adjusting for other covariates, frequent family relocation was associated with an increased risk of children failing a grade in school and four or more frequently occurring behavioral problems.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA USA; UCSF, SCH MED, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DIV BIOSTAT, SCI & CLIN COMP SERV, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; University of California System; University of California Los Angeles	WOOD, D (corresponding author), CEDARS SINAI MED CTR, AHAMANSON DEPT PEDIAT, DIV PRIMARY CARE PEDIAT, 310 N SAN VICENTE D, LOS ANGELES, CA 90048 USA.							ACHENBACH TM, 1981, MONOGR SOC RES CHILD, V46, P1, DOI 10.2307/1165983; ADAMS PF, 1989, VITAL HLTH STAT 10, V173, P1; ADAMS PF, 1989, VITAL HLTH STAT, V173, P133; BASSUK EL, 1988, YALE LAW POLICY REV, V6, P309; BEAUTRAIS AL, 1982, PEDIATRICS, V70, P774; CAMPBELL SB, 1982, J ABNORM CHILD PSYCH, V10, P569, DOI 10.1007/BF00920755; CHAMBERLAIN P, 1987, BEHAV ASSESS, V9, P97; DIAZ C, 1986, MED CARE, V24, P848, DOI 10.1097/00005650-198609000-00006; Eisen M., 1980, R2313HEW RAND; EMERY RF, 1988, MARRIAGE DIVORCE CHI, P14; GOULD MS, 1981, J AM ACAD CHILD PSY, V20, P462, DOI 10.1016/S0002-7138(09)61640-X; Haggerty RJ, 1975, CHILD HLTH COMMUNITY; HOCHSTADT NJ, 1987, CHILD ABUSE NEGLECT, V11, P53, DOI 10.1016/0145-2134(87)90033-0; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Jones Jacqueline, 1992, DISPOSSESSED AM UNDE; LEVINE M, 1966, COMMUNITY MENT HLT J, V2, P61, DOI 10.1007/BF01420324; Levy J. E., 1992, FUTURE CHILD, V2, P44; LOCHMAN JE, 1986, J CHILD ADOL PSYCHOL, V3, P91; MCGAUHEY PJ, 1991, PEDIATRICS, V88, P943; MCLANAHAN S, 1988, FOCUS, V2, P16; MCMAHON RC, 1979, J CLIN PSYCHOL, V35, P757, DOI 10.1002/1097-4679(197910)35:4<757::AID-JCLP2270350413>3.0.CO;2-B; NEWACHECK PW, 1988, AM J PUBLIC HEALTH, V78, P927, DOI 10.2105/AJPH.78.8.927; NEWCOMB MD, 1981, J HEALTH SOC BEHAV, V22, P400, DOI 10.2307/2136681; PAVENSTEDT E, 1967, DRIFTERS CHILDREN DI; REYNOLDS AJ, 1989, J EDUC PSYCHOL, V81, P594, DOI 10.1037/0022-0663.81.4.594; REYNOLDS AJ, 1991, ED334019; ROSSI PH, 1980, WHY FAMILIES MOVE, P32; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; SCHOR EL, 1982, PEDIATRICS, V69, P521; SHAF BV, 1992, SUDAAN USERS MANUAL; STANTON WR, 1991, PEDIATRICS, V88, P954; STOKOLS D, 1982, J SOC ISSUES, V38, P149, DOI 10.1111/j.1540-4560.1982.tb01776.x; STUBBLEFIELD RL, 1955, AM J ORTHOPSYCHIAT, V25, P12; Tyack D., 1992, FUTURE CHILD, V2, P19, DOI DOI 10.2307/1602459; WHALEN TE, 1973, J EDUC RES, V67, P163, DOI 10.1080/00220671.1973.10884593; WHITE KR, 1982, PSYCHOL BULL, V91, P461, DOI 10.1037/0033-2909.91.3.461; WOOD D, 1990, AM J PUBLIC HEALTH, V80, P1049, DOI 10.2105/AJPH.80.9.1049; WOOD DL, 1990, PEDIATRICS, V86, P858; 1989, US CHILDREN THEIR FA; 1992, FUTURE CHILD, V2, P6; 1989, CURRENT POPULATI P60, V166; 1990, 19R01 NAT ASS ED PRO; 1985, SAS USERS GUIDE BASI; 1989, CURRENT POPULATI P20, V430; [No title captured]	45	203	204	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1334	1338		10.1001/jama.270.11.1334	http://dx.doi.org/10.1001/jama.270.11.1334			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	7689659				2022-12-24	WOS:A1993LW34500031
J	BERLIN, C; BERG, EL; BRISKIN, MJ; ANDREW, DP; KILSHAW, PJ; HOLZMANN, B; WEISSMAN, IL; HAMANN, A; BUTCHER, EC				BERLIN, C; BERG, EL; BRISKIN, MJ; ANDREW, DP; KILSHAW, PJ; HOLZMANN, B; WEISSMAN, IL; HAMANN, A; BUTCHER, EC			ALPHA-4-BETA-7-INTEGRIN MEDIATES LYMPHOCYTE BINDING TO THE MUCOSAL VASCULAR ADDRESSIN MADCAM-1	CELL			English	Article							ENDOTHELIAL-CELL RECOGNITION; MONOCLONAL-ANTIBODIES; HOMING RECEPTOR; RECIRCULATING LYMPHOCYTES; ADHESION MOLECULE-1; DIVALENT-CATIONS; INTEGRIN VLA-4; IMMUNE-SYSTEM; FIBRONECTIN; LIGAND	The mucosal vascular addressin, MAdCAM-1, is an immunoglobulin superfamily adhesion molecule for lymphocytes that is expressed by mucosal venules and helps direct lymphocyte traffic into Peyer's patches (PP) and the intestinal lamina propria. We demonstrate that the lymphocyte integrin alpha4beta7, also implicated in homing to PP, is a receptor for MAdCAM-1. Certain antibodies to alpha4 and beta7 integrin chains but not to the beta2 integrin LFA-1 inhibit lymphocyte binding to purified MAdCAM-1 and to MAdCAM-1 transfectants. Lymph node lymphocytes, alpha4beta7+ TK1 lymphoma cells, and a beta7-transfected variant of an alpha4 + B cell line, 38C13, bind constitutively to MAdCAM-1. Binding is enhanced by Mn++-induced integrin activation. The related integrin alpha4beta1 supports efficient binding to VCAM-1 but not to MAdCAM-1, even after integrin activation, indicating that MAdCAM-1 is a preferential ligand for alpha4beta7. alpha4beta7 can also bind VCAM-1, but this requires greater integrin activation than binding to MAdCAM-1. The findings imply a selective role for the interaction of alpha4beta7 and MAdCAM-1 lymphocyte in homing to mucosal sites.	STANFORD UNIV,CTR DIGEST DIS,STANFORD,CA 94305; VET ADM MED CTR,FOOTHILL RES CTR,CTR MOLEC BIOL & MED,PALO ALTO,CA 94304; AFRC,INST ANIM PHYSIOL & GENET RES,DEPT CELL BIOL,CAMBRIDGE CB2 4AT,ENGLAND; TECH UNIV MUNICH,INST MED MICROBIOL,W-8000 MUNICH 80,GERMANY; STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; UNIV HAMBURG,KRANKENHAUS EPPENDORF,MED 1 KLIN,DIV IMMUNOL,W-2000 HAMBURG 20,GERMANY	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Technical University of Munich; Stanford University; Stanford University; University of Hamburg	BERLIN, C (corresponding author), STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.		Berg, Ellen/T-8827-2019; Berg, Ellen/D-9076-2014	Berg, Ellen/0000-0001-5149-6665	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037734, R01GM037734] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19957] Funding Source: Medline; NIDDK NIH HHS [DK45448] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; BARGATZE RF, 1993, IN PRESS J EXP MED; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, VASCULAR ADHESION MO, V2, P111; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GABRIELMASSON CS, 1992, THESIS PENNSYLVANIA; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAMANN A, 1988, J IMMUNOL, V140, P693; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MACKAY CR, 1993, IN PRESS ANN REV IMM; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; ONEILL JK, 1991, IMMUNOLOGY, V72, P520; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOODRUFF JJ, 1987, ANNU REV IMMUNOL, V5, P201, DOI 10.1146/annurev.immunol.5.1.201; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YUAN Q, 1992, J BIOL CHEM, V267, P7352; Zatz M M, 1970, Cell Immunol, V1, P3, DOI 10.1016/0008-8749(70)90057-2	61	1242	1302	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					185	195		10.1016/0092-8674(93)90305-A	http://dx.doi.org/10.1016/0092-8674(93)90305-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687523				2022-12-24	WOS:A1993LN62500018
J	HYDE, SC; GILL, DR; HIGGINS, CF; TREZISE, AEO; MACVINISH, LJ; CUTHBERT, AW; RATCLIFF, R; EVANS, MJ; COLLEDGE, WH				HYDE, SC; GILL, DR; HIGGINS, CF; TREZISE, AEO; MACVINISH, LJ; CUTHBERT, AW; RATCLIFF, R; EVANS, MJ; COLLEDGE, WH			CORRECTION OF THE ION-TRANSPORT DEFECT IN CYSTIC-FIBROSIS TRANSGENIC MICE BY GENE-THERAPY	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RESPIRATORY EPITHELIUM; CHLORIDE CHANNELS; LUNG-DISEASE; ACTIVATION; EXPRESSION; AMILORIDE; CFTR; MEMBRANE; CALCIUM	CYSTIC fibrosis (CF) is a lethal inherited disorder affecting about 1 in 2,000 Caucasians. The major cause of morbidity is permanent lung damage resulting from ion transport abnormalities in airway epithelia that lead to mucus accumulation and bacterial colonization. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene1 that encodes a cyclic-AMP-regulated chloride channel2,3. Cyclic-AMP-regulated chloride conductances are altered in airway epithelia from CF patients4-6, suggesting that the functional expression of CFTR in the airways of CF patients may be a strategy for treatment. Transgenic mice7-9 With a disrupted cftr gene are appropriate for testing gene therapy protocols. Here we report the use of liposomes to deliver a CFTR expression plasmid to epithelia of the airway and to alveoli deep in the lung, leading to the correction of the ion conductance defects found in the trachea of transgenic (cf/cf) mice. These studies illustrate the feasibility of gene therapy for the pulmonary aspects of CF in humans.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; UNIV CAMBRIDGE,DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,WELLCOME CRC INST CANC & DEV BIOL,CAMBRIDGE CB2 1QR,ENGLAND	Cancer Research UK; University of Oxford; University of Cambridge; University of Cambridge; University of Cambridge			Colledge, William/X-4976-2019	Colledge, William/0000-0002-9603-4429; Hyde, Stephen/0000-0002-8877-4005; Gill, Deborah/0000-0002-5264-054X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COLLEDGE WH, 1992, LANCET, V340, P680, DOI 10.1016/0140-6736(92)92223-3; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CUTHBERT AW, 1990, BRIT J CLIN PHARMACO, V29, P227, DOI 10.1111/j.1365-2125.1990.tb03624.x; DORIN JR, 1992, NATURE, V359, P211, DOI 10.1038/359211a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCCANN JD, 1990, AM J PHYSIOL, V258, pL334, DOI 10.1152/ajplung.1990.258.6.L334; RATCLIFF R, IN PRESS NATURE GENE; RIORDAN JR, 1989, SCIENCE, V245, P1066; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMITH SN, 1992, CLIN SCI, V82, P667, DOI 10.1042/cs0820667; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TREZISE AEO, IN PRESS HUM MOL GEN; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZEITLIN PL, 1991, P NATL ACAD SCI USA, V89, P1344	33	360	424	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					250	255		10.1038/362250a0	http://dx.doi.org/10.1038/362250a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	7681548				2022-12-24	WOS:A1993KT02600058
J	GOVERMAN, J; WOODS, A; LARSON, L; WEINER, LP; HOOD, L; ZALLER, DM				GOVERMAN, J; WOODS, A; LARSON, L; WEINER, LP; HOOD, L; ZALLER, DM			TRANSGENIC MICE THAT EXPRESS A MYELIN BASIC PROTEIN-SPECIFIC T-CELL RECEPTOR DEVELOP SPONTANEOUS AUTOIMMUNITY	CELL			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ANTIGEN RECEPTOR; EXTRATHYMIC TOLERANCE; CLONAL ELIMINATION; VIRUS-INFECTION; SELF-TOLERANCE; LYMPHOCYTES-T; INDUCTION; THYMUS; ANERGY	We constructed a transgenic mouse model that mimics the human autoimmune disease multiple sclerosis in its spontaneous induction and pathology. Transgenic mice were constructed expressing genes encoding a rearranged T cell receptor specific for myelin basic protein (MBP). T cell tolerance was not induced in the periphery, and functional, autoreactive T cells were found in the spleen and lymph nodes of these mice. Transgenic mice developed experimental allergic encephalomyelitis (EAE) following immunization with MBP and adjuvant plus pertussis toxin as well as with administration of pertussis toxin alone. Spontaneous EAE can develop in transgenic mice housed in a nonsterile facility but not in those maintained in a sterile, specific pathogen-free facility. This model system affords a unique opportunity to dissect the genetic and environmental variables that may contribute to the development of spontaneous autoimmune disease.	UNIV SO CALIF, SCH MED, DEPT NEUROBIOL, LOS ANGELES, CA 90033 USA; MERCK SHARP & DOHME LTD, DEPT MOLEC IMMUNOL, RAHWAY, NJ 07065 USA	University of Southern California; Merck & Company	GOVERMAN, J (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.			Goverman, Joan/0000-0002-7361-9424				Alvord E C Jr, 1984, Prog Clin Biol Res, V146, P503; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BROWN AM, 1981, LAB INVEST, V45, P278; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; HAMMERLING GJ, 1991, RES IMMUNOL, V142, P417, DOI 10.1016/0923-2494(91)90040-P; JAHNKE U, 1985, SCIENCE, V229, P282, DOI 10.1126/science.2409602; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; JONES LA, 1990, THYMUS, V16, P195; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KAMRADT T, 1991, J IMMUNOL, V147, P3296; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1991, IMMUNOL REV, V122, P69, DOI 10.1111/j.1600-065X.1991.tb00597.x; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; LINTHICUM DS, 1982, IMMUNOBIOLOGY, V162, P211, DOI 10.1016/S0171-2985(11)80001-X; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LUBLIN FD, 1981, J IMMUNOL, V126, P819; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MILICH DR, 1991, P NATL ACAD SCI USA, V88, P4348, DOI 10.1073/pnas.88.10.4348; MILLER JFAP, 1991, IMMUNOL REV, V122, P103, DOI 10.1111/j.1600-065X.1991.tb00599.x; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; Raine C. S., 1983, MULTIPLE SCLEROSIS P, P413; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; Suckling A J, 1984, Prog Clin Biol Res, V146, P75; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	40	585	596	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					551	560		10.1016/0092-8674(93)90074-Z	http://dx.doi.org/10.1016/0092-8674(93)90074-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679952				2022-12-24	WOS:A1993KP16500010
J	LUAN, DD; KORMAN, MH; JAKUBCZAK, JL; EICKBUSH, TH				LUAN, DD; KORMAN, MH; JAKUBCZAK, JL; EICKBUSH, TH			REVERSE TRANSCRIPTION OF R2BM RNA IS PRIMED BY A NICK AT THE CHROMOSOMAL TARGET SITE - A MECHANISM FOR NON-LTR RETROTRANSPOSITION	CELL			English	Article							R HYBRID DYSGENESIS; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENT; MAMMALIAN LINES; BOMBYX-MORI; RETROVIRAL PROTEINS; I-FACTOR; DNA; SEQUENCE; INSERTION	R2 is a non-LTR retrotransposable element that inserts at a specific site in the 28S rRNA genes of most insects. We have expressed the open reading frame of the R2 element from Bombyx mori, R2Bm, in E. coli and shown that it encodes both sequence-specific endonuclease and reverse transcriptase activities. The R2 protein makes a specific nick in one of the DNA strands at the insertion site and uses the 3' hydroxyl group exposed by this nick to prime reverse transcription of its RNA transcript. After reverse transcription, cleavage of the second DNA strand occurs. A similar mechanism of insertion may be used by other non-LTR retrotransposable elements as well as short interspersed nucleotide elements.			LUAN, DD (corresponding author), UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA.				NIGMS NIH HHS [GM42790] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DS, 1986, J MOL BIOL, V187, P465, DOI 10.1016/0022-2836(86)90327-X; BELL L, 1983, ANAL BIOCHEM, V130, P527, DOI 10.1016/0003-2697(83)90628-0; BERG JM, 1990, J BIOL CHEM, V265, P6513; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BOEKE JD, 1989, MOBILE DNA, P335; BRADFIELD JY, 1985, DNA-J MOLEC CELL BIO, V4, P357, DOI 10.1089/dna.1985.4.357; Brown N L, 1980, Methods Enzymol, V65, P391; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUCHETON A, 1990, TRENDS GENET, V6, P16, DOI 10.1016/0168-9525(90)90044-7; BURKE WD, 1987, MOL CELL BIOL, V7, P2221, DOI 10.1128/MCB.7.6.2221; BURKE WD, 1993, IN PRESS MOL BIOL EV, V10; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CHABOISSIER MC, 1990, EMBO J, V9, P3557, DOI 10.1002/j.1460-2075.1990.tb07566.x; DAWID IB, 1981, NUCLEIC ACIDS RES, V9, P5011, DOI 10.1093/nar/9.19.5011; Deininger PL, 1989, MOBILE DNA, P619; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; EICKBUSH TH, 1992, NEW BIOL, V4, P430; EICKBUSH TH, 1985, EMBO J, V4, P2281, DOI 10.1002/j.1460-2075.1985.tb03927.x; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; FINNEGAN DJ, 1989, MOBILE DNA, P503; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; IVANOV VA, 1991, EMBO J, V10, P2489, DOI 10.1002/j.1460-2075.1991.tb07788.x; JAKUBCZAK JL, 1991, P NATL ACAD SCI USA, V88, P3295, DOI 10.1073/pnas.88.8.3295; JAKUBCZAK JL, 1990, J MOL BIOL, V212, P37, DOI 10.1016/0022-2836(90)90303-4; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KIMMEL BE, 1987, MOL CELL BIOL, V7, P1465, DOI 10.1128/MCB.7.4.1465; Maniatis T., 1982, MOL CLONING; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; Martin SL, 1991, CURR OPIN GENET DEV, V1, P505, DOI 10.1016/S0959-437X(05)80199-6; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MINCHIOTTI G, 1991, MOL CELL BIOL, V11, P5171, DOI 10.1128/MCB.11.10.5171; MIZROKHI LJ, 1988, CELL, V54, P685, DOI 10.1016/S0092-8674(88)80013-8; MOUNT SM, 1985, MOL CELL BIOL, V5, P1630, DOI 10.1128/MCB.5.7.1630; NISSON PE, 1988, NUCLEIC ACIDS RES, V16, P1431, DOI 10.1093/nar/16.4.1431; OKADA N, 1991, TRENDS ECOL EVOL, V6, P358, DOI 10.1016/0169-5347(91)90226-N; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROIHA H, 1981, NATURE, V290, P749, DOI 10.1038/290749a0; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TEMIN HM, 1989, NATURE, V339, P254, DOI 10.1038/339254a0; VARMUS H, 1989, MOBILE DNA, P53; VOYTAS DF, 1988, NATURE, V336, P242, DOI 10.1038/336242a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; XIONG Y, 1988, MOL CELL BIOL, V8, P114, DOI 10.1128/MCB.8.1.114; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; [No title captured]	56	899	929	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					595	605		10.1016/0092-8674(93)90078-5	http://dx.doi.org/10.1016/0092-8674(93)90078-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679954				2022-12-24	WOS:A1993KP16500014
J	VIVILLE, S; NEEFJES, J; LOTTEAU, V; DIERICH, A; LEMEUR, M; PLOEGH, H; BENOIST, C; MATHIS, D				VIVILLE, S; NEEFJES, J; LOTTEAU, V; DIERICH, A; LEMEUR, M; PLOEGH, H; BENOIST, C; MATHIS, D			MICE LACKING THE MHC CLASS II-ASSOCIATED INVARIANT CHAIN	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL DETERMINANTS; HLA-DR MOLECULES; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; IA ANTIGENS; INTRACELLULAR-TRANSPORT; EXOGENOUS ANTIGEN; PEPTIDE BINDING	The invariant chain (Ii) has aroused much interest because of its close association with major histocompatibility complex (MHC) class II molecules. Various functions have been proposed for it; several of these have received experimental support, but most have not been definitively proven, owing largely to uncertainties inherent in the experimental systems employed. We have now generated a line of mice devoid of the invariant chain by introducing a drastic mutation into the Ii gene. Cells from mutant animals show aberrant transport of MHC class II molecules, resulting in reduced levels of class II complexes at the surface, and these do not have the typical compact conformation indicative of tight peptide binding. Consequently, mutant cells present protein antigens very poorly and mutant mice are deficient in producing and at negatively selecting CD4+ T cells.	NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; FAC MED PARIS,INST CORDELIERS,F-75006 PARIS,FRANCE	Netherlands Cancer Institute; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	VIVILLE, S (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,F-67085 STRASBOURG,FRANCE.		Neefjes, Jacques J.C./H-8780-2017; lotteau, vincent/M-8143-2014	Neefjes, Jacques J.C./0000-0001-6763-2211; Lotteau, Vincent/0000-0003-0997-3282; Viville, Stephane/0000-0002-5088-3003				ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BECK BN, 1986, J IMMUNOL, V136, P2953; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1411, DOI 10.1002/eji.1830210613; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CLEASSONWELSH L, 1985, J IMMUNOL, V135, P3551; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; ELLIOTT WL, 1987, J IMMUNOL, V138, P2949; FISCH A, 1992, EUR J IMMUNOL, V22, P1413, DOI 10.1002/eji.1830220613; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HACKETT CJ, 1991, J IMMUNOL, V146, P2944; HAMMERLING GJ, 1990, IMMUNOL TODAY, V11, P337; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOBORI JA, 1992, P NATL ACAD SCI USA, V89, P2940, DOI 10.1073/pnas.89.7.2940; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KOCH N, 1991, CURR OPIN IMMUNOL, V3, P10, DOI 10.1016/0952-7915(91)90069-D; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LEMEUR M, 1985, NATURE, V316, P38, DOI 10.1038/316038a0; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LORENZ RG, 1988, J IMMUNOL, V141, P4124; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MICHALEK MT, 1992, J IMMUNOL, V148, P1016; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORENO J, 1991, J IMMUNOL, V147, P3306; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OZATO K, 1980, J IMMUNOL, V124, P533; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; RATH S, 1992, EUR J IMMUNOL, V22, P2121, DOI 10.1002/eji.1830220824; REGNIERVIGOUROX A, 1988, J IMMUNOL, V140, P1069; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SEKALY RP, 1988, P NATL ACAD SCI USA, V85, P1209, DOI 10.1073/pnas.85.4.1209; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SIMONIS S, 1989, J IMMUNOL, V143, P3619; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WEI BY, 1991, INT IMMUNOL, V3, P833, DOI 10.1093/intimm/3.8.833; WEISS S, 1991, CELL, V64, P797; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	72	350	353	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					635	648		10.1016/0092-8674(93)90081-Z	http://dx.doi.org/10.1016/0092-8674(93)90081-Z			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679955				2022-12-24	WOS:A1993KP16500017
J	XUE, D; HORVITZ, HR				XUE, D; HORVITZ, HR			INHIBITION OF THE CAENORHABDITIS-ELEGANS CELL-DEATH PROTEASE CED-3 BY A CED-3 CLEAVAGE SITE IN BACULOVIRUS P35 PROTEIN	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; C-ELEGANS; GENE CED-3; EXPRESSION; TRANSCRIPTION; PURIFICATION; APOPTOSIS; REQUIRES; ENCODES; HOMOLOG	THE baculovirus protein p35 inhibits programmed cell death in such diverse animals as insects, nematodes and mammals(1-5). Here we show that p35 protein is a substrate for and inhibitor of the Caenorhabditis elegans cell-death protease CED-3 (refs 6, 7) and a substrate for four CED-3-like vertebrate cysteine protease activities implicated in apoptosis in mammals(7-14). A p35 mutation that greatly reduced p35 activity in vitro as a CED-3 substrate and inhibitor abolished p35 activity in vivo in protecting against cell death in C. elegans. Introduction of the CED-3 cleavage site in p35 into the cowpox virus protein crmA, which inhibits mammalian apoptosis(14-19) but not programmed cell death in C. elegans, caused crmA to block CED3-mediated cell death. These observations suggest that p35 may prevent programmed cell death in C. elegans and other species by acting as a competitive inhibitor of cysteine proteases.			XUE, D (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			XUE, DING/0000-0002-8429-8136				CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P75; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; FRIESEN PD, 1987, J VIROL, V61, P2264, DOI 10.1128/JVI.61.7.2264-2272.1987; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	435	449	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					248	251		10.1038/377248a0	http://dx.doi.org/10.1038/377248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7675111				2022-12-24	WOS:A1995RV87200045
J	VANHOUTTE, PM				VANHOUTTE, PM			THE MALE PARADOX	LANCET			English	Editorial Material							17-BETA-ESTRADIOL; RABBIT				VANHOUTTE, PM (corresponding author), INST RECH INT SERVIER,6 PL PLEIADES,F-92415 COURBEVOIE,FRANCE.		Vanhoutte, Paul M/B-4533-2009					FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; LAWRENCE WD, 1986, ENDOCRINOLOGY, V119, P2803, DOI 10.1210/endo-119-6-2803; Luscher T.F., 1990, ENDOTHELIUM MODULATO, V001-228; MILLER VM, 1990, AM J PHYSIOL, V258, pR1502, DOI 10.1152/ajpregu.1990.258.6.R1502; YUE P, 1995, CIRCULATION, V91, P1154, DOI 10.1161/01.CIR.91.4.1154	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					717	717		10.1016/S0140-6736(95)91497-8	http://dx.doi.org/10.1016/S0140-6736(95)91497-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658867				2022-12-24	WOS:A1995RU81000003
J	DEVRIES, A; VANOOSTROM, CTM; HOFHUIS, FMA; DORTANT, PM; BERG, RJW; DEGRUIJL, FR; WESTER, PW; VANKREIJL, CF; CAPEL, PJA; VANSTEEG, H; VERBEEK, SJ				DEVRIES, A; VANOOSTROM, CTM; HOFHUIS, FMA; DORTANT, PM; BERG, RJW; DEGRUIJL, FR; WESTER, PW; VANKREIJL, CF; CAPEL, PJA; VANSTEEG, H; VERBEEK, SJ			INCREASED SUSCEPTIBILITY TO ULTRAVIOLET-B AND CARCINOGENS OF MICE LACKING THE DNA EXCISION-REPAIR GENE XPA	NATURE			English	Article							A XERODERMA-PIGMENTOSUM; DAMAGED DNA; SEQUENCE; AFFINITY; CELLS	XERODERMA pigmentosum patients with a defect in the nucleotide-excision repair gene XPA are characterized by, for example, a >1,000-fold higher risk of developing sunlight-induced skin cancer(1-3). Nucleotide-excision repair (NER) is involved in the removal of a wide spectrum of DNA lesions, The XPA protein functions in a pre-incision step, the recognition of DNA damage(4-7). To permit the functional analysis of the XPA gene in vivo, we have generated XPA-deficient mice by gene targeting in embryonic stem cells, The YPA(-/-) mice appear normal, at least until the age of 13 months, XPA(-/-) mice are highly susceptible to ultraviolet (UV)-B-induced skin and eye tumours and to 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin tumours, We conclude that the XPA-deficient mice strongly mimic the phenotype of humans with xeroderma pigmentosum.	NATL INST PUBL HLTH & ENVIRONM PROTECT, CARCINOGENESIS & MUTAGENESIS LAB, 3720 BA BILTHOVEN, NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT, PATHOL LAB, 3720 BA BILTHOVEN, NETHERLANDS; UNIV UTRECHT, DEPT IMMUNOL, 3584 CX UTRECHT, NETHERLANDS; UNIV UTRECHT, DEPT DERMATOL, 3584 CX UTRECHT, NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University								ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DEGRUIJL FR, 1991, CANCER RES, V51, P979; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HOELJMAKERS JHJ, 1990, CANCER CELL, V2, P311; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; MAHER VM, 1984, PHARMACOL THERAPEUT, V25, P395, DOI 10.1016/0163-7258(84)90006-8; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SATOKATA I, 1992, HUM GENET, V88, P603, DOI 10.1007/BF02265282; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; VANOOSTROM CTM, 1994, NUCLEIC ACIDS RES, V22, P11, DOI 10.1093/nar/22.1.11; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x	17	345	350	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 14	1995	377	6545					169	173		10.1038/377169a0	http://dx.doi.org/10.1038/377169a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675086				2022-12-24	WOS:A1995RU75400054
J	SANDS, AT; ABUIN, A; SANCHEZ, A; CONTI, CJ; BRADLEY, A				SANDS, AT; ABUIN, A; SANCHEZ, A; CONTI, CJ; BRADLEY, A			HIGH SUSCEPTIBILITY TO ULTRAVIOLET-INDUCED CARCINOGENESIS IN MICE LACKING XPC	NATURE			English	Article							PIGMENTOSUM GROUP-C; CLONING; CELLS; GENE	COMPROMISE Of genetic information by mutation may result in the dysregulation of cellular growth control and subsequent tumour formation, Xeroderma pigmentosum (XP) is a rare autosomal disease characterized by hypersensitivity of the skin to sunlight and >1,000-fold increased risk of skin cancers in sun-exposed parts of the body, Cell fusion studies have revealed eight complementation groups In XP (A-G, and an XP-variant form); group C is one of the most common forms of the disease(1). We have isolated a mouse homologue of the human gene for XP group C and generated XPC-deficient mice by using embryonic stem cell technology. Mice homozygous for the XPC mutant allele (xpc(m1)/xpc(m1)) are viable and do not exhibit an increased susceptibility to spontaneous tumour generation at one year of age, However, xpc(m1)/xpc(m1) mice were found to be highly susceptible to ultraviolet-induced carcinogenesis compared with mice heterozygous for the mutant allele (xpc(m1)/+) and wild-type controls. Homozygous xpc(m1) mutant mice also display a spectrum of ultraviolet-exposure-related pathological skin and eye changes consistent with the human disease xeroderma pigmentosum group C.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV TEXAS MD ANDERSON,DEPT CARCINOGENESIS,SMITHVILLE,TX 78959	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center				Bradley, Allan/0000-0002-2349-8839				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1973, CANCER RES, V33, P362; GALIEGUEZOUITINA S, 1989, CARCINOGENESIS, V10, P1961, DOI 10.1093/carcin/10.10.1961; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HURT MA, 1993, PATHOLOGY INCIPIENT, P8; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEVER WF, 1990, HISTOPATHOLOGY SKIN, P523; LI L, 1993, NAT GENET, V5, P413, DOI 10.1038/ng1293-413; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; STICH HF, 1973, MUTAT RES, V17, P127, DOI 10.1016/0027-5107(73)90261-3; TAKEBE H, 1972, MUTAT RES, V15, P98, DOI 10.1016/0027-5107(72)90099-1	16	215	223	2	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 14	1995	377	6545					162	165		10.1038/377162a0	http://dx.doi.org/10.1038/377162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU754	7675084				2022-12-24	WOS:A1995RU75400052
J	VANDEVEN, PJG; BEUTLER, JJ; KAATEE, R; BEEK, FJA; MALI, WPTM; GEYSKES, GG; KOOMANS, HA				VANDEVEN, PJG; BEUTLER, JJ; KAATEE, R; BEEK, FJA; MALI, WPTM; GEYSKES, GG; KOOMANS, HA			TRANSLUMINAL VASCULAR STENT FOR OSTIAL ATHEROSCLEROTIC RENAL-ARTERY STENOSIS	LANCET			English	Note							RENOVASCULAR HYPERTENSION; ANGIOPLASTY	We implanted transluminal stents in 24 hypertensive patients with a critical atherosclerotic ostial renal artery stenosis (28 arteries). Immediate revascularisation was successful in all. Follow-up angiography at 6 months, available in 18 patients, revealed restenosis twice. In another patient restenosis was suspected and confirmed by angiography at 2 months. Hence, the total restenosis rate was 3 of 19 patients (16%) and 3 of 23 arteries (13%). Two patients developed renal insufficiency due to cholesterol embolism. In the remaining 22 patients renal function improved (n=8) or stabilised (n=14). Although all had to resume antihypertensive treatment, blood pressure normalised in 15 patients, improved in one, remained unchanged in five and worsened in one.	UNIV UTRECHT HOSP,DEPT HYPERTENS & NEPHROL,3508 GA UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT RADIOL,3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center			Mali, Willem PThM/I-1123-2014	Mali, Willem PThM/0000-0003-4391-0904				CANZANELLO VJ, 1989, HYPERTENSION, V13, P163, DOI 10.1161/01.HYP.13.2.163; DEAN RH, 1991, ANN SURG, V213, P446, DOI 10.1097/00000658-199105000-00010; Martin L G, 1992, J Vasc Interv Radiol, V3, P619, DOI 10.1016/S1051-0443(92)72907-8; NOVICK AC, 1987, JAMA-J AM MED ASSOC, V257, P498, DOI 10.1001/jama.257.4.498; PICOLI G, 1995, NEPHROL DIAL TRANSPL, V10, P444; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; REES CR, 1991, RADIOLOGY, V181, P505; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SOS TA, 1983, NEW ENGL J MED, V309, P274, DOI 10.1056/NEJM198308043090504; STRANDNESS DE, 1994, AM J KIDNEY DIS, V24, P630, DOI 10.1016/S0272-6386(12)80224-1	10	141	144	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					672	674		10.1016/S0140-6736(95)92283-0	http://dx.doi.org/10.1016/S0140-6736(95)92283-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658821				2022-12-24	WOS:A1995RU04800012
J	GIOVANNUCCI, E; EGAN, KM; HUNTER, DJ; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; SPEIZER, FE				GIOVANNUCCI, E; EGAN, KM; HUNTER, DJ; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; SPEIZER, FE			ASPIRIN AND THE RISK OF COLORECTAL-CANCER IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; LARGE-BOWEL; INDOMETHACIN TREATMENT; COLON CARCINOGENESIS; INTESTINAL TUMORS; REDUCED RISK; ADENOMAS; POLYPS; RATS	Background. Most data suggest that the regular use of aspirin reduces the risk of colorectal cancer, but some apparently conflicting evidence exists. The effects of the dose and the duration of aspirin consumption on the risk of colorectal cancer are not well understood. Methods. We determined rates of colorectal cancer according to the number of consecutive years of regular aspirin use (defined as two or more tablets per week) among women in the Nurses' Health Study who reported regular aspirin use on three consecutive questionnaires (1980, 1982, and 1984) and compared the rates in this group with the rates among women who said they did not use aspirin. Cases of cancer occurring from 1984 through 1992 (the eight years after the 1984 questionnaire) were included. Results. From 1984 through 1992, we documented 331 new cases of colorectal cancer during 551,651 person-years of follow-up. Women who consistently took two or more aspirin tablets per week had no appreciable reduction in the risk of colorectal cancer as compared with nonusers after four years (relative risk, 1.06; 95 percent confidence interval, 0.78 to 1.45) or after five to nine years (relative risk, 0.84; 95 percent confidence interval, 0.55 to 1.28). There was a slight reduction in risk among women who took aspirin for 10 to 19 years, but it was not statistically significant (relative risk, 0.70; 95 percent confidence interval, 0.41 to 1.20). However, there was a statistically significant reduction after 20 years of consistent use of aspirin (relative risk, 0.56; 95 percent confidence interval, 0.36 to 0.90; P for trend=0.008). The maximal reduction in risk was observed among women who took four to six tablets per week; higher doses had a similar apparent benefit. Controlling for risk factors for colorectal cancer, including diet, did not change the results, and the earlier diagnosis and removal of colorectal adenomas among aspirin users did not account for the results. Conclusions. Regular aspirin use, at doses similar to those recommended for the prevention of cardiovascular disease, substantially reduces the risk of colorectal cancer. However, this benefit may not be evident until after at least a decade of regular aspirin consumption.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	GIOVANNUCCI, E (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [P01CA055075, R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOMALASKI JS, 1986, BIOCHEM BIOPH RES CO, V139, P115, DOI 10.1016/S0006-291X(86)80087-0; CRAVEN PA, 1992, CARCINOGENESIS, V13, P541, DOI 10.1093/carcin/13.4.541; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HEATH CW, 1994, CANCER-AM CANCER SOC, V74, P2885, DOI 10.1002/1097-0142(19941115)74:10<2885::AID-CNCR2820741023>3.0.CO;2-P; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; ISOMAKI HA, 1978, J CHRON DIS, V31, P691, DOI 10.1016/0021-9681(78)90071-1; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LAAKSO M, 1986, J RHEUMATOL, V13, P522; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MARNETT LJ, 1992, CANCER RES, V52, P5575; MERETO E, 1994, CANCER LETT, V76, P5, DOI 10.1016/0304-3835(94)90127-9; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NARISAWA T, 1981, CANCER RES, V41, P1954; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; PINCZOWSKI D, 1994, GASTROENTEROLOGY, V107, P117, DOI 10.1016/0016-5085(94)90068-X; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; POWIS G, 1994, EUR J CANCER, V30A, P1138, DOI 10.1016/0959-8049(94)90473-1; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; REDDY BS, 1987, CANCER RES, V47, P5340; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Ruffin M. T., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P600; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; TRUJILLO MA, 1994, DIGEST DIS SCI, V39, P2260; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105	42	879	914	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					609	614		10.1056/NEJM199509073331001	http://dx.doi.org/10.1056/NEJM199509073331001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637720	Bronze			2022-12-24	WOS:A1995RR84000001
J	HAYERHARTL, MK; MARTIN, J; HARTL, FU				HAYERHARTL, MK; MARTIN, J; HARTL, FU			ASYMMETRICAL INTERACTION OF GROEL AND GROES IN THE ATPASE CYCLE OF ASSISTED PROTEIN-FOLDING	SCIENCE			English	Article							SURFACE-PLASMON RESONANCE; HEAT-SHOCK PROTEINS; CHAPERONIN PROTEINS; CENTRAL CAVITY; HYDROLYSIS; BINDING; MITOCHONDRIA; HSP60	The chaperonins GroEL and GroES of Escherichia coli facilitate protein folding in an adenosine triphosphate (ATP)-dependent reaction cycle, The kinetic parameters for the formation and dissociation of GroEL-GroES complexes were analyzed by surface plasmon resonance. Association of GroES and subsequent ATP hydrolysis in the interacting GroEL toroid resulted in the formation of a stable GroEL:ADP:GroES complex. The complex dissociated as a result of ATP hydrolysis in the opposite GroEL toroid, without formation of a symmetrical GroEL:(GroES)(2) intermediate. Dissociation was accelerated by the addition of unfolded polypeptide. Thus, the functional chaperonin unit is an asymmetrical GroEL:GroES complex, and substrate protein plays an active role in modulating the chaperonin reaction cycle.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019; Hayer-Hartl, Manajit/V-8078-2017	Hayer-Hartl, Manajit/0000-0001-8213-6742	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050908] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50908] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HAYERHARTL MK, UNPUB; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5664; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567	42	134	137	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 11	1995	269	5225					836	841		10.1126/science.7638601	http://dx.doi.org/10.1126/science.7638601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638601				2022-12-24	WOS:A1995RN65000044
J	SUNG, P; ROBBERSON, DL				SUNG, P; ROBBERSON, DL			DNA STRAND EXCHANGE MEDIATED BY A RAD51-SSDNA NUCLEOPROTEIN FILAMENT WITH POLARITY OPPOSITE TO THAT OF RECA	CELL			English	Article							ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; INITIATION SITE; RAD51; RECOMBINATION; PROTEIN; GENE; SEQUENCE; HOMOLOG; REPAIR	Yeast RAD51 gene functions in genetic recombination and DNA double-strand break repair. In vitro, in the presence of ATP and replication protein A, RAD51 protein pairs single-stranded DNA (ssDNA) with homologous double-stranded DNA (dsDNA) and catalyzes strand exchange between the synapsed DNA partners. Electron microscopic analyses show that RAD51 forms helical filaments on both ssDNA and dsDNA, in which the DNA is highly extended. However, results presented here indicate that only the RAD51-ssDNA nucleoprotein filament is functionally relevant. Strand exchange is arrested when heterology is encountered in the duplex partner, and analysis of the configuration of the terminal joint thus formed reveals that pairing and strand exchange initiate at the 5' end of the complementary strand in the linear duplex, a reaction polarity opposite to that of the bacterial prototype RecA.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	SUNG, P (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ESO7061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; KMIEC EB, 1983, CELL, V33, P857, DOI 10.1016/0092-8674(83)90028-4; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LOVETT ST, 1987, GENETICS, V116, P547; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	26	420	434	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					453	461		10.1016/0092-8674(95)90434-4	http://dx.doi.org/10.1016/0092-8674(95)90434-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634335	Bronze			2022-12-24	WOS:A1995RP24200015
J	LABARCA, C; NOWAK, MW; ZHANG, HY; TANG, LX; DESHPANDE, P; LESTER, HA				LABARCA, C; NOWAK, MW; ZHANG, HY; TANG, LX; DESHPANDE, P; LESTER, HA			CHANNEL GATING GOVERNED SYMMETRICALLY BY CONSERVED LEUCINE RESIDUES IN THE M2 DOMAIN OF NICOTINIC RECEPTORS	NATURE			English	Article							DESENSITIZATION	IN nicotinic acetylcholine receptors (nAChR), as well as glycine, GABA(A) (gamma-aminobutyric acid), serotonin (5-HT3), and GluCl glutamate receptors, a leucine residue at the approximate midpoint of the M2 transmembrane domain (the 9' position(1)) is conserved across most known subunits(2). Structural data for the nAChR suggest that the Leu 9' residues occupy a 'kink' in each of the five M2 helices and point into the closed channel; in the opening step, the M2 helices rotate so that Leu 9' side chains no longer occlude the conduction pathway(3), Mutation of Leu 9' to one of several other residues slows desensitization and increases sensitivity to agonist(4-6). We have exploited the alpha(2) beta gamma delta stoichiometry of muscle nAChR to express receptors with m(s)* = 0 to 5 Leu 9'Scr mutated subunits. Strikingly, each Leu 9'Ser mutation shifts the dose-response relation for ACh to the left by similar to 10-fold; a nAChR with m(s)* = 4 is 10(4)-fold more sensitive than the wild type, The results suggest that each of the five Leu 9' residues participates independently and symmetrically in a key step in the structural transition between the closed and open states.			LABARCA, C (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.			Nowak, Mark/0000-0001-5097-2682				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; CHARNET P, 1990, NEURON, V2, P87; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; JACKSON MB, 1984, P NATL ACAD SCI-BIOL, V81, P3901, DOI 10.1073/pnas.81.12.3901; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SIGURDSON W, 1994, BIOPHYS J, V66, pA212; SIGWORTH FJ, 1987, BIOPHYS J, V52, P147; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WATHEY JC, 1979, BIOPHYS J, V27, P145, DOI 10.1016/S0006-3495(79)85208-X; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030	15	266	269	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					514	516		10.1038/376514a0	http://dx.doi.org/10.1038/376514a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637783				2022-12-24	WOS:A1995RN62200044
J	SIMMONDS, AJ; BROOK, WJ; COHEN, SM; BELLE, JB				SIMMONDS, AJ; BROOK, WJ; COHEN, SM; BELLE, JB			DISTINGUISHABLE FUNCTIONS FOR ENGRAILED AND INVECTED IN ANTERIOR-POSTERIOR PATTERNING IN THE DROSOPHILA WING	NATURE			English	Article							GENE; EXPRESSION; DISK; MELANOGASTER; DIRECTS; LOCUS	SUBDIVISION Of the limb primordia into compartments initiates pattern formation in the developing limbs(1,2). Interaction between distinctly specific cells in adjacent compartments leads to localized expression of the secreted signalling molecules Wingless (Wg) or Decapentaplegic (Dpp) which in turn organize pattern and control growth of the limbs The homeobox gene engrailed has been implicated in specification of posterior cell fate(9-12), whereas the LIM/homeobox gene, apterous, specifies dorsal fate(3). Removing apterous activity causes a complete transformation from dorsal to ventral fate and leads to the formation of an ectopic dorsal-ventral boundary organizer(3,13). By contrast, removing engrailed activity causes incomplete morphological transformation from posterior to anterior fate in the wing(10,14,15), and fails to produce an ectopic anterior-posterior organizer (reviewed in ref, 2). Complete transformation can only be effected by simultaneously eliminating activity of engrailed and its homologue invected(16-18). Here we show that invected functions principally to specify posterior cell fate. Thus establishment of the anterior-posterior organizer and control of compartment identity are genetically distinguishable, and invected may perform a discrete subset of functions previously ascribed to engrailed.	UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2E9,CANADA; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	University of Alberta; European Molecular Biology Laboratory (EMBL)			Simmonds, Andrew J/D-3675-2009; Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163; Simmonds, Andrew/0000-0001-7165-9302				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Eker R, 1929, HEREDITAS, V12, P217; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GUBB D, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P236, DOI 10.1007/BF00848252; HIDALGO A, 1994, CURR BIOL, V4, P1087, DOI 10.1016/S0960-9822(00)00247-5; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LAWRENCE PA, 1982, EMBO J, V7, P827; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; SANICOLA M, 1995, GENETICS, V139, P745; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; SERRANO N, 1995, DEVELOPMENT, V121, P1691; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, IN PRESS DEVELOPMENT; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1990, GENETICS, V125, P833; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WURST W, 1994, DEVELOPMENT, V120, P2065	31	103	106	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					424	427		10.1038/376424a0	http://dx.doi.org/10.1038/376424a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630417				2022-12-24	WOS:A1995RM63900051
J	FERAT, JL; MICHEL, F				FERAT, JL; MICHEL, F			GROUP-II SELF-SPLICING INTRONS IN BACTERIA	NATURE			English	Article							DNA BINDING-PROTEIN; ESCHERICHIA-COLI; PURPLE BACTERIA; CHLOROPLASTS; SEQUENCES; ORIGINS	LIKE nuclear premessenger introns, group II self-splicing introns are excised from primary transcripts as branched molecules, containing a 2'-5' phosphodiester bond. For this reason, it is widely believed that the ribozyme (catalytic RNA) core of group II introns, or some evolutionarily related molecule, gave rise to the RNA components of the spliceosomal splicing machinery of the eukaryotic nucleus1. One difficulty with this hypothesis has been the restricted distribution of group II introns. Unlike group I self-splicing introns, which interrupt not only organelle primary transcripts, but also some bacterial and nuclear genes2-5, group II introns seemed to be confined to mitochondrial and chloroplast genomes (reviewed in ref. 6). We now report the discovery of group II introns both in cyanobacteria (the ancestors of chloroplasts7) and the gamma subdivision of purple bacteria, or proteobacteria8, whose alpha subdivision probably gave rise to mitochondria9. At least one of these introns actually self-splices in vitro.			FERAT, JL (corresponding author), CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel F, 1989, MOL REPROD DEV, V1, P146; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; HERDMAN M, 1973, J GEN MICROBIOL, V79, P233, DOI 10.1099/00221287-79-2-233; HIOM K, 1991, J BACTERIOL, V173, P7368, DOI 10.1128/jb.173.22.7368-7373.1991; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; KUCK U, 1989, MOL GEN GENET, V218, P257, DOI 10.1007/BF00331276; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; PEEBLES CL, 1987, COLD SPRING HARB SYM, V52, P223, DOI 10.1101/SQB.1987.052.01.027; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SKELLY PJ, 1991, CURR GENET, V20, P115, DOI 10.1007/BF00312773; STACKEBRANDT E, 1988, INT J SYST BACTERIOL, V38, P321, DOI 10.1099/00207713-38-3-321; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; WOESE CR, 1985, SYST APPL MICROBIOL, V6, P25, DOI 10.1016/S0723-2020(85)80007-2; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	26	205	209	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					358	361		10.1038/364358a0	http://dx.doi.org/10.1038/364358a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	7687328				2022-12-24	WOS:A1993LN57000064
J	GOVAN, JRW; BROWN, PH; MADDISON, J; DOHERTY, CJ; NELSON, JW; DODD, M; GREENING, AP; WEBB, AK				GOVAN, JRW; BROWN, PH; MADDISON, J; DOHERTY, CJ; NELSON, JW; DODD, M; GREENING, AP; WEBB, AK			EVIDENCE FOR TRANSMISSION OF PSEUDOMONAS-CEPACIA BY SOCIAL CONTACT IN CYSTIC-FIBROSIS	LANCET			English	Article								Pulmonary colonisation with Pseudomonas cepacia in patients with cystic fibrosis can be associated with increased morbidity and mortality. The modes of transmission of P cepacia are, however, unclear. We used selective media and phenotypic and genomic typing systems to investigate the acquisition of P cepacia by adults with cystic fibrosis. An analysis of isolates from 210 patients attending regional clinics in Edinburgh and Manchester between 1986 and 1992 showed that the main cause of increased isolations of P cepacia from 1989 was the emergence of an epidemic strain that had spread between patients in both clinics. Epidemiological evidence indicated that social contact was important in spread of the epidemic strain within and between clinics. We suggest that guidelines to limit the acquisition of P cepacia should not be restricted to patients in hospital, and that intimate or frequent social contact is associated with a high risk of cross-infection.	MONSAL HOSP,DEPT CHEST DIS,MANCHESTER,ENGLAND; WESTERN GEN HOSP,RESP UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	GOVAN, JRW (corresponding author), UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ANDERSON DJ, 1991, J CLIN MICROBIOL, V29, P648, DOI 10.1128/JCM.29.3.648-649.1991; Brown P, 1993, THORAX, V48, P425; BUTLER SL, 1992, 11TH INT CYST FIBR C; Editorial, 1992, LANCET, V339, P1385; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; GLADMAN G, 1992, ARCH DIS CHILD, V67, P192, DOI 10.1136/adc.67.2.192; GOVAN JRW, 1985, J CLIN MICROBIOL, V22, P490, DOI 10.1128/JCM.22.4.490-494.1985; GOVAN JRW, 1992, BRIT MED BULL, V48, P912, DOI 10.1093/oxfordjournals.bmb.a072585; ISLES A, 1984, J PEDIATR-US, V104, P206, DOI 10.1016/S0022-3476(84)80993-2; LEWIN C, 1993, ANTIMICROB AGENTS CH, V37, P123, DOI 10.1128/AAC.37.1.123; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; MILLARJONES L, 1992, LANCET, V340, P491, DOI 10.1016/0140-6736(92)91817-R; NELSON JW, 1991, LANCET, V338, P1525, DOI 10.1016/0140-6736(91)92342-Y; NELSON JW, IN PRESS J MED MICRO; SIMMONDS EJ, 1990, ARCH DIS CHILD, V65, P874, DOI 10.1136/adc.65.8.874; SMITH DL, 1992, LANCET, V339, P252, DOI 10.1016/0140-6736(92)90063-9; TABLAN OC, 1987, CHEST, V91, P527, DOI 10.1378/chest.91.4.527; 1992, NEWSLETTER ASS C APR, P2	18	381	385	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					15	19		10.1016/0140-6736(93)91881-L	http://dx.doi.org/10.1016/0140-6736(93)91881-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	7686239				2022-12-24	WOS:A1993LK98500010
J	HAYGOOD, MG; DISTEL, DL				HAYGOOD, MG; DISTEL, DL			BIOLUMINESCENT SYMBIONTS OF FLASHLIGHT FISHES AND DEEP-SEA ANGLERFISHES FORM UNIQUE LINEAGES RELATED TO THE GENUS VIBRIO	NATURE			English	Article							16S RIBOSOMAL-RNA; LUMINOUS BACTERIA; KRYPTOPHANARON-ALFREDI; EVOLUTION; ANOMALOPIDAE; PHYLOGENY; SEAWATER; GENES	BIOLUMINESCENT symbioses range from facultative associations to highly adapted. apparently obligate ones1. The family Anomalopidae (flashlight fishes) encompasses five genera of tropical reef fishes that have large suborbital light organs2. The suborder Ceratioidei (deep-sea anglerfishes) contains 11 families. In nine of these, females have a bioluminescent lure3,4 that contains bacterial symbionts5. In all other fish light-organ symbioses (occuring in 10 families in 5 orders6), the symbionts belong to three Photobacterium species7; nonsymbiotic luminous bacteria are Vibrio species8. The bacteria are extracellular and tightly packed in tubules that communicate with the exterior7, releasing bacteria into the gut of the host or the surrounding sea water. The released bacteria are usually cultivable and can contribute to planktonic populations9,10. Although anomalopids release bacteria9 and ceratioids have pores that would allow release, the fate of these bacteria is unknown and they cannot be cultured by standard isolation techniques. We report here phylogenetic analysis of 16S ribosomal RNA gene sequences from light organs that show that anomalopid and ceratioid symbionts are not known luminous bacteria, but are new groups related to Vibrio spp. They are characterized by host specificity, deep divergence between symbionts from different genera (anomalopids) or families (ceratioids) and, possibly, parallel divergence of hosts and symbionts.			HAYGOOD, MG (corresponding author), UNIV CALIF SAN DIEGO, SCRIPPS INST OCEANOG, DIV MARINE BIOL RES, 0202, LA JOLLA, CA 92093 USA.		Distel, Daniel/A-8047-2017	Distel, Daniel/0000-0002-3860-194X				Bertelsen E., 1986, P1371; BERTELSEN E, 1984, SPEC PUBL AM SOC ICH, V1, P323; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; DORSCH M, 1992, INT J SYST BACTERIOL, V42, P58, DOI 10.1099/00207713-42-1-58; EDWARDS DB, 1991, APPL ENVIRON MICROB, V57, P1082, DOI 10.1128/AEM.57.4.1082-1088.1991; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; HAYGOOD MG, 1986, GENE, V45, P203, DOI 10.1016/0378-1119(86)90255-6; HAYGOOD MG, 1984, MAR BIOL, V78, P249, DOI 10.1007/BF00393010; HAYGOOD MG, 1992, J MAR BIOL ASSOC UK, V72, P149, DOI 10.1017/S0025315400048852; HAYGOOD MG, 1990, ARCH MICROBIOL, V154, P496, DOI 10.1007/BF00245234; Herring P.J., 1987, Journal of Bioluminescence and Chemiluminescence, V1, P147, DOI 10.1002/bio.1170010303; HERRING PJ, 1982, OCEANOGR MAR BIOL, V20, P415; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; LEISMAN G, 1980, SCIENCE, V208, P1271, DOI 10.1126/science.208.4449.1271; MACDONELL MT, 1985, SYST APPL MICROBIOL, V6, P171, DOI 10.1016/S0723-2020(85)80051-5; NEALSON K, 1981, ANN NY ACAD SCI, V361, P76, DOI 10.1111/j.1749-6632.1981.tb46512.x; NEALSON KH, 1984, MICROBIAL ECOL, V10, P69, DOI 10.1007/BF02011596; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P2017, DOI 10.1093/nar/19.suppl.2017; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; OLSEN GJ, 1992, FASTDNAML; ROSENBLATT RH, 1991, P BIOL SOC WASH, V104, P328; ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348; Stackebrandt E, 1990, NUCL ACID TECHNIQUES, P115; Swofford D., 1990, B ILL NAT HIST SURV; VALLE O, 1990, SYST APPL MICROBIOL, V13, P257, DOI 10.1016/S0723-2020(11)80195-5; WOLFE CJ, 1991, BIOL BULL, V181, P135, DOI 10.2307/1542496	28	65	67	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1993	363	6425					154	156		10.1038/363154a0	http://dx.doi.org/10.1038/363154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	7683390				2022-12-24	WOS:A1993LB80100045
J	SINGHAL, A; DOHERTY, JF; RAYNES, JG; MCADAM, KPWJ; THOMAS, PW; SERJEANT, BE; SERJEANT, GR				SINGHAL, A; DOHERTY, JF; RAYNES, JG; MCADAM, KPWJ; THOMAS, PW; SERJEANT, BE; SERJEANT, GR			IS THERE AN ACUTE-PHASE RESPONSE IN STEADY-STATE SICKLE-CELL DISEASE	LANCET			English	Article							GROWTH; CHILDREN; ANEMIA	Metabolic and serum changes during steady-state homozygous sickle cell (SS) disease are consistent with an acute-phase response and raise the possibility that inflammation occurs in SS disease even during the steady state. To test this hypothesis, we measured concentrations of acute phase reactants in patients with SS disease, in patients with sickle cell haemoglobin C (SC) disease, and in normal (AA) control subjects. The concentrations of C-reactive protein and serum amyloid A were increased above 10 mg/L and 5 mg/L, respectively (our definition of an acute-phase response) in 18% (26/143) of subjects with SS disease even when they were symptom free, in 17% (6/35) of subjects with SC disease, and in 1% (1/80) of AA controls (p < 0.001). We suggest that subclinical vaso-occlusion may generate a covert inflammatory response and that the cytokine mediators of this response may contribute to the metabolic abnormalities and growth failure in sickle cell disease.	UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA; UNIV LONDON LONDON SCH HYG & TROP MED,DIV CLIN SCI,LONDON WC1E 7HT,ENGLAND	University West Indies Mona Jamaica; University of London; London School of Hygiene & Tropical Medicine	SINGHAL, A (corresponding author), UNIV W INDIES,MRC LABS,KINGSTON 7,JAMAICA.		Raynes, John G/G-7932-2011	Raynes, John G/0000-0002-8536-1328; Thomas, Peter/0000-0003-2478-4324				AKINOLA NO, 1992, J CLIN PATHOL, V45, P902, DOI 10.1136/jcp.45.10.902; BADALOO A, 1989, CLIN SCI, V77, P93, DOI 10.1042/cs0770093; BECTON DL, 1989, J PEDIATR-US, V115, P99, DOI 10.1016/S0022-3476(89)80339-7; BETKE GH, 1959, J CLIN PATHOL, V184, P1877; COOPER ES, 1990, EUR J CLIN NUTR, V44, P285; ENWONWU CO, 1990, AM J MED SCI, V300, P366, DOI 10.1097/00000441-199012000-00005; GILLESPIE SH, 1991, J CLIN PATHOL, V44, P228, DOI 10.1136/jcp.44.3.228; GRIMBLE R F, 1990, Nutrition Research Reviews, V3, P193, DOI 10.1079/NRR19900012; HEYMAN MB, 1985, LANCET, V1, P903; JACKSON AA, 1988, EUR J CLIN NUTR, V42, P491; KELTS DG, 1979, GASTROENTEROLOGY, V76, P720; KRAEMER R, 1978, ACTA PAEDIATR SCAND, V67, P33, DOI 10.1111/j.1651-2227.1978.tb16273.x; LUCAS GS, 1985, BRIT J HAEMATOL, V59, P363, DOI 10.1111/j.1365-2141.1985.tb03001.x; ODONKOR P O, 1982, IRCS (International Research Communications System) Medical Science Library Compendium, V10, P303; ODONKOR PO, 1984, HUM NUTR-CLIN NUTR, V38C, P23; PEPYS MB, 1981, LANCET, V1, P653; PETERSON CM, 1975, BLOOD, V46, P583; PHEBUS CK, 1988, AM J HEMATOL, V29, P67, DOI 10.1002/ajh.2830290203; PRASAD AS, 1976, JAMA-J AM MED ASSOC, V235, P2396, DOI 10.1001/jama.235.22.2396; STEVENS MCG, 1986, PEDIATRICS, V78, P124; TANGNEY CC, 1989, AM J HEMATOL, V32, P161, DOI 10.1002/ajh.2830320302; 1988, J CLIN PATHOL, V41, P1203	22	58	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					651	653		10.1016/0140-6736(93)90418-G	http://dx.doi.org/10.1016/0140-6736(93)90418-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	7680738				2022-12-24	WOS:A1993KR61300003
J	BAZZATO, G; FRACASSO, A; GAMBARO, G; BAGGIO, B				BAZZATO, G; FRACASSO, A; GAMBARO, G; BAGGIO, B			USE OF GLYCOSAMINOGLYCANS TO INCREASE EFFICIENCY OF LONG-TERM CONTINUOUS PERITONEAL-DIALYSIS	LANCET			English	Note							CELL-PROLIFERATION; HEPARIN	Long-term continuous ambulatory peritoneal dialysis (CAPD) frequently induces progressive structural changes in the peritoneal membrane, leading to dialysis failure. Because heparin and glycosaminoglycans favourably remodel anatomical barriers exposed to injury, we studied the effect of intraperitoneal administration of glycosaminoglycans on peritoneal dialysis efficiency. 16 CAPD patients received glycosaminoglycans for 30 days followed by a 30-day wash-out. Glycosaminoglycans in urea and creatinine dialysate-to-plasma ratios significantly increased (means 0.86 and 0.78 at baseline, 0.92 and 0.82 at 30 days, respectively). Peritoneal protein loss was reduced, and serum albumin concentration increased. We now need to assess whether glycosaminoglycans can postpone dialysis failure in the long term.	UNIV PADUA,INST INTERNAL MED,PADUA,ITALY; UNIV PADUA,DIV NEPHROL,PADUA,ITALY; UMBERTO I GEN HOSP,DIV NEPHROL,MESTRE,ITALY	University of Padua; University of Padua; ULSS 3 Serenissima								BREBOROWICZ A, 1994, NEPHRON, V67, P346, DOI 10.1159/000187991; CAENAZZO C, 1995, NEPHROL DIAL TRANSPL, V10, P175; CHAIMOVITZ C, 1994, KIDNEY INT, V45, P1226, DOI 10.1038/ki.1994.163; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COFFEY AK, 1985, AM J PATHOL, V120, P248; GAMBARO G, 1992, KIDNEY INT, V42, P285, DOI 10.1038/ki.1992.288; GAMBARO G, 1994, KIDNEY INT, V46, P797, DOI 10.1038/ki.1994.335; GAMBARO G, 1994, J AM SOC NEPHROL, V5, P448; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369	10	48	49	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					740	741						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658876				2022-12-24	WOS:A1995RU81000012
J	WHITEWAY, MS; WU, CL; LEEUW, T; CLARK, K; FOURESTLIEUVIN, A; THOMAS, DY; LEBERER, E				WHITEWAY, MS; WU, CL; LEEUW, T; CLARK, K; FOURESTLIEUVIN, A; THOMAS, DY; LEBERER, E			ASSOCIATION OF THE YEAST PHEROMONE RESPONSE G-PROTEIN BETA-GAMMA-SUBUNITS WITH THE MAP KINASE SCAFFOLD STE5P	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; GENE; PATHWAY; ENCODES; SEQUENCE; MUTANTS; RAS; TRANSCRIPTION	The mating response pathway of the yeast Saccharomyces cerevisiae includes a heterotrimeric guanine nucleotide-binding protein (G protein) that activates a mitogen-activated protein (MAP) kinase cascade by an unknown mechanism. An amino-terminal fragment of the MAP kinase scaffold protein Ste5p that interfered with pheromone-induced cell cycle arrest was identified. A haploid-specific interaction between the amino terminus of Ste5p and the G protein beta subunit Ste4p was also detected in a two-hybrid assay, and the product of a signaling-defective allele of STE4 was defective in this interaction. In cells with a constitutively activated pheromone response pathway, epitope-tagged Ste4p was coimmunoprecipitated with Ste5p, Thus, association of the G protein and the MAP kinase cassette via the scaffolding protein Ste5p may transmit the G protein signal.			WHITEWAY, MS (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,6100 ROYALMOUNT AVE,MONTREAL,PQ H4P 2R2,CANADA.		Fourest-Lieuvin, Anne/AGA-6504-2022; Thomas, David/M-7661-2017	Fourest-Lieuvin, Anne/0000-0003-1325-6788; Thomas, David/0000-0002-8854-762X				BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI KY, 1994, CELL, V78, P499; CLARK KL, 1993, MOL CELL BIOL, V13, P1; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARLOW E, 1988, ANTIBODIES LABORATOR; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MUKAI Y, 1993, MOL CELL BIOL, V13, P2050, DOI 10.1128/MCB.13.4.2050; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NEER EJ, 1995, CELL, V80, P247; NER SS, 1988, DNA-J MOLEC CELL BIO, V7, P127, DOI 10.1089/dna.1988.7.127; PERLMAN R, 1993, P NATL ACAD SCI USA, V90, P5474, DOI 10.1073/pnas.90.12.5474; PRINTEN JA, 1994, GENETICS, V138, P609; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; WHITEWAY M, 1992, BIOCHEM CELL BIOL, V70, P1230, DOI 10.1139/o92-169; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	43	155	162	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1572	1575		10.1126/science.7667635	http://dx.doi.org/10.1126/science.7667635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667635				2022-12-24	WOS:A1995RU81300040
J	MANSON, JE; WILLETT, WC; STAMPFER, MJ; COLDITZ, GA; HUNTER, DJ; HANKINSON, SE; HENNEKENS, CH; SPEIZER, FE				MANSON, JE; WILLETT, WC; STAMPFER, MJ; COLDITZ, GA; HUNTER, DJ; HANKINSON, SE; HENNEKENS, CH; SPEIZER, FE			BODY-WEIGHT AND MORTALITY AMONG WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELATIVE WEIGHT; CIGARETTE-SMOKING; UNITED-STATES; MASS INDEX; FOLLOW-UP; OBESITY; HEALTH; DEATH; RISK; MEN	Background. The relation between body weight and overall mortality remains controversial despite considerable investigation. Methods. We examined the association between body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and both overall mortality and mortality from specific causes in a cohort of 115,195 U.S. women enrolled in the prospective Nurses' Health Study. These women were 30 to 55 years of age and free of known cardiovascular disease and cancer in 1976. During 16 years of follow-up, we documented 4726 deaths, of which 881 were from cardiovascular disease, 2586 from cancer, and 1259 from other causes. Results. In analyses adjusted only for age, we observed a J-shaped relation between body-mass index and overall mortality. When women who had never smoked were examined separately, no increase in risk was observed among the leaner women, and a more direct relation between weight and mortality emerged (P for trend <0.001). In multivariate analyses of women who had never smoked and had recently had stable weight, in which the first four years of follow-up were excluded, the relative risks of death from all causes for increasing categories of body-mass index were as follows: body-mass index <19.0 (the reference category), relative risk = 1.0, 19.0 to 21.9, relative risk = 1.2; 22.0 to 24.9, relative risk = 1.2; 25.0 to 26.9, relative risk = 1.3; 27.0 to 28.9, relative risk = 1.6; 29.0 to 31.9, relative risk = 2.1; and greater than or equal to 32.0, relative risk = 2.2 (P for trend <0.001). Among women with body-mass indexes of 32.0 or higher who had never smoked, the relative risk of death from cardiovascular disease was 4.1 (95 percent confidence interval, 2.1 to 7.7), and that of death from cancer was 2.1 (95 percent confidence interval, 1.4 to 3.2), as compared with the risk among women with body-mass indexes below 19.0. A weight gain of 10 kg (22 lb) or more since the age of 18 was associated with increased mortality in middle adulthood. Conclusions. Body weight and mortality from all causes were directly related among these middle-aged women. Lean women did not have excess mortality. The lowest mortality rate was observed among women who weighed at least 15 percent less than the U.S. average for women of similar age and among those whose weight had been stable since early adulthood.	HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NIDDK NIH HHS [DK 36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COMSTOCK GW, 1966, AM J EPIDEMIOL, V83, P548, DOI 10.1093/oxfordjournals.aje.a120606; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GARRISON RJ, 1993, INT J OBESITY, V17, P417; GARRISON RJ, 1983, JAMA-J AM MED ASSOC, V249, P2199, DOI 10.1001/jama.249.16.2199; HARLAN WR, 1988, AM J EPIDEMIOL, V128, P1065; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HENNEKENS CH, 1979, LANCET, V1, P1390; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LINDSTED K, 1991, INT J OBESITY, V15, P397; MANN GV, 1974, NEW ENGL J MED, V291, P178, DOI 10.1056/NEJM197407252910405; MANN GV, 1974, NEW ENGL J MED, V291, P226, DOI 10.1056/NEJM197408012910504; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROMIEU I, 1988, AM J CLIN NUTR, V47, P406, DOI 10.1093/ajcn/47.3.406; SCHROLL M, 1981, DAN MED BULL, V28, P106; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; TROY LM, IN PRESS INT J OBES; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; VANDENBROUCKE JP, 1984, JAMA-J AM MED ASSOC, V252, P2859, DOI 10.1001/jama.252.20.2859; VANITALLIE TB, 1979, AM J CLIN NUTR, V32, P2723, DOI 10.1093/ajcn/32.12.2723; WAALER HT, 1984, ACTA MED SCAND, P1; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; [No title captured]; 1990, NUTRITION YOUR HLTH; 1959, STAT B METROP INSUR, V40, P1; [No title captured]; 1987, VITAL HLTH STATIS 11, V238; 1980, BUILD STUDY 1979	41	1450	1495	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					677	685		10.1056/NEJM199509143331101	http://dx.doi.org/10.1056/NEJM199509143331101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637744				2022-12-24	WOS:A1995RV22700001
J	HORTON, R				HORTON, R			WILL DUESBERG NOW CONCEDE DEFEAT	LANCET			English	Editorial Material																		DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DUESBERG P, 1994, INT ARCH ALLERGY IMM, V103, P118, DOI 10.1159/000236617	2	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					656	656		10.1016/S0140-6736(95)92277-6	http://dx.doi.org/10.1016/S0140-6736(95)92277-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7658817				2022-12-24	WOS:A1995RU04800006
J	FENTON, JE; HONE, S; GORMLEY, P; ODWYER, TP; MCSHANE, DP; TIMON, CI				FENTON, JE; HONE, S; GORMLEY, P; ODWYER, TP; MCSHANE, DP; TIMON, CI			LESSON OF THE WEEK - HYPOPHARYNGEAL TUMORS MAY BE MISSED ON FLEXIBLE ESOPHAGOGASTROSCOPY	BRITISH MEDICAL JOURNAL			English	Article									ST JAMES HOSP,DEPT OTOLARYNGOL,DUBLIN 8,IRELAND; ST JAMES HOSP,DEPT HEAD & NECK SURG,DUBLIN 8,IRELAND; UNIV COLL HOSP GALWAY,GALWAY,IRELAND; MATER MISERICORDIAE HOSP,DUBLIN 7,IRELAND; MANCH HOSP,DUBLIN,IRELAND	Trinity College Dublin; Trinity College Dublin; Ollscoil na Gaillimhe-University of Galway; Mater Misericordiae University Hospital; University College Dublin								ADAMS GL, 1993, OTOLARYNGOLOGY HEAD, V3, P1955; BINGHAM BJ, 1986, ANN ROYAL COLLEGE SU, V68, P22; Logemann JA, 1983, EVALUATION TREATMENT; MARAN AGD, 1993, STELL MARANS HEAD NE, P161; PAIROLERO PC, 1989, PRINCIPLES SURG, P1103; THOMSON HG, 1989, J LARYNGOL OTOL, V103, P399, DOI 10.1017/S0022215100109053	6	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					623	624		10.1136/bmj.311.7005.623	http://dx.doi.org/10.1136/bmj.311.7005.623			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7663260	Green Published			2022-12-24	WOS:A1995RT72300027
J	HEINSOHN, R; PACKER, C				HEINSOHN, R; PACKER, C			COMPLEX COOPERATIVE STRATEGIES IN GROUP-TERRITORIAL AFRICAN LIONS	SCIENCE			English	Article							PRISONERS-DILEMMA GAME; RECIPROCAL ALTRUISM; EVOLUTION; SCROUNGERS; PRODUCERS; FOOD	Female lions (Panthera leo) showed persistent individual differences in the extent to which they participated in group-territorial conflict. When intergroup encounters were simulated by playback of aggressive vocalizations, some individuals consistently led the approach to the recorded intruder, whereas others lagged behind and avoided the risks of fighting, The lead females recognized that certain companions were laggards but failed to punish them, which suggests that cooperation is not maintained by reciprocity. Modification of the ''odds'' in these encounters revealed that some females joined the group response when they were most needed, whereas other lagged even farther behind. The complexity of these responses emphasizes the great diversity of individual behavior in this species and the inadequacy of current theory to explain cooperation in large groups.	UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities	HEINSOHN, R (corresponding author), AUSTRALIAN NATL UNIV,DIV BOT & ZOOL,CANBERRA,ACT 0200,AUSTRALIA.							AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Barnard C. J., 1984, PRODUCERS SCROUNGERS; BARNARD CJ, 1981, ANIM BEHAV, V29, P543, DOI 10.1016/S0003-3472(81)80117-0; BOYD R, 1987, NATURE, V327, P58, DOI 10.1038/327058a0; BOYD R, 1988, J THEOR BIOL, V132, P337, DOI 10.1016/S0022-5193(88)80219-4; BOYD R, 1994, J THEOR BIOL, V168, P29; DUGATKIN LA, 1992, TRENDS ECOL EVOL, V7, P202, DOI 10.1016/0169-5347(92)90074-L; GRINNELL J, 1995, ANIM BEHAV, V49, P95, DOI 10.1016/0003-3472(95)80157-X; LIMA SL, 1989, AM NAT, V134, P828, DOI 10.1086/285015; MCCOMB K, 1993, P ROY SOC B-BIOL SCI, V252, P59, DOI 10.1098/rspb.1993.0046; MCCOMB K, 1994, ANIM BEHAV, V47, P379, DOI 10.1006/anbe.1994.1052; MESTERTONGIBBONS M, 1992, Q REV BIOL, V67, P267, DOI 10.1086/417658; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; NOWAK M, 1993, P NATL ACAD SCI USA, V90, P5091, DOI 10.1073/pnas.90.11.5091; PACKER C, 1990, AM NAT, V136, P1, DOI 10.1086/285079; PACKER C, 1988, AM NAT, V132, P159, DOI 10.1086/284844; Packer C., 1985, P173; PACKER C, 1977, NATURE, V265, P441, DOI 10.1038/265441a0; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; PUSEY AE, 1987, BEHAVIOUR, V101, P275, DOI 10.1163/156853987X00026; PUSEY AE, 1994, BEHAV ECOL, V5, P362, DOI 10.1093/beheco/5.4.362; Schaller G. B., 1972, SERENGETI LION; SCHEEL D, 1991, ANIM BEHAV, V4, P697; STANDER PE, 1992, BEHAV ECOL SOCIOBIOL, V29, P445; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; VICKERY WL, 1991, AM NAT, V137, P847, DOI 10.1086/285197; WILKINSON GS, 1984, NATURE, V308, P181, DOI 10.1038/308181a0; WILSON DS, 1994, TRENDS ECOL EVOL, V9, P442, DOI 10.1016/0169-5347(94)90134-1	29	256	263	1	122	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1260	1262		10.1126/science.7652573	http://dx.doi.org/10.1126/science.7652573			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7652573				2022-12-24	WOS:A1995RR84200032
J	QUINTERO, RA; JOHNSON, MP; ROMERO, R; SMITH, C; ARIAS, F; GUEVARAZULOAGA, F; COTTON, DB; EVANS, MI				QUINTERO, RA; JOHNSON, MP; ROMERO, R; SMITH, C; ARIAS, F; GUEVARAZULOAGA, F; COTTON, DB; EVANS, MI			IN-UTERO PERCUTANEOUS CYSTOSCOPY IN THE MANAGEMENT OF FETAL LOWER OBSTRUCTIVE UROPATHY	LANCET			English	Article							URINARY-TRACT OBSTRUCTION; CONGENITAL HYDRONEPHROSIS; RENAL-FUNCTION; INTERVENTION; INUTERO; BIOCHEMISTRY; DIAGNOSIS	In fetuses with lower obstructive uropathy, sonography cannot establish the cause of obstruction. We assessed whether percutaneous fetal cystoscopy could be useful in the evaluation and treatment of obstructive defects in utero. We inserted a fibreoptic endoscope through the lumen of the needle or trocar into the fetal bladder at the time of vesicocentesis or vesicoamniotic-shunt placement and looked at the the urethra, bladder neck, and ureteral orifices. Urethral vesicoamniotic shunting was considered in suitable cases; otherwise a percutaneous shunt was inserted. Fetal cystoscopy was possible in 11 of 13 patients referred. The bladder mucosa appeared haemorrhagic or oedematous in three, The ureteral orifices were seen in 9/11 fetuses, dilation was seen in five, but was only suspected in two by ultrasound. Ureteral webs were noted in two other fetuses. Two of seven fetuses underwent urethral vesicoamniotic shunting; urethral patency was achieved with urethral probing alone in one fetus. The remaining four fetuses were shunted with a standard technique. Fetal cystoscopy helps define the underlying conditions responsible for sonographic findings of lower obstructive uropathy, and allows the introduction of new treatments.	WAYNE STATE UNIV,HUTZEL HOSP,DEPT OBSTET & GYNECOL,DETROIT,MI; WAYNE STATE UNIV,HUTZEL HOSP,DEPT PEDIAT UROL,DETROIT,MI; ST JOHNS MERCY HOSP,DEPT OBSTET & GYNECOL,ST LOUIS,MO; CENT UNIV VENEZUELA,HOSP UNIV CARACAS,UNIDAD PERINATOL,CARACAS,VENEZUELA; NICHHD,PERINATOL RES BRANCH,BETHESDA,MD	Wayne State University; Wayne State University; Saint Johns Mercy Medical Center; University of Central Venezuela; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Romero, Roberto/A-5268-2019	Romero, Roberto/0000-0002-4448-5121				BECK AD, 1971, J UROLOGY, V105, P784, DOI 10.1016/S0022-5347(17)61629-X; BERKOWITZ RL, 1982, AM J OBSTET GYNECOL, V144, P367, DOI 10.1016/0002-9378(82)90239-3; BLACHAR A, 1994, PEDIATR NEPHROL, V8, P30, DOI 10.1007/BF00868254; CROMBLEHOLME TM, 1990, AM J OBSTET GYNECOL, V162, P1239, DOI 10.1016/0002-9378(90)90026-4; ELDER JS, 1987, LANCET, V2, P1007; EVANS MI, 1991, OBSTET GYNECOL, V77, P545; GOLBUS MS, 1982, AM J OBSTET GYNECOL, V142, P383, DOI 10.1016/S0002-9378(16)32377-8; GRANNUM PA, 1990, DIAGNOSTIC ULTRASOUN, P433; HARRISON MR, 1982, J PEDIATR SURG, V17, P965, DOI 10.1016/S0022-3468(82)80476-4; HARRISON MR, 1981, JAMA-J AM MED ASSOC, V246, P635, DOI 10.1001/jama.246.6.635; JOHNSON MP, 1994, AM J OBSTET GYNECOL, V170, P1770; KEATING M, 1993, PEDIATRIC SURGERY; KRAMER SA, 1983, J UROLOGY, V130, P641, DOI 10.1016/S0022-5347(17)51383-X; MANNING FA, 1983, AM J OBSTET GYNECOL, V145, P819, DOI 10.1016/0002-9378(83)90685-3; MCFADYEN IR, 1983, BRIT J OBSTET GYNAEC, V90, P342, DOI 10.1111/j.1471-0528.1983.tb08921.x; MULLER F, 1993, OBSTET GYNECOL, V82, P813; NAKAYAMA DK, 1986, J PEDIATR SURG, V21, P43, DOI 10.1016/S0022-3468(86)80651-0; NICOLINI U, 1991, PRENATAL DIAG, V11, P159, DOI 10.1002/pd.1970110305; NICOLINI U, 1987, LANCET, V2, P1338; NOIA G, 1989, Fetal Therapy, V4, P40; PADUANO L, 1991, J UROLOGY, V146, P1094, DOI 10.1016/S0022-5347(17)38009-6; QUINTERO RA, 1993, AM J OBSTET GYNECOL, V168, P1552, DOI 10.1016/S0002-9378(11)90797-2; QUINTERO RA, 1995, AM J OBSTET GYNECOL, V172, P206, DOI 10.1016/0002-9378(95)90115-9; REUSS A, 1988, LANCET, V2, P949; WILKINS IA, 1987, AM J OBSTET GYNECOL, V157, P694, DOI 10.1016/S0002-9378(87)80031-5	25	115	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					537	540		10.1016/S0140-6736(95)91381-5	http://dx.doi.org/10.1016/S0140-6736(95)91381-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658779				2022-12-24	WOS:A1995RQ98600009
J	RUSSELL, MB; OLESEN, J				RUSSELL, MB; OLESEN, J			INCREASED FAMILIAL RISK AND EVIDENCE OF GENETIC-FACTOR IN MIGRAINE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-POPULATION; PREVALENCE; AURA; HEADACHE	Objective-To investigate familial occurrence of migraine with and without aura. Design-Familial occurrence of migraine with and without aura among first degree relatives and spouses of probands with migraine with or without aura and those who had never had migraine. All interviews of first degree relatives and spouses were done blindly by a neurological resident. The operational diagnostic criteria of the International Headache Society were used. Setting-General population from Copenhagen County. Subjects-The 378 probands had 1109 first degree relatives and 229 spouses. Main outcome measures-Patterns of familial aggregation of migraine with and without aura as assessed by calculation of the population relative risk. Results-Compared with the general population the first degree relatives of probands with migraine without aura had 1.9 times the risk of migraine without aura and 1.4 times the risk of migraine with aura. The first degree relatives of probands with migraine with aura had nearly four times the risk of migraine with aura and no increased risk of migraine without aura. The first degree relatives of probands who had never had migraine had no increased risk of migraine either with or without aura. Spouses of probands with migraine without aura had 1.4 times the risk of migraine without aura whereas spouses of probands with migraine with aura had no increased risk of migraine with aura. Conclusion-The different familial patterns indicate that migraine without aura and migraine with aura have a different aetiology. Migraine without aura seems to be caused by a combination of genetic and environmental factors whereas migraine with aura is probably determined largely or exclusively by genetic factors.			RUSSELL, MB (corresponding author), UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT NEUROL,DK-2600 GLOSTRUP,DENMARK.			Olesen, Jes/0000-0002-6712-2702				ALLEN W, 1930, ARCH INTERN MED, V13, P590; BAIER WK, 1985, NEUROPEDIATRICS, V16, P84, DOI 10.1055/s-2008-1052549; BAROLIN GS, 1969, FORTSCHR NEUROL P I, V37, P521; CHRISTIANSEN V, 1925, REV NEUROL, V32, P854; DALSGAARDNIELSE.T, 1973, HEADACHE, V12, P168; DALSGAARDNIELSE.T, 1965, ACTA NEUROL SCAND, V41, P287; DAMICO D, 1991, ITAL J NEUROL SCI, V12, P581, DOI 10.1007/BF02336955; DEVOTO M, 1986, CEPHALALGIA, V6, P101, DOI 10.1046/j.1468-2982.1986.0602101.x; GOODELL H, 1954, ARCH NEUROLOGY PSYCH, V72, P375; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; LEONE M, 1994, CEPHALALGIA, V14, P280, DOI 10.1046/j.1468-2982.1994.1404280.x; MOCHI M, 1993, CEPHALALGIA, V13, P389, DOI 10.1046/j.1468-2982.1993.1306389.x; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLESEN J, 1981, LANCET, V2, P438; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; RASMUSSEN BK, 1992, INT J EPIDEMIOL, V21, P1138, DOI 10.1093/ije/21.6.1138; RUSSELL MB, 1995, INT J EPIDEMIOL, V24, P612, DOI 10.1093/ije/24.3.612; RUSSELL MB, 1993, NEUROLOGY, V43, P1369, DOI 10.1212/WNL.43.7.1369; SELBY G, 1960, J NEUROL NEUROSUR PS, V23, P23, DOI 10.1136/jnnp.23.1.23; VILATELA EA, 1992, NEUROEPIDEMIOLOGY, V11, P46, DOI 10.1159/000110908; WATERS WE, 1971, BRIT MED J, V2, P77, DOI 10.1136/bmj.2.5753.77; WEISS KM, 1982, J CHRON DIS, V35, P539, DOI 10.1016/0021-9681(82)90073-X	25	272	276	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					541	544		10.1136/bmj.311.7004.541	http://dx.doi.org/10.1136/bmj.311.7004.541			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7663209	Green Published			2022-12-24	WOS:A1995RR73700019
J	LIM, M; JACKSON, TA; ANFINRUD, PA				LIM, M; JACKSON, TA; ANFINRUD, PA			BINDING OF CO TO MYOGLOBIN FROM A HEME POCKET DOCKING SITE TO FORM NEARLY LINEAR FE-C-O	SCIENCE			English	Article							CARBON-MONOXIDE; INFRARED-SPECTROSCOPY; DIOXYGEN ADDUCT; RESOLUTION; PICOSECOND; CARBONMONOXYMYOGLOBIN; CARBOXYMYOGLOBIN; PHOTOSELECTION; OXYMYOGLOBIN; HEMOPROTEINS	The relative orientations of carbon monoxide (CO) bound to and photodissociated from myoglobin in solution have been determined with time-resolved infrared polarization spectroscopy. The bound CO is oriented less than or equal to 7 degrees from the heme normal, corresponding to nearly linear Fe-C-O. Upon dissociation from the Fe, CO becomes trapped in a docking site that orientationally constrains it to lie approximately in the plane of the heme. Because the bound and ''docked'' CO are oriented in nearly orthogonal directions, CO binding from the docking site is suppressed. These solution results help to establish how myoglobin discriminates against CO, a controversial issue dominated by the misconception that Fe-C-O is bent.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045306, R01DK045306] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANI J, 1986, CHEM PHYS LETT, V131, P147, DOI 10.1016/0009-2614(86)80533-4; ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; ANFINRUD PA, 1994, P SOC PHOTO-OPT INS, V2138, P107, DOI 10.1117/12.181348; ANSARI A, 1993, BIOPHYS J, V64, P838, DOI 10.1016/S0006-3495(93)81445-0; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; CAUGHEY WS, 1970, ANN NY ACAD SCI, V174, P148, DOI 10.1111/j.1749-6632.1970.tb49781.x; CHENG XD, 1991, J MOL BIOL, V220, P381, DOI 10.1016/0022-2836(91)90020-7; CHURG AK, 1978, J CHEM PHYS, V68, P1913, DOI 10.1063/1.435918; COLLMAN J P, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1326, DOI 10.1073/pnas.71.4.1326; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P3333, DOI 10.1073/pnas.73.10.3333; Eaton W A, 1981, Methods Enzymol, V76, P175; HANSEN PA, 1989, CHEM PHYS, V131, P49, DOI 10.1016/0301-0104(89)87080-6; HENRY ER, 1993, BIOPHYS J, V64, P869, DOI 10.1016/S0006-3495(93)81447-4; HU SZ, 1994, J AM CHEM SOC, V116, P11187, DOI 10.1021/ja00103a056; IVANOV D, 1994, J AM CHEM SOC, V116, P4139, DOI 10.1021/ja00088a084; JAMESON GB, 1980, J AM CHEM SOC, V102, P3224, DOI 10.1021/ja00529a055; JAMESON GB, 1978, INORG CHEM, V17, P850, DOI 10.1021/ic50182a012; JEWSBURY P, 1994, BIOPHYS J, V67, P2236, DOI 10.1016/S0006-3495(94)80708-8; JEWSBURY P, 1994, J AM CHEM SOC, V116, P11586, DOI 10.1021/ja00104a056; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LANDAW SA, 1970, J CLIN INVEST, V49, P914, DOI 10.1172/JCI106311; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; LOCKE B, 1995, CHEM PHYS, V190, P155, DOI 10.1016/0301-0104(94)00360-M; MOFFAT K, COMMUNICATION; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PENG SM, 1976, J AM CHEM SOC, V98, P8032, DOI 10.1021/ja00441a025; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PISTORIUS CWFT, 1959, J CHEM PHYS, V31, P1439, DOI 10.1063/1.1730631; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROTHBERG LJ, 1991, P SPIE INT SOC OPT E, V1599, P309; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Stryer L., 1988, BIOCHEMISTRY-US; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TRAYLOR TG, 1981, ACCOUNTS CHEM RES, V14, P102, DOI 10.1021/ar00064a002	38	296	299	2	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					962	966		10.1126/science.7638619	http://dx.doi.org/10.1126/science.7638619			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638619				2022-12-24	WOS:A1995RP73800031
J	OLSON, CR; GETTNER, SN				OLSON, CR; GETTNER, SN			OBJECT-CENTERED DIRECTION SELECTIVITY IN THE MACAQUE SUPPLEMENTARY EYE FIELD	SCIENCE			English	Article							UNILATERAL NEGLECT; VISUAL NEGLECT; RHESUS-MONKEYS; REPRESENTATION; RECOGNITION; MOVEMENTS; POSITION	Object-centered spatial awareness-awareness of the location, relative to an object, of its parts-plays an important role in many aspects of perception, imagination, and action. One possible basis for this capability is the existence in the brain of neurons with sensory receptive fields or motor action fields that are defined relative to an object-centered frame. In experiments described here, neuronal activity was monitored in the supplementary eye field of macaque monkeys making eye movements to the right or left end of a horizontal bar, Neurons were found to fire differentially as a function of the end of the bar to which an eye movement was made. This is direct evidence for the existence of neurons sensitive to the object-centered direction of movements.			OLSON, CR (corresponding author), UNIV MARYLAND,COLL DENT SURG,DEPT ORAL & CRANIOFACIAL BIOL SCI,BALTIMORE,MD 21201, USA.				NINDS NIH HHS [1 F32 NS09452, R01 NS27287] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009452, R01NS027287] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGUIN M, 1993, CORTEX, V29, P349, DOI 10.1016/S0010-9452(13)80188-8; BEHRMANN M, 1994, J COGNITIVE NEUROSCI, V6, P1, DOI 10.1162/jocn.1994.6.1.1; BEHRMANN M, 1994, ATTENTION PERFORMANC, V15, pCH14; BISIACH E, 1978, CORTEX, V14, P129, DOI 10.1016/S0010-9452(78)80016-1; BISIACH E, 1979, BRAIN, V102, P609, DOI 10.1093/brain/102.3.609; CARAMAZZA A, 1990, COGNITIVE NEUROPSYCH, V7, P391, DOI 10.1080/02643299008253450; CARAMAZZA A, 1990, NATURE, V346, P267, DOI 10.1038/346267a0; CHEN LL, 1995, J NEUROPHYSIOL, V73, P1104; Connor C. E., 1994, Society for Neuroscience Abstracts, V20, P1054; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; DERENZI E, 1989, CORTEX, V25, P231, DOI 10.1016/S0010-9452(89)80039-5; DRIVER J, 1991, COGNITIVE NEUROPSYCH, V8, P475, DOI 10.1080/02643299108253384; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; MCCLELLAND JL, 1986, PARALLEL DISTRIBUTED, V2, pCH16; MITZ AR, 1989, NEUROSCI LETT, V106, P157, DOI 10.1016/0304-3940(89)90219-X; NIKI H, 1974, BRAIN RES, V68, P197, DOI 10.1016/0006-8993(74)90389-8; OGDEN JA, 1985, NEUROPSYCHOLOGIA, V23, P273, DOI 10.1016/0028-3932(85)90112-5; OLSHAUSEN BA, 1993, J NEUROSCI, V13, P4700; REMMEL RS, 1984, IEEE T BIO-MED ENG, V31, P388, DOI 10.1109/TBME.1984.325352; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; RUSSO GS, 1993, J NEUROPHYSIOL, V69, P800, DOI 10.1152/jn.1993.69.3.800; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; SCHLAG J, 1987, J NEUROPHYSIOL, V57, P179, DOI 10.1152/jn.1987.57.1.179; SCHLAG J, 1992, EXP BRAIN RES, V90, P302; TEHOVNIK EJ, 1993, EXP BRAIN RES, V96, P430; YOUNG AW, 1992, BRAIN, V115, P51, DOI 10.1093/brain/115.1.51	26	186	186	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					985	988		10.1126/science.7638625	http://dx.doi.org/10.1126/science.7638625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638625				2022-12-24	WOS:A1995RP73800038
J	BURGERING, BMT; COFFER, PJ				BURGERING, BMT; COFFER, PJ			PROTEIN-KINASE-B (C-AKT) IN PHOSPHATIDYLINOSITOL-3-OH INASE SIGNAL-TRANSDUCTION	NATURE			English	Article							REGULATED KINASE-2; MOLECULAR-CLONING; PATHWAYS	A serine/threonine kinase, named protein kinase B (PKB)(1) for its sequence homology to both protein kinase A and C, has previously been isolated. PKB, which is identical to the kinase Rad, was later found to be the cellular homologue of the transforming v-Akt(3). Here we show that PKB is activated by stimuli such as insulin, platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). Activation of PKB was inhibited by the phosphatidylinositol-3-OH kinase (PI(3)K) inhibitor wortmannin and by coexpression of a dominant-negative mutant of PI(3)K. PDGF receptor mutants that lack detectable associated PI(3)K activity also fail to induce PKB activation. PKB kinase activity is correlated with phosphorylation of PKB on serine. Finally, we show that a constructed Gag-PKB fusion protein, homologous to the v-akt oncogene, displays significantly increased ligand-independent kinase activity. Furthermore, this activity is sufficient to activate the p70 S6-kinase (p70(S6k)). These results suggest a role for PKB in PI(3)K-mediated signal transduction.	NETHERLANDS INST DEV BIOL, HUBRECHT LAB, 3584 CT UTRECHT, NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	BURGERING, BMT (corresponding author), UNIV UTRECHT, PHYSIOL CHEM LAB, UNIV WEG 100, 3584 CG UTRECHT, NETHERLANDS.		Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Burgering, Boudewijn/0000-0002-4044-9596				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1994, CELL GROWTH DIFFER, V5, P341; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; WENNSTROM S, 1994, ONCOGENE, V9, P651	19	1796	1848	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	1995	376	6541					599	602		10.1038/376599a0	http://dx.doi.org/10.1038/376599a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637810				2022-12-24	WOS:A1995RP75600053
J	GOSHIMA, Y; NAKAMURA, F; STRITTMATTER, P; STRITTMATTER, SM				GOSHIMA, Y; NAKAMURA, F; STRITTMATTER, P; STRITTMATTER, SM			COLLAPSIN-INDUCED GROWTH CONE COLLAPSE MEDIATED BY AN INTRACELLULAR PROTEIN RELATED TO UNC-33	NATURE			English	Article							AXONAL GUIDANCE; ELEGANS; GAP-43; OUTGROWTH; NEURONS; BRAIN	COLLAPSIN(1), a member of the newly recognized semaphorin family(2-4), contributes to axonal pathfinding during neural development by inhibiting growth cone extension(1-5). The mechanism of collapsin action is poorly understood, Here we use a Xenopus laevis oocyte expression system to identify molecules involved in collapsin signalling, because several experiments have raised the possibility that heterotrimeric GTP-binding proteins might participate in these events(6-9). A collapsin response mediator protein of relative molecular mass (M(r)) 62K (CRMP-62) required for collapsin-induced inward currents in X. laevis oocytes is isolated. CRMP-62 shares homology with UNC-33, a nematode neuronal protein required for appropriately directed axonal extension(10-12), CRMP-62 is localized exclusively in the developing chick nervous system. Introduction of anti-CRMP-62 antibodies into dorsal root ganglion neurons blocks collapsin-induced growth cone collapse. CRMP-62 appears to be an intracellular component of a signalling cascade initiated by an unidentified transmembrane collapsin-binding protein.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT NEUROBIOL,NEW HAVEN,CT 06520	Yale University; Yale University			Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; BORASIO GD, 1989, NEURON, V2, P1087; DURIEUX ME, 1992, AM J PHYSIOL, V363, pC896; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LAPOINTE G, 1994, APPL ENVIRON MICROB, V60, P888, DOI 10.1128/AEM.60.3.888-895.1994; LI W, 1992, GENETICS, V132, P675; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MORIARTY TM, 1990, G PROTEINS, P479; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; RAPER JA, 1990, NEURON, V2, P21; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; TYGYL G, 1992, J BIOL CHEM, V267, P21360; YANG YS, 1993, J BIOL CHEM, V268, P10870	22	612	626	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					509	514		10.1038/376509a0	http://dx.doi.org/10.1038/376509a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637782				2022-12-24	WOS:A1995RN62200043
J	WEILERRAVELL, D; SHUPAK, A; GOLDENBERG, I; HALPERN, P; SHOSHANI, O; HIRSCHHORN, G; MARGULIS, A				WEILERRAVELL, D; SHUPAK, A; GOLDENBERG, I; HALPERN, P; SHOSHANI, O; HIRSCHHORN, G; MARGULIS, A			PULMONARY-EDEMA AND HEMOPTYSIS INDUCED BY STRENUOUS SWIMMING	BRITISH MEDICAL JOURNAL			English	Article									IDF,MED CORPS,ISRAEL NAVAL MED INST,IL-31080 HAIFA,ISRAEL									NORSK P, 1986, EUR J APPL PHYSIOL O, V54, P608, DOI 10.1007/BF00943349; PASCOE JR, 1981, AM J VET RES, V42, P703; WEST JB, 1992, LANCET, V340, P762, DOI 10.1016/0140-6736(92)92301-U; WILMSHURST PT, 1989, LANCET, V1, P62	4	94	94	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					361	362		10.1136/bmj.311.7001.361	http://dx.doi.org/10.1136/bmj.311.7001.361			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640542	Green Published			2022-12-24	WOS:A1995RN46900016
J	TANAKA, T; AMES, JB; HARVEY, TS; STRYER, L; IKURA, M				TANAKA, T; AMES, JB; HARVEY, TS; STRYER, L; IKURA, M			SEQUESTRATION OF THE MEMBRANE-TARGETING MYRISTOYL GROUP OF RECOVERIN IN THE CALCIUM-FREE STATE	NATURE			English	Article							BINDING PROTEIN; NERVOUS-SYSTEM; TRANSLOCATION; HIPPOCALCIN; TERMINUS; CLONING; FAMILY; RODS	RECOVERIN, a retinal calcium-binding protein of relative molecular mass (M(r)) 23K, participates In the recovery phase of visual excitation and in adaptation to background light(1-3) The Ca2+-bound form of recoverin prolongs the photoresponse(4), probably by blocking phosphorylation of photoexcited rhodopsin. Retinal recoverin contains a covalently attached myristoyl group or related acyl group at its amino terminus(6) and two Ca2+-binding sites(7). Ca2+ binding to myristoylated, but not unmyristoylated, recoverin induces its translocation to bilayer membranes, indicating that the myristoyl group is essential to the read-out of calcium signals (calcium-myristoyl switch)(8,9). Here we present the solution structure of Ca2+-free, myristoylated recombinant recoverin obtained by heteronuclear multidimensional NMR spectroscopy. The myristoyl group is sequestered in a deep hydrophobic pocket formed by many aromatic and other hydrophobic residues from five flanking helices.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	TANAKA, T (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.		Harvey, Timothy S/F-9863-2013	Harvey, Timothy S/0000-0001-6270-1943; Ikura, Mitsuhiko/0000-0002-9524-1303				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BABU YS, 1988, J MOL BIOL, V24, P191; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KIM JY, 1994, J BIOL CHEM, V269, P28214; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Koch K W, 1994, Rev Physiol Biochem Pharmacol, V125, P149, DOI 10.1007/BFb0030910; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LADANT D, 1995, J BIOL CHEM, V270, P3179; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; STRYER L, 1991, J BIOL CHEM, V266, P10711; WALKER F, 1993, J BIOL CHEM, V268, P19552; YAMAGATA K, 1990, NEURON, V2, P469; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	32	278	282	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					444	447		10.1038/376444a0	http://dx.doi.org/10.1038/376444a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630423				2022-12-24	WOS:A1995RM63900058
J	BLAMEY, A; MUTRIE, N; AITCHISON, T				BLAMEY, A; MUTRIE, N; AITCHISON, T			HEALTH PROMOTION BY ENCOURAGED USE OF STAIRS	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,INST BIOMED & LIFE SCI,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow	BLAMEY, A (corresponding author), GREATER GLASGOW HLTH BOARD,GLASGOW G2 4JT,LANARK,SCOTLAND.							BROWNELL KD, 1980, AM J PSYCHIAT, V137, P1540; CAMPBELL MJ, 1993, MED STAT COMMONSENSE, P126; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; 1992, ALLIED DUNBAR NATION	4	114	116	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					289	290		10.1136/bmj.311.7000.289	http://dx.doi.org/10.1136/bmj.311.7000.289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633234	Green Published			2022-12-24	WOS:A1995RM71900021
J	HINDLER, C; NAZARETH, I; KING, M; COHEN, J; FARMER, R; GERADA, C				HINDLER, C; NAZARETH, I; KING, M; COHEN, J; FARMER, R; GERADA, C			DRUG-USERS VIEWS ON GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article									UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY CARE, LONDON N19 5NF, ENGLAND; ST GEORGE HOSP, SCH MED, LONDON SW17 0RE, ENGLAND; HURLEY CLIN, LONDON SE11 4HJ, ENGLAND	University of London; University College London; UCL Medical School; St Georges University London	HINDLER, C (corresponding author), ROYAL FREE HOSP, ACAD DEPT PSYCHIAT, LONDON NW3 2QG, ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171; Nazareth, Irwin/0000-0003-2146-9628				BENNETT T, 1986, BRIT J ADDICT, V81, P757; RICHARDS T, 1988, BRIT MED J, V296, P1082, DOI 10.1136/bmj.296.6629.1082; TELFER I, 1990, BRIT J ADDICT, V85, P137; 1993, REPORT AIDS DRUG MIS, P16	4	22	22	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					302	302		10.1136/bmj.310.6975.302	http://dx.doi.org/10.1136/bmj.310.6975.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7646645	Green Published			2022-12-24	WOS:A1995QF71700029
J	CHO, CY; MORAN, EJ; CHERRY, SR; STEPHANS, JC; FODOR, SPA; ADAMS, CL; SUNDARAM, A; JACOBS, JW; SCHULTZ, PG				CHO, CY; MORAN, EJ; CHERRY, SR; STEPHANS, JC; FODOR, SPA; ADAMS, CL; SUNDARAM, A; JACOBS, JW; SCHULTZ, PG			AN UNNATURAL BIOPOLYMER	SCIENCE			English	Article							SOLID-PHASE SYNTHESIS; PROTECTED PEPTIDE-FRAGMENTS; DRUG DISCOVERY; NUCLEIC-ACIDS; ALCOHOL RESIN; LIBRARIES; ANTISENSE; ANALOGS	A highly efficient method has been developed for the solid-phase synthesis of an ''unnatural biopolymer'' consisting of chiral aminocarbonate monomers linked via a carbamate backbone. Oligocarbamates were synthesized from N-protected p-nitrophenyl carbonate monomers, substituted with a variety of side chains, with greater than 99 percent overall coupling efficiencies per step. A spatially defined library of oligocarbamates was generated by using photochemical methods and screened for binding affinity to a monoclonal antibody. A number of high-affinity ligands were then synthesized and analyzed in solution with respect to their inhibition concentration values, water/octanol partitioning coefficients, and proteolytic stability. These and other unnatural polymers may provide new frameworks for drug development and for testing theories of protein and peptide folding and structure.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; AFFYMAX RES INST,PALO ALTO,CA 94304	University of California System; University of California Berkeley				cherry, sara/0000-0003-3956-6610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014681] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 F32 GM14681] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BR, 1965, J PHARM SCI, V54, P987, DOI 10.1002/jps.2600540708; BLAKE J, 1992, BIOCONJUGATE CHEM, V3, P510, DOI 10.1021/bc00018a008; BRAY AM, 1990, TETRAHEDRON LETT, V31, P5811, DOI 10.1016/S0040-4039(00)97966-8; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; COULL JM, 1987, TETRAHEDRON LETT, V28, P745, DOI 10.1016/S0040-4039(01)80978-3; ESCHENMOSER A, 1992, HELV CHIM ACTA, V75, P218, DOI 10.1002/hlca.19920750120; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE CM, 1961, J AM CHEM SOC, V83, P4596, DOI 10.1021/ja01483a022; LU G, 1981, J ORG CHEM, V46, P3433, DOI 10.1021/jo00330a009; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MUNGALL WS, 1977, J ORG CHEM, V42, P703, DOI 10.1021/jo00424a028; NEEDELS MC, IN PRESS P NATL ACAD; NIKAWA J, 1979, CHEM LETT, P981, DOI 10.1246/cl.1979.981; OKI M, 1971, B CHEM SOC JPN, V44, P3148, DOI 10.1246/bcsj.44.3148; PATCHORNIK CA, 1970, J AM CHEM SOC, V92, P6333; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; SMITH AB, 1992, J AM CHEM SOC, V114, P10672, DOI 10.1021/ja00052a093; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VANDERWERF S, 1967, TETRAHEDRON LETT, P689; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; WELLER DD, 1991, J ORG CHEM, V56, P6000, DOI 10.1021/jo00021a009	32	293	634	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1303	1305		10.1126/science.7689747	http://dx.doi.org/10.1126/science.7689747			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	7689747				2022-12-24	WOS:A1993LV65600021
J	OESTERLING, JE; JACOBSEN, SJ; CHUTE, CG; GUESS, HA; GIRMAN, CJ; PANSER, LA; LIEBER, MM				OESTERLING, JE; JACOBSEN, SJ; CHUTE, CG; GUESS, HA; GIRMAN, CJ; PANSER, LA; LIEBER, MM			SERUM PROSTATE-SPECIFIC ANTIGEN IN A COMMUNITY-BASED POPULATION OF HEALTHY-MEN - ESTABLISHMENT OF AGE-SPECIFIC REFERENCE RANGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MARKER; ADENOCARCINOMA; HYPERPLASIA; IMMUNOASSAY; DISEASE; DENSITY	Objective.-To define the characteristics of serum prostate-specific antigen (PSA) in a population of healthy men without clinically evident prostate cancer, but who are at risk for developing the malignancy. The influence of patient age and prostatic size on the serum PSA concentration was assessed in order to use PSA more appropriately to detect clinically significant prostate cancer at an early, potentially curable stage. Design.-Prospective, community-based study. Participants.-Between December 1989 and March 1991, 2119 healthy men aged 40 to 79 years from Olmsted County, Minnesota, were entered into a prospective study to assess the natural history of benign prostatic hyperplasia. Of these, 537 (25%) were randomly chosen to participate in a detailed clinical examination that included a serum PSA determination (Tandem-R PSA assay), digital rectal examination, and transrectal ultrasonography. Four hundred seventy-one (88%) completed the prostatic evaluation and had no evidence of prostate cancer by any of these three diagnostic tests; these men formed the study population on which all analyses were performed. Main Outcome Measure.-Serum PSA concentration, prostatic volume, and PSA density (serum PSA level/prostatic volume) as a function of patient age. Results.-The serum PSA concentration is correlated with patient age (r=.43; P<.0001) and prostatic volume (r=.55; P<.0001). Prostatic volume, in turn, is directly correlated with patient age (r=.43; P<.0001), whereas the PSA density value is only weakly correlated with patient age (r=.25; P<.001). For a healthy 60-year-old man with no evidence of prostate cancer, the serum PSA concentration increases by approximately 3.2% per year (0.04 ng/mL per year). The recommended reference range for serum PSA (95th percentile) for men aged 40 to 49 years is 0.0 to 2.5 ng/mL; for 50 to 59 years, 0.0 to 3.5 ng/mL; 60 to 69 years, 0.0 to 4.5 ng/mL; and 70 to 79 years, 0.0 to 6.5 ng/mL. Conclusions.-The serum PSA concentration is directly correlated with patient age and prostatic volume, the latter of which also is directly related to age. Thus, rather than rely on a single reference range for men of all age groups, it is more appropriate to have age-specific reference ranges. These age-specific reference ranges have the potential to make serum PSA a more discriminating tumor marker for detecting clinically significant cancers in older men (increasing specificity) and to find more potentially curable cancers in younger men (increasing sensitivity).	MERCK RES LABS, DEPT EPIDEMIOL, BLUE BELL, PA USA; MAYO CLIN & MAYO FDN, CLIN EPIDEMIOL SECT, ROCHESTER, MN 55905 USA	Merck & Company; Mayo Clinic	OESTERLING, JE (corresponding author), MAYO CLIN & MAYO FDN, DEPT UROL, 200 1ST ST SW, ROCHESTER, MN 55905 USA.			Jacobsen, Steven/0000-0002-8174-8533	NIAMS NIH HHS [AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRAWER MK, 1989, UROLOGY, V34, P62; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CHAN DW, 1987, CLIN CHEM, V33, P1916; CHUTE CG, 1993, J UROLOGY, V150, P85, DOI 10.1016/S0022-5347(17)35405-8; COLLINS GN, IN PRESS BR J RADIOL; COONER WH, 1993, CAMPBELLS UROLOGY, P1; ELVEBACK LR, 1970, J AMER MED ASSOC, V211, P69, DOI 10.1001/jama.211.1.69; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; GLENSKI WJ, 1992, MAYO CLIN PROC, V67, P249, DOI 10.1016/S0025-6196(12)60101-3; KLEE GG, IN PRESS J UROL; KLEER E, IN PRESS AM J RADIOL; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; OESTERLING JE, 1992, JAMA-J AM MED ASSOC, V267, P2236, DOI 10.1001/jama.267.16.2236; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Oesterling JE, 1991, AM UROLOGICAL ASS UP, V10, P137; PANSER LA, IN PRESS AM J EPIDEM; ROBLES JM, 1988, EUR UROL, V14, P360; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; TERRIS MK, 1991, J UROLOGY, V145, P984, DOI 10.1016/S0022-5347(17)38508-7; VESSELLA RL, 1992, CLIN CHEM, V38, P2044; WEBER JP, 1989, J UROLOGY, V141, P987, DOI 10.1016/S0022-5347(17)41083-4; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; 1992, AM UROLOGICAL ASS 19, V4, P20	29	1027	1064	0	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					860	864		10.1001/jama.270.7.860	http://dx.doi.org/10.1001/jama.270.7.860			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	7688054				2022-12-24	WOS:A1993LR61200033
J	DODWELL, D; BOND, M; ELWELL, C; GILDERSLEVE, J; PARMAR, S; OWENS, J; BULMAN, A; CRELLIN, A; ASH, D				DODWELL, D; BOND, M; ELWELL, C; GILDERSLEVE, J; PARMAR, S; OWENS, J; BULMAN, A; CRELLIN, A; ASH, D			EFFECT OF MEDICAL AUDIT ON PRESCRIPTION OF PALLIATIVE RADIOTHERAPY	BRITISH MEDICAL JOURNAL			English	Article											DODWELL, D (corresponding author), COOKRIDGE HOSP,YORKSHIRE REG CTR CANC TREATMENT,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND.							CRELLIN AM, 1990, CLIN ONCOLOGY, V1, P63; Maher E J, 1990, Health Trends, V22, P78; PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167-8140(86)80191-8; Priestman T J, 1989, Clin Oncol (R Coll Radiol), V1, P39, DOI 10.1016/S0936-6555(89)80010-X; 1991, BRIT J CANCER, V63, P265	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					24	25		10.1136/bmj.307.6895.24	http://dx.doi.org/10.1136/bmj.307.6895.24			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	7688252	Green Published, Bronze			2022-12-24	WOS:A1993LL36900021
J	HSU, YT; MOLDAY, RS				HSU, YT; MOLDAY, RS			MODULATION OF THE CGMP-GATED CHANNEL OF ROD PHOTORECEPTOR CELLS BY CALMODULIN	NATURE			English	Article							FREE CALCIUM-CONCENTRATION; CYCLIC-GMP CASCADE; OUTER SEGMENTS; RETINAL RODS; GUANYLATE-CYCLASE; BINDING-PROTEINS; CONDUCTANCE; MEMBRANES; ADAPTATION; MECHANISM	PHOTOBLEACHING of rhodopsin in rod photoreceptors activates the visual cascade system leading to a decrease in cyclic GMP and the closure of cGMP-gated channels in the rod outer segment plasma membrane1-4. Calcium plays an important role in the recovery of the rod outer segment to its dark state by regulating the resynthesis of cGMP by guanylate cyclase5-7. Here we report that calmodulin, a Ca2+-binding protein present in the rod outer segment8,9, increases the apparent Michaelis constant of the channel for cGMP. This results in a decrease in the rate of cation influx into the rod outer segment by two- to sixfold at low cGMP concentrations and has the effect of increasing the sensitivity of the channel to small changes in cGMP levels during phototransduction. Biochemical studies indicate that calcium-calmodulin binds to a protein of M(r) 240K which is tightly associated with the channel10. On the basis of these studies, Ca2+ is suggested to play a central role in photorecovery and light adaptation, not only by regulating guanylate cyclase, possibly through recoverin6,7, but also by modulating the cGMP-gated channel through calmodulin interaction with the 240K protein.	UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia								CARETTA A, 1988, EUR J BIOCHEM, V177, P139, DOI 10.1111/j.1432-1033.1988.tb14354.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COTE RH, 1986, J BIOL CHEM, V261, P2965; DLZHOOR AM, 1991, SCIENCE, V251, P915; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; GLENNEY JR, 1982, P NATL ACAD SCI-BIOL, V79, P4002, DOI 10.1073/pnas.79.13.4002; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KAUPP UB, 1992, REV PHYSL, V54, P153; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOHNKEN RE, 1981, J BIOL CHEM, V256, P2517; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; OGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P19, DOI 10.1093/oxfordjournals.jbchem.a134584; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; RATTO GM, 1988, J NEUROSCI, V8, P3240; SCHNETKAMP PPM, 1990, J GEN PHYSIOL, V96, P517, DOI 10.1085/jgp.96.3.517; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TORRE V, 1986, P NATL ACAD SCI USA, V83, P7109, DOI 10.1073/pnas.83.18.7109; WONG S, 1986, BIOCHEMISTRY-US, V25, P6294, DOI 10.1021/bi00368a069; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	30	327	330	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 7	1993	361	6407					76	79		10.1038/361076a0	http://dx.doi.org/10.1038/361076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7678445				2022-12-24	WOS:A1993KF71800052
J	HOTAMISLIGIL, GS; SHARGILL, NS; SPIEGELMAN, BM				HOTAMISLIGIL, GS; SHARGILL, NS; SPIEGELMAN, BM			ADIPOSE EXPRESSION OF TUMOR-NECROSIS-FACTOR-ALPHA - DIRECT ROLE IN OBESITY-LINKED INSULIN RESISTANCE	SCIENCE			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; LIPOPROTEIN-LIPASE ACTIVITY; SERINE PROTEASE HOMOLOG; SKELETAL-MUSCLE; MESSENGER-RNA; DECREASED EXPRESSION; 3T3-L1 ADIPOCYTES; DIABETES-MELLITUS; LIPID-METABOLISM; GENE-EXPRESSION	Tumor necrosis factor-alpha (TNF-alpha) has been shown to have certain catabolic effects on fat cells and whole animals. An induction of TNF-alpha messenger RNA expression was observed in adipose tissue from four different rodent models of obesity and diabetes. TNF-alpha protein was also elevated locally and systemically. Neutralization of TNF-alpha in obese fa/fa rats caused a significant increase in the peripheral uptake of glucose in response to insulin. These results indicate a role for TNF-alpha in obesity and particularly in the insulin resistance and diabetes that often accompany obesity.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEISEL WR, 1975, ANNU REV MED, V26, P9, DOI 10.1146/annurev.me.26.020175.000301; BELL GI, 1991, DIABETES, V40, P413, DOI 10.2337/diabetes.40.4.413; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; CAMERON DP, 1978, CLIN EXP PHARMACOL P, V5, P41, DOI 10.1111/j.1440-1681.1978.tb00650.x; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOY LN, 1992, J BIOL CHEM, V267, P12736; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; COLEMAN DL, 1982, DIABETES, V31, P1; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DINARELLO CA, 1987, IMMUNOL LETT, V16, P227, DOI 10.1016/0165-2478(87)90151-9; DOBSON DE, 1987, J BIOL CHEM, V262, P1804; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; FEINGOLD KR, 1989, J CLIN INVEST, V83, P1116, DOI 10.1172/JCI113991; FEINGOLD KR, 1987, J CLIN INVEST, V80, P184, DOI 10.1172/JCI113046; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FRAKER DL, 1989, AM J PHYSIOL, V256, pE725, DOI 10.1152/ajpendo.1989.256.6.E725; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRUNFELD C, 1989, J LIPID RES, V30, P579; GRUNFELD C, 1989, CANCER RES, V49, P2554; GRUNFELD C, 1991, BIOTHERAPY, V3, P143, DOI 10.1007/BF02172087; HANDBERG A, 1990, DIABETOLOGIA, V33, P625, DOI 10.1007/BF00400207; HOTAMISLIGIL GS, UNPUB; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KERN PA, 1988, J LIPID RES, V29, P909; KETTELHUT IC, 1988, J CLIN INVEST, V81, P1384, DOI 10.1172/JCI113467; KOIVISTO VA, 1989, DIABETES, V38, P641, DOI 10.2337/diabetes.38.5.641; KUNKEL SL, 1989, CRIT REV IMMUNOL, V9, P93; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LARDY H, 1990, ANNU REV BIOCHEM, V59, P689, DOI 10.1146/annurev.biochem.59.1.689; LE JM, 1987, LAB INVEST, V56, P234; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LONNROTH P, 1991, J INTERN MED, V229, P23; Maniatis T, 1989, DECONTAMINATION DILU; MESZAROS K, 1987, BIOCHEM BIOPH RES CO, V149, P1, DOI 10.1016/0006-291X(87)91596-8; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MULLEN BJ, 1990, P SOC EXP BIOL MED, V193, P318; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PATTON JS, 1987, J CLIN INVEST, V80, P1587, DOI 10.1172/JCI113245; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; PLATA-SALAMAN C R, 1989, Brain Behavior and Immunity, V3, P193, DOI 10.1016/0889-1591(89)90036-6; PRICE SR, 1986, ARCH BIOCHEM BIOPHYS, V251, P738, DOI 10.1016/0003-9861(86)90384-X; REAVEN GM, 1988, AM J MED, V85, P106, DOI 10.1016/0002-9343(88)90402-0; REY DA, 1987, AM J PHYSIOL, V253, pR794; RODBELL M, 1964, J BIOL CHEM, V239, P375; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SEMB H, 1987, J BIOL CHEM, V262, P8390; SHAFRIR E, 1990, DIABETES MELLITUS TH, P299; SHARGILL NS, UNPUB; SHERMAN ML, 1988, J CLIN ONCOL, V6, P344, DOI 10.1200/JCO.1988.6.2.344; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; Snick JV, 1990, ANNU REV IMMUNOL, V8, P253; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; STEPHENS JM, 1992, BIOCHEM BIOPH RES CO, V183, P417, DOI 10.1016/0006-291X(92)90497-9; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TENG MN, 1991, P NATL ACAD SCI USA, V88, P3535, DOI 10.1073/pnas.88.9.3535; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TRACEY KJ, 1990, J CLIN INVEST, V86, P2014, DOI 10.1172/JCI114937; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; WASSERMANN F., 1965, HANDBOOK PHYSIOL, V5, P87	80	5657	5910	18	558	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					87	91		10.1126/science.7678183	http://dx.doi.org/10.1126/science.7678183			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	7678183				2022-12-24	WOS:A1993KE60100035
J	GALAKTIONOV, K; LEE, AK; ECKSTEIN, J; DRAETTA, G; MECKLER, J; LODA, M; BEACH, D				GALAKTIONOV, K; LEE, AK; ECKSTEIN, J; DRAETTA, G; MECKLER, J; LODA, M; BEACH, D			CDC25 PHOSPHATASES AS POTENTIAL HUMAN ONCOGENES	SCIENCE			English	Article							FISSION YEAST; BREAST-CARCINOMA; MITOTIC INDUCER; P34CDC2 KINASE; CDK2 ACTIVITY; CYCLIN; PHOSPHORYLATION; CELLS; ACTIVATION; INHIBITION	Cyclin-dependent kinases (CDKs) are activated by CDC25 phosphatases, which remove inhibitory phosphate from tyrosine and threonine residues. In human cells, CDC25 proteins are encoded by a multigene family, consisting of CDC25A, CDC25B, and CDC25C. In rodent cells, human CDC25A or CDC25B but not CDC25C phosphatases cooperate with either Ha-RAS(G12V) or loss of RB1 in oncogenic focus formation. Such transformants were highly aneuploid, grew in soft agar, and formed high-grade tumors in nude mice. Overexpression of CDC25B was detected in 32 percent of human primary breast cancers tested. The CDC25 phosphatases may contribute to the development of human cancer.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA; HARVARD UNIV, SCH MED, LAHEY CLIN MED CTR, BURLINGTON, MA 01805 USA; MITOTIX, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, DEACONESS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02215 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Harvard University; Lahey Hospital & Medical Center; Harvard University; Harvard Medical School								BOSARI S, 1992, VIRCHOWS ARCH A, V421, P291, DOI 10.1007/BF01660975; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, UNPUB; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE AKC, 1990, J CLIN ONCOL, V8, P1457, DOI 10.1200/JCO.1990.8.9.1457; LEE AKC, 1992, MODERN PATHOL, V5, P61; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MATSUDA M, 1991, JPN J GENET, V66, P701, DOI 10.1266/jjg.66.701; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; NAGATA A, 1991, NEW BIOL, V3, P959; NASSER IA, 1993, HUM PATHOL, V24, P950, DOI 10.1016/0046-8177(93)90108-S; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; POLYAK K, 1994, NATURE, V78, P59; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TOYOSHIMA H, 1994, NATURE, V78, P67; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	46	505	529	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1575	1577		10.1126/science.7667636	http://dx.doi.org/10.1126/science.7667636			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7667636				2022-12-24	WOS:A1995RU81300041
J	BOGUSKI, MS				BOGUSKI, MS			HUNTING FOR GENES IN COMPUTER-DATA BASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											BOGUSKI, MS (corresponding author), NIH,NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,8600 ROCKVILLE PIKE,BETHESDA,MD 20894, USA.							BOGUSKI MS, 1994, CURRENT PROTOCOLS HU; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509	4	11	11	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					645	647		10.1056/NEJM199509073331008	http://dx.doi.org/10.1056/NEJM199509073331008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637727				2022-12-24	WOS:A1995RR84000008
J	PSATY, BM; HECKBERT, SR; KOEPSELL, TD; SISCOVICK, DS; RAGHUNATHAN, TE; WEISS, NS; ROSENDAAL, FR; LEMAITRE, RN; SMITH, NL; WAHL, PW; WAGNER, EH; FURBERG, CD				PSATY, BM; HECKBERT, SR; KOEPSELL, TD; SISCOVICK, DS; RAGHUNATHAN, TE; WEISS, NS; ROSENDAAL, FR; LEMAITRE, RN; SMITH, NL; WAHL, PW; WAGNER, EH; FURBERG, CD			THE RISK OF MYOCARDIAL-INFARCTION ASSOCIATED WITH ANTIHYPERTENSIVE DRUG THERAPIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD-PRESSURE; NIFEDIPINE; DISEASE; ANGINA; TRIAL; PREVENTION; BLOCKERS	Objective.-To assess the association between first myocardial infarction and the use of antihypertensive agents. Design and Setting.-We conducted a population-based case-control study among enrollees of the Group Health Cooperative of Puget Sound (GHC). Patients and Methods.-Cases were hypertensive patients who sustained a first fatal or nonfatal myocardial infarction from 1986 through 1993 among women and from 1989 through 1993 among men. Controls were a stratified random sample of hypertensive GHC enrollees, frequency matched to the cases on age, sex, and calendar year, All 623 cases and 2032 controls had pharmacologically treated hypertension. Data collection included a review of the ambulatory medical record and a brief telephone interview of consenting survivors. Antihypertensive therapy was assessed using the GHC's computerized pharmacy database. Results.-The first analysis included only the 335 cases and 1395 controls initially free of cardiovascular disease. Compared with users of diuretics alone, the adjusted risk ratio of myocardial infarction was increased by about 60% among users of calcium channel blockers with or without diuretics (risk ratio=1.62; 95% confidence interval [CI], 1.11 to 2.34; P=.01). The second analysis was restricted to 384 cases and 1108 controls who were taking either a calcium channel blocker or a beta-blocker. Among these subjects, the use of calcium channel blockers compared with beta-blockers was associated with about a 60% increase in the adjusted risk of myocardial infarction (risk ratio=1.57; 95% CI, 1.21 to 2.04; P<.001). While high doses of beta-blockers were associated with a decreased risk of myocardial infarction (trend P=.04), high doses of calcium channel blockers were associated with an increased risk (trend P<.01). Conclusions.-In this study of hypertensive patients, the use of short-acting calcium channel blockers, especially in high doses, was associated with an increased risk of myocardial infarction. Ongoing targe-scale clinical trials will assess the effect of various antihypertensive therapies, including calcium channel blockers, on several important cardiovascular end points. Until these results are available, the findings of this study support the current guidelines from the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure that recommend diuretics and beta-blockers as first-line agents unless contraindicated, unacceptable; or not tolerated.	UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98101 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98101 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98101 USA; UNIV MICHIGAN, SURVEY RES CTR, INST SOCIAL RES, ANN ARBOR, MI USA; LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, LEIDEN, NETHERLANDS; CTR HLTH STUDIES, GRP HLTH COOPERAT PUGET SOUND, SEATTLE, WA USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; Leiden University; Leiden University Medical Center (LUMC); Group Health Cooperative; Wake Forest University; Wake Forest Baptist Medical Center	PSATY, BM (corresponding author), UNIV WASHINGTON, DEPT MED, CARDIOVASC HLTH RES UNIT, SEATTLE, WA 98101 USA.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040628, R01HL040628, R01HL043201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43201, HL40628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BETO JA, 1992, AM J HYPERTENS, V5, P125, DOI 10.1093/ajh/5.3.125; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Dahlof B, 1993, Blood Press, V2, P136, DOI 10.3109/08037059309077541; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DAVIS BR, IN PRESS AM J HYPERT; EGSTRUP K, 1993, AM J CARDIOL, V71, P177, DOI 10.1016/0002-9149(93)90735-U; FERGUSON JJ, 1994, CIRCULATION, V90, P2194; FURBERG CD, 1989, AM J MED, V86, P37, DOI 10.1016/0002-9343(89)90188-5; FURBERG CD, IN PRESS CIRCULATION; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOLDBOURT U, 1993, ARCH INTERN MED, V153, P345, DOI 10.1001/archinte.153.3.345; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HILLEGASS WB, 1994, AM J CARDIOL, V73, P835, DOI 10.1016/0002-9149(94)90805-2; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MCCLELLAN K, 1994, INPHARMA, V932, P4; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PSATY BM, 1987, J GEN INTERN MED, V2, P381, DOI 10.1007/BF02596362; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; PSATY BM, 1991, STAT MED, V10, P653, DOI 10.1002/sim.4780100416; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; PSATY BM, 1993, HYPERTENSION PRIMER, P197; ROHLFING JJ, 1986, WESTERN J MED, V145, P210; RUZICKA M, 1992, HYPERTENSION PATHOPH, P2815; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SEWESTER CS, 1994, DRUG FACTS COMP; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1993, BLOOD PRESS, V2, P314	38	877	887	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					620	625		10.1001/jama.274.8.620	http://dx.doi.org/10.1001/jama.274.8.620			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637142				2022-12-24	WOS:A1995RP70200029
J	PASTERNACK, RF; COLLINGS, PJ				PASTERNACK, RF; COLLINGS, PJ			RESONANCE LIGHT-SCATTERING - A NEW TECHNIQUE FOR STUDYING CHROMOPHORE AGGREGATION	SCIENCE			English	Article							PORPHYRINS	Light scattering experiments are usually performed at wavelengths away from absorption bands, but for species that aggregate,enhancements in light scattering of several orders of magnitude can be observed at wavelengths characteristic of these species. Resonance light scattering is shown to be a sensitive and selective method for studying electronically coupled chromophore arrays. The approach is illustrated with several examples drawn from porphyrin and chlorin chemistry. The physical principles underlying resonance light scattering are discussed, and the advantages and limitations of the technique are reviewed.	SWARTHMORE COLL,DEPT PHYS & ASTRON,SWARTHMORE,PA 19081	Swarthmore College	PASTERNACK, RF (corresponding author), SWARTHMORE COLL,DEPT CHEM,500 COL AVE,SWARTHMORE,PA 19081, USA.							AKINS DL, 1994, J PHYS CHEM-US, V98, P3612, DOI 10.1021/j100065a012; ANGLISTER J, 1981, J CHEM PHYS, V74, P786, DOI 10.1063/1.441179; ANGLISTER J, 1979, CHEM PHYS LETT, V65, P50, DOI 10.1016/0009-2614(79)80123-2; ANGLISTER J, 1983, J CHEM PHYS, V78, P5358, DOI 10.1063/1.445489; ARENA G, 1995, INORG CHEM, V34, P2994, DOI 10.1021/ic00115a030; BAUER DR, 1975, J CHEM PHYS, V63, P588, DOI 10.1063/1.431091; BLANKENSHIP RE, 1988, LIGHT ENERGY TRANSDU, P32; Bohren C. F., 2008, ABSORPTION SCATTERIN; CHIARELLO R, 1988, J CHEM PHYS, V88, P1253, DOI 10.1063/1.454246; DEPAULA JC, 1995, BIOPHYS J, V68, P335, DOI 10.1016/S0006-3495(95)80192-X; DOUGHERTY TJ, 1992, ADV PHOTOCHEM, P275; FORD NC, 1985, DYNAMIC LIGHT SCATTE, P7; GIBBS EJ, 1988, BIOCHEM BIOPH RES CO, V157, P350, DOI 10.1016/S0006-291X(88)80054-8; MAGILL JV, 1985, J PHYS CHEM-US, V89, P734, DOI 10.1021/j100251a003; MILLER GA, 1978, J PHYS CHEM-US, V82, P616, DOI 10.1021/j100494a023; NELSON WH, 1982, INORG CHEM, V21, P1483, DOI 10.1021/ic00134a043; PASTEMACK RF, UNPUB; PASTERNA.RF, 1972, J AM CHEM SOC, V94, P4511, DOI 10.1021/ja00768a016; PASTERNACK RF, 1994, INORG CHEM, V33, P2062, DOI 10.1021/ic00087a053; PASTERNACK RF, 1983, BIOCHEMISTRY-US, V22, P2406, DOI 10.1021/bi00279a016; PASTERNACK RF, 1993, J AM CHEM SOC, V15, P5393; PERKINS WR, 1992, BIOCHIM BIOPHYS ACTA, V1107, P271, DOI 10.1016/0005-2736(92)90414-H; RISEMAN J, 1950, J CHEM PHYS, V18, P512, DOI 10.1063/1.1747672; SCHUELER PA, 1993, ANAL CHEM, V65, P3177, DOI 10.1021/ac00070a003; STANTON SG, 1981, J CHEM PHYS, V75, P5615, DOI 10.1063/1.442000; STANTON SG, 1983, J CHEM PHYS, V78, P3365, DOI 10.1063/1.445212; ZERO K, 1985, DYNAMIC LIGHT SCATTE, P59	27	907	981	4	129	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					935	939		10.1126/science.7638615	http://dx.doi.org/10.1126/science.7638615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638615				2022-12-24	WOS:A1995RP73800024
J	WU, HM; WANG, H; CHEUNG, AY				WU, HM; WANG, H; CHEUNG, AY			A POLLEN-TUBE GROWTH-STIMULATORY GLYCOPROTEIN IS DEGLYCOSYLATED BY POLLEN TUBES AND DISPLAYS A GLYCOSYLATION GRADIENT IN THE FLOWER	CELL			English	Article							SELF-INCOMPATIBILITY; CELL-WALL; NICOTIANA-ALATA; AXONS; PROTEINS; MOVEMENT; INVITRO; CHEMOTROPISM; POLLINATION; CHEMOTAXIS	In plant sexual reproduction, pollen tubes elongate from the stigma, through the stylar transmitting tissue, to the ovary of the pistil to deliver the male gametes for fertilization. TTS protein is a tobacco transmitting tissue glycoprotein shown to attract pollen tubes and promote their growth. Here, we show TTS proteins adhere to the pollen tube surface and tips, suggesting that they may serve as adhesive substrates for pollen tube growth. TTS proteins are also incorporated into pollen tube walls and are deglycosylated by pollen tubes, suggesting that they may provide nutrients to this process, Within the transmitting tissue, TTS proteins display a gradient of increasing glycosylation from the stigmatic end to the ovarian end of the style, coincident with the direction of pollen tube growth. These results together suggest that the TTS protein-bound sugar gradient may contribute to guiding pollen tubes from the stigma to the ovary.			WU, HM (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.			Wang, Hong/0000-0003-4130-8741				CHEUNG AY, 1995, P NATL ACAD SCI USA, V92, P3077, DOI 10.1073/pnas.92.8.3077; CHEUNG AY, 1995, CELL, V82, P383, DOI 10.1016/0092-8674(95)90427-1; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DU H, 1994, PLANT CELL, V6, P1643, DOI 10.1105/tpc.6.11.1643; FOOTE HCC, 1994, P NATL ACAD SCI USA, V91, P2265, DOI 10.1073/pnas.91.6.2265; GRAY JE, 1991, PLANT CELL, V3, P271, DOI 10.1105/tpc.3.3.271; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEATH IB, 1990, TIP GROWTH PLANT FUN; HERRERO M, 1980, PLANTA, V148, P217, DOI 10.1007/BF00380030; Heslop-Harrison Y., 1988, Sexual Plant Reproduction, V1, P182, DOI 10.1007/BF00193749; HESLOPHARRISON J, 1987, INT REV CYTOL, V107, P1, DOI 10.1016/S0074-7696(08)61072-4; HESLOPHARRISON Y, 1985, ACTA BOT NEERL, V34, P193, DOI 10.1111/j.1438-8677.1985.tb01879.x; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JAUH GY, 1995, SEX PLANT REPROD, V8, P168, DOI 10.1007/BF00242262; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KANDASARNY MK, 1994, DEVELOPMENT, V20, P3405; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Knox R. B., 1984, Cellular interactions, P508; LI XM, 1994, PLANT CELL, V6, P1923, DOI 10.1105/tpc.6.12.1923; LI YQ, 1992, PLANTA, V188, P532, DOI 10.1007/BF00197045; LI YQ, 1994, SEX PLANT REPROD, V7, P145; LIND JL, 1994, PLANT J, V6, P491, DOI 10.1046/j.1365-313X.1994.6040491.x; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MASCARENHAS JP, 1975, BOT REV, V41, P259, DOI 10.1007/BF02860839; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MASCARENHAS JP, 1962, AM J BOT, V49, P482, DOI 10.2307/2439418; MASCARENHAS JP, 1962, NATURE, V196, P292, DOI 10.1038/196292a0; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NEWBIGIN E, 1993, PLANT CELL, V5, P1315, DOI 10.1105/tpc.5.10.1315; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PLACZEK M, 1990, DEVELOPMENT, V110, P19; REGER BJ, 1992, SEX PLANT REPROD, V5, P201, DOI 10.1007/BF00189812; REGER BJ, 1992, SEX PLANT REPROD, V5, P47, DOI 10.1007/BF00714557; ROSEN WG, 1961, AM J BOT, V48, P889, DOI 10.2307/2439530; SANDERS LC, 1989, SCIENCE, V243, P1606, DOI 10.1126/science.243.4898.1606; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SOMMERVILLE J, 1987, ELECTRON MICROSCOPY; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TRINKAUS JP, 1985, J NEUROSCI RES, V13, P1, DOI 10.1002/jnr.490130102; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; WANG C, 1989, DEV BIOL, V136, P405, DOI 10.1016/0012-1606(89)90266-2; WANG H, 1993, PLANT CELL, V5, P1639, DOI 10.1105/tpc.5.11.1639; YARIV J, 1967, BIOCHEM J, V105, P10; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	51	217	233	2	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					395	403		10.1016/0092-8674(95)90428-X	http://dx.doi.org/10.1016/0092-8674(95)90428-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634329	hybrid			2022-12-24	WOS:A1995RP24200009
J	RODRIGUES, JJ; MEHENDALE, SM; SHEPHERD, ME; DIVEKAR, AD; GANGAKHEDKAR, RR; QUINN, TC; PARANJAPE, RS; RISBUD, AR; BROOKMEYER, RS; GADKARI, DA; GOKHALE, MR; ROMPALO, AM; DESHPANDE, SG; KHALANDKAR, MM; MAWAR, N; BOLLINGER, RC				RODRIGUES, JJ; MEHENDALE, SM; SHEPHERD, ME; DIVEKAR, AD; GANGAKHEDKAR, RR; QUINN, TC; PARANJAPE, RS; RISBUD, AR; BROOKMEYER, RS; GADKARI, DA; GOKHALE, MR; ROMPALO, AM; DESHPANDE, SG; KHALANDKAR, MM; MAWAR, N; BOLLINGER, RC			RISK-FACTORS FOR HIV-INFECTION IN PEOPLE ATTENDING CLINICS FOR SEXUALLY-TRANSMITTED DISEASES IN INDIA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the risk factors for HIV infection in patients attending clinics for sexually transmitted diseases in India. Design-Descriptive study of HN serology, risk behaviour, and findings on physical examination. Subjects-2800 patients presenting to outpatient clinics between 13 May 1993 and 15 July 1994. Setting-Two clinics and the National AIDS Research Institute, in Pune, Maharashtra State, India. Main outcome measure-HIV status, presence of sexually transmitted diseases, and sexual behaviour. Results-The overall proportion of patients infected with HIV was 23.4% (655/2800); 34% (184) of the women and 21% (459) of the men were positive for HN infection. Of the 560 women screened, 338 (60%) had a reported history of sex working, of whom 153 (45%) were infected with HIV-1. The prevalence of HIV-1 infection in the 222 women who were not sex workers was 14%. The significant independent characteristics associated with HIV infection based on a logistic regression analysis included being a female sex worker, sexual contact with a sex worker, lack of formal education, receptive anal sex in the previous three months, lack of condom use in the previous three months, current or previous genital ulcer or genital discharge, and a positive result of a Venereal Disease Research Laboratory test. Conclusions-In India the prevalence of HIV infection is alarmingly high among female sex workers and men attending clinics for sexually transmitted diseases, particularly in those who had recently had contact with sex workers. A high prevalence of HIV infection was also found in monogamous, married women presenting to the clinics who denied any history of sex working. The HIV epidemic in India is primarily due to heterosexual transmission of HIV-1 and, as in other countries, HIV infection is associated with ulcerative and non-ulcerative sexually transmitted diseases.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; NATL AIDS RES INST,POONA,MAHARASHTRA,INDIA; NIAID,BETHESDA,MD 20892; BJ MED COLL,POONA,MAHARASHTRA,INDIA; SASSOON GEN HOSP,POONA,MAHARASHTRA,INDIA; PUNE MUNICIPAL CORP,DR KOTNIS HLTH CTR,POONA,MAHARASHTRA,INDIA	Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); B.J. Govt. Medical College & Sassoon General Hospitals, Pune				Bollinger, Robert/0000-0002-6798-6834; Paranjape, Ramesh/0000-0003-2948-9148	FIC NIH HHS [D43 TW0000] Funding Source: Medline; NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NIAID NIH HHS [AI 33879-02] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [N01TW000000] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAVE GG, 1992, 8TH INT C AIDS AMST; BHAVE GG, 1990, 6TH INT C AIDS SAN F; BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; HASMUKH S, 1992, 8TH INT C AIDS AMST; JACOB M, 1992, 8 INT C AIDS AMST; JAIN MK, 1994, J ACQ IMMUN DEF SYND, V7, P1185; JOSHI SH, 1992, 8 INT C AIDS AMST; KULKARNI S, 1992, INDIAN J MED RES-A, V95, P213; Kumar B, 1990, Int J STD AIDS, V1, P438; MANIAR JK, 1992, 8 INT C AIDS AMST; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; SIMOES EAF, 1987, INDIAN J MED RES, V85, P335; THAKUR T S, 1991, Indian Journal of Medical Sciences, V45, P332; THAKUR T S, 1991, Journal of Communicable Diseases, V23, P38; TRIPATHY S, 1993, 9TH INT C AIDS BERL; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1993, OVERVIEW HIV TRENDS	17	98	101	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					283	286		10.1136/bmj.311.7000.283	http://dx.doi.org/10.1136/bmj.311.7000.283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633230	Green Published			2022-12-24	WOS:A1995RM71900017
J	GODFREY, J				GODFREY, J			THE POPE AND THE ONTOGENY OF PERSONS	NATURE			English	Editorial Material									UNIV EDINBURGH,CTR HUMAN ECOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Edinburgh								AQUINAS T, SOMME THEOLOGIQUE; JOHNPAUL II, CROSSING THRESHOLD H; 1994, NATURE, V371, P185	3	23	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					100	100		10.1038/373100a0	http://dx.doi.org/10.1038/373100a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7646629	Bronze			2022-12-24	WOS:A1995QB06300026
J	MURPHY, JG; GERSH, BJ; MAIR, DD; FUSTER, V; MCGOON, MD; ILSTRUP, DM; MCGOON, DC; KIRKLIN, JW; DANIELSON, GK				MURPHY, JG; GERSH, BJ; MAIR, DD; FUSTER, V; MCGOON, MD; ILSTRUP, DM; MCGOON, DC; KIRKLIN, JW; DANIELSON, GK			LONG-TERM OUTCOME IN PATIENTS UNDERGOING SURGICAL REPAIR OF TETRALOGY OF FALLOT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN-DEATH; FOLLOW-UP; VENTRICULAR ARRHYTHMIAS; SURVIVAL; AGE	Background. Although corrective surgery for tetralogy of Fallot has been available for more than 30 years, the occurrence of late sudden death in patients in whom surgery was apparently successful remains worrisome. Methods. We studied long-term survival among 163 patients who survived 30 days after complete repair of tetralogy of Fallot, examining follow-up hospital records and death certificates when relevant. Results. The overall 32-year actuarial survival rate among all patients who survived surgery was 86 percent, as compared with an expected rate of 96 percent in a control population matched for age and sex (P<0.01). Thirty-year actuarial survival rates were calculated for the patient subgroups. The survival rates among patients less than 5 years old, 5 to 7 years old, and 8 to 11 years old were 90, 93, and 91 percent, respectively - slightly less than the expected rates (P<0.001, P = 0.06, and P = 0.02). Among patients 12 years old or older at the time of surgery, the survival rate was 76 percent, as compared with an expected rate of 93 percent (P<0.001). The performance of a palliative Blalock-Taussig shunt procedure before repair, unlike the performance of a Waterston or Potts shunt procedure, was not associated with reduced long-term survival, nor was the need for a trans-annular patch at the time of surgery. Independent predictors of long-term survival were older age at operation (P = 0.02) and a higher ratio of right ventricular to left ventricular systolic pressure after surgery (P = 0.008). Late sudden death from cardiac causes occurred in 10 patients during the 32-year period. Conclusions. Among patients with surgically repaired tetralogy of Fallot, the rate of long-term survival after the postoperative period is excellent but remains lower than that in the general population. The risk of late sudden death is small.	MAYO CLIN & MAYO FDN, PEDIAT CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT BIOSTAT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV THORAC & CARDIOVASC SURG, ROCHESTER, MN 55905 USA; MASSACHUSETTS GEN HOSP, DIV CARDIOL, BOSTON, MA 02114 USA; UNIV ALABAMA, MED CTR, DEPT SURG, BIRMINGHAM, AL 35233 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University; Massachusetts General Hospital; University of Alabama System; University of Alabama Birmingham	MURPHY, JG (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				AZAR H, 1969, ARCH SURG-CHICAGO, V99, P281; BERGSTRALH EJ, 1988, TECHNICAL REPORT SER, V37; COLE RB, 1971, CIRCULATION, V43, P263, DOI 10.1161/01.CIR.43.2.263; COX DR, 1972, J R STAT SOC B, V34, P187; DEANFIELD JE, 1991, INT J CARDIOL, V30, P143, DOI 10.1016/0167-5273(91)90088-7; DEANFIELD JE, 1984, BRIT HEART J, V52, P77; DEANFIELD JE, 1986, PEDIATR CARDIOL, P467; FUSTER V, 1980, AM J CARDIOL, V46, P635, DOI 10.1016/0002-9149(80)90514-7; GARSON A, 1980, AM J CARDIOL, V46, P1006, DOI 10.1016/0002-9149(80)90359-8; GARSON A, 1985, J AM COLL CARDIOL, V6, P221, DOI 10.1016/S0735-1097(85)80279-5; GARSON A, 1987, ADULT CONGENITAL HEA, P493; GILLETTE PC, 1977, CIRCULATION, V56, P566, DOI 10.1161/01.CIR.56.4.566; HARRINGTON DP, 1982, BIOMETRIKA, V69, P553, DOI 10.2307/2335991; HORNEFFER PJ, 1990, ANN THORAC SURG, V50, P179, DOI 10.1016/0003-4975(90)90728-O; HU DCK, 1985, J AM COLL CARDIOL, V5, P40, DOI 10.1016/S0735-1097(85)80083-8; JAMES FW, 1975, CIRCULATION, V52, P691, DOI 10.1161/01.CIR.52.4.691; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ NM, 1982, CIRCULATION, V65, P403, DOI 10.1161/01.CIR.65.2.403; KIRKLIN JK, 1989, ANN THORAC SURG, V48, P783, DOI 10.1016/0003-4975(89)90671-1; KIRKLIN JW, 1955, P STAFF M MAYO CLIN, V30, P201; KLINNER W, 1984, THORAC CARDIOV SURG, V32, P244, DOI 10.1055/s-2007-1023394; LILLEHEI CW, 1986, ANN SURG, V204, P490, DOI 10.1097/00000658-198610000-00017; QUATTLEBAUM TG, 1976, CIRCULATION, V54, P289, DOI 10.1161/01.CIR.54.2.289; SHEN WK, 1990, CIRCULATION, V81, P128, DOI 10.1161/01.CIR.81.1.128; VAKSMANN G, 1990, AM J CARDIOL, V66, P346, DOI 10.1016/0002-9149(90)90847-T; ZHAO HX, 1985, J THORAC CARDIOV SUR, V89, P204	26	670	701	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					593	599		10.1056/NEJM199308263290901	http://dx.doi.org/10.1056/NEJM199308263290901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	7688102				2022-12-24	WOS:A1993LU21700001
J	WYNICK, D; HAMMOND, PJ; AKINSANYA, KO; BLOOM, SR				WYNICK, D; HAMMOND, PJ; AKINSANYA, KO; BLOOM, SR			GALANIN REGULATES BASAL AND ESTROGEN-STIMULATED LACTOTROPH FUNCTION	NATURE			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; RAT PITUITARY-CELLS; THYROTROPIN-RELEASING-HORMONE; ANTERIOR-PITUITARY; PROLACTIN SECRETION; POSSIBLE INVOLVEMENT; ESTROGEN; IMMUNOREACTIVITY; POLYPEPTIDE; TUMOR	OESTROGEN, an essential physiological regulator of reproductive function1, controls lactotroph proliferation and prolactin release2. The neuropeptide galanin co-localizes to the lactotroph3, but its physiological function is largely unknown. Pituitary galanin expression is extremely sensitive to the oestrogen status of the animal. A marked elevation occurs during pregnancy and lactation 4, and exogenous 17beta-oestradiol can cause a 4,000-fold increase in messenger RNA levels5. Here we report that galanin is secreted by a minority of lactotrophs and is essential for the regulation of basal and vasoactive-intestinal-polypeptide-stimulated prolactin release. Hyperoestrogenization increases the number of galanin-secreting cells and the resulting increase in basal prolactin release is completely abolished by treatment with galanin antiserum. Galanin is a potent lactotroph growth factor and galanin-immunoneutralization completely inhibits the previously reported6-8 mitogenic effects of oestrogen on the lactotroph. These findings represent direct evidence for paracrine regulation of lactotroph function and demonstrate that the effect of oestrogen on lactotroph proliferation and prolactin release are mediated by locally secreted galanin.	HAMMERSMITH HOSP, DEPT MED, DUCANE RD, LONDON W12 0NN, ENGLAND	Imperial College London								AIZAWA T, 1985, ENDOCRINOLOGY, V116, P909, DOI 10.1210/endo-116-3-909; BAUER FE, 1986, GASTROENTEROLOGY, V91, P877, DOI 10.1016/0016-5085(86)90689-X; BJORO T, 1987, MOL CELL ENDOCRINOL, V49, P119, DOI 10.1016/0303-7207(87)90205-X; BJORO T, 1990, BIOSCIENCE REP, V10, P189, DOI 10.1007/BF01116578; CARRILLO AJ, 1992, ENDOCRINOLOGY, V131, P964, DOI 10.1210/en.131.2.964; DENEF C, 1989, METHOD ENZYMOL, V168, P47; FRANKS S, 1983, CLIN SCI, V65, P457, DOI 10.1042/cs0650457; GABRIEL SM, 1990, NEUROENDOCRINOLOGY, V51, P168, DOI 10.1159/000125333; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Inagaki H, 1989, No To Shinkei, V41, P593; KAPLAN LM, 1988, P NATL ACAD SCI USA, V85, P7408, DOI 10.1073/pnas.85.19.7408; KENDALL ME, 1987, ENDOCRINOLOGY, V121, P2260, DOI 10.1210/endo-121-6-2260; Knobil E, 1980, Recent Prog Horm Res, V36, P53; KOSHIYAMA H, 1987, NEUROSCI LETT, V75, P49, DOI 10.1016/0304-3940(87)90073-5; KROWN KA, 1992, ENDOCRINOLOGY, V131, P595, DOI 10.1210/en.131.2.595; LAM KSL, 1989, ENDOCRINOLOGY, V124, P1077, DOI 10.1210/endo-124-2-1077; MELANDER T, 1987, ACTA PHYSIOL SCAND, V131, P25, DOI 10.1111/j.1748-1716.1987.tb08201.x; MOREL G, 1982, NEUROENDOCRINOLOGY, V34, P85, DOI 10.1159/000123282; OHALLORAN DJ, 1990, ENDOCRINOLOGY, V127, P467, DOI 10.1210/endo-127-1-467; PHELPS C, 1983, NEUROENDOCRINOLOGY, V37, P23, DOI 10.1159/000123511; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; ROTSZTEJN WH, 1981, P NATL ACAD SCI-BIOL, V78, P7584, DOI 10.1073/pnas.78.12.7584; SHIMATSU A, 1983, NEUROSCI LETT, V43, P259, DOI 10.1016/0304-3940(83)90198-2; STEEL JH, 1989, HISTOCHEMISTRY, V93, P183, DOI 10.1007/BF00315973; TATAR P, 1991, EXP CLIN ENDOCRINOL, V97, P29, DOI 10.1055/s-0029-1211034; TROUILLAS J, 1990, CANCER RES, V50, P4081; VRONTAKIS ME, 1987, J BIOL CHEM, V262, P16755; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231; WYNICK D, 1990, J ENDOCRINOL, V128, P269	29	122	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1993	364	6437					529	532		10.1038/364529a0	http://dx.doi.org/10.1038/364529a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687748				2022-12-24	WOS:A1993LQ66700055
J	RESSLER, KJ; SULLIVAN, SL; BUCK, LB				RESSLER, KJ; SULLIVAN, SL; BUCK, LB			A ZONAL ORGANIZATION OF ODORANT RECEPTOR GENE-EXPRESSION IN THE OLFACTORY EPITHELIUM	CELL			English	Article							2-DEOXYGLUCOSE METHOD; BULB; RAT; PROJECTIONS; PATTERNS; NEURONS; NERVES; MOUSE; MODEL; DIFFERENTIATION	The mechanisms by which mammals discriminate a vast array of diverse odors are poorly understood. To gain insight into the organizational strategies underlying this discriminatory capacity, we have examined the spatial distribution of odorant receptor RNAs in the mouse olfactory epithelium. We have observed topographically distinct patterns of receptor RNAs suggesting that the nasal cavity is divided into a series of expression zones. The zones exhibit bilateral symmetry in the two nasal cavities and are organized along the dorsal-ventral and medial-lateral axes. Within each zone, a neuron may select a gene for expression from a zonal gene set via a stochastic mechanism. The observed zonal patterning may serve as an initial organizing step in olfactory sensory information coding.			RESSLER, KJ (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.		Ressler, Kerry J/N-8741-2018	Ressler, Kerry J/0000-0002-5158-1103	NIDCD NIH HHS [1-R01-DC01662-01] Funding Source: Medline; NIGMS NIH HHS [2-T32GM07753-14, T32 GM007753] Funding Source: Medline; NINDS NIH HHS [5T32NS07009-18] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001662] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMS DR, 1972, J MORPHOL, V137, P161, DOI 10.1002/jmor.1051370204; ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; ADRIAN ED, 1956, J LARYNGOL OTOL, V70, P1; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; AMOORE JE, 1964, SCI AM, V210, P42, DOI 10.1038/scientificamerican0264-42; [Anonymous], [No title captured]; ASTIC L, 1983, DEV BRAIN RES, V10, P257, DOI 10.1016/0165-3806(83)90142-6; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck L B, 1992, Curr Opin Neurobiol, V2, P282, DOI 10.1016/0959-4388(92)90116-3; Buck LB, 1992, CURR OPIN GENET DEV, V2, P467, DOI 10.1016/S0959-437X(05)80159-5; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CLANCY AN, 1985, CHEM SENSES, V10, P399; CLARK WEL, 1951, J NEUROL NEUROSUR PS, V14, P1, DOI 10.1136/jnnp.14.1.1; COOPERSMITH R, 1986, DEV BRAIN RES, V27, P191, DOI 10.1016/0165-3806(86)90245-2; COSTANZO RM, 1978, BRAIN RES, V139, P327, DOI 10.1016/0006-8993(78)90932-0; CUSCHIERI A, 1975, J ANAT, V119, P277; CUSCHIERI A, 1975, J ANAT, V119, P471; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DASTON MM, 1990, BRAIN RES, V537, P69, DOI 10.1016/0006-8993(90)90340-H; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EDWARDS DA, 1988, EXPERIENTIA, V44, P208, DOI 10.1007/BF01941707; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FREEMAN WJ, 1987, BIOL CYBERN, V56, P139, DOI 10.1007/BF00317988; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; HABERLY LB, 1989, TRENDS NEUROSCI, V12, P258, DOI 10.1016/0166-2236(89)90025-8; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LAND LJ, 1973, BRAIN RES, V63, P153, DOI 10.1016/0006-8993(73)90084-X; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MACKAYSIM A, 1991, EUR J NEUROSCI, V3, P209, DOI 10.1111/j.1460-9568.1991.tb00081.x; MACKAYSIM A, 1991, J NEUROSCI, V11, P979; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MOZELL MM, 1970, J GEN PHYSIOL, V56, P46, DOI 10.1085/jgp.56.1.46; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Sambrook J., 1989, MOL CLONING LAB MANU; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHOTZINGER RJ, 1988, NATURE, V335, P637, DOI 10.1038/335637a0; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; SHARP FR, 1977, J NEUROPHYSIOL, V40, P800, DOI 10.1152/jn.1977.40.4.800; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; Shepherd G.M., 2004, SYNAPTIC ORG BRAIN, V3rd Edn, P133; SKEEN LC, 1977, BRAIN RES, V124, P147, DOI 10.1016/0006-8993(77)90871-X; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STEWART WB, 1987, BRAIN RES, V411, P248, DOI 10.1016/0006-8993(87)91076-6; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	61	849	868	0	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					597	609		10.1016/0092-8674(93)90145-G	http://dx.doi.org/10.1016/0092-8674(93)90145-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	7683976				2022-12-24	WOS:A1993LA74300019
J	NABEL, EG; YANG, ZY; PLAUTZ, G; FOROUGH, R; ZHAN, X; HAUDENSCHILD, CC; MACIAG, T; NABEL, GJ				NABEL, EG; YANG, ZY; PLAUTZ, G; FOROUGH, R; ZHAN, X; HAUDENSCHILD, CC; MACIAG, T; NABEL, GJ			RECOMBINANT FIBROBLAST GROWTH FACTOR-I PROMOTES INTIMAL HYPERPLASIA AND ANGIOGENESIS IN ARTERIES INVIVO	NATURE			English	Article							GENE-EXPRESSION INVIVO; ENDOTHELIAL-CELLS; PROLIFERATION; SEQUENCE; CORONARY; VESSELS; INJURY; WALL	THE prototype members of the heparin-binding fibroblast growth factor (FGF) family1-6, acidic FGF (FGF-1) and basic FGF (FGF-2), are among the growth factors that act directly on vascular cells to induce endothelial cell growth and angiogenesis. In vivo, the role of the FGF prototypes in vascular pathology has been difficult to determine. We report here the introduction, by direct gene transfer into porcine arteries, of a eukaryotic expression vector encoding a secreted form of FGF-1. This somatic transgenic model defines gene function in the arterial wall in vivo. FGF-1 expression induced intimal thickening in porcine arteries 21 days after gene transfer, in contrast to control arteries transduced with an Escherichia coli beta-galactosidase gene. Where there was substantial intimal hyperplasia, neocapillary formation was detected in the expanded intima. These findings suggest that FGF-1 induces intimal hyperplasia in the arterial wall in vivo and, through its ability to stimulate angiogenesis in the neointima, FGF-1 could stimulate neovascularization of atherosclerotic plaques. Potentially, gene transfer of FGF-1 could also be used as a genetic intervention to improve blood flow to ischaemic tissues in selected clinical settings.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109; AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; AMER RED CROSS,HOLLAND LAB,DEPT EXPTL PATHOL,ROCKVILLE,MD 20855	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; American Red Cross; American Red Cross	NABEL, EG (corresponding author), UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.		Christian, Haudenschild C/D-1602-2009					ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAPMAN GD, 1992, CIRC RES, V71, P27, DOI 10.1161/01.RES.71.1.27; CLOWES AW, 1986, LAB INVEST, V54, P295; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GAJDUSEK CM, 1989, J CELL PHYSIOL, V139, P570, DOI 10.1002/jcp.1041390317; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LIM CS, 1991, CIRCULATION, V83, P2007, DOI 10.1161/01.CIR.83.6.2007; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1992, P NATL ACAD SCI USA, V89, P5157, DOI 10.1073/pnas.89.11.5157; PLAUTZ G, 1991, CIRCULATION, V83, P578, DOI 10.1161/01.CIR.83.2.578; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313	26	335	369	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					844	846		10.1038/362844a0	http://dx.doi.org/10.1038/362844a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	7683112	Green Published			2022-12-24	WOS:A1993KZ56300058
J	BAGBY, S; KIM, SJ; MALDONADO, E; TONG, KI; REINBERG, D; IKURA, M				BAGBY, S; KIM, SJ; MALDONADO, E; TONG, KI; REINBERG, D; IKURA, M			SOLUTION STRUCTURE OF THE C-TERMINAL CORE DOMAIN OF HUMAN TFIIB - SIMILARITY TO CYCLIN-A AND INTERACTION WITH TATA-BINDING PROTEIN	CELL			English	Article							TRANSCRIPTION FACTOR-TFIIB; RNA POLYMERASE-II; NUCLEAR MAGNETIC-RESONANCE; FUNCTIONAL DOMAINS; INITIATION-FACTORS; DISTANCE GEOMETRY; CRYSTAL-STRUCTURE; ACTIVATION; SEQUENCE; ENCODES	TFIIB is an essential component of the machinery that transcribes protein-coding genes. The three-dimensional structure of the human TFIIB core domain (TFIIBc) has been determined using multidimensional heteronuclear magnetic resonance spectroscopy. The molecule consists of two direct repeats that adopt similar alpha-helical folds, conferring pseudo-twofold symmetry. An extensive, central basic surface including an amphipathic alpha helix is critical to the function of TFIIB as a bridge between the TBP-promoter complex and RNA polymerase II and associated general and regulatory transcription factors. Similarities between the TFIIBc and cyclin A folds indicate that elements of the eukaryotic cell cycle control apparatus evolved from more fundamental transcriptional control components, demonstrating a link between the transcription and cell cycle molecular machineries.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	University of Toronto; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	BAGBY, S (corresponding author), UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,500 SHERBOURNE ST,TORONTO,ON M4X 1K9,CANADA.			Bagby, Stefan/0000-0003-2302-9511; Reinberg, Danny/0000-0003-4288-2016; Ikura, Mitsuhiko/0000-0002-9524-1303				ALEXANDROV NN, 1992, J MOL BIOL, V225, P5, DOI 10.1016/0022-2836(92)91021-G; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAGBY S, 1994, BIOCHEMISTRY-US, V33, P2409, DOI 10.1021/bi00175a009; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brunger A. T., 1993, X PLOR MANUAL VERSIO; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; COLGAN J, 1995, MOL CELL BIOL, V15, P2311; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CRETI R, 1993, NUCLEIC ACIDS RES, V21, P2942, DOI 10.1093/nar/21.12.2942; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE S, 1995, IN PRESS NATURE; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V365, P520; NILGES M, 1991, COMPUTATIONAL ASPECT, P41; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SWINDELLS MB, 1995, NAT STRUCT BIOL, V2, P596, DOI 10.1038/nsb0795-596; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	60	117	122	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					857	867		10.1016/0092-8674(95)90483-2	http://dx.doi.org/10.1016/0092-8674(95)90483-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671313	Bronze			2022-12-24	WOS:A1995RU75500021
J	VANBIESEN, T; HAWES, BE; LUTTRELL, DK; KRUEGER, KM; TOUHARA, K; PORFIRI, E; SAKAUE, M; LUTTRELL, LM; LEFKOWITZ, RJ				VANBIESEN, T; HAWES, BE; LUTTRELL, DK; KRUEGER, KM; TOUHARA, K; PORFIRI, E; SAKAUE, M; LUTTRELL, LM; LEFKOWITZ, RJ			RECEPTOR-TYROSINE-KINASE-MEDIATED AND G-BETA-GAMMA-MEDIATED MAP KINASE ACTIVATION BY A COMMON SIGNALING PATHWAY	NATURE			English	Article							PROTEIN; P21(RAS); FIBROBLASTS; GRB2; RAS	MITOGEN-ACTIVATED protein (MAP) kinases mediate the phosphorylation and activation of nuclear transcription factors that regulate cell growth(1). MAP kinase activation may result from stimulation of either tyrosine-kinase (RTK) receptors, which possess intrinsic tyrosine kinase activity, or G-protein-coupled receptors (GPCR)(2-4). RTK-mediated mitogenic signalling involves a series of SH2- and SH3-dependent protein-protein interactions between tyrosine-phosphorylated receptor, Shc, Grb2 and Sos, resulting in Ras-dependent MAP kinase activation(5-7). The beta gamma subunits of heterotrimeric G proteins (G beta gamma) also mediate Ras-dependent MAP kinase activations(8-10) by an as-yet unknown mechanism. Here we demonstrate that activation of MAP kinase by G(i)-coupled receptors is preceded by the G beta gamma-mediated tyrosine phosphorylation of Shc, leading to an increased functional association between Shc, Grb2 and Sos. Moreover, disruption of the Shc-Grb2-Sos complex blocks G beta gamma-mediated MAP kinase activation, indicating that G beta gamma does not mediate MAP kinase activation by a direct interaction with Sos. These results indicate that G beta gamma-mediated MAP kinase activation is initiated by a tyrosine phosphorylation event and proceeds by a pathway common to both GPCRs and RTKs.	DUKE UNIV,MED CTR,DEPT MED CARDIOL,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,DURHAM,NC 27710; GLAXO WELLCOME INC,DEPT MOLEC CELL BIOL,RES TRIANGLE PK,NC 27709; ONYX PHARMACEUT,RICHMOND,CA 94806; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; GlaxoSmithKline; Kobe University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SPANDIDOS DA, 1984, NATURE, V322, P469; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196	27	401	404	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					781	784		10.1038/376781a0	http://dx.doi.org/10.1038/376781a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651538				2022-12-24	WOS:A1995RR83600042
J	HEALEY, BG; FORAN, SE; WALT, DR				HEALEY, BG; FORAN, SE; WALT, DR			PHOTODEPOSITION OF MICROMETER-SCALE POLYMER PATTERNS ON OPTICAL IMAGING FIBERS	SCIENCE			English	Article							FABRICATION; ARRAYS	Microstructures were fabricated on optical imaging fibers with a photopolymerization technique. Monodisperse polymeric microarrays were produced containing spots of 2.5 micrometers in diameter spaced 4.5 micrometers apart. Polymer microarrays were also deposited on other substrates by using imaging fibers for light delivery. The technique allows micrometer-scale photopatterning with masks larger than the desired dimensions.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155	Tufts University					NIGMS NIH HHS [GM 48142] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNARD SM, 1991, NATURE, V353, P338, DOI 10.1038/353338a0; BEIN T, 1994, CHEM MATER, V6, P1109; BRONK KS, 1994, ANAL CHEM, V66, P3519, DOI 10.1021/ac00092a035; DABBOUSI BO, 1994, CHEM MATER, V6, P216, DOI 10.1021/cm00038a020; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GORMAN CB, 1995, CHEM MATER, V7, P252, DOI 10.1021/cm00050a003; GRANSTROM M, 1995, SCIENCE, V267, P1479, DOI 10.1126/science.267.5203.1479; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; HEALY BG, UNPUB; KLEIN JD, 1993, CHEM MATER, V5, P902, DOI 10.1021/cm00031a002; LANGER R, 1993, ACCOUNTS CHEM RES, V26, P537, DOI 10.1021/ar00034a004; LIU C, 1993, SCIENCE, V261, P597; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; MOGI M, 1989, P SPIE INT SOC OPT E, V1067, P172; NOBLE D, 1995, ANAL CHEM, V67, pA201; NOGLIK H, 1994, CHEM MATER, V6, P1593, DOI 10.1021/cm00046a003; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; PARTHASARATHY RV, 1994, CHEM MATER, V6, P1627, DOI 10.1021/cm00046a011; ROZSNYAI LF, 1992, ANGEW CHEM INT EDIT, V31, P759, DOI 10.1002/anie.199207591; SHIEH L, 1994, J CONTROL RELEASE, V29, P73, DOI 10.1016/0168-3659(94)90123-6; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; WALLENBERGER FT, 1995, SCIENCE, V267, P1274, DOI 10.1126/science.267.5202.1274; WHITNEY TM, 1993, SCIENCE, V261, P1316, DOI 10.1126/science.261.5126.1316; Y Chigusa, 1986, OPTOELECTRON DEVICES, V1, P203; YAN MD, 1993, J AM CHEM SOC, V115, P814, DOI 10.1021/ja00055a078; ZHOU HS, 1994, CHEM MATER, V6, P1534, DOI 10.1021/cm00045a010	26	54	74	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 25	1995	269	5227					1078	1080		10.1126/science.7652555	http://dx.doi.org/10.1126/science.7652555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652555				2022-12-24	WOS:A1995RQ74800036
J	TSUKIHARA, T; AOYAMA, H; YAMASHITA, E; TOMIZAKI, T; YAMAGUCHI, H; SHINZAWAITOH, K; NAKASHIMA, R; YAONO, R; YOSHIKAWA, S				TSUKIHARA, T; AOYAMA, H; YAMASHITA, E; TOMIZAKI, T; YAMAGUCHI, H; SHINZAWAITOH, K; NAKASHIMA, R; YAONO, R; YOSHIKAWA, S			STRUCTURES OF METAL SITES OF OXIDIZED BOVINE HEART CYTOCHROME-C-OXIDASE AT 2.8 ANGSTROM	SCIENCE			English	Article							MACROMOLECULAR CRYSTALLOGRAPHY; RESOLUTION; BINDING; COMPLEX; OXYGEN	The high resolution three-dimensional x-ray structure of the metal sites of bovine heart cytochrome c oxidase is reported. Cytochrome c oxidase is the largest membrane protein yet crystallized and analyzed at atomic resolution. Electron density distribution of the oxidized bovine cytochrome c oxidase at 2.8 Angstrom resolution indicates a dinuclear copper center with an unexpected structure similar to a [2Fe-2S]-type iron-sulfur center. Previously predicted zinc and magnesium sites have been located, the former bound by a nuclear encoded subunit on the matrix side of the membrane, and the latter situated between heme a(3) and Cu-A, at the interface of subunits I and II. The O-2 binding site contains heme a(3) iron and copper atoms (Cu-B) with an interatomic distance of 4.5 Angstrom; there is no detectable bridging ligand between iron and copper atoms in spite of a strong antiferromagnetic coupling between them. A hydrogen bond is present between a hydroxyl group of the hydroxyfarnesylethyl side chain of heme a(3) and an OH of a tyrosine. The tyrosine phenol plane is immediately adjacent and perpendicular to an imidazole group bonded to Cu-B, suggesting a possible role in intramolecular electron transfer or conformational control, the latter of which could induce the redox-coupled proton pumping. A phenyl group located halfway between a pyrrole plane of the heme a(3) and an imidazole plane liganded to the other home (heme a) could also influence electron transfer or conformational control.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University	TSUKIHARA, T (corresponding author), HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGOHRI AKOH,HYOGO 67812,JAPAN.		Yamashita, Eiki/V-6758-2019	Yamashita, Eiki/0000-0002-4278-0039; Aoyama, Hiroshi/0000-0001-7915-8975				BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAKER GM, 1987, J BIOL CHEM, V262, P595; BERTAGNOLLI H, 1995, ANGEW CHEM INT EDIT, V34, P771, DOI 10.1002/anie.199507711; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, V32, P832; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CAUGHEY WS, 1969, J BIOL CHEM, V250, P7602; EINERSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013; EINERSDOTTIR O, 1985, BIOCHEM BIOPH RES CO, V129, P840; ESPE MP, 1995, BIOCHEMISTRY-US, V34, P7593, DOI 10.1021/bi00023a005; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HILL BC, 1991, J BIOL CHEM, V266, P2219; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1983, TRENDS BIOCHEM SCI, V8, P398, DOI 10.1016/0968-0004(83)90302-X; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRONECK PMH, 1988, FEBS LETT, V247, P70; LEE SC, 1993, J AM CHEM SOC, V115, P5833, DOI 10.1021/ja00066a065; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MALMSTROM BG, 1993, FEBS LETT, V325, P49, DOI 10.1016/0014-5793(93)81411-R; NANTHAKUMAR A, 1993, J AM CHEM SOC, V115, P8513, DOI 10.1021/ja00071a097; OBLAD M, 1989, BIOCHIM BIOPHYS ACTA, V975, P267, DOI 10.1016/S0005-2728(89)80257-9; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; OTWINOWSKI Z, 1985, DENZO FILM PROCESSIN; PALMER G, 1976, P NATL ACAD SCI USA, V73, P2206, DOI 10.1073/pnas.73.7.2206; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; SEITER CHA, 1980, P NATL ACAD SCI-BIOL, V77, P1806, DOI 10.1073/pnas.77.4.1806; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Warburg O, 1929, BIOCHEM Z, V214, P64; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; YOSHIKAWA S, UNPUB	43	1281	1291	3	137	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 25	1995	269	5227					1069	1074		10.1126/science.7652554	http://dx.doi.org/10.1126/science.7652554			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ748	7652554				2022-12-24	WOS:A1995RQ74800034
J	LECKBAND, D				LECKBAND, D			THE SURFACE FORCE APPARATUS - A TOOL FOR PROBING MOLECULAR PROTEIN INTERACTIONS	NATURE			English	Article							ADHESION; LIQUIDS	Force measurements can probe directly the molecular impact of proteins' electrostatic surface properties, specific bond strengths, membrane composition, and membrane fluidity on biological recognition events.			LECKBAND, D (corresponding author), UNIV ILLINOIS,DEPT CHEM ENGN,URBANA,IL 61801, USA.		Ueno, Hiroshi/C-3301-2009					BALGI G, 1995, BIOPHYS J, V68, P2251, DOI 10.1016/S0006-3495(95)80407-8; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; HELM CA, 1992, BIOCHEMISTRY-US, V31, P1794, DOI 10.1021/bi00121a030; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HUNTER RJ, 1989, F COLLOID SCI, V1; ISRAELAC.JN, 1973, J COLLOID INTERF SCI, V44, P259, DOI 10.1016/0021-9797(73)90218-X; ISRAELACHVILI J, 1987, P NATL ACAD SCI USA, V84, P4722, DOI 10.1073/pnas.84.14.4722; ISRAELACHVILI JN, 1978, J CHEM SOC FARAD T 1, V74, P975, DOI 10.1039/f19787400975; ISRAELACHVILI JN, 1992, SURF SCI REP, V14, P109, DOI 10.1016/0167-5729(92)90015-4; Lauffenburger D.A., 1993, RECEPTORS MODELS BIN; LECKBAND D, 1993, ENZYME MICROB TECH, V15, P450, DOI 10.1016/0141-0229(93)90077-F; LECKBAND D, IN PRESS BIOCHEMISTR; LECKBAND D, IN PRESS BIOPHYS J; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; LEE CS, 1989, P NATL ACAD SCI USA, V86, P8392, DOI 10.1073/pnas.86.21.8392; MARRA J, 1986, BIOPHYS J, V49, P815; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.bb.18.060189.000553; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; OKUSA H, 1994, LANGMUIR, V10, P3577, DOI 10.1021/la00022a034; PATEL SS, 1989, ANNU REV PHYS CHEM, V40, P597; TABOR D, 1969, PROC R SOC LON SER-A, V312, P435, DOI 10.1098/rspa.1969.0169; TIMBS MM, 1991, BIOCHIM BIOPHYS ACTA, V1064, P219, DOI 10.1016/0005-2736(91)90305-R	23	52	54	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					617	618		10.1038/376617a0	http://dx.doi.org/10.1038/376617a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637815				2022-12-24	WOS:A1995RP75600059
J	NELSON, R; NORTON, N; CAUTLEY, E; FURNER, S				NELSON, R; NORTON, N; CAUTLEY, E; FURNER, S			COMMUNITY-BASED PREVALENCE OF ANAL INCONTINENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							FECAL INCONTINENCE	Objective.-To determine the prevalence of and Characteristics associated with anal incontinence in the general community. Setting.-Community survey. Participants.-The population of the state of Wisconsin sampled in the Wisconsin Family Health Survey. Subjects were identified by random digit dialing with telephone interview. The individual within each household identified as most knowledgeable about the health status of all other members of the household was asked about the health status of each member of the household. Approximately 200 households were surveyed each month. Main Outcome Measures.-The presence of anal incontinence to solid or liquid feces or gas, who suffered from it, the frequency of anal incontinence, and how the incontinent person coped with it. Results.-A total of 2570 households comprising 6959 individuals were surveyed, and 153 individuals were reported to have anal incontinence, representing 2.2% of the population (95% confidence interval [Cl], +/-0.3%). Thirty percent of the incontinent subjects were older than 65 years, and 63% were women. Of those with anal incontinence, 36% were incontinent to solid feces, 54% to liquid feces, and 60% to gas, In a multivariate analysis, independent associations of the following risk factors with anal incontinence were found: female sex (odds ratio [OR], 1.5, Cl, 1.1 to 2.1), age (continuously adjusted) (OR, 1.01; Cl, 1.01 to 1.02), physical limitations (OR, 1.8; Cl, 1.2 to 2.7), and poor general health (OR, 1.6, Cl, 1.4 to 1.9). Conclusions.-Anal incontinence was reported in 2.2% of the general population. Independent risk factors for incontinence include female sex, advancing age, poor general health, and physical limitations.	UNIV ILLINOIS,COLL MED,DEPT SURG,COLON & RECTAL SURG SECT,CHICAGO,IL; UNIV ILLINOIS,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,CHICAGO,IL; INT FDN BOWEL DYSFUNCT,MILWAUKEE,WI; STATE WISCONSIN DEPT HLTH & SOCIAL SERV,MADISON,WI	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								CAMPBELL AJ, 1985, AGE AGEING, V14, P65, DOI 10.1093/ageing/14.2.65; DEAN AG, 1991, EPI INFO MANUAL VERS; DENIS P, 1992, GASTROEN CLIN BIOL, V16, P344; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; DROSSMAN DA, 1989, AM J GASTROENTEROL, V84, P355; KOK ALM, 1992, AGE AGEING, V21, P211, DOI 10.1093/ageing/21.3.211; LEIGH RJ, 1982, LANCET, V1, P1349; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MADOFF RD, 1992, NEW ENGL J MED, V326, P1002; SCHILLER LR, 1982, NEW ENGL J MED, V307, P1666, DOI 10.1056/NEJM198212303072702; SMALL KA, 1990, AUST NZ J OBSTET GYN, V90, P41; Thomas T M, 1984, Community Med, V6, P216; 1994, 1993 WISCONSIN FAMIL; 1989, VITAL HLTH STAT 14, V33; 1994, PROFILE WISCONSIN NU	15	482	499	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					559	561		10.1001/jama.274.7.559	http://dx.doi.org/10.1001/jama.274.7.559			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629985				2022-12-24	WOS:A1995RN46600027
J	HARMER, M; DAVIES, KA; LUNN, JN				HARMER, M; DAVIES, KA; LUNN, JN			A SURVEY OF ACUTE PAIN SERVICES IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article											HARMER, M (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,DEPT ANAESTHET & INTENS CARE MED,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.							CARTWRIGHT PD, 1991, ANAESTHESIA, V46, P188, DOI 10.1111/j.1365-2044.1991.tb09406.x; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; WHEATLEY RG, 1991, BRIT J ANAESTH, V67, P353, DOI 10.1093/bja/67.3.353; 1990, PAIN SURGERY; 1992, PAIN DISCOMFORT PALL	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					360	361		10.1136/bmj.311.7001.360	http://dx.doi.org/10.1136/bmj.311.7001.360			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640541	Green Published			2022-12-24	WOS:A1995RN46900015
J	TOMLINSON, P; SUGARMAN, ID				TOMLINSON, P; SUGARMAN, ID			COMPLICATIONS WITH SHUNTS IN ADULTS WITH SPINA-BIFIDA	BRITISH MEDICAL JOURNAL			English	Article							INTRACRANIAL-PRESSURE; CHILDREN	Objective-To assess the incidence of malfunction of shunts in adults with spina bifida who have shunts to control hydrocephalus. Design-A retrospective review of the medical notes and contact by questionnaire of adults with spina bifida to assess symptoms, function of shunts, frequency of operative procedures, and follow up. Subjects-110 patients with shunts who attended Lord Mayor Treloar College for the physically disabled between 1978 and 1993. Results-The average (range) number of revisions of shunts per person was 3.6 (0-28). Although 37 patients underwent an emergency operation for revision in their first year of life, there was a continuing low incidence, increasing in the early teenage years, which persisted into the third decade. Intervals between emergency revisions varied:. 202/ 320 occurred within one year of the last shunt operation, 56 occurred after five years, 24 after 10 years, and 15 after 15 or more years. Fifteen patients had chronic intermittent headaches, of whom four died and three suffered severe morbidity. Thirteen died; three had raised intracranial pressure, and four died suddenly; these deaths were presumed to be related to their shunts. Up to the age of 16 there was 100% hospital follow up, but after that only 40% of young adults underwent review, including review of their shunt function. Conclusion-Shunts to control hydrocephalus may fail after many years without symptoms, This is difficult to diagnose and if missed may lead to chronic morbidity and death. As hospital follow up of this group is falling, both general practitioners and hospital doctors must be aware that a shunt may malfunction after prolonged quiescent periods.	LORD MAYOR TRELOAR COLL,ALTON,HANTS,ENGLAND; UNIV SOUTHAMPTON,DEPT CHILD HLTH,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton								BRYDON HL, 1994, EUR J PEDIATR SURG, V4, P37; DOYLE J, 1992, J CLIN MONITOR, V8, P81, DOI 10.1007/BF01618093; DRAKE JM, 1991, J NEUROSURG, V75, P535, DOI 10.3171/jns.1991.75.4.0535; EPSTEIN F, 1982, MONOGR NEURAL SCI, V8, P105; HEMMER R, 1976, DEV MED CHILD NEUROL, V18, P69; HEMMER R, 1982, MONOGR NEURAL SCI, V8, P227; LORBER J, 1982, MONOGR NEUROL SCI, V8, P134; MOSS SM, 1991, EUR J PEDIATR SURG, V1, P25, DOI 10.1055/s-2008-1042533; PIATT JH, 1993, PEDIATR NEUROSURG, V19, P233, DOI 10.1159/000120738; POPLE IK, 1992, CHILD NERV SYST, V8, P124, DOI 10.1007/BF00298265; RICHMOND TS, 1993, CLIN ISSUES CRITICAL, V4, P148; UVEBRANT P, 1992, CHILD NERV SYST, V8, P76, DOI 10.1007/BF00298444	12	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					286	287		10.1136/bmj.311.7000.286	http://dx.doi.org/10.1136/bmj.311.7000.286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633231	Green Published			2022-12-24	WOS:A1995RM71900018
J	MIETTINEN, PJ; BERGER, JE; MENESES, J; PHUNG, Y; PEDERSEN, RA; WERB, Z; DERYNCK, R				MIETTINEN, PJ; BERGER, JE; MENESES, J; PHUNG, Y; PEDERSEN, RA; WERB, Z; DERYNCK, R			EPITHELIAL IMMATURITY AND MULTIORGAN FAILURE IN MICE LACKING EPIDERMAL GROWTH-FACTOR RECEPTOR	NATURE			English	Article							FACTOR EXPRESSION; LUNG MATURATION; MOUSE; GENE; ALPHA; MILK; EGF	SINCE the discovery that epidermal growth factor (EGF) can accelerate opening of the eyelids(1), the EGF receptor (EGF-R) has been extensively studied and is now considered to be a prototype tyrosine kinase receptor(2). Binding of EGF or of transforming growth factor-alpha (TGF-alpha) or other related factors activates the receptor and induces cell proliferation and differentiation. Although it is not found on haematopoietic cells, the EGF-R is widely expressed in mammals and has been implicated in various stages of embryonic development(3). Here we investigate the developmental and physiological roles of this receptor and its ligands by inactivating the gene encoding EGF-R. We find that EGF-R(-/-) mice survive for up to 8 days after birth and suffer from impaired epithelial development in several organs, including skin, lung and gastrointestinal tract.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEV BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	MIETTINEN, PJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143, USA.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BEARDMORE JM, 1983, PEDIATR RES, V17, P825, DOI 10.1203/00006450-198310000-00012; CATTERTON WZ, 1979, PEDIATR RES, V13, P104, DOI 10.1203/00006450-197902000-00004; COHEN S, 1962, J BIOL CHEM, V237, P1555; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; FONDACCI C, 1994, J CLIN INVEST, V93, P1149, DOI 10.1172/JCI117067; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FUJITA Y, 1991, J CLIN ENDOCR METAB, V72, P1340, DOI 10.1210/jcem-72-6-1340; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GOETZMAN BW, 1993, PEDIATR RES, V35, P30; Hogan B, 1994, MANIPULATING MOUSE E; JOBE AH, 1991, ANN MED, V23, P687, DOI 10.3109/07853899109148104; Joyner AL, 1993, GENE TARGETING PRACT; LUETTEKE NC, 1994, GENE DEV, V6, P399; LUETTEKE NC, 1993, CELL, V73, P249; MALO C, 1982, GASTROENTEROLOGY, V83, P28; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MENARD D, 1988, GASTROENTEROLOGY, V94, P656, DOI 10.1016/0016-5085(88)90236-3; MIETTINEN PJ, 1993, PEDIATR RES, V33, P481, DOI 10.1203/00006450-199305000-00012; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; OKADA M, 1991, LIFE SCI, V48, P1151, DOI 10.1016/0024-3205(91)90452-H; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; PLOPPER CG, 1992, AM J PHYSIOL, V262, pL313, DOI 10.1152/ajplung.1992.262.3.L313; RAABERG L, 1995, PEDIATR RES, V37, P175, DOI 10.1203/00006450-199502000-00009; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIBILLIA M, IN PRESS SCIENCE; SUNDELL HW, 1980, AM J PATHOL, V100, P707; THREADGILL DW, IN PRESS SCIENCE; WARBURTON D, 1992, DEV BIOL, V149, P123, DOI 10.1016/0012-1606(92)90269-M; YASUI S, 1993, PEDIATR PULM, V15, P251, DOI 10.1002/ppul.1950150412	32	819	842	1	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					337	341		10.1038/376337a0	http://dx.doi.org/10.1038/376337a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630400				2022-12-24	WOS:A1995RL44300046
J	MAYADAS, TN; JOHNSON, RC; RAYBURN, H; HYNES, RO; WAGNER, DD				MAYADAS, TN; JOHNSON, RC; RAYBURN, H; HYNES, RO; WAGNER, DD			LEUKOCYTE ROLLING AND EXTRAVASATION ARE SEVERELY COMPROMISED IN P-SELECTIN-DEFICIENT MICE	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; HUMAN-ENDOTHELIAL-CELLS; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; VONWILLEBRAND-FACTOR; ADHESION DEFICIENCY; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; LUNG INJURY; STEM-CELLS	P selectin, expressed on surfaces of activated endothelial cells and platelets, is an adhesion receptor for leukocytes. We report that P selectin-deficient mice, generated by gene targeting in embryonic stem cells, exhibit a number of defects in leukocyte behavior, including elevated numbers of circulating neutrophils, virtually total absence of leukocyte rolling in mesenteric venules, and delayed recruitment of neutrophils to the peritoneal cavity upon experimentally induced inflammation. These results clearly demonstrate a role for P selectin in leukocyte interactions with the vessel wall and in the early steps of leukocyte recruitment at sites of inflammation. These mutant mice should prove useful in deciphering the contributions of P selectin in various inflammatory responses as well as in platelet functions.	TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; TUFTS UNIV,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CTR CANC RES,CAMBRIDGE,MA 02139	Tufts Medical Center; Tufts University; Tufts University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL042443, T32HL007437] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07437, P01 HL42443, HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1993, CURR OPIN HEMATOL, V1, P113; ATHERTON A, 1973, J PHYSIOL-LONDON, V233, P157, DOI 10.1113/jphysiol.1973.sp010303; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BONFANTI R, 1989, BLOOD, V73, P1109; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FRIES JWU, 1993, IN PRESS AM J PATHOL; FRYDMAN M, 1993, AM J MED GENET, V44, P297; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KOUTTS J, 1978, J CLIN INVEST, V62, P1255, DOI 10.1172/JCI109246; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, INFLAMMATION BASIC P; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, BLOOD, V77, P2553; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS WE, 1992, BLOOD, V80, P795; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; VONANDRIAN UH, 1993, IN PRESS J CLIN INVE; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; Wagner R., 1839, ERLAUTERUNGSTAFELN P; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; WELLER A, 1992, J BIOL CHEM, V267, P15176	55	922	954	2	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					541	554		10.1016/0092-8674(93)80055-J	http://dx.doi.org/10.1016/0092-8674(93)80055-J			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	7688665				2022-12-24	WOS:A1993LT73900015
J	SIGMAN, DS; CHEN, CB; GORIN, MB				SIGMAN, DS; CHEN, CB; GORIN, MB			SEQUENCE-SPECIFIC SCISSION OF DNA BY RNAS LINKED TO A CHEMICAL NUCLEASE	NATURE			English	Article							1,10-PHENANTHROLINE COPPER-ION; DELTA-1 CRYSTALLIN GENE; CLEAVAGE; CONVERSION; SITE		UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV PITTSBURGH,DEPT OPHTHALMOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT HUMAN GENET,PITTSBURGH,PA 15213; EYE & EAR INST,PITTSBURGH,PA 15213	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SIGMAN, DS (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.							BRUICE TW, 1991, J AM CHEM SOC, V113, P5446, DOI 10.1021/ja00014a042; CHEN CHB, 1988, J AM CHEM SOC, V110, P6570, DOI 10.1021/ja00227a052; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; CHEN CHB, 1993, BIOCONJUGATE CHEM, V4, P69, DOI 10.1021/bc00019a010; COREY DR, 1989, BIOCHEMISTRY-US, V28, P8277, DOI 10.1021/bi00447a004; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DERVAN PB, 1992, NATURE, V359, P87, DOI 10.1038/359087a0; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GOYNE TE, 1987, J AM CHEM SOC, V109, P2846, DOI 10.1021/ja00243a060; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LONGMIRE JL, 1987, NUCLEIC ACIDS RES, V15, P859, DOI 10.1093/nar/15.2.859; NICKERSON JM, 1985, J BIOL CHEM, V260, P9100; NICKERSON JM, 1986, J BIOL CHEM, V261, P552; PENDERGRAST PS, 1993, J CELL BIOCHEM, V17, P156; Rosbash M, 1979, Methods Enzymol, V68, P454; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; SIGMAN DS, 1979, J BIOL CHEM, V254, P2269; SIGMAN DS, 1990, ANNU REV BIOCHEM, V59, P207, DOI 10.1146/annurev.biochem.59.1.207; SIGMAN DS, 1993, ACCOUNTS CHEM RES, V26, P98, DOI 10.1021/ar00027a004; SUTTON CL, 1993, BIOCHEMISTRY-US, V32, P4225, DOI 10.1021/bi00067a009; THOMAS M, 1976, P NATL ACAD SCI USA, V73, P2294, DOI 10.1073/pnas.73.7.2294	24	20	21	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					474	475		10.1038/363474a0	http://dx.doi.org/10.1038/363474a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	7684825				2022-12-24	WOS:A1993LE93800067
J	RUPPERT, S; WANG, EH; TJIAN, R				RUPPERT, S; WANG, EH; TJIAN, R			CLONING AND EXPRESSION OF HUMAN TAF(II)250 - A TBP-ASSOCIATED FACTOR IMPLICATED IN CELL-CYCLE REGULATION	NATURE			English	Article							BINDING-PROTEIN; TFIID COMPLEX; MUTANTS; TRANSCRIPTION; COACTIVATORS; PROGRESSION; ACTIVATION; SYSTEM; GENES; CCG1	BASAL transcription by human RNA polymerase II requires the coordinate action of several ancillary factors (TFIIA-J)1 and can be regulated by various promoter-specific DNA binding proteins. An additional class of factors, called coactivators, are dispensable for basal transcription but are indispensable for regulation by transcriptional activators2-4. Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex3-6. We therefore set out to define the relationship between TBP and these TBP-associated factors (TAFs). Here we describe the cloning, expression and properties of the first human TAF, hTAF(II)250. The hTAF(II)250 gene is identical to a gene, CCG1 (refs 7, 8), implicated in cell-cycle progression. Recombinant hTAF(II)250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex. This largest TAF may therefore play a central role in TFIID assembly by interacting with both TBP and other TAFs, as well as serving to link the control of transcription to the cell cycle.			RUPPERT, S (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,401 BARKER HALL,BERKELEY,CA 94720, USA.							CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOEY T, 1993, CELL, V72, P1; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LIU HT, 1985, J BIOL CHEM, V260, P3269; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	22	223	252	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					175	179		10.1038/362175a0	http://dx.doi.org/10.1038/362175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680771				2022-12-24	WOS:A1993KR02800065
J	IMAI, Y; LASKY, LA; ROSEN, SD				IMAI, Y; LASKY, LA; ROSEN, SD			SULFATION REQUIREMENT FOR GLYCAM-1, AN ENDOTHELIAL LIGAND FOR L-SELECTIN	NATURE			English	Article							LYMPHOCYTE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE LIGAND; CELL-ADHESION; SIALYL-LEX; RECOGNITION; ELAM-1; RECIRCULATION; CDNA	L-SELECTIN participates in the initial attachment of leukocytes to the vascular endothelium1-3. On lymphocytes, it mediates binding to high endothelial venules of lymph nodes. As a selectin 4-6 it functions as a calcium-dependent lectin7,8 recognizing carbohydrate-bearing ligands on endothelial cells9-11. Two lymph node ligands for L-selectin have been identified as sulphated glycoproteins of M(r) approximately 50K and approximately 90K, called Sgp50 and Sgp90 (ref. 10). The recently cloned Sgp50 (ref 12), now designated GlyCAM-1, is a high endothelial venule-associated, mucin-like glycoprotein containing predominantly O-linked carbohydrate chains. Sialylation of GlyCAM-1 is necessary for its ligand activity9,10,13 and a role for fucosylation is suspected13. We have used chlorate as a metabolic inhibitor of sulphation, and report here that GlyCAM-1 has an additional requirement for sulphate.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM IMMUNOL,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT IMMUNOBIOL,S SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Roche Holding; Genentech			Imai, Yasuyuki/E-8701-2010	Imai, Yasuyuki/0000-0002-8937-0221				BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; IMAI Y, IN PRESS GLYCOCONJUG; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725	29	338	350	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					555	557						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	7679207				2022-12-24	WOS:A1993KL71400067
J	KORPI, ER; KLEINGOOR, C; KETTENMANN, H; SEEBURG, PH				KORPI, ER; KLEINGOOR, C; KETTENMANN, H; SEEBURG, PH			BENZODIAZEPINE-INDUCED MOTOR IMPAIRMENT LINKED TO POINT MUTATION IN CEREBELLAR GABA(A) RECEPTOR	NATURE			English	Article							ANT RAT LINE; <H-3>RO 15-4513; PLASMID DNA; CELLS; SENSITIVITY; CHANNELS; BINDING; INVERSE; BRAIN	THE selectively outbred alcohol-non-tolerant (ANT) rat line1 is highly susceptible to impairment of postural reflexes by benzodiazepine agonists2 such as diazepam. ANT cerebella are generally devoid3 of diazepam-insensitive high-affinity binding of the benzodiazepine [H-3]Ro15-4513 (refs 4, 5), whereas in non-selected strains such binding marks a granule-cell-specific GABA(A) (gamma-aminobutyric acid) receptor containing the alpha6 subunit5,6. A critical determinant for diazepam insensitivity of this 'wild-type' cerebellar GABA(A) receptor is an arginine residue7 in alpha6 position 100, where other alpha subunits carry a histidine8. Here we report that the alpha6 gene of ANT rats is expressed at wild-type levels but carries a point mutation generating an arginine-to-glutamine substitution at position 100. In consequence, alpha6(Q100)beta2gamma2 receptors show diazepam-mediated potentiation of GABA-activated currents and diazepam-sensitive binding of [H-3]Ro15-4513. Our results suggest that cerebellar motor control may be a distinct behavioural correlate of the alpha6-subunit-containing GABA(A) receptor subtype.	ALKO LTD,BIOMED RES CTR,SF-00101 HELSINKI,FINLAND; UNIV HEIDELBERG,DEPT NEUROBIOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	KORPI, ER (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL,MOLEC NEUROENDOCRINOL LAB,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY.		Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Eriksson K., 1981, DEV ANIMAL MODELS PH, P87; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS RA, 1989, FASEB J, V3, P1689, DOI 10.1096/fasebj.3.6.2467834; HELLEVUO K, 1989, PHARMACOL BIOCHEM BE, V34, P399, DOI 10.1016/0091-3057(89)90333-X; KLEINGOOR C, 1991, NEUROSCI LETT, V130, P169, DOI 10.1016/0304-3940(91)90389-B; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MALMINIEMI O, 1989, EUR J PHARMACOL, V169, P53, DOI 10.1016/0014-2999(89)90816-9; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; ROTHSTEIN JD, 1992, J NEUROCHEM, V58, P2102, DOI 10.1111/j.1471-4159.1992.tb10952.x; SANGAMESWARAN L, 1985, P NATL ACAD SCI USA, V82, P5560, DOI 10.1073/pnas.82.16.5560; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TUOMINEN K, 1991, PHARMACOL BIOCHEM BE, V40, P409, DOI 10.1016/0091-3057(91)90572-J; UUSIOUKARI M, 1990, J NEUROCHEM, V54, P1980, DOI 10.1111/j.1471-4159.1990.tb04901.x; UUSIOUKARI M, 1991, ALCOHOL CLIN EXP RES, V15, P241, DOI 10.1111/j.1530-0277.1991.tb01864.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; WISDEN W, 1992, J NEUROSCI, V12, P1040	24	220	224	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					356	359		10.1038/361356a0	http://dx.doi.org/10.1038/361356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	7678923				2022-12-24	WOS:A1993KJ59000059
J	CARR, TW				CARR, TW			NATURAL-HISTORY OF PROSTATE-CANCER	LANCET			English	Editorial Material											CARR, TW (corresponding author), SOUTHEND HOSP,DEPT UROL,ESSEX,ENGLAND.							ANDREWS GS, 1949, J CLIN PATHOL, V2, P197, DOI 10.1136/jcp.2.3.197; CARR TW, 1988, LANCET, V1, P776; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; FAIR WR, 1992, PROSTATE S, V4, P79; FRANKS LM, 1956, LANCET, V2, P1037; GEORGE NJR, 1988, LANCET, V1, P494; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; HANKS GE, 1988, LANCET, V2, P217; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LERNER SP, 1991, J UROLOGY, V146, P1040, DOI 10.1016/S0022-5347(17)37997-1; Madsen P O, 1988, Scand J Urol Nephrol Suppl, V110, P95; WHITMORE WF, 1991, CANCER, V67, P1092	13	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					91	92		10.1016/0140-6736(93)92565-B	http://dx.doi.org/10.1016/0140-6736(93)92565-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	7678121				2022-12-24	WOS:A1993KF87000012
J	TOKGOZOGLU, LS; ASHIZAWA, T; PACIFICO, A; ARMSTRONG, RM; EPSTEIN, HF; ZOGHBI, WA				TOKGOZOGLU, LS; ASHIZAWA, T; PACIFICO, A; ARMSTRONG, RM; EPSTEIN, HF; ZOGHBI, WA			CARDIAC INVOLVEMENT IN A LARGE KINDRED WITH MYOTONIC-DYSTROPHY - QUANTITATIVE ASSESSMENT AND RELATION TO SIZE OF CTG REPEAT EXPANSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMISSION COMPUTED-TOMOGRAPHY; TRINUCLEOTIDE CAG REPEAT; MUSCULAR-DYSTROPHY; MESSENGER-RNA; ECHOCARDIOGRAPHIC EVALUATION; CONDUCTION SYSTEM; TRIPLET REPEAT; GCT REPEAT; DISEASE; PROTEIN	Objective.-To evaluate and quantitate cardiac involvement in myotonic dystrophy and assess whether the size of the trinucleotide (cytosine-thymine-guanine [CTG]) repeat expansion is a significant predictor of cardiac abnormalities. Design.-Case-control study of a large kindred with myotonic dystrophy. Patients.-Ninety-one bloodline members of the kindred underwent clinical and cardiac evaluation with electrocardiograms, echocardiography (with Doppler in the majority of cases), and genetic and neurologic evaluations. Affected individuals were age-matched to normal family members. Main Outcome Measures.-Electrocardiographic conduction abnormalities, wall motion abnormalities, mitral valve prolapse, and global parameters of systolic and diastolic function were determined by an observer blinded to all clinical data and genetic analysis. Results.-Compared with age-matched normals, patients with myotonic dystrophy (n=25) were more likely to have conduction abnormality (52% vs 9%), mitral valve prolapse (32% vs 9%), and wall motion abnormality (28% vs 0%) (all P<.05). Left ventricular ejection fraction and stroke volume were reduced compared with normals matched for age and heart rate (P<.05), whereas Doppler indexes of diastolic function were only marginally altered. Using multivariate analysis, the number of CTG repeats (range, 69 to 1367; normal, less than or equal to 37) was the strongest predictor of abnormalities in wall motion and electrocardiographic conduction (odds ratio of 16.5 and 5.07 per 500 repeats, respectively). The relation of mitral valve prolapse to the size of the CTG repeat was of borderline significance, Patients with more extensive neurologic findings (n=12) had a higher incidence of wall motion and/or electrocardiographic conduction abnormalities (83% vs 43%; P=.04). Conclusions.-Cardiac involvement in myotonic dystrophy affects predominantly the conduction system and myocardial function. Alterations in myocardial relaxation and diastolic properties, in contrast to skeletal muscle myotonia, are minor. In this kindred, the number of CTG repeats was a significant predictor of cardiac dysfunction in myotonic dystrophy.	METHODIST HOSP,ECHOCARDIOG LAB,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,CARDIOL SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030; VET AFFAIRS MED CTR,HOUSTON,TX 77030	The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ANVRET M, 1993, HUM MOL GENET, V2, P1397, DOI 10.1093/hmg/2.9.1397; ASHIZAWA T, 1993, NEUROLOGY, V43, P2674, DOI 10.1212/WNL.43.12.2674; ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; ASHIZAWA T, 1992, NEUROLOGY, V42, P1877; ASHIZAWA T, 1992, AM J MED GENET, V42, P55, DOI 10.1002/ajmg.1320420113; BHARATI S, 1984, CHEST, V86, P444, DOI 10.1378/chest.86.3.444; BORGESNETO S, 1988, J AM COLL CARDIOL, V11, P962, DOI 10.1016/S0735-1097(98)90052-3; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1989, GENOMICS, V5, P589, DOI 10.1016/0888-7543(89)90027-X; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CHURCH SC, 1967, ARCH INTERN MED, V119, P176, DOI 10.1001/archinte.119.2.176; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; FORSBERG H, 1988, CARDIOLOGY, V75, P241, DOI 10.1159/000174380; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GOTTDIENER JS, 1982, AM HEART J, V104, P77, DOI 10.1016/0002-8703(82)90644-5; GRIFFITH TW, 1911, QUART J MED, V5, P229; GRIGGS RC, 1975, AM J MED, V59, P37, DOI 10.1016/0002-9343(75)90319-8; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1992, AM J HUM GENET, V51, P10; HARPER PS, 1989, MYOTONIC DYSTROPHY, P13; HARTWIG GB, 1983, NEUROLOGY, V33, P657, DOI 10.1212/WNL.33.5.657; HIROMASA S, 1987, AM HEART J, V113, P1482, DOI 10.1016/0002-8703(87)90665-X; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; JANSEN G, 1994, AM J HUM GENET, V54, P575; KOVICK RB, 1975, CIRCULATION, V52, P447, DOI 10.1161/01.CIR.52.3.447; LAVEDAN C, 1993, AM J HUM GENET, V52, P875; LEWIS JF, 1984, CIRCULATION, V3, P425; MAHMARIAN JJ, 1990, J AM COLL CARDIOL, V15, P318, DOI 10.1016/S0735-1097(10)80055-5; MELACINI P, 1988, CLIN CARDIOL, V11, P231, DOI 10.1002/clc.4960110407; MOORMAN JR, 1985, MEDICINE, V64, P371, DOI 10.1097/00005792-198511000-00002; MOTTA J, 1979, AM J MED, V67, P467, DOI 10.1016/0002-9343(79)90795-2; MULVAGH S, 1992, J AM COLL CARDIOL, V20, P112, DOI 10.1016/0735-1097(92)90146-E; NGUYEN HH, 1988, J AM COLL CARDIOL, V11, P662, DOI 10.1016/0735-1097(88)91547-1; NOVELLI G, 1993, BIOCHEM MOL BIOL INT, V29, P291; NOVELLI G, 1993, BIOCHEM MED METAB B, V50, P85, DOI 10.1006/bmmb.1993.1049; OLOFSSON BO, 1988, BRIT HEART J, V59, P47; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PAYNE CA, 1963, AM HEART J, V65, P436, DOI 10.1016/0002-8703(63)90092-9; PERLOFF JK, 1984, AM J CARDIOL, V54, P1074, DOI 10.1016/S0002-9149(84)80147-2; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; REEVES WC, 1980, ARCH NEUROL-CHICAGO, V37, P273, DOI 10.1001/archneur.1980.00500540051004; RICKER K, 1994, NEUROLOGY, V44, P1448, DOI 10.1212/WNL.44.8.1448; ROKEY R, 1985, CIRCULATION, V71, P543, DOI 10.1161/01.CIR.71.3.543; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; SCHILLER NB, 1989, J AM SOC ECHO, V5, P358; SMITH M D, 1991, Cardiology Clinics, V9, P193; STREIB EW, 1985, MUSCLE NERVE, V8, P650, DOI 10.1002/mus.880080804; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; VANREET RE, 1984, J AM COLL CARDIOL, V3, P243, DOI 10.1016/S0735-1097(84)80007-8; VENCO A, 1978, BRIT HEART J, V40, P1262; WEYMAN AE, 1994, PRINCIPLES PRACTICE, P391; WINTERS SJ, 1976, ANN INTERN MED, V85, P19, DOI 10.7326/0003-4819-85-1-19; WINTZEN AR, 1987, J NEUROL SCI, V80, P259, DOI 10.1016/0022-510X(87)90160-2; ZOGHBI WA, 1990, CIRCULATION, V82, P1316, DOI 10.1161/01.CIR.82.4.1316	59	64	65	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					813	819		10.1001/jama.274.10.813	http://dx.doi.org/10.1001/jama.274.10.813			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650805				2022-12-24	WOS:A1995RU32400029
J	HARTLEY, KO; GELL, D; SMITH, GCM; ZHANG, H; DIVECHA, N; CONNELLY, MA; ADMON, A; LEESMILLER, SP; ANDERSON, CW; JACKSON, SP				HARTLEY, KO; GELL, D; SMITH, GCM; ZHANG, H; DIVECHA, N; CONNELLY, MA; ADMON, A; LEESMILLER, SP; ANDERSON, CW; JACKSON, SP			DNA-DEPENDENT PROTEIN-KINASE CATALYTIC SUBUNIT - A RELATIVE OF PHOSPHATIDYLINOSITOL 3-KINASE AND THE ATAXIA-TELANGIECTASIA GENE-PRODUCT	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; KU-AUTOANTIGEN; PHOSPHORYLATION; ANTIGEN; REPAIR	DNA-dependent protein kinase (DNA-PK), which is involved in DNA double-stranded break repair and V(D)J recombination, comprises a DNA-targeting component called Ku and an similar to 460 kDa catalytic subunit, DNA-PKcs. Here, we describe the cloning of the DNA-PKcs cDNA and show that DNA-PKcs falls into the phosphatidylinositol (PI) 3-kinase family. Biochemical assays, however, indicate that DNA-PK phosphorylates proteins but has no detectable activity toward lipids, Strikingly, DNA-PKcs is most similar to PI kinase family members involved in cell cycle control, DNA repair, and DNA damage responses. These include the FKBP12-rapamycin-binding proteins Tor1p, Tor2p, and FRAP, S. pombe rad3, and the product of the ataxia telangiectasia gene, mutations in which lead to genomic instability and predisposition to cancer. The relationship of these proteins to DNA-PKcs provides important clues to their mechanisms of action.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; BABRAHAM INST,INOSITIDE LAB,CAMBRIDGE CB2 4AT,ENGLAND; TECHNION ISRAEL INST TECHNOL,IL-32000 HAIFA,ISRAEL	University of Cambridge; United States Department of Energy (DOE); Brookhaven National Laboratory; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Technion Israel Institute of Technology	HARTLEY, KO (corresponding author), UNIV CAMBRIDGE,WELCOME TRUST,CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Gell, David/0000-0003-0382-1181; Admon, Arie/0000-0003-0504-3950; divecha, nullin/0000-0001-9695-6039; Lees-Miller, Susan/0000-0001-5809-2516	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, IN PRESS TRENDS BIOC; JEGGO PA, 1995, IN PRESS BIOESSAYS; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; OKADA T, 1994, J BIOL CHEM, V269, P3563; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	34	668	692	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					849	856		10.1016/0092-8674(95)90482-4	http://dx.doi.org/10.1016/0092-8674(95)90482-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671312	Bronze			2022-12-24	WOS:A1995RU75500020
J	MOL, CD; ARVAI, AS; SANDERSON, RJ; SLUPPHAUG, G; KAVLI, B; KROKAN, HE; MOSBAUGH, DW; TAINER, JA				MOL, CD; ARVAI, AS; SANDERSON, RJ; SLUPPHAUG, G; KAVLI, B; KROKAN, HE; MOSBAUGH, DW; TAINER, JA			CRYSTAL-STRUCTURE OF HUMAN URACIL-DNA GLYCOSYLASE IN COMPLEX WITH A PROTEIN INHIBITOR - PROTEIN MIMICRY OF DNA	CELL			English	Article							BACTERIOPHAGE-PBS2; DEAMINATION; GENE	Uracil-DNA glycosylase inhibitor (Ugi) is a B. subtilis bacteriophage protein that protects the uracil-containing phage DNA by irreversibly inhibiting the key DNA repair enzyme uracil-DNA glycosylase (UDG). The 1.9 Angstrom crystal structure of Ugi complexed to human UDG reveals that the Ugi structure, consisting of a twisted five-stranded antiparallel beta sheet and two alpha helices, binds by inserting a beta strand into the conserved DNA-binding groove of the enzyme without contacting the uracil specificity pocket, The resulting interface, which buries over 1200 Angstrom(2) on Ugi and involves the entire beta sheet and an alpha helix, is polar and contains 22 water molecules. Ugi binds the sequence-conserved DNA-binding groove of UDG via shape and electrostatic complementarity, specific charged hydrogen bonds, and hydrophobic packing enveloping Leu-272 from a protruding UDG loop. The apparent mimicry by Ugi of DNA interactions with UDG provides both a structural mechanism for UDG binding to DNA, including the enzyme-assisted expulsion of uracil from the DNA helix, and a crystallographic basis for the design of inhibitors with scientific and therapeutic applications.	OREGON STATE UNIV, DEPT AGR CHEM, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, CTR ENVIRONM HLTH SCI, CORVALLIS, OR 97331 USA; UNIV TRONDHEIM, UNIGEN CTR MOLEC BIOL, N-7005 TRONDHEIM, NORWAY	Oregon State University; Oregon State University; Oregon State University	MOL, CD (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES BLVD, LA JOLLA, CA 92037 USA.		Tainer, John/GWQ-4878-2022; Slupphaug, Geir/AAN-3794-2020	Tainer, John/0000-0003-1659-2429; Slupphaug, Geir/0000-0002-7498-3500	NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823, GM46312] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312, R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; BALASUBRAMANIAN S, 1995, J BIOL CHEM, V270, P296, DOI 10.1074/jbc.270.1.296; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICHARDSON JS, 1989, PREDICTION PROTEIN S, P2; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VERRI A, 1992, BIOCHEM J, V287, P1007, DOI 10.1042/bj2871007; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31	33	235	253	1	14	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					701	708		10.1016/0092-8674(95)90467-0	http://dx.doi.org/10.1016/0092-8674(95)90467-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7671300	Bronze			2022-12-24	WOS:A1995RU75500005
J	MILLER, E; WAIGHT, PA; TEDDER, RS; SUTHERLAND, S; MORTIMER, PP; SHAFI, MS				MILLER, E; WAIGHT, PA; TEDDER, RS; SUTHERLAND, S; MORTIMER, PP; SHAFI, MS			INCIDENCE OF HIV-INFECTION IN HOMOSEXUAL MEN IN LONDON, 1988-94	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,LONDON W1P 6DB,ENGLAND; UNIV LONDON KINGS COLL,DULWICH HOSP,SCH MED & DENT,PUBL HLTH LAB,LONDON SE22 8QF,ENGLAND; CENT PUBL HLTH LAB,DIV VIRUS REFERENCE,LONDON NW9 5HT,ENGLAND; CENT MIDDLESEX HOSP NHS TRUST,PUBL HLTH LAB,LONDON NW10 7NS,ENGLAND	University of London; University College London; University of London; King's College London; Public Health England	MILLER, E (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.			Shafi, Shuja/0000-0002-4659-8365; Tedder, Richard/0000-0002-9672-5721				HEYWARD WL, 1994, AIDS, V8, P1285, DOI 10.1097/00002030-199409000-00011; Waight P A, 1992, Commun Dis Rep CDR Rev, V2, pR85; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V76, P685	3	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					545	545		10.1136/bmj.311.7004.545	http://dx.doi.org/10.1136/bmj.311.7004.545			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RR737	7663211	Green Published			2022-12-24	WOS:A1995RR73700021
J	HANSEN, SK; TJIAN, R				HANSEN, SK; TJIAN, R			TAFS AND TFIIA MEDIATE DIFFERENTIAL UTILIZATION OF THE TANDEM ADH PROMOTERS	CELL			English	Article							ALCOHOL-DEHYDROGENASE GENE; DROSOPHILA TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; RNA-POLYMERASE; 2 PROMOTERS; CELL-LINES; FAT-BODY; MELANOGASTER; EXPRESSION; ENHANCER	The D. melanogaster alcohol dehydrogenase (Adh) gene is transcribed from two tandem promoters that are differentially utilized at various stages during development. To determine the mechanism of promoter selectivity, we have analyzed the activity of the Adh promoters both in vitro and in transfected cells. We found that selective promoter utilization is controlled by distinct initiator elements. Reconstitution of Adh transcription with purified components requires a specific TBP-TAF complex that, in concert with TFIIA, directs differential Adh promoter transcription. Fractionation of this TBP-TAF complex reveals that TAF(II)150 is required for discrimination between the proximal and distal promoters. We propose a mechanism for regulating differential promoter utilization during Drosophila development that involves the recognition of specific initiator elements by TAFs in the TFIID complex.			HANSEN, SK (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; ABEL T, 1993, DEVELOPMENT, V119, P623; AYER S, 1990, MOL CELL BIOL, V10, P3512, DOI 10.1128/MCB.10.7.3512; AYER S, 1992, MOL CELL BIOL, V12, P661, DOI 10.1128/MCB.12.2.661; BENYAJATI C, 1987, NUCLEIC ACIDS RES, V15, P7903, DOI 10.1093/nar/15.19.7903; BENYAJATI C, 1983, CELL, V33, P125, DOI 10.1016/0092-8674(83)90341-0; BENYAJATI C, 1992, NUCLEIC ACIDS RES, V20, P4481, DOI 10.1093/nar/20.17.4481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBIN V, 1989, GENE DEV, V3, P2191, DOI 10.1101/gad.3.12b.2191; CORBIN V, 1990, GENETICS, V124, P637; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; ENGLAND BP, 1990, J BIOL CHEM, V265, P5086; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FRANK DJ, 1995, J BIOL CHEM, V270, P6292, DOI 10.1074/jbc.270.11.6292; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Jackle H, 1993, CURR OPIN CELL BIOL, V5, P505, DOI 10.1016/0955-0674(93)90017-K; JORGENSEN EM, 1987, GENE DEV, V1, P544, DOI 10.1101/gad.1.6.544; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MOSES K, 1990, MOL CELL BIOL, V10, P539, DOI 10.1128/MCB.10.2.539; PETERSON MG, 1991, NATURE, V354, P369; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SAVAKIS C, 1986, DEV BIOL, V114, P194, DOI 10.1016/0012-1606(86)90395-7; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SIMCOX AA, 1985, SOMAT CELL MOLEC GEN, V11, P63, DOI 10.1007/BF01534735; STJOHNSTON D, 1992, CELL, V68, P201; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WEEKS JR, 1982, J BIOL CHEM, V257, P5884; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	43	101	102	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					565	575		10.1016/0092-8674(95)90029-2	http://dx.doi.org/10.1016/0092-8674(95)90029-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664336	Bronze			2022-12-24	WOS:A1995RR73400008
J	LEVYLAHAD, E; WASCO, W; POORKAJ, P; ROMANO, DM; OSHIMA, J; PETTINGELL, WH; YU, CE; JONDRO, PD; SCHMIDT, SD; WANG, K; CROWLEY, AC; FU, YH; GUENETTE, SY; GALAS, D; NEMENS, E; WIJSMAN, EM; BIRD, TD; SCHELLENBERG, GD; TANZI, RE				LEVYLAHAD, E; WASCO, W; POORKAJ, P; ROMANO, DM; OSHIMA, J; PETTINGELL, WH; YU, CE; JONDRO, PD; SCHMIDT, SD; WANG, K; CROWLEY, AC; FU, YH; GUENETTE, SY; GALAS, D; NEMENS, E; WIJSMAN, EM; BIRD, TD; SCHELLENBERG, GD; TANZI, RE			CANDIDATE GENE FOR THE CHROMOSOME-1 FAMILIAL ALZHEIMERS-DISEASE LOCUS	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; CATHEPSIN-E; LINKAGE; MUTATION; KINDREDS; MARKERS	A candidate gene for the chromosome 1 Alzheimer's disease (AD) locus was identified (STM2). The predicted amino acid sequence for STM2 is homologous to that of the recently cloned chromosome 14 AD gene (S182). A point mutation in STM2, resulting in the substitution of an isoleucine for an asparagine (N141I), was identified in affected people from Volga German AD kindreds. This N141I mutation occurs at an amino acid residue that is conserved in human S182 and in the mouse S182 homolog. The presence of missense mutations in AD subjects in two highly similar genes strongly supports the hypothesis that mutations in both are pathogenic.	VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,SEATTLE,WA 98108; MASSACHUSETTS GEN HOSP,GENET & AGING UNIT,BOSTON,MA 02129; DARWIN MOLEC,BOTHELL,WA 98021; UNIV WASHINGTON,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; VET AFFAIRS MED CTR,DIV NEUROL,SEATTLE,WA 98108	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Massachusetts General Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Tanzi, Rudolph/AAE-9622-2019; Schmidt, Stephen/B-5398-2012; Levy-Lahad, Ephrat/F-2186-2018; Schmidt, Stephen/AAC-6967-2019	Tanzi, Rudolph/0000-0002-7032-1454; Levy-Lahad, Ephrat/0000-0002-2637-1921; 	NATIONAL INSTITUTE ON AGING [R01AG011762, R01AG011899] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG11762, AG0513C, R01-AG11899] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AZUMA T, 1992, J BIOL CHEM, V267, P1609; BERNSTEIN HG, 1994, BRAIN RES, V667, P287, DOI 10.1016/0006-8993(94)91509-1; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BIRD TD, 1991, J AM HISTO SOC GERM, V49, P1; BIRD TD, 1992, HETEROGENEITY ALZHEI, P118; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; KAMINO K, 1992, AM J HUM GENET, V51, P998; KOCH F, 1977, VOLGA GERMANS; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MULLAN M, 1992, NAT GENET, V2, P340, DOI 10.1038/ng1292-340; MUNROE DJ, 1995, P NATL ACAD SCI USA, V92, P2209, DOI 10.1073/pnas.92.6.2209; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NAKANISHI H, 1993, EXP NEUROL, V121, P215, DOI 10.1006/exnr.1993.1088; Sambrook J., 1989, MOL CLONING LAB MANU; SCHELLENBERG GD, 1993, AM J HUM GENET, V53, P619; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; Scheuerman R. D., 1985, VOLGA GERMANS PIONEE; SCHEUNER D, IN PRESS SOC NEUR AB; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SONG XH, IN PRESS SOC NEUR AB	30	2066	2151	1	77	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 18	1995	269	5226					973	977		10.1126/science.7638622	http://dx.doi.org/10.1126/science.7638622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP738	7638622				2022-12-24	WOS:A1995RP73800035
J	BOSE, R; VERHEIJ, M; HAIMOVITZFRIEDMAN, A; SCOTTO, K; FUKS, Z; KOLESNICK, R				BOSE, R; VERHEIJ, M; HAIMOVITZFRIEDMAN, A; SCOTTO, K; FUKS, Z; KOLESNICK, R			CERAMIDE SYNTHASE MEDIATES DAUNORUBICIN-INDUCED APOPTOSIS - AN ALTERNATIVE MECHANISM FOR GENERATING DEATH SIGNALS	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SPHINGANINE N-ACYLTRANSFERASE; NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; HL-60 CELLS; ANTICANCER DRUGS; SPHINGOLIPID BIOSYNTHESIS; CHEMOTHERAPEUTIC AGENTS; FUSARIUM-MONILIFORME; SPHINGOMYELIN	The sphingomyelin pathway, which is initiated by sphingomyelin hydrolysis to generate the second messenger ceramide, signals apoptosis for tu mor necrosis factor alpha, Fas, and ionizing radiation. In the present studies, the anticancer drug daunorubicin also stimulated ceramide elevation and apoptosis in P388 and U937 cells, Cell-permeable analogs of ceramide, but not other lipid second messengers, mimicked daunorubicin in inducing apoptosis. Daunorubicin-stimulated ceramide elevation, however, did not result from sphingomyelin hydrolysis, but rather from de novo synthesis via activation of the enzyme ceramide synthase. An obligatory role for ceramide synthase was defined, since its natural specific inhibitor, fumonisin B1, blocked daunorubicin-induced ceramide elevation and apoptosis. These studies demonstrate that ceramide synthase activity can be regulated in eukaryotes and constitute definitive evidence for a requirement for ceramide elevation in the induction of apoptosis.	MEM SLOAN KETTERING CANC CTR,EUKARYOT TRANSCRIPT LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DIV RADIAT ONCOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	BOSE, R (corresponding author), MEM SLOAN KETTERING CANC CTR,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R01CA057400] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462, CA57400, CA42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS DS, 1971, CLIN PHARMACOL THER, V12, P96; ANILKUMAR TV, 1992, BRIT J CANCER, V65, P552, DOI 10.1038/bjc.1992.113; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALABRESI P, 1990, PHARMACOL BASIS THER, P1202; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CIFONE MG, 1994, J EXP MED, V177, P1547; DIVE C, 1993, FRONTIERS PHARM CANC, P21; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUVALL E, 1985, IMMUNOLOGY, V56, P351; DYSON JED, 1986, CELL TISSUE KINET, V19, P311, DOI 10.1111/j.1365-2184.1986.tb00683.x; EPSTEIN RJ, 1990, J CLIN ONCOL, V8, P2062, DOI 10.1200/JCO.1990.8.12.2062; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDM.A, 1994, J EXP MED, V180, P525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAREL R, 1993, J BIOL CHEM, V268, P14476; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LING YH, 1993, CANCER RES, V53, P1845; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SMITH PJ, 1994, ANN HEMATOL, V69, pS7, DOI 10.1007/BF01757348; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPETH PAJ, 1989, SEMIN ONCOL, V16, P2; STRUM JC, 1994, J BIOL CHEM, V269, P15493; THAKKAR NS, 1992, BIOCHEM PHARMACOL, V43, P1683, DOI 10.1016/0006-2952(92)90697-H; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZWELLING LA, 1993, BIOCHEM PHARMACOL, V45, P516, DOI 10.1016/0006-2952(93)90091-A	57	764	798	1	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					405	414		10.1016/0092-8674(95)90429-8	http://dx.doi.org/10.1016/0092-8674(95)90429-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634330	Bronze			2022-12-24	WOS:A1995RP24200010
J	PELLEGRINI, L; SONG, T; RICHMOND, TJ				PELLEGRINI, L; SONG, T; RICHMOND, TJ			STRUCTURE OF SERUM RESPONSE FACTOR CORE BOUND TO DNA	NATURE			English	Article							TERNARY COMPLEX-FORMATION; C-FOS; SACCHAROMYCES-CEREVISIAE; BINDING SPECIFICITIES; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; PROTEIN; MCM1; ELEMENT; SRF	The human serum response factor is a transcription factor belonging to the MADS domain protein family with members characterized from the plant and animal kingdoms. The X-ray crystal structure of the serum response factor core in a specific-recognition DNA complex shows that the functions of DNA binding, dimerization and accessory-factor Interaction are compactly Integrated into a novel protein unit. The intrinsic and induced conformation of the serum response element DNA is the principal DNA feature recognized in the specific complex.	ETH ZURICH,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Pellegrini, Luca/AAE-2312-2022	Pellegrini, Luca/0000-0002-9300-497X				AFFOLTER M, 1994, DEVELOPMENT, V120, P743; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; BRUHN L, 1992, MOL CELL BIOL, V12, P3563, DOI 10.1128/MCB.12.8.3563; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAGEN DC, 1993, MOL CELL BIOL, V13, P6866, DOI 10.1128/MCB.13.11.6866; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LLANG H, 1994, STRUCT BIOL, V1, P871; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAKANO Y, 1991, GENE, V99, P285; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NURRISH SJ, IN PRESS MOL CELL BI; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; Sprague G F Jr, 1990, Adv Genet, V27, P33; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TRELSMAN R, 1994, CURR OPIN GENE DEV, V4, P96; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	51	291	296	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					490	498		10.1038/376490a0	http://dx.doi.org/10.1038/376490a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637780				2022-12-24	WOS:A1995RN62200038
J	BROMBERG, JEC; RINKEL, GJE; ALGRA, A; GREEBE, P; VANDUYN, CM; HASAN, D; LIMBURG, M; TERBERG, HWM; WIJDICKS, EFM; VANGIJN, J				BROMBERG, JEC; RINKEL, GJE; ALGRA, A; GREEBE, P; VANDUYN, CM; HASAN, D; LIMBURG, M; TERBERG, HWM; WIJDICKS, EFM; VANGIJN, J			SUBARACHNOID HEMORRHAGE IN FIRST-DEGREE AND 2ND-DEGREE RELATIVES OF PATIENTS WITH SUBARACHNOID HEMORRHAGE	BRITISH MEDICAL JOURNAL			English	Article							INTRACRANIAL ANEURYSMS; HEMORRHAGE		UNIV ROTTERDAM,DEPT NEUROL,ROTTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,1105 AZ AMSTERDAM,NETHERLANDS; SITTARD HOSP,DEPT NEUROL,SITTARD,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam	BROMBERG, JEC (corresponding author), UNIV UTRECHT,DEPT NEUROL,POB 85500,3508 GA UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008	Hasan, Djo/0000-0003-4610-5433				BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; RONKAINEN A, 1993, NEUROSURGERY, V33, P787; TERBERG HWM, 1992, STROKE, V23, P1024, DOI 10.1161/01.STR.23.7.1024; WANG PS, 1995, ARCH NEUROL-CHICAGO, V52, P202, DOI 10.1001/archneur.1995.00540260108026	5	134	136	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					288	289		10.1136/bmj.311.7000.288	http://dx.doi.org/10.1136/bmj.311.7000.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633233	Green Published			2022-12-24	WOS:A1995RM71900020
J	BUTLER, C; PETERS, J; STOTT, N				BUTLER, C; PETERS, J; STOTT, N			GLYCATED HEMOGLOBIN AND METABOLIC CONTROL OF DIABETES-MELLITUS - EXTERNAL VERSUS LOCALLY ESTABLISHED CLINICAL TARGETS FOR PRIMARY-CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MICROVASCULAR COMPLICATIONS; TASK-PERFORMANCE; GENERAL-PRACTICE; HEMOGLOBIN	Objectives-To examine current targets for glycated haemoglobin as a marker for metabolic control in diabetes mellitus in relation to datasets from several areas, and to consider whether target setting could be improved. Design-Data collected from enhanced care records of general practices for a representative community based sample of people with diabetes. Setting and subjects-3022 people with diabetes on the lists of 37 general practices (total list size 222 550) in South Glamorgan in 1992; samples of glycated haemoglobin had been processed at two laboratories with different methodologies and reference ranges. Main outcome measures-Last glycated haemoglobin level measured in subjects for 1992 and published data from other studies considered in relation to existing goals and standards for the metabolic control of diabetes. Results-An ascertainment rate for people with diabetes of 1.36% was obtained. The rate of data capture for haemoglobin A1 was 75.7%, and the mean level for study samples was 10.5% at one laboratory and 10.0% at the other (similar values to those of comparable studies). These mean levels of haemoglobin A1 in representative populations of people with diabetes are poor or very. poor according to published standards, including those of the British Diabetic Association. These findings are set in the context of the psychology of goal setting and performance in complex clinical situations. Conclusion-Targets for clinical care that are set in the absence of normative data and local feasibility assessments should be treated with caution. Targets are more likely to enhance health care if target setters recognise the importance of psychological aspects of goal setting and motivation.	UNIV WALES HOSP, DEPT MED, CARDIFF CF4 4XW, S GLAM, WALES	Cardiff University	BUTLER, C (corresponding author), UNIV WALES COLL MED, LLANEDEYRN HLTH CTR, DEPT GEN PRACTICE, CARDIFF CF3 7PN, S GLAM, WALES.			Butler, Christopher/0000-0002-0102-3453				ALBERTI KGMM, 1994, DIABETIC MED, V11, P899, DOI 10.1111/j.1464-5491.1994.tb00376.x; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; [Anonymous], 1994, Diabetes Care, V17, P616; BANDURA A, 1991, NEBR SYM MOTIV, V38, P69; BOULTON AJM, 1993, DIABETIC MED, V10, P687, DOI 10.1111/j.1464-5491.1993.tb00148.x; DAY JL, 1992, DIABETIC MED, V9, P855, DOI 10.1111/j.1464-5491.1992.tb01905.x; DECI EL, 1971, J PERS SOC PSYCHOL, V18, P105, DOI 10.1037/h0030644; Deci EL, 1991, NEBR SYM MOTIV, P237; EARLEY PC, 1989, J APPL PSYCHOL, V74, P24, DOI 10.1037/0021-9010.74.1.24; FARMER A, 1991, BRIT J GEN PRACT, V41, P135; GROL R, 1993, BRIT J GEN PRACT, V43, P146; HAINES A, 1992, 58 ROYAL COLL GEN PR; HIGGS ER, 1992, DIABETIC MED, V9, P550, DOI 10.1111/j.1464-5491.1992.tb01837.x; HOWITT AJ, 1993, BRIT MED J, V307, P1046, DOI 10.1136/bmj.307.6911.1046; Krans H., 1992, DIABETES CARE RES EU; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; LESTER E, 1989, ANN CLIN BIOCHEM, V26, P213, DOI 10.1177/000456328902600301; LOCKE EA, 1981, PSYCHOL BULL, V90, P125, DOI 10.1037/0033-2909.90.1.125; McWhinney I. R., 1981, TXB FAMILY MED; MORRIS LS, 1993, CLIN THER, V15, P593; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; NEIL HAW, 1989, DIABETIC MED, V6, P608, DOI 10.1111/j.1464-5491.1989.tb01237.x; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PICKUP JC, 1993, DIABETIC MED, V10, P402, DOI 10.1111/j.1464-5491.1993.tb00090.x; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STOTT NCH, 1994, 1988 1933 U WAL COLL; TUCKET D, 1985, M EXPERTS; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Vroom V.H, 1964, WORK MOTIVATION; WILLIAMS G, 1994, LANCET, V343, P95, DOI 10.1016/S0140-6736(94)90822-2; WOOD RE, 1987, J APPL PSYCHOL, V72, P416, DOI 10.1037/0021-9010.72.3.416; 1993, BRIT MED J, V307, P1542; [No title captured]; 1993, RECOMMENDATIONS MANA	36	37	37	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	1995	310	6982					784	788		10.1136/bmj.310.6982.784	http://dx.doi.org/10.1136/bmj.310.6982.784			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP609	7677834	Green Published			2022-12-24	WOS:A1995QP60900024
J	DURIE, FH; FAVA, RA; FOY, TM; ARUFFO, A; LEDBETTER, JA; NOELLE, RJ				DURIE, FH; FAVA, RA; FOY, TM; ARUFFO, A; LEDBETTER, JA; NOELLE, RJ			PREVENTION OF COLLAGEN-INDUCED ARTHRITIS WITH AN ANTIBODY TO GP39, THE LIGAND FOR CD40	SCIENCE			English	Article							B-CELL ACTIVATION; II COLLAGEN; T-CELLS; PROTEIN; PROLIFERATION; INDUCTION	The ligand for the CD40 antigen is a 39-kilodalton protein, gp39, expressed on the surface of activated CD4+ T cells and is essential for thymus-dependent humoral immunity. The role of gp39-CD40 interactions in autoimmune disease was investigated in vivo with the use of an antibody that blocks their interactions (anti-gp39). Arthritis induced in mice by immunization with type II collagen was inhibited by anti-gp39. Anti-gp39 blocked the development of joint inflammation, serum antibody titers to collagen, the infiltration of inflammatory cells into the subsynovial tissue, and the erosion of cartilage and bone. Thus, interference with gp39-CD40 interactions may have therapeutic potential in the treatment of autoimmune disease.	DARTMOUTH COLL,SCH MED,DEPT MICROBIOL,LEBANON,NH 03756; DEPT VET ADM MED CTR,WHITE RIVER JCT,VT 05009; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; DARTMOUTH COLL,SCH MED,DEPT MED,WHITE RIVER JCT,VT 05009	Dartmouth College; Bristol-Myers Squibb; Dartmouth College					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026296, R37AI026296] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26296] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; CATHCART ES, 1986, LAB INVEST, V54, P26; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; COOPER WO, 1992, CLIN EXP IMMUNOL, V89, P244; COURTENAY JS, 1980, NATURE, V283, P665; CREMER MA, 1992, J IMMUNOL, V149, P1045; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURIE FH, UNPUB; FOY TM, UNPUB; FOY TM, IN PRESS J EXP MED; HOLMDAHL R, 1986, AGENTS ACTIONS, V19, P295, DOI 10.1007/BF01971231; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANE PJL, 1990, J IMMUNOL, V144, P3684; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOELLE RJ, UNPUB; SEKI N, 1992, J IMMUNOL, V148, P3093; SHIZURU JA, 1992, IMMUNOL REV, V129, P105, DOI 10.1111/j.1600-065X.1992.tb01421.x; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857	23	443	502	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1328	1330		10.1126/science.7689748	http://dx.doi.org/10.1126/science.7689748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	7689748				2022-12-24	WOS:A1993LV65600030
J	SCHMID, MF; ROBINSON, JP; DASGUPTA, BR				SCHMID, MF; ROBINSON, JP; DASGUPTA, BR			DIRECT VISUALIZATION OF BOTULINUM NEUROTOXIN-INDUCED CHANNELS IN PHOSPHOLIPID-VESICLES	NATURE			English	Article							TETANUS TOXIN; ELECTRON; MEMBRANES; IMAGES	THE seven botulinum neurotoxin (NT) serotypes produced by strains of Clostridium botulinum inhibit neurotransmitter release from synaptic vesicles. Neurotoxin is synthesized as a roughly 150K single-chain protein. Proteolysis produces two fragments, the 50K L-chain and 100K H-chain, that remain linked by a disulphide bond. Intoxication involves membrane attachment by the C-terminal half of the H-chain, endocytotic/lysosomal internalization, vesicle channel formation mediated by the 50K N-terminal half of the H-chain at low pH, and finally blockade of synaptic vesicle fusion after the L-chain reaches the cytosol1-4 . We report here the visualization of the neurotoxin-membrane complex by electron cryomicroscopy and image processing. Three-dimensional reconstructions show the neurotoxin bound to the exterior of ganglioside/PC lipid vesicles and show channels entirely perforating the vesicle wall. Each channel appears to arise from the interaction of four neurotoxin molecules.	BAYLOR COLL MED,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77030; UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706	Baylor College of Medicine; University of Wisconsin System; University of Wisconsin Madison	SCHMID, MF (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030, USA.		Taylor, Graham/A-4027-2012	Schmid, Michael/0000-0003-1077-5750				BINZ T, 1990, J BIOL CHEM, V265, P9153; CHANG CF, 1988, J ULTRA MOL STRUCT R, V100, P166, DOI 10.1016/0889-1605(88)90023-7; DASGUPTA BR, 1990, J PHYSIOL-PARIS, V84, P220; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DOLLY JO, 1990, J PHYSIOL-PARIS, V84, P237; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; GRANT RA, 1986, BIOPHYS J, V49, P251, DOI 10.1016/S0006-3495(86)83638-4; HOCH DH, 1985, ANN NY ACAD SCI, V456, P33, DOI 10.1111/j.1749-6632.1985.tb14841.x; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KORNBERG RD, 1991, CURR OPIN STRUC BIOL, V1, P632; MONTAL MS, 1992, FEBS LETT, V313, P12, DOI 10.1016/0014-5793(92)81173-J; ROBINSON JP, 1988, J MOL BIOL, V200, P367, DOI 10.1016/0022-2836(88)90247-1; SCHMID MF, 1991, J MOL BIOL, V221, P711, DOI 10.1016/0022-2836(91)80082-6; SCHMID MF, 1990, 12TH P INT C EL MICR, P496; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235	16	76	76	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					827	830		10.1038/364827a0	http://dx.doi.org/10.1038/364827a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689178				2022-12-24	WOS:A1993LU58100063
J	SHAHINIAN, A; PFEFFER, K; LEE, KP; KUNDIG, TM; KISHIHARA, K; WAKEHAM, A; KAWAI, K; OHASHI, PS; THOMPSON, CB; MAK, TW				SHAHINIAN, A; PFEFFER, K; LEE, KP; KUNDIG, TM; KISHIHARA, K; WAKEHAM, A; KAWAI, K; OHASHI, PS; THOMPSON, CB; MAK, TW			DIFFERENTIAL T-CELL COSTIMULATORY REQUIREMENTS IN CD28-DEFICIENT MICE	SCIENCE			English	Article							ACCESSORY MOLECULE CD28; CD4+ LYMPHOCYTES-T; MESSENGER-RNA; SIGNAL TRANSDUCTION; STEM-CELLS; ACTIVATION ANTIGEN-B7; IL-2 PRODUCTION; MURINE HOMOLOG; EXPRESSION; GENE	T cell receptor stimulation without costimulation is insufficient for the induction of an optimal immune response. It is thought that engagement of the CD28 molecule with its ligand B7 provides an essential costimulatory signal without which full activation of T cells cannot occur. A mouse strain with a defective CD28 gene was established. Development of T and B cells in the CD28-deficient mice appeared normal. However, T lymphocytes derived from CD28-/- mutant mice had impaired responses to lectins. Lectin stimulation did not trigger interleukin-2 (IL-2) production, IL-2 receptor alpha expression was significantly decreased, and exogenous IL-2 only partially rescued the CD28 defect. Basal immunoglobulin (Ig) concentrations in CD28-deficient mice were about one-fifth of those found in wild-type controls, with low titers of IgG1 and IgG2b but an increase in IgG2a. In addition, activity of T helper cells in CD28-/- mice was reduced and immunoglobulin class switching was diminished after infection with vesicular stomatitis virus. However, cytotoxic T cells could still be induced and the mice showed delayed-type hypersensitivity after infection with lymphocytic choriomeningitis virus. Thus, CD28 is not required for all T cell responses in vivo, suggesting that alternative costimulatory pathways may exist.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, AMGEN INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Kawai, Kazuhiro/D-4998-2011	Kawai, Kazuhiro/0000-0001-9375-0713; Ohashi, Pamela S./0000-0003-2915-9317; Pfeffer, Klaus/0000-0002-5652-6330				ABE R, 1992, J IMMUNOL, V149, P3429; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; AHMANN GB, 1978, J IMMUNOL, V121, P1981; BRADLEY A, 1986, CURR TOP DEV BIOL, V20, P357, DOI 10.1016/S0070-2153(08)60675-4; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; CERDAN C, 1992, J IMMUNOL, V149, P2255; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DAMLE NK, 1992, J IMMUNOL, V149, P2541; DAMLE NK, 1992, J IMMUNOL, V148, P1985; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1992, J IMMUNOL, V149, P3795; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GROSS JA, 1990, J IMMUNOL, V144, P3201; GROSS JA, 1992, J IMMUNOL, V149, P380; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPER K, 1991, J IMMUNOL, V147, P1037; JANEWAY CA, 1989, COLD SH Q B, V54, P1; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LEDBETTER JA, 1990, BLOOD, V75, P1531; LEE KP, 1990, J IMMUNOL, V145, P344; LEIST TP, 1987, J IMMUNOL, V138, P2278; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1992, EUR J IMMUNOL, V22, P2855, DOI 10.1002/eji.1830221115; LIU Y, 1990, P NATL ACAD SCI USA, V87, P5031; LU YL, 1992, J IMMUNOL, V149, P24; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NORTON SD, 1992, J IMMUNOL, V149, P1556; PURKERSON J, 1992, FASEB J, V6, P3245, DOI 10.1096/fasebj.6.14.1385241; ROOST H, 1988, EUR J IMMUNOL, V18, P511, DOI 10.1002/eji.1830180404; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, UNPUB; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TURKA LA, 1991, J IMMUNOL, V146, P1428; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VALLE A, 1991, INT IMMUNOL, V3, P229, DOI 10.1093/intimm/3.3.229; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P; YOUNG JW, 1990, J EXP MED, V171, P1315, DOI 10.1084/jem.171.4.1315; YOUNG JW, 1992, J CLIN INVEST, V90, P229, DOI 10.1172/JCI115840	59	1156	1187	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					609	612		10.1126/science.7688139	http://dx.doi.org/10.1126/science.7688139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	7688139				2022-12-24	WOS:A1993LP72800039
J	HIDE, M; FRANCIS, DM; GRATTAN, CEH; HAKIMI, J; KOCHAN, JP; GREAVES, MW				HIDE, M; FRANCIS, DM; GRATTAN, CEH; HAKIMI, J; KOCHAN, JP; GREAVES, MW			AUTOANTIBODIES AGAINST THE HIGH-AFFINITY IGE RECEPTOR AS A CAUSE OF HISTAMINE-RELEASE IN CHRONIC URTICARIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-SUBUNIT; MAST-CELLS; ANTIBODIES	Background. Most urticarias are induced by vasoactive mediators such as histamine released from mast cells. Although mast cells are activated by allergens through cross-linking of cell-surface-bound IgE, this mechanism does not appear to explain most cases of chronic urticaria, which, when allergic, infectious, drug-induced, or physical causes cannot be identified, are classified as idiopathic. Methods. We recruited 26 patients with chronic idiopathic urticaria, in whom intradermal injection of autologous serum caused a wheal-and-flare response. Serum from four patients that induced marked histamine release from basophils from a donor with very low serum IgE levels was studied with respect to the IgE dependence of the histamine release, the activity of the IgG fractions, and the neutralizing effect of a recombinant preparation of the soluble extracellular domain of the a subunit of the high-affinity IgE receptor (sFcepsilonRIalpha). Results. The histamine-releasing activity of the serum was abolished by passive sensitization of basophils with myeloma IgE, enhanced after dissociation of IgE by treatment with lactic acid, and induced by IgG fractions from the serum of all four patients. Preincubation of the serum and isolated IgG with sFcepsilonRIalpha resulted in almost complete neutralization. Conclusions. Histamine-releasing IgG autoantibodies against the a subunit of the high-affinity IgE receptor are present in the circulation of some patients with chronic urticaria. Autoantibody-induced cross-linking of IgE receptors may be an important mechanism in the pathogenesis of chronic urticaria and other diseases mediated by mast cells.	HOFFMANN LA ROCHE INC,DEPT MOLEC GENET,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT IMMUNOPHARMACOL,NUTLEY,NJ 07110	Roche Holding; Roche Holding			Hide, Michihiro/H-2519-2019	Hide, Michihiro/0000-0002-1569-6034				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BENDTZEN K, 1990, IMMUNOL TODAY, V11, P167, DOI 10.1016/0167-5699(90)90068-K; BLANK U, 1991, J BIOL CHEM, V266, P2639; BOROS P, 1991, J EXP MED, V173, P1473, DOI 10.1084/jem.173.6.1473; CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P221, DOI 10.1111/j.1365-2222.1990.tb02671.x; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HOLGATE ST, 1991, INT ARCH ALLER A IMM, V94, P210, DOI 10.1159/000235363; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MACDONALD SM, 1991, INT ARCH ALLER A IMM, V94, P144, DOI 10.1159/000235347; METZGER H, 1991, CLIN EXP ALLERGY, V21, P269, DOI 10.1111/j.1365-2222.1991.tb01658.x; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P57; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROSMAN H, 1962, ACTA ALLERGOL, V17, P168; SCHWARTZ LB, 1991, J AM ACAD DERMATOL, V25, P190, DOI 10.1016/S0190-9622(08)80468-9; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SMITH BR, 1974, LANCET, V2, P427; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	28	697	721	3	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1599	1604		10.1056/NEJM199306033282204	http://dx.doi.org/10.1056/NEJM199306033282204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	7683772				2022-12-24	WOS:A1993LE28900004
J	AMMALA, C; ASHCROFT, FM; RORSMAN, P				AMMALA, C; ASHCROFT, FM; RORSMAN, P			CALCIUM-INDEPENDENT POTENTIATION OF INSULIN RELEASE BY CYCLIC-AMP IN SINGLE BETA-CELLS	NATURE			English	Article							SECRETION; CA-2+; CAMP; EXOCYTOSIS; ACTIVATION; INTERPLAY; CURRENTS	How does cyclic AMP potentiate insulin secretion from pancreatic islet beta-cells? This question is fundamental to understanding how hormones such as glucagon, which elevates cAMP1, stimulate insulin secretion and so contribute to the normal secretory response of the islet2,3. It is well established that a rise in the cytoplasmic Ca2+ concentration ([Ca2+]i) is essential for insulin secretion4 and therefore cAMP has been proposed to act by elevating [Ca2+]i. But studies on permeabilized beta-cells indicate that cAMP increases insulin release even when [Ca2+]i is held constant5,6. We have used microfluorimetry and the patch-clamp technique to measure changes simultaneously in Ca2+ currents, [Ca2+]i and exocytosis7-9 in a single beta-cell in response to cAMP. We show here that cAMP, through activation of protein kinase A, increases Ca2+-influx through voltage-dependent L-type Ca2+ channels, thereby elevating [Ca2+]i and accelerating exocytosis. More importantly, cAMP also promotes insulin release by a direct interaction with the secretory machinery, which accounts for as much as 80% of its effect.	DEPT MED BIOPHYS,MEDICINAREGATAN 11,S-41390 GOTHENBURG,SWEDEN; UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND	University of Oxford			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767				AMMALA C, 1991, BIOCHIM BIOPHYS ACTA, V1092, P347; AMMALA C, IN PRESS J PHYSL LON; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P1; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P97; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; FIDLERLIM N, 1990, NATURE, V344, P449; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HENQUIN JC, 1985, ARCH INT PHYSIOL BIO, V93, P37, DOI 10.3109/13813458509104514; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUGHES SJ, 1989, MOL CELL ENDOCRINOL, V65, P35, DOI 10.1016/0303-7207(89)90162-7; JONES PM, 1992, BIOCHEM J, V285, P973, DOI 10.1042/bj2850973; JONES PM, 1988, BIOCHEM J, V254, P397, DOI 10.1042/bj2540397; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; MARTY A, 1982, P NATL ACAD SCI USA, V79, P6712; PERSAUD SJ, 1990, BIOCHEM BIOPH RES CO, V173, P833, DOI 10.1016/S0006-291X(05)80862-9; PIPELEERS D, 1982, P NATL ACAD SCI-BIOL, V79, P7322, DOI 10.1073/pnas.79.23.7322; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; RORSMAN P, 1992, EMBO J, V11, P2877, DOI 10.1002/j.1460-2075.1992.tb05356.x; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; RORSMAN P, 1988, PFLUGERS ARCH, V412, P587; SIKDAR SK, 1990, FEBS LETT, V273, P150, DOI 10.1016/0014-5793(90)81072-V	23	346	351	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					356	358		10.1038/363356a0	http://dx.doi.org/10.1038/363356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	7684514				2022-12-24	WOS:A1993LD91700055
J	KENNELL, JC; MORAN, JV; PERLMAN, PS; BUTOW, RA; LAMBOWITZ, AM				KENNELL, JC; MORAN, JV; PERLMAN, PS; BUTOW, RA; LAMBOWITZ, AM			REVERSE-TRANSCRIPTASE ACTIVITY ASSOCIATED WITH MATURASE-ENCODING GROUP-II INTRONS IN YEAST MITOCHONDRIA	CELL			English	Article							CYTOCHROME-OXIDASE; RNA MATURASE; S-CEREVISIAE; SUBUNIT-I; GENE; DNA; EVOLUTION; PROTEINS; ORIGIN; RIBONUCLEOPROTEIN	Group II introns al1 and al2 of the yeast mtDNA cox1 gene encode reverse transcriptase-like proteins that function in RNA splicing and may play a role in intron mobility and excision. We find that ribonucleoprotein particles from yeast mitochondria contain a reverse transcriptase activity that is likely encoded by al1 and al2 and is highly specific for the introns and their flanking exons. Using a mutant strain with elevated activity, we show that the reverse transcriptase uses either excised intron RNA or cox1 pre-mRNA as template and initiates cDNA synthesis near the 3' end of al2 and immediately downstream in E3. Our results suggest that introns al1 and al2 are retroelements, which encode reverse transcriptases that have adapted to function in RNA splicing.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KENNELL, JC (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NIGMS NIH HHS [GM37949, GM31480, GM35510] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM037949, R01GM035510] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER NJ, 1979, J BIOL CHEM, V254, P2471; ANZIANO PQ, 1990, NUCLEIC ACIDS RES, V18, P3233, DOI 10.1093/nar/18.11.3233; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; CARIGNANI G, 1986, CURR GENET, V11, P55, DOI 10.1007/BF00389426; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Dujon B., 1989, MOBILE DNA, P861; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; Gargouri A., 1983, MITOCHONDRIA 1983, P259; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEBBAR SK, 1992, NUCLEIC ACIDS RES, V20, P1747, DOI 10.1093/nar/20.7.1747; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; KUCK U, 1985, CURR GENET, V9, P373, DOI 10.1007/BF00421608; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1992, CR ACAD SCI III-VIE, V315, P37; LEVRAJUILLET E, 1989, MOL GEN GENET, V217, P168, DOI 10.1007/BF00330957; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; PEEBLES CL, 1993, IN PRESS J BIOL CHEM; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J., 1989, MOL CLONING LAB MANU; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHERMAN F, 1986, LABORATORY COURSE MA; SIPICZKI M, 1977, MOL GEN GENET, V151, P77, DOI 10.1007/BF00446915; SKELLY PJ, 1991, CURR GENET, V20, P115, DOI 10.1007/BF00312773; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WENZLAU JM, 1989, THESIS OHIO STATE U; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	46	115	119	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					133	146		10.1016/0092-8674(93)90166-N	http://dx.doi.org/10.1016/0092-8674(93)90166-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	7681727				2022-12-24	WOS:A1993KW75300014
J	COLEMAN, TR; TANG, ZH; DUNPHY, WG				COLEMAN, TR; TANG, ZH; DUNPHY, WG			NEGATIVE REGULATION OF THE WEE1 PROTEIN-KINASE BY DIRECT ACTION OF THE NIM1/CDR1 MITOTIC INDUCER	CELL			English	Article							XENOPUS CDC2 PROTEIN; FISSION YEAST; TYROSINE PHOSPHORYLATION; CELL-CYCLE; ACTIVATES P34CDC2; DNA-REPLICATION; M-PHASE; MITOSIS; DEPHOSPHORYLATION; PHOSPHATASE	The wee1 protein kinase suppresses the entry into mitosis by mediating the inhibitory tyrosine phosphorylation of p34cdc2. Genetic studies have suggested that the nim1 protein kinase (also known as cdr1) acts as a positive regulator of mitosis by down-regulating the wee1 pathway in yeast cells. We have overexpressed the nim1 protein in both bacteria and insect cells. The recombinant nim1 protein autophosphorylates on both tyrosine and serine residues and can phosphorylate the isolated wee1 protein directly in a cell-free system. The nim1-catalyzed phosphorylation of the wee1 protein occurs in its C-terminal region and leads to a substantial drop in its activity as a cdc2-specific tyrosine kinase. This nim1-dependent inhibition of the wee1 protein kinase can be reversed readily in vitro by treatment with a protein phosphatase. These experiments provide direct biochemical evidence that the wee1 protein is subject to negative regulation by phosphorylation and indicate that the nim1 protein acts as an inhibitory, wee1-specific kinase.			COLEMAN, TR (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; Fleig U N, 1991, Semin Cell Biol, V2, P195; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MILARSKI KL, 1991, COLD SH Q B, V56, P377; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	43	148	150	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					919	929		10.1016/0092-8674(93)90580-J	http://dx.doi.org/10.1016/0092-8674(93)90580-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7681363				2022-12-24	WOS:A1993KU17500012
J	KASSAVETIS, GA; GEIDUSCHEK, EP				KASSAVETIS, GA; GEIDUSCHEK, EP			RNA-POLYMERASE MARCHING BACKWARD	SCIENCE			English	Editorial Material							TRANSCRIPTION ELONGATION; TERNARY COMPLEXES; GENE; TERMINATION; INVITRO; DOMAIN; TFIIS		UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	KASSAVETIS, GA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AGARWAL KL, COMMUNICATION; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, IN PRESS CELL; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; HAGLER J, IN PRESS J BIOL CHEM; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, COMMUNICATION; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1992, J BIOL CHEM, V267, P2795; REINES D, IN PRESS P NATL ACAD; ROZOVSKAYA TA, 1988, MOL BIOL, V15, P498; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V18, P6443, DOI 10.1093/nar/18.21.6443; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	29	82	83	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					944	945		10.1126/science.7679800	http://dx.doi.org/10.1126/science.7679800			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	7679800				2022-12-24	WOS:A1993KL80000034
J	KORTHAUER, U; GRAF, D; MAGES, HW; BRIERE, F; PADAYACHEE, M; MALCOLM, S; UGAZIO, AG; NOTARANGELO, LD; LEVINSKY, RJ; KROCZEK, RA				KORTHAUER, U; GRAF, D; MAGES, HW; BRIERE, F; PADAYACHEE, M; MALCOLM, S; UGAZIO, AG; NOTARANGELO, LD; LEVINSKY, RJ; KROCZEK, RA			DEFECTIVE EXPRESSION OF T-CELL CD40 LIGAND CAUSES X-LINKED IMMUNODEFICIENCY WITH HYPER-IGM	NATURE			English	Article							HUMAN LYMPHOCYTES-B; HYPERIMMUNOGLOBULINEMIA-M; ANTIGEN; PROLIFERATION; FORM	X CHROMOSOME-LINKED immunodeficiency with hyper-IgM (HIGM1, MIM number 308230) is a rare disorder characterized by recurrent bacterial infections, very low or absent IgG, IgA and IgE, and normal to increased IgM and IgD serum levels1-3. HIGM1 has been suggested to result from ineffective T-cell help for B cells4. We and others5-8 have identified a novel, TNF-related activation protein (TRAP) that is exclusively expressed on the surface of stimulated T cells6,8. TRAP, a type II transmembrane protein of M(r) 33,000, is the physiological ligand for CD40 (refs 5-8). Crosslinking of CD40 on B cells induces, in the presence of lymphokines, immunoglobulin class switching from IgM to IgG, IgA or IgE5,9-11. Mapping of the TRAP gene to the X-chromosomal location q26.3-q27.1 (ref. 6) suggested a causal relationship to HIGM1, which had previously been assigned to Xq26 (refs 12-14). Here we present evidence that point mutations in the TRAP gene give rise to nonfunctional or defective expression of TRAP on the surface of T cells in patients with HIGM1. The resultant failure of TRAP to interact with CD40 on functionally intact B cells is responsible for the observed immunoglobulin isotype defect in HIGM1.	UNIV ERLANGEN NURNBERG, INST KLIN IMMUNOL, ARBEITSGRP IMMUNOL, MAX PLANCK GESELLSCH, W-8520 ERLANGEN, GERMANY; SCHERING PLOUGH CORP, IMMUNOL RES LAB, F-69571 DARDILLY, FRANCE; INST CHILD HLTH, LONDON WC1N 1EH, ENGLAND; UNIV BRESCIA, I-25123 BRESCIA, ITALY	Max Planck Society; University of Erlangen Nuremberg; Merck & Company; Schering Plough Corporation; University of London; University College London; University of Brescia			Ugazio, Alberto/AAA-6092-2020; Graf, Daniel/H-1214-2011; Notarangelo, Luigi D/F-9718-2016	Graf, Daniel/0000-0003-1163-8117; Notarangelo, Luigi D/0000-0002-8335-0262				ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BURTIN P, 1961, REV FR ETUD CLIN BIO, V6, P286; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HERMANN P, IN PRESS EUR J IMMUN; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PADAYACHEE M, IN PRESS J MED GENET; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543	18	673	696	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 11	1993	361	6412					539	541		10.1038/361539a0	http://dx.doi.org/10.1038/361539a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	7679206				2022-12-24	WOS:A1993KL71400061
J	MULLER, B; ZULEWSKI, H; HUBER, P; RATCLIFFE, JG; STAUB, JJ				MULLER, B; ZULEWSKI, H; HUBER, P; RATCLIFFE, JG; STAUB, JJ			IMPAIRED ACTION OF THYROID-HORMONE ASSOCIATED WITH SMOKING IN WOMEN WITH HYPOTHYROIDISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; GOITER; THYROTROPIN; SMOKERS; DISEASE; TISSUES; CANCER; TSH	Background. The effect of smoking on thyroid function is controversial, and its effect on thyroid hormone action is unknown. We investigated the effects of cigarette smoking in women with various grades of hypothyroidism and in normal women. Methods. We studied 138 normal women and 135 women with primary hypothyroidism, of whom 84 had subclinical hypothyroidism and 51 overt hypothyroidism. Sixty of the women with hypothyroidism were reevaluated during thyroxine therapy. The women were categorized as smokers or nonsmokers according to their responses to a questionnaire. Thyroid function was evaluated by measurements of serum thyrotropin, free thyroxine, and triiodothyronine. Peripheral thyroid hormone action was assessed by a clinical score and measurements of ankle-reflex time and serum lipids and creatine kinase. Results. Among the women with subclinical hypothyroidism, the smokers had a higher mean (+/-SD) serum thyrotropin concentration (21.3+/-16.6 vs. 12.7+/-7.2 mU per liter, P=0.004) and a higher ratio of serum triiodothyronine to serum free thyroxine (by 30 percent, P=0.003) than the nonsmokers. Their serum concentrations of total cholesterol and low-density lipoprotein (LDL) cholesterol were higher (by 16 percent, P=0.013; and 28 percent, P=0.003, respectively). Among the women with overt hypothyroidism, the serum concentrations of thyrotropin, free thyroxine, and triiodothyronine were similar in the smokers and nonsmokers. As compared with the nonsmokers, the smokers had a clinical score indicating a greater degree of hypothyroidism (P<0.001), higher serum concentrations of total and LDL cholesterol (by 25 percent, P<0.001; and 24 percent, P=0.002, respectively), longer ankle-reflex time (by 25 percent, P<0.001), and higher serum concentrations of creatine kinase (by 236 percent, P<0.001). There were dose-response relations between smoking and serum concentrations of total and LDL cholesterol, serum creatine kinase concentrations, and ankle-reflex time in the women with overt hypothyroidism, and between smoking and serum concentrations of total and LDL cholesterol in the women with subclinical hypothyroidism. Conclusions. Smoking increases the metabolic effects of hypothyroidism in a dose-dependent way. This may be explained by alteration of both thyroid function and hormone action.	UNIV BASEL HOSP, DEPT CHEM PATHOL, HORMONE LAB, CH-4031 BASEL, SWITZERLAND; QUEEN ELIZABETH MED CTR, DEPT CLIN CHEM, WOLFSON RES LABS, BIRMINGHAM, W MIDLANDS, ENGLAND	University of Basel; Birmingham City University; University of Birmingham	MULLER, B (corresponding author), UNIV BASEL HOSP, DEPT MED, DIV ENDOCRINOL DIABET & METAB, PETERSGRABEN 4, CH-4031 BASEL, SWITZERLAND.		Mueller, Beat/G-2662-2012					ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; BERGHOUT A, 1987, CLIN ENDOCRINOL, V26, P273, DOI 10.1111/j.1365-2265.1987.tb00784.x; BILLEWICZ WZ, 1969, Q J MED, V38, P255; BRENT GA, 1994, NEW ENGL J MED, V331, P847; BROWMAN GP, 1993, NEW ENGL J MED, V328, P159, DOI 10.1056/NEJM199301213280302; CHRISTENSEN SB, 1984, J CLIN ENDOCR METAB, V58, P615, DOI 10.1210/jcem-58-4-615; CUZICK J, 1990, INT J CANCER, V45, P673, DOI 10.1002/ijc.2910450417; EDELMAN IS, 1974, NEW ENGL J MED, V290, P1303, DOI 10.1056/NEJM197406062902308; ERICSSON UB, 1991, J INTERN MED, V229, P67, DOI 10.1111/j.1365-2796.1991.tb00308.x; ERMANS AM, 1980, ROLE CASSAVA ETIOLOG, P93; HANDA K, 1990, ATHEROSCLEROSIS, V84, P189, DOI 10.1016/0021-9150(90)90090-6; HEGEDUS L, 1985, CLIN ENDOCRINOL, V22, P287, DOI 10.1111/j.1365-2265.1985.tb03242.x; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; LAVECCHIA C, 1988, PREV MED, V17, P712, DOI 10.1016/0091-7435(88)90090-4; LOEB JN, 1991, WERNER INGBARS THYRO, P1064; MELANDER A, 1981, ACTA MED SCAND, V209, P41; MUSCAT JE, 1991, AM HEART J, V121, P141, DOI 10.1016/0002-8703(91)90967-M; PETERSEN K, 1991, J INTERN MED, V229, P407, DOI 10.1111/j.1365-2796.1991.tb00367.x; ROSS DS, 1991, WERNER INGBARS THYRO, P1256; SACHS L, 1984, APPLIED STATISTICS H; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; Searle S.R., 1971, LINEAR MODELS; SEPKOVIC DW, 1984, ARCH INTERN MED, V144, P501, DOI 10.1001/archinte.144.3.501; STAUB JJ, 1985, CLIN ENDOCRINOL, V22, P567, DOI 10.1111/j.1365-2265.1985.tb00158.x; STAUB JJ, 1983, J CLIN ENDOCR METAB, V56, P449, DOI 10.1210/jcem-56-3-449; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; SUGAWARA M, 1982, P SOC EXP BIOL MED, V170, P431	27	115	119	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					964	969		10.1056/NEJM199510123331503	http://dx.doi.org/10.1056/NEJM199510123331503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666915	Bronze			2022-12-24	WOS:A1995RY58600003
J	TELZAK, EE; SEPKOWITZ, K; ALPERT, P; MANNHEIMER, S; MEDARD, F; ELSADR, W; BLUM, S; GAGLIARDI, A; SALOMON, N; TURETT, G				TELZAK, EE; SEPKOWITZ, K; ALPERT, P; MANNHEIMER, S; MEDARD, F; ELSADR, W; BLUM, S; GAGLIARDI, A; SALOMON, N; TURETT, G			MULTIDRUG-RESISTANT TUBERCULOSIS IN PATIENTS WITHOUT HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; PULMONARY TUBERCULOSIS; DRUG	Background. Investigations of outbreaks of multidrug-resistant tuberculosis have found low rates of treatment response and very high mortality, and they have mainly involved patients with advanced human immunodeficiency virus (HIV) infection. For patients without HIV infection, one study reported an overall rate of response to treatment of 56 percent, and the mortality from tuberculosis was 22 percent. We investigated treatment response and mortality rates in 26 HIV-negative patients in New York with multidrug-resistant tuberculosis. Methods. We obtained detailed data from seven teaching hospitals in New York City on patients with multidrug-resistant tuberculosis - defined as tuberculosis resistant at least to isoniazid and rifampin - who were HIV-negative on serologic testing. Lengths of times from diagnosis to the initiation of appropriate therapy and from the initiation of appropriate therapy to conversion to negative cultures were assessed. Therapeutic responses were evaluated by both microbiologic and clinical criteria. Results. Between March 1991 and September 1994, 26 HIV-negative patients were identified and treated. Of the 25 patients for whom adequate data were available for analysis, 24 (96 percent) had clinical responses; all 17 patients for whom data on microbiologic response were available had such a response. The median times from diagnosis to the initiation of appropriate therapy and from the initiation of therapy to culture conversion were 44 days (range, 0 to 181) and 69 days (range, 2 to 705), respectively. Side effects requiring the discontinuation of medication occurred in 4 of 23 patients (17 percent) who were treated with second-line antituberculosis medications. The median follow-up for the 23 patients who responded and who received appropriate therapy was 91 weeks (range, 41 to 225). Conclusions. In this report from New York City, HIV-negative patients with multidrug-resistant tuberculosis, contrary to previous reports, responded well to appropriate chemotherapy, both clinically and microbiologically.	ST CLARES HOSP & HLTH CTR,NEW YORK,NY 10019; NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY; HARLEM HOSP MED CTR,NEW YORK,NY; MONTEFIORE MED CTR,BRONX,NY; N CENT BRONX HOSP,BRONX,NY 10467; ST VINCENTS MED CTR,NEW YORK,NY 10011; BETH ISRAEL MED CTR,NEW YORK,NY	Cornell University; NewYork-Presbyterian Hospital; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Saint Vincents Hospital Manhattan; Harvard University; Beth Israel Deaconess Medical Center	TELZAK, EE (corresponding author), ALBERT EINSTEIN COLL MED,BRONX LEBANON HOSP CTR,DIV INFECT DIS,1650 GRAND CONCOURSE,BRONX,NY 10457, USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EDLIN BR, 1993, 9TH INT C AIDS 4TH S; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Heifets Leonid B., 1994, P85; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; SEPKOWITZ KA, 1994, CLIN INFECT DIS, V18, P755, DOI 10.1093/clinids/18.5.755; SHAFER RW, 1995, J INFECT DIS, V171, P170, DOI 10.1093/infdis/171.1.170; SHARP V, 1994, 8TH INT S INF IMM HO; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; TELZAK EE, 1994, 8TH INT S INF IMM HO; VALLSPINOSA A, 1970, NEW ENGL J MED, V283, P616, DOI 10.1056/NEJM197009172831202; 1993, MMWR-MORBID MORTAL W, V42, P427; 1991, MMWR-MORBID MORTAL W, V40, P585	18	199	205	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					907	911		10.1056/NEJM199510053331404	http://dx.doi.org/10.1056/NEJM199510053331404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666876	Bronze, Green Published			2022-12-24	WOS:A1995RX19900004
J	WELLIVER, RC				WELLIVER, RC			RSV AND CHRONIC ASTHMA	LANCET			English	Editorial Material							VIRUS-SPECIFIC IGE; RESPIRATORY SYNCYTIAL VIRUS; INFECTION; PATHOGENESIS; SUBSEQUENT; CHILDHOOD; CHILDREN		CHILDRENS HOSP,BUFFALO,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	WELLIVER, RC (corresponding author), SUNY BUFFALO,DEPT PEDIAT,DIV INFECT DIS,BUFFALO,NY 14260, USA.							BUI RHD, 1987, J PEDIATR-US, V110, P87; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; HENDERSON FW, 1992, AM REV RESPIR DIS, V145, P283, DOI 10.1164/ajrccm/145.2_Pt_1.283; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; SIGURS N, 1995, PEDIATRICS, V95, P500; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEMPEL DA, 1981, MED CLIN N AM, V65, P1045, DOI 10.1016/S0025-7125(16)31488-2; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; WELLIVER RC, 1986, AM J DIS CHILD, V140, P34, DOI 10.1001/archpedi.1986.02140150036029	11	49	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					789	790		10.1016/S0140-6736(95)91615-6	http://dx.doi.org/10.1016/S0140-6736(95)91615-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674741				2022-12-24	WOS:A1995RW25800006
J	DOUGLAS, JDM; MCSHARRY, C; BLAIKIE, L; MORROW, T; MILES, S; FRANKLIN, D				DOUGLAS, JDM; MCSHARRY, C; BLAIKIE, L; MORROW, T; MILES, S; FRANKLIN, D			OCCUPATIONAL ASTHMA CAUSED BY AUTOMATED SALMON PROCESSING	LANCET			English	Article							LABORATORY-ANIMALS; FLOW; WORKERS; SMOKING; ALLERGY	Within 3 months of the opening of a salmon-processing plant in the UK, some workers complained of symptoms suggestive of occupational asthma. A survey of all 291 employees identified 24 (8.2%) with occupational asthma. The employees worked near machines which generated respirable aerosols containing salmon-serum proteins. The IgE response to these proteins was associated with occupational asthma (p<0.001), with increasing severity of symptoms (p<0.001), and with working distance from the aerosol source (p=0.037). The main factor which predisposed to IgE-antibody production and asthma was cigarette smoking (p<0.001), whereas atopy and a previous allergic history did not. The affected employees were reallocated to a low-exposure worksite and factory ventilation was improved. Eleven showed significant clinical and pulmonary function improvement, and continued in employment. Thirteen who still had symptoms were advised to leave, thereafter becoming symptom-free, and regaining normal respiratory function. Early recognition of symptoms and prompt action to reduce aerosol exposure avoided the long-term reduction in pulmonary functions often associated with occupational asthma.	WESTERN INFIRM & ASSOCIATED HOSP,DEPT IMMUNOL,GLASGOW,LANARK,SCOTLAND; UNILEVER RES & ENGN,SHARNBROOK,BEDS,ENGLAND; RAIGMORE HOSP,INVERNESS,SCOTLAND	Unilever	DOUGLAS, JDM (corresponding author), TWEEDDALE MED PRACTICE,HIGH ST,FT WILLIAM PH33 6EU,SCOTLAND.			McSharry, Charles/0000-0003-4758-9038				BURGE PS, 1993, OCCUP MED, V8, P279; BURGE PS, 1988, CHEST, V81, P105; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CARTIER A, 1994, EUR RESPIR J, V7, P153, DOI 10.1183/09031936.94.07010153; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; DAVIES GE, 1983, BRIT J IND MED, V40, P442; EDWARDS RG, 1980, INT ARCH ALLER A IMM, V68, P352; GADDIE J, 1980, LANCET, V2, P1350; GANNON PF, 1993, J ALLERGY CLIN IMMUN, V91, P1121; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MALO JL, 1988, AM REV RESPIR DIS, V128, P807; MCSHARRY C, 1994, CLIN EXP IMMUNOL, V97, P499, DOI 10.1111/j.1365-2249.1994.tb06116.x; MEGURO T, 1990, IND HEALTH, V28, P133, DOI 10.2486/indhealth.28.133; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; NEWMANTAYLOR A, 1990, CHEST, V98, P209; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; SHERSON D, 1989, ALLERGY, V44, P336, DOI 10.1111/j.1398-9995.1989.tb00455.x; STENTON SC, 1995, BRIT MED J, V310, P1299, DOI 10.1136/bmj.310.6990.1299a; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; VENABLES KM, 1988, BRIT J IND MED, V45, P667; 1991, IND INJURIES DISABLE; 1990, HSE HSG61	24	78	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					737	740		10.1016/S0140-6736(95)91505-2	http://dx.doi.org/10.1016/S0140-6736(95)91505-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658875				2022-12-24	WOS:A1995RU81000011
J	HARRISON, LH; ALI, A; DWYER, DM; LIBONATI, JP; REEVES, MW; ELLIOTT, JA; BILLMANN, L; LASHKERWALA, T; JOHNSON, JA				HARRISON, LH; ALI, A; DWYER, DM; LIBONATI, JP; REEVES, MW; ELLIOTT, JA; BILLMANN, L; LASHKERWALA, T; JOHNSON, JA			RELAPSING INVASIVE GROUP-B STREPTOCOCCAL INFECTION IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; RECURRENCE; ENDOCARDITIS; OSTEOMYELITIS	MULTILOCUS ENZYME ELECTROPHORESIS; DISEASE; PENICILLIN; INFANT; COLONIZATION; ANTIBODY; FAILURE	Objective: To study recurrent group B streptococcal infection in adults. Design: Patients with more than one reported group B streptococcal infection were identified through active surveillance for this infection. Sterile-site group B streptococcal isolates were evaluated for serotype and molecular subtyping using restriction endonuclease analysis of chromosomal DNA (REAC). Setting: All acute-care hospitals in Maryland. Patients: Nonpregnant residents of Maryland 18 years of age or older. Results: 22 adults had at least two group B streptococcal episodes that were separated by 2 to 95 weeks (mean, 24 weeks). Of 395 patients with invasive group B streptococcal infection who survived the first episode and were followed for at least 1 year, 17 (4.3% [95% CI, 2.6% to 6.9%]) had more than one episode. Several patients were found to have endocarditis or osteomyelitis during the second episode. Group B streptococcal isolates from both episodes were obtained from 18 of 22 patients. Of the 18 isolate pairs, 13 (72% [CI, 46% to 90%]) had identical REAC patterns; the probability that at least 13 matches would be found by chance alone was less than 0.00001. Among patients with recurrent infection caused by the same strain, the interval between episodes was shorter (mean, 14 weeks) than that among patients with recurrent infection caused by another strain (mean, 43 weeks; P = 0.05). Conclusions: Recurrent group B streptococcal infection is common among adults and in most cases appears to be caused by relapse. The optimal management of adults with a first episode of group B streptococcal infection needs to be further defined to minimize the likelihood of recurrent disease.	UNIV MARYLAND, VET AFFAIRS MED CTR, SCH MED, BALTIMORE, MD 21201 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30333 USA; MARYLAND DEPT HLTH & MENTAL HYG, BALTIMORE, MD 21210 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Centers for Disease Control & Prevention - USA; Maryland Department of Health & Mental Hygiene	HARRISON, LH (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH, ROOM 5515, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							BAKER CJ, 1974, JAMA-J AM MED ASSOC, V230, P1158, DOI 10.1001/jama.230.8.1158; BAKER CJ, 1981, PEDIATRICS, V68, P544; BARTON LL, 1982, CLIN PEDIATR, V21, P100, DOI 10.1177/000992288202100206; BINNICK AN, 1980, ARCH DERMATOL, V116, P798, DOI 10.1001/archderm.116.7.798; BLUMBERG HM, 1992, J INFECT DIS, V166, P574, DOI 10.1093/infdis/166.3.574; BRENNER DJ, 1988, J CLIN MICROBIOL, V26, P1524, DOI 10.1128/JCM.26.8.1524-1534.1988; BROUGHTON DD, 1976, J PEDIATR-US, V89, P183, DOI 10.1016/S0022-3476(76)80441-6; Campos A, 1992, Enferm Infecc Microbiol Clin, V10, P59; CHMEL H, 1984, OBSTET GYNECOL, V63, P862; DENNING DW, 1988, PEDIATR INFECT DIS J, V7, P729, DOI 10.1097/00006454-198810000-00013; DORAND RD, 1976, J PEDIATR-US, V89, P188, DOI 10.1016/S0022-3476(76)80444-1; ELLISON RT, 1987, JAMA-J AM MED ASSOC, V257, P3260, DOI 10.1001/jama.257.23.3260; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; Fleiss J. L., 1981, STATISTICAL METHODS, P1; GARDNER SE, 1979, AM J OBSTET GYNECOL, V135, P1062, DOI 10.1016/0002-9378(79)90737-3; HALL MA, 1992, INFECT IMMUN, V60, P5030, DOI 10.1128/IAI.60.12.5030-5035.1992; HAQUE KN, 1986, ANN TROP PAEDIATR, V6, P219, DOI 10.1080/02724936.1986.11748443; HARRISON LH, 1995, J INFECT DIS, V171, P513, DOI 10.1093/infdis/171.2.513; HARRISON LH, 1993, MOL EPIDEMIOLOGY PRI; HUNTER W, 1991, P ANN M AM SOC MICRO; KENNY JF, 1977, J PEDIATR-US, V91, P158, DOI 10.1016/S0022-3476(77)80473-3; Lancefield RC, 1934, J EXP MED, V59, P441, DOI 10.1084/jem.59.4.441; MCCRACKEN GH, 1976, J PEDIATR-US, V89, P313, DOI 10.1016/S0022-3476(76)80477-5; MILLARD DD, 1985, AM J DIS CHILD, V139, P964, DOI 10.1001/archpedi.1985.02140120010009; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; PAREDES A, 1976, J PEDIATR-US, V89, P191, DOI 10.1016/S0022-3476(76)80445-3; Passick J, 1989, J Arthroplasty, V4, P87, DOI 10.1016/S0883-5403(89)80057-9; PRUNIER L, 1988, ARCH MAL COEUR VAISS, V81, P925; REEVES MW, 1989, J CLIN MICROBIOL, V27, P313, DOI 10.1128/JCM.27.2.313-320.1989; RENCH MA, 1993, 33RD INT C ANT AG CH; RUIZGOMEZ D, 1979, SCAND J INFECT DIS, V11, P35, DOI 10.3109/inf.1979.11.issue-1.05; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SIEGEL JD, 1981, J PEDIATR-US, V99, P920, DOI 10.1016/S0022-3476(81)80022-4; TRUOG WE, 1976, J PEDIATR-US, V89, P185, DOI 10.1016/S0022-3476(76)80442-8; WALKER SH, 1976, J PEDIATR-US, V89, P187, DOI 10.1016/S0022-3476(76)80443-X; WALKER SH, 1977, J PEDIATR-US, V90, P333, DOI 10.1016/S0022-3476(77)80686-0; WESSELS MR, 1993, NEW ENGL J MED, V328, P1843, DOI 10.1056/NEJM199306243282510	38	53	56	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					421	427		10.7326/0003-4819-123-6-199509150-00004	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639441				2022-12-24	WOS:A1995RU43700004
J	FAUCI, AS				FAUCI, AS			NEW SCIENCE AIMED AT AN ANCIENT KILLER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											FAUCI, AS (corresponding author), NIAID,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							JACOBS WR, 1994, SCIENCE, V263, P227; 1995, P NATL ACAD SCI USA, V92, P1530; 1995, SCIENCE, V267, P1638	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					786	786		10.1001/jama.274.10.786	http://dx.doi.org/10.1001/jama.274.10.786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU324	7650787				2022-12-24	WOS:A1995RU32400005
J	ASO, T; LANE, WS; CONAWAY, JW; CONAWAY, RC				ASO, T; LANE, WS; CONAWAY, JW; CONAWAY, RC			ELONGIN (SIII) - A MULTISUBUNIT REGULATOR OF ELONGATION BY RNA-POLYMERASE-II	SCIENCE			English	Article							TRANSCRIPTION FACTOR; PURIFICATION; IDENTIFICATION; SEQUENCE; PROTEIN	The Elongin (SIII) complex activates elongation by mammalian RNA polymerase II by suppressing transient pausing of the polymerase at many sites within transcription units. Elongin is a heterotrimer composed of A, B, and C subunits of 110, 18, and 15 kilodaltons, respectively. Here, the mammalian Elongin A gene was isolated and expressed, and the Elongin (SIII) complex reconstituted with recombinant subunits. Elongin A is shown to function as the transcriptionally active component of Elongin (SIII) and Elongin B and C as regulatory subunits. Whereas Elongin C assembles with Elongin A to form an AC complex with increased specific activity, Elongin B, a member of the ubiquitin-homology gene family, appears to serve a chaperone-like function, facilitating assembly and enhancing stability of the Elongin (SIII) complex.	OKLAHOMA MED RES FDN, PROGRAM MOLEC & CELL BIOL, OKLAHOMA CITY, OK 73104 USA; HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	Oklahoma Medical Research Foundation; Harvard University				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, UNPUB; ASO T, IN PRESS FASEB J; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GARRETT KP, 1994, GENE, V150, P413, DOI 10.1016/0378-1119(94)90467-7; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1994, TRANSCRIPTION MECHAN, P263; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, BIOTECHNIQUES, V16, P824; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	28	287	296	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	1995	269	5229					1439	1443		10.1126/science.7660129	http://dx.doi.org/10.1126/science.7660129			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7660129				2022-12-24	WOS:A1995RT80600050
J	GERASIMOVA, TI; GDULA, DA; GERASIMOV, DV; SIMONOVA, O; CORCES, VG				GERASIMOVA, TI; GDULA, DA; GERASIMOV, DV; SIMONOVA, O; CORCES, VG			A DROSOPHILA PROTEIN THAT IMPARTS DIRECTIONALITY ON A CHROMATIN INSULATOR IS AN ENHANCER OF POSITION-EFFECT VARIEGATION	CELL			English	Article							GYPSY TRANSPOSABLE ELEMENT; HAIRY-WING PROTEIN; ZINC FINGER PROTEIN; YELLOW LOCUS; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; MELANOGASTER; GENE; EXPRESSION; SUPPRESSOR	The suppressor of Hairy wing (su(Hw)) protein inhibits the function of transcriptional enhancers located distally from the promoter with respect to the location of su(Hw)-binding sites, This polarity is due to the ability of the su(Hw)-binding region to form a chromatin insulator. Mutations in modifier of mdg4 (mod(mdg4)) enhance the effect of su(Hw) by inhibiting the function of enhancers located on both sides of the su(Hw)-binding region. This inhibition results in a variegated expression pattern, and mutations in mod(mdg4) act as classical enhancers of position-effect variegation. The mod(mdg4) and su(Hw) proteins interact with each other. The mod(mdg4) protein controls the nature of the repressive effect of su(Hw): in the absence of mod(mdg4) protein, su(Hw) exerts a bidirectional silencing effect, whereas in the presence of mod(mdg4), the silencing effect is transformed into unidirectional repression.	RUSSIAN ACAD SCI,INST GENE BIOL,MOSCOW 117334,RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	GERASIMOVA, TI (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.		Simonova, Olga B/K-8890-2014	Corces, Victor/0000-0001-5140-4337; Simonova, Olga/0000-0001-9439-524X	NIGMS NIH HHS [GM35463] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035463] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CORCES VG, 1991, TRENDS GENET, V7, P86, DOI 10.1016/0168-9525(91)90062-U; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; GEORGIEV PG, 1989, MOL GEN GENET, V220, P121, DOI 10.1007/BF00260865; GEYER PK, 1988, P NATL ACAD SCI USA, V85, P8593, DOI 10.1073/pnas.85.22.8593; GEYER PK, 1987, GENE DEV, V1, P996, DOI 10.1101/gad.1.9.996; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GINIGER E, 1994, DEVELOPMENT, V120, P1385; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; Henikoff S, 1992, CURR OPIN GENET DEV, V2, P907, DOI 10.1016/S0959-437X(05)80114-5; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; JACK J, 1991, DEVELOPMENT, V113, P735; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; MARTIN M, 1989, MOL GEN GENET, V218, P118, DOI 10.1007/BF00330574; MAZO AM, 1989, EMBO J, V8, P903, DOI 10.1002/j.1460-2075.1989.tb03451.x; MOHLER J, 1982, CHROMOSOMA, V86, P457, DOI 10.1007/BF00330121; PARKHURST SM, 1988, GENE DEV, V2, P1205, DOI 10.1101/gad.2.10.1205; PARKHURST SM, 1986, MOL CELL BIOL, V6, P47, DOI 10.1128/MCB.6.1.47; PEIFER M, 1988, P NATL ACAD SCI USA, V85, P9650, DOI 10.1073/pnas.85.24.9650; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; Sambrook J., 1989, MOL CLONING LAB MANU; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PA, 1992, MOL GEN GENET, V233, P65, DOI 10.1007/BF00587562; SPANA C, 1988, GENE DEV, V2, P1414, DOI 10.1101/gad.2.11.1414; SPANA C, 1990, GENE DEV, V4, P1505, DOI 10.1101/gad.4.9.1505; SPRADLING AC, 1979, CELL, V16, P589, DOI 10.1016/0092-8674(79)90032-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLFFE AP, 1994, CURR BIOL, V4, P85, DOI 10.1016/S0960-9822(00)00022-1; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	42	248	255	1	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 25	1995	82	4					587	597		10.1016/0092-8674(95)90031-4	http://dx.doi.org/10.1016/0092-8674(95)90031-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RR734	7664338	hybrid			2022-12-24	WOS:A1995RR73400010
J	ROSE, J; GERKEN, S; LYNCH, S; PISANI, P; VARVIL, T; OTTERUD, B; LEPPERT, M				ROSE, J; GERKEN, S; LYNCH, S; PISANI, P; VARVIL, T; OTTERUD, B; LEPPERT, M			GENETIC SUSCEPTIBILITY IN FAMILIAL MULTIPLE-SCLEROSIS NOT LINKED TO THE MYELIN BASIC-PROTEIN GENE	LANCET			English	Note								The myelin basic- protein (MBP) gene is a candidate locus for disease susceptibility in familial multiple sclerosis. Amplification of a polymorphic tetranucleotide repeat region immediately 5' to MBP exon 1 demonstrated the presence of eight different alleles among members of 14 multiplex multiple sclerosis families (36 affected individuals). Linkage analysis was performed with autosomal dominant and autosomal recessive models, normal individuals with abnormal magnetic resonance scans being scored as either unknown or affected. Cumulative LOD scores were negative for both models of inheritance. The results do not demonstrate linkage between the MBP gene region and multiple sclerosis.	UNIV UTAH,DEPT NEUROL,SALT LAKE CITY,UT 84112; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	ROSE, J (corresponding author), VET ADM MED CTR,NEUROVIROL RES LAB 151B,SALT LAKE CITY,UT 84148, USA.							BOYLAN KB, 1990, ANN NEUROL, V27, P291, DOI 10.1002/ana.410270311; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; ELDRIDGE R, 1984, NEW ENGL J MED, V311, P948, DOI 10.1056/NEJM198410113111504; LYNCH SG, 1990, NEUROLOGY, V40, P900, DOI 10.1212/WNL.40.6.900; LYNCH SG, 1992, NEUROLOGY, V42, P839, DOI 10.1212/WNL.42.4.839; MARTIN R, 1990, J IMMUNOL, V145, P540; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; NELSON L M, 1986, Neuroepidemiology, V5, P17, DOI 10.1159/000110809; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658; TIENARI PJ, 1992, LANCET, V340, P987, DOI 10.1016/0140-6736(92)93007-A	10	67	67	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1179	1181		10.1016/0140-6736(93)91003-5	http://dx.doi.org/10.1016/0140-6736(93)91003-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	7683738				2022-12-24	WOS:A1993LB01700005
J	POPE, SK; WHITESIDE, L; BROOKSGUNN, J; KELLEHER, KJ; RICKERT, VI; BRADLEY, RH; CASEY, PH				POPE, SK; WHITESIDE, L; BROOKSGUNN, J; KELLEHER, KJ; RICKERT, VI; BRADLEY, RH; CASEY, PH			LOW-BIRTH-WEIGHT INFANTS BORN TO ADOLESCENT MOTHERS - EFFECTS OF CORESIDENCY WITH GRANDMOTHER ON CHILD-DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; LONGITUDINAL ANALYSIS; PRETERM INFANTS; PREGNANCY; TEENAGE; PROGRAMS; FAMILY; CHILDBEARING; IMPACT	Objective.-To explore the impact of young maternal age, coresidency with infant's grandmother, and other familial and environmental factors on development of low-birth-weight (LBW) infants. Design.-Prospective cohort analyses. Setting.-Eight medical institutions in different geographical locations participating in the Infant Health and Development Program. Participants.-Control population of 272 LBW, preterm infants enrolled in the Infant Health and Development Program born to mothers aged 15 to 24 years. Main Outcome Measure.-Child cognitive, behavioral, and health outcomes at 36 months' gestation-corrected age. Results.-Maternal age was not significantly related to child development. Coresidence with infant's grandmother was associated with improved cognitive and health outcomes. Maternal ethnicity, maternal verbal ability, and other environmental factors were also associated with child outcomes. Conclusions.-Findings of this study support the need for programs that include the extended family of at-risk infants, providing education and literacy skills to the mothers and encouraging participation of all care givers of the child.	UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT & PSYCHIAT,LITTLE ROCK,AR 72205; UNIV ARKANSAS,COLL EDUC,LITTLE ROCK,AR 72204; COLUMBIA UNIV TEACHERS COLL,NEW YORK,NY 10027	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Columbia University Teachers College			Kelleher, Kelly/E-3361-2011					ACHENBACH TM, 1987, J ABNORM CHILD PSYCH, V15, P629, DOI 10.1007/BF00917246; ADLER ES, 1985, FAM RELAT, V34, P183, DOI 10.2307/583890; BOYCE WT, 1991, AM J DIS CHILD, V145, P267, DOI 10.1001/archpedi.1991.02160030035017; Bronfenbrenner U., 1983, HDB CHILD PSYCHOL, VVol. 1; BROOKSGUNN J, 1991, PEDIATR ANN, V20, P467, DOI 10.3928/0090-4481-19910901-06; BROOKSGUNN J, 1992, J PEDIATR-US, V120, P350, DOI 10.1016/S0022-3476(05)80896-0; BROOKSGUNN J, IN PRESS CHILD DEV; BROOKSGUNN J, 1987, MALLEABILITY CHILDRE, P171; CARLSON DB, 1986, INT J BEHAV DEV, V9, P1; CASEY PH, 1990, J PEDIATR-US, V117, P298, DOI 10.1016/S0022-3476(05)80551-7; Chase-Lansdale P, 1993, ESCAPE POVERTY WHAT; CHASELANSADLE PL, IN PRESS CHILD DEV; CHASELANSDALE PL, 1991, FAM RELAT, V40, P396, DOI 10.2307/584896; CLAPP DF, 1978, SOC WORK, V23, P149; CLEWELL BC, 1989, FAM RELAT, V38, P201, DOI 10.2307/583676; COLL CG, 1986, J DEV BEHAV PEDIATR, V7, P230, DOI 10.1097/00004703-198608000-00003; DARABI KF, 1984, J MARRIAGE FAM, V46, P993; DUNCAN GJ, IN PRESS CHILD DEV; Dunn L. M., 1981, PEABODY PICTURE VOCA; Eisen MDC, 1990, CONCEPTUALIZATION ME; FIELD TM, 1980, CHILD DEV, V51, P426; FURSTENBERG FF, 1989, AM PSYCHOL, V44, P313, DOI 10.1037/0003-066X.44.2.313; FURSTENBERG FF, 1980, J SOC ISSUES, V36, P64, DOI 10.1111/j.1540-4560.1980.tb01899.x; Goldberg DP., 1972, DETECTION PSYCHIATRI; GROSS RT, 1992, PSYCHOL DEV LOW BIRT, P411; GULLO DF, 1988, CHILD STUDY J, V18, P223; HELD L, 1981, ADOLESCENCE, V16, P905; HUSTON AC, 1991, CHILDREN POVERTY; KING T, 1982, J ADOLESCENCE, V5, P333, DOI 10.1016/S0140-1971(82)80003-1; LANDY S, 1983, ADOLESCENCE, V18, P679; LEE VE, 1988, DEV PSYCHOL, V24, P210, DOI 10.1037/0012-1649.24.2.210; LIAW FR, IN PRESS DEV PSYCHOL; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; MCCORMICK MC, 1992, JAMA-J AM MED ASSOC, V267, P2204, DOI 10.1001/jama.267.16.2204; MCCORMICK MC, 1989, HDB MED SOCIOLOGY, P347; MERCER RT, 1985, ANN REV NURS RES, V3, P49; MILLER KA, 1984, MAYO CLIN PROC, V59, P311, DOI 10.1016/S0025-6196(12)61426-8; PARKER S, 1988, PEDIATR CLIN N AM, V35, P1227; RAMEY CT, 1992, PEDIATRICS, V89, P454; SCOTT DT, 1989, PEDIATR RES, V25, P263; SPENCER MB, 1990, CHILD DEV, V61, P267, DOI 10.1111/j.1467-8624.1990.tb02778.x; STEVENSSIMON C, 1991, PEDIATR ANN, V20, P322, DOI 10.3928/0090-4481-19910601-09; STEVENSSIMON C, 1992, CURR PROBL PEDIATR, P295; TERMAN LM, 1973, STANFORDBINET INTELL; VINCENT ML, 1987, JAMA-J AM MED ASSOC, V257, P3382, DOI 10.1001/jama.257.24.3382; 1990, JAMA-J AM MED ASSOC, V263, P3035	46	37	37	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1396	1400		10.1001/jama.269.11.1396	http://dx.doi.org/10.1001/jama.269.11.1396			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ857	7680076				2022-12-24	WOS:A1993KQ85700033
J	NGUYEN, HQ; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				NGUYEN, HQ; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			THE ZINC FINGER TRANSCRIPTION FACTOR EGR-1 IS ESSENTIAL FOR AND RESTRICTS DIFFERENTIATION ALONG THE MACROPHAGE LINEAGE	CELL			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; IMMEDIATE EARLY RESPONSE; INDUCED TERMINAL DIFFERENTIATION; TETRADECANOYL PHORBOL ACETATE; COLONY-STIMULATING FACTORS; C-MYC; GENE-EXPRESSION; ONCOGENE EXPRESSION; INHIBITORY FACTOR; GROWTH-FACTORS	We have isolated cDNA clones of myeloid differentiation primary response (MyD) genes, activated in the absence of de novo protein synthesis following induction for differentiation along either the macrophage or granulocyte lineage in human myeloblastic leukemia HL-60 cells. One cDNA clone of a primary response gene, expressed upon macrophage differentiation, encoded for Egr-1, a zinc finger transcription factor. The Egr-1 gene was observed to be transcriptionally silent in HL-60 cells, but active in U-937 and M1 cells, the latter two being predetermined for macrophage differentiation. Egr-1 antisense oligomers in the culture media blocked macrophage differentiation in both myeloid leukemia cell lines and normal myeloblasts. HL-60 cells constitutively expressing an Egr-1 transgene (HL-60Egr-1) could be induced for macrophage, but not granulocyte, differentiation. These observations indicate that expression of Egr-1 is essential for and restricts differentiation of myeloblasts along the macrophage lineage.			NGUYEN, HQ (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.				NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA43618-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACON TA, 1991, ONCOGENE RES, V6, P13; BERNSTEIN SH, 1991, CELL GROWTH DIFFER, V2, P273; BOISE LH, 1992, CELL GROWTH DIFFER, V3, P43; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DALTON WT, 1988, BLOOD, V71, P242; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GALLAGHER R, 1979, BLOOD, V54, P713; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HORAK H, 1982, EXP HEMATOL, V10, P123; JINGWEN L, 1991, J BIOL CHEM, V266, P5929; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KOEFFLER HP, 1983, BLOOD, V62, P709; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; METCALF D, 1985, CELL, V43, P5, DOI 10.1016/0092-8674(85)90004-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; NAGARAJAN L, 1990, BLOOD, V75, P82; NELSON DA, 1983, HEMATOLOGY, P1651; NEWBURGER PE, 1981, CANCER RES, V41, P1861; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SHABO Y, 1990, LEUKEMIA, V4, P797; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TORELLA C, 1982, CANCER RES, V42, P445; TOTORA G, 1990, P NATL ACAD SCI USA, V87, P705; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WINTROBE MM, 1981, CLIN HEMATOLOGY, P35; WU J, 1990, ONCOGENE, V5, P873	60	377	388	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					197	209		10.1016/0092-8674(93)90660-I	http://dx.doi.org/10.1016/0092-8674(93)90660-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678779				2022-12-24	WOS:A1993KK03800005
